<SEC-DOCUMENT>0001628280-21-022015.txt : 20211105
<SEC-HEADER>0001628280-21-022015.hdr.sgml : 20211105
<ACCEPTANCE-DATETIME>20211105161235
ACCESSION NUMBER:		0001628280-21-022015
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		69
CONFORMED PERIOD OF REPORT:	20210930
FILED AS OF DATE:		20211105
DATE AS OF CHANGE:		20211105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PROCEPT BioRobotics Corp
		CENTRAL INDEX KEY:			0001588978
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				260199180
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40797
		FILM NUMBER:		211384642

	BUSINESS ADDRESS:	
		STREET 1:		900 ISLAND DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		650-232-7200

	MAIL ADDRESS:	
		STREET 1:		900 ISLAND DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>prct-20210930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:05140f27-a3ec-43bc-a461-9ef7bd6589c5,g:c5500a2c-3da2-4c15-b44b-608117d5a861,d:d6896dbd221a471485ce149196fbcf44--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:prct="http://www.procept-biorobotics.com/20210930" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns="http://www.w3.org/1999/xhtml" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>prct-20210930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NTMvZnJhZzoyNjQxY2Y5YjNjYWY0ZGVkODQzYjMzNzUzMTFhOGRhNC90YWJsZTowMzQ0ZTFkMjJkMWY0NjgzOGYxMGYwZDYzNDhhZjBmZi90YWJsZXJhbmdlOjAzNDRlMWQyMmQxZjQ2ODM4ZjEwZjBkNjM0OGFmMGZmXzAtMS0xLTEtNDExNzM_f85fb5e1-009d-40f3-a537-70b776a569d9">0001588978</ix:nonNumeric><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt:date-month-day" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NTMvZnJhZzoyNjQxY2Y5YjNjYWY0ZGVkODQzYjMzNzUzMTFhOGRhNC90YWJsZTowMzQ0ZTFkMjJkMWY0NjgzOGYxMGYwZDYzNDhhZjBmZi90YWJsZXJhbmdlOjAzNDRlMWQyMmQxZjQ2ODM4ZjEwZjBkNjM0OGFmMGZmXzEtMS0xLTEtNDExNzM_ad6fc04d-8fd3-4b0f-b8e1-99125a7b0a3d">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NTMvZnJhZzoyNjQxY2Y5YjNjYWY0ZGVkODQzYjMzNzUzMTFhOGRhNC90YWJsZTowMzQ0ZTFkMjJkMWY0NjgzOGYxMGYwZDYzNDhhZjBmZi90YWJsZXJhbmdlOjAzNDRlMWQyMmQxZjQ2ODM4ZjEwZjBkNjM0OGFmMGZmXzItMS0xLTEtNDExNzM_2f7bd4c9-2bc4-4a8b-98f4-bb55a102c67a">2021</ix:nonNumeric><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt:fixed-false" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NTMvZnJhZzoyNjQxY2Y5YjNjYWY0ZGVkODQzYjMzNzUzMTFhOGRhNC90YWJsZTowMzQ0ZTFkMjJkMWY0NjgzOGYxMGYwZDYzNDhhZjBmZi90YWJsZXJhbmdlOjAzNDRlMWQyMmQxZjQ2ODM4ZjEwZjBkNjM0OGFmMGZmXzMtMS0xLTEtNDExNzM_551c16b8-193c-461d-bc46-1a3ffb4b000b">FALSE</ix:nonNumeric><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NTMvZnJhZzoyNjQxY2Y5YjNjYWY0ZGVkODQzYjMzNzUzMTFhOGRhNC90YWJsZTowMzQ0ZTFkMjJkMWY0NjgzOGYxMGYwZDYzNDhhZjBmZi90YWJsZXJhbmdlOjAzNDRlMWQyMmQxZjQ2ODM4ZjEwZjBkNjM0OGFmMGZmXzQtMS0xLTEtNDExNzM_c53787ca-6820-48b6-b182-5cb72f248748">Q3</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ib8664e9a7cee4889bdb472916c610c7d_D20210901-20210930" decimals="INF" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NzAvZnJhZzpkMjM2ODkxODQ4NDE0OGJhOTkwZGQwNTYxYWI5OTMyZi90YWJsZTo5NzZmYmI1ZTRiMDc0ZDU0YWJmNTYxYTBlNGNmOWVhNi90YWJsZXJhbmdlOjk3NmZiYjVlNGIwNzRkNTRhYmY1NjFhMGU0Y2Y5ZWE2XzItMS0xLTEtNDgxMzU_0e20ff93-c0f9-40be-be5c-bb2c1f48151f">0.2105263158</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="prct-20210930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ife2115ee5766464a8a5a08c494796bcc_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894ed293fa3742e3a04a1df94f575575_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01918d59a04b4c499b05ee2466db1b59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i100c23f92bda49a28c0877949b1a0fbd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55a781d4fc84f41a41fcb23206c4b8c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565b2c3bc8fb41c3b592ad68c4361808_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69c82465ba6d48e6b9185da02a84e2b4_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7eb6a1e27a14c97a0ea1c2cf23a8098_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49c187172a454793b7a939d7e48946ac_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f6cea14ac0417b98a3dd1cea4a266d_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4658dd5cdc744b40a5f591e4cd3f85e0_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d5816a787b74534b5f25f18a706ccf0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2cb5f33c9274d0097af2dc64d06de5c_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6de1f8c86cea46dc902859f13d99afc9_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eec3bd752b2481d9dc300830ea16b5f_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9403ca6a5054b1f88c93a222d45cd64_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e13c67478f6478e8541be8a44bb1f4c_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i802e7d5b07ff4ca5b8093189adc87bb0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e3cb976587c4b1d83bc6098c98b5efe_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72403aeb9eb44de7b079046542387a2e_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie60a74e01b9041ce961b1963ccfbf1d1_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0047bc2007a74490b97d13e8976d3dbf_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e1bb70ea6094ea29f8dc5001a1cdf43_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaacff7f78ad74cae9c3705649ac848a3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i529b692fd02c440cb93775020fee3392_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i655db423d80146ba9a5fc4791da055de_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2578d1ae003e4df39157ff0cedef50d3_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad0956d1fac424f955531bf976553b6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad55634ed8394953ba4771879c737291_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77e0b2f826e241698ef40dc6384a75c7_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f72d70743b3499b96f9d263ba7b8823_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia092c91a3f084cdcbfb9a7581c7384e8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2962c8287fb9466283c88ab19620b70a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa21a99062154fbdb875876427776118_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bba4b69cf534b07bff7fadc5c5880e1_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i350149917e7c4dad952ac65149521110_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfd71f7a814d4c54bda649dd20cbfc19_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63de44b1b5764b5484ed75a0180e0f06_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if86cc355897b4827abd740147e1208da_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8c4f5ac282a46bfb9afbc186bba95e2_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i207a558e6bf54b419ced15aa4da0802b_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee7a556f8ed44411b236ac803a34efa5_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ba09fbe2d8e41ae91b530bd0fd4aabf_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28789e1867f6489181082ded2abe46bd_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47808217616c42a1bde3b298ba31d9ec_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if3221c2435d1479a8c4fbc3f096a5d50_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b07359bb1524f11b21ca2e21f932d05_I20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b42bfa189674105a63a13810f164fee_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dc6976f7625478f8a1e700402e190e8_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83a299a91bc0478bbe2f8a0bce7ff85b_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74d430c7456149008291631a41455fb6_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0c1cb22a76846d88fe33bc3ec293fe5_D20200401-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb23ec3142464357adefd10788d9dc21_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5d7ddae2bf4b4c9ff977f94e8bf4df_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43a77154c7e44d6c916d662730d39095_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c72799a37ef4b6996ae6377297e5d8b_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i406bac8d8e3c42e8ba906eba2383e727_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82411be0df684d5999a14b0a6ad94e9a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402b4853a118490284a4c268556e6aa9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f878035d2ed48dc9860fc0e9a488f55_D20200701-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ae4098982084df789f8c32460ce665d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fc7c14ea459484dbff851cda6151300_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i333242aedc914ccab277eab2cc3188fe_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1af9fd0db1144ceb9953d270a352e2d_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8aa66f1be4e40d5b3e68af93a816d5b_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2eb4717194044992b7d6a3ba0a73a671_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e6d9aca39d64536ad610f06bc65f7f3_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9679f5b41fb34cf6abfae1649202e1c5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2b1c007cb5a4990af1e1f1d862c4d24_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3acfe77b8a2f44e79e9ac544b7465414_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesGRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a1b74e1acd043bda78eed560ea4270b_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i679a14a77cd0453ca47285769b9db2d0_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8664e9a7cee4889bdb472916c610c7d_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i719157466752459aa43b7047e2f317c7_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55fff3d953504e32a8bb1767e17be163_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i685a759150ca4001b06e6ef8169b3a0a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia13ef5c367424e9b87f0aa0201302d21_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic790d5759ab443cba375a13c77efc8a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic53305bb04ab4021944c4163701dcd71_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib383b7e5ad6141079ebfdfb1678720a6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i372dc095e6bb4b4fab2fda830e21a778_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26689b208bf84601a3e040e4ce73ce49_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80cf655a5572442ab5b3157b560431bf_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i932b6afd06b54dfdbf042021f1fb619a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735e2352ec40490980b3c86c7253982d_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87940b64ee9940b29b568ac0a865184b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f0a6d3d6a5d41aabc418f290a24224b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5998e1db9c1d41c4b57ba2aac373504c_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i821880a0f0ea457fb74d98beb2145b75_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4acb9ad050634e849a2a2923e0940cae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide057d850a674c1faa90ee7654a9dcba_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="ibf0b64a5bcea498e9f11e448dcbfd834_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70cffcb762f444178b8ff9f5925b1a05_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i669bfb53914c4eb98abef7a0bb67beb4_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149316ff5b004dd4a6c20c85ec67c952_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia44bb9ced3444ecab70c0374b5456e34_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3604760cd7da443ebd82948c1de89a0c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec7eb3e7ffce40f691737cf9a773acc7_I20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5706bc22431543fd88f03f8d8b69bf07_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i70e3fa6d51e049b29372b92a12097b3b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i552d18e694c74d6ea1105c6c060177c9_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e3327002d624963bd45eaa1f8569e6c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c34540459ad463592472f93bf90d0d6_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i521f9bcdc3594f5cad2c4aaf7085a016_I20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i886693e4845143ee9412596e575e4081_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic400b41cd47342848644ec9514f047c0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b9ba7023422472682b16a20f5f463a1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c26f250c925422aa863c70b7a19551d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a170ab8421b4089a99080c2ea10af97_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idabe1c5a57964ddb9bd5d12ab67202b8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d0c0948cc8f4e1280e0195a16e98801_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic44775719b294dc1913d8311a089ebaf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd2dcb59faa3426288a132975960e82e_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie17f18e3e20e4d43aae76b23a39a3be8_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89eb2bbd1924e0fb717bfba7cc199c8_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d1f490ec27b47feb871022c21515bab_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8353a9a7b034508bb8f01dbd8917e72_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieeada33fd4aa4372b8bd11229fdf8032_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ac6cd3dce7f43fda61bce4f9ba59555_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if05a3e115a3c4a69bedce4615d0524f0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf79d1655d82439f9563d7390347f8f3_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81c94b64a4fe411c90294df282895066_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe009ff3d8a84467b238828dc96fa66e_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a203d4671604af189dd4efe9cfc3f3c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib054ba1212a040a5ba7001b1a2bc8aaa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad3a4897b0f74d93b212ccf2d92ceb95_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa5d2fc51a09454fb9410268366249f0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c6ae97130174160926aac368d44e969_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ff4ab44021547058325efd92af9bd8b_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i018b3765196146e48322f8a859dbb4d5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52ad0f1364cd409c9f18e002b7381a5f_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfa97cb67f4c48af906ec7b00d213a04_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd005e7d887548c48d2e442a699161c8_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b33b0f044bd43a19422b9118049e601_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee4ecb3e06be41628c57d8da452ede6d_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2968256b5824a29a2ac8033c768dcc5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c940d5581a0431aaaeb6016386ef835_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fde91df02034661a6ff9d0d3c072933_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2df0a857498b4af18745e51eab13a016_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5de6b566d9af4bbbbdb356901e72ac2f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39c4d84b986e41378d377fdb579b0a86_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2eba5a66004f438219847cad5c1e9a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">prct:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb63ff2219e442f2819551ec884c0008_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">prct:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic982c9e58b554c3082d06d2c3a72e4fd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">prct:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49ee07a01cc44074a4d6e760f58e4643_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">prct:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe92bd4b50d543f59cb5bba7fd59e5d6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib43d1b122a854476a24a6c9ee1ab3406_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i621e3ef4440f48c2b9f769e24af4620f_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">prct:Customer1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bfac2758f3446a3ad3a43b3803a084a_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">prct:Customer2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bc8fda665ae45fda75450551e6878fb_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">prct:Customer3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7708603bb2ff47579ddc870b44b0fbb0_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52f5aefc16b34dfda582cd7651908024_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62921dc1224a460e89216f894a1e2b07_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">prct:Customer1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ac307246bd746a78220da47930dbd09_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">prct:Customer2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icec9f26499284935a6a375b0c451fdcb_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39ecf903be504ecdaf949aece1345593_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prct:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic86cf6a985714467a558f903d60ea686_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prct:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4cacff96a36941f49fc136cd9987bba8_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56f7a99ae3cc46a48d7f360c4949ca50_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0930250516e46df8adee1ddbea619bb_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id08e754d707e4d5ca56a878c541eb772_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia890f1a1f9ea4925ac24d0577d19ee3c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prct:EvaluationUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2daf6e575dd487a9593c9105221c75c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prct:EvaluationUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i323691aee3ba4470beeb781efc9f7d5a_D20190301-20190331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-03-01</xbrli:startDate><xbrli:endDate>2019-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9df1ea4e38a48c3958b823d207dc494_I20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="installment"><xbrli:measure>prct:installment</xbrli:measure></xbrli:unit><xbrli:context id="ie747bb89dfe9448486f081a8d7c662b9_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e54cc3200146fb8da3275f099dcd86_D20200301-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e17326bb20948edb8a8ca7d92913aaa_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id581c96bb97e44a48ba70ae2493b16db_D20210101-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc0b522093084b14a072138407b528ec_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d291c059d984acabb11a4e041ff93bc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9578e35c34594195b4553614451e762d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1237e90024844c78a16dad0cbdc499c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2270b85069d4e108aafb93ea6264888_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03b0c48c8ac947c3a489c6f136a47201_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee83fb3442a945c89e3036e0c6098fdb_D20190901-20190930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbe7a57a89de4a8285e98235fc3da48b_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib126ee67697d4fdc82b80a04fe0cc629_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheFourMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7425a248d0c54625b60e82800726ba6e_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37a93df4a20d471fa73a04fadd763398_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a6641bdf6a04d2a9f8abd5a3282a1c4_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8ca34d460bd431e9f40af8ba7f4941d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if5da641970b84172a5c935038a6a1c8e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibecb2734dfdd4390b231ca7dcd3bc7eb_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc65b7919fd243f887cb7aa91fed512f_I20150731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i869c38d090bb4baa8be1f5e855808baa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i103b94ebee224533bc1827781430d1ba_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d86103fd3bc4740a8b6c0bfaf50e9e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i90bf229ad34d4baba483ea11a398bc08_I20170630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i927e6688e0294af2a421eef76a378dca_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3019d42f68fb44eaa750274de9c831ec_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied497de295f14e1f827bd811b22ff9f1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie352732829a944e8bcad696ed9555ae7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0c5306798ce4d5cbf19af58bc03c7b0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9144a17da8024a6fa09ae89276a70ce7_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86acacb511a247ad99b9d153e72b9538_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43040eb9775b4ce6978553e3936f3b76_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea718991298743b4bf83f37c95537401_D20200701-20200731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffd69005bc104609a9a1664e72d42b12_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesGRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60e32c082ec946839e6d084bceac21a6_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesGRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e1b4a8dca7145f3b32508e4106c7c5b_I20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4185c7d482a4d408c70efb88bc2655b_D20200701-20200831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7aa86dd5567043e78dbeaa1869e5a838_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i006123c4fa5d483a9e5463519395740b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f4ede9a776146de87f610eeb9409d5d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f35ad14fa9c4afd9f180294ec2f5da1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de321a1c268402ab2b16faea56fdb02_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e48ea26dceb47ec879e15c92c50d98e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e43455a41214ba3a21927edd8a4845d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a5a5773de0d4f218c0162ed76015607_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4321f4042af4f5cb3cf13c10279d51d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4982cd5fdb3f431caecb3cf5474a994c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice8d36bf1b564de9b741f74e90346ae9_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74e05f7559ad44e2b03cdce92864389e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesGRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="customer"><xbrli:measure>prct:customer</xbrli:measure></xbrli:unit><xbrli:context id="ib06a5da95c7042d7b94adeb6559177b2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbaeafd33bbd4e6888b366b6103f762f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ece297f570a4b82a416279c7fdc8910_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:OwnershipAxis">prct:ShareholderOfTenPercentOwnershipOrGreaterMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">prct:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i775e9da970104587a8e43c336154fd28_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">prct:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06d1766f867741e985119b9837680d50_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ecfd2799a3b484db31278a912812179_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id017d7645c90419b8f85f400f2c78e30_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2008StockPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29a3508d251b4bde9f8eb210f942bfaa_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10a6eebd2df541eca35c8a3094153817_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12898071c0444fe7844142bb4d3cd49c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccd781125894469891eb522580c6b2aa_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f72c2550a004f309da2bc458a30adfe_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78b24385d55b4a209c528145906fa5ce_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i445258736c484e52b6ddb965454bb1ff_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c80643e4da242ecbd5c44667621fad4_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f0e6e6c797846fa8312b60ebb59afb3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i190871b1575a4e8db9bd9f80d3702fa0_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffd4490b13ce46d8825d6f990c341beb_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bd6c00e464c4f16bf14f0e616cee1d1_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008a0e4e1310456bb44ece232d2da544_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95da0a4005cc41b88796003dc99be3ea_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2e662689b684020aedbed74e67c085f_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09198490d2f441a08b39181593f1f255_D20200701-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i90a0eaa9861b47338cef7b3ddc5fa8d1_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i147dde6bfea84bb5a5a2eab1578869ea_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2b70c21dbc4b32895eedfc71019388_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03b8cb9f698a47d698415757c8e483bf_D20150501-20150531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5398d7157b274e53afc37f43c4fb9f1a_D20150501-20150531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-05-01</xbrli:startDate><xbrli:endDate>2015-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id13f0093eaaa458181bd8b489d0fa71e_I20130731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:RedwoodCityCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i51e569731e334d18b46ce30b6992446f_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:RedwoodCityCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0882844190cf46d882aec93c3be61895_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:RedwoodCityCAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcde0d5c3d85476888c4854555b60153_I20200101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c89c558562342acb1a97bac5a006107_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c6bcd3416cb4dff84912e6e977f510e_D20210101-20210131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001588978</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id6896dbd221a471485ce149196fbcf44_746"></div><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2MzU_fbd5ba26-32c5-4e56-9742-7b092817bc70">10-Q</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTphODVjZmNiMzE4ZDU0YzRjOTA4MGFjMWM4ZDA4MWRlZi90YWJsZXJhbmdlOmE4NWNmY2IzMThkNTRjNGM5MDgwYWMxYzhkMDgxZGVmXzAtMC0xLTEtNDA5Nzk_eb1c61e0-a2c8-46c4-b182-1c2a1544004a">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt:date-monthname-day-year-en" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzQzOTgwNDY1MzE3NjA_4e8526a5-9777-435d-9512-6cd379aa780d">September&#160;30, 2021</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.094%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.706%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTplNGYyN2Q1ZmFmNTM0MDQ0YTg3NzZjYjI0OGNhMWIxYy90YWJsZXJhbmdlOmU0ZjI3ZDVmYWY1MzQwNDRhODc3NmNiMjQ4Y2ExYjFjXzAtMC0xLTEtNDA5ODE_7e630ec0-3991-469c-9b50-3aae93970476">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from &#160;                        to  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NDQ_9a32c87e-aacf-4db5-b2dd-5f34879a74be">001-40797</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NDc_4a8f37de-801c-4ad2-b0df-3678026d7198">PROCEPT BioRobotics Corporation</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.485%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzAtMC0xLTEtNDA5ODg_2d915474-e45e-4b53-b3d1-2099da82c970">Delaware</ix:nonNumeric></span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzAtMy0xLTEtNDA5ODg_937963dd-23bc-420c-8421-0039fc022202">26-0199180</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="6" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzMtMC0xLTEtNDA5ODg_bb1fa591-f5fa-413a-8fde-764d9373780e">900 Island Drive</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzMtMS0xLTEtNDA5ODg_33c7485d-857f-4f1e-a915-f2eac624bead">Redwood City</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzMtMi0xLTEtNDA5ODg_7b3c6391-fdfd-4202-8b86-77f49bc9b0ce">CA</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzMtMy0xLTEtNDA5ODg_3b2917ff-4caf-4ee6-bb2e-ad2b339b686d">94065</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of Principal Executive Offices)</span></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2Mzc_c3b40839-8969-46c5-8285-b8bc11dddf1c">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NDE_36a43650-b9a3-4d96-bd5c-9cd6e818fd84">232-7200</ix:nonNumeric> </span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant's telephone number, including area code</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.955%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.038%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.707%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTo1YmM0YzNmZGRmODM0N2VkYjA3ZTBlOWNiZWVhMTk3My90YWJsZXJhbmdlOjViYzRjM2ZkZGY4MzQ3ZWRiMDdlMGU5Y2JlZWExOTczXzEtMC0xLTEtNDEwMDA_5b420947-ec81-4474-b7a6-4c7e1c39334c">Common stock, $0.00001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTo1YmM0YzNmZGRmODM0N2VkYjA3ZTBlOWNiZWVhMTk3My90YWJsZXJhbmdlOjViYzRjM2ZkZGY4MzQ3ZWRiMDdlMGU5Y2JlZWExOTczXzEtMS0xLTEtNDEwMDA_fee7db68-e482-4772-8ee9-4eb165d23e2d">PRCT</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTo1YmM0YzNmZGRmODM0N2VkYjA3ZTBlOWNiZWVhMTk3My90YWJsZXJhbmdlOjViYzRjM2ZkZGY4MzQ3ZWRiMDdlMGU5Y2JlZWExOTczXzEtMi0xLTEtNDEwMDA_8d1bcf17-9c10-4cb6-923d-a274728f8d08">Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;Yes&#160;&#160;&#9744;&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTcxOTE_db321bff-d293-4ce5-8d5f-dcd746e688ce">No</ix:nonNumeric>&#160;&#160;&#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NDk_f09d210d-d168-47bc-be9c-cc91db3138ad">Yes</ix:nonNumeric>&#160;&#160;&#9746;&#160;&#160;&#160;No&#160;&#160;&#9744;&#160;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule 12b-2 of the Exchange Act. (Check one):</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.277%"><tr><td style="width:1.0%"></td><td style="width:31.925%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.213%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTozOTI5YzE0YTQ2ZTM0MTdlYjY4ODk2ZWU1NjM5ZmEwNS90YWJsZXJhbmdlOjM5MjljMTRhNDZlMzQxN2ViNjg4OTZlZTU2MzlmYTA1XzEtMC0xLTEtNDYzNzM_8cdc8853-eeaa-4587-bd7b-a73524f412fd">Non-accelerated filer</ix:nonNumeric>&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTozOTI5YzE0YTQ2ZTM0MTdlYjY4ODk2ZWU1NjM5ZmEwNS90YWJsZXJhbmdlOjM5MjljMTRhNDZlMzQxN2ViNjg4OTZlZTU2MzlmYTA1XzEtMy0xLTEtNDEwNzQ_3b53a470-aa4d-4339-b467-0701da822f91">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTozOTI5YzE0YTQ2ZTM0MTdlYjY4ODk2ZWU1NjM5ZmEwNS90YWJsZXJhbmdlOjM5MjljMTRhNDZlMzQxN2ViNjg4OTZlZTU2MzlmYTA1XzItMy0xLTEtNDEwNzQ_6bf1398b-3c35-4918-ab0b-4a02511b09e6">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NTA_bd02bc37-e735-4cc5-b78f-c09d0be3bf50">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). &#160;&#160;&#160;&#160;Yes&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NTE_5cb291e0-638e-450b-b2ae-5c68c245f656">&#9744;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="margin-bottom:3pt"><span><br/></span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The registrant had outstanding <ix:nonFraction unitRef="shares" contextRef="ife2115ee5766464a8a5a08c494796bcc_I20211031" decimals="INF" format="ixt:num-dot-decimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzQzOTgwNDY1MzE2Njg_07b3760a-1ff4-4357-8cf4-fd78fa808852">43,496,831</ix:nonFraction> shares of common stock as of October&#160;31, 2021.</span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:5pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_4"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROCEPT BioRobotics Corporation </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Form 10-Q &#8211; QUARTERLY REPORT </span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the Quarter Ended September 30, 2021</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.714%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:83.675%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.311%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_7">Part I. Financial Information</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_10">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_10">Condensed Consolidated F</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_10">inancial Statement</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_10">s (unaudited)</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_19">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_19">Condensed Consolidated Balance Sheet</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_19">5</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_22">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_22">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_25">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_25">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_28">9</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_31">10</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_70">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_70">33</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_103">Item 3.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_103">Quantitative and Qualitative Disclosure About Market Risk</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_103">43</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_106">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_106">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_106">44</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_109">Part II. Other Information</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_112">Item 1.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_112">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_112">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_115">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_115">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_115">46</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">Item 2.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">Item </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">Item </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">4</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">Item </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">5</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_118">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_130">Item 6.</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_130">Exhibits</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_130">104</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id6896dbd221a471485ce149196fbcf44_133">Signatures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_763"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; "can," &#8220;will,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical facts contained in this Quarterly Report, including without limitation statements regarding our business model and strategic plans for our products, technologies and business, including our implementation thereof, the impact on our business, financial condition and results of operations from the ongoing and global COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide, the timing of and our ability to obtain and maintain regulatory approvals, our commercialization, marketing and manufacturing capabilities and strategy, our expectations about the commercial success and market acceptance of our products, the sufficiency of our cash, cash equivalents and short-term investments, and the plans and objectives of management for future operations and capital expenditures are forward-looking statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                The forward-looking statements in this Quarterly Report are only predictions and are based largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements speak only as of the date of this Quarterly Report and are subject to a number of known and unknown risks, uncertainties, and assumptions, including those described under the sections in this Quarterly Report entitled &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere in this Quarterly Report. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this Quarterly Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely upon these forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance, or achievements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. We intend the forward-looking statements contained in this Quarterly Report to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;).</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY RISK FACTORS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous risks and uncertainties, including those described in Part II. Item 1A. &#8220;Risk Factors&#8221; in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common stock. The principal risks and uncertainties affecting our business include the following:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are an early-stage company with a history of significant net losses, we expect to continue to incur operating losses for the foreseeable future and we may not be able to achieve or sustain profitability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our revenue is primarily generated from sales of our AquaBeam Robotic System and the accompanying single-use disposable handpieces, and we are therefore highly dependent on the success of those products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our quarterly and annual operating results may fluctuate significantly and may not fully reflect the underlying performance of our business. This makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The terms of our loan and security agreement require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need additional funding beyond the proceeds of this offering to finance our planned operations, and may not be able to raise capital when needed, which could force us to delay, reduce or eliminate one or more of our product development programs and future commercialization efforts.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The commercial success of our AquaBeam Robotic System and Aquablation therapy will depend upon the degree of market acceptance of our products among hospitals, surgeons and patients. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience in training and marketing and selling our products and we may provide inadequate training, fail to increase our sales and marketing capabilities or fail to develop and maintain broad brand awareness in a cost-effective manner.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to obtain or maintain adequate levels of third-party coverage and reimbursement, and third parties may rescind or modify their coverage or delay payments related to our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face competition from many sources, including larger companies, and we may be unable to compete successfully. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited experience manufacturing our products in large-scale commercial quantities, and we face a number of manufacturing risks that may adversely affect our manufacturing abilities which could delay, prevent or impair our growth.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply shortages and price fluctuations that could negatively affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our internal computer systems, or those used by our contractors or consultants, may fail or suffer security breaches, and such failure could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The sizes of the addressable markets for our AquaBeam Robotic System have not been established with precision and our potential market opportunity may be smaller than we estimate and may decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our products. The expense and potential unavailability of insurance coverage for liabilities resulting from our products could harm us and our ability to sell our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cost-containment efforts of our customers, purchasing groups and governmental organizations could have a material adverse effect on our sales and profitability. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes to the reimbursement rates for BPH treatments and measures to reduce healthcare costs may adversely impact our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We must comply with anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our AquaBeam Robotic System and our operations are subject to extensive government regulation and oversight in the United States. If we fail to maintain necessary marketing authorizations for our AquaBeam Robotic System, or if approvals or clearances for future products or modifications to existing products are delayed or not issued, it will negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even though we have obtained marketing authorization for our AquaBeam Robotic System, we are subject to ongoing regulatory review and scrutiny.  Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have to obtain, maintain and protect our intellectual property and failure to do so may adversely impact our competitive position. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may become a party to intellectual property litigation or administrative proceedings that could be expensive, time-consuming, unsuccessful, and could interfere with our ability to sell and market our products or services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market price of our common stock may be volatile or may decline steeply or suddenly regardless of our operating performance, which could result in substantial losses for purchasers of our common stock in this offering, and we may not be able to meet investor or analyst expectations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Future securities issuances could result in significant dilution to our stockholders and impair the market price of our common stock. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_7"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="id6896dbd221a471485ce149196fbcf44_10"></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="id6896dbd221a471485ce149196fbcf44_19"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROCEPT BioRobotics Corporation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNS0xLTEtMS0zNDQwMQ_c99fbdbd-687d-4c64-9eba-806f6eac9a28">320,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNS0zLTEtMS0zNDQwMQ_7530e9d5-4a87-4d38-b42d-2ca5fb705cc2">100,130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNi0xLTEtMS0zNDQwMQ_b46a03dd-5aa4-4b05-8f95-f6a9aa5b164c">6,353</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNi0zLTEtMS0zNDQwMQ_66f6eed7-f582-49b0-9cf7-f2bd99dc2ad8">1,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNy0xLTEtMS0zNDQwMQ_6855e7ff-80f1-4a7d-be65-e92b927238b0">10,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNy0zLTEtMS0zNDQwMQ_a015a155-4150-4fc9-8de2-da040ea47092">6,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfOC0xLTEtMS0zNDQwMQ_d63623fe-5ac3-487d-9685-0a56b8eecad2">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfOC0zLTEtMS0zNDQwMQ_ec286ab6-8d73-4a2b-bb61-2f7295303cc1">1,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfOS0xLTEtMS0zNDQwMQ_b2b4c175-61d1-4d8d-96a6-c5b80b473218">339,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfOS0zLTEtMS0zNDQwMQ_1d3ace37-984e-408b-b48e-86e29fb512c3">110,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTAtMS0xLTEtMzQ0MDE_967da144-b4da-4300-b8f3-3fbffd8ba5d7">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:RestrictedCashNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTAtMy0xLTEtMzQ0MDE_34c26d43-2775-449f-a48f-b3fbbf1164d1">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTEtMS0xLTEtMzQ0MDE_7598835a-581c-4189-9c68-a1a1b999f4a9">5,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTEtMy0xLTEtMzQ0MDE_a04eac76-1009-4a4c-a08a-2599fe01ba6f">8,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease right-of-use assets, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTItMS0xLTEtMzQ0MDE_e1b6df23-7594-48b2-ae6d-7285d2d5b766">3,667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTItMy0xLTEtMzQ0MDE_dcd0798c-e3d6-43df-9e96-0c41b9b6b47a">4,641</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTMtMS0xLTEtMzQ0MDE_3e071631-f1a2-47b2-be32-5461458fa277">1,818</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTMtMy0xLTEtMzQ0MDE_3310b682-6a91-4403-a3c9-e76f5f7e5e2e">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTUtMS0xLTEtMzQ0MDE_311ce768-d215-40c3-8470-d67e1ca176fc">351,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTUtMy0xLTEtMzQ0MDE_2f91a78f-4096-41b0-8459-c9379c131ff3">125,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTgtMS0xLTEtMzQ0MDE_b888b31e-2031-48ea-94c9-f868cb83172f">3,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTgtMy0xLTEtMzQ0MDE_95cd4300-9d65-418c-8882-3b662d9930e9">1,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTktMS0xLTEtMzQ0MDE_c04603e5-dd39-497e-8eea-2cb923e1e4f0">4,875</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccruedSalariesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTktMy0xLTEtMzQ0MDE_f3aa5745-c8c8-4a93-a77f-44e90a3aa486">4,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Note payable &#8211; current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjAtMS0xLTEtMzQ0MDE_6b928a7d-4cb2-432d-8bdd-fae2d78e3842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjAtMy0xLTEtMzQ0MDE_01a418fd-db86-4a2b-a1fb-c4d7151f83f2">4,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease &#8211; current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjEtMS0xLTEtMzQ0MDE_ec86a6cf-c466-4c8d-8d9c-393bc88dcd62">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjEtMy0xLTEtMzQ0MDE_33a9b646-9036-439f-8679-dde9b645af7e">1,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjItMS0xLTEtNDYwNDY_a231e80e-94af-48ad-b887-9bcdba174fb5">848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjItMy0xLTEtNDYwNTM_b6b85640-1f67-4a1d-91c0-b462915eef1a">233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convertible preferred stock warrant liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjItMS0xLTEtMzQ0MDE_a8778c16-3477-48ee-88b0-350a48d17d0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjItMy0xLTEtMzQ0MDE_2ea898ad-a106-4c66-815b-dbf7e982acd1">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjMtMS0xLTEtMzQ0MDE_f9ee264e-73d2-47be-b1bc-3cd7921e1ef9">2,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjMtMy0xLTEtMzQ0MDE_53c28d26-0bb9-433a-81d0-090dbaad6385">1,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjQtMS0xLTEtMzQ0MDE_5db89b08-237a-45e5-a897-4837fc01615f">14,179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjQtMy0xLTEtMzQ0MDE_5649e46d-b591-4666-a74e-6123f3e32d3b">14,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Note payable &#8211; non-current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjUtMS0xLTEtMzQ0MDE_92bc053c-5e00-44fc-b233-3c4e81954a23">49,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjUtMy0xLTEtMzQ0MDE_e91573b7-796c-4acc-836c-51fc75c54a32">44,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease &#8211; non-current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjYtMS0xLTEtMzQ0MDE_f8b7317b-7141-4f23-8714-0ce28ba33ad4">2,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjYtMy0xLTEtMzQ0MDE_96543532-ea86-4dc4-a62e-2930fa82b7c2">4,096</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Loan facility derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjctMS0xLTEtMzQ0MDE_f1c196fb-105a-46d8-8831-7460f1790e21">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjctMy0xLTEtMzQ0MDE_02572d38-4bae-4c07-8c9e-82be138a772d">1,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjktMS0xLTEtMzQ0MDE_6aae964f-0455-4462-8953-c6c161d130f3">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjktMy0xLTEtMzQ0MDE_e2939165-3eb1-44dc-8c80-82ac0a155fa5">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzAtMS0xLTEtMzQ0MDE_e01913e7-b75b-4dac-b4db-fcf14b69d2c9">68,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzAtMy0xLTEtMzQ0MDE_79aa965a-5fea-497d-a4a6-aa2fe15884d9">65,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commitments and contingencies (see Note 9)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzEtMS0xLTEtNDU3NjI_e5b5b907-a415-4ea8-bdc9-f3ec8a506a36"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzEtMy0xLTEtNDU3NjI_760f32cb-9f4e-46e3-bfd0-330117354b9a"></ix:nonFraction></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock issuable in series, $<ix:nonFraction unitRef="usdPerShare" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzItMC0xLTEtMzQ3MTEvdGV4dHJlZ2lvbjpjMWIyZWM2MGVhY2Q0YTdiYjMxM2Q1YWVhNmRhOTBjZl8xNjQ5MjY3NDQxNzU0_12946eaa-339f-4e3a-b0ca-018e6a09b821"><ix:nonFraction unitRef="usdPerShare" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" name="us-gaap:TemporaryEquityParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzItMC0xLTEtMzQ3MTEvdGV4dHJlZ2lvbjpjMWIyZWM2MGVhY2Q0YTdiYjMxM2Q1YWVhNmRhOTBjZl8xNjQ5MjY3NDQxNzU0_7b4ba982-460e-4bd5-86ca-71feec0b24f2">0.00001</ix:nonFraction></ix:nonFraction> par value;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized shares: <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzMtMC0xLTEtMzQ3MjQvdGV4dHJlZ2lvbjphZjJhOWM1MjgxYjM0ZDA0ODFlMTlhZjVkZjYyZGUzZl80Mzk4MDQ2NTExMzAz_f322ee1c-1cce-4213-a0f8-a2b8dc6d72f9">none</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzMtMC0xLTEtMzQ3MjQvdGV4dHJlZ2lvbjphZjJhOWM1MjgxYjM0ZDA0ODFlMTlhZjVkZjYyZGUzZl80Mzk4MDQ2NTExMzY1_cb80277f-0606-41d0-b3b7-e62fbdb67df4">26,984</ix:nonFraction>, at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issued and outstanding shares: <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzQtMC0xLTEtMzQ3NDQvdGV4dHJlZ2lvbjo0YWVhMzUzNzRmMjM0MDk1YTA3OTJjMmVhYTVkY2M0Ml8xNjQ5MjY3NDQxODIz_86bd8a12-5b04-422c-88e4-25c671c526f5"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzQtMC0xLTEtMzQ3NDQvdGV4dHJlZ2lvbjo0YWVhMzUzNzRmMjM0MDk1YTA3OTJjMmVhYTVkY2M0Ml8xNjQ5MjY3NDQxODIz_e6ac6332-049d-49d2-a6cc-f0b7480c165a">none</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzQtMC0xLTEtMzQ3NDQvdGV4dHJlZ2lvbjo0YWVhMzUzNzRmMjM0MDk1YTA3OTJjMmVhYTVkY2M0Ml80Mzk4MDQ2NTExMzY1_5cc24912-593b-44d3-b793-4de40152a91f"><ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzQtMC0xLTEtMzQ3NDQvdGV4dHJlZ2lvbjo0YWVhMzUzNzRmMjM0MDk1YTA3OTJjMmVhYTVkY2M0Ml80Mzk4MDQ2NTExMzY1_c3e5de88-55cb-4cbd-805f-9917e72343c3">25,402</ix:nonFraction></ix:nonFraction> at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Aggregate liquidation preference: <ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt-sec:numwordsen" name="us-gaap:TemporaryEquityLiquidationPreference" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzUtMC0xLTEtMzQ3NjQvdGV4dHJlZ2lvbjpjY2Q2Y2QwZGMzMjU0NjA5OGMyODNmODZhYTJjMDZiNF8xNjQ5MjY3NDQxODM4_b6b0cdd2-b8fe-4be0-a871-e8a02fca2f37">none</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityLiquidationPreference" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzUtMC0xLTEtMzQ3NjQvdGV4dHJlZ2lvbjpjY2Q2Y2QwZGMzMjU0NjA5OGMyODNmODZhYTJjMDZiNF80Mzk4MDQ2NTExMzgx_fb017473-6452-47a4-bb73-d5beb63da16a">245,768</ix:nonFraction> at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzUtMS0xLTEtMzQ0MDE_bd11dcf9-04f4-4387-adcd-5ccc0ff425b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzUtMy0xLTEtMzQ0MDE_fa4aa41d-52a6-4c6e-b878-6bc82a7bc118">243,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzctMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjozN2VjMTE0MGI1NmM0NjQyOWNlNWQ3ODVjNmFlOTY0MV80Mzk4MDQ2NTExMTUy_4d2b24ad-4741-4eff-abd3-4c82e5572b79"><ix:nonFraction unitRef="usdPerShare" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzctMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjozN2VjMTE0MGI1NmM0NjQyOWNlNWQ3ODVjNmFlOTY0MV80Mzk4MDQ2NTExMTUy_725af891-d516-44e6-aa51-1f8bfdb31e27">0.00001</ix:nonFraction></ix:nonFraction> par value;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized shares: <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzgtMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZWZkZjE3M2E1N2M0YmEyOGZjYTA3MjNkOTU1N2JiMV80Mzk4MDQ2NTExMjQ1_cd7ff86a-383d-4322-af74-362f0bd92c63">10,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzgtMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZWZkZjE3M2E1N2M0YmEyOGZjYTA3MjNkOTU1N2JiMV80Mzk4MDQ2NTExMjQx_22d6d281-3941-4026-a6f1-18a28b219ef6">none</ix:nonFraction> at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issued and outstanding shares: <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZjM4MWQ2MWI2NWU0MzI3OTQyODgzYjNjYjg3ZGNjOV80Mzk4MDQ2NTExMjQz_4523a8fa-ebb1-4d28-a296-4c34268815df"><ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZjM4MWQ2MWI2NWU0MzI3OTQyODgzYjNjYjg3ZGNjOV80Mzk4MDQ2NTExMjQz_574ddbf2-b45b-4008-828b-3a9839bd12ac"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZjM4MWQ2MWI2NWU0MzI3OTQyODgzYjNjYjg3ZGNjOV80Mzk4MDQ2NTExMjQz_6f53e6e3-4612-441c-aa51-e5b57162c1b6"><ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZjM4MWQ2MWI2NWU0MzI3OTQyODgzYjNjYjg3ZGNjOV80Mzk4MDQ2NTExMjQz_d96068cf-edc1-40e7-8d4e-da62de8b1910">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> at September&#160;30, 2021 and December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMS0xLTEtNDA0NTg_c90246e6-d251-46b5-b663-96a2800bdcfb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:PreferredStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMy0xLTEtNDA0NjU_b3213796-e625-4b46-87f1-b2eeef5fa783">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzctMC0xLTEtMzQ3ODIvdGV4dHJlZ2lvbjoxYTc0N2JiMjEyYTQ0MjExYjkwMjI0MzMzMWQwZDQ2Zl8xNjQ5MjY3NDQxNzA5_348b0320-4f5e-4c6a-bff8-6c7f74140145"><ix:nonFraction unitRef="usdPerShare" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzctMC0xLTEtMzQ3ODIvdGV4dHJlZ2lvbjoxYTc0N2JiMjEyYTQ0MjExYjkwMjI0MzMzMWQwZDQ2Zl8xNjQ5MjY3NDQxNzA5_99bbc897-d54a-4367-835f-273b8b15f947">0.00001</ix:nonFraction></ix:nonFraction> par value;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Authorized shares: <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzgtMC0xLTEtMzQ3ODgvdGV4dHJlZ2lvbjoxNTk2NzU3MjA0YTE0MmY3OGJkOThkYTYxNzJhYzhjYl8xNjQ5MjY3NDQxODA3_d0182880-efb3-4207-9046-c25b069a6b62">300,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzgtMC0xLTEtMzQ3ODgvdGV4dHJlZ2lvbjoxNTk2NzU3MjA0YTE0MmY3OGJkOThkYTYxNzJhYzhjYl80Mzk4MDQ2NTExMzA3_1756c1c7-5c74-44c6-af30-87178d69a985">40,000</ix:nonFraction> at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issued and outstanding shares: <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzQ4MDYvdGV4dHJlZ2lvbjpjNmRmNjIzNzBlNzA0ZDE3YmQ4Y2M5ZTEwODJlMWY1ZV8xNjQ5MjY3NDQxODEz_08bdbf17-42ee-4294-b1ff-6571aa8110f1"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzQ4MDYvdGV4dHJlZ2lvbjpjNmRmNjIzNzBlNzA0ZDE3YmQ4Y2M5ZTEwODJlMWY1ZV8xNjQ5MjY3NDQxODEz_59a8b1b0-8706-4a12-96b4-6259ec3bfe55">43,472</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzQ4MDYvdGV4dHJlZ2lvbjpjNmRmNjIzNzBlNzA0ZDE3YmQ4Y2M5ZTEwODJlMWY1ZV80Mzk4MDQ2NTExMzEz_820d4324-1a64-41cb-a1b8-2a9b558cfcb8"><ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzQ4MDYvdGV4dHJlZ2lvbjpjNmRmNjIzNzBlNzA0ZDE3YmQ4Y2M5ZTEwODJlMWY1ZV80Mzk4MDQ2NTExMzEz_ac325c52-46d4-4e3e-be15-bc8761e6af7b">4,713</ix:nonFraction></ix:nonFraction> at September&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMS0xLTEtMzQ0MDE_cb2a9be9-0f45-404e-9506-3aac75421dae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CommonStockValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMy0xLTEtMzQ0MDE_d19b26d2-4944-43a3-be4c-839802d385fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDAtMS0xLTEtMzQ0MDE_8000b5d2-b532-429e-a2c9-ba422308f798">526,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDAtMy0xLTEtMzQ0MDE_c8b4b9f7-ee86-4c1a-b152-8cc90789f6fa">18,788</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDEtMS0xLTEtMzQ0MDE_4f739b7d-d551-4c8e-931f-3c6d2344cb14">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDEtMy0xLTEtMzQ0MDE_5a98b309-a8e3-48aa-a15d-8deefc813825">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDItMS0xLTEtMzQ0MDE_45a42ddc-c6bd-4e4c-b9dd-288d29dfdf15">243,173</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDItMy0xLTEtMzQ0MDE_7c1c6862-b6a2-4218-a661-9478a8c19042">201,668</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity (deficit)</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDMtMS0xLTEtMzQ0MDE_11488a60-f4f8-4bf4-9387-b3155151a0a4">283,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDMtMy0xLTEtMzQ0MDE_bc6025d8-4df2-4c4f-86bb-36a40f035391">182,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total liabilities, convertible redeemable preferred stock and stockholders&#8217; equity (deficit)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDQtMS0xLTEtMzQ0MDE_8615aaec-764f-4d8d-a8af-99e1f74c44cf">351,463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDQtMy0xLTEtMzQ0MDE_75961915-6bcd-4a67-b147-ff725f9fbc74">125,971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements. </span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROCEPT BioRobotics Corporation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share data)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMy0xLTEtMS0zNDQwMQ_d7eeb5d2-c886-452c-b524-887af7ca1d8b">8,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMy0zLTEtMS0zNDQwMQ_bdf111e3-d10f-458e-86a2-bd5ce0693954">2,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMy01LTEtMS0zNDQwMQ_93c6adbf-5e9b-4779-8ab0-fd6d22d05b2c">24,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMy03LTEtMS0zNDQwMQ_cd570f52-7478-4d53-a1ef-9143d0510660">4,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNC0xLTEtMS0zNDQwMQ_b67d3829-42aa-43ae-99aa-535e1736f960">4,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNC0zLTEtMS0zNDQwMQ_a6866d21-be98-4adc-a291-14bbf50bd10d">2,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNC01LTEtMS0zNDQwMQ_f0a29716-e453-4dfb-a90b-4f521fe29e14">12,986</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CostOfRevenue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNC03LTEtMS0zNDQwMQ_3b6007bf-9241-44d3-ab36-8635782b6e66">6,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNS0xLTEtMS0zNDQwMQ_330662ff-d93d-4823-8ad8-67e2aec852d8">4,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNS0zLTEtMS0zNDQwMQ_ac669d33-b89d-4137-9555-d94bd5b5a8d7">31</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNS01LTEtMS0zNDQwMQ_fad64024-ffaa-44b0-8abe-9f5106f70e87">11,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:GrossProfit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNS03LTEtMS0zNDQwMQ_1d344113-8387-4a68-8ffb-07550df174de">1,725</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNy0xLTEtMS0zNDQwMQ_6eb8bece-860f-4839-84b0-0254834eb1d0">4,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNy0zLTEtMS0zNDQwMQ_aadecadd-3532-42c5-8322-822a16758640">3,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNy01LTEtMS0zNDQwMQ_b94f69b9-47a1-4d0a-b145-b631f2a56992">13,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNy03LTEtMS0zNDQwMQ_0b0ed51f-8841-43a5-893b-3e2e01804d5b">11,732</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOC0xLTEtMS0zNDQwMQ_99e798ba-d1d1-4ea9-b9fc-bb80f68085e5">12,118</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOC0zLTEtMS0zNDQwMQ_da07a493-fd8d-4492-a5dc-98a13bb171d9">7,054</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOC01LTEtMS0zNDQwMQ_0f4b4764-6580-4c69-b6f7-ff132b7cb727">34,765</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOC03LTEtMS0zNDQwMQ_74beeb2f-e036-45cf-9c93-0d80214127fd">21,138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOS0xLTEtMS0zNDQwMQ_52749bd2-7da3-4cdb-a94f-ddd37b0725e2">17,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOS0zLTEtMS0zNDQwMQ_ab8c2e0b-139f-46d2-ad67-e8e1b36aed3a">10,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOS01LTEtMS0zNDQwMQ_67130da0-2d01-447f-a281-352afdf64272">48,682</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOS03LTEtMS0zNDQwMQ_119300b4-092b-4b5e-933b-b54d1fedaabd">32,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTAtMS0xLTEtMzQ0MDE_2c8907c7-b6f2-427b-ab49-b9900d426eeb">12,797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTAtMy0xLTEtMzQ0MDE_dffb1b56-8c17-4fa9-8e52-70b75723b271">10,978</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTAtNS0xLTEtMzQ0MDE_b2b8fe73-1c6e-4fbd-ad0d-ccfda90a0aba">37,333</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTAtNy0xLTEtMzQ0MDE_bad8ca60-7c21-4fff-8fac-8e4b2a907898">34,595</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTEtMS0xLTEtMzQ0MDE_2138e7ce-a2c6-4b4c-a1c7-43591151552b">1,469</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTEtMy0xLTEtMzQ0MDE_dd4272fe-f36a-45fa-bb0d-fc9c1fbf1a86">1,387</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTEtNS0xLTEtMzQ0MDE_6344a636-7df9-40a7-917e-2affe86d27f4">4,370</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTEtNy0xLTEtMzQ0MDE_a0765539-ea92-44b0-9ad6-f770946a6953">3,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" name="prct:InterestAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTItMS0xLTEtMzQ0MDE_6c358b60-8391-4806-86b1-62f51ff48011">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" name="prct:InterestAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTItMy0xLTEtMzQ0MDE_9424f5a1-c84d-4423-8554-7b52dea357ba">357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="prct:InterestAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTItNS0xLTEtMzQ0MDE_d3f842ed-48be-4e1f-bda0-c8c50a30d0be">198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="prct:InterestAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTItNy0xLTEtMzQ0MDE_8b0e921a-363d-4675-9865-c9687ffffc1d">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTMtMS0xLTEtMzQ0MDE_52b988ed-3aa7-4c4a-b9b9-828f1afadd70">14,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTMtMy0xLTEtMzQ0MDE_d34dfd23-ddac-414e-9b53-77bb8855fa8b">12,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTMtNS0xLTEtMzQ0MDE_a7890653-1663-4818-895b-a4e512f01b2d">41,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTMtNy0xLTEtMzQ0MDE_92b9556d-19cf-4621-932c-d0f3e4bc92ee">37,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtMS0xLTEtMzQ0MDE_8fe0f799-6fa4-43cd-b015-8360b9964bee"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtMS0xLTEtMzQ0MDE_941952fe-661c-4237-bfa9-b213cca81c56">1.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtMy0xLTEtMzQ0MDE_2ab8dbe6-cc32-41e0-a43c-700c2497a9a2"><ix:nonFraction unitRef="usdPerShare" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtMy0xLTEtMzQ0MDE_4c1f0129-c4f5-4f1c-a347-622e7cbbda24">2.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtNS0xLTEtMzQ0MDE_17bfa606-6c1e-4184-af2f-6dff56b54421"><ix:nonFraction unitRef="usdPerShare" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtNS0xLTEtMzQ0MDE_d4b5f550-3859-4113-a089-cb096d5494e5">5.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtNy0xLTEtMzQ0MDE_3168c2ef-ba15-41bc-8b1d-dfadab88ceb4"><ix:nonFraction unitRef="usdPerShare" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtNy0xLTEtMzQ0MDE_f8fb25f1-2482-4196-adaa-e2c33cc36a5e">11.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares used to</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">compute net loss per share attributable to</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">common shareholders, basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctMS0xLTEtMzQ0MDE_3c9e6119-1713-4948-81e7-789cd8986ace"><ix:nonFraction unitRef="shares" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctMS0xLTEtMzQ0MDE_a9ff3ed0-39b1-450a-8602-6402be635e40">11,580</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctMy0xLTEtMzQ0MDE_5bedbb54-fb28-4c85-93dc-8d04a754f7eb"><ix:nonFraction unitRef="shares" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctMy0xLTEtMzQ0MDE_90622652-1bf9-436a-8e70-2effe0a6ebd5">4,329</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctNS0xLTEtMzQ0MDE_1e87593b-4d1e-48fe-a0f0-74c81b935bf2"><ix:nonFraction unitRef="shares" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctNS0xLTEtMzQ0MDE_a55aad25-9676-41ec-96e5-921b64619070">7,361</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctNy0xLTEtMzQ0MDE_5660c2e0-c25f-41fb-a33f-c6fe7c9e7de4"><ix:nonFraction unitRef="shares" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="0" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctNy0xLTEtMzQ0MDE_61ad7dbe-f8c9-4296-b37e-a1c01be2738f">3,327</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized (loss) gain on cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTktMS0xLTEtMzQ0MDE_f16594ab-c52d-449f-8504-6496fde4e332">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTktMy0xLTEtMzQ0MDE_146f29a4-5b00-439a-b1d4-b0d01f747b0d">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTktNS0xLTEtMzQ0MDE_688fdc19-7593-41a6-81d2-fd813453af96">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTktNy0xLTEtMzQ0MDE_01177d9e-8dfe-4b0b-9241-63c95347e75c">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMjAtMS0xLTEtMzQ0MDE_16193f2f-7eca-4e4a-8327-edc43bb870c1">14,105</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMjAtMy0xLTEtMzQ0MDE_bb4e2d63-f885-4a6e-9670-450f641d90d7">12,024</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMjAtNS0xLTEtMzQ0MDE_cd298a40-da03-4119-96ef-61e9af1dc1f9">41,532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMjAtNy0xLTEtMzQ0MDE_4b6bec44-e75e-4498-901c-d6a766bdc417">37,738</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROCEPT BioRobotics Corporation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#8217; EQUITY (DEFICIT) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)  </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)  </span></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.129%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable<br/>Convertible<br/>Preferred Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Deficit</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMS0xLTEtMzQ0MDE_edf82d8b-c93b-4ef1-bf3c-b4dd3df7a8b1">25,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMy0xLTEtMzQ0MDE_3873a59f-74a1-49b9-974a-f0a228f200fe">243,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i01918d59a04b4c499b05ee2466db1b59_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtNi0xLTEtMzQ0MDE_2928052b-5cc6-4cf3-865d-57618967c48e">4,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01918d59a04b4c499b05ee2466db1b59_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtOC0xLTEtMzQ0MDE_58d59aff-22a6-40ae-be04-4c95ba7f1ff4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i100c23f92bda49a28c0877949b1a0fbd_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMTAtMS0xLTM0NDAx_276ed026-7cfc-4565-a1e8-fbd2fe3eda90">18,788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia55a781d4fc84f41a41fcb23206c4b8c_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMTItMS0xLTM0NDAx_0a1a293f-425c-4c32-b28e-f543874df4ad">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i565b2c3bc8fb41c3b592ad68c4361808_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMTQtMS0xLTM0NDAx_2f9c959e-6b6d-4116-ab0f-075a5954942f">201,668</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMTYtMS0xLTM0NDAx_78616af4-9e63-41a3-86a3-aedd60e40f5d">182,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance upon exercise of options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69c82465ba6d48e6b9185da02a84e2b4_D20210101-20210331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTgtNi0xLTEtMzQ0MDE_e3a84567-3af1-4243-bca0-37f0d7dbdf73">504</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7eb6a1e27a14c97a0ea1c2cf23a8098_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTgtMTAtMS0xLTM0NDAx_0bd22731-74d3-4dbc-88ab-f1ae9047bdc5">1,225</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c187172a454793b7a939d7e48946ac_D20210101-20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTgtMTYtMS0xLTM0NDAx_aa26e72d-bd1e-49f8-a2c1-b7548be70045">1,225</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7eb6a1e27a14c97a0ea1c2cf23a8098_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTktMTAtMS0xLTM0NDAx_980733ad-b353-4dc8-aea9-f6d627a87ccf">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49c187172a454793b7a939d7e48946ac_D20210101-20210331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTktMTYtMS0xLTM0NDAx_f3f32eb9-bcc9-4a65-8380-bc4b53752325">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35f6cea14ac0417b98a3dd1cea4a266d_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjAtMTItMS0xLTM0NDAx_ad4db523-20d3-4a84-bf6a-7c31ebd6f858">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c187172a454793b7a939d7e48946ac_D20210101-20210331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjAtMTYtMS0xLTM0NDAx_ffaafde8-6b71-48a9-8606-2ebb838114d5">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4658dd5cdc744b40a5f591e4cd3f85e0_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjEtMTQtMS0xLTM0NDAx_3e5a0642-2c51-4c01-a1a4-3f149e0b81db">12,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49c187172a454793b7a939d7e48946ac_D20210101-20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjEtMTYtMS0xLTM0NDAx_f3ded4f5-44c3-4e65-92f0-f068c4ad132b">12,822</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6d5816a787b74534b5f25f18a706ccf0_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMS0xLTEtNDQ1ODg_106498dd-8865-49f5-b989-b53821379316">25,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d5816a787b74534b5f25f18a706ccf0_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMy0xLTEtNDQ2MDQ_de8dc772-ec6f-47f9-80b1-e429013a2f68">243,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2cb5f33c9274d0097af2dc64d06de5c_I20210331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtNi0xLTEtNDQ2MjY_e0f41428-9358-4cfb-a422-ba8ac151534f">5,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2cb5f33c9274d0097af2dc64d06de5c_I20210331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtOC0xLTEtNDQ2Mzg_5f003a5f-7b85-4970-8828-f9eff9eebbec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6de1f8c86cea46dc902859f13d99afc9_I20210331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMTAtMS0xLTQ0NjUw_f0c29b77-5d59-4788-b17d-07e695e00c48">20,663</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2eec3bd752b2481d9dc300830ea16b5f_I20210331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMTItMS0xLTQ0NjYx_38268d92-e388-4974-9c70-98916eacccae">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9403ca6a5054b1f88c93a222d45cd64_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMTQtMS0xLTQ0Njcy_ae6ab071-14e8-4d26-b4ab-26cca5b493ae">214,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d5816a787b74534b5f25f18a706ccf0_I20210331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMTYtMS0xLTQ0Njgz_68fe633f-37e2-4e4e-8c3a-7f58891e6b23">193,857</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of redeemable convertible preferred stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i2e13c67478f6478e8541be8a44bb1f4c_D20210601-20210630" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjctMC0xLTEtNDU4NjAvdGV4dHJlZ2lvbjowYzVkNTg0ZjYyNzA0Y2YyOTI2N2IyMDUxMTVmZjc5M180Mzk4MDQ2NTExMTg5_f0f8cdcb-2f7c-4fad-9fee-7cfe6406e2be">290</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjYtMS0xLTEtNDQ1ODg_41385773-e50c-4a7a-b9b4-e8abe139424c">4,448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjYtMy0xLTEtNDQ2MDQ_7c2541e5-0774-49d0-952c-9e9e19ffc458">84,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i802e7d5b07ff4ca5b8093189adc87bb0_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjgtNi0xLTEtNDQ2MjY_0503dd26-df9e-474f-844c-1d77340e010a">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3cb976587c4b1d83bc6098c98b5efe_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjgtMTAtMS0xLTQ0NjUw_13622901-f59c-4296-b735-9b88723a5d70">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjgtMTYtMS0xLTQ0Njgz_d8aa4fe2-5b4f-42f7-a914-0c390ac9e751">1,415</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3cb976587c4b1d83bc6098c98b5efe_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjktMTAtMS0xLTQ0NjUw_5bde4faa-c2b1-431c-a28e-75f530694abb">725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjktMTYtMS0xLTQ0Njgz_fba6d21a-a166-47b3-97ea-6fcaa1c72bdc">725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72403aeb9eb44de7b079046542387a2e_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzAtMTItMS0xLTQ0NjYx_850e5f7f-222c-41ed-833a-3a212ac05bc3">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzAtMTYtMS0xLTQ0Njgz_f16bee4d-59d3-4dd5-a049-2d7c53aeb125">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie60a74e01b9041ce961b1963ccfbf1d1_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzEtMTQtMS0xLTQ0Njcy_24592525-5a11-4515-ad14-a92663dc7947">14,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzEtMTYtMS0xLTQ0Njgz_0a0faa08-bcaf-442f-b55a-f563475ea0aa">14,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0047bc2007a74490b97d13e8976d3dbf_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMS0xLTEtNDQ1ODg_34137368-47b6-432f-8661-808e97465e03">29,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0047bc2007a74490b97d13e8976d3dbf_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMy0xLTEtNDQ2MDQ_cb5bbe6d-5aa7-4c39-a7cb-c4e0b98acb7b">328,564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e1bb70ea6094ea29f8dc5001a1cdf43_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItNi0xLTEtNDQ2MjY_98456088-4702-4786-8e53-0a3284c0f62f">5,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e1bb70ea6094ea29f8dc5001a1cdf43_I20210630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItOC0xLTEtNDQ2Mzg_ea6fa476-adc8-4a4e-832c-cf827136a17a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaacff7f78ad74cae9c3705649ac848a3_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTAtMS0xLTQ0NjUw_a2506d10-eb5a-49e4-a552-1b0cac0f222f">22,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i529b692fd02c440cb93775020fee3392_I20210630" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTItMS0xLTQ0NjYx_17d0aa7d-b5ad-4d85-8fa4-c01e3dc9055a">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i655db423d80146ba9a5fc4791da055de_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTQtMS0xLTQ0Njcy_f8861ee7-f767-428f-995c-d0f00a701a49">229,070</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0047bc2007a74490b97d13e8976d3dbf_I20210630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTYtMS0xLTQ0Njgz_509ecc53-d001-45de-a0c7-0ca9b07a359c">206,306</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMS0xLTEtNDQ1ODg_f60aa7f5-ceef-4a2b-a3ab-a32fc90305e4">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" name="prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMy0xLTEtNDQ2MDQ_15327acd-e580-4729-92ce-514379c750b8">970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="prct:TemporaryEquitySharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMS0xLTEtNDQ4NzQ_c20bdcbc-052c-4356-b847-6fd610345e2a">29,912</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="prct:TemporaryEquityAmountConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMy0xLTEtNDQ4ODE_2e5e63a8-fc81-4fe3-b7dc-54fb68ba899a">329,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2578d1ae003e4df39157ff0cedef50d3_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctNi0xLTEtNDQ4ODg_356f6373-fd52-41c6-9e63-11b9c7934ca6">29,912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTAtMS0xLTQ0OTAy_9ca9ccb7-f936-4b97-b817-376e131e21d6">329,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTYtMS0xLTQ0OTIz_1d120d26-e481-4a35-8cf2-4ee330365ffd">329,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock upon initial public offering, net of underwriting discounts, commissions and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzgtMC0xLTEtNDU5NTYvdGV4dHJlZ2lvbjo2M2UyZDcyZmVhMjc0ODU4YTcwMDRlNzMxNGUxZGMxYV80Mzk4MDQ2NTExMTk1_bd494c4d-94d2-44c4-b85e-a031e36d6fdd">16,076</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2578d1ae003e4df39157ff0cedef50d3_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzUtNi0xLTEtNDQ2MjY_ad2e379b-0e0b-4813-b0bc-2a7b312d8bd0">7,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzUtMTAtMS0xLTQ0NjUw_da87cd9d-3878-4818-804c-17ccb223dfd2">172,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzUtMTYtMS0xLTQ0Njgz_34f72f0a-414a-422f-b539-ce266c7bce11">172,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2578d1ae003e4df39157ff0cedef50d3_D20210701-20210930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzYtNi0xLTEtNDQ2MjY_e376e369-2ba2-4112-969e-072df6f26fed">229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzYtMTAtMS0xLTQ0NjUw_059f2dff-bf41-4413-9500-5a5909663d01">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzYtMTYtMS0xLTQ0Njgz_f4bce0a3-e60d-4ca7-a356-4cd6e3920034">855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTAtMS0xLTQ0NjUw_e121fa5b-a0c5-4959-9f1b-3e345b747377">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTYtMS0xLTQ0Njgz_7309ddb6-202e-4dc6-9b12-a5eb1e0ee7c7">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icad0956d1fac424f955531bf976553b6_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzgtMTItMS0xLTQ0NjYx_28d44b0d-4b94-4516-868e-1b1dccbfe97d">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzgtMTYtMS0xLTQ0Njgz_e2a546cf-6649-4956-9621-5bece43c8d2d">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad55634ed8394953ba4771879c737291_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzktMTQtMS0xLTQ0Njcy_89a21618-9f88-4f4a-bdf9-9bc7894750e5">14,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzktMTYtMS0xLTQ0Njgz_4430ddfe-cbba-4664-82f0-ce7e427edfe4">14,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMS0xLTEtMzQ0MDE_a7fabd60-e6a1-4862-9732-36c7121c5aea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMy0xLTEtMzQ0MDE_e8f17828-77d5-44b6-b159-d5b2f967cbec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i77e0b2f826e241698ef40dc6384a75c7_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItNi0xLTEtMzQ0MDE_53d094d7-3f1e-41a0-8c8c-408edfa2f822">43,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77e0b2f826e241698ef40dc6384a75c7_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItOC0xLTEtMzQ0MDE_09b64c74-0c1f-4560-bdab-40687db523ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f72d70743b3499b96f9d263ba7b8823_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMTAtMS0xLTM0NDAx_83b0d7e1-c657-4dc3-804e-7f2c7c5d0d2d">526,526</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia092c91a3f084cdcbfb9a7581c7384e8_I20210930" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMTItMS0xLTM0NDAx_1d95778c-6818-4171-9af7-2a3506326c1a">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2962c8287fb9466283c88ab19620b70a_I20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMTQtMS0xLTM0NDAx_55c9a452-fbf6-412d-aec1-918d9dc763d4">243,173</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMTYtMS0xLTM0NDAx_d3ef1d2a-c54a-4250-a927-fded96b9cc81">283,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.705%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.129%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable<br/>Convertible<br/>Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders'<br/>Deficit</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa21a99062154fbdb875876427776118_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMS0xLTEtMzQ0MDE_d6b1c240-9799-4053-92c9-ec16b1072c25">20,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa21a99062154fbdb875876427776118_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMy0xLTEtMzQ0MDE_94ae636d-f815-4933-8fda-93aba9cea16c">173,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bba4b69cf534b07bff7fadc5c5880e1_I20191231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtNi0xLTEtMzQ0MDE_8502530a-969d-4363-82c2-d7b6d9fee288">2,290</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bba4b69cf534b07bff7fadc5c5880e1_I20191231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtOC0xLTEtMzQ0MDE_02ac711e-8063-4d24-9139-cbede02a2c29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i350149917e7c4dad952ac65149521110_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMTAtMS0xLTM0NDAx_f0827d90-5a01-4e0a-8872-76568fcc2dd5">4,808</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfd71f7a814d4c54bda649dd20cbfc19_I20191231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMTItMS0xLTM0NDAx_e0300ebf-ca17-4b0e-9bae-f156220dbeba">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i63de44b1b5764b5484ed75a0180e0f06_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMTQtMS0xLTM0NDAx_1fd80342-ee16-49fd-a7b6-10a52125ef4a">148,649</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa21a99062154fbdb875876427776118_I20191231" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMTYtMS0xLTM0NDAx_678e6127-dbb8-48fa-9f31-a52b413cb761">143,837</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331" decimals="-3" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjctMS0xLTEtMzQ0MDE_127bd6c4-72bc-44a2-b7f6-0f101c53eee1">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331" decimals="-3" name="prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjctMy0xLTEtMzQ0MDE_6e5308c4-4db8-441c-ae25-fa0a0ca9e824">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if86cc355897b4827abd740147e1208da_D20200101-20200331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjktNi0xLTEtMzQ0MDE_745a8c63-91a8-4fcf-a09f-2a63ff479853">602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c4f5ac282a46bfb9afbc186bba95e2_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjktMTAtMS0xLTM0NDAx_5296e94f-c93b-4fb2-a9d0-2067096a813c">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjktMTYtMS0xLTM0NDAx_900b3457-a633-4dfb-beaa-666afe89a633">1,024</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8c4f5ac282a46bfb9afbc186bba95e2_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzAtMTAtMS0xLTM0NDAx_3f33334d-32b6-4d36-b7cf-12dc2852e3cf">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzAtMTYtMS0xLTM0NDAx_533dc9cd-5a2b-47f8-b308-a128e0c6c7f2">561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i207a558e6bf54b419ced15aa4da0802b_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzEtMTItMS0xLTM0NDAx_6569451f-1af3-491d-aea9-5713272df587">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzEtMTYtMS0xLTM0NDAx_35977e41-f120-497e-beac-f307cb7c6f97">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee7a556f8ed44411b236ac803a34efa5_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTQtMS0xLTM0NDAx_5127308d-6dd8-4538-a578-fd6ee35a3fd2">13,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTYtMS0xLTM0NDAx_ff1b2071-86ac-489a-9a37-e99ef1294f84">13,126</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ba09fbe2d8e41ae91b530bd0fd4aabf_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMS0xLTEtNDE1MTM_73f800f9-7d05-4531-b7cc-6c464c1c139f">21,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba09fbe2d8e41ae91b530bd0fd4aabf_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMy0xLTEtNDE1NDU_67bc49c9-5200-4e13-939f-8d93488725b4">173,447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28789e1867f6489181082ded2abe46bd_I20200331" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtNi0xLTEtNDE1NTY_b718d985-1dc2-491e-83d1-009b0a47e49d">2,892</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28789e1867f6489181082ded2abe46bd_I20200331" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtOC0xLTEtNDE1NjQ_3d9f8049-526f-49ab-9089-5d0f7feecf48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47808217616c42a1bde3b298ba31d9ec_I20200331" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTAtMS0xLTQxNTc4_9414a443-9e7d-44c5-88e3-38fcd5ca74fa">6,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if3221c2435d1479a8c4fbc3f096a5d50_I20200331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTItMS0xLTQxNTky_8b1c29c4-c663-4ca8-899f-686fb3f3fa0f">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b07359bb1524f11b21ca2e21f932d05_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTQtMS0xLTQxNjA2_94814cf2-5306-4c17-a930-53db2b694047">161,775</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ba09fbe2d8e41ae91b530bd0fd4aabf_I20200331" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTYtMS0xLTQxNjIw_f5f88240-de9c-4f0e-9afa-267481640d9d">155,385</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance upon exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630" decimals="-3" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzUtMS0xLTEtNDE1MzE_f22edc9a-06f5-4e4a-a6b9-603888b94b49">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630" decimals="-3" name="prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzUtMy0xLTEtNDE1NDU_9c6999b0-47f3-46ac-b001-6d2d95010897">230</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9dc6976f7625478f8a1e700402e190e8_D20200401-20200630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctNi0xLTEtNDE1NTY_1614e504-88b2-462b-9213-a732b33fbdf9">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a299a91bc0478bbe2f8a0bce7ff85b_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTAtMS0xLTQxNTc4_63643435-6427-4802-b8a9-5ebcd58dc2ee">979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTYtMS0xLTQxNjIw_7af5395b-7997-4576-b2f0-e968db6392b1">979</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83a299a91bc0478bbe2f8a0bce7ff85b_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzgtMTAtMS0xLTQxNTc4_cd0bfbf3-2995-4dcf-8884-ec560115d981">445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzgtMTYtMS0xLTQxNjIw_bd99faa9-0471-41f9-9dc8-c1d9fa8f0fdf">445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74d430c7456149008291631a41455fb6_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzktMTItMS0xLTQxNTky_133b0d2d-4ac7-4b2d-bba5-9913e5606d8e">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzktMTYtMS0xLTQxNjIw_c6e1873e-fce3-454f-b8bf-89ac7b071de9">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0c1cb22a76846d88fe33bc3ec293fe5_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDAtMTQtMS0xLTQxNjA2_5f59491e-cd1c-45cb-8b3a-d35cde539839">12,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDAtMTYtMS0xLTQxNjIw_b9c5217b-d3f1-4c55-8518-88536fd5851e">12,606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibb23ec3142464357adefd10788d9dc21_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMS0xLTEtNDE1MzE_45e6ff51-0a7f-4d2b-913f-0555186c229a">21,118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb23ec3142464357adefd10788d9dc21_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMy0xLTEtNDE1NDU_bbc1acab-a1b2-4fbe-b423-6ec987b8fc58">173,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3a5d7ddae2bf4b4c9ff977f94e8bf4df_I20200630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtNi0xLTEtNDE1NTY_3cd66d82-2c7a-47de-9c34-441fda5d6d8b">3,110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a5d7ddae2bf4b4c9ff977f94e8bf4df_I20200630" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtOC0xLTEtNDE1NjQ_9e78ad0b-e406-473f-87b8-2d36b917cf06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43a77154c7e44d6c916d662730d39095_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMTAtMS0xLTQxNTc4_7b80d588-7472-4340-8fd4-49f083e3af97">7,817</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c72799a37ef4b6996ae6377297e5d8b_I20200630" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMTItMS0xLTQxNTky_78792078-5424-4542-b8d8-5b58de28c011">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i406bac8d8e3c42e8ba906eba2383e727_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMTQtMS0xLTQxNjA2_27cdd6a9-b10e-44b9-9dc8-5b9678ca6a02">174,381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibb23ec3142464357adefd10788d9dc21_I20200630" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMTYtMS0xLTQxNjIw_c1facf88-803a-4d3b-ae22-ffd489467b8f">166,541</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Conversion of redeemable convertible preferred stock to common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="prct:TemporaryEquitySharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDItMS0xLTEtNDE1MzE_d6bb6319-d7b3-440f-a31b-410aa4af595a">1,474</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="prct:TemporaryEquityAmountConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDItMy0xLTEtNDE1NDU_e1b64536-0041-454c-ac0e-a138fda7315f">9,520</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82411be0df684d5999a14b0a6ad94e9a_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDItNi0xLTEtNDE1NTY_18713bbd-0e2e-4d08-bced-85535f4ccdc0">1,474</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402b4853a118490284a4c268556e6aa9_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDItMTAtMS0xLTQxNTc4_6b69af9c-3f44-4e55-809d-a7dbcd8d4b0f">9,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDItMTYtMS0xLTQxNjIw_fb3addf2-145c-427a-a7f4-b5f051751e05">9,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDMtMS0xLTEtNDE1MzE_462c4006-14ca-48cc-916e-5fb70f512bb3">531</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDMtMy0xLTEtNDE1NDU_e7df037b-8382-4f23-bd1e-4d2c540dbf12">3,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of redeemable convertible preferred stock, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="i5f878035d2ed48dc9860fc0e9a488f55_D20200701-20200831" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNjUtMC0xLTEtNDcyNjAvdGV4dHJlZ2lvbjo1YTA4YTI1MzZmNTY0NjVlYTJiMjcwY2FlY2UxOTc2NF80Mzk4MDQ2NTExMTg5_99790780-2782-4014-a635-b66eb625820d">496</ix:nonFraction></span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDQtMS0xLTEtNDE1MzE_edf5e390-e126-4956-aab2-7077a7e268b5">5,227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDQtMy0xLTEtNDE1NDU_2fe39cb5-d05d-4166-aa0d-6edd1e23ff8c">76,486</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance upon exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82411be0df684d5999a14b0a6ad94e9a_D20200701-20200930" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDUtNi0xLTEtNDE1NTY_1058745f-f60b-4391-908d-35f62d321608">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402b4853a118490284a4c268556e6aa9_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDUtMTAtMS0xLTQxNTc4_ce2efd3c-2954-4d74-8a52-701ace7c65ca">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDUtMTYtMS0xLTQxNjIw_35c79501-1e65-4177-8484-a61126ec2cb1">51</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402b4853a118490284a4c268556e6aa9_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDYtMTAtMS0xLTQxNTc4_c4eccb85-dd6a-435e-bae0-28031736f864">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDYtMTYtMS0xLTQxNjIw_50be2fe7-9921-46d6-b29b-2692a78114a3">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized loss on cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ae4098982084df789f8c32460ce665d_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDctMTItMS0xLTQxNTky_8b3168fe-a64e-4a12-9f12-66a0caf4b3d1">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDctMTYtMS0xLTQxNjIw_c724d3eb-5e9f-445e-addd-c0ba93c3b9e0">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3fc7c14ea459484dbff851cda6151300_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDgtMTQtMS0xLTQxNjA2_62cade76-606a-4d4e-ab96-8c3e44a61eea">12,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDgtMTYtMS0xLTQxNjIw_b9dd4663-1ee2-4ede-bf44-ae4b38a570fc">12,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMS0xLTEtMzQ0MDE_a7772c56-d630-4853-90d0-5228dd8f1dee">25,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMy0xLTEtMzQ0MDE_3a0d731a-a13c-4437-ba1e-21a3a04d53f4">243,852</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1af9fd0db1144ceb9953d270a352e2d_I20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtNi0xLTEtMzQ0MDE_dc8e206f-849b-47d2-b3e0-40c4d32df27b">4,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1af9fd0db1144ceb9953d270a352e2d_I20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtOC0xLTEtMzQ0MDE_f631060d-d380-40cc-9af6-00b43a788202">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8aa66f1be4e40d5b3e68af93a816d5b_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTAtMS0xLTM0NDAx_5a0037f3-2c21-4b2d-86ce-87e739b9f872">17,951</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eb4717194044992b7d6a3ba0a73a671_I20200930" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTItMS0xLTM0NDAx_96986387-f002-4075-8f61-227affca7e6d">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e6d9aca39d64536ad610f06bc65f7f3_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTQtMS0xLTM0NDAx_98bb66cd-9a42-400f-8ee4-31b0bb331eff">186,389</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTYtMS0xLTM0NDAx_61318c2e-9744-432d-9143-45e64be9323c">168,431</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_28"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROCEPT BioRobotics Corporation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited) </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNC0xLTEtMS0zNDQwMQ_00688956-a41d-4df8-b894-0d43a6b7f7b0">41,505</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNC0zLTEtMS0zNDQwMQ_0785b95e-2da8-45ed-a1f4-887e0055cecb">37,741</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Adjustments to reconcile net loss to cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNi0xLTEtMS0zNDQwMQ_37e16b1b-52dd-4e72-b57d-ca4e5e2d8d1f">2,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNi0zLTEtMS0zNDQwMQ_d991bf7e-b3d4-41bd-8099-26254895bc16">2,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNy0xLTEtMS0zNDQwMQ_7099de4b-38fb-4df9-bc7d-f1041aa508a5">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNy0zLTEtMS0zNDQwMQ_cfd24697-c444-46e1-ae7e-a33c13addc53">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Change in fair value of redeemable convertible preferred stock warrants and derivative liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" name="prct:FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfOC0xLTEtMS0zNDQwMQ_5437c044-a40c-42d8-96d3-38fbeb5d426f">235</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" name="prct:FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfOC0zLTEtMS0zNDQwMQ_8de469a7-a488-4ee5-813a-cfc604d8b96b">408</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="prct:NonCashLeaseAccretionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfOS0xLTEtMS0zNDQwMQ_1270ed96-2e64-404d-a16e-892470a0282c">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="prct:NonCashLeaseAccretionExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfOS0zLTEtMS0zNDQwMQ_74c25ec6-433e-4371-b293-af049adf836a">82</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory write-down</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTAtMS0xLTEtMzQ0MDE_556b4e3f-41b4-4376-8922-5ff139ad81a2">537</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="us-gaap:InventoryWriteDown" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTAtMy0xLTEtMzQ0MDE_5831e311-8a11-4f58-95d8-f06a50a09acf">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTQtMS0xLTEtMzQ0MDE_98a0c7be-9cdd-4596-bd32-898ba66a8926">4,804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTQtMy0xLTEtMzQ0MDE_3f18231e-23ee-4533-9da5-9315706265e7">729</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inventory</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTUtMS0xLTEtMzQ0MDE_da12a3ac-54ae-49d6-a6f8-fce59287e659">3,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTUtMy0xLTEtMzQ0MDE_773bc180-0e31-4dde-8142-6df9d04165ff">895</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTYtMS0xLTEtMzQ0MDE_dec53793-00db-4c29-9e5b-77ce548ce341">606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTYtMy0xLTEtMzQ0MDE_7cf6d52f-4c53-4078-8029-802136d4c276">200</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accounts payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTctMS0xLTEtMzQ0MDE_304e1cef-c825-44b2-aec3-7b2dd2214b02">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTctMy0xLTEtMzQ0MDE_743f2cff-9d2a-4c47-a895-69ae55fdfeee">262</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTgtMS0xLTEtMzQ0MDE_61a6c0ad-a8c2-43d1-8dd3-3b60479dee18">235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:IncreaseDecreaseInAccruedSalaries" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTgtMy0xLTEtMzQ0MDE_3046d8fb-fdd1-47a6-918e-29d639a7414f">1,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Accrued interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTktMS0xLTEtMzQ0MDE_51024a22-a2f4-4830-8b04-0df49144cfe8">804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInInterestPayableNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTktMy0xLTEtMzQ0MDE_5e408a97-6c16-4cdf-8189-c00c446c51a7">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjAtMS0xLTEtMzQ0MDE_2641f452-a02d-47c9-9e45-c4db8b3ace2d">615</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjAtMy0xLTEtMzQ0MDE_b3cd3304-6b72-46b4-850c-b0d68dcdc8af">182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjItMS0xLTEtMzQ0MDE_408d12d5-3323-4b73-a62b-f7858f566329">707</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjItMy0xLTEtMzQ0MDE_a49433c2-e0cc-4657-a6dd-0e7781704e77">672</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjMtMS0xLTEtMzQ0MDE_b74b8bb1-febf-43c3-b129-62e64f35132f">40,858</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjMtMy0xLTEtMzQ0MDE_3961a1fa-bedf-43cc-b2f3-6948c7fd06ec">34,898</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjctMS0xLTEtMzQ0MDE_b6a4e776-e463-44dc-ac86-c640da2898fd">260</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjctMy0xLTEtMzQ0MDE_53a28071-8ca6-47de-83fb-e40f990576fc">224</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjgtMS0xLTEtMzQ0MDE_58377d22-7fe1-4fef-af93-c91cf979982c">260</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjgtMy0xLTEtMzQ0MDE_430c65e8-1b78-4571-a9d3-32a7f2b0c02e">224</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock from the exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzAtMS0xLTEtMzQ0MDE_1de441f0-7531-4a1c-8c78-438d11bf34f4">3,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzAtMy0xLTEtMzQ0MDE_3a6b4ffb-4d88-48b4-8976-7cc41d2ae2bb">2,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from issuance of note payable, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzEtMS0xLTEtMzQ0MDE_3ee9e80d-85d1-44a8-b1e5-2f33ac84e58c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromDebtNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzEtMy0xLTEtMzQ0MDE_8ca6ed8b-de8f-401b-8131-a914134a74f3">24,685</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from the exercise of redeemable convertible preferred stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzItMS0xLTEtMzQ0MDE_74811ed7-1f18-455d-b35d-fc86fa96eb64">858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromWarrantExercises" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzItMy0xLTEtMzQ0MDE_0ed77289-ad89-45d9-97ac-0ed86e3938e3">3,310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from issuance of Series F redeemable convertible preferred stock, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9679f5b41fb34cf6abfae1649202e1c5_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="prct:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzMtMS0xLTEtMzQ0MDE_79451d09-fc98-49ad-ab25-e3a6b31d1171">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="if2b1c007cb5a4990af1e1f1d862c4d24_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="prct:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzMtMy0xLTEtMzQ0MDE_16f2319d-1920-42be-838b-4f86ffe8dd48">76,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from issuance of Series G redeemable convertible preferred stock, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i3acfe77b8a2f44e79e9ac544b7465414_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="prct:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzQtMS0xLTEtMzQ0MDE_46ab3d01-5c53-49e1-9e60-190d49661b17">84,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzUtMS0xLTEtNDQxMDE_90d6e1fa-3875-493d-80a8-4ecd605676df">172,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzUtMy0xLTEtNDQxMDk_176d8675-bf07-4b03-8ecf-cd471657f1da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzUtMS0xLTEtMzQ0MDE_6b49a94e-983b-4773-9ff0-05109ab747e0">261,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzUtMy0xLTEtMzQ0MDE_8c5e0cf1-ba02-4188-b7c7-c5142935c59e">106,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Net increase in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzYtMS0xLTEtMzQ0MDE_4d609376-94a5-44a9-b693-9960e5af4652">220,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzYtMy0xLTEtMzQ0MDE_b16cf68c-158c-41f0-91aa-fe872644ef11">71,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzgtMS0xLTEtMzQ0MDE_afdaf566-0948-4afe-aae2-f2db2c5888ce">100,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="ifa21a99062154fbdb875876427776118_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzgtMy0xLTEtMzQ0MDE_3494c8ae-e5ea-4ebd-bac3-b122a78c1676">42,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">End of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzktMS0xLTEtMzQ0MDE_f17de370-1a36-471e-9518-14ec5a79feb8">321,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzktMy0xLTEtMzQ0MDE_3b4ceece-a120-4898-b119-08df6bb70146">114,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Reconciliation of cash, cash equivalents and restricted cash to balance sheets:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDEtMS0xLTEtMzQ0MDE_f109a9c3-9f6c-4b1c-a0f7-01800fbee8fd">320,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDEtMy0xLTEtMzQ0MDE_eaa3d2ad-dd5e-4bfe-b57e-395e8be96745">113,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDItMS0xLTEtMzQ0MDE_f090a1b9-d620-40eb-b8e5-ed87623d995d">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930" decimals="-3" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDItMy0xLTEtMzQ0MDE_a177adff-016a-4179-aaf4-8707f187f84d">777</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Cash, cash equivalents and restricted cash in balance sheets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDMtMS0xLTEtMzQ0MDE_47ba6685-5952-46c8-a9f9-bc2d69bcaab9">321,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDMtMy0xLTEtMzQ0MDE_734f51f3-3101-4aa6-9559-1cc39c839a26">114,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Supplemental cash flow information</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDUtMS0xLTEtMzQ0MDE_9bb63cc0-c197-41ea-8316-3ad6f8f61bd6">3,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InterestPaidNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDUtMy0xLTEtMzQ0MDE_1b22e90d-438a-4cb3-9153-6eab4c6ba6ef">2,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Transfer of evaluation units from inventory to property and equipment, net</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="prct:TransferFromInventoryToPropertyAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDgtMS0xLTEtMzQ0MDE_9769a5a7-02bb-418f-991a-b6c272c4de23">1,227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="prct:TransferFromInventoryToPropertyAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDgtMy0xLTEtMzQ0MDE_df48ab6f-3e04-4927-a0e2-a9e62c375dc0">1,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Property and equipment included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDktMS0xLTEtMzQ0MDE_fa61bf32-3e2d-423c-a099-060832d42f5f">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDktMy0xLTEtMzQ0MDE_82a96600-1f42-4e85-ac1e-6de543b6c694">200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Deferred offering costs included in accounts payable and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="prct:DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNTAtMS0xLTEtMzQ0MDE_112bbd5f-414c-4913-bb10-14f77d920f23">819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="prct:DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNTAtMy0xLTEtMzQ0MDE_6af7b1d9-d59c-4953-b345-327522d30b6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these condensed consolidated financial statements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_31"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROCEPT BioRobotics Corporation</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited) </span></div><div id="id6896dbd221a471485ce149196fbcf44_34"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfOTM0NTg0ODgzODk2MQ_f391b0b5-6e91-4b35-b093-f9bb635b812e" continuedAt="if1f8ebd920c148d0bc2c3ed760c96db1" escape="true">Organization </ix:nonNumeric></span></div><ix:continuation id="if1f8ebd920c148d0bc2c3ed760c96db1" continuedAt="i9af39ca14dd2455e9037aeeb835fac2b"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PROCEPT BioRobotics Corporation (the &#8220;Company&#8221;) was incorporated in the state of California in 2007 and its headquarters are located in Redwood City, California. In April 2021, the Company re-incorporated in the state of Delaware. The Company received U.S. Food and Drug Administration clearance in December 2017 to market its AquaBeam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Robotic System, an automated surgical robot providing tissue removal for the treatment of benign prostatic hyperplasia, a prostate gland enlargement condition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company had cash and cash equivalents of $<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfNDM5ODA0NjUxMzc4Mw_2f902dc9-a6f4-4d19-a5bd-86ea09e924fd">320.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfMTY0OTI2NzQ0MzkwOA_1834702a-7622-409c-a035-1af073a3c64e">100.1</ix:nonFraction> million, respectively, and an accumulated deficit of $<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfNDM5ODA0NjUxMzc5OA_04187b1b-c6ac-4448-ac5b-22593ab18300">243.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfMTY0OTI2NzQ0Mzk0Mg_1267c55a-18c9-4fec-8f84-152d86ce2cc4">201.7</ix:nonFraction> million, respectively. In September 2021, the Company completed its initial public offering (&#8220;IPO&#8221;) for net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i0a1b74e1acd043bda78eed560ea4270b_D20210901-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfNDM5ODA0NjUxNDExOA_bd2cff67-5d08-478d-841a-08455518fe3b">172.4</ix:nonFraction> million, after deducting underwriting discounts and commissions, and offering expenses. Since its inception, the Company has financed its operations with a combination of debt and equity financing arrangements. The Company expects its cash and cash equivalents, revenue and available debt financing arrangements will be sufficient to fund its operations through at least the next twelve months from the issuance date of these financial statements. The Company has not achieved positive cashflow from operations to date and expects to continue incurring losses for the foreseeable future as it focuses on growing its business.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9af39ca14dd2455e9037aeeb835fac2b">The COVID-19 pandemic and the resulting economic downturn are affecting business conditions in the industry in which the Company operates. In response to the pandemic, many state and local governments in the United States issued orders that temporarily precluded elective medical procedures in order to conserve scarce health system resources. The Company has taken necessary precautions to safeguard its employees, patients, customers, and other stakeholders from the COVID-19 pandemic, while maintaining business continuity to support its patients, customers and employees. The timing, extent and continuation of any increase in procedures, and any corresponding increase in sales of the Company&#8217;s products, and whether there could be a future decrease in the current level of procedures as a result of the COVID-19 pandemic or otherwise, remain uncertain and are subject to a variety of factors.</ix:continuation> </span></div><div id="id6896dbd221a471485ce149196fbcf44_37"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NjY5MA_3dc39f8f-6374-4d97-924c-3abc19099184" continuedAt="i0f3bd483575d460fab3fc1a27be10ec4" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span></div><ix:continuation id="i0f3bd483575d460fab3fc1a27be10ec4" continuedAt="i92d3a22ee8b24f64ad5c8a9343c7e24d"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NjY4Nw_a818a4ed-e32b-40f5-bf1a-5bb7bb792876" continuedAt="i92fde72ed13a41be9a97857cdf1a557d" escape="true">Basis of Preparation </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i92fde72ed13a41be9a97857cdf1a557d">The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). These consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NjY4OA_d7c4aa6c-88ad-4d40-b22e-b9e497f1c567" continuedAt="i307413fd40d4440ebc4d7b6adcaacc83" escape="true">Use of Estimates </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i307413fd40d4440ebc4d7b6adcaacc83">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements. Management uses significant judgment when making estimates related to its common stock valuation in periods before the Company&#8217;s IPO and related stock-based compensation, right-of-use lease asset, lease liability, the valuations of the redeemable convertible preferred stock warrant liability and loan facility derivative liability, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.</ix:continuation> </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i92d3a22ee8b24f64ad5c8a9343c7e24d" continuedAt="i861bf4a81bb64c449b7fe1b46e53609b"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Board of Directors and stockholders approved, and the Company filed, an amended and restated certificate of incorporation effecting a 1-for-4.75 reverse stock split of common stock and all redeemable convertible preferred stock. The par value of the common and redeemable convertible preferred stock was not adjusted as a result of the reverse stock split. All authorized, issued and outstanding common stock, redeemable convertible preferred stock, warrants for preferred stock, stock options and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company completed its IPO by issuing <ix:nonFraction unitRef="shares" contextRef="i0a1b74e1acd043bda78eed560ea4270b_D20210901-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MTk3Nw_d855d22f-f2e4-413e-a62f-a840812e51b9">6,556,000</ix:nonFraction> shares of common stock, and the exercise of the underwriters option for <ix:nonFraction unitRef="shares" contextRef="i679a14a77cd0453ca47285769b9db2d0_D20210901-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MjA1Mw_7418820b-4a90-4a28-9c77-85d26771e95a">983,400</ix:nonFraction> shares, at an offering price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MjA4OQ_350adf67-0ea1-4007-87d7-107107722a86">25.00</ix:nonFraction> per share, for total net proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i0a1b74e1acd043bda78eed560ea4270b_D20210901-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MjE0NA_bd2cff67-5d08-478d-841a-08455518fe3b">172.4</ix:nonFraction> million, after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="usd" contextRef="ib8664e9a7cee4889bdb472916c610c7d_D20210901-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsForUnderwritingExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NDc0Nw_8858eed4-fcdc-49e3-a2c1-c889581b0ec5">13.2</ix:nonFraction> million and offering expenses of $<ix:nonFraction unitRef="usd" contextRef="ib8664e9a7cee4889bdb472916c610c7d_D20210901-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NDc1MA_e3815d76-9118-4c14-8061-0a72e160e34e">2.9</ix:nonFraction> million. Offering costs are capitalized, and consist of fees and expenses incurred in connection with the sale of common stock in its IPO, including legal, accounting, printing and other IPO-related costs. Upon completion of its IPO, these deferred offering costs were reclassified to stockholders&#8217; equity and recorded against the proceeds from the offering. In addition, all <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NjEyOA_080bcfa1-af45-4252-af29-85b40683fa55"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NjEyOA_c67bb575-5e73-493b-9fee-a555ef693c48">29,912,264</ix:nonFraction></ix:nonFraction> shares of its then-outstanding redeemable convertible preferred stock automatically converted into <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NjEzMg_080bcfa1-af45-4252-af29-85b40683fa55"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NjEzMg_c67bb575-5e73-493b-9fee-a555ef693c48">29,912,264</ix:nonFraction></ix:nonFraction> shares of common stock and it reclassified $<ix:nonFraction unitRef="usd" contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MzE1NQ_d5a4071a-8dff-415f-99a3-daf3c6f22d7c">329.5</ix:nonFraction> million of redeemable convertible preferred stock to additional paid-in capital on its condensed consolidated balance sheet. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Statements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying balance sheet as of September&#160;30, 2021, the statements of operations and comprehensive loss for the three and nine months ended September 30, 2021 and 2020, cash flows for the nine months ended September 30, 2021 and 2020, and the statements of redeemable convertible preferred stock and stockholders&#8217; equity (deficit) as of September&#160;30, 2021 and 2020, are unaudited. The financial data and other information disclosed in these notes to the financial statements related to September&#160;30, 2021, and the three and nine months ended September 30, 2021 and 2020, are also unaudited. The accompanying balance sheet as of December&#160;31, 2020 has been derived from the audited consolidated financial statements included in the Company&#8217;s Registration Statement on Form S-1 filed with the Securities and Exchange Commission.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to a fair statement of the Company&#8217;s financial position as of September&#160;30, 2021, and the results of its operations for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. The results for the three and nine months ended September 30, 2021, are not necessarily indicative of results to be expected for the year ending December&#160;31, 2021, or for any other interim period or for any future year and should be read in conjunction with the annual consolidated financial statements included in the Company&#8217;s Registration Statement on Form S-1.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Par Value and Shares Authorized Change </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Board of Directors and stockholders approved, and the Company filed, an amended and restated certificate of incorporation effecting a change in par value from $<ix:nonFraction unitRef="usdPerShare" contextRef="i719157466752459aa43b7047e2f317c7_I20210531" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjM1NQ_f6a9e743-0f8d-424b-9e95-27fd4181a547">0.001</ix:nonFraction> to $<ix:nonFraction unitRef="usdPerShare" contextRef="i55fff3d953504e32a8bb1767e17be163_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjM2OA_14a8107b-ceba-4a0f-8342-096924cf05c6">0.00001</ix:nonFraction> per share of common stock and all redeemable convertible preferred stock. All issued and outstanding common stock and redeemable convertible preferred stock contained in the financial statements have been retroactively corrected to reflect this immaterial change in par value for all periods presented. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NzYyOQ_cd7ff86a-383d-4322-af74-362f0bd92c63">10.0</ix:nonFraction> million shares of preferred stock was authorized and the shares of common stock authorized was increased to <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDk0NzgwMjM4NzE5NQ_d0182880-efb3-4207-9046-c25b069a6b62">300.0</ix:nonFraction> million shares, both having a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i55fff3d953504e32a8bb1767e17be163_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2Nzc5Mg_14a8107b-ceba-4a0f-8342-096924cf05c6">0.00001</ix:nonFraction> per share. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY0NQ_d0d303a4-9153-4965-a092-e4e8dd46592e" continuedAt="i02e4116b70a94b5997462196a5aa0268" escape="true">Cash, Cash Equivalents and Restricted Cash </ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i861bf4a81bb64c449b7fe1b46e53609b" continuedAt="i2605efcc46fa47aba4ff5ee9f724e9a6"><ix:continuation id="i02e4116b70a94b5997462196a5aa0268"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in banks and highly liquid securities, which are readily convertible to cash, that mature within 90 days or less from the original date of purchase, to be cash equivalents, which include money market funds. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. Unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity (deficit). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash is related to the Company&#8217;s letter of credit for the lease of its corporate headquarters.</span></div></ix:continuation><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY0Ng_0404d571-54c1-4a14-8f81-cc873f762f45" continuedAt="iafc72d38870b4a39ab6397aaad62b664" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash and cash equivalents, and accounts receivable, accounts payable and accrued liabilities, which approximate fair value due to their relatively short maturities as well as the redeemable convertible preferred stock warrant liability and loan facility derivative liability. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: </span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt">Observable inputs such as quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt">Other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt">Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iafc72d38870b4a39ab6397aaad62b664">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</ix:continuation> </span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY0Nw_b7261d71-b2af-4774-86ed-6b569dc54813" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.156%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.433%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685a759150ca4001b06e6ef8169b3a0a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS0xLTEtMS0zNDQwMQ_a446648d-8ad4-44d9-94d7-7251db5fe5d0">179,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS0zLTEtMS0zNDQwMQ_214d4766-e5d9-4665-84a2-dd602173a200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS01LTEtMS0zNDQwMQ_dc6f41dc-99ad-47be-bdf1-a7c908351c6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13ef5c367424e9b87f0aa0201302d21_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS03LTEtMS0zNDQwMQ_63e1d909-03f4-4fe1-abad-86edb38edf9a">179,797</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic790d5759ab443cba375a13c77efc8a1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS05LTEtMS0zNDQwMQ_26708850-975b-4713-ab69-cfb8d6811813">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS0xMS0xLTEtMzQ0MDE_8feee18f-22ac-4ca1-b769-1bdecc5eba93">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS0xMy0xLTEtMzQ0MDE_93bf7ec3-a249-4991-8ecd-3a70b89e3ee6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53305bb04ab4021944c4163701dcd71_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS0xNS0xLTEtMzQ0MDE_dfd0ae39-0bb0-448f-ac41-68c08f36e746">1,502</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685a759150ca4001b06e6ef8169b3a0a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi0xLTEtMS0zNDQwMQ_b8df0734-3cb1-4a9e-9390-34b65debd77c">140,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi0zLTEtMS0zNDQwMQ_a64f1abc-292c-451c-8d7d-d589b5c5b364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi01LTEtMS0zNDQwMQ_59ae9035-56a5-403d-8242-8cf3850099cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13ef5c367424e9b87f0aa0201302d21_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi03LTEtMS0zNDQwMQ_28388b1b-6519-41e7-a806-7367cef425c2">140,687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic790d5759ab443cba375a13c77efc8a1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi05LTEtMS0zNDQwMQ_0c967c72-3079-4c52-beab-de0b8e4b86b3">98,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi0xMS0xLTEtMzQ0MDE_8ed374f4-c24d-4b15-8609-9cc95217caf0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi0xMy0xLTEtMzQ0MDE_43cbf6ae-a2b2-4df9-bc29-27a4eb691ee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53305bb04ab4021944c4163701dcd71_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi0xNS0xLTEtMzQ0MDE_0e64aad9-7ce6-42d9-9327-0f3d488fff5d">98,628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685a759150ca4001b06e6ef8169b3a0a_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy0xLTEtMS0zNDQwMQ_1fe68c7c-44f1-4237-9a41-c06a66f8b96f">320,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy0zLTEtMS0zNDQwMQ_5db6bb00-df62-4228-89f6-05ca9a19c67d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy01LTEtMS0zNDQwMQ_92bfff50-0b29-4e3d-b17c-9a945574a0e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13ef5c367424e9b87f0aa0201302d21_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy03LTEtMS0zNDQwMQ_e8ce6a30-74be-4d1f-83ce-e5fba78815b3">320,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic790d5759ab443cba375a13c77efc8a1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy05LTEtMS0zNDQwMQ_0f167121-fe91-4939-9803-fe555bb53a20">100,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy0xMS0xLTEtMzQ0MDE_b6c1dca7-328a-40fa-ab60-6102a23c8e0c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy0xMy0xLTEtMzQ0MDE_5ccc6f25-2344-47fa-81cf-bc85447e03b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53305bb04ab4021944c4163701dcd71_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy0xNS0xLTEtMzQ0MDE_b6645f06-25f5-439a-a7a6-08ece9220beb">100,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Preferred stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685a759150ca4001b06e6ef8169b3a0a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS0xLTEtMS0zNDQwMQ_f37a33fc-0daf-4912-82d5-46378d80e1bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS0zLTEtMS0zNDQwMQ_4394e12a-93d9-4113-9386-d467e8b578c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS01LTEtMS0zNDQwMQ_bfc98592-0be7-4a2b-bc99-4add8216c50b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13ef5c367424e9b87f0aa0201302d21_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS03LTEtMS0zNDQwMQ_80e1388d-ccdc-4c21-863d-de7b2eebd54b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic790d5759ab443cba375a13c77efc8a1_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS05LTEtMS0zNDQwMQ_2da02a59-3a57-42c3-bce2-9a0adaeb32cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS0xMS0xLTEtMzQ0MDE_927d6779-0c6f-469f-b53a-7120e72039ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS0xMy0xLTEtMzQ0MDE_4e3b3da7-d6ef-4f21-8ade-197c75ef9ec9">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53305bb04ab4021944c4163701dcd71_I20201231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS0xNS0xLTEtMzQ0MDE_87e072b2-faf6-4d50-a1f5-a575d3c0fa3d">177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Loan facility derivative liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i685a759150ca4001b06e6ef8169b3a0a_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtMS0xLTEtMzQ0MDE_87ac83eb-c7d7-444b-beb6-c6732f187af2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtMy0xLTEtMzQ0MDE_f0faa565-5006-4124-ae13-494223437edf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtNS0xLTEtMzQ0MDE_0a6783de-825d-4c8b-a035-4309c34024e6">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia13ef5c367424e9b87f0aa0201302d21_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtNy0xLTEtMzQ0MDE_13c30e67-6111-4776-81bf-3d828e2e0120">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic790d5759ab443cba375a13c77efc8a1_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtOS0xLTEtMzQ0MDE_b264773c-52ea-4e27-93a6-64c64abdd42b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtMTEtMS0xLTM0NDAx_579005a1-2e8e-4f8d-8a46-d7e2904facde">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtMTMtMS0xLTM0NDAx_9458b81f-a711-49bd-b961-dfc324c9fbaa">1,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic53305bb04ab4021944c4163701dcd71_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DerivativeLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtMTUtMS0xLTM0NDAx_a7b03b49-1ba0-45cd-bcb3-c8ab1cacd047">1,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist primarily of money market funds. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers in and out of Level 3 during the nine months ended September 30, 2021 and year ended December&#160;31, 2020. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Convertible Preferred Stock Warrants </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4NQ_3ea082a5-3573-4e36-8037-01efb5d83882" continuedAt="ib4d7aab7869d4bb7815051d0f4e1aeb5" escape="true">The following table sets forth a summary of the changes in the estimated fair value of the Company&#8217;s redeemable convertible preferred stock warrants, which represents financial instruments with valuations classified as </ix:nonNumeric></span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i2605efcc46fa47aba4ff5ee9f724e9a6" continuedAt="i193a7516c2a04b409fbb813f004c3246"><ix:continuation id="ib4d7aab7869d4bb7815051d0f4e1aeb5" continuedAt="i36f73b3b11774253a7e14a9120065ab7"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. However, Level 3 financial instruments typically include, in addition to the unobservable inputs, observable inputs (that is, components that are actively quoted and can be validated to external sources). Accordingly, the gain or loss in the table below includes changes in fair value due in part to observable factors that are part of the Level 3 methodology recognized in the statement of operations as a component of interest and other income or expense as appropriate (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib383b7e5ad6141079ebfdfb1678720a6_I20210630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfMy0xLTEtMS0zNDQwMQ_4a925a41-fe4f-4fb1-bce8-09c11f69d287">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i372dc095e6bb4b4fab2fda830e21a778_I20200630" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfMy0zLTEtMS0zNDQwMQ_274ed5dc-c5d4-475e-8586-25b0f146872f">749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26689b208bf84601a3e040e4ce73ce49_I20201231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfMy01LTEtMS0zNDQwMQ_460a317e-f105-4e86-abfc-070890ea3203">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80cf655a5572442ab5b3157b560431bf_I20191231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfMy03LTEtMS0zNDQwMQ_88f8da77-21b2-43b9-818d-20947084a11e">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i932b6afd06b54dfdbf042021f1fb619a_D20210701-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNC0xLTEtMS0zNDQwMQ_32f92f1c-0d9b-4ea9-982b-571727167327">112</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i735e2352ec40490980b3c86c7253982d_D20200701-20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNC0zLTEtMS0zNDQwMQ_237a8dd4-5d2c-4d2e-bec6-fc753f10fc3e">532</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87940b64ee9940b29b568ac0a865184b_D20210101-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNC01LTEtMS0zNDQwMQ_b39c34b3-5d8d-4277-b99a-756a26a0aec3">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNC03LTEtMS0zNDQwMQ_c8015c98-f0ca-4fe6-8d79-0952071b3098">653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i932b6afd06b54dfdbf042021f1fb619a_D20210701-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS0xLTEtMS00MjUzMQ_b6d1611c-87c7-48e8-b56e-cc58b8989f4a">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i735e2352ec40490980b3c86c7253982d_D20200701-20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS0zLTEtMS00MjUzMQ_0b7e9132-db2d-4dba-8522-1c67b4bb3345">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87940b64ee9940b29b568ac0a865184b_D20210101-20210930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS01LTEtMS00MjUzMQ_20248db6-6fc7-448a-8f44-49e1287d562a">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS03LTEtMS00MjUzMQ_634c6162-beb3-42dc-b9e0-c13b3ae19ecb">22</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i932b6afd06b54dfdbf042021f1fb619a_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS0xLTEtMS0zNDQwMQ_32ef6db8-d48c-4d54-84c0-41caaa77e871">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i735e2352ec40490980b3c86c7253982d_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS0zLTEtMS0zNDQwMQ_8b76472f-442a-46e3-95c6-1a64a78e42e4">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i87940b64ee9940b29b568ac0a865184b_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS01LTEtMS0zNDQwMQ_6542b8e6-fd2a-472a-9eef-f8d94a8959d3">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS03LTEtMS0zNDQwMQ_3556e9e7-e013-40ba-babd-a8b9949ed2f4">67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0a6d3d6a5d41aabc418f290a24224b_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNi0xLTEtMS0zNDQwMQ_a7c9f030-3a8b-42f5-9447-d9ac60b96eff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5998e1db9c1d41c4b57ba2aac373504c_I20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNi0zLTEtMS0zNDQwMQ_afce97b6-5f1c-4b3b-b9c2-8dcee0efc8f5">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0a6d3d6a5d41aabc418f290a24224b_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNi01LTEtMS0zNDQwMQ_6ad933fb-e3aa-49b4-92e9-49f4e3895854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5998e1db9c1d41c4b57ba2aac373504c_I20200930" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNi03LTEtMS0zNDQwMQ_8cc1a4cd-352f-4ec6-ab5a-e09747b69e7a">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the Company&#8217;s IPO in September 2021, warrants exercised for redeemable convertible preferred stock were automatically converted into <ix:nonFraction unitRef="shares" contextRef="i821880a0f0ea457fb74d98beb2145b75_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MTc2Mg_a79c51b0-7c59-4539-90a6-fb3299291210"><ix:nonFraction unitRef="shares" contextRef="i4acb9ad050634e849a2a2923e0940cae_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MTc2Mg_ce90b69b-fe8a-4a11-81d2-51c3d730e7c7">62,454</ix:nonFraction></ix:nonFraction> shares of common stock and the remaining unexercised warrants expired, therefore <ix:nonFraction unitRef="shares" contextRef="ide057d850a674c1faa90ee7654a9dcba_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3NDI5NA_750e6288-cab8-463a-882b-89c41a21962f">no</ix:nonFraction> warrants outstanding at September&#160;30, 2021.</span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4Ng_f7973e7e-da81-4deb-a40c-6d916c8a2ead" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the redeemable convertible preferred stock warrant liability was determined using the Black-Scholes option pricing model using the following assumptions: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.957%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930" format="ixt-sec:duryear" name="prct:WarrantsAndRightsOutstandingWeightedAverageTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjg3NzY4YmJhYjY4NTQzMjNiNmEzNjRlMjRiNTk0NDg1L3RhYmxlcmFuZ2U6ODc3NjhiYmFiNjg1NDMyM2I2YTM2NGUyNGI1OTQ0ODVfMy03LTEtMS0zNDQwMQ_82ebedf0-1408-4d93-9554-9b7becf362d0">1.4</ix:nonNumeric></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf0b64a5bcea498e9f11e448dcbfd834_I20200930" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjg3NzY4YmJhYjY4NTQzMjNiNmEzNjRlMjRiNTk0NDg1L3RhYmxlcmFuZ2U6ODc3NjhiYmFiNjg1NDMyM2I2YTM2NGUyNGI1OTQ0ODVfNC03LTEtMS0zNDQwMQ_9c335750-b238-48cf-929d-425bcd744268">80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70cffcb762f444178b8ff9f5925b1a05_I20200930" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjg3NzY4YmJhYjY4NTQzMjNiNmEzNjRlMjRiNTk0NDg1L3RhYmxlcmFuZ2U6ODc3NjhiYmFiNjg1NDMyM2I2YTM2NGUyNGI1OTQ0ODVfNS03LTEtMS0zNDQwMQ_bd74ed93-c9cb-4721-9475-4ac20706b769">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i669bfb53914c4eb98abef7a0bb67beb4_I20200930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjg3NzY4YmJhYjY4NTQzMjNiNmEzNjRlMjRiNTk0NDg1L3RhYmxlcmFuZ2U6ODc3NjhiYmFiNjg1NDMyM2I2YTM2NGUyNGI1OTQ0ODVfNi03LTEtMS0zNDQwMQ_630b8b19-1493-407b-8250-ea5a844328a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loan facility derivative liability </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s loan facility, the Company is obligated to pay a fee upon the earlier occurrence of a defined liquidity event, including but not limited to, a merger or sale of our assets or voting stock, or achieving a $<ix:nonFraction unitRef="usd" contextRef="i149316ff5b004dd4a6c20c85ec67c952_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjM4Mw_b96b4f21-d237-4946-a05f-b57bcd82fb3b">200.0</ix:nonFraction>&#160;million trailing twelve months revenue target, in each case, by September 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fee is calculated at the time of the liquidity event occurrence to be $<ix:nonFraction unitRef="usd" contextRef="ia44bb9ced3444ecab70c0374b5456e34_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjM5OQ_0042ca1b-1dcf-4693-b221-046fd82a0d2b">1.0</ix:nonFraction>&#160;million if only the first installment has been drawn, $<ix:nonFraction unitRef="usd" contextRef="ia44bb9ced3444ecab70c0374b5456e34_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQxNQ_990e6826-1761-438d-88f1-753a23eb00ef">2.0</ix:nonFraction> million if the first two installments have been drawn, $<ix:nonFraction unitRef="usd" contextRef="ia44bb9ced3444ecab70c0374b5456e34_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQzMQ_64f235f5-52c9-49b9-9292-89999d562ad8">2.4</ix:nonFraction> million if the first three installments have been drawn, or $<ix:nonFraction unitRef="usd" contextRef="ia44bb9ced3444ecab70c0374b5456e34_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQ0NQ_4e8d348d-ce78-4020-9674-711a82bad25f">3.0</ix:nonFraction> million if all four installments have been drawn, in each case, upon the occurrence of the liquidity event. The Company has determined this fee is a freestanding derivative instrument. The $<ix:nonFraction unitRef="usd" contextRef="ia44bb9ced3444ecab70c0374b5456e34_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQ2Mg_d17f782b-88eb-42d2-957e-b2a16a478167">1.4</ix:nonFraction> million fair value of this loan facility derivative was recorded as a debt discount and liability on the date of issuance in connection with obtaining additional financing as applicable and will be revalued every reporting period until the earlier occurrence of a defined liquidity event or achieving a revenue target by September 2029 or termination of such fee arrangement.  </span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4Nw_76f1f637-e0f6-4ac7-b740-f03322f369e2" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the estimated fair value of the Company&#8217;s loan facility derivative liability, classified as Level 3 (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3604760cd7da443ebd82948c1de89a0c_I20210630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfMy0xLTEtMS0zNDQwMQ_8aa26d8c-057c-4f60-8be0-c111d8a84813">1,787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec7eb3e7ffce40f691737cf9a773acc7_I20200630" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfMy0zLTEtMS0zNDQwMQ_df3d856b-7900-41ab-9a01-818118b3f77c">1,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfMy01LTEtMS0zNDQwMQ_66433ea3-9145-4efe-9d2a-c1b5503aee8f">1,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5706bc22431543fd88f03f8d8b69bf07_I20191231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfMy03LTEtMS0zNDQwMQ_33e46fae-1da6-47e0-beb8-414958cad98e">1,482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e3fa6d51e049b29372b92a12097b3b_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNC0xLTEtMS0zNDQwMQ_61d25dd5-6941-4476-a2dd-7d3fbbc29257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552d18e694c74d6ea1105c6c060177c9_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNC0zLTEtMS0zNDQwMQ_ccfc161e-af8c-44e5-85c8-3049f7fa580b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3327002d624963bd45eaa1f8569e6c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNC01LTEtMS0zNDQwMQ_5a32a245-0c49-4dde-bede-7ae41d67f25f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c34540459ad463592472f93bf90d0d6_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNC03LTEtMS0zNDQwMQ_7c818806-26ab-4e8f-b74d-c46cc44ee1db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i70e3fa6d51e049b29372b92a12097b3b_D20210701-20210930" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNS0xLTEtMS0zNDQwMQ_c5923fa2-fa70-4e85-9d67-6b38c58617bd">177</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i552d18e694c74d6ea1105c6c060177c9_D20200701-20200930" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNS0zLTEtMS0zNDQwMQ_bebe7fd1-7408-4780-86a3-5b0b6746e8a5">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e3327002d624963bd45eaa1f8569e6c_D20210101-20210930" decimals="-3" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNS01LTEtMS0zNDQwMQ_cbd1cc5a-2a51-4965-8477-422d4fcc4404">172</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c34540459ad463592472f93bf90d0d6_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNS03LTEtMS0zNDQwMQ_b6d09294-0512-4c40-94c4-a28eaf92f0da">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of success fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i70e3fa6d51e049b29372b92a12097b3b_D20210701-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi0xLTEtMS00MjI4NQ_3aa22454-0a44-477a-9570-96b1cebe1bea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i552d18e694c74d6ea1105c6c060177c9_D20200701-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi0zLTEtMS00MjI3OA_b3982194-257a-493a-bd75-487196a82f8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3327002d624963bd45eaa1f8569e6c_D20210101-20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi01LTEtMS00MjI3MQ_57e3cd94-af68-463b-9bfd-6b3f31aa5ffc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c34540459ad463592472f93bf90d0d6_D20200101-20200930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi03LTEtMS00MjI2NA_75588e4b-a6ef-427f-b785-813e8ee287f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi0xLTEtMS0zNDQwMQ_26f0be7f-3768-4982-950c-633e2cf378c3">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521f9bcdc3594f5cad2c4aaf7085a016_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi0zLTEtMS0zNDQwMQ_6390f140-e3d9-4899-9d68-3f27279cd331">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi01LTEtMS0zNDQwMQ_84277c35-6a48-433e-876d-d906e6b38bf9">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521f9bcdc3594f5cad2c4aaf7085a016_I20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi03LTEtMS0zNDQwMQ_5b0ac285-48a5-4a5f-9f77-ff4fa5b81b33">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i193a7516c2a04b409fbb813f004c3246" continuedAt="ia3ca628e06d14d26bc1f6ea259f17977"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the loan facility derivative liability was determined using a discounted cash flow calculation discounted at <ix:nonFraction unitRef="number" contextRef="i886693e4845143ee9412596e575e4081_I20210930" decimals="INF" name="us-gaap:LongTermDebtMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQ2OQ_6e051b7d-965c-41d4-afc9-de999ae2858c">10</ix:nonFraction>%. </span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2Mg_4f3f492e-65ae-4443-adf3-2ccb94e122a1" continuedAt="i445d4008839c457aa96cf1f9d5e4ac3e" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents and, to a lesser extent, accounts receivable. The Company believes that credit risk in its accounts receivable is mitigated by its credit evaluation process, relatively short collection terms and diversity of its customer base. The Company generally does not require collateral and losses on accounts receivable have historically been within management&#8217;s expectations. </span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i445d4008839c457aa96cf1f9d5e4ac3e">The Company&#8217;s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings, as well as corporate debt or commercial paper issued by the highest quality financial and non-financial companies, and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash and cash equivalents and issuers of investments to the extent recorded on the balance sheets. The Company has limited its credit risk associated with cash and cash equivalents by placing its investments with banks it believes are highly creditworthy and with highly rated investments.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2Mw_eeda4d73-2582-401c-b13a-70c45ee4a7a4" continuedAt="idae1ec9b87734a75aefafcf5d63d5f00" escape="true">Allowance for Doubtful Accounts </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idae1ec9b87734a75aefafcf5d63d5f00">The Company provides for uncollectible accounts receivable by recording an allowance for doubtful accounts for balances deemed uncollectible. The Company evaluates the collectability of its accounts receivable based on known collection risks and historical experience. In circumstances where the Company is aware of a specific customer&#8217;s inability to meet its financial obligations to the Company (e.g., bankruptcy filings, substantial downgrading of credit ratings), the Company records a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount it reasonably believes will be collected. The Company has not experienced any significant collection issues.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2NA_ca0674a0-c760-4d55-ba0a-95c5584fff79" continuedAt="i0840068fe21c41fcb93e9f8491137b98" escape="true">Inventory </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0840068fe21c41fcb93e9f8491137b98">Inventories are valued at the lower of cost, computed on a first-in, first-out basis, or net realizable value. The allocation of production overhead to inventory costs is based on normal production capacity. Abnormal amounts of idle facility expense, freight, handling costs, and consumption are expensed as incurred, and not included in overhead. The Company maintains provisions for excess and obsolete inventory based on management&#8217;s estimates of forecasted demand and, where applicable, product expiration. The Company has initiated voluntary recalls for a limited number of handpieces due to certain issues related to supply chain and manufacturing processes, of which the provision recognized was not material.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2NQ_9a1ebb7f-f0fa-4a28-99e5-80f68d65dd39" continuedAt="ie390921ae6534774a6942317a10c73b7" escape="true">Property and Equipment and Intangible Assets</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie390921ae6534774a6942317a10c73b7">Property and equipment and Intangible Assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization for property and equipment are determined using the straight-line method over the estimated useful lives of the respective assets, generally <ix:nonNumeric contextRef="ic400b41cd47342848644ec9514f047c0_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQ4OA_f4a2cb27-cd91-4b98-9300-85633e335dd4">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i7b9ba7023422472682b16a20f5f463a1_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2Ng_5b453c46-cc8d-40f1-a6aa-2fae33df87fb">5</ix:nonNumeric> years. The Company reclassifies inventory used at customer sites for evaluation purposes to property and equipment due to a limited history of sales of evaluation units. Amortization of intangible assets are determined using the straight-line method over the estimated useful lives, generally through the patent expiration date. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Maintenance and repairs are charged to operating expenses as incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2Nw_4cb2dec3-6883-488f-80c0-6328ce7428e6" continuedAt="i590a8bc787144e3499d92f8bb1204c2f" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist primarily of property and equipment and intangible assets, net, and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that a long-lived asset be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated by the asset group to the carrying amount of the </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ia3ca628e06d14d26bc1f6ea259f17977" continuedAt="ibc8889aaef4b4939bfdb60f94d8d1c9d"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i590a8bc787144e3499d92f8bb1204c2f">asset group. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. The Company determines fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. The Company&#8217;s cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors. Since inception, the Company has not recorded impairment charges on its long-lived assets.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:DeferredChargesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2OA_29064728-b92f-41a5-9148-31cede6717ab" continuedAt="ib5d9ad9a25954b21b66f525ae7db4e02" escape="true">Deferred Offering Costs</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib5d9ad9a25954b21b66f525ae7db4e02">The Company capitalizes, within other assets, certain legal, accounting and other third-party fees that are directly related to the Company&#8217;s in-process equity financings, including its recent initial public offering, until such financings are consummated. After consummation of the equity financing, these costs are recorded to additional paid in capital as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses.</ix:continuation> There were <ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DeferredOfferingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjIzNQ_60b370b4-7b98-4886-b9c9-11d8a5e4eb0f"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DeferredOfferingCosts" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjIzNQ_ace9773f-1e79-4dc3-9fb0-ee908a9ebb94">no</ix:nonFraction></ix:nonFraction> deferred offering costs as of September&#160;30, 2021 and December&#160;31, 2020. Upon the completion of the Company&#8217;s IPO in September 2021, all deferred offering costs were reclassified to cost of issuance in additional paid in capital.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2OQ_7f7ca6e8-7e16-4f33-ab70-3c53586bfc7a" continuedAt="i2972a745e28b4e65be56f9ec7d2cb652" escape="true">Deferred Revenue</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2972a745e28b4e65be56f9ec7d2cb652">The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue will be recognized subsequent to invoicing. Service agreements are generally invoiced annually at the beginning of each coverage period and recorded as deferred revenue and recognized as revenue ratably over the coverage period. Deferred revenue that will be recognized during the twelve months following the balance sheet date is recorded as the current portion of deferred revenue, and the remaining portion, if any, would be recorded as non-current.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="prct:RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3MA_9bdffed9-9684-4ff0-98f8-d5cc19380b16" continuedAt="i87b8e4a3ee454f56a8d4d20deb180277" escape="true">Redeemable Convertible Preferred Stock</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i87b8e4a3ee454f56a8d4d20deb180277">The Company records redeemable convertible preferred stock at fair value on the date of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because it contains liquidation features that are not solely within the Company&#8217;s control. The Company determined that the carrying values of the redeemable convertible preferred stock should not be adjusted to the liquidation preferences because it is uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock. Subsequent adjustments to the carrying values of the redeemable convertible preferred stock to the liquidation preferences will be made only when it is probable that the redeemable convertible preferred stock will become redeemable.</ix:continuation> Upon the completion of the Company&#8217;s IPO in September 2021, all <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjA2MQ_080bcfa1-af45-4252-af29-85b40683fa55"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjA2MQ_c67bb575-5e73-493b-9fee-a555ef693c48">29,912,264</ix:nonFraction></ix:nonFraction> shares of its then-outstanding redeemable convertible preferred stock automatically converted into <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjE2NA_080bcfa1-af45-4252-af29-85b40683fa55"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjE2NA_c67bb575-5e73-493b-9fee-a555ef693c48">29,912,264</ix:nonFraction></ix:nonFraction> shares of common stock and it reclassified $<ix:nonFraction unitRef="usd" contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MzM1MA_d5a4071a-8dff-415f-99a3-daf3c6f22d7c">329.5</ix:nonFraction> million of redeemable convertible preferred stock to additional paid-in capital on its condensed consolidated balance sheet.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="prct:RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3MQ_b643e0b1-57b1-492e-8ff2-b26ac781e01f" continuedAt="iebef452276d4461f9b9a0d24d2df4a1d" escape="true">Redeemable Convertible Preferred Stock Warrant Liability </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iebef452276d4461f9b9a0d24d2df4a1d">The Company has issued freestanding warrants to purchase shares of redeemable convertible preferred stock to investors in connection with sales of certain of its redeemable convertible preferred stock. The Company classified these warrants as a derivative liability because they create a conditional obligation for the Company to repurchase its own shares for cash or other assets. The fair value of the warrants are recorded on the consolidated balance sheets at the issuance of the warrants and remeasured to fair value at each financial reporting date. The changes in the fair value of the warrants are recorded in the statement of operations as a component of interest and other income or expense as appropriate. The Company will continue to adjust the carrying value of the redeemable convertible preferred stock warrant liability for changes in the fair value of the warrants until the earlier of: the exercise of the warrants, at which time the liability will be reclassified to temporary equity or the expiration of the warrant, at which time the entire amount would be reversed and reflected in the consolidated statements of operations and comprehensive loss.</ix:continuation> Upon the completion of the Company&#8217;s IPO in September 2021, warrants exercised for redeemable convertible preferred stock were automatically converted into <ix:nonFraction unitRef="shares" contextRef="i821880a0f0ea457fb74d98beb2145b75_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MTgxOA_a79c51b0-7c59-4539-90a6-fb3299291210"><ix:nonFraction unitRef="shares" contextRef="i4acb9ad050634e849a2a2923e0940cae_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MTgxOA_ce90b69b-fe8a-4a11-81d2-51c3d730e7c7">62,454</ix:nonFraction></ix:nonFraction> shares of common stock and the remaining unexercised warrants expired.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ibc8889aaef4b4939bfdb60f94d8d1c9d" continuedAt="i97152017a04445d4888328a9d7ce461c"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3Mg_fc03a0b9-1c25-4a5b-9f98-84cf15008964" continuedAt="i3a583bfa11a24369b89fe389fa2c6988" escape="true">Loan Facility Derivative Liability</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3a583bfa11a24369b89fe389fa2c6988">The Company has determined that its obligation to pay success fees to a lender upon a successful liquidation event or achieving a revenue target represents freestanding financial instruments. The instruments are classified as a non-current liability in the consolidated balance sheets and are subject to remeasurement at each financial reporting date. Any change in fair value was recognized through other income (expense) in the condensed consolidated statements of operations and comprehensive loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3Mw_b0c41cce-0395-4a5c-8769-b8619e4c1c64" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements with a term of more than twelve months, the Company determines if an agreement contains a lease at inception. Operating lease liabilities represent an obligation to make lease payments arising from the lease agreement. Operating lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the remaining lease term. In determining the present value of lease payments, the Company estimates its incremental borrowing rate as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, of an amount equal to the lease payments in a similar economic environment. Operating lease liabilities are included in the Company&#8217;s consolidated balance sheet. Right-of-use assets represent our right to use an underlying asset for the lease term and are classified as non-current assets. Lease expense is recognized on a straight-line basis over the expected lease term in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2019, the Company recorded the difference between rent paid and the straight-line rent as a deferred rent liability and leasehold improvements funded by landlord incentives or allowances are recorded as leasehold improvement assets and a corresponding deferred rent liability. Upon adoption of Accounting Standards Codification (&#8220;ASC 842&#8221;) on January 1, 2020, the unamortized deferred rent liability has been reclassified to reduce the right-of-use asset.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not elected to separate lease and non-lease components for any leases within its existing classes of assets and, as a result, records a right-of-use asset and lease liability based on the present value of the future minimum lease payments over the term at commencement date. Variable lease payments are expensed as incurred. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:LessorLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg5NjkyNQ_68016953-f64c-4506-be4d-f9904e6d1a87" escape="true">The Company has lessor arrangements with customers for a fixed monthly fee with no non-lease components, typically for 3-12 months. These arrangements are accounted for as an operating lease in accordance with ASC 842. These arrangements and related revenue are immaterial to the periods presented.</ix:nonNumeric> </span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3NQ_9c1cb9e7-2915-41d5-b3f1-74f0eac1e60e" continuedAt="if4efa29579cb4b6bb8c5d5c0ab5ede84" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is derived primarily from the sales of the AquaBeam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Robotic Systems, and handpieces that are for one-time use during each surgery using the AquaBeam Robotic System. The AquaBeam Robotic System contains both software and non-software components that are delivered together as a single product and generally contain a one-year warranty. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), the Company performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct based on the contract. </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i97152017a04445d4888328a9d7ce461c" continuedAt="i5d6dd8e7f19f44b4b7507d7c060b8b33"><ix:continuation id="if4efa29579cb4b6bb8c5d5c0ab5ede84" continuedAt="i34f8fbf400144b9bae417b7e906325a0"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contracts are typically in the form of an agreement and a purchase order from the customer. The Company&#8217;s AquaBeam Robotic System sales generally contain multiple products and services and can include a combination of the following performance obligations: robotic system, handpieces and consumables, and service. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the transaction price it expects to be entitled to in exchange for transferring the promised product to the customer, which is based on the invoiced price for the products. All prices are at fixed amounts per the sales agreement with the customer and there are generally no discounts, rebates or other price concessions or a right of return, once the agreement is signed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations at the following points in time:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AquaBeam Robotic Systems</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the time of delivery. Systems rented for a fixed monthly fee during an evaluation period, typically 3-12 months, are recognized as revenue straight-line during the lease term, in accordance with ASC 842, and are not material. For systems sold following an evaluation period, revenue is recognized generally once sales terms are mutually agreed (as the system is already install at the customer site). For systems sold through distributors, revenue is recognized generally at the time of delivery. The Company&#8217;s system arrangements generally do not provide a right of return. The systems are generally covered by a <ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:durwordsen" name="prct:ProductWarrantyTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4OA_a9f80850-1c41-496e-8baa-2d5fe7f7a4cf">one-year</ix:nonNumeric> service agreement. The service agreements have a stand alone selling price and are typically recognized as deferred revenue and amortized over the <ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:durwordsen" name="prct:ServiceAgreementAmortizationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODkwMTY2OQ_6fdcad0d-b1bc-4cc0-8975-f66c65e1b9ae">one-year</ix:nonNumeric> service period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hand pieces and other consumables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Revenue from sales of handpieces and other consumables is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also occurs at the time of delivery.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Service revenue, inclusive of the amounts associated with the AquaBeam Robotic System warranties, is recognized over the term of the service period, as the customer benefits from the services throughout the service period. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that certain promises in the multiple-element arrangements, such as installation, training and certain ancillary products, are immaterial, and/or do not represent separate performance obligations for which transaction price is allocated. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue is recognized subsequent to invoicing, such as service contracts, which are recognized ratably as revenue over the performance period, which is not material. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s typical payment terms are between approximately 30 to 90 days. The Company expenses shipping and handling costs as incurred and includes them in the cost of sales. In those cases where shipping and handling costs are billed to customers, the Company classifies the amounts billed as a component of revenue. Taxes collected from customers and remitted to governmental authorities are excluded from revenue. The Company expenses any incremental costs of obtaining a contract, including but not limited to, sales commissions, as and when </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i5d6dd8e7f19f44b4b7507d7c060b8b33" continuedAt="i804d48e309a847a499ae7da92e504e15"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i34f8fbf400144b9bae417b7e906325a0">incurred as the expected amortization period of the incremental costs would have been less than one year and are reported in selling, general and administrative expense in the statements of operations and comprehensive loss.</ix:continuation></span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY5MA_17d01520-8256-40a7-bf4e-d675968441ca" escape="true"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY5MA_a3e10956-5a12-4b6a-8a1c-f79b4da2a48f" continuedAt="i3912529e75c447cf97a5a30bd9b8ebf4" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue disaggregated by type and geography (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System sales and rentals</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c26f250c925422aa863c70b7a19551d_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNC0xLTEtMS0zNDQwMQ_24178f82-db19-476a-ac99-97471f3de8db">5,038</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a170ab8421b4089a99080c2ea10af97_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNC0zLTEtMS0zNDQwMQ_71c4f619-617a-4fe3-a614-98340ed11d75">646</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idabe1c5a57964ddb9bd5d12ab67202b8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNC01LTEtMS0zNDQwMQ_af419756-16d6-4361-a7df-49b090e27cbd">14,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d0c0948cc8f4e1280e0195a16e98801_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNC03LTEtMS0zNDQwMQ_361a2bf9-d8c6-4157-856b-98790c215f00">1,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Handpieces and other consumables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic44775719b294dc1913d8311a089ebaf_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNS0xLTEtMS0zNDQwMQ_322374bd-ee1e-41c7-b31a-fa74de042e77">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd2dcb59faa3426288a132975960e82e_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNS0zLTEtMS0zNDQwMQ_517655f0-248c-4997-b24e-e399e34ccf9f">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie17f18e3e20e4d43aae76b23a39a3be8_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNS01LTEtMS0zNDQwMQ_77c6a5f9-406d-4d46-adaf-1183f07e32c5">5,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic89eb2bbd1924e0fb717bfba7cc199c8_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNS03LTEtMS0zNDQwMQ_3d90a8a7-211b-4f4f-9252-f92cac7cee2f">930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d1f490ec27b47feb871022c21515bab_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNi0xLTEtMS0zNDQwMQ_9a812880-0fc4-4495-9570-261e4f6b214b">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8353a9a7b034508bb8f01dbd8917e72_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNi0zLTEtMS0zNDQwMQ_842c521c-f769-478f-8407-b7a196af8920">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieeada33fd4aa4372b8bd11229fdf8032_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNi01LTEtMS0zNDQwMQ_d0154268-b61c-42a7-bc94-ee77d1b2b340">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac6cd3dce7f43fda61bce4f9ba59555_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNi03LTEtMS0zNDQwMQ_a2102bff-1421-48ea-9a89-2ab7874e8ac5">26</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if05a3e115a3c4a69bedce4615d0524f0_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNy0xLTEtMS0zNDQwMQ_7c73f487-5278-4786-b686-d90280489229">7,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf79d1655d82439f9563d7390347f8f3_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNy0zLTEtMS0zNDQwMQ_894e54a9-9019-408b-83c3-a7c04e062001">1,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81c94b64a4fe411c90294df282895066_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNy01LTEtMS0zNDQwMQ_bd9ff3ca-6889-465e-8de7-1a62ea406606">20,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe009ff3d8a84467b238828dc96fa66e_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNy03LTEtMS0zNDQwMQ_39865880-1e7e-464c-bafc-983668b4c867">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System sales and rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a203d4671604af189dd4efe9cfc3f3c_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfOS0xLTEtMS0zNDQwMQ_13c2279f-5dfe-4aac-8578-4638df9ea211">481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib054ba1212a040a5ba7001b1a2bc8aaa_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfOS0zLTEtMS0zNDQwMQ_66cd3686-580c-45de-abfa-4acc1b6c4736">369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad3a4897b0f74d93b212ccf2d92ceb95_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfOS01LTEtMS0zNDQwMQ_f891b011-b609-4ede-8391-b405b17a1792">1,725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa5d2fc51a09454fb9410268366249f0_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfOS03LTEtMS0zNDQwMQ_58d5e856-79a4-4050-94e7-79ae93e6da69">1,111</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Handpieces and other consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c6ae97130174160926aac368d44e969_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTAtMS0xLTEtMzQ0MDE_0ab7dfed-45be-418b-bf0a-41169ff3fb27">666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ff4ab44021547058325efd92af9bd8b_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTAtMy0xLTEtMzQ0MDE_be0c518c-06f4-462d-b93a-d6d727529297">596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i018b3765196146e48322f8a859dbb4d5_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTAtNS0xLTEtMzQ0MDE_4f09b60f-1534-4075-a69d-d75463c62a14">2,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52ad0f1364cd409c9f18e002b7381a5f_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTAtNy0xLTEtMzQ0MDE_b5ea5d3c-1180-4ca4-8219-06a674186d1b">1,278</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfa97cb67f4c48af906ec7b00d213a04_D20210701-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTEtMS0xLTEtMzQ0MDE_819e47a6-1fdc-4361-ac04-3250f96eebcb">130</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd005e7d887548c48d2e442a699161c8_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTEtMy0xLTEtMzQ0MDE_16e8976c-2b53-447e-9a97-27fb01c65dda">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b33b0f044bd43a19422b9118049e601_D20210101-20210930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTEtNS0xLTEtMzQ0MDE_84dd35c1-a307-456c-8d37-d3eadcc1bc03">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee4ecb3e06be41628c57d8da452ede6d_D20200101-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTEtNy0xLTEtMzQ0MDE_eccdbee3-c677-4d8c-8a94-cea28f905f0f">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outside of U.S. revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2968256b5824a29a2ac8033c768dcc5_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTItMS0xLTEtMzQ0MDE_27fe747c-729f-4836-be85-4b9a7de8c73f">1,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c940d5581a0431aaaeb6016386ef835_D20200701-20200930" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTItMy0xLTEtMzQ0MDE_4feb1dea-eb0a-4450-bcda-427c0a101e00">994</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fde91df02034661a6ff9d0d3c072933_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTItNS0xLTEtMzQ0MDE_8fb27dbe-9575-43e7-8c54-917869189dbd">4,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2df0a857498b4af18745e51eab13a016_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTItNy0xLTEtMzQ0MDE_82820a12-a8cb-4d20-b1b2-e5b7023cf498">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTMtMS0xLTEtMzQ0MDE_37b15083-951d-40c4-85ef-d1f24b6cee70">8,668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTMtMy0xLTEtMzQ0MDE_68525fb4-7d47-4c4e-b9e2-6760bfe2bacb">2,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTMtNS0xLTEtMzQ0MDE_0e76fa5a-155b-4180-a057-42caa1c0d76c">24,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTMtNy0xLTEtMzQ0MDE_3ff5df78-052a-450d-9d10-3aa87b64c7c7">4,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:CostOfSalesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3Ng_a1c80d63-4360-4f4a-856a-d9b23db3aafe" continuedAt="ifea649dc94dd488d89b62e05cb855f11" escape="true">Cost of Sales </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ifea649dc94dd488d89b62e05cb855f11">Cost of sales consists primarily of manufacturing overhead costs, material costs and direct labor, including stock-based compensation. A significant portion of the Company&#8217;s cost of sales currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of sales also includes depreciation expense for production equipment, warranty and field service costs, and purchased intangibles and certain direct costs such as shipping costs.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3Nw_d9325d17-6d7e-467c-a735-5d81ce510da5" continuedAt="i28b992babc63450fb36bc47460666e15" escape="true">Research and Development </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i28b992babc63450fb36bc47460666e15">Research and development costs are expensed as incurred. Research and development costs consist primarily of engineering, product development, and regulatory affairs, consulting services, materials, depreciation and other costs associated with products and technologies being developed, including employee and non-employee compensation, stock-based compensation, supplies, quality assurance expenses, related travel expenses and facilities expenses.</ix:continuation> </span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3OA_032cd9a1-39d8-4819-834b-2e50c4cd4dd6" continuedAt="i3981c5b5045a4713be4e784659520c30" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a payment equity incentive plan to provide long-term incentives for employees, consultants and members of the board of directors. The plan allows for the issuance of non-statutory and incentive stock options to employees and non-statutory stock options to consultants and non-employee directors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to determine the fair value of equity incentive awards and recognize compensation expense for all equity incentive awards made to employees and directors, including employee stock options. Stock-based compensation expense is recognized over the requisite service period in the statements of operations and comprehensive loss. The Company uses the straight-line method for expense attribution.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation model used for calculating the fair value of awards for stock-based compensation expense is the Black-Scholes option-pricing model (the &#8220;Black-Scholes model&#8221;). The Black-Scholes model requires the Company to make assumptions and judgments about the variables used in the calculation, including the fair value of the Company&#8217;s common stock, the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate and an expected dividend rate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s common stock underlying the stock options has historically been determined by the Company&#8217;s board of directors (&#8220;Board&#8221;). Because there was no public market for the Company&#8217;s common </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i804d48e309a847a499ae7da92e504e15" continuedAt="ib357cab6e0524ecf809e5de0f813393d"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i3981c5b5045a4713be4e784659520c30">stock prior to the IPO, the Board determined the fair value of the Company&#8217;s common stock at the time of grant of the option by considering a number of objective and subjective factors, including valuations of comparable companies, sales of the Company&#8217;s redeemable convertible preferred stock, operating and financial performance and the general and industry-specific economic outlook. The Company used the &#8220;simplified method&#8221; to determine the expected term of the stock option. Expected volatility is based on an average of the historical volatilities of the common stock of publicly-traded companies with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected term of the option. The Company has elected to account for forfeitures when they occur.</ix:continuation></span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="prct:CommonStockValuationPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3OQ_7582bbf7-bbc5-4aef-9e36-48911e9de571" continuedAt="i73cfc0133a6a48e69f5dcc633bcd2244" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Valuation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intent has been to grant all options with an exercise price not less than the fair value of its common stock underlying those options on the date of grant. Prior to its IPO, the Company has determined the estimated fair value of its common stock at each valuation date in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Practice Aid&#8221;). The Company&#8217;s board of directors, with the assistance of management, developed these valuations using significant judgment and taking into account numerous factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">valuations of its common stock with the assistance of independent third-party valuation specialists;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the stage of development and business strategy, including the status of research and development efforts, of its products and product candidates, and the material risks related to its business and industry;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of operations and financial position, including its levels of available capital resources;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the valuation of publicly traded companies in the life sciences and medical device sectors, as well as recently completed mergers and acquisitions of peer companies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prices of its redeemable convertible preferred stock sold to investors in arm&#8217;s length transactions and the rights, preferences, and privileges of its redeemable convertible preferred stock relative to those of its common stock;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering or a sale of the Company given prevailing market conditions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of the Company&#8217;s stockholders to freely trade its common stock in the public markets, resulting in a discount to reflect the lack of marketability of the Company&#8217;s common stock based on the weighted-average expected time to liquidity. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trends and developments in its industry; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external market conditions affecting the life sciences and medical device industry sectors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s board of directors determined the fair value of its common stock by first determining the enterprise value of the Company&#8217;s business using the market approach, income approach or from the value implied by the latest round of equity financing, and then allocating the value among the various classes of its equity securities to derive a per share value of its common stock. The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all option granted prior to the Company&#8217;s IPO in September 2021, the Board allocated the enterprise value based on the option pricing method (&#8220;OPM&#8221;). OPM treats the rights of the holders of preferred and common stock as equivalent to call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders of preferred stock, as well as their rights to participation and conversion. Thus, the estimated value of the common stock can be determined by estimating the value of its portion of each of these call option rights. When valuing options granted round the time of an equity financing that is considered arms-</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ib357cab6e0524ecf809e5de0f813393d" continuedAt="ib2696b2e51aa4f668c52263f389d23d7"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i73cfc0133a6a48e69f5dcc633bcd2244">length, OPM derived the Company&#8217;s equity value of a company from the price of the securities issued by the Company in the equity financing. Following the completion of the Company&#8217;s IPO in September 2021, the fair value of the Company&#8217;s common stock is determined based on the closing price of its common stock on The Nasdaq Global Market.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4MA_5d72a835-7c8c-42c9-b251-64a6645cbb73" continuedAt="ic6c4bc35db0c477fa1a407059d40f057" escape="true">Advertising Expenses </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic6c4bc35db0c477fa1a407059d40f057">The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were not significant.</ix:continuation> </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4MQ_c696f16a-c701-4a31-a027-21a37302f616" continuedAt="i1deeaa6501b94752acad5d0d23742bc8" escape="true">Defined Contribution Plan</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1deeaa6501b94752acad5d0d23742bc8">The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their annual compensation on a pre-tax basis.</ix:continuation> The Company is authorized to make matching contributions but has not made such contributions for the three and nine months ended September 30, 2021 and 2020.</span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4Mg_81d4cb19-b602-4f39-82de-1ef468b7fc5b" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established when necessary to reduce deferred tax assets to the amounts expected to be realized. Currently, the Company has recorded a full valuation allowance against its deferred tax assets and there is no provision for income taxes, as the Company has incurred operating losses to-date. The Company&#8217;s policy is to record interest and penalties expense related to uncertain tax positions as a component of income tax expense in the statement of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg5NjkyNg_5a16d820-0a56-49d7-a68f-5b2309920dfa" continuedAt="i72fc93b5d4a6477387431bf9b55a2e8e" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalent shares from dilutive stock options and common stock warrants outstanding during the period. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods as all potentially dilutive securities were antidilutive in those periods.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i72fc93b5d4a6477387431bf9b55a2e8e">The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company&#8217;s redeemable convertible preferred stock participated in any dividends declared by the Company and were therefore considered to be participating securities.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the Company&#8217;s IPO in September 2021, all <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjY2Mg_080bcfa1-af45-4252-af29-85b40683fa55"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjY2Mg_c67bb575-5e73-493b-9fee-a555ef693c48">29,912,264</ix:nonFraction></ix:nonFraction> shares of its then-outstanding redeemable convertible preferred stock automatically converted into <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3Mjc2NQ_080bcfa1-af45-4252-af29-85b40683fa55"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3Mjc2NQ_c67bb575-5e73-493b-9fee-a555ef693c48">29,912,264</ix:nonFraction></ix:nonFraction> shares of common stock.</span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY5Mw_02f341be-ad34-46ad-878d-3e7c3d5348eb" escape="true"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY5Mw_a884cdb4-b3cd-443b-be4d-b8c99b44069f" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share was determined as follows (in thousands, except per share amounts): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfMy0xLTEtMS0zNDQwMQ_4d2794ba-1b3c-4098-9471-791f6da8a5b2">14,103</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfMy0zLTEtMS0zNDQwMQ_2d028043-5036-40fc-a289-6c40c8a64319">12,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfMy01LTEtMS0zNDQwMQ_5b159ebb-4162-4d23-a45e-b51610acce25">41,505</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" format="ixt:num-dot-decimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfMy03LTEtMS0zNDQwMQ_e726fdae-6822-480a-94fd-6857130a761e">37,741</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC0xLTEtMS0zNDQwMQ_89e1e34e-1d3c-414f-b093-48e9d0a10ef6"><ix:nonFraction unitRef="shares" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC0xLTEtMS0zNDQwMQ_adf39b38-6544-403a-b27e-d68be620d580">11,580</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC0zLTEtMS0zNDQwMQ_324c98f1-b9b9-4c3f-a31e-5d510ff9cba5"><ix:nonFraction unitRef="shares" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC0zLTEtMS0zNDQwMQ_b09392b6-6337-4d88-bd83-d484b2c5893a">4,329</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC01LTEtMS0zNDQwMQ_2309d38a-1bbb-4c50-91ee-ff63be3a8569"><ix:nonFraction unitRef="shares" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC01LTEtMS0zNDQwMQ_659b361b-9336-4cd0-a6df-f5ac2abc96f4">7,361</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC03LTEtMS0zNDQwMQ_8922e589-e8b5-4294-a002-b693fadac5c5"><ix:nonFraction unitRef="shares" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC03LTEtMS0zNDQwMQ_d53b85b9-d85b-499a-a025-01dfe46a571d">3,327</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS0xLTEtMS0zNDQwMQ_030aee9f-41e0-4613-a893-6264d0155090"><ix:nonFraction unitRef="usdPerShare" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS0xLTEtMS0zNDQwMQ_fd4ef9bd-5648-429f-945e-4d41afb0e925">1.22</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS0zLTEtMS0zNDQwMQ_67d1b832-7193-422c-bfcc-a186487fc782"><ix:nonFraction unitRef="usdPerShare" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS0zLTEtMS0zNDQwMQ_b7e46c66-c7a8-4db0-836a-62a4ec935d06">2.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS01LTEtMS0zNDQwMQ_274b2b0b-f7ce-4fb1-ba72-60ba461457fd"><ix:nonFraction unitRef="usdPerShare" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS01LTEtMS0zNDQwMQ_285fe056-6d49-4a00-b6f0-e25ffc06b666">5.64</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS03LTEtMS0zNDQwMQ_4927145d-ff6f-40eb-ba08-79b9baea24b5"><ix:nonFraction unitRef="usdPerShare" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS03LTEtMS0zNDQwMQ_4b06c655-a679-47f7-a4c0-93c2c00876a4">11.34</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ib2696b2e51aa4f668c52263f389d23d7" continuedAt="ie85885ade1d64c6c8bc29422acb86f9b"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzcxNw_913e9c6c-7f4a-4259-9139-b50de56299d4" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computations of weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5de6b566d9af4bbbbdb356901e72ac2f_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfMy0xLTEtMS0zNDQwMQ_1fcb0f98-3e87-441c-8b55-174dde97539c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39c4d84b986e41378d377fdb579b0a86_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfMy0zLTEtMS0zNDQwMQ_ed24625b-a1b0-4093-9b92-a60577ec8dd0">25,402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb2eba5a66004f438219847cad5c1e9a_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNC0xLTEtMS0zNDQwMQ_f3d92a1b-582d-42bb-ba70-b8c029bab222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb63ff2219e442f2819551ec884c0008_D20200101-20200930" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNC0zLTEtMS0zNDQwMQ_65c166ae-a243-44f8-930a-3a48a9c7c4bb">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic982c9e58b554c3082d06d2c3a72e4fd_D20210101-20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNS0xLTEtMS0zNDQwMQ_85fce5f8-ac33-4ffe-95f6-340918342331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i49ee07a01cc44074a4d6e760f58e4643_D20200101-20200930" decimals="INF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNS0zLTEtMS0zNDQwMQ_7987709e-952c-4697-ace1-9dea8d2b31d1">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe92bd4b50d543f59cb5bba7fd59e5d6_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNi0xLTEtMS0zNDQwMQ_99bbf775-a686-4839-b2d9-920140160303">6,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib43d1b122a854476a24a6c9ee1ab3406_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNi0zLTEtMS0zNDQwMQ_70205049-faf5-4619-a0bc-09692bc96da6">6,143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNy0xLTEtMS0zNDQwMQ_5d3bfc07-8eab-487c-a8e0-b9927504f92b">6,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNy0zLTEtMS0zNDQwMQ_7d2001b8-87a4-4517-beac-d0e8a9d6b180">31,629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss consists of net loss and changes in unrealized gains and losses on cash equivalents and available-for-sale marketable securities. Accumulated other comprehensive income (loss) is presented in the accompanying balance sheets, when applicable. </span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4Mw_e079b64f-c1cd-4c7e-881a-8d8631ddb22b" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment, Geographical and Customer Concentration </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. The Company&#8217;s assets are primarily based in the United States.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No customers accounted for more than 10% of revenue during the three and nine months ended September 30, 2021. Three customers accounted for <ix:nonFraction unitRef="number" contextRef="i621e3ef4440f48c2b9f769e24af4620f_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2Mzg2OA_5301e594-6534-42d2-a1c5-1452dece9eca">16</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i9bfac2758f3446a3ad3a43b3803a084a_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2Mzg3Mw_1e9bfc52-0f4c-431f-b3a5-f09a075faca8">13</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i8bc8fda665ae45fda75450551e6878fb_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2Mzg4MQ_8666f45e-6403-4feb-9cbf-a2a0174ac856">13</ix:nonFraction>% of revenue during the three months ended September 30, 2020. No customers accounted for more than 10% of revenue during the nine months ended September 30, 2020. </span></div><ix:continuation id="i3912529e75c447cf97a5a30bd9b8ebf4"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by significant geographical locations outside the United States for the periods presented:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7708603bb2ff47579ddc870b44b0fbb0_D20200701-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjMwMzdlYTIzNzRiYjQ4ZGZhMjBhNGUwOTM5ZjZiMTdiL3RhYmxlcmFuZ2U6MzAzN2VhMjM3NGJiNDhkZmEyMGE0ZTA5MzlmNmIxN2JfMy0zLTEtMS00MjQ1MQ_c1b54428-8e9f-4919-94a1-ef8a02d36142">41</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i52f5aefc16b34dfda582cd7651908024_D20200101-20200930" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjMwMzdlYTIzNzRiYjQ4ZGZhMjBhNGUwOTM5ZjZiMTdiL3RhYmxlcmFuZ2U6MzAzN2VhMjM3NGJiNDhkZmEyMGE0ZTA5MzlmNmIxN2JfMy03LTEtMS00MjQ1Nw_b6f7e5de-6d46-4a49-a94c-a3589ce7b784">32</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Less than 10% of total net revenues for the period indicated.</span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No customers accounted for more than 10% of accounts receivable at September&#160;30, 2021. Two customers each accounted for <ix:nonFraction unitRef="number" contextRef="i62921dc1224a460e89216f894a1e2b07_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3Mjg3NQ_99cd408f-b3ed-436b-bd53-492c4c2dfa31">22</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0ac307246bd746a78220da47930dbd09_D20200101-20201231" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3Mjg4MQ_c7a935bb-1c8d-4d3d-baab-0aa8ebe6d9c5">13</ix:nonFraction>% of accounts receivable at December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="prct:JobsActAccountingElectionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4NA_0d93582a-c29d-4968-abae-a3914f86f215" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act Accounting Election </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to avail itself of this exemption and, therefore, for new or revised accounting standards applicable to public companies, the Company will be subject to an extended transition period until those standards would otherwise apply to private companies.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NjY4OQ_7d0a5a83-be99-4628-b30f-69c564212a77" continuedAt="i9b53392137744d1f908ad32abe1ce825" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2018-13&#8221;). The amendments on changes in unrealized gains and losses recognized in other comprehensive income categorized within Level 3, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively in the initial fiscal year of adoption. All other amendments </span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ie85885ade1d64c6c8bc29422acb86f9b"><ix:continuation id="i9b53392137744d1f908ad32abe1ce825"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should be applied retrospectively to all periods presented upon their effective date. The Company adopted ASU 2018-13 as of January 1, 2020, which did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (&#8220;ASU 2018-11&#8221;). ASU 2018-11 provided an alternative implementation method in addition to the current modified retrospective transition method for ASU No. 2016-2, Leases: Amendments to the FASB Accounting Standards Codification (&#8220;ASU 2016-2&#8221;), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-2, a lessee is required to recognize assets and liabilities for leases with lease terms of more than twelve months. ASU 2016-2 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted ASC Topic 842, Leases, on January 1, 2020 using the modified retrospective transition method. In addition, the Company elected certain practical expedients permitted under the transition guidance, which allowed it to carryforward its historical long-term lease classification, its assessment on whether a contract is or contains a lease and the treatment of its initial direct costs for any leases that existed prior to the adoption of Topic 842. In determining the lease term at commencement date, any renewal or termination options are considered if they are reasonably assured of exercise. The Company has elected to exclude from its consolidated balance sheet any leases having a term of 12 months or less. The Company recorded a right-of-use leased asset of approximately $<ix:nonFraction unitRef="usd" contextRef="icec9f26499284935a6a375b0c451fdcb_I20200101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3Mjk0Mw_98b24172-f871-4b57-b637-60baa9decd12">6.0</ix:nonFraction> million and a corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="icec9f26499284935a6a375b0c451fdcb_I20200101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3Mjk1OQ_65270e02-53a5-4309-9b1f-0bb0a364af6c">7.4</ix:nonFraction> million in its adoption of Topic 842. In addition, as of the adoption date, the Company derecognized a deferred rent obligation of $<ix:nonFraction unitRef="usd" contextRef="icec9f26499284935a6a375b0c451fdcb_I20200101" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3Mjk3NQ_ee847e22-9b0b-41b0-b07f-c5985d3d9e2f">1.4</ix:nonFraction> million. There was no cumulative effect adjustment upon the adoption of Topic 842.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;), which requires an entity to utilize a new impairment model known as the current expected credit loss (&#8220;CECL&#8221;) model to estimate its lifetime &#8220;expected credit loss&#8221; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. This standard is effective for fiscal periods beginning after December 15, 2021, and for fiscal years beginning after December 15, 2020 for public business entities. The Company adopted ASU 2019-12, effective of January 1, 2021, and the adoption did not have a material impact on its consolidated financial statements.</span></div></ix:continuation></ix:continuation><div id="id6896dbd221a471485ce149196fbcf44_40"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzMg_5f77ea1b-672d-4edb-a7c6-5bd3a32718d0" continuedAt="i52228173becf4eaa91793f0df7b52b93" escape="true">Composition of Certain Consolidated Financial Statement Items </ix:nonNumeric></span></div><ix:continuation id="i52228173becf4eaa91793f0df7b52b93" continuedAt="i1b62341e7b0f42f28749ab429e92d2cb"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzNw_b64c7fff-4065-44cb-9ce6-ee5128f90b04" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"></td><td style="width:65.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.224%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfMy0xLTEtMS0zNDQwMQ_137d8c0b-f062-451d-af4c-67a34fee5e80">4,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfMy0zLTEtMS0zNDQwMQ_1a07f994-65d2-48c2-b174-e3d08d17cc8f">2,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNC0xLTEtMS0zNDQwMQ_f219c7ed-536a-4f08-bc64-b3c9e0dfd385">612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNC0zLTEtMS0zNDQwMQ_eee95bb4-c88e-48b0-9d17-3133b20bbbb2">51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNS0xLTEtMS0zNDQwMQ_16153de8-9875-4ddc-8f0a-7735beab684e">5,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNS0zLTEtMS0zNDQwMQ_7523f6a9-7877-4cb6-8ac4-baea4cee1672">4,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNi0xLTEtMS0zNDQwMQ_54fa2212-baaa-406e-b260-f6f2ed41ca44">10,401</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNi0zLTEtMS0zNDQwMQ_17f3cb9c-7679-4751-bb46-2bf4ac4fedfa">6,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i1b62341e7b0f42f28749ab429e92d2cb" continuedAt="ia0c68e02250f40d9a394d9eccfdfb89f"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzNA_1232030a-7988-408f-814a-a03b642efc97" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"></td><td style="width:65.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.224%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="prct:PrepaidInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfMy0xLTEtMS0zNDQwMQ_84a3cecf-c19b-499a-baf9-0fb9c6e6e8b0">310</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="prct:PrepaidInventory" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfMy0zLTEtMS0zNDQwMQ_0a88c0ee-06ed-4378-847e-7b1fba0e0b20">553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="prct:PrepaidSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNC0xLTEtMS0zNDQwMQ_c7a87fd6-d007-4035-9492-5d730cbe2a9c">580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="prct:PrepaidSoftware" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNC0zLTEtMS0zNDQwMQ_ad55820f-d775-469e-a285-b1565108167e">375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:PrepaidRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNS0xLTEtMS0zNDQwMQ_4038008b-3f28-404c-9e93-f27926a464d0">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:PrepaidRent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNS0zLTEtMS0zNDQwMQ_12f3ff16-9130-4b29-928b-b544bf4876f5">245</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNi0xLTEtMS0zNDQwMQ_fdd75a2d-8419-4c89-b579-5ddddc1285b9">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:PrepaidInsurance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNi0zLTEtMS0zNDQwMQ_08480654-fdcb-4da4-927c-4d03d0639825">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNy0xLTEtMS0zNDQwMQ_d875548e-38dd-4564-b18a-471b1c36fee5">643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:OtherPrepaidExpenseCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNy0zLTEtMS0zNDQwMQ_9f2f2c6b-443e-4607-ba5c-8b5524c73df9">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfOC0xLTEtMS0zNDQwMQ_d867ba8c-4673-4a94-b4e2-5f5a786a4111">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfOC0zLTEtMS0zNDQwMQ_42baaedf-7aec-429a-aecf-14af2d73b2c5">1,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzNQ_edc65a2b-d2a3-443f-b661-0a9142ddb159" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"></td><td style="width:65.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.224%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory, manufacturing and computer equipment and furniture</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ecf903be504ecdaf949aece1345593_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNC0xLTEtMS0zNDQwMQ_2949ce60-5a3a-4eb3-926e-dc9956d53aad">2,911</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic86cf6a985714467a558f903d60ea686_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNC0zLTEtMS0zNDQwMQ_f61722c3-cfa1-4776-918d-3946a4981b41">2,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cacff96a36941f49fc136cd9987bba8_I20210930" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNi0xLTEtMS0zNDQwMQ_cb5fe1e7-92a2-4319-aa83-12b269fa5281">821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56f7a99ae3cc46a48d7f360c4949ca50_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNi0zLTEtMS0zNDQwMQ_8f6ca15f-4178-4012-9252-9243a0c15f11">1,247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0930250516e46df8adee1ddbea619bb_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNy0xLTEtMS0zNDQwMQ_46120463-48da-481f-babf-2e4b8880dca3">4,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id08e754d707e4d5ca56a878c541eb772_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNy0zLTEtMS0zNDQwMQ_d55495a8-8d6e-4f56-9c6d-709c4e6524c2">4,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluation units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia890f1a1f9ea4925ac24d0577d19ee3c_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfOC0xLTEtMS0zNDQwMQ_732a198f-be64-47b5-afa3-38f07f1fa0d0">3,492</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2daf6e575dd487a9593c9105221c75c_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfOC0zLTEtMS0zNDQwMQ_894152d3-0049-4fb2-b0ea-2d085eaf15ad">4,229</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfOS0xLTEtMS0zNDQwMQ_0df8e0fd-34e7-497d-a0f0-623b88fdb981">12,165</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfOS0zLTEtMS0zNDQwMQ_e07a7a2b-259d-4add-8368-6e20a672a3d0">13,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfMTAtMS0xLTEtMzQ0MDE_18facadd-cada-4cdd-9ca0-3fd98de58789">6,434</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfMTAtMy0xLTEtMzQ0MDE_f3a58492-3884-400a-85fd-f05c367ae0fb">4,788</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfMTEtMS0xLTEtMzQ0MDE_dc685417-88cf-4344-bca9-53e8e7c79dc7">5,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfMTEtMy0xLTEtMzQ0MDE_ca61d579-e14d-4479-a363-4003a178749c">8,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzNg_a672d2fc-583d-447d-8ba8-41a4af64cb3b" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"></td><td style="width:65.504%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.222%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.550%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.224%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued purchases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="prct:AccruedPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMy0xLTEtMS0zNDQwMQ_e099ddcb-4cef-4032-9ae4-4a6b104a20ef">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="prct:AccruedPurchases" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMy0zLTEtMS0zNDQwMQ_3ff60dbb-adb7-4f68-80f6-7028e9666759">432</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNC0xLTEtMS0zNDQwMQ_627a3d83-5199-457d-9685-d5e8cb2a1289">390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:InterestPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNC0zLTEtMS0zNDQwMQ_368993af-3900-4a25-a647-bb027e8be006">403</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNS0xLTEtMS0zNDQwMQ_4629f339-fde0-49d1-99cc-ea45ea02f6c5">579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNS0zLTEtMS0zNDQwMQ_8f6218c3-adf9-4e60-a6a4-b6dab180e08a">339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNi0xLTEtMS0zNDQwMQ_df57d97c-40a5-4f8c-ba42-ca15988393e6">482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:SalesAndExciseTaxPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNi0zLTEtMS0zNDQwMQ_4ac46d47-5689-486c-a49a-2288747030a9">302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="prct:AccruedClinicalTrialExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfOC0xLTEtMS0zNDQwMQ_32528439-2c55-4325-98d2-4348b12dc430">117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="prct:AccruedClinicalTrialExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfOC0zLTEtMS0zNDQwMQ_1c5aa8be-f6c4-4dae-b799-7d59a7da1543">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMTItMS0xLTEtMzQ0MDE_f525d78f-06bf-469e-b790-8f9da98ba67e">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMTItMy0xLTEtMzQ0MDE_2d0daa81-6a77-4574-bf56-a287db361462">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMTMtMS0xLTEtMzQ0MDE_8729920d-7431-4ece-9fc1-1b6e0586f326">2,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMTMtMy0xLTEtMzQ0MDE_e0f959ee-5d58-4482-9ea5-ab94cebd77a2">1,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, other non-current liabilities consisted of an asset retirement obligation for the facility lease.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ia0c68e02250f40d9a394d9eccfdfb89f"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzOQ_761323a8-f112-4f8a-8d2a-1b797dbdcc8d" escape="true"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income (Expense), net (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfMy0xLTEtMS0zNDQwMQ_b1299a52-a9bd-4253-b292-3bb9fcf30703">22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfMy0zLTEtMS0zNDQwMQ_14e6fb0f-a15c-44f6-ad9b-6f062217eedc">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfMy01LTEtMS0zNDQwMQ_53a56366-4523-49c2-8a00-7e22da6456fd">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfMy03LTEtMS0zNDQwMQ_c7d63d6e-e301-4d04-90a9-0b4340e415ba">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in fair value of preferred stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNC0xLTEtMS0zNDQwMQ_09b055b8-5fcd-46a7-9b00-1c70ac4ff303">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNC0zLTEtMS0zNDQwMQ_8eba6215-148b-4b6c-b6a2-0ae4c1c1c3fc">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNC01LTEtMS0zNDQwMQ_4206eb4e-be18-4bec-bdab-b95986c1af70">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:FairValueAdjustmentOfWarrants" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNC03LTEtMS0zNDQwMQ_c37d7df3-9f2a-4338-82a3-e68bcf918e97">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in fair value of loan facility derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNS0xLTEtMS0zNDQwMQ_89762a6b-3bd8-4f11-a8c7-aa7fcb1e631b">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNS0zLTEtMS0zNDQwMQ_1ba0c8ea-5b1c-437d-b47b-8af2ba4f23c8">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNS01LTEtMS0zNDQwMQ_4cab714c-3e9d-4d2b-8c6c-5f50bac29a3e">158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNS03LTEtMS0zNDQwMQ_c226cb6c-4859-41c2-9775-f6237a79763d">41</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNi0xLTEtMS0zNDQwMQ_a53a9839-5eb7-4514-bb82-694dc9e3dcac">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNi0zLTEtMS0zNDQwMQ_111dbc41-9488-45c0-accd-8b89ce5f6055">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNi01LTEtMS0zNDQwMQ_d02f2582-1363-48bf-86a8-564c8eab1ebb">87</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNi03LTEtMS0zNDQwMQ_c523300b-ea70-4908-9106-6edb383d64e9">9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest and other income (expense), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" name="prct:InterestAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNy0xLTEtMS0zNDQwMQ_9dc4a486-7e17-432d-a95a-cfe5878dc6c9">163</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" name="prct:InterestAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNy0zLTEtMS0zNDQwMQ_95983e6e-4558-4619-b871-ad7bcce2654c">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" name="prct:InterestAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNy01LTEtMS0zNDQwMQ_4768f2f5-8f64-413f-aa8c-7a6722aaf123">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" name="prct:InterestAndOtherIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNy03LTEtMS0zNDQwMQ_b9eb81e4-c608-4777-b5c4-0eca49de4cbd">344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id6896dbd221a471485ce149196fbcf44_43"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfOTM0NTg0ODgzODQ0NQ_e7de680b-059d-4d1a-9e93-631f4d32a828" continuedAt="i91b3934721114dc391a2ef3839ca09a3" escape="true">Intangible Assets </ix:nonNumeric></span></div><ix:continuation id="i91b3934721114dc391a2ef3839ca09a3"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company entered into a license agreement with HydroCision, Inc. This agreement grants the Company an exclusive, perpetual, irrevocable, worldwide, fully paid-up license to develop, manufacture and commercialize products in the field of urology using the patented technology and know-how controlled by HydroCision as of the effective date and as well as new patented technology developed by HydroCision that cover certain activities and improvements that relate to the use of fluid jet technology in connection with the licensed products during the period commencing on the effective date and ending on the earlier of the date that the Company ceases to use HydroCision&#8217;s existing contract manufacturers and the third anniversary of the effective date. Also included is the right to utilize HydroCision&#8217;s contract manufacturers, if desired. The consideration paid was a one-time upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i323691aee3ba4470beeb781efc9f7d5a_D20190301-20190331" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfMTA5OTUxMTYyOTU2Nw_b3d11ab4-daf7-45ba-acfc-3f8c03c49eca">2.5</ix:nonFraction> million, as well as allowing HydroCision (a reciprocal license) to use any new patented technology and know-how developed by the Company relating to the HydroCision patented technology and know-how in the field of urology for HydroCision use outside the field of urology. HydroCision will pay for any patent maintenance fees on HydroCision&#8217;s licensed patents. As of September&#160;30, 2021 and December&#160;31, 2020, accumulated amortization was $<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfNDM5ODA0NjUxMzQ1Nw_8509a7c8-7c03-4550-a03b-44653a5f073c">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfMTA5OTUxMTYyOTYyMA_b77d432b-1f88-409b-a6d6-d31362149317">0.5</ix:nonFraction> million, respectively, and the net carrying amount is expected to be amortized at a rate of $<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="prct:FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfMTA5OTUxMTYyOTY1Mw_95b80278-2644-4265-a1b6-1c60bd23e656">0.3</ix:nonFraction> million per year until fully amortized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $<ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfNDM5ODA0NjUxMzQ4OA_141db712-5cde-491d-b8dc-1855d673a140"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfNDM5ODA0NjUxMzQ4OA_6dc52d08-f60e-4d6c-a246-5afa8b16b044">0.1</ix:nonFraction></ix:nonFraction> million for each of the three months ended September 30, 2021 and 2020, and $<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfNDM5ODA0NjUxMzUwOA_237358cc-525d-428d-975c-11e041404419"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfNDM5ODA0NjUxMzUwOA_2c9a86a4-b0ae-46b9-a1b4-58d92c68c014">0.2</ix:nonFraction></ix:nonFraction> million for each of the nine months ended September 30, 2021 and 2020.</span></div></ix:continuation><div id="id6896dbd221a471485ce149196fbcf44_46"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTI3MQ_9b027d63-3ef9-4025-985a-11e3b7a7f4b9" continuedAt="i46b22d7012764868a2f5d1a3e73046dc" escape="true">Loan Facility </ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i46b22d7012764868a2f5d1a3e73046dc" continuedAt="id8e347f3c226429cb84febcad87bd182">In September 2019, the Company entered into a loan facility for up to $<ix:nonFraction unitRef="usd" contextRef="ic9df1ea4e38a48c3958b823d207dc494_I20190930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTg3MA_c6e7cedd-7f7d-4802-bfdf-76c674401bc4">75</ix:nonFraction> million available in <ix:nonFraction unitRef="installment" contextRef="ic9df1ea4e38a48c3958b823d207dc494_I20190930" decimals="INF" format="ixt-sec:numwordsen" name="prct:LineOfCreditFacilityNumberOfInstallments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4Nw_2dfdc7f1-7b9b-4b59-adba-617c99f3b213">four</ix:nonFraction> installments. The Company borrowed $<ix:nonFraction unitRef="usd" contextRef="ie747bb89dfe9448486f081a8d7c662b9_D20210901-20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTg4NQ_1cc652f3-ce8d-443f-8fff-8f1277f568c1">25</ix:nonFraction> million in September 2019. An additional $<ix:nonFraction unitRef="usd" contextRef="i69e54cc3200146fb8da3275f099dcd86_D20200301-20200331" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTkwMA_3c78ebad-9b55-440d-80d4-c9fe63e61f34">25</ix:nonFraction> million was borrowed in March 2020. The third installment of $<ix:nonFraction unitRef="usd" contextRef="i9e17326bb20948edb8a8ca7d92913aaa_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTkxNQ_783ec568-2b1b-4395-8bc4-03ad5c2cd874">10</ix:nonFraction> million was originally available for draw through March 31, 2021 contingent upon achieving $<ix:nonFraction unitRef="usd" contextRef="id581c96bb97e44a48ba70ae2493b16db_D20210101-20210331" decimals="-6" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTkzMA_0bfeb69b-1221-4453-86b7-8fddf2da2951">20</ix:nonFraction> million in trailing six months revenue. In January 2021, the third installment was amended to be available for draw through June 30, 2021 contingent upon achieving $<ix:nonFraction unitRef="usd" contextRef="idc0b522093084b14a072138407b528ec_D20210101-20210131" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTk1NA_ee387057-f7f9-4ec3-ae0c-8a0ee33ea2da">6.4</ix:nonFraction> million trailing six months revenue. The remaining $<ix:nonFraction unitRef="usd" contextRef="i8d291c059d984acabb11a4e041ff93bc_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTk3OQ_64d6260b-384b-4dd4-a523-be8dde369365">15</ix:nonFraction> million was originally available for draw through June 30, 2021 and is contingent upon achieving $<ix:nonFraction unitRef="usd" contextRef="i9578e35c34594195b4553614451e762d_D20210101-20210630" decimals="-6" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTk5NA_a66cf3b5-964d-452d-9c1b-18f1c049168d">25</ix:nonFraction>&#160;million in trailing six months revenue. In January 2021, this installment was amended to be available for draw through June 30, 2022. The facility bears an interest rate of <ix:nonFraction unitRef="number" contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMjAxMw_728fcc21-c776-4008-ba43-22b198eaed56">9.37</ix:nonFraction>%, which is <ix:nonFraction unitRef="number" contextRef="ie2270b85069d4e108aafb93ea6264888_D20210101-20210930" decimals="INF" name="us-gaap:LineOfCreditFacilityInterestRateDuringPeriod" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMjAyMQ_795e385b-28f1-4b32-91f9-4b6d9121406c">7.17</ix:nonFraction>% plus the greater of <ix:nonFraction unitRef="number" contextRef="i03b0c48c8ac947c3a489c6f136a47201_D20210101-20210930" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMjAyOA_0de70838-1bc5-4930-914f-e4d3e73f0504">2.2</ix:nonFraction>% or 30-day LIBOR. The initial term of the facility is <ix:nonNumeric contextRef="iee83fb3442a945c89e3036e0c6098fdb_D20190901-20190930" format="ixt-sec:durmonth" name="us-gaap:DebtInstrumentTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4MQ_eef1f59a-1aa2-48ac-9b31-2dc353a818d3">60</ix:nonNumeric> months with interest-only payments each month for <ix:nonNumeric contextRef="iee83fb3442a945c89e3036e0c6098fdb_D20190901-20190930" format="ixt-sec:durmonth" name="prct:DebtInstrumentInterestOnlyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4MA_7cea175e-c37c-498e-9649-00556f5e114e">24</ix:nonNumeric> months followed by <ix:nonNumeric contextRef="iee83fb3442a945c89e3036e0c6098fdb_D20190901-20190930" format="ixt-sec:durmonth" name="prct:DebtInstrumentPrincipalAndInterestPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA5OA_e34c87e8-52f1-4bd3-b98b-41205d5535f4">36</ix:nonNumeric> months amortization of principal and interest. In January 2021, the interest-only period was amended to <ix:nonNumeric contextRef="ifbe7a57a89de4a8285e98235fc3da48b_D20210101-20210131" format="ixt-sec:durmonth" name="prct:DebtInstrumentInterestOnlyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4Mg_4875ec98-31a6-4a82-9b5d-4aea83793d73">36</ix:nonNumeric> months followed by <ix:nonNumeric contextRef="ifbe7a57a89de4a8285e98235fc3da48b_D20210101-20210131" format="ixt-sec:durmonth" name="prct:DebtInstrumentPrincipalAndInterestPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA5OQ_83c4c6e3-a5d6-457c-97fa-dbd4957bc54d">24</ix:nonNumeric> months amortization (principal and interest) beginning October 1, 2022 since the amended trailing six months target revenue of $<ix:nonFraction unitRef="usd" contextRef="idc0b522093084b14a072138407b528ec_D20210101-20210131" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NTk2MQ_2618ab9d-778c-4b75-8e23-c83b552802cb">6.4</ix:nonFraction> million was achieved, and accordingly, the current portion of the amount due was reclassified to non-current. Upon drawing the final $<ix:nonFraction unitRef="usd" contextRef="i8d291c059d984acabb11a4e041ff93bc_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NTk4NA_81670ef8-547f-4c09-be87-0c22ea44bfa0">15</ix:nonFraction> million tranche, interest-only period is extended <ix:nonNumeric contextRef="ib126ee67697d4fdc82b80a04fe0cc629_D20210101-20210930" format="ixt-sec:durmonth" name="prct:DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4Mw_5e003efb-f749-4b8a-85b4-62aff2e0966e">12</ix:nonNumeric> months followed by <ix:nonNumeric contextRef="ib126ee67697d4fdc82b80a04fe0cc629_D20210101-20210930" format="ixt-sec:durmonth" name="prct:DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTEwMA_9e2ed306-08a4-411a-8b02-f37abd2fb5f3">24</ix:nonNumeric> months amortization of principal and interest. Upon the completion of the Company raising over $<ix:nonFraction unitRef="usd" contextRef="i7425a248d0c54625b60e82800726ba6e_D20210901-20210930" decimals="-6" format="ixt:num-dot-decimal" name="prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjAwOQ_6a77f5ea-34ce-4852-8864-21b4cbcd6463">50</ix:nonFraction> million in its IPO in September 2021, interest-only payments were extended an additional <ix:nonNumeric contextRef="i7425a248d0c54625b60e82800726ba6e_D20210901-20210930" format="ixt-sec:durmonth" name="prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4NA_a3ac46e7-fa16-4516-a82f-5ba7e123a9d6">12</ix:nonNumeric> months followed by <ix:nonNumeric contextRef="i7425a248d0c54625b60e82800726ba6e_D20210901-20210930" format="ixt-sec:durmonth" name="prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTEwMQ_b9994148-b02c-42ad-9649-e627ecebe66b">12</ix:nonNumeric> months amortization of principal and interest. Substantially all assets of the Company are pledged as collateral. Commencing with the earlier of June 30, 2021 and the month following the funding of either the third or final installment, the Company is required to achieve revenues for the previous six months ended equal to the greater of (1) <ix:nonFraction unitRef="number" contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930" decimals="INF" name="prct:DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjAzNA_946acc19-28bf-4d20-9ba2-8506d8f881d3">70</ix:nonFraction>% of the forecast for the commensurate period, (2) $<ix:nonFraction unitRef="usd" contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="prct:DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA0Nw_248410ca-3c52-42d1-a9e1-bb004ed8581c">15</ix:nonFraction> million if neither third or final </ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="id8e347f3c226429cb84febcad87bd182"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">installments have been drawn, (3) $<ix:nonFraction unitRef="usd" contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="prct:DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA2NQ_fee79478-3552-4e64-863e-c31a063527da">20</ix:nonFraction> million if the third but not final installment has been drawn and (4) $<ix:nonFraction unitRef="usd" contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930" decimals="-6" format="ixt:num-dot-decimal" name="prct:DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA4MA_51c84e38-aa36-4482-a032-600d13b54a5d">25</ix:nonFraction> million if both the third and final installments have been drawn.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan facility includes certain fees payable to the lender recorded as a loan discount that are accrued and amortized to interest expense during the loan term. A <ix:nonFraction unitRef="number" contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930" decimals="INF" name="prct:LineOfCreditFacilityFinalPaymentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA4Ng_1839a3e6-9981-4bc5-8ed1-c347fa7e0475">6</ix:nonFraction>% final payment fee of each funded tranche is payable at the earlier of prepayment or loan maturity and a <ix:nonFraction unitRef="number" contextRef="i37a93df4a20d471fa73a04fadd763398_D20210101-20210930" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA5NA_357ce054-fc6b-48f2-9071-3685a9ae6ced">0.25</ix:nonFraction>% facility fee paid at each funded tranche. A prepayment fee was originally payable if the loan is paid before maturity in the amount of <ix:nonFraction unitRef="number" contextRef="ic9df1ea4e38a48c3958b823d207dc494_I20190930" decimals="INF" name="prct:LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA5OQ_96a5e5df-7171-44d1-bf36-eee3a24139ec">3</ix:nonFraction>% of loans outstanding if paid in full during first 12 months, <ix:nonFraction unitRef="number" contextRef="ic9df1ea4e38a48c3958b823d207dc494_I20190930" decimals="INF" name="prct:LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjEwOQ_098b0c26-c3e6-455f-b2ef-c5afcafc07df">2</ix:nonFraction>% if loan is paid in full during second 12 months, or <ix:nonFraction unitRef="number" contextRef="ic9df1ea4e38a48c3958b823d207dc494_I20190930" decimals="INF" name="prct:LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjExOQ_f90f0195-594a-4fee-8d0f-4f27b3bafa9a">1</ix:nonFraction>% if loan is paid in full thereafter before maturity. In January 2021, the prepayment fee was removed as part of the amendments. In addition, the Company should pay the lender&#8217;s loan initiation fees and a fee upon the earlier occurrence of a defined liquidity event, including but not limited to, a merger or sale of the Company&#8217;s assets or voting stock, or achieving a $<ix:nonFraction unitRef="usd" contextRef="i37a93df4a20d471fa73a04fadd763398_D20210101-20210930" decimals="-6" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjEzNQ_df69b854-41dc-45ed-9910-9196253355fe">200</ix:nonFraction> million trailing twelve months revenue target, in each case, by September 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success fees are calculated at the time of the liquidity event occurrence to be $<ix:nonFraction unitRef="usd" contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjQxOQ_123912d6-489d-4f56-9cf2-3cada7ffd8ed">1.0</ix:nonFraction> million if only the first installment has been drawn, $<ix:nonFraction unitRef="usd" contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjQzMw_7c3bb320-2567-43de-b8ac-7886b3cdfba5">2.0</ix:nonFraction> million if the first two installments have been drawn, $<ix:nonFraction unitRef="usd" contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjQ0OQ_6e27bebc-039f-41ec-8d6f-5c9d45644bf7">2.4</ix:nonFraction> million if the first three installments have been drawn, or $<ix:nonFraction unitRef="usd" contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjQ2Mw_1dd9c9b5-8779-4026-aafc-fb10f54ccce5">3.0</ix:nonFraction> million if all four installments have been drawn, in each case, upon the occurrence of the defined liquidity event. The Company determined that this obligation to pay success fees represents freestanding financial instruments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in January 2021 were accounted for as a debt modification under ASC 470-50-40 as the changes in the debt terms are not considered substantial, and thus no gain or loss was recorded and a new effective interest rate was established based on the carrying value of the loan and the revised cash flows.</span></div></ix:continuation><div id="id6896dbd221a471485ce149196fbcf44_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfOTM0NTg0ODgzOTgxOQ_8ac2b1ee-9d8f-492e-90d9-937c8e183951" continuedAt="idb220288602e4e98be782c9ae6259cf8" escape="true">Redeemable Convertible Preferred Stock Warrant Liability </ix:nonNumeric></span></div><ix:continuation id="idb220288602e4e98be782c9ae6259cf8" continuedAt="i20eb8729330b464ca5e473b58b2d3314"><ix:continuation id="i36f73b3b11774253a7e14a9120065ab7"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase shares of redeemable convertible preferred stock outstanding and exercisable are as follows (in thousands, except per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.621%"><tr><td style="width:1.0%"></td><td style="width:8.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:8.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.473%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.484%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.523%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.477%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares Outstanding at</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:10pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Dates</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:10pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0a6641bdf6a04d2a9f8abd5a3282a1c4_I20150731" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC04LTEtMS0zNDQwMQ_11ba3427-7f9f-4863-becc-2131cc8bb163">13.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib8ca34d460bd431e9f40af8ba7f4941d_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC0xMC0xLTEtMzQ0MDE_9665bd98-ec0b-4fe0-a2a3-76a5113c9289">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if5da641970b84172a5c935038a6a1c8e_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC0xMi0xLTEtMzQ0MDE_0c470a4d-01e9-4195-a34a-db9c2291992f">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibecb2734dfdd4390b231ca7dcd3bc7eb_I20170630" decimals="INF" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC0xNi0xLTEtMzQ0MDE_be5995b8-8b14-4679-98c4-6a81273214cb">763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ca34d460bd431e9f40af8ba7f4941d_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC0xOC0xLTEtMzQ0MDE_a7554b3a-eb93-43bc-b818-62c4cee971e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5da641970b84172a5c935038a6a1c8e_I20201231" decimals="-3" name="us-gaap:WarrantsAndRightsOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC0yMC0xLTEtMzQ0MDE_0ca8c1b7-b9e2-4127-bfb7-012113ed7c2f">177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, in connection with the issuance of convertible notes, the Company issued <ix:nonFraction unitRef="shares" contextRef="ifc65b7919fd243f887cb7aa91fed512f_I20150731" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfMTA5OTUxMTYyOTY2Mw_b8fa5185-8dc2-4d0b-ab84-f6bdc816d18c">869,842</ix:nonFraction> redeemable convertible preferred stock warrants that were exercisable into Series D redeemable convertible preferred stock immediately, with $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc65b7919fd243f887cb7aa91fed512f_I20150731" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfMTA5OTUxMTYyOTY3MQ_f351feae-eb5e-44ec-8d5a-16705adf5d9e">5.08</ix:nonFraction> exercise price and expiration in <ix:nonNumeric contextRef="ifc65b7919fd243f887cb7aa91fed512f_I20150731" format="ixt-sec:durwordsen" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfOTM0NTg0ODgzOTgxNg_b72c731d-1f7e-4951-9bb7-c42e25348290">five years</ix:nonNumeric>. During the three and nine months ended September 30, 2020, warrants for <ix:nonFraction unitRef="shares" contextRef="i869c38d090bb4baa8be1f5e855808baa_D20200701-20200930" decimals="INF" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDgzMQ_7f635955-d7b1-419c-9da0-604a34fbd54d">531,423</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i103b94ebee224533bc1827781430d1ba_D20200101-20200930" decimals="INF" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfMTA5OTUxMTYyOTcxMA_4d81142f-8544-447e-af57-53cce89b75ee">651,328</ix:nonFraction> shares were exercised, respectively, and <ix:nonFraction unitRef="shares" contextRef="i4d86103fd3bc4740a8b6c0bfaf50e9e0_I20201231" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxMzc4Ng_bf6a398c-6d51-41bf-87d2-a6f84e81b60b">none</ix:nonFraction> were outstanding at December&#160;31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, in connection with the issuance of convertible notes, the Company issued <ix:nonFraction unitRef="shares" contextRef="i90bf229ad34d4baba483ea11a398bc08_I20170630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfMTA5OTUxMTYyOTcyMA_dcf4a815-c638-450d-842a-5275b6f9e3df">108,145</ix:nonFraction> redeemable convertible preferred stock warrants that were exercisable into Series E or the next round of redeemable convertible preferred stock. During the and three and nine months ended September 30, 2021, <ix:nonFraction unitRef="shares" contextRef="i821880a0f0ea457fb74d98beb2145b75_D20210701-20210930" decimals="INF" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDgxNg_a79c51b0-7c59-4539-90a6-fb3299291210"><ix:nonFraction unitRef="shares" contextRef="i4acb9ad050634e849a2a2923e0940cae_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDgxNg_ce90b69b-fe8a-4a11-81d2-51c3d730e7c7">62,454</ix:nonFraction></ix:nonFraction> warrants were exercised and the remaining unexercised warrants expired, <ix:nonFraction unitRef="shares" contextRef="ide057d850a674c1faa90ee7654a9dcba_I20210930" decimals="INF" format="ixt:fixed-zero" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDgzNQ_750e6288-cab8-463a-882b-89c41a21962f">none</ix:nonFraction> were outstanding at September&#160;30, 2021. During the three and nine months ended September 30, 2020, <ix:nonFraction unitRef="shares" contextRef="i927e6688e0294af2a421eef76a378dca_D20200701-20200930" decimals="INF" format="ixt:fixed-zero" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDY5Nw_1e4c64d4-a08e-4c75-b979-1a254fafbb10"><ix:nonFraction unitRef="shares" contextRef="i3019d42f68fb44eaa750274de9c831ec_D20200101-20200930" decimals="INF" format="ixt:fixed-zero" name="prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDY5Nw_3e40aa1b-f056-4806-9b4b-fd2d659cded0">no</ix:nonFraction></ix:nonFraction> warrants were exercised.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_52"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:continuation id="i20eb8729330b464ca5e473b58b2d3314" continuedAt="i90aa72c7fd384c91875259fb6781a996">Redeemable Convertible Preferred Stock </ix:continuation></span></div><ix:continuation id="i90aa72c7fd384c91875259fb6781a996" continuedAt="i221661049c53482eb830404739d4832f"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:TemporaryEquityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfOTM0NTg0ODg0Njg5NA_a097f9b7-ee41-4fae-81fe-d8855fd099d1" continuedAt="if72a87e5c237440c8099f57cdc9ce513" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s redeemable convertible preferred stock are as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.156%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares<br/>Authorized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares <br/>Issued and Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying <br/>Value <br/>(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied497de295f14e1f827bd811b22ff9f1_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMy03LTEtMS0zNDQwMQ_880b0e92-93a3-4805-b8e9-99589d721a4d">1,243,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied497de295f14e1f827bd811b22ff9f1_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMy05LTEtMS0zNDQwMQ_fcb70220-08ff-4dd7-b091-c7eb4874eb60">1,104,728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied497de295f14e1f827bd811b22ff9f1_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMy0xMS0xLTEtMzQ0MDE_027b234a-9584-4564-9f08-101777ff9e32">2,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie352732829a944e8bcad696ed9555ae7_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNC03LTEtMS0zNDQwMQ_a08d9678-3389-4837-938c-b5713859cf26">1,841,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie352732829a944e8bcad696ed9555ae7_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNC05LTEtMS0zNDQwMQ_6528e1f7-8ca0-435c-a93f-57c42385d02b">1,543,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie352732829a944e8bcad696ed9555ae7_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNC0xMS0xLTEtMzQ0MDE_416555f2-f8c8-4805-abb1-d8fd7ff86b78">5,404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0c5306798ce4d5cbf19af58bc03c7b0_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNS03LTEtMS0zNDQwMQ_6ff4fe39-1d06-4b9e-8b70-248ceffd71b8">1,564,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id0c5306798ce4d5cbf19af58bc03c7b0_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNS05LTEtMS0zNDQwMQ_ca658b3d-b6bc-4208-b629-621cd1d90652">1,564,851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0c5306798ce4d5cbf19af58bc03c7b0_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNS0xMS0xLTEtMzQ0MDE_75e71ac8-9b90-4df1-a88a-f98c62ec720e">7,073</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">D</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9144a17da8024a6fa09ae89276a70ce7_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNi03LTEtMS0zNDQwMQ_9dc536df-5a99-42e6-9a32-9cae8801e191">8,245,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9144a17da8024a6fa09ae89276a70ce7_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNi05LTEtMS0zNDQwMQ_d38023d1-36bd-4106-be38-2e420059e16d">7,547,542</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9144a17da8024a6fa09ae89276a70ce7_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNi0xMS0xLTEtMzQ0MDE_9ea328e1-972c-460f-bfd9-bd321bc7ec4c">36,879</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">E</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86acacb511a247ad99b9d153e72b9538_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNy03LTEtMS0zNDQwMQ_4813201e-2f5f-41f3-a114-5f520536aaa0">8,825,653</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86acacb511a247ad99b9d153e72b9538_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNy05LTEtMS0zNDQwMQ_36adcec8-9c63-43c5-937e-c55075f7a68e">8,414,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86acacb511a247ad99b9d153e72b9538_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNy0xMS0xLTEtMzQ0MDE_3ebd8b70-f0e4-4e09-b198-88393a3efc50">115,229</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">F</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43040eb9775b4ce6978553e3936f3b76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfOC03LTEtMS0zNDQwMQ_30cca840-ca7c-449f-91b8-add0c290d4e4">5,263,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i43040eb9775b4ce6978553e3936f3b76_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfOC05LTEtMS0zNDQwMQ_e07c03df-d3c4-4c59-b68c-46717346d67f">5,226,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43040eb9775b4ce6978553e3936f3b76_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfOC0xMS0xLTEtMzQ0MDE_249a0865-a8c1-4854-8818-24b32f28e3a6">76,488</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesAuthorized" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMTAtNy0xLTEtMzQ0MDE_4c09698a-89d3-4e70-95cc-1d4ce7598c24">26,983,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMTAtOS0xLTEtMzQ0MDE_9f68defa-462a-4940-abd7-f8f455741741"><ix:nonFraction unitRef="shares" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMTAtOS0xLTEtMzQ0MDE_e7a343b3-13ba-4bc5-877a-a5f740d2203b">25,402,402</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMTAtMTEtMS0xLTM0NDAx_28f729e1-91d6-4573-b36b-5e9cb0ac4a78">243,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the Company&#8217;s IPO in September 2021, all <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMjIyMg_080bcfa1-af45-4252-af29-85b40683fa55"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMjIyMg_c67bb575-5e73-493b-9fee-a555ef693c48">29,912,264</ix:nonFraction></ix:nonFraction> shares of its then-outstanding redeemable convertible preferred stock automatically converted into <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMjMyNQ_080bcfa1-af45-4252-af29-85b40683fa55"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMjMyNQ_c67bb575-5e73-493b-9fee-a555ef693c48">29,912,264</ix:nonFraction></ix:nonFraction> shares of common stock and it reclassified $<ix:nonFraction unitRef="usd" contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyNjI2MQ_d5a4071a-8dff-415f-99a3-daf3c6f22d7c">329.5</ix:nonFraction> million of redeemable convertible preferred stock to additional paid-in capital on our condensed consolidated balance sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, an aggregate of $<ix:nonFraction unitRef="usd" contextRef="iea718991298743b4bf83f37c95537401_D20200701-20200731" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ReclassificationsOfTemporaryToPermanentEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMTA5OTUxMTYzNjczMw_c9929d62-b504-430f-8df9-ec2031da5e17">1.5</ix:nonFraction> million shares of redeemable convertible preferred stock was converted to common stock as requested by the holder. The corresponding carrying value was reclassified from redeemable convertible preferred stock to common stock and additional paid in capital.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series G Redeemable Convertible Preferred Stock </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company issued <ix:nonFraction unitRef="shares" contextRef="iffd69005bc104609a9a1664e72d42b12_I20210630" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMDkwMQ_349faa5a-de3a-4e26-80f1-71f3ca30aa65">4,447,530</ix:nonFraction>&#160;shares of Series&#160;G redeemable convertible preferred stock for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="i60e32c082ec946839e6d084bceac21a6_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMDk4NQ_f601c554-fa78-44ba-beec-198589810da6">85.0</ix:nonFraction> million. Issuance costs totaled $<ix:nonFraction unitRef="usd" contextRef="i60e32c082ec946839e6d084bceac21a6_D20210601-20210630" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyNjI1MQ_921a44a1-d492-43e8-bd02-2c6df92c5e95">0.3</ix:nonFraction> million and were recorded as an offset to gross proceeds.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series F Redeemable Convertible Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July and August 2020, the Company issued <ix:nonFraction unitRef="shares" contextRef="i0e1b4a8dca7145f3b32508e4106c7c5b_I20200831" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:TemporaryEquitySharesIssued" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMTA5OTUxMTYzNjc0Ng_0bac72af-e7aa-444a-827c-0f252a5cb732">5,226,969</ix:nonFraction> shares of Series F redeemable convertible preferred stock for gross proceeds of $<ix:nonFraction unitRef="usd" contextRef="ib4185c7d482a4d408c70efb88bc2655b_D20200701-20200831" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMTA5OTUxMTYzNjc2Mg_83117bb6-69b6-4bc1-8e92-39b8ed8c9a4f">77.0</ix:nonFraction> million. Issuance costs totaled $<ix:nonFraction unitRef="usd" contextRef="ib4185c7d482a4d408c70efb88bc2655b_D20200701-20200831" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyNjI1Ng_da9d1072-0ce4-4829-afe7-d6f9d454248f">0.5</ix:nonFraction> million and were recorded as an offset to gross proceeds. </span></div><ix:continuation id="if72a87e5c237440c8099f57cdc9ce513"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s redeemable convertible preferred stock terms were as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Preference<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8%<br/>Dividend<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7aa86dd5567043e78dbeaa1869e5a838_I20210930" decimals="INF" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMS0xLTEtMS0zNDQwMQ_831d70ad-9ec6-4d8f-a42e-44b8f474c9e2">2.5175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i006123c4fa5d483a9e5463519395740b_D20210101-20210930" decimals="4" name="prct:TemporaryEquityDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMS0zLTEtMS0zNDQwMQ_e89108e4-7ad7-4f00-83d0-e160b0bfd13c">0.2014</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8f4ede9a776146de87f610eeb9409d5d_I20210930" decimals="INF" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMi0xLTEtMS0zNDQwMQ_ed0a1d67-72a7-4586-8cdd-d72bdbe15c75">3.2376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6f35ad14fa9c4afd9f180294ec2f5da1_D20210101-20210930" decimals="4" name="prct:TemporaryEquityDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMi0zLTEtMS0zNDQwMQ_fde5a5cd-2fe6-4cd2-8814-c7c48d790dde">0.2590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7de321a1c268402ab2b16faea56fdb02_I20210930" decimals="INF" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMy0xLTEtMS0zNDQwMQ_bff7d634-e66a-4ec8-8d05-2e4a8242ac13">4.5600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0e48ea26dceb47ec879e15c92c50d98e_D20210101-20210930" decimals="4" name="prct:TemporaryEquityDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMy0zLTEtMS0zNDQwMQ_c719cb51-f403-45c4-bd28-d8612d066450">0.3648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e43455a41214ba3a21927edd8a4845d_I20210930" decimals="INF" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNC0xLTEtMS0zNDQwMQ_3a1b500d-b22c-4efc-9007-8acad1ba21f0">5.0825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3a5a5773de0d4f218c0162ed76015607_D20210101-20210930" decimals="4" name="prct:TemporaryEquityDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNC0zLTEtMS0zNDQwMQ_14e8abc2-582a-43c8-a9b6-3bebe677092c">0.4066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib4321f4042af4f5cb3cf13c10279d51d_I20210930" decimals="INF" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNS0xLTEtMS0zNDQwMQ_e422c51e-67a8-44f3-acc6-17e2454318f9">13.7275</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i4982cd5fdb3f431caecb3cf5474a994c_D20210101-20210930" decimals="4" name="prct:TemporaryEquityDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNS0zLTEtMS0zNDQwMQ_feef5276-2c82-4073-88d9-a0085fa63fdd">1.0982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ice8d36bf1b564de9b741f74e90346ae9_I20210930" decimals="INF" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNi0xLTEtMS0zNDQwMQ_da701938-172c-48b3-a92f-ef8b8ef67629">14.7279</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9679f5b41fb34cf6abfae1649202e1c5_D20210101-20210930" decimals="4" name="prct:TemporaryEquityDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNi0zLTEtMS0zNDQwMQ_61be8d50-10bb-4813-8c02-e5035057fccf">1.1782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i74e05f7559ad44e2b03cdce92864389e_I20210930" decimals="INF" name="us-gaap:TemporaryEquityLiquidationPreferencePerShare" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNy0xLTEtMS0zNDQwMQ_6e874511-718b-48b2-a38d-9a7c2d376ce9">19.1116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3acfe77b8a2f44e79e9ac544b7465414_D20210101-20210930" decimals="4" name="prct:TemporaryEquityDividends" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNy0zLTEtMS0zNDQwMQ_3a0a24ec-abd5-4f85-a7a0-005097a71bc6">1.5289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs. A redemption event would only occur upon the liquidation or winding up of the Company, a greater than 50% change in control, or sale of substantially all of the assets of the Company. As the redemption event was outside the control of the Company, all shares of redeemable convertible preferred stock were presented outside of permanent equity. Further, the Company had determined the carrying values of the redeemable convertible preferred stock should not be adjusted to the redemption value of such shares, since it was uncertain whether or when a </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i221661049c53482eb830404739d4832f" continuedAt="i3318377ebea748ae92e56f8e7cd104f9"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redemption event would occur. Subsequent adjustments to increase the carrying values of the redeemable convertible preferred stock to the redemption values would have been made when it became probable that such redemption would occur. As of September&#160;30, 2021, no shares of redeemable convertible preferred stock were outstanding, and as of December&#160;31, 2020, it was not probable that such redemption would occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Series D, E, F and G redeemable convertible preferred stock, in preference to the holders of Series A, B and C redeemable convertible preferred stock and common stock, were entitled to receive noncumulative dividends at the rate of <ix:nonFraction unitRef="usdPerShare" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="2" name="prct:TemporaryEquityDividends" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMTA5OTUxMTYzNjgzMA_18a8e75a-568b-47c8-88cb-6f4f84807b5a">8</ix:nonFraction>% per share of the original issuance price, when and as declared by the board of directors. After the payment of any dividends to holders of Series D, E, F and G redeemable convertible preferred stock, and in preference to the holders of common stock, the holders of Series A, B, and C redeemable convertible preferred stock would have been entitled to receive noncumulative dividends at the rate of <ix:nonFraction unitRef="usdPerShare" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="2" name="prct:TemporaryEquityDividends" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMTA5OTUxMTYzNjgzNQ_f6a900e4-b569-4b88-942b-c24ace890866">8</ix:nonFraction>% per share of the original issuance price, when and as declared by the board of directors. <ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMjc0ODc3OTA3ODU0NA_884a4f45-53df-4cd3-b946-38b341bfb9f5"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-5" format="ixt:fixed-zero" name="us-gaap:DividendsPayableCurrentAndNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMjc0ODc3OTA3ODU0NA_f91d7324-ea0b-4688-ac28-a307eea9edfe">No</ix:nonFraction></ix:nonFraction> dividends were declared and payable for the nine months ended September 30, 2021 and year ended December&#160;31, 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of any liquidation, dissolution, or winding-up of the Company, including a merger, acquisition, or sale of assets, as defined in the certificate of incorporation, each holder of Series G redeemable convertible preferred stock was entitled to receive a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C, D, E or F redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series G redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series G redeemable convertible preferred stock, each holder of Series F redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C, D or E redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series F redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series F redeemable convertible preferred stock, each holder of Series E redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C or D redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series E redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series E redeemable convertible preferred stock, each holder of Series D redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B or C redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series D redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series D redeemable convertible preferred stock, each holder of Series A, B and C redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of common stock. If the assets of the Company were insufficient to make payment in full to all holders of Series A, B or C redeemable convertible preferred stock, then the assets or consideration would have been distributed ratably among </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="i3318377ebea748ae92e56f8e7cd104f9" continuedAt="i2b70a5e97a07456aa5b1bf9c4acbe84b"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the payment of the full liquidation preference to holders of redeemable convertible preferred stock, the remaining assets of the Company legally available for distribution would have been distributed ratably to the holders of the common stock. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder had the right to <ix:nonFraction unitRef="customer" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt-sec:numwordsen" name="prct:TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfOTM0NTg0ODg0Njg5NQ_d4a17b0c-6d31-42ab-baae-b31ab5153aea">one</ix:nonFraction> vote for each share of common stock into which such redeemable convertible preferred stock would have been converted. So long as any shares of redeemable convertible preferred stock were outstanding, the Company was prohibited, without first obtaining the approval of more than 50% of the holders of redeemable convertible preferred stock then outstanding, voting together as a separate class to (a) amend certificate of incorporation in any way that would materially and adversely alter or change the rights, preferences, or privileges of the series preferred stock or (b) increase the total number of authorized shares of any Series Preferred stock. Additionally, the vote of at least a majority of the holders of Series D, E, F and G redeemable convertible preferred stock was needed to materially and adversely affect the rights of such holders of each series, including increasing or decreasing the number of authorized shares of Series D, E, F and G redeemable convertible preferred stock, as applicable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable convertible preferred shares were not mandatorily redeemable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion </span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2b70a5e97a07456aa5b1bf9c4acbe84b">Upon the completion of the Company&#8217;s IPO in September 2021, all <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMzUyOQ_080bcfa1-af45-4252-af29-85b40683fa55"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMzUyOQ_c67bb575-5e73-493b-9fee-a555ef693c48">29,912,264</ix:nonFraction></ix:nonFraction> shares of its then-outstanding redeemable convertible preferred stock automatically converted into <ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMzYzMg_080bcfa1-af45-4252-af29-85b40683fa55"><ix:nonFraction unitRef="shares" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMzYzMg_c67bb575-5e73-493b-9fee-a555ef693c48">29,912,264</ix:nonFraction></ix:nonFraction> shares of common stock and it reclassified $<ix:nonFraction unitRef="usd" contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyNjI2NQ_d5a4071a-8dff-415f-99a3-daf3c6f22d7c">329.5</ix:nonFraction> million of redeemable convertible preferred stock to additional paid-in capital on our condensed consolidated balance sheet.</ix:continuation> </span></div><div id="id6896dbd221a471485ce149196fbcf44_55"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfOTg5NTYwNDY3MDUzNw_6a9ecb3e-564d-4369-a764-7acbb99b4775" continuedAt="i576f0ad7df1547d38c39f5f8db808ce7" escape="true">Stockholder&#8217;s Equity </ix:nonNumeric></span></div><ix:continuation id="i576f0ad7df1547d38c39f5f8db808ce7" continuedAt="ic1d01ac9c1bb4a6380c99aae76cf4abb"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Equity Incentive Award Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company adopted the 2021 Equity Incentive Award Plan (the &#8220;2021 Plan&#8221;), which allows for the granting of stock options and stock purchase rights to the employees, members of the board of directors, and consultants of the Company. A total of <ix:nonFraction unitRef="shares" contextRef="ib06a5da95c7042d7b94adeb6559177b2_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUzMTY3Nw_c3d68eef-9080-4bfc-93ca-371bc367fdd8">3,303,910</ix:nonFraction> shares of common stock were initially reserved for issuance under the 2021 Plan. Options granted under the 2021 Plan may be either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options (&#8220;NSOs&#8221;). ISOs may be granted only to the Company&#8217;s employees, including officers and directors who are also employees. NSOs may be granted to employees and consultants. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options under the 2021 Plan may be granted for periods of up to <ix:nonNumeric contextRef="icbaeafd33bbd4e6888b366b6103f762f_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTcwNQ_4c296e57-ad44-477c-bb20-ae6618347225">10</ix:nonNumeric> years and at prices no less than <ix:nonFraction unitRef="number" contextRef="icbaeafd33bbd4e6888b366b6103f762f_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTcxMw_a90a7811-1525-4a41-8a39-51ed86259dbf">100</ix:nonFraction>% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a <ix:nonFraction unitRef="number" contextRef="i4ece297f570a4b82a416279c7fdc8910_I20210930" decimals="2" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTcxOQ_6d0fe349-d171-4ee6-ad39-f5873553066b">10</ix:nonFraction>% shareholder shall not be less than <ix:nonFraction unitRef="number" contextRef="i775e9da970104587a8e43c336154fd28_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTcyNg_b3079ff4-9b45-4de4-a06f-47e102a39502">110</ix:nonFraction>% of the estimated fair value of the shares on the date of grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted options for newly hired employees usually vest over <ix:nonNumeric contextRef="i06d1766f867741e985119b9837680d50_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTczOQ_be3de5b5-1a3b-41e1-9c47-90106ca1f233">four years</ix:nonNumeric> monthly with a <ix:nonNumeric contextRef="i06d1766f867741e985119b9837680d50_D20210101-20210930" format="ixt-sec:durwordsen" name="prct:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfOTg5NTYwNDY3MDUzOQ_5cf5522c-8176-4ee8-a9b4-78a40024f859">one-year</ix:nonNumeric> cliff vesting, and follow-on options vest monthly over <ix:nonNumeric contextRef="i06d1766f867741e985119b9837680d50_D20210101-20210930" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTc2MA_83ac284d-95c2-4074-ab4d-0ecc040d1276">four years</ix:nonNumeric> with no cliff vesting. Options granted to consultants have various vesting schedules depending on the underlying consulting arrangement and anticipated period of service. As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="i1ecfd2799a3b484db31278a912812179_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxNzg4MQ_a8a54f9d-7ec9-4e20-b572-055c90a4b577">3.2</ix:nonFraction> million shares are available for grant under the 2021 Plan.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2008 Stock Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company ceased making awards under the 2008 Stock Plan upon the effective date of the Company&#8217;s IPO. In 2008, the Company adopted the 2008 Stock Plan (the &#8220;2008 Plan&#8221;), which allows for the granting of stock options and stock purchase rights to the employees, members of the board of directors, and consultants of the </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ic1d01ac9c1bb4a6380c99aae76cf4abb" continuedAt="ie20bb3bf66384996b10e4c543e2cd4f5"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company. Options granted under the 2008 Plan may be either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options (&#8220;NSOs&#8221;). ISOs may be granted only to the Company&#8217;s employees, including officers and directors who are also employees. NSOs may be granted to employees and consultants. Options granted under the 2008 Plan will start expiring in August 2021. Options outstanding under the 2008 Plan will expire upon forfeiture. As of September&#160;30, 2021, <ix:nonFraction unitRef="shares" contextRef="id017d7645c90419b8f85f400f2c78e30_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUzMTM4Nw_0a75e29a-8d17-4eff-a5bf-c62b07321128">6.5</ix:nonFraction> million options were outstanding under the 2008 Plan. </span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfOTM0NTg0ODg1NjY2Mw_b9ad5378-0d84-439e-a538-4875738231e8" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information are as follows (options in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i29a3508d251b4bde9f8eb210f942bfaa_I20201231" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNC0xLTEtMS0zNDQwMQ_eaef181f-f33a-4465-bb93-d487d058c247">6,507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i29a3508d251b4bde9f8eb210f942bfaa_I20201231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNC0zLTEtMS0zNDQwMQ_7d63f4f8-3f59-4486-80df-e19d575fa3c4">3.94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNS0xLTEtMS0zNDQwMQ_113a176b-f2d3-4801-b9a2-b811325eb15f">1,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNS0zLTEtMS0zNDQwMQ_dd629a5e-2c55-4845-8c74-f433b5da3728">8.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNi0xLTEtMS0zNDQwMQ_f6045098-1f37-4182-a747-34efd4ad5d36">1,307</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNi0zLTEtMS0zNDQwMQ_732b3e2b-4e2c-4ece-8837-e0545907015d">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNy0xLTEtMS0zNDQwMQ_8492448b-85cc-4689-a775-be53a276fc52">104</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNy0zLTEtMS0zNDQwMQ_08632432-2f8d-4d2f-999f-5de361672c5c">6.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfOC0xLTEtMS0zNDQwMQ_3a39f25f-f1a4-4a7f-8ffe-07e167d2d03b">6,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfOC0zLTEtMS0zNDQwMQ_f0cfeef6-6c02-4304-addf-f2b6034089fa">5.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfOS0xLTEtMS0zNDQwMQ_d5b18eb2-f837-4305-8544-c5727d4388ca">6,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfOS0zLTEtMS0zNDQwMQ_209396ad-95da-4f6e-97ac-b4ebf497aa44">5.08</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfMTAtMS0xLTEtMzQ0MDE_53bd64dc-96da-471a-a68d-cadb387b6716">2,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfMTAtMy0xLTEtMzQ0MDE_3dbc46b8-887a-49a6-9e9d-4045a80557e2">3.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the aggregate pre-tax intrinsic value of options outstanding and exercisable was $<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxNzkxMg_2f27d068-86e2-4546-866d-276a6db4977c">98.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTgyMg_84ba2973-86a1-4f8d-9fd7-98874e933872">6.9</ix:nonFraction> million, respectively, and options outstanding were $<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxNzkyNQ_459d7019-48ca-489d-ab0c-c50f12f4086c">218.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTg2OA_1a3ed788-6a24-462f-979e-6821fec8e84a">9.9</ix:nonFraction> million, respectively. The aggregate pre-tax intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTk0Mw_4c26ae1e-c989-4b33-9f25-31a1d34ddc88">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxODExMw_b55a49a6-ceb0-4101-9d22-9c04cfca2750">1.8</ix:nonFraction> million during the nine months ended September&#160;30, 2021 and 2020, respectively. The aggregate pre-tax intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. The total fair value of options vested was $<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxODE5NA_45884f6e-d486-41d0-95a3-d6e52d312c1f">2.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTk3Mw_b73416d8-0ea7-471f-9012-a79ff36bc503">1.2</ix:nonFraction> million during the nine months ended September&#160;30, 2021 and 2020, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock-based compensation on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model determines the fair value of stock-based payment awards based on the fair market value of the Company&#8217;s common stock on the date of grant and is affected by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the fair market value of the Company&#8217;s common stock, volatility over the expected term of the awards and actual and projected employee stock option exercise behaviors. The Company has opted to use the &#8220;simplified method&#8221; for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company generally selected companies with comparable characteristics to it, including enterprise value, stages of clinical development, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the share-based payments. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company&#8217;s common stock becomes available. The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company&#8217;s stock options. The expected dividend assumption is based on the Company&#8217;s history of not paying dividends and its expectation that it will not declare dividends for the foreseeable future. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="ie20bb3bf66384996b10e4c543e2cd4f5" continuedAt="i0df54fa41a4e4b5abc8648d5894a7ad3"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfOTM0NTg0ODg1NjY2NA_5f1efe7e-8b06-4616-92ea-f760f84d72f9" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation recognized, before taxes, is as follows (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12898071c0444fe7844142bb4d3cd49c_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfMy0xLTEtMS0zNDQwMQ_4432d410-a692-4d13-99e8-c715fd33b9e0">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccd781125894469891eb522580c6b2aa_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfMy0zLTEtMS0zNDQwMQ_22152434-b5ce-4aa1-b288-228bbdf4a61f">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f72c2550a004f309da2bc458a30adfe_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfMy01LTEtMS0zNDQwMQ_d19390a7-1f22-468b-b59f-c76d8860e511">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78b24385d55b4a209c528145906fa5ce_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfMy03LTEtMS0zNDQwMQ_2ec075c4-0ddd-4fb3-8dc7-28aadd2769ff">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i445258736c484e52b6ddb965454bb1ff_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNC0xLTEtMS0zNDQwMQ_bc6365ad-ede9-428f-9c74-b3a0c6bd9f02">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c80643e4da242ecbd5c44667621fad4_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNC0zLTEtMS0zNDQwMQ_8bac306f-3277-40c9-8e9e-ffef511f4cc3">134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f0e6e6c797846fa8312b60ebb59afb3_D20210101-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNC01LTEtMS0zNDQwMQ_e451badc-1cbf-46a2-9c55-83d5489b164a">482</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i190871b1575a4e8db9bd9f80d3702fa0_D20200101-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNC03LTEtMS0zNDQwMQ_e36014ee-730a-4db3-b1a5-2eea833ae016">397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffd4490b13ce46d8825d6f990c341beb_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNS0xLTEtMS0zNDQwMQ_d5ed210b-3fa1-4ee7-b73b-fa4c8eb15291">689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bd6c00e464c4f16bf14f0e616cee1d1_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNS0zLTEtMS0zNDQwMQ_9a7efcd5-fbc3-4674-85a1-bccc838645c6">411</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i008a0e4e1310456bb44ece232d2da544_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNS01LTEtMS0zNDQwMQ_ae0100c3-633c-4c94-82e4-5ac1561f2fa7">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95da0a4005cc41b88796003dc99be3ea_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNS03LTEtMS0zNDQwMQ_e7295d58-e5b4-45a2-98fb-4396fcba82ba">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNi0xLTEtMS0zNDQwMQ_c2a66db0-2319-4f71-ad14-53909cbd4fa9">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNi0zLTEtMS0zNDQwMQ_52dd6feb-15ce-4c21-8074-4c4d55cbf729">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNi01LTEtMS0zNDQwMQ_f38d4f2a-df1c-48c7-88e2-c42e606b13be">2,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNi03LTEtMS0zNDQwMQ_ec7bec39-29ef-4fbe-a0e0-f0299d40f1ef">1,569</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unearned stock-based compensation related to unvested employee stock-based payment awards as of September&#160;30, 2021 and December&#160;31, 2020 is $<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NjAzNA_7dbc8570-af67-4e7c-b50a-1f44916e67f4">9.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxODIzMQ_5ad4fb42-afde-460a-908a-c252f2040254">6.5</ix:nonFraction> million, respectively. The weighted-average period over which the unearned stock-based compensation is expected to be recognized as of September&#160;30, 2021 and December&#160;31, 2020 is <ix:nonNumeric contextRef="ic2e662689b684020aedbed74e67c085f_D20200101-20201231" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NjA2MQ_6d4d9dc9-8226-4ed9-bfb7-1e2b844e7f2f"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NjA2MQ_8f153139-236a-405a-b327-4867990f2393">2.9</ix:nonNumeric></ix:nonNumeric> years for both periods.</span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfOTM0NTg0ODg1NjY2NQ_7938c9e5-7961-43ff-9867-7dd12cd5825f" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the options granted to employees or directors was estimated as of the grant date using the Black-Scholes model assuming the weighted-average assumptions listed in the following table: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfMy0xLTEtMS0zNDQwMQ_3f010d6a-e2db-4924-a091-70e8848a17ad">5.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i09198490d2f441a08b39181593f1f255_D20200701-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfMy0zLTEtMS0zNDQwMQ_e53f949b-1241-4187-8071-a1e863c67a88">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfMy01LTEtMS0zNDQwMQ_bda8b246-f601-45b5-90b9-ac97f7a3c2da">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfMy03LTEtMS0zNDQwMQ_9336cc65-6f6a-4fe4-ba80-0b90820520a6">6.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNC0xLTEtMS0zNDQwMQ_b4b6e10c-32d0-4700-a7f9-181139e9d43e">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i09198490d2f441a08b39181593f1f255_D20200701-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNC0zLTEtMS0zNDQwMQ_5e372d50-28f4-4331-81d7-aa3ca27e2ffd">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNC01LTEtMS0zNDQwMQ_0d38bfc2-0a7f-4875-a02c-f2ec1bbb80e8">50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNC03LTEtMS0zNDQwMQ_aa3e4073-1f11-4b1a-bae9-cc228292ce9a">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNS0xLTEtMS0zNDQwMQ_062d582f-524d-4fe1-83ee-5c289092204f">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i09198490d2f441a08b39181593f1f255_D20200701-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNS0zLTEtMS0zNDQwMQ_4cad327d-5792-4a55-88a4-fbdd21de74cd">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNS01LTEtMS0zNDQwMQ_198591f8-7cea-4310-80d0-97a86086b8f9">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNS03LTEtMS0zNDQwMQ_cbcd63b5-8c52-4759-8dae-52b72bf1e7c6">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNi0xLTEtMS0zNDQwMQ_5bc1680a-ca71-43ad-829c-d4a1885e37f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i09198490d2f441a08b39181593f1f255_D20200701-20200930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNi0zLTEtMS0zNDQwMQ_5bc93d95-ab9d-43f5-9c60-4ca226b2b74d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNi01LTEtMS0zNDQwMQ_53eca202-8e86-4ab0-aba3-1320edd331a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930" decimals="2" format="ixt:fixed-zero" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNi03LTEtMS0zNDQwMQ_e5144c75-eaee-4f6b-a927-ad546d67c4c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNy0xLTEtMS0zNDQwMQ_df76d7c3-954f-4f76-ab09-6fada56be3c4">7.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i09198490d2f441a08b39181593f1f255_D20200701-20200930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNy0zLTEtMS0zNDQwMQ_8d024542-4f7b-42fc-adbc-b6b00061198a">2.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNy01LTEtMS0zNDQwMQ_3e7924c4-3672-466b-a78b-6c16e76e0414">3.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNy03LTEtMS0zNDQwMQ_9f5671bf-f56d-4a7b-bd60-3dcbb210cb8c">1.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company adopted the 2021 Employee Stock Purchase Plan (the &#8220;2021 ESPP&#8221;). The 2021 ESPP became effective on the effective date of the IPO. A total of <ix:nonFraction unitRef="shares" contextRef="i90a0eaa9861b47338cef7b3ddc5fa8d1_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUzMTY4OA_7fc3a503-41ba-4418-b9ae-ffd6982cc069">412,988</ix:nonFraction> shares were initially reserved for issuance under the 2021 ESPP. Additionally, the number of shares of common stock reserved for issuance under the 2021 ESPP will increase automatically each year, beginning on January&#160;1, 2022, and continuing through and including January&#160;1, 2031, by the lesser of (1) <ix:nonFraction unitRef="number" contextRef="i147dde6bfea84bb5a5a2eab1578869ea_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUzMTczMQ_db7d4db0-6223-465a-9ed6-b248da662586">1</ix:nonFraction>% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; or (2) such lesser number as determined by the Company&#8217;s board of directors. The number of shares that may be issued under the 2021 ESPP shall not exceed a total of <ix:nonFraction unitRef="shares" contextRef="i7d2b70c21dbc4b32895eedfc71019388_I20210930" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUzMTc1MA_232d47b4-2fb1-4dce-a143-55992d04e9c7">10,526,315</ix:nonFraction> shares. As of September 30, 2021, the Company has not implemented the 2021 ESPP. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants </span></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0df54fa41a4e4b5abc8648d5894a7ad3">In May 2015, the Company issued warrants to purchase <ix:nonFraction unitRef="shares" contextRef="i03b8cb9f698a47d698415757c8e483bf_D20150501-20150531" decimals="INF" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NjA4NA_b1213f54-dec3-44ed-8221-5f38e4f7d3cc">12,308</ix:nonFraction> shares of the Company&#8217;s common stock in exchange for recruiting services. These warrants are exercisable immediately and expire on April 30, 2025. These common stock warrants of $<ix:nonFraction unitRef="usd" contextRef="i5398d7157b274e53afc37f43c4fb9f1a_D20150501-20150531" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NjA5OA_b6649c30-c063-4547-96f0-d4e1772d73df">15,000</ix:nonFraction> were recorded as general and administrative expense and additional paid-in capital, as this warrant met the equity classification requirements. In November 2020, these warrants were fully exercised.</ix:continuation> </span></div><div id="id6896dbd221a471485ce149196fbcf44_58"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDEzMQ_81623619-fa47-453e-b42e-71bd94c881e6" continuedAt="i81fe11497c7140caa66b9b91663e26e6" escape="true"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDEzMw_33d7ea78-808f-40a4-8a08-cfd657a22ef6" continuedAt="i3e0858c3104e462285ba3b070c69589b" escape="true">Commitments and Contingencies </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="i81fe11497c7140caa66b9b91663e26e6" continuedAt="id2781661cca1440f97e0af57aa92dc68"><ix:continuation id="i3e0858c3104e462285ba3b070c69589b" continuedAt="ia1931448cdd446bba6df722c43179dba"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September&#160;30, 2021 and December&#160;31, 2020, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities. </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><ix:continuation id="id2781661cca1440f97e0af57aa92dc68" continuedAt="i84945d3ad345426b819f34a172fe2dba"><ix:continuation id="ia1931448cdd446bba6df722c43179dba" continuedAt="ibb7705edfdbd4a2c8b5efcb0c7b31556"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Facility Lease </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2013, the Company entered into a <ix:nonNumeric contextRef="id13f0093eaaa458181bd8b489d0fa71e_I20130731" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDI5OA_55ec6fe8-defb-46b7-8b84-85627cc00697">three-year</ix:nonNumeric> lease agreement for its current facility located in Redwood City, California. In 2018, the Company expanded the lease space and extended the lease agreement through October 2023. The lease agreement provides for an escalation of rent payments each year and the Company records rent expense on a straight-line basis over the term of the lease. Rent is payable monthly. As of September&#160;30, 2021 and December&#160;31, 2020, the remaining future minimum lease payments under this lease is $<ix:nonFraction unitRef="usd" contextRef="i51e569731e334d18b46ce30b6992446f_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfNDM5ODA0NjUxNDkwNw_5eb6e195-07f5-4e0f-92c1-58d80e7dddbc">5.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i0882844190cf46d882aec93c3be61895_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTE0MQ_c65558e3-9150-4b81-97fd-edeae409ce0c">6.7</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s adoption of ASC Topic 842, Leases, on January 1, 2020, the Company recorded a right-of-use leased asset of $<ix:nonFraction unitRef="usd" contextRef="ibcde0d5c3d85476888c4854555b60153_I20200101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTMxMw_b52d336f-1d23-4fe0-b1f7-df6f7c34390d">6.0</ix:nonFraction> million and a corresponding lease liability of $<ix:nonFraction unitRef="usd" contextRef="ibcde0d5c3d85476888c4854555b60153_I20200101" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTMyOA_1c4e9317-e252-4695-90ea-4a6e88c0a06d">7.4</ix:nonFraction> million and derecognized a deferred rent obligation of $<ix:nonFraction unitRef="usd" contextRef="ibcde0d5c3d85476888c4854555b60153_I20200101" decimals="-5" sign="-" format="ixt:num-dot-decimal" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTM0Mw_d6598a22-ba08-4b78-8149-8704f3d59327">1.4</ix:nonFraction> million. The Company used its borrowing rate of <ix:nonFraction unitRef="number" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="2" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTM1Mg_00dc5f65-b94f-4dc6-b52d-7b5e86a863c2">10</ix:nonFraction>% as its discount rate and the remaining operating lease term was <ix:nonNumeric contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDI4NA_57d32ff8-7d65-46ae-8359-d1b34d77655f">3.8</ix:nonNumeric> years. The results for the year ended December&#160;31, 2020 subsequent periods are presented under Topic 842.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense recognized under the lease, including additional rent charges for utilities, parking, maintenance, and real estate taxes, was $<ix:nonFraction unitRef="usd" contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTQwMw_18d4ab6a-3710-40e3-8365-6d16cba6ae55"><ix:nonFraction unitRef="usd" contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTQwMw_c9eba0ea-2c5c-4349-a579-1ba2e343d38c">0.5</ix:nonFraction></ix:nonFraction> million for each of the three months ended September 30, 2021 and 2020, and $<ix:nonFraction unitRef="usd" contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfNDM5ODA0NjUxNTI3MQ_aadeb2d1-bac6-4ac3-bce6-af82ea636d15"><ix:nonFraction unitRef="usd" contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930" decimals="-5" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfNDM5ODA0NjUxNTI3MQ_d694bdc8-ac52-45ab-89f0-b596bbfbe3f0">1.5</ix:nonFraction></ix:nonFraction> million for each of the nine months ended September 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company has future commitments of $<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-5" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfNDM5ODA0NjUxNTA3Ng_cabfa55e-b95f-4ef9-aa52-82f309d1b3ea">55.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-5" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTQ3NA_330a618c-cb22-41b2-ae79-64e501669b62">56.7</ix:nonFraction> million from debt repayments and office space under a non-cancelable operating lease expiring October 2023, respectively. </span></div><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDEzNQ_38f61a79-19bc-4672-94d5-4751ef3a549a" escape="true"><ix:nonNumeric contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDEzNQ_964a0d8b-17b1-4c76-b7ff-14145524d05e" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum annual operating lease and debt repayments are as follows (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;30, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Repayments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMS0xLTEtMS00MzAxMA_4eb5c2eb-6943-4ae8-b186-bebae51bd44f">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMS0zLTEtMS00MzQzNA_0f6021ac-d9f2-4d48-a8b1-28e53fa2d52a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMS01LTEtMS00MzQzOQ_9f0cd5ff-ad60-4bab-a104-6a0a39539394">604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMi0xLTEtMS00MzAxMA_3788c145-dad9-4fa4-a0d4-ac706f397b04">2,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMi0zLTEtMS00MzQzNA_f069e5d7-6d57-4e3b-bca8-1cc25005b0fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMi01LTEtMS00MzQzOQ_ab2b5c80-69d0-4c26-859f-9c2812b6dffe">2,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMy0xLTEtMS00MzAxMA_5b51138b-222f-42e3-84eb-ef3f637ab7b5">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMy0zLTEtMS00MzQzNA_d1cca2b9-272f-4136-b187-17b8964d41ed">12,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMy01LTEtMS00MzQzOQ_1611ca6d-1683-40fa-a862-eb23d98e5528">14,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNC0xLTEtMS00MzAxMA_44edd4b1-e648-44e1-9368-589107f9e243">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNC0zLTEtMS00MzQzNA_bf5c25e4-c541-4a93-9242-12dbb7e3a794">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNC01LTEtMS00MzQzOQ_c98cff6e-9212-4b96-ad70-3425d9f5b1cf">37,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNS0xLTEtMS00MzAxMA_42ff0971-d9b1-4ed1-a65e-ea6af02e6a9a">5,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNS0zLTEtMS00MzQzNA_e3e89e47-e30c-43ed-a59d-c368d6cc12db">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNS01LTEtMS00MzQzOQ_06077f6d-15d2-4654-9c27-d88216e5d140">55,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest/unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNi0xLTEtMS00MzAxMA_f931f5c8-b475-4cf6-8bdf-478940d0ee1c">559</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNi0zLTEtMS00MzQzNA_d5fd863c-0def-4167-a1a9-22be451684eb">238</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNi01LTEtMS00MzQzOQ_aa465ec9-a291-4b93-b326-09b8b3adc673">797</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNy0xLTEtMS00MzAxMA_08ca80c3-524b-45dd-a399-1285dca66f77">4,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNy0zLTEtMS00MzQzNA_ced637d5-c536-4d5a-a8d0-7fda2835983d">49,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNy01LTEtMS00MzQzOQ_774cae75-1fbd-4fd9-9a59-0428583224f2">54,344</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOC0xLTEtMS00MzAxMA_e26fd55c-fc5a-4bf9-9068-c96662c573db">2,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOC0zLTEtMS00MzQzNA_a254b81f-3082-4a5d-9bc5-a48dc3a9e059">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOC01LTEtMS00MzQzOQ_f3d6bf78-e620-4026-a850-4b5506e10f3e">2,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOS0xLTEtMS00MzAxMA_59fa4b63-d3a5-40a4-8aab-3ac432641c1f">2,550</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOS0zLTEtMS00MzQzNA_87c6d59d-90f4-4069-92f1-d71a5d26fa90">49,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOS01LTEtMS00MzQzOQ_52704f6a-37d2-4f19-b9fa-39aa325d8d55">52,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31, 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Repayments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMS0xLTEtMS0zNDQwMQ_683341c6-4e16-4798-ab24-d61d4fffce92">2,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMS0zLTEtMS0zNDQwMQ_1940ca92-d3af-45a3-b0a6-85b3dea48714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMS01LTEtMS0zNDQwMQ_e01dc8a7-d746-47a8-88b5-aac81e30d0c1">2,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMi0xLTEtMS0zNDQwMQ_996515fd-c936-4fc0-b898-c0be0d862b8c">2,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMi0zLTEtMS0zNDQwMQ_44e5a509-c1d2-4655-98bc-884e85edbce6">6,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMi01LTEtMS0zNDQwMQ_0bfef07c-217a-4f6e-a268-d5a64bee9020">8,695</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMy0xLTEtMS0zNDQwMQ_76604ccf-3337-43a7-9c7e-733d451f040c">2,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMy0zLTEtMS0zNDQwMQ_8e97c37d-0a82-45df-ab4d-36b0f4c8e8ff">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMy01LTEtMS0zNDQwMQ_9d9b0a06-d832-4218-8698-b15a8e84f584">27,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:fixed-zero" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNC0xLTEtMS0zNDQwMQ_683d141b-2ce5-4b58-affc-4f48817c60a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNC0zLTEtMS0zNDQwMQ_21c932bb-7914-45e5-97d7-78619b40f97e">18,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNC01LTEtMS0zNDQwMQ_759150ab-01ce-48c2-829f-0714a4997827">18,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNS0xLTEtMS0zNDQwMQ_0bf551ae-5339-4a19-bd50-64f682efd441">6,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentCarryingAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNS0zLTEtMS0zNDQwMQ_f069df29-2eea-4051-bc25-b660d3e3322c">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNS01LTEtMS0zNDQwMQ_44e47bb8-d36b-4f9b-8ebe-fc6caaf9c970">56,716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest/unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNi0xLTEtMS0zNDQwMQ_fb8fdbd3-36e6-41fe-af6d-6460e1a2dec7">912</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNi0zLTEtMS0zNDQwMQ_f4f3add5-4cab-4345-a698-fdfe02689912">1,042</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNi01LTEtMS0zNDQwMQ_a752189b-aa46-4948-bb69-c09136eb458b">1,954</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNy0xLTEtMS0zNDQwMQ_44fcfc4d-f45d-43db-8263-185e195ade4a">5,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNy0zLTEtMS0zNDQwMQ_66b6e8bc-5a38-40c5-9883-a9750dd88beb">48,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebt" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNy01LTEtMS0zNDQwMQ_481e9f34-ba56-42f1-85a7-3685530d3695">54,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOC0xLTEtMS0zNDQwMQ_3b6aec82-9409-49b9-8f65-9f2109bf88b5">1,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOC0zLTEtMS0zNDQwMQ_c53a258d-b3cf-4df4-a8cc-0db957a3b7c1">4,551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOC01LTEtMS0zNDQwMQ_ae6d2093-4ff0-46d7-aa03-b0d6aa4b3694">6,259</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOS0xLTEtMS0zNDQwMQ_ec5c51a3-29cf-43a5-9584-4d3b231031b8">4,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="us-gaap:LongTermDebtNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOS0zLTEtMS0zNDQwMQ_ab39ea0b-d858-4346-bfa1-c4c15134e0f9">44,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231" decimals="-3" format="ixt:num-dot-decimal" name="prct:OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOS01LTEtMS0zNDQwMQ_514a85b5-783f-4b37-8340-326f80edfa5e">48,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s security deposit is in the form of, and recorded as, restricted cash. In January 2021, in connection with the Company&#8217;s amended loan agreement with modified terms, the interest-only period was modified from <ix:nonNumeric contextRef="i6c89c558562342acb1a97bac5a006107_D20200101-20201231" format="ixt-sec:durmonth" name="prct:DebtInstrumentInterestOnlyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDI4NQ_f393b504-375d-42e8-8b9d-c81f22b6adc1">24</ix:nonNumeric> months beginning October 1, 2021 to <ix:nonNumeric contextRef="i9c6bcd3416cb4dff84912e6e977f510e_D20210101-20210131" format="ixt-sec:durmonth" name="prct:DebtInstrumentInterestOnlyPeriod" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDI4Ng_b6afac38-4666-4f77-a2d3-db7e21812ba5">36</ix:nonNumeric> months </span></div></ix:continuation></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i84945d3ad345426b819f34a172fe2dba"><ix:continuation id="ibb7705edfdbd4a2c8b5efcb0c7b31556">beginning October 1, 2022, and accordingly, the current portion of the amount due was reclassified to non-current. Upon the completion of the Company raising over $<ix:nonFraction unitRef="usd" contextRef="i7425a248d0c54625b60e82800726ba6e_D20210901-20210930" decimals="-6" format="ixt:num-dot-decimal" name="prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfNDM5ODA0NjUxNTM2MA_6a77f5ea-34ce-4852-8864-21b4cbcd6463">50</ix:nonFraction> million in its IPO in September 2021, interest-only payments were extended an additional 12 months followed by 12 months of amortization of principal and interest.</ix:continuation></ix:continuation></span></div><div id="id6896dbd221a471485ce149196fbcf44_61"></div><div style="margin-bottom:9pt"><span><br/></span></div><div id="id6896dbd221a471485ce149196fbcf44_64"></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="id6896dbd221a471485ce149196fbcf44_67"></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_70"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations together with our financial statements and related notes included elsewhere in this report. In addition to historical financial information, the following discussion and analysis contains forward-looking statements that involve risks, uncertainties and assumptions. Our actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of many factors, including those discussed in the section titled &#8220;Risk Factors&#8221; and elsewhere in this report. Please also see the section titled &#8220;Cautionary Note Regarding Forward-Looking Statements.&#8221;</span></div><div id="id6896dbd221a471485ce149196fbcf44_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. We develop, manufacture and sell the AquaBeam Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. BPH is the most common prostate disease and impacts approximately 40 million men in the United States. The AquaBeam Robotic System employs a single-use disposable handpiece to deliver our proprietary Aquablation therapy, which combines real-time, multi-dimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. We designed our AquaBeam Robotic System to enable consistent and reproducible BPH surgery outcomes. We believe that Aquablation therapy represents a paradigm shift in the surgical treatment of BPH by addressing compromises associated with alternative surgical interventions. We designed Aquablation therapy to deliver effective, safe and durable outcomes for males suffering from lower urinary tract symptoms, or LUTS, due to BPH that are independent of prostate size and shape or surgeon experience. We have developed a significant and growing body of clinical evidence, which includes nine clinical studies and over 100 peer-reviewed publications, supporting the benefits and clinical advantages of Aquablation therapy. As of September 30, 2021, we had an install base of 125 AquaBeam Robotic Systems globally and 75 in the United States.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our U.S. pivotal trial, the WATER study, is the only FDA pivotal study randomized against transurethral resection of prostate, or TURP, which is the historical standard of care for the surgical treatment of BPH. In this study, Aquablation therapy demonstrated superior safety and non-inferior efficacy compared to TURP across prostate sizes between 30 ml and 80 ml, and superior efficacy in a subset of patients with prostates larger than 50 ml. We have established strong relationships with key opinion leaders, or KOLs, within the urology community and collaborated with key urological societies in global markets. This support has been instrumental in facilitating broader acceptance and adoption of Aquablation therapy. As a result of our strong KOL network and our compelling clinical evidence, Aquablation therapy has been added to clinical guidelines of various professional associations, including the American Urological Association. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, we sell our products to hospitals. We are initially targeting 860 high-volume hospitals that perform, on average, more than 200 resective procedures annually and account for approximately 70% of all hospital-based resective procedures. Over time, we will gradually expand our focus to also include mid- and low-volume hospitals. These customers in turn bill various third-party payors, such as commercial payors and government agencies, for treatment payment of each patient. Effective in 2021, all local Medicare Administrative Contractors, or MACs, which represent 100% of eligible Medicare patients, issued final positive local coverage determinations to provide Medicare beneficiaries with access to Aquablation therapy in all 50 states. We also have favorable coverage decisions from several large commercial payors, including Anthem, BlueCross &#8211; Massachusetts, Cigna, Emblem Health, Health Care Service Corp, and Humana. We plan to leverage these recent successes in our active discussions with all commercial payors to establish additional positive national and regional coverage policies. Outside of the United States, we have ongoing efforts in key markets to expand established coverage and improve payment which we believe will expand patient access to Aquablation therapy.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manufacture the AquaBeam Robotic System, the handpiece, integrated scope and other accessories at our facility in Redwood City, California. This includes supporting the supply chain distribution and logistics of the various components. Components, sub-assemblies and services required to manufacture our products are purchased </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from numerous global suppliers. Each AquaBeam Robotic System is shipped to our customers with a third-party manufactured ultrasound system and probe. We utilize a well-known third-party logistics provider located in the United States and the Netherlands to ship our products to our customers globally. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generated revenue of $24.3&#160;million and incurred a net loss of $41.5&#160;million for the nine months ended September 30, 2021, compared to revenue of $4.5&#160;million and a net loss of $37.7&#160;million for the nine months ended September 30, 2020. As of September 30, 2021, we had cash and cash equivalents of $320.5&#160;million and an accumulated deficit of $243.2&#160;million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed our IPO in September 2021, which raised $172.4 million, net of issuance costs. Previously, our primary sources of capital have been from private placements of redeemable convertible preferred securities and debt financing agreements. As of September 30, 2021, we have raised $337.1 million from private placements of redeemable convertible preferred securities from our investors. We expect our expenses will increase for the foreseeable future, in particular as we continue to make substantial investments in sales and marketing, operations and research and development. Moreover, we expect to incur additional expenses as a result of operating as a public company, including legal, accounting, insurance, compliance with the rules and regulations of the SEC and those of any stock exchange on which our securities are traded, investor relations, and other administrative and professional services expenses. Based on our operating plan, we currently believe that our existing cash and cash equivalents, anticipated revenue and available debt financing arrangements will be sufficient to meet our capital requirements and fund our operations through at least the next twelve months from the issuance date of these financial statements. If these sources are insufficient to satisfy our liquidity requirements, we may seek to sell additional public equity or debt securities or obtain an additional credit facility. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Additional financing may not be available at all, or in amounts or on terms unacceptable to us. If we are unable to obtain additional financing, we may be required to delay the development, commercialization and marketing of our products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Factors Affecting Our Performance</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe there are several important factors that have impacted and that we expect will impact our operating performance and results of operations for the foreseeable future. While these factors may present significant opportunities for us, they also pose significant risks and challenges that we must address. See the section titled &#8220;Risk Factors&#8221; for more information. These factors include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Grow our install base of AquaBeam Robotic Systems:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September 30, 2021, we had an install base of 125 AquaBeam Robotic Systems globally and 75 in the United States. In the United States, we are initially focused on driving adoption of Aquablation therapy among urologists that perform hospital-based resective BPH surgery. We are initially targeting 860 high-volume hospitals that we estimate perform, on average, more than 200 resective procedures annually and account for approximately 70% of all hospital-based resective procedures. To penetrate these hospitals, we will continue to increase our direct team of capital sales representatives, who are focused on driving system placement within hospitals by engaging with key surgeons and decision makers to educate them about the compelling value proposition of Aquablation therapy. As we increase our install base of AquaBeam Robotic systems our revenue will increase as a result of the system sale and resulting utilization.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Increase system utilization:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our revenue is significantly impacted by the utilization of our AquaBeam robotic system. Once we place a system within a hospital our objective is to establish Aquablation therapy as the surgical treatment of choice for BPH. Within each hospital we are initially focused on targeting urologists who perform medium-to-high volumes of resective procedures and converting their resective cases to Aquablation therapy. To accomplish this, we will continue expanding our team of highly trained Aquablation representatives and clinical specialists who are focused on driving system utilization within the hospital, providing education and training support and ensuring excellent user experiences. As urologists </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gain experience with Aquablation therapy we will leverage their experiences to capture more surgical volumes and establish Aquablation therapy as the surgical standard of care. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Reimbursement and coverage decisions by third-party payors.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Healthcare providers in the United States generally rely on third-party payors, principally federal Medicare, state Medicaid and private health insurance plans, to cover all or part of the cost of procedures using our AquaBeam Robotic System. The revenue we are able to generate from sales of our products depends in large part on the availability of sufficient reimbursement from such payors. Effective in 2021, all local MACs, representing 100% of eligible Medicare patients, issued final positive local coverage determinations to provide Medicare beneficiaries with access to Aquablation therapy in all 50 states. We believe that these favorable coverage decisions have been a catalyst for hospital adoption of our AquaBeam Robotic System. Our strong body of clinical evidence and support from key societies, supplemented by the momentum from Medicare coverage, have led to favorable coverage decisions from several large commercial payors, including Anthem, BlueCross &#8211; Massachusetts, Cigna, Emblem Health, Health Care Service Corp and Humana. We plan to leverage these recent successes in our active discussions with commercial payors to establish additional positive national and regional coverage policies. We believe that additional commercial payor coverage will contribute to increasing utilization of our system over time. Outside of the United States, we have ongoing efforts in key markets to expand established coverage and further improve patient access to Aquablation therapy.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cost of sales.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The results of our operations will depend, in part, on our ability to increase our gross margins by more effectively managing our costs to produce our AquaBeam Robotic System and single-use disposable handpieces, and to scale our manufacturing operations efficiently. We anticipate that as we expand our sales and marketing efforts and drive further sales growth, our purchasing costs on a per unit basis may decrease, and in turn improve our gross margin. As our commercial operations continue to grow, we expect to continue to realize operating leverage through increased scale efficiencies. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Investment in research and development to drive continuous improvements and innovation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are currently developing additional and next generation technologies to support and improve Aquablation therapy to further satisfy the evolving needs of surgeons and their patients as well as to further enhance the usability and scalability of the AquaBeam Robotic System. We also plan to leverage our treatment data and software development capabilities to integrate artificial intelligence and machine learning to enable computer-assisted anatomy recognition and improved treatment planning and personalization. Our future growth is dependent on these continuous improvements which require significant resources and investment.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impact of the COVID-19 Pandemic</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 outbreak and the consequential economic disruptions have negatively impacted and may continue to negatively impact our operations, revenue and overall financial condition. In response to the pandemic, numerous state&#160;and local jurisdictions imposed, and others in the future may impose, &#8220;shelter-in-place&#8221; orders, quarantines, executive orders, and similar government orders and restrictions for their residents to control the spread of&#160;COVID-19. Starting in mid-March 2020, the governor of California, where our headquarters are located, issued &#8220;shelter-in-place&#8221; or &#8220;stay at home&#8221; orders restricting non-essential activities, travel, and business operations, subject to certain exceptions for necessary activities.&#160;Such orders or restrictions have resulted in our headquarters closing, slowdowns and delays, travel restrictions, and cancellation of training and other events, among other effects, thereby negatively impacting our operations. Additionally, in the United States, governmental authorities have recommended, and in certain cases required, that elective, specialty and other procedures and appointments be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of&#160;COVID-19.&#160;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These measures and challenges have decreased the number of BPH procedures generally, and consequently slowed adoption of our AquaBeam therapy and impacted our ability to sell our AquaBeam Robotic System. We believe the number of our systems sold has been impacted as health care organizations globally have prioritized the treatment of patients with COVID-19, and as health care organizations continue to experience consequential economic disruptions from the COVID-19 pandemic such as budget shortfalls and staffing shortages. Numerous </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">procedures have been and in certain jurisdictions in which we operate are continuing to be cancelled or delayed as a result of local public health measures and hospital policies. We have also experienced disruptions, and may experience future disruptions, including: delays in sales personnel becoming fully trained and productive; difficulties and delays in physician outreach and training physicians to use our AquaBeam Robotic System; restrictions on personnel to travel; delays in follow-ups of our clinical studies; challenges with maintaining adequate supply from third-party manufacturers of components and finished goods and distribution providers; and access to physicians for training and case support.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While many restrictions associated with COVID-19 have more recently been relaxed, the longevity and extent of the various COVID-19 pandemic remains uncertain, including due to the emergence and impact of the COVID-19 variants and continued economic disruptions. These measures and challenges may continue for the duration of the pandemic and may negatively impact our revenue growth while the pandemic continues. </span></div><div id="id6896dbd221a471485ce149196fbcf44_76"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Our Results of Operations </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generate our revenue primarily from the capital portion of our business, which includes sales and rentals of our AquaBeam Robotic System, and from the recurring revenue associated with sales of our single-use disposable handpieces that are used during each surgery performed with our system. The initial sale of an AquaBeam Robotic System involves a capital purchase by the hospital, which may require approval of senior management at the hospital, or in some cases, inclusion in the hospital&#8217;s budget process. Other revenue is derived primarily from service and repair and extended service contracts with our existing customers. We expect our revenue to increase in absolute dollars for the foreseeable future as we continue to focus on driving adoption of Aquablation therapy, and increased system utilization, though it may fluctuate from quarter to quarter.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by significant geographical locations for the periods indicated:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside the United States</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Less than 10% of total net revenues for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that both our U.S. and international revenue will increase in the near term as we continue to expand the install base of AquaBeam Robotic Systems and increase the related customer utilization in the United States. We expect our increase in revenues in absolute dollars to be larger in the United States.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales and Gross Margin </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of manufacturing overhead costs, material costs, warranty and service costs, direct labor and other direct costs such as shipping costs. A significant portion of our cost of sales currently consists of manufacturing overhead costs. These overhead costs include compensation for personnel, including stock-based compensation, facilities, equipment and operations supervision, quality assurance and material procurement. We expect our cost of sales to increase in absolute dollars for the foreseeable future primarily as, and to the extent, our revenue grows, or we make additional investments in our manufacturing capabilities, though it may fluctuate from quarter to quarter. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We calculate gross margin percentage as gross profit divided by revenue. Our gross margin has been and will continue to be affected by a variety of factors, primarily, product and geographic mix and the resulting average selling prices, production volumes, manufacturing costs and product yields, and to a lesser extent the implementation of cost reduction strategies. We expect our gross margin to increase over the long term as our production volume increases and as we spread the fixed portion of our manufacturing overhead costs over a larger number of units produced, thereby significantly reducing our per unit manufacturing costs, though it may fluctuate </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from quarter to quarter. Our gross margins can fluctuate due to geographic mix. To the extent we sell more systems and handpieces in the United States, we expect our margins will increase due to the higher average selling prices as compared to sales outside of the United States.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development, or R&amp;D, expenses consist primarily of engineering, product development, regulatory affairs, consulting services, materials, depreciation and other costs associated with products and technologies being developed. These expenses include employee and non-employee compensation, including stock-based compensation, supplies, materials, quality assurance expenses, consulting, related travel expenses and facilities expenses. We expect our R&amp;D expenses to increase in absolute dollars for the foreseeable future as we continue to develop, enhance and commercialize new products and technologies, though it may fluctuate from quarter to quarter. However, we expect our R&amp;D expenses as a percentage of revenue to vary over time depending on the level and timing of initiating new product development efforts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative, or SG&amp;A, expenses consist primarily of compensation for personnel, including stock-based compensation, related to selling, marketing, clinical affairs, professional education, finance, information technology, and human resource functions. SG&amp;A expenses also include commissions, training, travel expenses, promotional activities, conferences, trade shows, professional services fees, audit fees, legal fees, insurance costs and general corporate expenses including allocated facilities-related expenses. Clinical expenses include clinical trial design, clinical site reimbursement, data management and travel expenses. We expect our SG&amp;A expenses to increase in absolute dollars for the foreseeable future as we expand our commercial infrastructure and incur additional fees associated with operating as a public company, including legal, accounting, insurance, compliance with the rules and regulations of the SEC and those of any stock exchange on which our securities are traded, investor relations, and other administrative and professional services expenses, though it may fluctuate from quarter to quarter. However, over time, we expect our SG&amp;A expenses to decrease as a percentage of revenue. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income (Expense), Net </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense consists primarily of interest expense from our loan payable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and Other Income (Expense), Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income (expense), net, consists primarily of interest income from our cash and cash equivalents balances, and fair value adjustments from our redeemable convertible preferred stock warrant liabilities and our loan facility derivative liability.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our sales of redeemable convertible preferred stock, we issued warrants to purchase shares of our Series D and Series E redeemable convertible preferred stock. We classify these warrants as a liability on our balance sheets that we remeasure to fair value at each reporting date with the corresponding change in fair value being recognized in our statements of operations. Upon completion of our IPO in September 2021, the redeemable convertible preferred stock warrant liability was reclassified to additional paid-in capital in stockholders&#8217; equity (deficit) for warrants exercised and statement of operations for warrants expired.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in connection with the loan facility, we are obligated to pay a fee upon the earlier occurrence of a defined liquidity event, including but not limited to, a merger or sale of our assets or voting stock, or our achieving a $200 million trailing twelve months revenue target, in each case, by September 2029. The fee is calculated at the time of the liquidity event occurrence to be $1.0 million if only the first installment has been drawn, $2.0 million if the first two installments have been drawn, $2.4 million if the first three installments have been drawn, or $3.0 million if all four installments have been drawn, in each case, upon the occurrence of the liquidity event. We adjust </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the carrying values of the loan facility derivative liability for changes in fair value and recognize those changes in interest and other income (expense), net.</span></div><div id="id6896dbd221a471485ce149196fbcf44_79"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show our results of operations for the three and nine months ended September 30, 2021 and 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,561&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,240&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,271&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,777&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,118&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,054&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,064&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,037&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,947&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,090&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,797)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,978)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,819)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,469)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,387)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,103)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,008)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,095)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.207%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,986&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,349&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,725)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,074&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">758&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,732&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34,765&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,682&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,333)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,595)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,738)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,370)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,490)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(880)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,505)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,741)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,764)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Three and Nine Months Ended September 30, 2021 and 2020 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.955%"><tr><td style="width:1.0%"></td><td style="width:42.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System sales and rentals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,519&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,504&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Handpieces and other consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,850&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,561&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">311&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.955%"><tr><td style="width:1.0%"></td><td style="width:42.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.139%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.282%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System sales and rentals</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,217&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">626&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Handpieces and other consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">780&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,335&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,839&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">441&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue increased $6.6 million, or 311%, to $8.7 million during the three months ended September 30, 2021, compared to $2.1 million during the three months ended September 30, 2020, and increased $19.8 million, or 441%, to $24.3 million during the nine months ended September 30, 2021, compared to $4.5 million during the nine months ended September 30, 2020. The growth in revenue was primarily attributable to an increase of $6.1 million and $17.8 million in the sales volumes of both our AquaBeam Robotic System and our single-use disposable handpieces in the United States for the three and nine months ended September 30, 2021, respectively, resulting from the expansion of insurance coverage and the increase in personnel in our sales and marketing organizations. In addition, sales of both our AquaBeam Robotic System and our single-use disposable handpieces outside of the United States increased by $0.2 million and $1.5 million in sales volume for the three and nine months ended September 30, 2021, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cost of Sales and Gross Margin </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales increased $2.3 million, or 107%, to $4.4 million during the three months ended September 30, 2021, compared to $2.1 million during the three months ended September 30, 2020, and increased $6.8 million, or 109%, to $13.0 million during the nine months ended September 30, 2021, compared to $6.2 million during the nine months ended September 30, 2020. The increase in cost of sales was primarily attributable to the growth in the number of units sold.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross margin increased to 49% during the three months ended September 30, 2021, compared to a negative 1% for the three months ended September 30, 2020, and increased to 47% during the nine months ended September 30, 2021, compared to a negative 38% for the nine months ended September 30, 2020. The increase in gross margin was primarily attributable to the growth in unit sales, which allowed us to spread the fixed portion of our manufacturing overhead costs over more production units, and a higher percentage of sales in the United States at higher average selling prices.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses increased $1.0 million, or 26%, to $4.9 million during the three months ended September 30, 2021, compared to $3.9 million during the three months ended September 30, 2020, and increased $2.2 million, or 19%, to $13.9 million during the nine months ended September 30, 2021, compared to $11.7 million during the nine months ended September 30, 2020. The increase in R&amp;D expenses was primarily due to employee-related expenses of our R&amp;D organization. These expenses support ongoing product improvements and the development of additional and next generation technologies. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Selling, General and Administrative Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SG&amp;A expenses increased $5.1 million, or 72%, to $12.1 million during the three months ended September 30, 2021, compared to $7.0 million during the three months ended September 30, 2020, and increased $13.7 million, or 64%, to $34.8 million during the nine months ended September 30, 2021, compared to $21.1 million during the nine months ended September 30, 2020. The increase in SG&amp;A expenses was primarily due to employee-related expenses of our sales and marketing, reimbursement and administrative organizations as we expanded our infrastructure to drive and support the anticipated growth in revenue.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest Expense </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense increased $0.1 million to $1.5 million during the three months ended September 30, 2021, compared to $1.4 million during the three months ended September 30, 2020, and increased $0.9 million to $4.4 million during the nine months ended September 30, 2021, compared to $3.5 million during the nine months ended September 30, 2020. The increase was due to increased borrowings under our debt financing arrangements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interest and Other Income (Expense), Net </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest and other income (expense), net, decreased $0.2 million to $0.2 million during the three months ended September 30, 2021, compared to $0.4 million during the three months ended September 30, 2021, and decreased $0.1 million to $0.2 million during the nine months ended September 30, 2021, compared to $0.3 million during the nine months ended September 30, 2020. The decrease in other income (expense), net during the three months ended September 30, 2021 was primarily attributable to a decrease in other expenses. The decrease in other income (expense), net during the nine months ended September 30, 2021 was primarily attributable to a decrease in the fair value of loan facility derivative liability. </span></div><div id="id6896dbd221a471485ce149196fbcf44_82"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We completed our IPO in September 2021, which raised $172.4 million, net of issuance costs. Previously, our primary sources of capital have been from private placements of redeemable convertible preferred securities and debt financing agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had cash and cash equivalents of $320.5 million, an accumulated deficit of $243.2&#160;million, and $50.0&#160;million outstanding on our loan facility. We expect our expenses will increase for the foreseeable future, in particular as we continue to make substantial investments in sales and marketing, operations and research and development. Moreover, we expect to incur additional expenses as a result of operating as a public company, including legal, accounting, insurance, compliance with the rules and regulations of the SEC and those of any stock exchange on which our securities are traded, investor relations, and other administrative and professional services expenses. Our future funding requirements will depend on many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and rate of market acceptance of our products and Aquablation therapy;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and timing of investment in our sales force and expansion of our commercial organization;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our business from the ongoing and global COVID-19 pandemic and the end of the COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, rate of progress and cost of our current or future clinical trials and registries;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of our research and development activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of additional regulatory clearances or approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with any product recall that may occur;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the manufacturing of our products at increased production levels;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of attaining, defending and enforcing our intellectual property rights;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we acquire third-party companies, products or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any other collaborative, licensing and other arrangements that we may establish;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies or other adverse market developments; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate at which we expand internationally.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our operating plan, we currently believe that our existing cash and cash equivalents, anticipated revenue and available debt financing arrangements will be sufficient to meet our capital requirements and fund our operations through at least the next twelve months from the issuance date of these financial statements. We have based this estimate on assumptions that may prove to be wrong, and we may need to utilize additional available capital resources. If these sources are insufficient to satisfy our liquidity requirements, we may seek to sell additional public equity or debt securities or obtain an additional credit facility. The sale of equity and convertible debt securities may result in dilution to our stockholders and, in the case of preferred equity securities or convertible debt, those securities could provide for rights, preferences or privileges senior to those of our common stock. Debt financing, if available, may involve covenants restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Additional financing may not be available at all, or in amounts or on terms unacceptable to us. If we are unable to obtain additional financing, we may be required to delay the development, commercialization and marketing of our products. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Indebtedness</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we entered into a loan facility for up to $75.0 million available in four installments. We borrowed $25.0 million in September 2019 and an additional $25.0 million in March 2020. The third installment is for $10.0 million and was originally available for draw through March 31, 2021 contingent upon our achieving $20.0 million trailing six months revenue in any month before March 31, 2021. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The remaining $15.0 million was originally available for draw through June 30, 2021 contingent upon achieving $25.0 million in trailing six months revenue. In January 2021, the third installment was amended to be available for draw through March 31, 2022 contingent upon our achieving $6.4 million trailing six months revenue prior to June 30, 2021, and the fourth installment was amended to be available for draw though June 30, 2022. The facility bears an interest rate of the greater of (i) 9.37% and (ii) 7.17% plus 30-day LIBOR. The facility includes customary negative covenants that, among other things, restrict our ability to incur indebtedness or enter into certain change of control transactions. It also contains customary events of default that would result in the termination of the commitments under the facility and permit the lender to accelerate payment on outstanding borrowings. As of September 30, 2021, we were in compliance with all covenants under the facility. The initial term of the facility is 60 months with interest-only payments, with the repayment of principal being amortized over a period of: 36 months, if we fail to achieve the revenue target for the third installment, 24 months if we achieve the revenue target for the third installment but have not raised at least $50.0 million in an initial public offering, or 12 months if we achieve the revenue target for the third installment and raise at least $50.0 million in an initial public offering. Upon completion of raising over $50.0 million in our IPO in September 2021, interest-only payments was extended an additional 12 months followed by 12 months amortization of principal and interest. We pledged substantially all of our assets as collateral for the loan. Commencing with the quarter ended June 30, 2021, we are required to achieve revenue for the previous six months ended equal to 70% of the forecast for the commensurate quarterly period. Additionally, in connection with the loan facility, we are obligated to pay a fee upon the earlier occurrence of a defined liquidity event, including but not limited to, a merger or sale of our assets or voting stock, or our achieving a $200.0 million trailing twelve months revenue target, in each case, by September 2029. The fee is calculated at the time of the liquidity event occurrence to be $1.0 million if only the first installment has been drawn, $2.0 million if the first two installments have been drawn, $2.4 million if the first three installments have been drawn, or $3.0 million if all four installments have been drawn, in each case, upon the occurrence of the liquidity event. As of September 30, 2021, we had $50.0 million outstanding under the loan facility.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_85"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flows for the nine months ended September 30, 2021 and 2020:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.842%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.843%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended<br/>September 30, </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40,858)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34,898)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(260)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(224)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;text-indent:18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261,472&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">220,354&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71,412&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div id="id6896dbd221a471485ce149196fbcf44_88"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in Operating Activities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, net cash used in operating activities was $40.9 million, consisting primarily of a net loss of $41.5 million and an increase in net operating assets of $4.3 million, partially offset by non-cash charges of $4.9 million. The cash used in operations was primarily due to our net loss due to the increase in operating expenses to support our commercialization and development activities. The expansion of our commercialization resulted in an increase in accounts receivable and inventory, partially offset by an increase in accounts payable. Non-cash charges consisted primarily of depreciation and stock-based compensation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2020, net cash used in operating activities was $34.9 million, consisting primarily of a net loss of $37.7 million and an increase in net operating assets of $0.4 million, partially offset by non-cash charges of $3.2 million. The cash used in operations was primarily due to our net loss. The increase in net operating assets was primarily due to an increase in inventory and accounts receivable, partially offset by an increase in accrued compensation. Non-cash charges consisted primarily of depreciation and stock-based compensation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Used in by Investing Activities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, net cash used in investing activities was $0.3 million, consisting of purchases of property and equipment. During the nine months ended September 30, 2020, net cash used in investing activities was $0.2 million, consisting of purchases of property and equipment. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Cash Provided by Financing Activities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the nine months ended September 30, 2021, net cash provided by financing activities was $261.5 million, consisting primarily of net proceeds from our IPO of $172.4 million and the issuance of shares of our Series G redeemable convertible preferred stock of $84.7 million. During the nine months ended September 30, 2020, net cash provided by financing activities was $106.5 million, consisting primarily of net proceeds from the issuance of shares of our Series F redeemable convertible preferred stock of $76.5 million and notes payable of $24.7 million.</span></div><div id="id6896dbd221a471485ce149196fbcf44_91"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Commitments and Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in Note 9 to the condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.</span></div><div id="id6896dbd221a471485ce149196fbcf44_94"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not have during the periods presented, and we do not currently have any off-balance sheet arrangements, such as structured finance, special purpose entities or variable interest entities. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_97"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions for the reported amounts of assets, liabilities, revenue, expenses and related disclosures. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions and any such differences may be material. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant accounting policies and estimates used in preparation of the unaudited condensed consolidated financial statements are described in our audited consolidated financial statements as of and for the year ended December 31, 2020, and the notes thereto, which are included in our prospectus dated September 14, 2021 and in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our prospectus dated September 14, 2021&#8221;. There have been no material changes to our significant accounting policies during the three and nine months ended September 30, 2021. </span></div><div id="id6896dbd221a471485ce149196fbcf44_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOBS Act Accounting Election and Smaller Reporting Company Status </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our consolidated financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also a &#8220;smaller reporting company&#8221; as defined in the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and non-voting common stock held by non-affiliates is less than $250.0 million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0 million during the most recently completed fiscal year and our voting and non-voting common stock held by non-affiliates is less than $700.0 million measured on the last business day of our second fiscal quarter.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information included in Note 2 to the condensed consolidated financial statements included in Part I, Item 1 of this Quarterly Report on Form 10-Q is incorporated herein by reference.</span></div><div id="id6896dbd221a471485ce149196fbcf44_103"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents of $320.5 million as of September 30, 2021, consisted of securities carried at quoted market prices with an original maturity of three months or less and therefore there is minimal risk associated with fluctuating interest rates. We do not currently use or plan to use financial derivatives in our investment portfolio. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as described above under the subsection titled &#8220;Indebtedness,&#8221; amounts outstanding under our loan facility bear interest at a floating rate equal to 7.17% plus the greater of 2.2% or 30-day LIBOR. As a result, we are exposed to risks from changes in interest rates. We do not believe that a hypothetical 100 basis point increase or decrease in interest rates or 30-day LIBOR would have had a material impact on our financial statements included elsewhere in this Quarterly Report on Form 10-Q. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain our cash and cash equivalents with two financial institutions in the United States, and our current deposits are in excess of insured limits. We have reviewed the financial statements of these institutions and believe it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to us. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounts receivable primarily relate to revenue from the sale or rental of our products. No customer accounted for more than 10% of accounts receivable at September 30, 2021. We believe that credit risk in our accounts receivable is mitigated by our credit evaluation process, relatively short collection terms and diversity of our customer base.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Risk </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our net sales and expenses are denominated in foreign currencies, most notably the Euro. Future fluctuations in the value of the U.S. Dollar may affect the price competitiveness of our products outside the United States. For direct sales outside the United States, we sell in both U.S. Dollars and local currencies, which could expose us to additional foreign currency risks, including changes in currency exchange rates. Our operating expenses in countries outside the United States, are payable in foreign currencies and therefore expose us to currency risk. We do not believe that a hypothetical 10% increase or decrease in the relative value of the U.S. dollar to other currencies would have had a material impact on our financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently maintain a program to hedge exposures to non-U.S. dollar currencies.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Effects of Inflation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our cost of labor and research and development contract costs. We do not believe that inflation had a material effect on our financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span></div><div id="id6896dbd221a471485ce149196fbcf44_106"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were not effective at the reasonable assurance level because of a material weakness in our internal control over financial reporting as described below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, our management, including our Chief Executive Officer and our Chief Financial Officer, has concluded that, notwithstanding the identified material weakness in our internal control over financial reporting, the condensed consolidated financial statements in this Quarterly Report fairly present, in all material respects, our financial position, results of operations and cash flows for the periods presented in conformity with U.S. GAAP.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Weakness in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We previously identified a material weakness in our internal control over financial reporting that continues to exist. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness is the result of our failure to design and maintain effective controls over certain information technology, or IT, general controls for information systems that are relevant to the preparation of our financial statements. Specifically, we did not design and maintain:</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">program change management controls to ensure that information technology program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately, and</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial applications, programs and data to appropriate company personnel.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These IT general control deficiencies did not result in a material misstatement to the consolidated financial statements; however, the deficiencies, when aggregated, could impact maintaining effective segregation of duties, as well as the effectiveness of IT-dependent controls (such as automated controls that address the risk of material misstatement to one or more assertions, along with the IT controls and underlying data that support the effectiveness of system-generated data and reports) that could result in misstatements potentially impacting all financial statement accounts and disclosures that would result in a material misstatement to the annual or interim consolidated financial statements that would not be prevented or detected. Accordingly, our management determined these deficiencies in the aggregate constitute a material weakness.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Plan to Remediate the Material Weakness</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of designing, implementing, and testing the operating effectiveness of measures to remediate the material weakness in our internal control over financial reporting. During the three months ended September 30, 2021, we completed the design and implementation of controls over the review and update of user access rights and privileges, and controls over program changes to our information systems that contain data used for financial reporting. We plan to complete the design and implementation of controls over segregation of duties subsequent to the three months ended September 30, 2021. The material weakness will not be considered remediated until management completes the design and implementation of the measures described above and the controls operate for a sufficient period of time and management has concluded, through testing, that these controls are effective.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on Effectiveness of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_109"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div id="id6896dbd221a471485ce149196fbcf44_112"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceeding</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may be involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any legal proceedings that, in the opinion of management, would have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity and reputation harm, and other factors.</span></div><div id="id6896dbd221a471485ce149196fbcf44_115"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operations and financial results are subject to various risks and uncertainties including those described below. You should consider carefully the risks and uncertainties described below, in addition to other information contained in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and related notes. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. If any of the following risks or others not specified below materialize, our business, financial condition and results of operations could be materially and adversely affected. In that case, the trading price of our common stock could decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an early-stage company with a history of significant net losses, we expect to continue to incur operating losses for the foreseeable future and we may not be able to achieve or sustain profitability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred significant net losses in each reporting period since our inception. For the nine months ended September 30, 2021 and 2020, we had a net loss of $41.5&#160;million and $37.7&#160;million, respectively. For the year ended December 31, 2020, we had a net loss of $53.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million. We expect to continue to incur additional losses in the future. As of September 30, 2021, we had an accumulated deficit of $243.2&#160;million. To date, we have financed our operations primarily through net proceeds from the sale of our redeemable convertible preferred stock in private placements, indebtedness, including our loan and security agreement, and, to a lesser extent, product revenue from sales of our AquaBeam Robotic System and single-use disposable handpieces. The losses and accumulated deficit have primarily been due to the substantial investments we have made to develop our products, costs related to our sales and marketing efforts, including costs related to clinical and regulatory initiatives to obtain marketing approval, and infrastructure improvements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by early-stage medical technology companies in rapidly evolving fields. In addition, as a public company, we will incur significant legal, accounting and other expenses that we did not incur as a private company. Accordingly, we expect to continue to incur significant operating losses for the foreseeable future and we cannot assure you that we will achieve profitability in the future or that, if we do become profitable, we will sustain profitability. Our failure to achieve and sustain profitability in the future will make it more difficult to finance our capital requirements needed to operate our business and accomplish our strategic objectives, which would have a material adverse effect on our business, financial condition and results of operations and cause the market price of our common stock to decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our revenue is primarily generated from sales of our AquaBeam Robotic System and the accompanying single-use disposable handpieces, and we are therefore highly dependent on the success of those products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, substantially all of our revenue has been derived, and we expect it to continue to be substantially derived, from sales of our AquaBeam Robotic System and its accompanying single-use disposable handpieces. Our products deliver our Aquablation therapy, the first and only image-guided, heat-free robotic therapy for BPH.  We began commercializing our products in the United States in 2017 and physician awareness of, and experience with, our products has been and is currently limited. As a result, our products have limited product and brand recognition </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">within the medical industry for the treatment of BPH. We do not have a long history operating as a commercial company, and the novelty of our products, together with our limited commercialization experience, makes it difficult to evaluate our current business and predict our future prospects with precision. These factors also make it difficult for us to forecast our financial performance and future growth, and such forecasts are subject to a number of uncertainties, including those outside of our control.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our quarterly and annual operating results may fluctuate significantly and may not fully reflect the underlying performance of our business. This makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual results of operations, including our revenue, profitability and cash flow, may vary significantly in the future, and period-to-period comparisons of our operating results may not be meaningful. Accordingly, the results of any one quarter or period should not be relied upon as an indication of future performance. Our quarterly and annual operating results may fluctuate significantly as a result of a variety of factors, many of which are outside our control and, as a result, may not fully reflect the underlying performance of our business. Such fluctuations in quarterly and annual operating results may decrease the value of our common stock. Because our quarterly operating results may fluctuate, period-to-period comparisons may not be the best indication of the underlying results of our business and should only be relied upon as one factor in determining how our business is performing. These fluctuations may occur due to a variety of factors, many of which are outside of our control, including, but not limited to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of surgeon and hospital adoption and demand for our products and Aquablation therapy;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in reimbursement rates by government or commercial payors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">positive or negative coverage in the media or clinical publications, or changes in public, patient and/or physician perception, of our products or competing products and treatments, including our brand reputation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree of competition in our industry and any change in the competitive landscape, including consolidation among competitors or future partners;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any safety, reliability or effectiveness concerns that arise regarding our products or other procedures to treat BPH;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated pricing pressures in connection with the sale of our products and downward pressure on healthcare costs in general;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the effectiveness of our sales and marketing efforts, including our ability to deploy a sufficient number of qualified sales representatives to sell and market our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of customer orders or medical procedures using our products and the number of available selling days in any quarterly period, which can be impacted by holidays, the mix of products sold and the geographic mix of where products are sold;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated delays in product development or product launches; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our products, which may vary depending on the quantity of production and the terms of our agreements with third-party suppliers;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to raise additional capital on acceptable terms, or at all, if needed to support the commercialization of our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to achieve and maintain compliance with all regulatory requirements applicable to our products and services;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain, maintain and enforce our intellectual property rights;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability and our third-party suppliers&#8217; ability to supply the components of our products in a timely manner, in accordance with our specifications, and in compliance with applicable regulatory requirements; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">introduction of new products, technologies or alternative treatments for BPH that compete with our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effects of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. If our assumptions regarding the risks and uncertainties we face, which we use to plan our business, are incorrect or change due to circumstances in our business or our markets, or if we do not address these risks successfully, our operating and financial results could deviate materially from our expectations and our business could suffer.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This variability and unpredictability could also result in our failure to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, it will negatively affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The terms of our loan and security agreement require us to meet certain operating and financial covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, we had $50.0 million outstanding in the form of a term loan under our loan and security agreement with Oxford Finance LLC, which was entered into in September 2019. The loan is secured by substantially all of our assets, including all of the capital stock held by us, if any. The loan and security agreement contains a number of restrictive covenants, and the terms may restrict our current and future operations, particularly our ability to respond to certain changes in our business or industry, or take future actions. See the section of this Quarterly Report on Form 10-Q titled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8212;Liquidity and Capital Resources&#8212;Indebtedness.&#8221; </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan and security agreement contains customary representations and warranties and affirmative covenants and also contains certain restrictive covenants, including, among others, limitations on: the incurrence of additional debt, liens or other encumbrances on property, acquisitions and investments, loans and guarantees, mergers, consolidations, liquidations and dissolutions, asset sales, dividends and other payments in respect of our capital stock, prepayments of certain debt, transactions with affiliates and changes to our type of business, management of the business, control of the business or business locations. The loan and security agreement also includes financial covenants that require us to, among other things, meet certain revenue targets detailed in an approved forecast. The loan and security agreement also contains customary events of default. If we fail to comply with such covenants, payments or other terms of the agreement, our lender could declare an event of default, which would give it the right to declare all borrowings outstanding, together with accrued and unpaid interest and fees, to be immediately due and payable. In addition, our lender would have the right to proceed against the assets we provided as collateral pursuant to the loan and security agreement. If the debt under the loan and security agreement were accelerated, we may not have sufficient cash or be able to sell sufficient assets to repay this debt, which would harm our business and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need additional funding to finance our planned operations, and may not be able to raise capital when needed, which could force us to delay, reduce or eliminate one or more of our product development programs and future commercialization efforts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant net losses and expect to continue to incur net losses for the foreseeable future. Since our inception, our operations have been financed primarily by net proceeds from the sale of our redeemable convertible preferred stock in private placements, indebtedness and, to a lesser extent, product revenue from sales of our AquaBeam Robotic System and single-use disposable handpieces. As of September 30, 2021, we had $320.5&#160;million in cash and cash equivalents, and an accumulated deficit of $243.2&#160;million. Based on our current operating plan, we currently believe that our cash and cash equivalents, anticipated revenue and available debt financing arrangements, will be sufficient to meet our capital requirements and fund our operations through at </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">least the next 12 months.  However, we have based these estimates on assumptions that may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect. Changing circumstances could result in lower revenues or cause us to consume capital significantly faster than we currently anticipate, and we may need to raise capital sooner or in greater amounts than currently expected because of circumstances beyond our control.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional capital in the future as we expect to continue to invest in clinical trials and registries that are designed to provide clinical evidence of the safety and efficacy of our products, expanding our sales and marketing organization, and research and development of product improvements and future products. Moreover, we expect to incur additional expenses associated with operating as a public company, including legal, accounting, insurance, exchange listing and SEC compliance, investor relations and other expenses. To the extent additional capital is necessary, there are no assurances that we will be able to raise additional capital on favorable terms or at all, and therefore we may not be able to execute our business plan. Our future funding requirements will depend on many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree and rate of market acceptance of our current and future products and Aquablation therapy;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and timing of investment in our sales force and expansion of our commercial organization;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact on our business from the ongoing and global COVID-19 pandemic and the end of the COVID-19 pandemic, or any other pandemic, epidemic or outbreak of an infectious disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, rate of progress and cost of our current or future clinical trials and registries;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of our research and development activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of additional regulatory clearances or approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with any product recall that may occur;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs associated with the manufacturing of our products at increased production levels;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of attaining, defending and enforcing our intellectual property rights;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">whether we acquire third-party companies, products or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the terms and timing of any other collaborative, licensing and other arrangements that we may establish;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the emergence of competing technologies or other adverse market developments; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate at which we expand internationally.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek to raise additional capital through equity offerings or debt financings and such additional financing may not be available to us on acceptable terms, or at all. In addition, any additional equity or debt financing that we raise may contain terms that are not favorable to us or our stockholders. For example, if we raise funds by issuing equity or equity-linked securities, the issuance of such securities could result in dilution to our stockholders. Any equity securities issued may also provide for rights, preferences or privileges senior to those of holders of our common stock. In addition, the issuance of additional equity securities by us, or the possibility of such issuance, may cause the market price of our common stock to decline, and the price per share at which we sell additional shares of our common stock, or securities convertible into or exercisable or exchangeable for shares of our common stock, in future transactions may be higher or lower than the price per share paid by investors in our prior offerings. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the terms of debt securities issued or borrowings could impose significant restrictions on our operations including restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to pay dividends, limitations on our ability to acquire or license intellectual property rights, and other operating restrictions that could adversely affect our ability to conduct our business. For example, our current loan and security agreement prohibits us from incurring additional indebtedness </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">without the prior written consent of our lender. In the event that we enter into collaborations or licensing arrangements to raise capital, we may be required to accept unfavorable terms, such as relinquishment or licensing of certain technologies or products that we otherwise would seek to develop or commercialize ourselves, or reserve for future potential arrangements when we might otherwise be able to achieve more favorable terms. In addition, we may be forced to work with a partner on one or more of our products or market development programs, which could lower the economic value of those programs to us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain adequate financing on terms satisfactory to us when we require it, we may be required to terminate or delay the development of one or more of our products, delay clinical trials necessary to market our products, or delay establishment of sales and marketing capabilities or other activities necessary to commercialize our products. If this were to occur, our ability to grow and support our business and to respond to market challenges could be significantly limited, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The commercial success of our AquaBeam Robotic System and Aquablation therapy will depend upon the degree of market acceptance of our products among hospitals, surgeons and patients. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend, in large part, on the acceptance of our AquaBeam Robotic System as safe, effective, reliable and durable and, with respect to hospitals, healthcare providers and patients, as cost-effective. We believe Aquablation therapy represents a new approach for treating BPH, employing a computer-assisted patient-specific visualization system, a heat-free waterjet and automated robotic system to target and remove prostate tissue. We believe that market acceptance will be driven primarily by surgeons and hospitals, and if they do not adopt the concept of computer-assisted robotics-enabled technology and perceive such technology as having significant advantages over other surgical alternatives, patients will be less likely to accept or be offered Aquablation therapy and we will fail to meet our business objectives. Surgeons&#8217; and hospitals&#8217; perceptions of such technology having significant advantages are likely to be based on a determination that, among other factors, our products are safe, cost-effective and represent acceptable methods of treatment. Even if we can prove the effectiveness of Aquablation therapy through clinical trials, there may not be broad adoption and use of our products and surgeons may elect not to use our products for any number of other reasons, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of experience with our products and concerns that we are relatively new to market;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perceived liability risk generally associated with the use of new products and treatment options;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack or perceived lack of sufficient clinical evidence, including long-term data, supporting clinical benefits or the cost-effectiveness of our products over existing treatment alternatives;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of key opinion leaders to provide recommendations regarding our products, or to assure surgeons, patients and healthcare payors of the benefits of our products as an attractive alternative to other treatment options;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">perception that our products are unproven;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">long-standing relationships with companies and distributors that sell other products or treatment options for BPH;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">concerns over the capital investment required to purchase our AquaBeam Robotic System and perform Aquablation therapy procedures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of availability of adequate third-party payor coverage or reimbursement;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing pressure, including from Group Purchasing Organizations, or GPOs, and Integrated Delivery Networks, or IDNs, seeking to obtain discounts on our AquaBeam Robotic System based on the collective buying power of the GPO and IDN members;  </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competitive response and negative selling efforts from providers of alternative treatments; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limitations or warnings contained in the labeling cleared or approved by the FDA or other authorities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our AquaBeam Robotic System achieves widespread market acceptance, it may not maintain such level of market acceptance over the long term if competing products or technologies, which are more cost-effective or received more favorably, are introduced. In addition, our limited commercialization experience makes it difficult to evaluate our current business and predict our future prospects. We cannot predict how quickly, if at all, hospitals, surgeons and patients will accept our AquaBeam Robotic System or, if accepted, how frequently it will be used. Failure to achieve or maintain market acceptance and/or market share could materially and adversely affect our ability to generate revenue and would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in training and marketing and selling our products and we may provide inadequate training, fail to increase our sales and marketing capabilities or fail to develop and maintain broad brand awareness in a cost-effective manner.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience marketing and selling our products. We currently rely on our direct sales force and distributors to sell our products in targeted geographic regions and territories, and any failure to maintain and grow our direct sales force and distributor relationships could harm our business. The members of our direct sales force are adequately trained and possess technical expertise, which we believe is critical in driving the awareness and adoption of our products. The members of our U.S. sales force are at-will employees. The loss of these personnel to competitors, or otherwise, could materially harm our business. If we are unable to retain our direct sales force personnel or replace them with individuals of comparable expertise and qualifications, or if we are unable to successfully instill such expertise in replacement personnel, our product sales, revenues and results of operations could be materially harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to generate future growth, we plan to continue to significantly expand and leverage our commercial infrastructure to increase our customer base and increase awareness and adoption by existing customers to drive our growth. Identifying and recruiting qualified sales and marketing professionals and training them on our products and Aquablation therapy, on applicable federal and state laws and regulations and on our internal policies and procedures requires significant time, expense and attention. It can take several months or more before a sales representative is fully trained and productive. Our sales force may subject us to higher fixed costs than those of companies with competing products or treatments that can utilize independent third parties, placing us at a competitive disadvantage. Our business may be harmed if our efforts to expand and train our sales force do not generate a corresponding increase in product sales and revenue, and our higher fixed costs may slow our ability to reduce costs in the face of a sudden decline in demand for our products. Any failure to hire, develop and retain talented sales personnel, to achieve desired productivity levels in a reasonable period of time or timely reduce fixed costs, could have material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase our customer base and achieve broader market acceptance of our products will depend, to a significant extent, on our ability to expand our sales and marketing and educational efforts. We plan to dedicate significant resources to our sales and marketing and educational programs. Our business may be harmed if these efforts and expenditures do not generate a corresponding increase in revenue. In addition, we believe that developing and maintaining broad awareness of our Aquablation therapy in a cost-effective manner is critical to achieving broad acceptance of our products and reaching new physicians, hospitals and patients. Promotion and educational activities may not generate hospital or surgeon awareness or increase revenue, and even if they do, any increase in revenue may not offset the costs and expenses we incur. If we fail to successfully promote Aquablation therapy in a cost-effective manner, we may fail to attract or retain the market acceptance necessary to realize a sufficient return on our promotional and educational efforts, or to achieve broad adoption of our products.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to obtain or maintain adequate levels of third-party coverage and reimbursement, and third parties may rescind or modify their coverage or delay payments related to our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive the majority of our revenue from sales of our AquaBeam Robotic System and single-use disposable handpieces to hospitals. Sales of our products will depend, in part, on the extent to which the procedures using our products are covered and reimbursed by third-party payors, including private insurers and government healthcare </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">programs. Even if a third-party payor covers a particular treatment that uses our products, the resulting reimbursement rate may not be adequate to cover a provider&#8217;s cost to purchase our products or ensure such purchase is profitable for the provider. As a result, access to adequate coverage and reimbursement for our products by third-party payors is essential to the acceptance and adoption of our products</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Coverage and reimbursement by governmental and third-party payors may depend upon a number of factors, including the determination that the product or service and its use or administration for a particular patient is:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a covered benefit;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safe, effective and medically necessary;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">appropriate for the specific patient;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">supported by guidelines established by the relevant professional societies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">cost-effective; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">neither experimental nor investigational.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our customers typically bill third-party payors for the costs and fees associated with the procedures in which our products are used. Because there is often no separate reimbursement for supplies used in surgical procedures or for the purchase of the capital equipment needed to perform a procedure, the additional cost associated with the use of our products can affect the profit margin of the hospital or surgery center where the procedure is performed. Some of our target customers may be unwilling to adopt our products in light of potential additional associated cost. In addition, customers that perform the procedure may be subject to reimbursement claim denials upon submission of the claim. Customers may also be subject to recovery of overpayments if a payor makes payment for the claim and subsequently determines that the payor&#8217;s coding, billing or coverage policies were not followed. These events, or any other decline in the amount payors are willing to reimburse our customers, could make it difficult for existing customers to continue using or to adopt our products and could create additional pricing pressure for us. If we are forced to lower the price we charge for our products, our gross margins will decrease, which could have a material adverse effect on our business, financial condition and results of operations and impair our ability to grow our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party payors, whether foreign or domestic, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs by limiting coverage and the amount of reimbursement for particular products. In addition, no uniform policy of coverage and reimbursement for procedures using our products exists among third-party payors. Therefore, coverage and reimbursement for procedures using our products can differ significantly from payor to payor. Obtaining coverage and reimbursement can be a time-consuming process that could require us to provide supporting scientific, clinical and cost-effectiveness data for the use of our products. We may not be able to provide data sufficient to satisfy governmental and third-party payors that procedures using our products should be covered and reimbursed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payors continually review new and existing technologies for possible coverage and can, without notice, deny or reverse coverage for new or existing products and procedures. There can be no assurance that third-party payor policies will provide coverage for procedures in which our products are used. Many third-party payors do not currently cover our products and the related procedures because they have determined that our products and the related procedures are experimental or investigational. When our products and the related procedures are reimbursed, they are reimbursed primarily on a per-patient prior authorization basis for patients covered by commercial insurers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we believe that future coverage and reimbursement may be subject to increased restrictions, such as additional prior authorization requirements, both in the United States and in relevant international markets in which we plan to operate. If Medicare no longer covers any of our products, there would be a material adverse effect on our business, financial condition and results of operations. In addition, Medicare Administrative Contractors could issue a local coverage determination decision that could restrict the patients eligible for the treatment with our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products or in another manner unfavorable to our business. Third-party coverage and reimbursement for procedures using our products or any of our products in development for which we may receive regulatory clearance or approval may not be available or adequate in either the United States or international markets. Further, other BPH treatments may be more widely covered or subject to different co-pay policies and requirements, which could impact demand for our products. If hospital, surgeon and/or patient demand for our products is adversely affected by changes in third-party reimbursement policies and decisions, it could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from many sources, including larger companies, and we may be unable to compete successfully. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical device industry is highly competitive, subject to rapid change and significantly affected by the introduction of new products and technologies and other activities of industry participants. We compete with pharmaceutical products marketed to treat BPH, such as Flomax marketed by Boehringer Ingelheim, Rapaflow marketed by Allergan plc, Avodart marketed by GlaxoSmithKline plc, and Proscar marketed by Merck &amp; Co., Inc., and with medical device companies that manufacture resective or non-resective surgical alternatives for treating BPH. Resective alternatives include devices for the TURP procedure, laser-based therapies and simple prostatectomy, each of which is intended to remove the prostate tissue, and non-resective alternatives such as UroLift marketed by Teleflex Incorporated and Rezum marketed by Boston Scientific Corporation, which are intended to reshape the prostate and widen the cavity. Our primary medical device competitors are Boston Scientific Corporation and smaller companies that have single products or a limited range of products. Moreover, other products that are in current clinical trials, new drugs or additional indications for existing drugs could demonstrate better safety, effectiveness, clinical results, lower costs or greater physician and market acceptance than our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete, or may compete in the future, against other companies which have longer, more established operating histories and significantly greater financial, technical, marketing, sales, distribution and other resources, which may prevent us from achieving significant market penetration or improved operating results. These companies may enjoy several competitive advantages, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established treatment patterns pursuant to which drugs are generally first-line or concurrent therapies for the treatment of BPH;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established relationships with hospitals and physicians who are familiar with other surgical alternatives for the treatment of BPH;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater financial and human capital resources;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significantly greater name recognition;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional lines of products, and the ability to offer rebates or bundle products to offer greater discounts or incentives to gain a competitive advantage; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">established sales, marketing and worldwide distribution networks.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our continued success depends on our ability to: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">improve outcomes for patients;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain product safety, efficacy, reliability and durability;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand the quality and volume of our clinical data;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively market to and educate patients, physicians and hospitals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain company, product and brand recognition;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">broaden our sales force experience and access;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain product support and service;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain and widen our technology lead over competitors by continuing to innovate and deliver new product enhancements on a continuous basis;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop successful pricing and revenue strategies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to maintain and expand reimbursement coverage for procedures using our products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">achieve desired regulatory status and speed to market; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain dedicated clinical representatives.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the major hurdles to adoption of our products will be overcoming established treatment patterns, which will require education of surgeons and supportive clinical data. However, because of the size of the market opportunity for the treatment of BPH, we believe current and potential future competitors will dedicate significant resources to aggressively promote their products or develop new products or treatments. New treatment options may be developed that could compete more effectively with our products due to the prevalence of BPH and the research and technological progress that exist within the market.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to continue to innovate and improve our AquaBeam Robotic System, we could lose customers or market share. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend on our ability to keep ahead of innovative developments in the treatment of BPH. It is critical to our competitiveness that we continue to innovate and make improvements to our AquaBeam Robotic System&#8217;s functionality and efficiency. If we fail to make improvements to our AquaBeam Robotic System&#8217;s functionality over time, our competitors may develop products that offer features and functionality similar or superior to those of our AquaBeam Robotic System. If we fail to make improvements to our AquaBeam Robotic System&#8217;s efficiency, our competitors may develop products that are more cost-effective than our AquaBeam Robotic System. Our failure to make continuous improvements to our AquaBeam Robotic System to keep ahead of the products of our competitors could result in the loss of customers or market share that would adversely affect our business, results of operations, and financial condition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience manufacturing our products in large-scale commercial quantities, and we face a number of manufacturing risks that may adversely affect our manufacturing abilities which could delay, prevent or impair our growth.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth strategy depends on our ability to manufacture our current and future products in sufficient quantities and on a timely basis to meet customer demand, while adhering to product quality standards, complying with regulatory quality system requirements and managing manufacturing costs in our current manufacturing facility or any future manufacturing facilities. We have a sole manufacturing facility located in Redwood City, California, where we manufacture, assemble, inspect, test, package and ship our products. We currently assemble all of our AquaBeam Robotic System and single-use disposable handpieces at this one facility, and we do not have additional facilities. If this facility, or any of our future manufacturing facilities, suffers damage, or a force majeure event, such damage or event could materially impact our ability to operate, which could materially and adversely affect our business and financial performance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous other risks relating to our manufacturing capabilities, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">quality and reliability of components, sub-assemblies and materials that we source from third-party suppliers, who are required to meet our quality specifications, almost all of whom are single source suppliers for the items and materials that they supply;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to secure components, sub-assemblies and materials in a timely manner, in sufficient quantities or on commercially reasonable terms;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to maintain compliance with quality system requirements or pass regulatory quality inspections;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our failure to increase production capacity or volumes to meet demand; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential risks associated with disruptions in our supply chain, such as on account of the COVID-19 pandemic or other macroeconomic events;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lead times associated with securing key components;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to design or modify production processes to enable us to produce future products efficiently or implement changes in current products in response to design or regulatory requirements; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty identifying and qualifying, and obtaining new regulatory approvals, for alternative suppliers for components in a timely manner.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These risks are likely to be exacerbated by our limited experience with our current products and manufacturing processes. For instance, in both 2019 and 2021, we initiated voluntary recalls for a limited number of lots of our handpiece. These were both due to certain issues related to our supply chain and manufacturing processes. We remedied the issue leading to the 2019 recall and are remedying the issue leading to the 2021 recall as we continue to develop and improve our manufacturing processes to scale the production of our handpieces at a higher volume. As demand for our products increases, we will have to invest additional resources to purchase components, sub-assemblies and materials, hire and train employees and enhance our manufacturing processes. If we fail to increase our production capacity efficiently, we may not be able to fill customer orders on a timely basis, our sales may not increase in line with our expectations and our operating margins could fluctuate or decline. In addition, although some future products may share product features, components, sub-assemblies and materials with our existing products, the manufacture of these products may require modification of our current production processes or unique production processes, the hiring of specialized employees, the identification of new suppliers for specific components, sub-assemblies and materials or the development of new manufacturing technologies. It may not be possible for us to manufacture these products at a cost or in quantities sufficient to make these products commercially viable or to maintain current operating margins, all of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend upon third-party suppliers, including contract manufacturers and single source suppliers, making us vulnerable to supply shortages and price fluctuations that could negatively affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third-party suppliers, almost all of whom are single source suppliers, to provide us with certain components, sub-assemblies and materials for our products.  These components, sub-assemblies and materials are critical and, for certain items, there are relatively few alternative sources of supply. These single source suppliers may be unwilling or unable to supply the necessary materials and components or manufacture and assemble our products in a reliable manner and at the levels we anticipate or at levels adequate to satisfy demand for our products. While our suppliers have generally met our demand for their products and services on a timely basis in the past, we cannot guarantee that they will in the future be able to meet our demand for such products, either because of acts of nature, the nature of our agreements with those suppliers or our relative importance to them as a customer, and our suppliers may decide in the future to discontinue or reduce the level of business they conduct with us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not been qualified or obtained necessary regulatory approvals for additional suppliers for most of these components, sub-assemblies and materials. While we currently believe that alternative sources of supply or sterilization may be available, we cannot be certain whether they will be available if and when we need them, or that any alternative suppliers or providers would be able to provide the quantity and quality of components, materials and sterilization that we would need to manufacture and ship our products if our existing suppliers and providers were unable to satisfy our requirements. To utilize other sources, we would need to identify and qualify new providers to our quality standards and obtain any additional regulatory approvals required to change providers, which could result in manufacturing delays and increase our expenses.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our dependence on third-parties subjects us to a number of risks that could impact our ability to manufacture our products and harm our business, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">interruption of supply or sterilization resulting from modifications to, or discontinuation of, a third party&#8217;s operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in product shipments resulting from uncorrected defects, reliability issues or a third party&#8217;s failure to produce components or complete sterilizations that consistently meet our quality specifications;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price fluctuations due to a lack of long-term supply arrangements with our third parties for key components or sterilization requirements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to obtain adequate supply or services in a timely manner or on commercially reasonable terms;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulty identifying and qualifying alternative third parties for the supply of components or for sterilization of our products in a timely manner;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability of third parties to comply with applicable provisions of the FDA&#8217;s Quality System Regulations, or QSR, or other applicable laws or regulations enforced by the FDA, state and global regulatory authorities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inability to ensure the quality of products manufactured or sterilization conducted by third parties;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">production delays related to the evaluation and testing of products and services from alternative third parties and corresponding regulatory qualifications; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trends towards consolidation within the medical device manufacturing supplier industry; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in delivery by our suppliers and service providers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we require our third-party suppliers and providers to supply us with components and services that meet our specifications and other applicable legal and regulatory requirements in our agreements and contracts, and we perform incoming inspection, testing or other acceptance activities to ensure the components meet our requirements, there is a risk that these third parties will not always act consistent with our best interests, and may not always supply components or provide services that meet our requirements or in a timely manner.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we receive a significant number of warranty claims or our AquaBeam Robotic Systems require significant amounts of service after sale, our operating expenses may substantially increase and our business and financial results will be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently warrant each AquaBeam Robotic System against defects in materials and workmanship for a period of approximately 12 months from the installation of our product by a customer. We also expect to provide technical and other services to customers beyond the warranty period pursuant to a supplemental service plan that we sell for our AquaBeam Robotic System. We have a limited history of commercial placements from which to judge our rate of warranty claims, and we expect that the number of warranty claims we receive may increase as we scale our operations and as our existing commercial placements age. If product returns or warranty claims are significant or exceed our expectations, we could incur unanticipated reductions in sales or additional operating expenditures for parts and service. In addition, our reputation could be damaged and our products may not achieve the level of market acceptance that we are targeting in order to achieve and maintain profitability. Unforeseen warranty exposure could negatively impact our business and financial results.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We need to ensure strong product performance and reliability to maintain and grow our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need to maintain and continuously improve the performance and reliability of our AquaBeam Robotic System to achieve our profitability objectives. Poor product performance and reliability could lead to customer dissatisfaction, adversely affect our reputation and revenues, and increase our service and distribution costs and working capital requirements. In addition, software and hardware incorporated into our AquaBeam Robotic System may contain errors or defects, especially when first introduced and while we have made efforts to test this software </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and hardware extensively, we cannot assure that the software and hardware, or software and hardware developed in the future, will not experience errors or performance problems. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business, financial condition, results of operations and growth have been adversely impacted by the effects of the COVID-19 pandemic and may continue to be adversely impacted. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to risks related to the public health crises such as the global pandemic associated with COVID-19. The COVID-19 outbreak and the consequential economic disruptions have negatively impacted and may continue to negatively impact, including the emergence and impact of the various COVID-19 variants, our operations and revenues and overall financial condition by decreasing the number of BPH procedures generally, which has slowed adoption of our AquaBeam Robotic System during the course of the pandemic. We believe the number of our systems sold has also been impacted as health care organizations globally have prioritized the treatment of patients with COVID-19, and as health care organizations have dealt with other consequential economic disruptions from the COVID-19 pandemic such as budget shortfalls and staffing shortages. For example, for a period of time in the United States, governmental authorities recommended, and in certain cases required, that elective, specialty and other procedures and appointments be suspended or canceled to avoid non-essential patient exposure to medical environments and potential infection with COVID-19 and to focus limited resources and personnel capacity toward the treatment of COVID-19. These measures and challenges led to our decision to reforecast our revenue for 2020, and they may continue or resume for the duration of the pandemic, which is uncertain, and may negatively impact our revenue growth while the pandemic continues. Further, once the pandemic subsides, we anticipate that health care organizations may face budgetary and personnel disruptions during the recovery, and that there may be a backlog of patients seeking appointments with physicians and surgeries to be performed at hospitals relating to a variety of medical conditions. As a result, patients seeking to have our Aquablation therapy performed will have to navigate limited provider capacity. We also experienced a slowdown of enrollment in certain clinical trials.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous state&#160;and local jurisdictions have imposed, and others in the future may impose, &#8220;shelter-in-place&#8221; orders, quarantines, executive orders, and similar government orders and restrictions for their residents to control the spread of&#160;COVID-19. Starting in mid-March 2020, the governor of California, where our headquarters are located, issued &#8220;shelter-in-place&#8221; or &#8220;stay at home&#8221; orders restricting non-essential activities, travel, and business operations, subject to certain exceptions for necessary activities.&#160;Such orders or restrictions have resulted in our headquarters closing, slowdowns and delays, travel restrictions, and cancellation of training and other events, among other effects, thereby negatively impacting our operations. Employees whose tasks can be performed offsite have been encouraged to work from home. Additionally, if the COVID-19 situation persists or worsens in certain geographies around the world, shutdowns and continued government restrictions may impact our sales activities, supply chain, and business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying and recruiting qualified sales and marketing personnel and training them has been, and continues to be, more difficult as a result of the COVID-19 pandemic as many of these activities must be conducted remotely, and we believe that some candidates are reluctant to change jobs during the pandemic. In addition, even when we are able to hire additional sales and marketing personnel, we must then train them on our product, applicable federal and state laws, and regulations, and on our internal policies and procedures. This training process was initially conducted remotely, which made training more challenging. We recently resumed partial in-person training with respect to training sales and marketing personnel, among others. Upon completion of the training, the lead time that our territory managers typically require in the field to grow their network of accounts and achieve the productivity levels we expect them to reach in any individual territory, has been, and continues to be, prolonged during and as a result of the COVID-19 pandemic. We have also experienced disruptions, and may experience future disruptions, including: delays in territory managers becoming fully trained and productive; challenges in analyzing territory manager performance and in recruiting and hiring new employees; difficulties and delays in physician outreach and training physicians to use our AquaBeam Robotic System; restrictions on personnel to travel; delays in initiation, enrollment and follow-ups of our clinical studies; challenges with maintaining adequate supply from third-party manufacturers of components and finished goods and distribution providers; and access to physicians for training and case support. In addition, our customers have experienced and may continue to experience financial and staffing hardship during the COVID-19 pandemic and the consequential economic disruptions, and some of them may not fully recover. This could lead to some of these customers temporarily or permanently shutting down, filing for </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">bankruptcy, or being acquired by larger health systems, leading to reduced procedures or additional pricing pressure on our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, to the extent the recovery from the COVID-19 pandemic is prolonged for any reason, including due to the emergence and impact of the various COVID-19 variants or other consequential economic disruptions, and continues to adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may encounter difficulties in managing our growth, which could disrupt our operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced substantial growth in our operations, and we expect to experience continued substantial growth in our business. Over the next several years, we expect to increase significantly the scope of our operations, particularly in the areas of manufacturing, sales and support, research and development, product development, regulatory affairs, marketing and other functional areas, including finance, accounting, quality control, and legal, especially as we transition to operating as a public company. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational quality and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources, we may not be able to manage the expansion of our operations or recruit and train additional qualified personnel in an effective manner. In addition, the physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations will be materially harmed if we are unable to accurately forecast customer demand for, and utilization of, our AquaBeam Robotic System and manage our inventory. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To ensure adequate inventory supply, we must forecast inventory needs and manufacture our AquaBeam Robotic System console and the single-use disposable handpieces based on our estimates of future demand for, and utilization of, our AquaBeam Robotic System. Our ability to accurately forecast demand and utilization could be negatively affected by many factors, including our failure to accurately manage our expansion strategy, product introductions by competitors, an increase or decrease in customer demand for our products or for products of our competitors, our failure to accurately forecast customer acceptance of new products, unanticipated changes in general market conditions or regulatory matters and weakening of economic conditions or consumer confidence in future economic conditions. Inventory levels in excess of customer demand may result in inventory write-downs or write-offs, which would cause our gross margin to be adversely affected and could impair the strength of our brand. Conversely, if we underestimate customer demand and utilization, our supply chain, manufacturing partners and/or internal manufacturing team may not be able to deliver components and products to meet our requirements, and this could result in damage to our reputation and customer relationships. In addition, if we experience a significant increase in demand or utilization, additional supplies of raw materials or additional manufacturing capacity may not be available when required on terms that are acceptable to us, or at all, or suppliers may not be able to allocate sufficient capacity in order to meet our increased requirements, which will adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems, or those used by our contractors or consultants, may fail or suffer security breaches, and such failure could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our information technology systems for the efficient functioning of our business, including the manufacture, distribution and maintenance of our products, as well as for accounting, data storage, compliance, purchasing, inventory management and other related functions. We do not have redundant information technology in all aspects of our systems at this time. Despite the implementation of security and back-up measures, our internal computer, server, and other information technology systems as well as those of our third-party consultants, contractors, suppliers, and service providers, may be vulnerable to damage from physical or electronic break-ins, accidental or intentional exposure of our data by employees or others with authorized access to our networks, computer viruses, malware, ransomware, supply chain attacks, natural disasters, terrorism, war, telecommunication and electrical failure, denial of service, and other cyberattacks or disruptive incidents that could result in unauthorized access to, use or disclosure of, corruption of, or loss of sensitive, and/or proprietary data, including </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personal information, including health-related information, and could subject us to significant liabilities and regulatory and enforcement actions, and reputational damage. Additionally, theft of our intellectual property or proprietary business information could require substantial expenditures to remedy. Such theft could also lead to loss of intellectual property rights through disclosure of our proprietary business information, and such loss may not be capable of remedying. If we or our third-party consultants, contractors, suppliers, or service providers were to suffer an attack or breach, for example, that resulted in the unauthorized access to or use or disclosure of personal or health information, we may have to notify consumers, partners, collaborators, government authorities, and the media, and may be subject to investigations, civil penalties, administrative and enforcement actions, and litigation, any of which could harm our business and reputation. Likewise, we rely on third parties to conduct clinical trials, and similar events relating to their computer systems and networks could also have a material adverse effect on our business. The COVID-19 pandemic has generally increased the risk of cybersecurity intrusions. Our reliance on internet technology and the number of our employees who are working remotely may create additional opportunities for cybercriminals to exploit vulnerabilities. For example, there has been an increase in phishing and spam emails as well as social engineering attempts from &#8220;hackers&#8221; hoping to use the recent COVID-19 pandemic to their advantage. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or systems or data or systems of our commercial partners, or inappropriate or unauthorized access to or disclosure or use of confidential, proprietary, or other sensitive, personal, or health information, we could incur liability and suffer reputational harm. Failure to maintain or protect our information technology systems effectively could negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to comply with data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation, and/or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to federal, state, and foreign data protection laws and regulations (i.e., laws and regulations that address privacy and data security). In the United States, numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws, and federal and state consumer protection laws and regulations that govern the collection, processing, use, disclosure, and protection of health-related and other personal information could apply to our operations or the operations of our partners. For example, the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their respective implementing regulations, impose obligations on &#8220;covered entities,&#8221; including certain health care providers, health plans, and health care clearinghouses, and their respective &#8220;business associates&#8221; that create, receive, maintain or transmit individually identifiable health information for or on behalf of a covered entity, as well as their covered subcontractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information. We may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA. Entities that are found to be in violation of HIPAA, whether as the result of a breach of unsecured PHI, a complaint about privacy practices, or an audit by the Department of Health and Human Services, or HHS, may be subject to significant civil, criminal, and administrative fines and penalties and/or additional reporting and oversight obligations if required to enter into a resolution agreement and corrective action plan  with HHS to settle allegations of HIPAA non-compliance. Depending on the facts and circumstances, we could be subject to penalties if we violate HIPAA.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when HIPAA does not apply, according to the Federal Trade Commission, or the FTC, failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair acts or practices in or affecting commerce in violation of the Federal Trade Commission Act. The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain state laws govern the privacy and security of health-related and other personal information in certain circumstances, some of which may be more stringent, broader in scope or offer greater individual rights </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with respect to protected health information than HIPAA, many of which may differ from each other, thus, complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties and private litigation. For example, California recently enacted the California Consumer Privacy Act, or CCPA, which creates new individual privacy rights for California consumers (as defined in the law), including the right to opt out of certain disclosures of their information, and places increased privacy and security obligations on entities handling certain personal data of consumers or households and may apply to us in the future. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. Further, the California Privacy Rights Act, or CPRA, recently passed in California. The CPRA will impose additional data protection obligations on covered businesses, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It will also create a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. The majority of the provisions will go into effect on January 1, 2023, and additional compliance investment and potential business process changes may be required. The CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the United States, as other states or the federal government may follow California's lead and increase protections for U.S. residents. For example, on March 2, 2021, the Virginia Consumer Data Protection Act, which will take effect on January 1, 2023, was signed into law. The CCPA has already prompted a number of proposals for new federal and state privacy legislation that, if passed, could increase our potential liability, add layers of complexity to compliance in the U.S. market, increase its compliance costs and adversely affect its business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign data protection laws, including the General Data Protection Regulation, or GDPR, which went into effect in May 2018, may also apply to our processing of health-related and other personal data regardless of where the processing in question is carried out.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR imposes stringent requirements for controllers and processors of personal data of individuals within the European Economic Area, or EEA. The GDPR applies to any company established in the EEA as well as to those outside the EEA if they collect, process, and use personal data in connection with the offering of goods or services to individuals in the EEA or the monitoring of their behavior. The GDPR, together with national legislation, regulations and guidelines of the EEA Member States and the United Kingdom, or UK, governing the processing of personal data, impose strict obligations and restrictions on the ability to collect, analyze and transfer personal data, including health data from clinical trials and adverse event reporting. In particular, these obligations and restrictions involve the consent of the individuals to whom the personal data relates, the information provided to the individuals, the transfer of personal data out of the EEA or the UK to jurisdictions deemed to have inadequate, security breach notifications, security and confidentiality of the personal data and imposition of substantial potential fines for breaches of the data protection obligations. Companies that must comply with the GDPR face increased compliance obligations and risk, including more robust regulatory enforcement of data protection requirements and potential fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater. Further, from January 1, 2021, companies have to comply with the GDPR and also the UK GDPR, which, together with the amended UK Data Protection Act 2018, retains the GDPR in UK national law. The UK GDPR mirrors the fines under the GDPR, e.g. fines up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of global turnover. The relationship between the UK and the European Union in relation to certain aspects of data protection law remains unclear, and it is unclear how UK data protection laws and regulations will develop in the medium to longer term, and how data transfers to and from the UK will be regulated in the long term. These changes will lead to additional costs and increase our overall risk exposure. Currently there is a four to six-month grace period agreed in the EU and UK Trade and Cooperation Agreement, ending June 30, 2021 at the latest, during which time the parties discuss an adequacy decision. The European Commission published a draft adequacy decision on February 19, 2021. If adopted, the decision will enable data transfers from EU Member States to the UK for a four-year period, subject to subsequent extensions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Implementing mechanisms that endeavor to ensure compliance with the GDPR and relevant local legislation in EEA Member States and the UK may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations, and prospects. In addition to the foregoing, a breach of the GDPR or other applicable privacy and data protection laws and regulations could result in regulatory </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigations, reputational damage, and orders to cease/change our use of data, enforcement notices, or potential civil claims including class action-type litigation. While we have taken steps to comply with the GDPR where applicable, including by reviewing our security procedures, and entering into data processing agreements with relevant contractors, our efforts to achieve and remain in compliance may not be fully successful.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with US, foreign, and local privacy and security laws, rules and regulations could require us to take on more onerous obligations in our contracts, require us to engage in costly compliance exercises, restrict our ability to collect, use and disclose data, or in some cases, impact our or our partners&#8217; or suppliers&#8217; ability to operate in certain jurisdictions. Each of these constantly evolving laws can be subject to varying interpretations. Failure to comply with US and foreign data protection laws and regulations could result in government investigations and enforcement actions (which could include civil or criminal penalties), fines, private litigation, and/or adverse publicity and could negatively affect our operating results and business. Moreover, patients about whom we or our partners obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Natural or man-made disasters and other similar events may significantly disrupt our business, and negatively impact our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our employee base, and our primary operating facility and infrastructure are centralized in Northern California. Our facility may be harmed or rendered inoperable by natural or man-made disasters, including earthquakes, wildfires, floods, nuclear disasters, riots, acts of terrorism or other criminal activities, public health emergencies such as infectious disease outbreaks, including the COVID-19 pandemic, power outages and other infrastructure failures, which may render it difficult or impossible for us to operate our business for some period of time. Our facilities would likely be costly to repair or replace, and any such efforts would likely require substantial time. Any disruptions in our operations could adversely affect our business and results of operations and harm our reputation. Moreover, although we have disaster recovery plans, they may prove inadequate. We may not carry sufficient business insurance to compensate for losses that may occur. Any such losses or damages could have a material adverse effect on our business and results of operations. In addition, the facilities of our suppliers and manufacturers may be harmed or rendered inoperable by such natural or man-made disasters, which may cause disruptions, difficulties or otherwise materially and adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The sizes of the addressable markets for our AquaBeam Robotic System have not been established with precision and our potential market opportunity may be smaller than we estimate and may decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of the annual total addressable market for our AquaBeam Robotic System are based on a number of internal and third-party estimates, including, without limitation, the assumed prices at which we can sell our AquaBeam Robotic System and the single-use disposable handpieces. While we believe our assumptions and the data underlying our estimates are reasonable, these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, thereby reducing the predictive accuracy of these underlying factors. As a result, our estimates of the annual total addressable market for our AquaBeam Robotic System may prove to be incorrect. If the actual number of patients who would benefit from our AquaBeam Robotic System, the price at which we can sell our AquaBeam Robotic System, or the total addressable market for our AquaBeam Robotic System is smaller than we have estimated, it may impair our sales growth and materially and adversely affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Until we are able to achieve broader market acceptance of our AquaBeam Robotic System and Aquablation therapy, we may face risks associated with a more concentrated customer base.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No customers accounted for more than 10% of revenue during the nine months ended September 30, 2021 and 2020, and year ended December 31, 2020. No customer accounted for more than 10% of accounts receivable at September 30, 2021. Two of our customers accounted for 22% and 13% of accounts receivable at December 31, 2020. While we believe this concentration is primarily attributable to our limited history of commercial operations, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">until we are able to achieve broader market acceptance of our AquaBeam Robotic System and Aquablation therapy, we may face risks associated with a more concentrated customer base. There are risks whenever a significant percentage of revenue is concentrated with a limited number of customers. For example, revenue from these customers may fluctuate from time to time based on these customers&#8217; business needs, the timing of which may be affected by market conditions or other facts outside of our control. These customers could also potentially pressure us to reduce the prices we charge for our single-use disposable handpieces, which could have an adverse effect on our margins and financial position and could negatively affect our revenue and results of operations. If any of our largest customers terminates its relationship with us, such termination could negatively affect our revenues and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit or halt the marketing and sale of our products. The expense and potential unavailability of insurance coverage for liabilities resulting from our products could harm us and our ability to sell our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability as a result of the marketing and sale of our products. For example, we may be sued if our AquaBeam Robotic System, the single-use disposable handpiece or any of their component parts causes, or is perceived to cause, injury or is found to be otherwise unsuitable during manufacturing, marketing or sale. We may also be subject to product liability claims if our products or services are deemed non-compliant with applicable laws or regulations. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. In addition, we may be subject to claims against us even if the apparent injury is due to the actions of others or the pre-existing health conditions of the patient. We may also be subject to claims that are caused by the activities of our suppliers, such as those who provide us with components and sub-assemblies, or manufacturers who produce our AquaBeam Robotic System and the single-use disposable handpieces. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit or halt the marketing and sale of our products. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">harm to our reputation; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">initiation of investigations by regulators, which could result in enforcement action against us or our contract manufacturers; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs to defend the related litigation; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a diversion of management&#8217;s time and our resources; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls, withdrawals or labeling, marketing or promotional restrictions; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exhaustion of any available insurance and our capital resources. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk of a product liability lawsuit may increase if our products were deemed to be non-compliant with applicable laws and regulation. In the event we face a product liability lawsuit, we believe we have adequate product liability insurance, but it may not prove to be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain or obtain insurance at a reasonable cost or in an amount adequate to satisfy any liability that may arise. Our insurance policy contains various exclusions, and we may be subject to a product liability claim for which we have no coverage. The potential inability to obtain sufficient product liability insurance at an acceptable cost to protect against product liability claims could prevent or inhibit the marketing and sale of our products. We may have to pay any amounts awarded by a court or negotiated in a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts, which would have a material adverse effect on our business, financial condition and results of operations. In addition, any product liability claims brought against us, with or without merit, could increase our product liability insurance rates or prevent us from securing continuing coverage, harm our reputation in the industry, significantly increase our expenses and reduce product sales. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost-containment efforts of our customers, purchasing groups and governmental organizations could have a material adverse effect on our sales and profitability. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to reduce costs, many hospitals in the United States have become members of GPOs and IDNs. GPOs and IDNs negotiate pricing arrangements with medical device companies and distributors and then offer these negotiated prices to affiliated hospitals and other members. GPOs and IDNs typically award contracts on a category-by-category basis through a competitive bidding process. Bids are generally solicited from multiple providers with the intention of driving down pricing or reducing the number of vendors. Due to the highly competitive nature of the GPO and IDN contracting processes, we may not be able to obtain new, or maintain existing, contract positions with major GPOs and IDNs. Furthermore, the increasing leverage of organized buying groups may reduce market prices for our AquaBeam Robotic System, thereby reducing our revenue and margins. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While having a contract with a GPO or IDN for a given product category can facilitate sales to members of that GPO or IDN, such contract positions can offer no assurance that any level of sales will be achieved, as sales are typically made pursuant to individual purchase orders. Even when a provider is the sole contracted supplier of a GPO or IDN for a certain product category, members of the GPO or IDN are generally free to purchase from other suppliers. Furthermore, GPO and IDN contracts typically are terminable without cause by the GPO or IDN upon 60 to 90 days&#8217; notice. Accordingly, the members of such groups may choose to purchase alternative products due to the price or quality offered by other companies, which could result in a decline in our revenue. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek strategic alliances, joint ventures or collaborations, or enter into licensing or partnership arrangements in the future and may not be successful in doing so, and even if we are, we may not realize the benefits or costs of such relationships. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may form or seek strategic alliances, create joint ventures or collaborations or enter into licensing or partnership arrangements with third parties that we believe will compliment or augment our sales and marketing efforts with respect to our AquaBeam Robotic System. We may not be successful in our efforts to establish such collaborations. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic alliance or other alternative arrangements for our products. We cannot be certain that, following a strategic alliance or similar arrangement, we will achieve the revenue or specific net income that justifies such transaction. In addition, any potential future collaborations may be terminable by our collaborators, and we may not be able to adequately protect our rights under these agreements. Any termination of collaborations we enter into in the future, or delays in entering into new strategic partnership agreements could delay tour sales and marketing efforts, which would harm our business prospects, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future growth may depend, in part, on our ability to penetrate foreign markets, where we would be subject to additional regulatory burdens and other risks and uncertainties.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently market and sell our products in 11 countries outside of the United States, including Germany, France, Italy, Spain and the United Kingdom. The sale and shipment of our products across international borders, as well as the purchase of components and products from international sources, subjects us to extensive U.S. and other foreign governmental trade, import and export and customs laws and regulations. Compliance with these laws and regulations is costly and exposes us to penalties for non-compliance. We expect our international activities will be </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dynamic over the foreseeable future as we continue to pursue opportunities in international markets. Our international business operations are subject to a variety of risks, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in staffing and managing foreign and geographically dispersed operations, to the extent we establish non-U.S. operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing and multiple payor reimbursement regimes, government payors or patient self-pay systems;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">difficulties in determining and creating the proper sales pathway in new, international markets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with various U.S. and international laws, including export control laws and the U.S. Foreign Corrupt Practices Act of 1977, or the FCPA, and anti-money laundering laws;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">differing regulatory requirements for obtaining clearances or approvals to market our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in, or uncertainties relating to, foreign rules and regulations that may impact our ability to sell our products, perform services or repatriate profits to the United States;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">tariffs and trade barriers, export regulations, sanctions and other regulatory and contractual limitations on our ability to sell our products in certain foreign markets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential adverse tax consequences, including imposition of limitations on or increase of withholding and other taxes on remittances and other payments by foreign subsidiaries or joint ventures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">imposition of differing labor laws and standards;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">armed conflicts or economic, political or social instability in foreign countries and regions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in foreign currency exchange rates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability, or reduced ability, to protect our intellectual property, including any effect of compulsory licensing imposed by government action; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">availability of government subsidies or other incentives that benefit competitors in their local markets that are not available to us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are assessing the opportunity to expand into other international markets. However, our expansion plans may not be realized, or if realized, may not be successful. We expect each market to have particular regulatory hurdles to overcome, and future developments in these markets, including the uncertainty relating to governmental policies and regulations, could harm our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are highly dependent on our senior management team and key personnel, and our business could be harmed if we are unable to attract and retain personnel necessary for our success. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on our senior management, including our chief executive officer, Reza Zadno, Ph.D., and other key personnel. Our success will depend on our ability to retain senior management and to attract, recruit, retain, manage and motivate qualified personnel in the future, particularly with respect to an expected increase in hiring in connection with becoming a public company, including sales and marketing professionals, scientists, clinical specialists, engineers and other highly skilled personnel and to integrate current and additional personnel in all departments. The loss of members of our senior management, sales and marketing professionals, scientists, clinical and regulatory specialists and engineers could result in delays in product development and harm our business. If we are not successful in attracting and retaining highly qualified personnel, it would have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition for skilled personnel in our market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms, or at all. To induce valuable employees to remain at our company, we have issued and may continue to issue equity awards that vest over time, in addition to salary and cash incentives. The value to employees of equity awards that vest over time may be significantly affected by movements in our stock </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Our employment arrangements with our employees provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We also do not maintain &#8220;key man&#8221; insurance policies on the lives of these individuals or the lives of any of our other employees. This lack of insurance means that we may not have adequate compensation for the loss of the services of these individuals.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be adversely affected by violations of the FCPA and similar worldwide anti-bribery laws, as well as violations of export or import controls or economic sanctions laws and regulations.  Any investigation, and the outcome of any investigation, by government agencies of possible violations by us of such laws and regulations could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to anti-corruption laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute in 18 U.S.C. 201, the International Travel Act of 1961, as amended, or the U.S. Travel Act, the U.K. Bribery Act 2010, or the Bribery Act, and similar anti-bribery laws in jurisdictions in which we conduct activities.  Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, and intermediaries from corruptly authorizing, promising, providing, or offering, directly or indirectly, improper payments or anything else of value to government officials and persons in the private sector for the purpose of obtaining or retaining business.  In addition, an organization that fails to prevent bribery by anyone associated with the organization can be charged under the Bribery Act, unless the organization can establish the defense of having implemented adequate procedures to prevent bribery.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department&#8217;s Office of Foreign Assets Controls.  Compliance with applicable regulatory requirements regarding the export of our products may require us to obtain licenses and authorizations prior to export, create delays in the introduction of our products in certain international markets or, in some cases, prevent the export of our products to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of further enhancing policies designed to ensure compliance by us and our directors, officers, employees, representatives, consultants and agents with the FCPA, the Bribery Act, OFAC laws and regulations, and other export control, anti-corruption, anti-money-laundering and anti-terrorism laws and regulations. In the future, we may operate in parts of the world that pose a heightened corruption risk. Moreover, because of the significant role government entities play in the regulation of many foreign healthcare markets, we may be exposed to heightened FCPA and similar risks arising from our efforts to seek regulatory approval of and reimbursement for our products in such countries. We cannot assure you that our internal control policies and procedures will protect us from improper acts committed by our employees or agents, nor can we assure you that our business partners have not engaged and will not engage in improper conduct that could materially affect their ability to perform their contractual obligations to us or even result in our being held liable for such conduct. The U.S. Departments of Justice, Commerce, State and Treasury and other federal agencies and authorities have a broad range of civil and criminal penalties they may seek to impose against corporations and individuals for violations of anti-corruption laws, economic sanctions laws, and export control and import laws.  In addition, violations of these laws, or allegations of such violations, would significantly disrupt our business and have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize our net operating loss carryforwards and research and development credit may be limited. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2020, we had U.S. federal and state net operating loss, or NOL, carryforwards of approximately $170.8 million and $100.7 million, respectively, and U.S. federal and state research and development credit carryforwards of $3.1 million and $2.5 million, respectively. NOLs incurred in taxable years beginning after December 31, 2017, may be carried forward indefinitely, but the deductibility of such federal NOLs in taxable years beginning after December 31, 2020, is limited to 80% of current year taxable income. In general, under Sections 382 </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and 383 of the Internal Revenue Code of 1986, as amended, or the Code, a corporation that undergoes an &#8220;ownership change,&#8221; generally defined as a greater than 50 percentage point change by value in its equity ownership over a rolling three-year period, is subject to limitations on its ability to utilize its pre-change NOLs and its research and development credit carryforwards to offset post-change taxable income. Similar rules may apply under state tax laws. Our existing NOLs and research and development credit carryforwards have been, and may in the future be, subject to limitations arising from previous ownership changes, and if we undergo an ownership change, our ability to utilize NOLs and research and development credit carryforwards could be further limited by Sections 382 and 383 of the Code. Future changes in our stock ownership, some of which might be beyond our control, could result in an ownership change under Section 382 of the Code. For these reasons, in the event we experience a future change of control, we may not be able to utilize a material portion of the NOLs, research and development credit carryforwards or disallowed interest expense carryovers, even if we attain profitability. In addition, for state income tax purposes, the extent to which states will conform to the federal laws is uncertain and there may be periods during which the use of NOL carryforwards is suspended or otherwise limited, which could accelerate or permanently increase state taxes owed. For example, California imposed limits on the usability of California state NOLs and tax credits in tax years beginning after 2019 and before 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the tax benefit of NOLs, temporary differences and credit carryforwards are required to be recorded as an asset to the extent that we assess that realization is more likely than not. We believe that recognition of the deferred tax asset arising from these future tax benefits is not likely to be realized and, accordingly, have provided a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">full valuation allowance against our net deferred tax asset.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may acquire other businesses which could require significant management attention, disrupt our business, dilute stockholder value and adversely affect our results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our business strategy, we may in the future make acquisitions or investments in complementary companies, products or technologies that we believe fit within our business model and can address the needs of our existing and potential customers. However, we may not be able to acquire and integrate other companies, products or technologies in a successful manner. We may not be able to find suitable acquisition candidates, and we may not be able to complete such acquisitions on favorable terms, if at all. In addition, the pursuit of potential acquisitions may divert the attention of management and cause us to incur additional expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated. If we do complete acquisitions, we may not ultimately strengthen our competitive position or achieve our goals, including increases in revenue, and any acquisitions we complete could be viewed negatively by our customers, investors and industry analysts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future acquisitions may reduce our cash available for operations and other uses and could result in amortization expense related to identifiable assets acquired. We may have to pay cash, incur debt or issue equity securities to pay for any such acquisition, each of which could adversely affect our financial condition or the value of our common stock. The sale or issuance of equity to finance any such acquisitions would result in dilution to our stockholders. The incurrence of indebtedness to finance any such acquisition would result in fixed obligations and could also include covenants or other restrictions that could impede our ability to manage our operations. In addition, our future results of operations may be adversely affected by the dilutive effect of an acquisition, performance earn-outs or contingent bonuses associated with an acquisition. Furthermore, acquisitions may require large, one-time charges and can result in increased debt or contingent liabilities, adverse tax consequences, additional stock-based compensation expenses and the recording and subsequent amortization of amounts related to certain purchased intangible assets, any of which items could negatively affect our future results of operations. We may also incur goodwill impairment charges in the future if we do not realize the expected value of any such acquisitions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, the anticipated benefit of any acquisition may not materialize, or such acquisition may be prohibited. In September 2019, we entered into the loan and security agreement with Oxford Finance LLC which also restricts our ability to pursue certain mergers, acquisitions, amalgamations or consolidations that we may believe to be in our best interest. Additionally, future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could harm our financial condition. We cannot predict the number, timing or size of future joint ventures or acquisitions, or the effect that any such transactions might have on our operating results. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Governmental Regulation</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes to the reimbursement rates for BPH  treatments and measures to reduce healthcare costs may adversely impact our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our revenue from sales of our products to hospitals, ambulatory surgery centers and other healthcare facilities, which typically bill all or a portion of the costs and fees associated with using our products to various third-party payors, including Medicare, Medicaid, private commercial insurance companies, health maintenance organizations and other healthcare-related organizations. Because a vast majority of U.S. patients with BPH are covered by Medicare, the Medicare coverage policy and reimbursement rate are important factors in a physician&#8217;s decision to use Aquablation therapy and limits the prices we may charge for our products. In order to facilitate access for Medicare beneficiaries to new devices, the Centers for Medicare &amp; Medicaid Services, or CMS, the federal agency responsible for administering the Medicare program, grants approval for transitional pass-through payments under the Medicare hospital outpatient prospective payment system, or OPPS, and ambulatory surgical center, or ASC, payment system for medical devices that meet certain criteria.  Effective January 1, 2020, hospitals and ASCs receive an additional payment for the single-use handpiece when performing Aquablation therapy in the hospital outpatient setting until December 31, 2022. When that payment expires, hospitals will no longer receive separate reimbursement for our device and instead, receive a single bundled payment rate intended to cover the costs of all items and services, including our products, using during the Aquablation therapy. Accordingly, the additional cost associated with the use of our products may affect the profit margin of the hospital or ASC where the procedure is performed. Some of our target customers may be unwilling to adopt our products in light of potential additional associated cost.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many BPH patients have Medicaid coverage that is supplemental to Medicare coverage, and some BPH patients may have Medicaid as their primary coverage. Because Medicaid is a state-administered program, Medicaid coverage policies and reimbursement vary by state. Changes in state Medicaid or other non-Medicare government-based programs or payment rates could have an adverse effect on our customer&#8217;s business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, some patients may have coverage through private insurance, for example through a marketplace plan set up under the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively, the ACA, or through an employer or union group health plan. Private insurance coverage policies can vary and reimbursement is generally higher than government reimbursement, but it varies by sponsor and plan. Commercial payment rates are negotiated between our customers and insurers or other third-party administrators, and commercial payors may also exert downward pressure on payment rates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in reimbursement rates for Aquablation therapy may adversely affect our customers&#8217; businesses and cause them to enact cost reduction measures that may include reducing the scope of their programs, which could result in a reduced demand for our product or additional pricing pressures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could hinder or prevent the commercial success of our AquaBeam Robotic System. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system in ways that may harm our future revenues and profitability and the demand for our AquaBeam Robotic System. Federal and state lawmakers regularly propose and, at times, enact legislation that would result in significant changes to the healthcare system, some of which are intended to contain or reduce the costs of medical products and services. Current and future legislative and regulatory proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our AquaBeam Robotic System. The cost containment measures that payors and providers are instituting and the effect of any healthcare reform initiative implemented in the future could impact our revenue from the sale of our AquaBeam Robotic System. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By way of example, in the United States, the ACA was enacted in March 2010 and substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacts our industry. The ACA contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse measures, all of which have impacted existing government healthcare programs and will result in the development of new programs. Since its enactment, there have been numerous </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">amendments to the ACA and revisions to implementing regulations, along with judicial, executive and Congressional challenges to certain aspects of the ACA. On June 17, 2021, the Supreme Court ruled that states and individuals lacked standing to challenge the constitutionality of the ACA&#8217;s individual mandate, post-repeal of its associated tax penalty. Additionally, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the ACA marketplace, which began on February 15, 2021 and will remain open through August 15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. Additional legislative changes, regulatory changes and judicial challenges related to the ACA remain possible. We cannot predict what effect further changes related to the ACA, including under the Biden administration, will have on our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, and in connection with subsequent legislation, reduced Medicare payments to providers of, on average, 2% per fiscal year, which went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030, with the exception of a temporary suspension from May 1, 2020 through December 31, 2021, unless additional Congressional action is taken. Additionally, the American Taxpayer Relief Act of 2012, among other things, further reduced Medicare payments to several categories of healthcare providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare may harm: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to set a price that we believe is fair for our AquaBeam Robotic System; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to generate revenue and achieve or maintain profitability; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of capital. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The current presidential administration and Congress may continue to pursue significant changes to the current healthcare laws. We cannot predict what other laws and regulations will ultimately be enacted and implemented at the federal or state level or the effect of any future legislation or regulation in the United States on our business, financial condition, and results of operations. Future changes in healthcare policy could increase our costs and subject us to additional requirements that may interrupt commercialization of our current and future solutions, decrease our revenue and impact sales of and pricing for our current and future products.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must comply with anti-kickback, fraud and abuse, false claims, transparency, and other healthcare laws and regulations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and future operations are subject to various federal and state healthcare laws and regulations. These laws affect our sales, marketing and other promotional activities by limiting the kinds of financial arrangements, including sales programs, we may have with hospitals, physicians or other potential purchasers or users, including patients, of medical devices and services. They also impose additional administrative and compliance burdens on us. In particular, these laws influence, among other things, how we structure our sales, placement and rental offerings, including discount practices, customer support, education and training programs and physician consulting and other service arrangements. The laws that affect our practices and arrangements include, but are not limited to: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order, or arranging for or recommending the purchase, lease or order of, any good or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value, and the government can establish a violation of the Anti-Kickback Statute without proving that a </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">person or entity had actual knowledge of, or a specific intent to violate, the law. The Anti-Kickback Statute is subject to evolving interpretations and has been applied by government enforcement officials to a number of common business arrangements in the medical device industry. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; however, those exceptions and safe harbors are drawn narrowly, and there is no exception or safe harbor for many common business activities. Failure to meet all of the requirements of a particular statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute, but the legality of the arrangement will be evaluated on a case-by-case basis based on the totality of the facts and circumstances. Practices that involve remuneration to those who prescribe, purchase, or recommend medical device products, including discounts, or engaging individuals as speakers, consultants, or advisors, may be subject to scrutiny if they do not fit squarely within an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, there are no safe harbors for many common practices, such as reimbursement support programs, educational or research grants, or charitable donations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the U.S. federal civil False Claims Act, which prohibits any person from, among other things, knowingly presenting, or causing to be presented false or fraudulent claims for payment of government funds; knowingly making, using or causing to be made or used, a false record or statement material to an obligation to pay money to the government or knowingly and improperly avoiding, decreasing or concealing an obligation to pay money to the U.S. federal government. In addition, any claims submitted as a result of a violation of the federal Anti-Kickback Statute constitute false claims and are subject to enforcement under the False Claims Act. Actions under the False Claims Act may be brought by the government or as a qui tam action by a private individual in the name of the government and to share in any monetary recovery. Qui tam actions are filed under seal and impose a mandatory duty on the U.S. Department of Justice to investigate such allegations. False Claims Act liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties (adjusted annually for inflation) per false claim or statement for violations. Because of the potential for large monetary exposure, healthcare companies often resolve allegations without admissions of liability for significant and sometimes large settlement amounts to avoid the uncertainty of treble damages and per claim penalties that may be awarded in litigation proceedings.  Many device manufacturers have resolved investigations of alleged improper activities, including causing false claims to be submitted as a result of the marketing of their products for unapproved and thus non reimbursable uses, and other interactions with prescribers and other customers including those that may have affected their billing or coding practices and submission to the federal government. Moreover, to avoid the risk of exclusion from federal healthcare programs as a result of a False Claims Act settlement, companies may enter into corporate integrity agreements with the government, which may impose substantial costs on companies to ensure compliance. There are also criminal penalties, including imprisonment and criminal fines, for making or presenting a false or fictitious or fraudulent claim or statement to the federal government; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal healthcare statutes that were added by HIPAA, and its implementing regulations, which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for healthcare benefits, items or services by a healthcare benefit program, which includes both government and privately funded benefits programs; similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate them in order to have committed a violation; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Physician Payments Sunshine Act, or Sunshine Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program to report annually to the CMS information related to certain payments made in the preceding calendar year and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">members. Beginning January 1, 2022, manufacturers will also be required to report payments and other transfers of value made during the prior calendar year to physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, anesthesiology assistants and certified nurse-midwives; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign and state laws and regulations, including state payment reporting, anti-kickback and false claims laws, that may apply to items or services reimbursed by any third-party payor, including private insurers; foreign and state laws that require medical device companies to comply with the medical device industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government and other national governments, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and foreign and state laws and regulations that require drug and device manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of these laws is substantial and subject to rapid change. The shifting compliance environment and the need to build and maintain robust compliance programs, systems, and processes to comply with different compliance and/or reporting requirements in multiple jurisdictions increase the possibility that we may run afoul of one or more of the requirements or that federal or state regulatory authorities might challenge our current or future activities under these laws. Additionally, we cannot predict the impact of any changes in these laws, whether or not retroactive. Because of the breadth of these laws and the narrowness of available statutory and regulatory exemptions or safe harbors, it is possible that some of our activities, such as stock-option compensation paid to physicians or our practice of loaning equipment to customers at no additional cost, could be subject to challenge under one or more of such laws. Any government investigation, even if we are able to successfully defend against it, will require the expenditure of significant resources, is likely to generate negative publicity, harm our reputation and potentially our financial condition and divert the attention of our management.  Moreover, any investigation into our practices could cause adverse publicity and require a costly and time-consuming response. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment of individuals, exclusion from government funded healthcare programs, such as Medicare and Medicaid, imposition of compliance obligations and monitoring, and the curtailment or restructuring of our operations. Any of the foregoing consequences could seriously harm our business and our financial results.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our AquaBeam Robotic System and our operations are subject to extensive government regulation and oversight in the United States. If we fail to maintain necessary marketing authorizations for our AquaBeam Robotic System, or if approvals or clearances for future products or modifications to existing products are delayed or not issued, it will negatively affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our AquaBeam Robotic System is a medical device subject to extensive regulation in the United States and elsewhere, including by the FDA and its foreign counterparts. Government regulations specific to medical devices are wide ranging and govern, among other things: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product design, development, manufacture, and release; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laboratory and clinical testing, labeling, packaging, storage and distribution; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product safety and efficacy; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">premarketing clearance or approval; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">service operations, including relationships with healthcare providers;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">record keeping; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product marketing, promotion and advertising, registration, sales and distribution; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-marketing surveillance, including reporting of deaths or serious injuries and recalls and correction and removals; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">post-market approval studies; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product import and export. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations to which we are subject are complex and have tended to become more stringent over time. Regulatory changes could result in restrictions on our ability to carry on or expand our operations, higher than anticipated costs or lower than anticipated sales. The FDA enforces these regulatory requirements through, among other means, periodic unannounced inspections. We do not know whether we will be found compliant in connection with any future regulatory inspections. Moreover, the FDA and state authorities have broad enforcement powers. Our failure to comply with applicable regulatory requirements could result in enforcement action by any such agency, which may include any of the following sanctions: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse publicity, warning letters, untitled letters, it has come to our attention letters, fines, injunctions, consent decrees and civil penalties; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">repair, replacement, refunds, recall or seizure of our AquaBeam Robotic System; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions, partial suspension or total shutdown of production; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">denial of our requests for regulatory clearance or approval of new products, new intended uses or modifications to existing products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal or suspension of regulatory clearance or approval that have already been granted; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these events were to occur, it will negatively affect our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not receive, or may be delayed in receiving, the necessary clearances or approvals for our future products or modifications to our current products, and failure to timely obtain necessary clearances or approvals for our future products or modifications to our current products would adversely affect our ability to grow our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA classifies medical devices into one of three classes on the basis of the intended use of the device, the risk associated with the use of the device for that indication, as determined by the FDA, and on the controls deemed by the FDA to be necessary to reasonably ensure their safety and effectiveness. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Class I includes devices with the lowest risk to the patient and are those for which safety and effectiveness can be assured by adherence to the FDA&#8217;s General Controls for medical devices, which include compliance with the applicable portions of the QSR facility registration and product listing, reporting of adverse medical events, and truthful and non-misleading labeling, advertising, and promotional materials. Class II devices are subject to the FDA&#8217;s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device. These special controls can include performance standards, post-market surveillance, patient registries and FDA guidance documents. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While most Class I devices are exempt from the 510(k) premarket notification requirement, manufacturers of most Class II devices are required to submit to the FDA a premarket notification under Section 510(k) of the FDCA requesting permission to commercially distribute the device. The FDA&#8217;s permission to commercially distribute a device subject to a 510(k) premarket notification is generally known as 510(k) clearance. Devices deemed by the FDA to pose the greatest risks, such as life sustaining, life supporting or some implantable devices, or devices that have a new intended use, or use advanced technology that is not substantially equivalent to that of a legally marketed device, are placed in Class III, requiring approval of a premarket approval application, or PMA. Some pre-amendment devices are unclassified, but are subject to FDA&#8217;s premarket notification and clearance process in order to be commercially distributed. Our AquaBeam Robotic System is a Class II device subject to 510(k) clearance. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before a new medical device, or a new intended use of, claim for, or significant modification to an existing device, can be marketed in the United States, a company must first submit an application for and receive either </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">510(k) clearance pursuant to a premarket notification submitted under Section 510(k) of the FDCA, de novo classification, or approval of a PMA from the FDA, unless an exemption applies. Most Class I devices and some Class II devices are exempt from these premarket review requirements. In the 510(k) clearance process, before a device may be marketed, the FDA must determine that a proposed device is substantially equivalent to a legally-marketed predicate device, which includes a device that has been previously cleared through the 510(k) process, a device that was legally marketed prior to May 28, 1976 (pre-amendments device), a device that was originally on the U.S. market pursuant to an approved PMA and later down-classified, or a 510(k)-exempt device. To be substantially equivalent, the proposed device must have the same intended use as the predicate device, and either have the same technological characteristics as the predicate device or have different technological characteristics and not raise different questions of safety or effectiveness than the predicate device. Clinical data are sometimes required to support substantial equivalence. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the process of obtaining PMA approval the FDA must determine that a proposed device is safe and effective for its intended use based, in part, on extensive data, including, but not limited to, technical, clinical trial, manufacturing and labeling data. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the de novo classification process, a manufacturer whose novel device would otherwise be automatically classified as Class III and require the submission and approval of a PMA prior to marketing is able to request down-classification of the device to Class I or Class II on the basis that the device presents a low or moderate risk. If the FDA grants the de novo classification request, the applicant will receive authorization to market the device. This device type may be used subsequently as a predicate device for future 510(k) submissions. Prior to the enactment of the Food and Drug Administration Safety and Innovation Act of 2012, or FDASIA, a medical device could only be eligible for de novo classification if the manufacturer first submitted a 510(k) premarket notification and received a determination from the FDA that the device was not substantially equivalent. FDASIA streamlined the de novo classification pathway by permitting manufacturers to request de novo classification directly without first submitting a 510(k) premarket notification to the FDA and receiving a not substantially equivalent determination. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 510(k), de novo or PMA processes can be expensive, lengthy and unpredictable. The FDA&#8217;s 510(k) clearance process usually takes from three to 12 months, but can last longer. The process of obtaining a PMA is much more costly and uncertain than the 510(k) clearance process and generally takes from one to three years, or even longer, from the time the application is filed with the FDA. In addition, a PMA generally requires the performance of one or more clinical trials. Despite the time, effort and cost, a device may not be approved or cleared by the FDA. Any delay or failure to obtain necessary regulatory clearances or approvals could harm our business. Furthermore, even if we are granted regulatory clearances or approvals, they may include significant limitations on the indicated uses for the device, which may limit the market for the device. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We originally obtained de novo classification of our AquaBeam Robotic System for use in patients with BPH, and have subsequently obtained 510(k) clearances for modifications to the system. Any modification to these systems that has not been previously cleared may require us to submit a new 510(k) premarket notification and obtain clearance, or depending on the change, we may be required to submit a PMA and obtain FDA approval before implementing the change. Specifically, any modification to a 510(k)-cleared device that could significantly affect its safety or effectiveness, or that would constitute a major change in its intended use, design or manufacture, requires a new 510(k) clearance or, possibly, approval of a PMA. The FDA requires every manufacturer to make this determination in the first instance, but the FDA may review any manufacturer&#8217;s decision. The FDA may not agree with our decisions regarding whether new clearances or approvals are necessary. We have made modifications to 510(k)-cleared products in the past and have determined based on our review of the applicable FDA regulations and guidance that in certain instances new 510(k) clearances or PMA approvals were not required. We may make modifications or add additional features in the future that we believe do not require a new 510(k) clearance or approval of a PMA. If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or PMA applications for modifications to our previously cleared products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties. If the FDA requires us to go through a lengthier, more rigorous examination for future products or modifications to existing products than we had expected, product introductions or modifications could be delayed or canceled, which could adversely affect our ability to grow our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA or other regulators can delay, limit, or deny clearance or approval of a device for many reasons, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to demonstrate to the satisfaction of the FDA or the applicable regulatory entity or notified body that our AquaBeam Robotic System, or any other future device, and any accessories are substantially equivalent to a legally marketed predicate device or safe or effective for their proposed intended uses; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the disagreement of the FDA with the design or implementation of any clinical trials or the interpretation of data from preclinical studies or clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">serious and unexpected adverse device effects experienced by participants in our clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the insufficiency of the data from preclinical studies or clinical trials to support clearance or approval, where required; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to demonstrate that the clinical and other benefits of the device outweigh the risks; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of our manufacturing process or facilities to meet applicable requirements; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential for approval policies or regulations of the FDA or applicable foreign regulatory bodies to change significantly in a manner rendering our clinical data or regulatory filings insufficient for clearance or approval. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to develop, receive regulatory clearance or approval for, and introduce new products that will be accepted by the market in a timely manner. There is no guarantee that the FDA will grant 510(k) clearance or PMA approval of our future products on a timely basis, if at all, and failure to obtain necessary clearances or approvals for our future products would adversely affect our ability to grow our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is important to our business that we build a pipeline of product offerings that address limitations of current BPH products. As such, our success will depend in part on our ability to develop and introduce new products. However, we may not be able to successfully develop and obtain regulatory clearance or approval for product enhancements, or new products for any number of reasons, including due to the cost associated with certain regulatory approval requirements, or these products may not be accepted by physicians or users. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of any new product offering or enhancement to an existing product will depend on a number of factors, including our ability to, among others: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">identify and anticipate physician and patient needs properly; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop and introduce new products or product enhancements in a timely manner; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">avoid infringing upon the intellectual property rights of third parties; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstrate, if required, the safety and efficacy of new products with data from clinical studies; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain the necessary regulatory clearances or approvals for new products or product enhancements; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">comply fully with the FDA and foreign regulations on marketing of new products or modified products; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide adequate training to potential users of our AquaBeam Robotic System. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not develop new products or product enhancements in time to meet market demand or if there is insufficient demand for these products or enhancements, or if our competitors introduce new products with functionalities that are superior to ours, our results of operations will suffer. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our future products will require FDA clearance of a 510(k). Other products may require the approval of a PMA. In addition, some of our future products may require clinical trials to support regulatory approval and we </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may not successfully complete these clinical trials. The FDA may not approve or clear these products for the indications that are necessary or desirable for successful commercialization. Indeed, the FDA may refuse our requests for 510(k) clearance or PMA of new products. Failure to receive clearance or approval for our new products would have an adverse effect on our ability to expand our business. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Modifications to our marketed products may require new 510(k) clearances or PMA approvals, or may require us to cease marketing or recall the modified products until clearances or approvals are obtained. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Modifications to our AquaBeam Robotic System and associated consumables may require new regulatory approvals or clearances, including 510(k) clearances or PMAs, or require us to recall or cease marketing the modified systems until these clearances or approvals are obtained. The FDA requires device manufacturers to initially make and document a determination of whether or not a modification requires a new approval, supplement or clearance. A manufacturer may determine that a modification could not significantly affect safety or efficacy and does not represent a major change in its intended use, so that no new 510(k) clearance is necessary. However, the FDA can review a manufacturer&#8217;s decision and may disagree. The FDA may also on its own initiative determine that a new clearance or approval is required. We have made modifications to our AquaBeam Robotic System in the past and may make additional modifications in the future that we believe do not or will not require additional clearances or approvals. If the FDA disagrees and requires new clearances or approvals for the modifications, we may be required to recall and to stop marketing our AquaBeam Robotic System as modified, which could require us to redesign our AquaBeam Robotic System and/or seek new marketing authorizations and harm our operating results. In these circumstances, we may be subject to significant enforcement actions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a manufacturer determines that a modification to an FDA-cleared device could significantly affect its safety or effectiveness, or would constitute a major change in its intended use, then the manufacturer must file for a new 510(k) clearance or possibly a PMA application. Where we determine that modifications to our AquaBeam Robotic System require a new 510(k) clearance or PMA application, we may not be able to obtain those additional clearances or approvals for the modifications or additional indications in a timely manner, or at all. Obtaining clearances and approvals can be a time-consuming process, and delays in obtaining required future clearances or approvals would adversely affect our ability to introduce new or enhanced products in a timely manner, which in turn would harm our future growth. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even though we have obtained marketing authorization for our AquaBeam Robotic System, we are subject to ongoing regulatory review and scrutiny.  Failure to comply with post-marketing regulatory requirements could subject us to enforcement actions, including substantial penalties, and might require us to recall or withdraw a product from the market. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though we have obtained marketing authorization for our AquaBeam Robotic System, it and any other product for which we obtain clearance or approval, and the manufacturing processes, post-market surveillance, post-approval clinical data and promotional activities for such product, are or, in the case of future products, will be, subject to continued regulatory review, oversight, requirements, and periodic inspections by the FDA and other domestic and foreign regulatory bodies. In particular, we and our suppliers are required to comply with FDA&#8217;s QSR and other regulations enforced outside the United States which cover the manufacture of our products and the methods and documentation of the design, testing, production, control, quality assurance, labeling, packaging, storage and shipping of medical devices. Regulatory bodies, such as the FDA, enforce the QSR and other regulations through periodic inspections. The failure by us or one of our suppliers to comply with applicable statutes and regulations administered by the FDA and other regulatory bodies, or the failure to timely and adequately respond to any adverse inspectional observations or product safety issues, could result in, among other things, any of the following enforcement actions: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">untitled letters, warning letters, fines, injunctions, consent decrees and civil penalties; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unanticipated expenditures to address or defend such actions; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">customer notifications for repair, replacement, refunds; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recall, detention or seizure of our products; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions or partial suspension or total shutdown of production; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusing or delaying our requests for 510(k) clearance or PMA of new products or modified products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating restrictions; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of 510(k) clearances on PMA approvals that have already been granted; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal to grant export approval for our products; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">criminal prosecution. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these actions were to occur it would harm our reputation and cause our product sales and profitability to suffer and may prevent us from generating revenue. Furthermore, our key component suppliers may not currently be or may not continue to be in compliance with all applicable regulatory requirements which could result in our failure to produce our products on a timely basis and in the required quantities, if at all. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are required to conduct costly post-market testing and surveillance to monitor the safety or effectiveness of our products, and we must comply with medical device reporting requirements, including the reporting of adverse events and malfunctions related to our products. Later discovery of previously unknown problems with our products, including unanticipated adverse events or adverse events of unanticipated severity or frequency, manufacturing problems, or failure to comply with regulatory requirements such as QSR, may result in changes to labeling, restrictions on such products or manufacturing processes, withdrawal of the products from the market, voluntary or mandatory recalls, a requirement to repair, replace or refund the cost of any medical device we manufacture or distribute, fines, suspension of regulatory approvals, product seizures, injunctions or the imposition of civil or criminal penalties which would adversely affect our business, operating results and prospects. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products may cause or contribute to adverse medical events or be subject to failures or malfunctions that we are required to report to the FDA, and if we fail to do so, we would be subject to sanctions that could harm our reputation, business, financial condition and results of operations. The discovery of serious safety issues with our products, or a recall of our products either voluntarily or at the direction of the FDA or another governmental authority, could have a negative impact on us. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the FDA&#8217;s medical device reporting regulations and similar foreign regulations, which require us to report to the FDA when we receive or become aware of information that reasonably suggests that one or more of our products may have caused or contributed to a death or serious injury or malfunctioned in a way that, if the malfunction were to recur, it could cause or contribute to a death or serious injury. The timing of our obligation to report is triggered by the date we become aware of the adverse event as well as the nature of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to recognize that we have become aware of a reportable adverse event, especially if it is not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of the product. If we fail to comply with our reporting obligations, the FDA could take action, including warning letters, untitled letters, administrative actions, criminal prosecution, imposition of civil monetary penalties, revocation of our device clearance or approval, seizure of our products or delay in clearance or approval of future products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and foreign regulatory bodies have the authority to require the recall of commercialized products in the event of material deficiencies or defects in design or manufacture of a product or in the event that a product poses an unacceptable risk to health. The FDA&#8217;s authority to require a recall must be based on a finding that there is reasonable probability that the device could cause serious injury or death. We may also choose to voluntarily recall a product if any material deficiency is found. A government-mandated or voluntary recall by us could occur as a result of an unacceptable risk to health, component failures, malfunctions, manufacturing defects, labeling or design deficiencies, packaging defects or other deficiencies or failures to comply with applicable regulations. Product defects or other errors may occur in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on the corrective action we take to redress a product&#8217;s deficiencies or defects, the FDA may require, or we may decide, that we will need to obtain new clearances or approvals for the device before we may market or </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">distribute the corrected device. Seeking such clearances or approvals may delay our ability to replace the recalled devices in a timely manner. Moreover, if we do not adequately address problems associated with our devices, we may face additional regulatory enforcement action, including FDA warning letters, product seizure, injunctions, administrative penalties or civil or criminal fines. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Companies are required to maintain certain records of recalls and corrections, even if they are not reportable to the FDA. We may initiate voluntary withdrawals or corrections for our products in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, it could require us to report those actions as recalls and we may be subject to enforcement action. A future recall announcement could harm our reputation with customers, potentially lead to product liability claims against us and negatively affect our sales. Any corrective action, whether voluntary or involuntary, as well as defending ourselves in a lawsuit, will require the dedication of our time and capital, will distract management from operating our business and may harm our reputation and financial results. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products must be manufactured in accordance with federal and state regulations, and we could be forced to recall our devices or terminate production if we fail to comply with these regulations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The methods used in, and the facilities used for, the manufacture of our products must comply with the FDA&#8217;s QSR, which is a complex regulatory scheme that covers the procedures and documentation of the design, testing, production, process controls, quality assurance, labeling, packaging, handling, storage, distribution, installation, servicing and shipping of medical devices. Furthermore, we are required to verify that our suppliers maintain facilities, procedures and operations that comply with our quality standards and applicable regulatory requirements. The FDA enforces the QSR through periodic announced or unannounced inspections of medical device manufacturing facilities, which may include the facilities of subcontractors. Our products are also subject to similar state regulations and various laws and regulations of foreign countries governing manufacturing. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We or our third-party manufacturers may not take the necessary steps to comply with applicable regulations, which could cause delays in the delivery of our products. For instance, in 2019 we initiated a voluntary recall for a limited number of lots of our handpiece due to certain issues related to our supply chain and manufacturing processes. We have remedied these issues as we developed our manufacturing processes to scale the production of our handpieces at a higher volume. In addition, failure to comply with applicable FDA requirements or later discovery of previously unknown problems with our products or manufacturing processes could result in, among other things: warning letters or untitled letters; fines, injunctions or civil penalties; suspension or withdrawal of approvals; seizures or recalls of our products; total or partial suspension of production or distribution; administrative or judicially imposed sanctions; the FDA&#8217;s refusal to grant pending or future clearances or approvals for our products; clinical holds; refusal to permit the import or export of our products; and criminal prosecution of us, our suppliers, or our employees. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these actions could significantly and negatively affect supply of our products. If any of these events occurs, our reputation could be harmed, we could be exposed to product liability claims and we could lose customers and experience reduced sales and increased costs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our products, such as our AquaBeam Robotic System, may in the future be subject to product recalls that could harm our reputation, business and financial results. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical devices can experience performance problems in the field that require review and possible corrective action. The occurrence of component failures, manufacturing errors, software errors, design defects or labeling inadequacies affecting a medical device could lead to a government-mandated or voluntary recall by the device manufacturer, in particular when such deficiencies may endanger health. The FDA requires that certain classifications of recalls be reported to the FDA within 10 working days after the recall is initiated. Companies are required to maintain certain records of recalls, even if they are not reportable to the FDA. We may initiate voluntary recalls involving our AquaBeam Robotic System in the future that we determine do not require notification of the FDA. If the FDA disagrees with our determinations, they could require us to report those actions as recalls. Product recalls may divert management attention and financial resources, expose us to product liability or other claims, harm our reputation with customers and adversely impact our business, financial condition and results of operations. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to regulatory or enforcement actions if we engage in improper marketing or promotion of our AquaBeam Robotic System. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our educational and promotional activities and training methods must comply with FDA and other applicable laws, including the prohibition of the promotion of a medical device for a use that has not been cleared or approved by the FDA. Use of a device outside of its cleared or approved indications is known as &#8220;off-label&#8221; use. Physicians may use our AquaBeam Robotic System off-label in their professional medical judgment, as the FDA does not restrict or regulate a physician&#8217;s choice of treatment within the practice of medicine. However, if the FDA determines that our educational and promotional activities or training constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of warning letters, untitled letters, fines, penalties, injunctions, or seizures, which could have an adverse impact on our reputation and financial results. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our educational and promotional activities or training methods to constitute promotion of an off-label use, which could result in significant fines or penalties under other statutory authorities, such as laws prohibiting false claims for reimbursement. In that event, our reputation could be damaged, and adoption of the products could be impaired. Although our policy is to refrain from statements that could be considered off-label promotion of our AquaBeam Robotic System, the FDA or another regulatory agency could disagree and conclude that we have engaged in off-label promotion. It is also possible that other federal, state or foreign enforcement authorities might take action, including, but not limited to, through a whistleblower action under the federal civil False Claims Act, or FCA, if they consider our business activities constitute promotion of an off-label use, which could result in significant penalties, including, but not limited to, criminal, civil or administrative penalties, treble damages, fines, disgorgement, exclusion from participation in government healthcare programs, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, physicians may misuse our products or use improper techniques if they are not adequately trained, potentially leading to injury and an increased risk of product liability. If our devices are misused or used with improper technique, we may become subject to costly litigation by our customers or their patients. Product liability claims are expensive to defend and could divert our management&#8217;s attention, result in substantial damage awards against us, and harm our reputation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product liability claims are expensive to defend and could divert our management&#8217;s attention, result in substantial damage awards against us, and harm our reputation. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislative or regulatory reforms may make it more difficult and costly for us to obtain regulatory clearance or approval of any future products and to manufacture, market and distribute our products after clearance or approval is obtained. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the regulatory approval, manufacture and marketing of regulated products or the reimbursement thereof. In addition, the FDA may change its clearance and approval policies, adopt additional regulations or revise existing regulations, or take other actions, which may prevent or delay approval or clearance of our future products under development or impact our ability to modify our currently cleared products on a timely basis. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of planned or future products. It is impossible to predict whether legislative changes will be enacted or FDA regulations, guidance or interpretations changed, and what the impact of such changes, if any, may be. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last several years, the FDA has proposed reforms to its 510(k) clearance process, and such proposals could include increased requirements for clinical data and a longer review period, or could make it more difficult for manufacturers to utilize the 510(k) clearance process for their products. For example, in November 2018, FDA officials announced forthcoming steps that the FDA intended to take to modernize the premarket notification pathway under Section 510(k) of the FDCA. Among other things, the FDA announced that it planned to develop </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proposals to drive manufacturers utilizing the 510(k) pathway toward the use of newer predicates. These proposals included plans to potentially sunset certain older devices that were used as predicates under the 510(k) clearance pathway, and to potentially publish a list of devices that have been cleared on the basis of demonstrated substantial equivalence to predicate devices that are more than 10 years old. The FDA also announced that it intended to finalize guidance to establish a premarket review pathway for &#8220;manufacturers of certain well-understood device types&#8221; as an alternative to the 510(k) clearance pathway and that such premarket review pathway would allow manufacturers to rely on objective safety and performance criteria recognized by the FDA to demonstrate substantial equivalence, obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, in September 2019, the FDA issued revised final guidance describing an optional &#8220;safety and performance based&#8221; premarket review pathway for manufacturers of &#8220;certain, well-understood device types&#8221; to demonstrate substantial equivalence under the 510(k) clearance pathway by showing that such device meets objective safety and performance criteria established by the FDA, thereby obviating the need for manufacturers to compare the safety and performance of their medical devices to specific predicate devices in the clearance process. The FDA maintains a list device types appropriate for the &#8220;safety and performance based&#8221; pathway and continues to develop product-specific guidance documents that identify the performance criteria for each such device type, as well as recommended testing methods, where feasible. The FDA may establish performance criteria for classes of devices similar to ours, and it is unclear the extent to which such performance standards, if established, could impact our ability to obtain marketing authorization or otherwise create competition that may negatively affect our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and our products. Any new statutes, regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of any future products or make it more difficult to obtain clearance or approval for, manufacture, market or distribute our products. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require additional testing prior to obtaining clearance or approval; changes to manufacturing methods; recall, replacement or discontinuance of our products; or additional record keeping. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s and other regulatory authorities&#8217; policies may change and additional government regulations may be promulgated that could prevent, limit or delay regulatory clearance or approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may be subject to enforcement action, and we may not achieve or sustain profitability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials may be necessary to support future product submissions to the FDA. The clinical trial process is lengthy and expensive with uncertain outcomes, and often requires the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Delays or failures in our clinical trials will prevent us from commercializing any modified or new products and will adversely affect our business, operating results and prospects. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Initiating and completing clinical trials necessary to support any future PMA applications, and additional safety and efficacy data beyond that typically required for a 510(k) clearance, for our possible future product candidates, will be time-consuming and expensive and the outcome uncertain. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials. The results of preclinical studies and clinical trials of our products conducted to date and ongoing or future studies and trials of our current, planned or future products may not be predictive of the results of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. Our interpretation of data and results from our clinical trials do not ensure that we will achieve similar results in future clinical trials. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in preclinical studies and earlier clinical trials have nonetheless failed to replicate results in later clinical trials. Products in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earlier clinical trials. Failure can occur at any stage of clinical testing. Our clinical studies may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical and non-clinical testing in addition to those we have planned. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The initiation and completion of any clinical studies may be prevented, delayed, or halted for numerous reasons. We may experience delays in our ongoing clinical trials for a number of reasons, which could adversely affect the costs, timing or successful completion of our clinical trials, including related to the following: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be required to submit an investigational device exemption application, or IDE, to the FDA, which must become effective prior to commencing certain human clinical trials of medical devices, and the FDA may reject our IDE and notify us that we may not begin clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators and other comparable foreign regulatory authorities may disagree as to the design or implementation of our clinical trials; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators and/or an Institutional Review Board, or IRB, or other reviewing bodies may not authorize us or our investigators to commence a clinical trial, or to conduct or continue a clinical trial at a prospective or specific trial site; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not reach agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of subjects or patients required for clinical trials may be larger than we anticipate, enrollment in these clinical trials may be insufficient or slower than we anticipate, and the number of clinical trials being conducted at any given time may be high and result in fewer available patients for any given clinical trial, or patients may drop out of these clinical trials at a higher rate than we anticipate; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors, including those manufacturing products or conducting clinical trials on our behalf, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we might have to suspend or terminate clinical trials for various reasons, including a finding that the subjects are being exposed to unacceptable health risks; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to amend clinical trial protocols or conduct additional studies to reflect changes in regulatory requirements or guidance, which we may be required to submit to an IRB and/or regulatory authorities for re-examination;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, IRBs, or other parties may require or recommend that we or our investigators suspend or terminate clinical research for various reasons, including safety signals or noncompliance with regulatory requirements; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials may be greater than we anticipate; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical sites may not adhere to the clinical protocol or may drop out of a clinical trial; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to recruit a sufficient number of clinical trial sites; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators, IRBs, or other reviewing bodies may fail to approve or subsequently find fault with our manufacturing processes or facilities of third-party manufacturers with which we enter into agreement for clinical and commercial supplies, the supply of devices or other materials necessary to conduct clinical trials may be insufficient, inadequate or not available at an acceptable cost, or we may experience interruptions in supply; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval policies or regulations of the FDA or applicable foreign regulatory agencies may change in a manner rendering our clinical data insufficient for approval; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our current or future products may have undesirable side effects or other unexpected characteristics. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials must be conducted in accordance with the laws and regulations of the FDA and other applicable regulatory authorities&#8217; legal requirements, regulations or guidelines, and are subject to oversight by these governmental agencies and IRBs at the medical institutions where the clinical trials are conducted. Conducting successful clinical studies will require the enrollment of large numbers of patients, and suitable patients may be difficult to identify and recruit. Patient enrollment in clinical trials and completion of patient participation and follow-up depends on many factors, including the size of the patient population, the nature of the trial protocol, the attractiveness of, or the discomforts and risks associated with, the treatments received by enrolled subjects, the availability of appropriate clinical trial investigators, support staff, and proximity of patients to clinical sites and able to comply with the eligibility and exclusion criteria for participation in the clinical trial and patient compliance. For example, patients may be discouraged from enrolling in our clinical trials if the trial protocol requires them to undergo extensive post-treatment procedures or follow-up to assess the safety and effectiveness of our products or if they determine that the treatments received under the trial protocols are not attractive or involve unacceptable risks or discomforts. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on our collaborators and on medical institutions and CROs to conduct our clinical trials in compliance with good clinical practice, or GCP, requirements. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, we may be affected by increased costs, program delays or both. In addition, clinical trials that are conducted in countries outside the United States may subject us to further delays and expenses as a result of increased shipment costs, additional regulatory requirements and the engagement of non-U.S. CROs, as well as expose us to risks associated with clinical investigators who are unknown to the FDA, and different standards of diagnosis, screening and medical care. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development of sufficient and appropriate clinical protocols to demonstrate safety and efficacy are required and we may not adequately develop such protocols to support clearance and approval. Further, the FDA may require us to submit data on a greater number of patients than we originally anticipated and/or for a longer follow-up period or change the data collection requirements or data analysis applicable to our clinical trials. Delays in patient enrollment or failure of patients to continue to participate in a clinical trial may cause an increase in costs and delays in the approval and attempted commercialization of our products or result in the failure of the clinical trial. In addition, despite considerable time and expense invested in our clinical trials, the FDA may not consider our data adequate to demonstrate safety and efficacy. Such increased costs and delays or failures could adversely affect our business, operating results and prospects. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the third parties on which we rely to conduct our clinical trials and to assist us with pre-clinical development do not perform as required or expected, we may not be able to obtain regulatory clearance or approval for or commercialize our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have the ability to independently conduct our pre-clinical and clinical trials for our future products and we may need to rely on third parties, such as CROs, medical institutions, collaborators, clinical investigators and contract laboratories to conduct such trials. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for products in clinical development. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before clearing or approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our future clinical trials complies with the GCP regulations. To the extent our collaborators or the CROs fail to enroll participants for our clinical trials, fail to conduct the study to GCP standards or are delayed for a significant time in the execution of trials, including achieving full enrollment, including on account of the outbreak of infectious disease, such as the COVID-19 pandemic, or otherwise, we may be affected by increased costs, program delays or both, any resulting data may be unreliable or unusable for regulatory purposes, and we may be subject to enforcement action. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if these third parties need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our pre-clinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, our products on a timely basis, if at all, and our business, operating results and prospects may be adversely affected.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in funding or disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA and other agencies may also slow the time necessary for new product applications to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, in response to the COVID-19 pandemic, on March 10, 2020, the FDA announced its intention to postpone inspections of foreign manufacturing facilities and products, and on March 18, 2020, the FDA temporarily postponed routine surveillance inspections of domestic manufacturing facilities. Subsequently, on July 10, 2020, the FDA announced its intention to resume certain on-site inspections of domestic manufacturing facilities subject to a risk-based prioritization system. The FDA intends to use this risk-based assessment system to identify the categories of regulatory activity that can occur within a given geographic area, ranging from mission critical inspections to resumption of all regulatory activities. Other regulatory authorities may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting business as usual or conducting inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, collaborators, independent contractors and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, collaborators, independent contractors and consultants may engage in fraudulent or other illegal activity with respect to our business. Misconduct by these persons could include intentional, reckless and/or negligent conduct or unauthorized activity that violates: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA requirements, including those laws requiring the reporting of true, complete and accurate information to the FDA authorities; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manufacturing standards; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal and state healthcare fraud and abuse laws and regulations; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">laws that require the true, complete and accurate reporting of financial information or data. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve individually identifiable information, including, without limitation, the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. Any incidents or any other conduct that leads to an employee, contractor, or other agent, or our company, receiving an FDA debarment or exclusion by OIG could result in penalties, a loss of business from third parties, and severe reputational harm. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is not always possible to identify and deter misconduct by our employees and other agents, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, treble damages, monetary fines, disgorgement, imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We must comply with environmental and occupational safety laws. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development programs as well as our manufacturing operations involve the controlled use of hazardous materials. Accordingly, we are subject to federal, state and local laws, as well as the laws of foreign countries, governing the use, handling and disposal of these materials. In the event of an accident or failure to comply with environmental or occupational safety laws, we could be held liable for resulting damages, and any such liability could exceed our insurance coverage. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have to obtain, maintain and protect our intellectual property and failure to do so may adversely impact our competitive position. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success and ability to compete will depend in part in our ability to obtain, maintain and enforce issued patents, trademark and other intellectual property rights and proprietary technology in the United States and elsewhere. If we cannot adequately obtain, maintain and enforce our intellectual property rights and proprietary technology, competitors may be able to use our technologies or the goodwill we have acquired in the marketplace and erode or negate any competitive advantage we may have and our ability to compete, which could harm our business and ability to achieve profitability and/or cause us to incur significant expenses.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a combination of contractual provisions, confidentiality procedures and patent, trade secret, copyright and trademark laws to protect our proprietary technology, products, services, brands, trade secrets, know-how and data and prevent others from duplicating our AquaBeam Robotic System or its disposable components, and our other current and future products, services and technology. However, these legal means afford only limited protection and may not: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent our competitors from duplicating our AquaBeam Robotic System or its disposable components, and our other current and future products; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prevent our competitors from gaining access to our proprietary information and technology; or </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit us to gain or maintain a competitive advantage. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend, in part, on preserving our trade secrets, maintaining the security of our data and know-how and obtaining, maintaining and enforcing other intellectual property rights. We may not be able to obtain, maintain and/or enforce our intellectual property or other proprietary rights necessary to our business or in a form that provides us with a competitive advantage.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to obtain, maintain and/or enforce intellectual property rights necessary to our business and failure to protect, monitor and control the use of our intellectual property rights could negatively impact our ability to compete and cause us to incur significant expenses. The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property rights, products and services, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely in part on our portfolio of issued patents and pending patent applications in the United States and other countries to protect our intellectual property and competitive position. However, our patent applications may not result in issued patents, and any patents that are issued may not provide meaningful protection against competitors or competitive technologies. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. It is also possible that we will fail to identify patentable aspects of inventions made in the course of our development, manufacture and commercialization activities before it is too late to obtain patent protection on them. If we fail to timely file for a patent in any jurisdiction, we may be precluded from doing so at a later date. Although we enter into non-disclosure and confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our employees, corporate collaborators, outside scientific collaborators, suppliers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in any of our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. Moreover, should we become a licensee of a third party&#8217;s patents or patent applications, depending on the terms of any future in-licenses to which we may become a party, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain or enforce the patents, covering technology in-licensed from third parties. Therefore, these patents and patent applications may not be prosecuted, maintained and/or enforced in a manner consistent with the best interests of our business. While we generally apply for patents in those countries where we intend to make, have made, use, import, offer to sell or sell patented products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. Furthermore, the issuance of a patent does not give us the right to practice the patented invention. Third parties may have blocking patents that could prevent us from manufacturing and/or commercializing our own products or services, or otherwise practicing our own technology. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of medical device companies, including our patent position, may involve complex legal and factual questions that have been the subject of much litigation in recent years, and, therefore, the scope of any patent claims that we have or may obtain cannot be predicted with certainty. Accordingly, we cannot provide any assurances about which of our patent applications will issue, the breadth of any resulting patent, whether any of the issued patents will be found to be infringed, invalid or unenforceable or will be threatened or challenged by third parties, that any of our issued patents have, or that any of our currently pending or future patent applications that mature into issued patents will include, claims with a scope sufficient to protect our products and services. Our pending and future patent applications may not result in the issuance of patents or, if issued, may not issue in a form that will be advantageous to us. The coverage claimed in a patent application can be significantly reduced before the patent is issued. The scope of a patent may also be reinterpreted after issuance. The rights that may be granted under our future issued patents may not provide us with the proprietary protection or competitive advantages we are seeking. We cannot offer any assurances that the breadth of our granted patents will be sufficient to stop a competitor from developing, manufacturing and commercializing a product or a service in a non-infringing manner that would be competitive with one or more of our products or services, or otherwise provide us with any competitive advantage. Furthermore, any successful challenge to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for our commercial success. Further, there can be no assurance that we will have adequate resources to enforce our patents. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the United States, the natural expiration of a utility patent is generally 20 years from the earliest effective non-provisional filing date. Further, if we encounter delays in any future regulatory approvals, the period of time during which we could market a product or a service under patent protection could be reduced, and, given the amount of time required for the development, testing and regulatory review of planned or future products or services, patents protecting such products or services might expire before or shortly after such products or services are commercialized. As a result, our patent rights may not provide us with sufficient rights to exclude others from manufacturing or commercializing products or services similar or identical to ours.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain, maintain and enforce our issued patent, trademarks and other intellectual property rights related to our products, services or technology, or if the scope of the issued patents, trademarks or other intellectual property right protection is insufficient, our competitors could develop, manufacture and commercialize products, services or technology similar or superior to ours, and our competitive position may be adversely affected. In addition, the patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our patents and patent applications may in the future be co-owned with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent applications, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products, services and technology. In addition, we may need the cooperation of any such co-owners of our patents in order to enforce such patents against third parties, and such cooperation may not be provided to us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government retains certain rights in inventions produced with its financial assistance under the Bayh-Dole Act. The federal government retains a &#8220;nonexclusive, nontransferable, irrevocable, paid-up license&#8221; for its own benefit. The Bayh-Dole Act also provides federal agencies with &#8220;march-in rights.&#8221; March-in rights allow the government, in specified circumstances, to require the patent owner or successors in title to the patent to grant a &#8220;nonexclusive, partially exclusive, or exclusive license&#8221; to a &#8220;responsible applicant or applicants.&#8221; If the patent owner refuses to do so, the government may grant the license to itself. We cannot be sure that if we acquire intellectual property rights in the future it will be free from government rights or regulations pursuant to the Bayh-Dole Act. If, in the future, we own, co-own or license in technology that is critical to our business that is developed in whole or in part with federal funds subject to the Bayh-Dole Act, our ability to enforce or otherwise exploit patents covering such technology may be adversely affected. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, while software and other of our proprietary works may be protected under copyright law, we have chosen not to register any copyrights in these works, and instead, primarily rely on protecting our software as a trade </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">secret. In order to bring a copyright infringement lawsuit in the United States, the copyright must be registered. Accordingly, the remedies and damages available to us for unauthorized use of our software may be limited. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Patent and Trademark Office, or USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on issued patents often must be paid to the USPTO and foreign patent agencies over the lifetime of the patent and/or applications and any patent rights we may obtain in the future. While an unintentional lapse of a patent or patent application can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. If we fail to maintain the patents and patent applications covering our products or services, we may not be able to stop a competitor from marketing products or services that are the same as or similar to our products or services, which would have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful, and if unsuccessful, the commercial value of our products and services will be adversely affected and our competitive position may be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties, including our competitors, may currently, or in the future, infringe, misappropriate or otherwise violate our issued patents or other intellectual property rights, and we may file lawsuits or initiate other proceedings to protect or enforce our patents or other intellectual property rights, which could be expensive, time-consuming and unsuccessful. While we are not aware of any unauthorized use of our intellectual property rights, we do not regularly conduct monitoring for unauthorized use at this time. In the future, we may, from time to time, seek to analyze our competitors&#8217; products and services, or seek to enforce our rights against potential infringement, misappropriation or violation of our intellectual property rights. The steps we have taken to protect our proprietary rights may not be adequate to enforce our rights as against such infringement, misappropriation or violation of our intellectual property rights. In certain circumstances it may not be practicable or cost-effective for us to enforce our intellectual property rights fully, particularly in certain developing countries or where the initiation of a claim might harm our business relationships. We may also be hindered or prevented from enforcing our rights with respect to a government entity or instrumentality because of the doctrine of sovereign immunity. Our ability to enforce our patent or other intellectual property rights depends on our ability to detect infringement. It may be difficult to detect infringers who do not advertise the components or methods that are used in connection with their products and services. Moreover, it may be difficult or impossible to obtain evidence of infringement in a competitor&#8217;s or potential competitor&#8217;s product or service. Thus, we may not be able to detect unauthorized use of, or take appropriate steps to enforce, our intellectual property rights. Any inability to meaningfully enforce our intellectual property rights could harm our ability to compete and reduce demand for our products and services. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the future, we may become involved in lawsuits to protect or enforce our intellectual property rights. An adverse result in any litigation proceeding could harm our business. In any lawsuit we bring to enforce our intellectual property rights, a court may refuse to stop the other party from using the technology at issue on grounds that our intellectual property rights do not cover the technology in question. If we initiate legal proceedings against a third party to enforce a patent covering a product or a service, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are common, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Any claims we assert against perceived infringers could also provoke these parties to assert counterclaims against us alleging that we infringe, misappropriate or otherwise violate their intellectual property rights. Grounds for a validity challenge could be an alleged failure to meet any of several statutory </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, including lack of patentable subject matter, novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from USPTO, or made a misleading statement, during prosecution. Mechanisms for such challenges include re-examination, post-grant review, inter partes review, interference proceedings, derivation proceedings, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decisions by courts and governmental patent agencies may introduce uncertainty in the enforceability or scope of patents and other intellectual properties owned by us. A court may decide that a patent or other intellectual property right of ours is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims or other intellectual property narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents or other intellectual property do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated or interpreted narrowly. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, even if our patents or other intellectual property rights are found to be valid and infringed, a court may refuse to grant injunctive relief against the infringer and instead grant us monetary damages and/or ongoing royalties. Such monetary compensation may be insufficient to adequately offset the damage to our business caused by the infringer&#8217;s competition in the market. An adverse result in any litigation or administrative proceeding could put one or more of our patents or other intellectual property rights at risk of being invalidated or interpreted narrowly, which could adversely affect our competitive business position, financial condition and results of operations. Moreover, even if we are successful in any litigation, we may incur significant expense in connection with such proceedings, and the amount of any monetary damages may be inadequate to compensate us for damage as a result of the infringement and the proceedings. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our management and other personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on our common stock price. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Any of the foregoing could have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unsuccessful in licensing or acquiring intellectual property rights from third parties that may be necessary to develop, manufacture and/or commercialize our current and/or future products or services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property rights, including patent rights, that are important or necessary to the development, manufacture and/or commercialization of our current and/or future products or services, in which case we would be need to acquire or obtain a license to such intellectual property rights from such third party. A third party that perceive us to be a competitor may be unwilling to assign or license its intellectual property rights to us. In addition, the licensing or acquisition of third party intellectual property rights is a competitive area, and other companies may also pursue similar strategies to license or acquire such third party&#8217;s intellectual property rights. Some of these companies may be established and may have a competitive advantage over us due to their size, capital resources and greater development, manufacture and commercialization capabilities. We also may be unable to license or acquire third party intellectual property rights on commercially reasonable terms that would allow us to make an appropriate return on our investment, or at all, or we may be unable to obtain any such license or acquisition at all. If we are unable to successfully obtain rights to necessary third party intellectual property rights, we may not be able to develop, manufacture or commercialize our current and/or future products or services, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims challenging the ownership or inventorship of our patents and other intellectual property and, if unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, or to cease the development, manufacture and commercialization of our AquaBeam Robotic System and our other current and future products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to claims that current or former employees, collaborators or other third parties have an interest in our current or future patents, patent applications, trade secrets or other intellectual property rights as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our AquaBeam Robotic System or our other current or future products, services or technology. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property rights to execute agreements assigning such intellectual property rights to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property rights that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge, or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property rights, and other owners may be able to license their rights to other third parties, including our competitors. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may be subject to claims from third parties challenging ownership interest in or inventorship of intellectual property rights we regard as our own, based on claims that our agreements with employees or consultants obligating them to assign their intellectual property rights to us are ineffective or in conflict with prior or competing contractual obligations to assign inventions and intellectual property rights to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against such claims, and it may be necessary or we may desire to obtain a license to such third party&#8217;s intellectual property rights to settle any such claim, however, there can be no assurance that we would be able to obtain such license on commercially reasonable terms, if at all . If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our AquaBeam Robotic System and our other current and future products, services or technology. If we were to lose exclusive ownership of such intellectual property, other owners may be able to license their rights to other third parties, including our competitors. We also may be required to obtain and maintain licenses from third parties, including parties involved in any such disputes. Such licenses may not be available on commercially reasonable terms, or at all, or may be non-exclusive. If we are unable to obtain and maintain such licenses, we may need to cease the development, manufacture and commercialization of our AquaBeam Robotic System, or our other current or future products, services and technologies, and we could be prohibited from using our other technologies, features or intellectual property rights that are essential to our products or services, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of another person or entity, including another or former employers. An inability to incorporate technologies, features or other intellectual property rights that are important or essential to our products or services could have a material adverse effect on our business, financial condition, results of operations, and competitive position, and may prevent us from developing, manufacturing and/or selling our products or services. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management and our employees. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to develop, manufacture and/or commercialize our products or services, which could materially and adversely affect our business, financial condition and results of operations. The loss of exclusivity or the narrowing of our patent claims could limit our ability to stop others from using or commercializing similar or identical technology and products. Even if we are successful in defending against such </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">claims, litigation could result in substantial costs and be a distraction to management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patent protection for our AquaBeam Robotic System and our other current and future products and services, we also rely upon unpatented trade secrets, know-how and continuing technological innovation to develop and maintain a competitive position. We seek to protect such proprietary information, in part, through confidentiality agreements with our employees, collaborators, contractors, advisors, consultants and other third parties and invention assignment agreements with our employees. We also have agreements with some of our consultants that require them to assign to us any inventions created as a result of their working with us. The confidentiality agreements are designed to protect our proprietary information and, in the case of agreements or clauses containing invention assignment, to grant us ownership of technologies that are developed through a relationship with employees or third parties. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot guarantee that we have entered into such agreements with each party that has or may have had access to our trade secrets or proprietary information and we may not enter into such agreements with all employees, consultants and third parties who have been involved in the development of our intellectual property rights. Although we generally require all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed. In addition, despite the protections we place on our intellectual property or other proprietary rights, monitoring unauthorized use and disclosure of our intellectual property rights by employees, consultants and other third parties who have access to such intellectual property or other proprietary rights is difficult, and we do not know whether the steps we have taken to protect our intellectual property or other proprietary rights will be adequate. Therefore, we may not be able to prevent the unauthorized disclosure or use of our technical knowledge or other trade secrets by such employees, consultants, advisors or third parties, despite the existence generally of these confidentiality restrictions. These agreements may not provide meaningful protection against the unauthorized use or disclosure of our trade secrets, know-how or other proprietary information in the event the unwanted use is outside the scope of the provisions of the contracts or in the event of any unauthorized use, misappropriation, or disclosure of such trade secrets, know-how, or other proprietary information. There can be no assurances that such employees, consultants, advisors or third parties will not breach their agreements with us, that we will have adequate remedies for any breach, or that our trade secrets will not otherwise become known or independently developed by third parties, including our competitors. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. The exposure of our trade secrets and other proprietary information would impair our competitive advantages and could have a material adverse effect on our business, financial condition and results of operations. In particular, a failure to protect our proprietary rights may allow competitors to copy our technology, which could adversely affect our pricing and market share.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to, or independently developed by, a competitor or other third party, our competitive position would be materially and adversely harmed. Furthermore, we expect these trade secrets, know-how and proprietary information to over time be disseminated within the industry through independent development, the publication of journal articles describing the methodology, the movement of personnel within the industry and from academic to industry scientific positions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known, or be independently discovered by, competitors. To the extent that our employees, consultants, contractors or collaborators use intellectual property owned by others in their work for us, disputes may arise as to the rights in related or resulting know-how and inventions could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that we or our employees have misappropriated the intellectual property of a third party, including trade secrets or know-how, or are in breach of non-competition or non-solicitation agreements with our competitors and third parties may claim an ownership interest in intellectual property we regard as our own. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our employees and consultants were previously employed at or engaged by other medical device, biotechnology or pharmaceutical companies, including our competitors or potential competitors. Some of these employees, consultants and contractors, may have executed proprietary rights, non-disclosure and non-competition agreements in connection with such previous employment. Although we try to ensure that our employees and consultants do not use the intellectual property, proprietary information, know-how or trade secrets of others in their work for us, we may be subject to claims that we or these individuals have, inadvertently or otherwise, misappropriated the intellectual property or disclosed the alleged trade secrets or other proprietary information, of these former employers or competitors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we may be subject to claims from third parties challenging our ownership interest in intellectual property we regard as our own, based on claims that our employees or consultants have breached an obligation to assign inventions to another employer, to a former employer, or to another person or entity. Litigation may be necessary to defend against any other claims, and it may be necessary or we may desire to enter into a license to settle any such claim; however, there can be no assurance that we would be able to obtain a license on commercially reasonable terms, if at all. If our defense to those claims fails, in addition to paying monetary damages, a court could prohibit us from using technologies or features that are essential to our AquaBeam Robotic System or our other current and future products or services, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An inability to incorporate technologies or features that are important or essential to our product could have a material adverse effect on our business, financial condition and results of operations, and may prevent us from selling our AquaBeam Robotic System or our other current and future products or services. In addition, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against these claims, litigation could result in substantial costs and could be a distraction to management. Any litigation or the threat thereof may adversely affect our ability to hire employees or contract with independent sales representatives. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product, which could have an adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our existing and future products or services, and could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our current or future patents. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to obtain patents and the breadth of any patents obtained is uncertain in part because, to date, some legal principles remain unresolved, and there has not been a consistent policy regarding the breadth or interpretation of claims allowed in patents in the United States and other countries. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property rights or narrow the scope of our patent protection, which in turn could diminish the commercial value of our products and services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent reform legislation may pass in the future that could lead to additional uncertainties and increased costs surrounding the prosecution, enforcement and defense of our patents and applications. Furthermore, the U.S. Supreme Court and the U.S. Court of Appeals for the Federal Circuit have made, and will likely continue to make, changes in how the patent laws of the United States are interpreted. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by the United States Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we own or that we might obtain or license in the future. An inability to obtain, enforce, and defend patents covering our proprietary technologies would materially and adversely affect our business prospects and financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, foreign courts have made, and will likely continue to make, changes in how the patent laws in their respective jurisdictions are interpreted. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. In addition, any protection afforded by foreign patents may be more limited than that provided under U.S. patent and intellectual property laws. We may encounter significant problems in enforcing and defending our intellectual property both in the United States and abroad. For example, if the issuance in a given country of a patent covering an invention is not followed by the issuance in other countries of patents covering the same invention, or if any judicial interpretation of the validity, enforceability or scope of the claims or the written description or enablement in a patent issued in one country is not similar to the interpretation given to the corresponding patent issued in other countries, our ability to protect our intellectual property rights in those countries may be limited. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may materially diminish the value of our intellectual property rights or narrow the scope of our patent protection. We cannot predict future changes in the interpretation of patent laws or changes to patent laws that might be enacted into law by U.S. and foreign legislative bodies. Those changes may materially affect our patents or patent applications and our ability to obtain additional patent protection in the future. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our trademarks and tradenames are not adequately protected, then we may not be able to build name recognition in our markets and our business may be adversely affected. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our trademarks, trade names and brand names to distinguish our products and services from the products and services of our competitors, and have registered or applied to register many of these trademarks in the United States and certain countries outside the United States. There can be no assurance that our trademark applications will be approved for registration. During trademark registration proceedings, we may receive rejections. Although we are given an opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in proceedings before the USPTO and comparable agencies in many foreign jurisdictions, third parties may also oppose our trademark applications and may seek to cancel trademark registrations or otherwise challenge our use of the trademarks. Opposition or cancellation proceedings may be filed against our trademark filings in these agencies, and such filings may not survive such proceedings. While we may be able to continue the use of our trademarks in the event registration is not available, particularly in the United States, where trademark rights are acquired based on use and not registration, third parties may be able to enjoin the continued use of our trademarks if such parties are able to successfully claim infringement in court.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our trademarks or trade names may be challenged, invalidated, infringed, circumvented and circumvented by third parties, and our trademarks could also be diluted, declared generic or determined to be violating or infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners and customers in our markets of interest. If any of the foregoing occurs, we could be forced to re-brand our products or services, resulting in loss of brand recognition and requiring us to devote resources to advertising and marketing new brands, and suffer other competitive harm. Third parties may also adopt trademarks similar to ours, which could harm our brand identity and lead to market confusion. Further, there can be no assurance that competitors will not infringe our trademarks or that we will have adequate resources to enforce our trademarks. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">confusion. Certain of our current or future trademarks may become so well known by the public that their use becomes generic and they lose trademark protection. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively and our business may be adversely affected. Any of the foregoing could have a material adverse effect on our competitive position, business, financial condition, operating results and prospects.   </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become a party to intellectual property litigation or administrative proceedings that could be expensive, time-consuming, unsuccessful, and could interfere with our ability to sell and market our products or services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends, in part, on our ability to develop, manufacture, market and sell our products and services and use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of third parties. The medical device industry has been characterized by extensive litigation regarding patents, trademarks, trade secrets, and other intellectual property rights, and companies in the industry have used intellectual property litigation to gain a competitive advantage. While we take steps to ensure that we do not infringe upon, misappropriate or otherwise violate the intellectual property rights of others, there may be other more pertinent rights of which we are presently unaware.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business. It is possible that U.S. and foreign patents and pending patent applications controlled by third parties may be alleged to cover our products and services, or that we may be accused of misappropriating third parties&#8217; trade secrets or infringing third parties&#8217; trademarks. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our products or services, including interference proceedings, post grant review and inter partes review before the USPTO or equivalent foreign regulatory authority. Furthermore, we may also become involved in other proceedings, such as reexamination, derivation or opposition proceedings before the USPTO or other jurisdictional body relating to our intellectual property rights or the intellectual property rights of others. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. Because patent applications can take many years to issue and because publication schedules for pending applications vary by jurisdiction, there may be applications now pending of which we are unaware and which may result in issued patents, which our current or future products or services infringe. Also, because the claims of published patent applications can change between publication and patent grant, there may be published patent applications that may ultimately issue with claims that we infringe. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third party patents are valid and enforceable, and infringed by the use of our products and/or services, which could have a negative impact on the commercial success of our current and any future products or services. If we were to challenge the validity of any such third party U.S. patent in federal court, we would need to overcome a presumption of validity. As this burden is a high one requiring us to present clear and convincing evidence as to the invalidity of any such U.S. patent claim, there is no assurance that a court of competent jurisdiction would invalidate the claims of any such U.S. patent. Conversely, in the United States, the patent owner need only prove infringement by a preponderance of the evidence, which is a lower burden of proof. We will have similar burdens to overcome in foreign courts in order to successfully challenge a third party claim of patent infringement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our defense of any litigation or interference proceedings may fail and, even if successful, defending such claims brought against us would cause us to incur substantial expenses. If such claims are successfully asserted against us, they may result in substantial costs and distract our management and other employees and could cause us to pay substantial damages. Further, if a patent infringement or other intellectual property rights-related lawsuit were brought against us, we could be forced, including by court order, to cease developing, manufacturing and/or commercializing the infringing product or service. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. Although patent, trademark, trade secret, and other intellectual property disputes in the medical device area have often been settled through licensing or similar arrangements, costs associated with such arrangements may be substantial and could include ongoing royalties. We may not be able to obtain licenses on commercially reasonable terms, or at all, in which event our business would be materially and adversely affected. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we were able to obtain a license, the rights may be nonexclusive, which could result in our competitors and other third parties gaining access to the same intellectual property. Ultimately, if we are unable to obtain such licenses or make any necessary changes to our products or services, we could be forced to cease some aspect of our business operations, which could harm our business significantly.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A finding of infringement, or an unfavorable interference or derivation proceedings outcome could prevent us from developing, manufacturing and/or commercializing our products or services, or force us to cease some or all of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources and more mature and developed intellectual property portfolios. We could encounter delays in product or service introductions while we attempt to develop alternative products or services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If third parties assert infringement, misappropriation or other claims against our customers, these claims may require us to initiate or defend protracted and costly litigation on behalf of our customers, regardless of the merits of these claims. If any of these claims succeed or settle, we may be forced to pay damages or settlement payments on behalf of our customers or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, our customers may be forced to stop using our products or services.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our products include components that we purchase from suppliers and may include design components that are outside of our direct control. Our competitors, many of which have substantially greater resources and have made substantial investments in patent portfolios, trade secrets, trademarks, and competing technologies, may have applied for or obtained, or may in the future apply for or obtain, patents or trademarks that will prevent, limit or otherwise interfere with our ability to make, use, sell and/or export our products, services or to use our technologies or product names. As the number of competitors in our market grows and the number of patents issued in this area increases, the possibility of patent infringement claims against us may increase. Moreover, individuals and groups that are non-practicing entities, commonly referred to as &#8220;patent trolls,&#8221; purchase patents and other intellectual property assets for the purpose of making claims of infringement in order to extract settlements. From time to time, we may receive threatening letters, notices or &#8220;invitations to license,&#8221; or may be the subject of claims that our products, services and business operations infringe, misappropriate or otherwise violate the intellectual property rights of others. The defense of these matters can be time-consuming, costly to defend in litigation, divert management&#8217;s attention and resources, damage our reputation and brand and cause us to incur significant expenses or make substantial payments. In addition, suppliers from whom we purchase hardware or software may not indemnify us in the event that such hardware or software is accused of infringing a third party&#8217;s patent or trademark or of misappropriating a third party&#8217;s trade secret.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, inter partes review and equivalent proceedings in foreign jurisdictions (for example, opposition proceedings). Such proceedings could result in revocation of or amendment to our patents in such a way that they no longer cover our products or services. Two of our applications filed in Europe are currently subject to opposition challenges. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel, and the patent examiner were unaware during prosecution. If a third party were to prevail on a legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on our products or services. Such a loss of patent protection would have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during litigation. There could also be public announcements of the results of hearing, motions, or other interim developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of shares of our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">common stock. Even if we ultimately prevail, a court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may not be an adequate remedy. Furthermore, the monetary cost of such litigation and the diversion of the attention of our management could outweigh any benefit we receive as a result of the proceedings. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our business. Any of the foregoing may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use of &#8220;open source&#8221; software could subject our proprietary software to general release, adversely affect our ability to sell our AquaBeam Robotic System or our other current or future products and services and subject us to possible litigation. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of the products or technologies licensed, developed and/or distributed by us incorporate so-called &#8220;open source&#8221; software and we may incorporate open source software into other products in the future. Such open source software is generally licensed by its authors or other third parties under open source licenses. Some open source licenses contain requirements that we disclose source code for modifications we make to the open source software and that we license such modifications to third parties at no cost. In some circumstances, distribution of our software in connection with open source software could require that we disclose and license some or all of our proprietary code in that software, as well as distribute our software that uses particular open source software at no cost to the user. We monitor our use of open source software in an effort to avoid uses in a manner that would require us to disclose or grant licenses under our proprietary source code; however, there can be no assurance that such efforts will be successful. Open source license terms are often ambiguous and such use could inadvertently occur. There is little legal precedent governing the interpretation of many of the terms of these licenses, and the potential impact of these terms on our business may result in unanticipated obligations regarding our AquaBeam Robotic System and our technologies. Companies that incorporate open source software into their products have, in the past, faced claims seeking enforcement of open source license provisions and claims asserting ownership of open source software incorporated into their product. If an author or other third party that distributes such open source software were to allege that we had not complied with the conditions of an open source license, we could incur significant legal costs defending ourselves against such allegations. In the event such claims were successful, we could be subject to significant damages or be enjoined from the distribution of our AquaBeam Robotic System and our other current and future products. In addition, if we combine our proprietary software with open source software in certain ways, under some open source licenses, we could be required to release the source code of our proprietary software, which could substantially help our competitors develop products that are similar to or better than ours and otherwise adversely affect our business. These risks could be difficult to eliminate or manage, and, if not addressed, could harm our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property rights do not necessarily address all potential threats. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may be able to make products that are similar to our AquaBeam Robotic System and our other current or future products or utilize similar technology but that are not covered by the claims of our patents or that incorporate certain technology in our AquaBeam Robotic System and our other current and future products that is in the public domain; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our future licensors or collaborators, might not have been the first to make the inventions covered by the applicable issued patent or pending patent application that we own now or may own or license in the future; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we, or our future licensors or collaborators, might not have been the first to file patent applications covering certain of our or their inventions; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">it is possible that our current or future pending patent applications will not lead to issued patents; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors or other third parties; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitors or other third parties might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may not develop additional proprietary technologies that are patentable; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patents of others may harm our business; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may choose not to file a patent in order to maintain certain trade secrets or know-how, and a third party may subsequently file a patent covering such intellectual property. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of the foregoing could have a material adverse effect on our business, financial condition and results of operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property and proprietary rights throughout the world. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may attempt to develop, manufacture and/or commercialize competitive products or services in foreign countries utilizing our proprietary technology, design, trademarks or tradenames in foreign countries where we do not have any patents or patent applications, trademarks, and/or other forms of intellectual property rights and/or where legal recourse may be limited. This may have a significant commercial impact on our foreign business operations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents or trademarks on our AquaBeam Robotic System and all of our other current and future products and services in all countries throughout the world would be prohibitively expensive, and the laws of foreign countries particularly those of developing countries, may not protect our rights to the same extent as the laws of the United States. For example, as of May 1, 2021, the Patent Cooperation Treaty had 153 contracting states, and it is only economically feasible to file for protection in a portion of these countries. With the COVID-19 pandemic, some of our foreign associates have requested instructions well in advance of deadlines, which could adversely affect our ability to meet foreign deadlines for filing and prosecuting patent applications. Also, it is unclear to what extent the COVID-19 pandemic will adversely impact operations at some foreign patent offices where we have sought protection. Consequently, we may not be able to prevent third parties from practicing our inventions or trademarks in all jurisdictions outside the United States to the same extent as the United States, or from developing, manufacturing, selling or importing products or services using or incorporating our inventions or trademarks in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent or trademark protection to develop, manufacture and/or market their own products or services and, further, may export otherwise infringing products or services to territories where we have patent or trademark protection, but enforcement on infringing activities is inadequate or not as strong as that in the United States. These products or services may compete with our AquaBeam Robotic System or other current or future products or services, and our patents, trademarks or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may decide to abandon national and regional patent applications before they are granted. The examination of each national or regional patent application is an independent proceeding. As a result, patent applications in the same family may issue as patents in some jurisdictions, such as in the United States, but may issue as patents with claims of different scope or may even be refused in other jurisdictions. It is also quite common that depending on the country, the scope of patent protection may vary for the same product or technology. For example, certain jurisdictions do not allow for patent protection with respect to method of treatment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we seek to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to manufacture or market our products or services. Accordingly, our efforts to protect our intellectual property rights in such countries </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may be inadequate, which may have an adverse effect on our ability to successfully manufacture or commercialize our products or services in all of our expected significant foreign markets. If we encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions. Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition and results of operations may be adversely affected. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We heavily depend on intellectual property licensed from third parties and our licensors may not always act in our best interest. If we fail to comply with our obligations under our intellectual property licenses, if the licenses are terminated, or if disputes regarding these licenses arise, we could lose significant rights that are important to our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are dependent on patents, know-how and other proprietary technology licensed from AquaBeam LLC. This and other licenses we currently possess or may possess in the future may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses. Moreover, if we fail to comply with our obligations under such licenses, or if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected technology or products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain provisions in our intellectual property agreements with third parties may also be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology, or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, results of operations, financial condition, cash flows and prospects. In spite of our efforts, our current and future licensors might also conclude that we have breached our obligations under our license agreements and might therefore seek to terminate such license agreements, thereby removing or limiting our ability to develop and commercialize products and technology covered by these license agreements. As a result, any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our products, including, for example, the AquaBeam Robotic System, and our financial results. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may need to obtain additional licenses from our existing licensors and others to allow commercialization of products we may develop. Moreover, we may be required to expend significant time and resources to redesign our technology, products, or the methods for manufacturing them or to develop or license replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected technology or products. Even if we are able to obtain such additional licenses, they may be non-exclusive thereby giving our competitors and other third parties access to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the same technology licensed to us. Any of the foregoing could have an adverse impact on our business and financial results.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market price of our common stock may be volatile or may decline steeply or suddenly regardless of our operating performance, which could result in substantial losses for holders of our common stock, and we may not be able to meet investor or analyst expectations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock may be highly volatile and fluctuate or decline significantly in response to numerous factors, many of which are beyond our control, including: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations between our actual operating results, or those of companies that are perceived to be similar to us, and the expectations of securities analysts, investors and the financial community; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any forward-looking financial or operating information we may provide to the public or securities analysts, any changes in this information or our failure to meet expectations based on this information; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions of securities analysts who initiate or maintain coverage of us, changes in financial estimates by any securities analysts who follow our Company or our failure to meet these estimates or the expectations of investors; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additional shares of our common stock being sold into the market by us or our existing stockholders, or the anticipation of such sales, including if existing stockholders sell shares into the market when applicable &#8220;lock-up&#8221; period ends; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hedging activities by market participants; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements by us or our competitors of significant products or features, technical innovations, acquisitions, strategic partnerships, joint ventures or capital commitments; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in operating performance and stock market valuations of companies in our industry, including our competitors; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in third-party payor reimbursement policies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an inability to obtain additional funding;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions, including price and volume fluctuations in the overall stock market; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expiration of market stand-off or lock-up agreements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lawsuits threatened or filed against us; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in new legislation and pending lawsuits or regulatory actions, including interim or final rulings by judicial or regulatory bodies; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other events or factors, including those resulting from political conditions, election cycles, war or incidents of terrorism, or responses to these events, many of which are outside of our control. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, extreme price and volume fluctuations in the stock markets have affected and continue to affect many life sciences and technology companies&#8217; stock prices. Stock prices often fluctuate in ways unrelated or disproportionate to the companies&#8217; operating performance. In the past, stockholders have filed securities class action litigation following periods of market volatility. This risk is especially relevant for us because medical technology companies have experienced significant stock price volatility in recent years. If we were to become involved in securities litigation, it could subject us to substantial costs, divert resources and the attention of management from our business and seriously harm our business. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because of these fluctuations, comparing our operating results on a period-to-period basis may not be meaningful. You should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failure to meet the expectations of industry or financial analysts or investors for any period. If our revenues or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated revenue or earnings forecasts that we may provide. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future sales of shares by existing stockholders could cause our stock price to decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the lock-up and legal restrictions on resale discussed in our prospectus lapse, the trading price of our common stock could decline. As of September 30, 2021, we had a total of 43,471,678 shares of common stock outstanding. Of these shares, only the shares of common stock sold in our IPO are currently freely tradable, without restriction, in the public market. Each of our directors, executive officers and other holders of substantially all our outstanding equity securities are subject to lock-up and market standoff agreements that restrict their ability to, among other things and subject to certain exceptions, sell or transfer their shares until March 13, 2022, subject to certain exceptions. However, BofA Securities, Inc. and Goldman Sachs &amp; Co. LLC may, in their sole discretion, waive the contractual lock-up before the lock-up agreements expire. After the lock-up agreements expire, all shares outstanding will be eligible for sale in the public market, of which the shares are held by directors, executive officers and other affiliates and will be subject to volume limitations under Rule 144 of the Securities Act, and various vesting agreements. Sales of a substantial number of such shares upon expiration of the lock-up and market stand-off agreements, the perception that such sales may occur or early release of these agreements, could cause our market price to fall or make it more difficult for you to sell your common stock at a time and price that you deem appropriate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, 6,606,871 shares of our common stock were issuable upon the exercise of options outstanding as of September 30, 2021. These shares will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements, the lock-up agreements and Rules 144 and 701 of the Securities Act. We filed a registration statement on Form S-8 under the Securities Act covering all the shares of common stock subject to stock options outstanding and reserved for issuance under our stock plans. Shares covered by that registration statement are eligible for sale in the public markets, subject to Rule 144 limitations applicable to affiliates and the lock-up agreement described above. If these additional shares are sold, or if it is perceived that they will be sold in the public market, the trading price of our common stock could decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to pay dividends for the foreseeable future and, as a result, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid any cash dividends on our common stock and do not intend to pay any cash dividends in the foreseeable future. We anticipate that we will retain all of our future earnings for use in the development of our business and for general corporate purposes. Any determination to pay dividends in the future will be at the discretion of our board of directors. In addition, the terms of our loan and security agreement with Oxford Finance LLC restrict our ability to pay dividends to limited circumstances. Accordingly, investors must rely on sales of their common stock after price appreciation, which may never occur, as the only way to realize any future gains on their investments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our principal stockholders and management own a significant percentage of our stock and will be able to exercise significant influence over matters subject to stockholder approval. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2021, our executive officers, directors and 5% stockholders beneficially owned more than 25% of our outstanding shares of common stock. Therefore these stockholders will have the ability to influence us through this ownership position. The interests of these stockholders may not be the same as or may even conflict with your interests. For example, these stockholders could attempt to delay or prevent a change in control of us, even if such change in control would benefit our other stockholders, which could deprive our stockholders of an opportunity to receive a premium for their common stock as part of a sale of us or our assets, and might affect the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prevailing market price of our common stock due to investors&#8217; perceptions that conflicts of interest may exist or arise. As a result, this concentration of ownership may not be in the best interests of our other stockholders. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future securities issuances could result in significant dilution to our stockholders and impair the market price of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future issuances of shares of our common stock, or the perception that these sales may occur, could depress the market price of our common stock and result in dilution to existing holders of our common stock. Also, to the extent outstanding options to purchase shares of our common stock are exercised or options, restricted stock units or other stock-based awards are issued or become vested, there will be further dilution. The amount of dilution could be substantial depending upon the size of the issuances or exercises. Furthermore, we may issue additional equity securities that could have rights senior to those of our common stock. As a result, holders of our common stock  bear the risk that future issuances of debt or equity securities may reduce the value of our common stock and further dilute their ownership interest. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and provisions in our amended and restated certificate of incorporation and bylaws could make a merger, tender offer or proxy contest difficult, thereby depressing the trading price of our common stock. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation and bylaws currently in effect contain provisions that could depress the trading price of our common stock by acting to discourage, delay or prevent a change of control of our company or changes in our management that the stockholders of our company may deem advantageous. These provisions include the following: </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing a classified board of directors so that not all members of our board of directors are elected at one time; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permitting our board of directors to establish the number of directors and fill any vacancies and newly-created directorships; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing that directors may only be removed for cause and only by the affirmative vote of the holders of at least a majority of the voting power of all then outstanding shares of our capital stock; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">requiring the approval of holders of two-thirds of our outstanding common stock to amend some provisions in our amended and restated certificate of incorporation and bylaws; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorizing the issuance of &#8220;blank check&#8221; preferred stock that our board of directors could use to implement a stockholder rights plan; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibiting stockholders from calling special meetings of stockholders; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">prohibiting stockholder action by written consent, which has the effect of requiring all stockholder actions to be taken at a meeting of our stockholders; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">providing that the board of directors is expressly authorized to make, alter or repeal our bylaws; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restricting the forum for certain litigation involving us to Delaware or federal courts, as applicable; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing advance notice requirements for nominations for election to our board of directors or for proposing matters that can be acted upon by stockholders at annual stockholder meetings. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any provision of our amended and restated certificate of incorporation currently in effect or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provisions of our amended and restated certificate of incorporation requiring exclusive forum in the Court of Chancery of the State of Delaware and the federal district courts of the United States for certain types of lawsuits may have the effect of discouraging lawsuits against our directors and officers.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amended and restated certificate of incorporation currently in effect provide that, unless we consent in writing to the selection of an alternative forum, the sole and exclusive forum, to the fullest extent permitted by law, for (i) any derivative action or proceeding brought on our behalf, (ii) any action asserting a breach of a fiduciary duty owed by any director, officer or other employee to us or our stockholders, (iii) any action asserting a claim against us or any director, officer, or other employee arising pursuant to the Delaware General Corporation Law, (iv) any action to interpret, apply, enforce, or determine the validity of our second amended and restated certificate of incorporation or amended and restated bylaws, or (v) any other action asserting a claim that is governed by the internal affairs doctrine, shall be the Court of Chancery of the State of Delaware (or another state court or the federal court located within the State of Delaware if the Court of Chancery does not have or declines to accept jurisdiction), in all cases subject to the court&#8217;s having jurisdiction over indispensable parties named as defendants. In addition, our amended and restated certificate of incorporation will provide that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act but that the forum selection provision will not apply to claims brought to enforce a duty or liability created by the Exchange Act.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we believe these provisions benefit us by providing increased consistency in the application of Delaware law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and officers. Alternatively, if a court were to find the choice of forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, financial condition, and operating results. For example, under the Securities Act, federal courts have concurrent jurisdiction over all suits brought to enforce any duty or liability created by the Securities Act, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. These provisions may also result in increased costs for investors seeking to bring a claim against us or any of our directors, officers or other employees.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Being a Public Company</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future or otherwise fail to maintain effective internal control over financial reporting, which may result in material misstatements of our financial statements or cause us to fail to meet our periodic reporting obligations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the preparation of our consolidated financial statements, a material weakness in our internal control over financial reporting was identified as of December 31, 2020. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. The material weakness is the result of our failure to design and maintain effective controls over certain information technology, or IT, general controls for information systems that are relevant to the preparation of our financial statements. Specifically, we did not design and maintain:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">program change management controls to ensure that information technology program and data changes affecting financial IT applications and underlying accounting records are identified, tested, authorized and implemented appropriately, and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">user access controls to ensure appropriate segregation of duties and that adequately restrict user and privileged access to financial applications, programs and data to appropriate Company personnel.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These IT general control deficiencies did not result in a material misstatement to the financial statements; however, the deficiencies, when aggregated, could impact maintaining effective segregation of duties, as well as the effectiveness of IT-dependent controls (such as automated controls that address the risk of material misstatement to one or more assertions, along with the IT controls and underlying data that support the effectiveness of system-generated data and reports) that could result in misstatements potentially impacting all financial statement accounts </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and disclosures that would result in a material misstatement to the annual or interim financial statements that would not be prevented or detected. Accordingly, our management determined these deficiencies in the aggregate constitute a material weakness.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are in the process of designing and implementing measures to remediate the material weakness in our internal control over financial reporting, which includes designing and implementing controls over the review and update of user access rights and privileges, including segregation of duties, and controls over program changes to our information systems that contain data used for financial reporting. While we are designing and implementing measures to remediate the material weakness, we cannot predict the success of such measures or the outcome of our assessment of these measures at this time. We can give no assurance that these measures will remediate the material weakness in our internal control over financial reporting or that additional material weaknesses in our internal control over financial reporting will not be identified in the future. The material weakness will not be considered remediated until management completes the design and implementation of the measures described above and the controls operate for a sufficient period of time and management has concluded, through testing, that these controls are effective.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to design and maintain effective internal control over financial reporting could result in errors in our financial statements that may lead to a restatement of our financial statements or cause us to fail to meet our reporting obligations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, our management is required to report upon the effectiveness of our internal control over financial reporting beginning with the annual report for our fiscal year ending December 31, 2022. This assessment will need to include disclosure of any material weaknesses identified by our management in our internal control over financial reporting. When we lose our status as an &#8220;emerging growth company,&#8221; our independent registered public accounting firm will be required to audit the effectiveness of our internal control over financial reporting. Failure to comply with the Sarbanes-Oxley Act could potentially subject us to sanctions or investigations by the SEC or other regulatory authorities, which would require additional financial and management resources. Failure to remediate any material weakness in our internal control over financial reporting, or to design and maintain effective internal control over financial reporting, could also restrict our future access to the capital markets.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. Any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The requirements of being a public company may strain our resources, result in more litigation, and divert management&#8217;s attention.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of The Nasdaq Stock Market, and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some activities more difficult, time consuming or costly, and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly, and current reports with respect to our business and operating results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control and procedures on a quarterly basis. In order to maintain and, if required, improve our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management&#8217;s attention may be diverted from other business concerns, which could adversely affect our business and operating results. We may also need to hire additional employees or engage outside consultants to comply with these requirements, which will increase our costs and expenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, changing laws, regulations, and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs, and making some activities more time consuming. These laws, regulations, and standards are subject to varying interpretations, in many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations, and standards, and this investment may result in increased general and administrative expenses and a diversion of management&#8217;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business may be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These new rules and regulations may make it more expensive for us to obtain director and officer liability insurance and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our Board, particularly to serve on our audit committee and compensation committee, and qualified executive officers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By disclosing information in this Quarterly Report on Form 10-Q and in future filings required of a public company, our business and financial condition will become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#8217;s resources and seriously harm our business.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risks</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation and other legal proceedings may adversely affect our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time-to-time we may become involved in legal proceedings relating to patent and other intellectual property matters, product liability claims, employee claims, tort or contract claims, federal regulatory investigations, securities class action and other legal proceedings or investigations, which could have an adverse impact on our reputation, business and financial condition and divert the attention of our management from the operation of our business. Litigation is inherently unpredictable and can result in excessive or unanticipated verdicts and/or injunctive relief that affect how we operate our business. We could incur judgments or enter into settlements of claims for monetary damages or for agreements to change the way we operate our business, or both. There may be an increase in the scope of these matters or there may be additional lawsuits, claims, proceedings or investigations in the future, which could have a material adverse effect on our business, financial condition and results of operations. Adverse publicity about regulatory or legal action against us could damage our reputation and brand image, undermine our customers&#8217; confidence and reduce long-term demand for our AquaBeam Robotic System, even if the regulatory or legal action is unfounded or not material to our operations. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General economic and financial market conditions may exacerbate our business risks. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global macroeconomic conditions and the world&#8217;s financial markets remain susceptible to significant stresses, resulting in reductions in available credit and government spending, economic downturn or stagnation, foreign currency fluctuations and volatility in the valuations of securities generally. Our customers and distributors may respond to such economic pressures by reducing or deferring their capital spending or reducing staff. Furthermore, unfavorable changes in foreign exchange rates versus the U.S. dollar could increase our product and labor costs, thus reducing our gross profit. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts either do not publish research about us or publish inaccurate or unfavorable research about us, our business or our market, or if they change their recommendations regarding our common stock adversely, the trading price or trading volume of our common stock could decline. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock will be influenced in part by the research and reports that securities or industry analysts may publish about us, our business, our market or our competitors. If one or more analysts initiate research with an unfavorable rating or downgrade our common stock, provide a more favorable recommendation about our competitors or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If any analyst who may cover us were to cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause the trading price or trading volume of our common stock to decline. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are an emerging growth company and a &#8220;smaller reporting company,&#8221; and any decision on our part to comply only with certain reduced reporting and disclosure requirements applicable to emerging growth companies and smaller growth companies could make our common stock less attractive to investors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an &#8220;emerging growth company&#8221; as defined in the JOBS Act and, for as long as we continue to be an emerging growth company, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to emerging growth companies, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not being required to have our independent registered public accounting firm audit our internal control over financial reporting under Section 404 of the Sarbanes-Oxley Act;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced disclosure obligations regarding executive compensation in our periodic reports and annual report on Form 10-K; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">exemptions from the requirements of holding non-binding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could be an emerging growth company for up to five years following the completion of our initial public offering. Our status as an emerging growth company will end as soon as any of the following takes place:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the last day of the fiscal year in which we have more than $1.07 billion in annual revenue;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the date we qualify as a &#8220;large accelerated filer;&#8221;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the date on which we have issued, in any three-year period, more than $1.0 billion in non-convertible debt securities; or</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">December 31, 2026.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict if investors will find our common stock less attractive if we choose to rely on any of the exemptions afforded to emerging growth companies. If some investors find our common stock less attractive because we rely on any of these exemptions, there may be a less active trading market for our common stock and the market price of our common stock may be more volatile.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. We have elected to avail ourselves of this exemption and, therefore, for new or revised accounting standards applicable to public companies, we will be subject to an extended transition period until those standards would otherwise apply to private companies. As a result, our consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even after we no longer qualify as an &#8220;emerging growth company,&#8221; we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to continue to take advantage of many of the same exemptions from disclosure </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements, including, among other things, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.</span></div><div id="id6896dbd221a471485ce149196fbcf44_118"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2021, we closed our initial public offering (&#8220;IPO&#8221;) of our common stock in which we issued and sold 6,556,000 shares of our common stock, and sold an additional 983,400 shares of common stock upon the full exercise of the underwriters&#8217; option to purchase additional shares at a price to the public of $25.00 per share. The shares were offered pursuant to registration statements on Form S-1 (File Nos. 333-258898 and 333-259527), which became effective on September 14, 2021. The underwriters of the offering were led by BofA Securities, Inc. and Goldman Sachs &amp; Co. LLC. The offering did not terminate until after the sale of all shares of common stock registered on the registration statements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We raised approximately $172.4 million in proceeds, net of underwriting discounts and commissions of $13.2 million and estimated offering costs of $2.9 million. No payments for such expenses were made directly or indirectly to (i) any of our officers or directors or their associates, (ii) any persons owning 10% or more of any class of our equity securities or (iii) any of our affiliates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net proceeds from our IPO have been used and will be used, together with our cash and cash equivalents: (i) to hire additional sales and marketing personnel; (ii) to fund product development and research and development activities; and (iii) for working capital and other general corporate purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also use a portion of the net proceeds from the IPO to acquire, in-license or invest in products, technologies or businesses that are complementary to our business. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no material change in the intended use of proceeds from our IPO as described in our final prospectus dated September 14, 2021 and filed with the SEC pursuant to Rule 424(b)(4) on September 16, 2021.</span></div><div id="id6896dbd221a471485ce149196fbcf44_121"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id6896dbd221a471485ce149196fbcf44_124"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="id6896dbd221a471485ce149196fbcf44_127"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_130"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;6. Exhibits </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following exhibits are filed or furnished as a part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018923/exhibit31-closing8xk.htm">Amended and Restated Certificate of Incorporation</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s Current Report on Form 8-K filed on September 21, 2021)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018923/exhibit32-closing8xk.htm">Amended and Restated Bylaws</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (incorporated by reference to Exhibit 3.2 to the registrant&#8217;s Current Report on Form 8-K filed on September 21, 2021)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018188/ex1010-sx1a1.htm">Non-Employee Director Compensation Program</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (incorporated by reference to Exhibit 10.10 to the registrant&#8217;s registration statement on Form S-1 (File No. 333-258898))</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1588978/000162828021018188/exhibit1011-sx1a1.htm">2021 Equity Incentive Award Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (incorporated by reference to Exhibit 10.11 to the registrant&#8217;s registration statement on Form S-1 (File No. 333-258898))</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2(a)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1588978/000162828021018188/ex1011a-sx1a1.htm">Form of Stock Option Agreement under the 2021 Equity Incentive Award Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (incorporated by reference to Exhibit 10.11(a) to the registrant&#8217;s registration statement on Form S-1 (File No. 333-258898))</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2(b)+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1588978/000162828021018188/exhibit1011b-sx1a1.htm">Form of Restricted Stock Unit Agreement under the 2021 Equity Incentive Award Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (incorporated by reference to Exhibit 10.11(b) to the registrant&#8217;s registration statement on Form S-1 (File No. 333-258898))</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.3+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1588978/000162828021018188/exhibit1012-sx1a1.htm">2021 Employee Stock Purchase Plan</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (incorporated by reference to Exhibit 10.12 to the registrant&#8217;s registration statement on Form S-1 (File No. 333-258898))</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018188/exhibit1013-sx1a1.htm">Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Reza Zadno, Ph.D., </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018188/exhibit1013-sx1a1.htm">dated September 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018188/exhibit1013-sx1a1.htm">7, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (incorporated by reference to Exhibit 10.13 to the registrant&#8217;s registration statement on Form S-1 (File No. 333-258898)).</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018188/exhibit1014-sx1a1.htm">Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Kevin Waters, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018188/exhibit1014-sx1a1.htm">dated September 1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018188/exhibit1014-sx1a1.htm">7, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (incorporated by reference to Exhibit 10.14 to the registrant&#8217;s registration statement on Form S-1 (File No. 333-258898))</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6+</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018188/exhibit1015-sx1a1.htm">Amended and Restated Change of Control Severance Agreement, by and between the Registrant and Hisham Shiblaq, </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018188/exhibit1015-sx1a1.htm">dated </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001588978/000162828021018188/exhibit1015-sx1a1.htm">September 17, 2021</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> (incorporated by reference to Exhibit 10.15 to the registrant&#8217;s registration statement on Form S-1 (File No. 333-258898))</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="prct-ex311soxcertification.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="prct-ex312soxcertification.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="prct-ex312soxcertification.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="prct-ex321soxcertification.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="prct-ex321soxcertification.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="prct-ex322soxcertification.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="prct-ex322soxcertification.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data file because its XBRL tags are embedded within the Inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Schema Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.352%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.452%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File (embedded within the Inline XBRL document)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;padding-left:14pt">Filed herewith.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.&#160;&#160;&#160;&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates management contract or compensatory plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><div id="id6896dbd221a471485ce149196fbcf44_133"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: November 5, 2021</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.791%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.292%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PROCEPT BIOROBOTICS CORPORATION</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Reza Zadno</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reza Zadno, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal executive officer)</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kevin Waters</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kevin Waters</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SVP, Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial and accounting officer)</span></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>prct-ex311soxcertification.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ifa5840844637416aa8fa13185f05e31d_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I, Reza Zadno, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">I have reviewed this Quarterly Report on Form&#160;10-Q of PROCEPT BioRobotics Corporation&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;&#91;omitted&#93;&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.880%"><tr><td style="width:1.0%"></td><td style="width:44.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; November 5, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Reza Zadno</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Reza Zadno, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Chief Executive Officer </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>prct-ex312soxcertification.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i33a213c1afea4ef0917fe6a2e862012a_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">I, Kevin Waters, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">I have reviewed this Quarterly Report on Form&#160;10-Q of PROCEPT BioRobotics Corporation&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;&#91;omitted&#93;&#59;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:24.5pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:17pt">The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.880%"><tr><td style="width:1.0%"></td><td style="width:44.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.726%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.893%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.491%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; November 5, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Kevin Waters</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Kevin Waters</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Principal Financial Officer and </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Principal Accounting Officer)</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>prct-ex321soxcertification.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="iae523c5ee30b42edaafb4c8d15e248a0_1"></div><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.1</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report of PROCEPT BioRobotics Corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; November 5, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Reza Zadno</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Reza Zadno, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Chief Executive Officer </font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div><font><br></font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>prct-ex322soxcertification.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ifdb7fe3694544ca8b5a89cce1e54c28e_1"></div><div style="min-height:47.64pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.2</font></div><div style="margin-top:18pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Quarterly Report of PROCEPT BioRobotics Corporation (the &#8220;Company&#8221;) on Form 10-Q for the period ending September 30, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:49pt;text-indent:-24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="padding-left:24.5pt;text-indent:-24.5pt"><font><br></font></div><div style="margin-bottom:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.066%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.650%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.429%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58; November 5, 2021</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47; Kevin Waters</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:0.25pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:125%">Kevin Waters</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Chief Financial Officer </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(Principal Financial Officer and </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Principal Accounting Officer)</font></div></td></tr></table></div><div style="margin-top:12pt;text-indent:24.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. &#167; 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.</font></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>prct-20210930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:05140f27-a3ec-43bc-a461-9ef7bd6589c5,g:c5500a2c-3da2-4c15-b44b-608117d5a861-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:prct="http://www.procept-biorobotics.com/20210930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.procept-biorobotics.com/20210930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prct-20210930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prct-20210930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prct-20210930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="prct-20210930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Coverpage" roleURI="http://www.procept-biorobotics.com/role/Coverpage">
        <link:definition>0001001 - Document - Cover page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParentheticals" roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets - Parentheticals</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical">
        <link:definition>1405401 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Parenthetical</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1006006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Organization" roleURI="http://www.procept-biorobotics.com/role/Organization">
        <link:definition>2101101 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationDetails" roleURI="http://www.procept-biorobotics.com/role/OrganizationDetails">
        <link:definition>2402402 - Disclosure - Organization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2103102 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2406403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesFairValueDetails" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails">
        <link:definition>2407404 - Disclosure - Summary of Significant Accounting Policies - Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails">
        <link:definition>2408405 - Disclosure - Summary of Significant Accounting Policies - Fair Value Rollforward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails">
        <link:definition>2409406 - Disclosure - Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails">
        <link:definition>2410407 - Disclosure - Summary of Significant Accounting Policies - Loan Facility Derivative Liability (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails">
        <link:definition>2411408 - Disclosure - Summary of Significant Accounting Policies - Revenue by Type and Geographic Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails">
        <link:definition>2412409 - Disclosure - Summary of Significant Accounting Policies - Significant Geographical Locations Outside the United States (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEarningPerShareDetails" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesEarningPerShareDetails">
        <link:definition>2413410 - Disclosure - Summary of Significant Accounting Policies - Earning Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>2414411 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails" roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails">
        <link:definition>2415412 - Disclosure - Summary of Significant Accounting Policies - Customer Concentration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainConsolidatedFinancialStatementItems" roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItems">
        <link:definition>2116103 - Disclosure - Composition of Certain Consolidated Financial Statement Items</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainConsolidatedFinancialStatementItemsTables" roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables">
        <link:definition>2317302 - Disclosure - Composition of Certain Consolidated Financial Statement Items (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails" roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails">
        <link:definition>2418413 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>2419414 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails" roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails">
        <link:definition>2420415 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails" roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails">
        <link:definition>2421416 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails" roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails">
        <link:definition>2422417 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Interest and Other Income (Expense), net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.procept-biorobotics.com/role/IntangibleAssets">
        <link:definition>2123104 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsDetails" roleURI="http://www.procept-biorobotics.com/role/IntangibleAssetsDetails">
        <link:definition>2424418 - Disclosure - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanFacility" roleURI="http://www.procept-biorobotics.com/role/LoanFacility">
        <link:definition>2125105 - Disclosure - Loan Facility</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LoanFacilityDetails" roleURI="http://www.procept-biorobotics.com/role/LoanFacilityDetails">
        <link:definition>2426419 - Disclosure - Loan Facility (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockWarrantLiability" roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiability">
        <link:definition>2127106 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockWarrantLiabilityTables" roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityTables">
        <link:definition>2328303 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails" roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails">
        <link:definition>2429420 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability - Schedule of Warrants to Purchase Shares of Redeemable Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails" roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails">
        <link:definition>2430421 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStock" roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStock">
        <link:definition>2131107 - Disclosure - Redeemable Convertible Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockTables" roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockTables">
        <link:definition>2332304 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails" roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails">
        <link:definition>2433422 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Temporary Equity by Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockNarrativeDetails" roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails">
        <link:definition>2434423 - Disclosure - Redeemable Convertible Preferred Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails" roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails">
        <link:definition>2435424 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Liquidation Preference (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.procept-biorobotics.com/role/StockholdersEquity">
        <link:definition>2136108 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityTables">
        <link:definition>2337305 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityNarrativeDetails" roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails">
        <link:definition>2438425 - Disclosure - Stockholders' Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofStockOptionActivityDetails" roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails">
        <link:definition>2439426 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofShareBasedCompensationExpenseDetails" roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails">
        <link:definition>2440427 - Disclosure - Stockholders' Equity - Schedule of Share Base d Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityFairValueAssumptionsDetails" roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails">
        <link:definition>2441428 - Disclosure - Stockholders' Equity - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.procept-biorobotics.com/role/CommitmentsandContingencies">
        <link:definition>2142109 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesTables" roleURI="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesTables">
        <link:definition>2343306 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesNarrativeDetails" roleURI="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails">
        <link:definition>2444429 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails" roleURI="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails">
        <link:definition>2445430 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Long-Term Debt Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="prct_TemporaryEquitySharesConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquitySharesConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="prct_Customer3Member" abstract="true" name="Customer3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_LineOfCreditFacilityNumberOfInstallments" abstract="false" name="LineOfCreditFacilityNumberOfInstallments" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="prct_SeriesBRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesBRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_CommonStockValuationPolicyPolicyTextBlock" abstract="false" name="CommonStockValuationPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="prct_LaboratoryAndManufacturingEquipmentMember" abstract="true" name="LaboratoryAndManufacturingEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree" abstract="false" name="OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn" abstract="false" name="LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_A2021EmployeeStockPurchasePlanMember" abstract="true" name="A2021EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_ShareholderOfTenPercentOwnershipOrGreaterMember" abstract="true" name="ShareholderOfTenPercentOwnershipOrGreaterMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_LoanFacilityTrancheThreeMember" abstract="true" name="LoanFacilityTrancheThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly" abstract="false" name="DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount" abstract="false" name="DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_ServiceRevenueMember" abstract="true" name="ServiceRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod" abstract="false" name="DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear" abstract="false" name="OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" abstract="false" name="DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_SeriesDRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesDRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly" abstract="false" name="DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_PrepaidInventory" abstract="false" name="PrepaidInventory" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_SeriesARedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesARedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_LoanFacilityTrancheOneMember" abstract="true" name="LoanFacilityTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_PrepaidSoftware" abstract="false" name="PrepaidSoftware" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_TransferFromInventoryToPropertyAndEquipmentNet" abstract="false" name="TransferFromInventoryToPropertyAndEquipmentNet" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities" abstract="false" name="OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod" abstract="false" name="DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget" abstract="false" name="LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prct_RedwoodCityCAMember" abstract="true" name="RedwoodCityCAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod" abstract="false" name="DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prct_SeriesFRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesFRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_A2008StockPlanMember" abstract="true" name="A2008StockPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_JobsActAccountingElectionPolicyTextBlock" abstract="false" name="JobsActAccountingElectionPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="prct_ServiceAgreementAmortizationPeriod" abstract="false" name="ServiceAgreementAmortizationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prct_A2021EquityIncentiveAwardPlanMember" abstract="true" name="A2021EquityIncentiveAwardPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent" abstract="false" name="LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne" abstract="false" name="OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_NonCashLeaseAccretionExpense" abstract="false" name="NonCashLeaseAccretionExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" abstract="false" name="RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross" abstract="false" name="OperatingLeaseLiabilityAndLongTermDebtMaturityGross" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_EvaluationUnitsMember" abstract="true" name="EvaluationUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_AccruedClinicalTrialExpenses" abstract="false" name="AccruedClinicalTrialExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_SeriesCRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesCRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod" abstract="false" name="DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn" abstract="false" name="LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_ProductWarrantyTerm" abstract="false" name="ProductWarrantyTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent" abstract="false" name="LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted" abstract="false" name="TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="prct_AccruedPurchases" abstract="false" name="AccruedPurchases" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_DebtInstrumentPrincipalAndInterestPeriod" abstract="false" name="DebtInstrumentPrincipalAndInterestPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax" abstract="false" name="FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_LoanFacilityTrancheFourMember" abstract="true" name="LoanFacilityTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" abstract="false" name="TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" abstract="false" name="ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_RedeemableConvertiblePreferredStockWarrantsMember" abstract="true" name="RedeemableConvertiblePreferredStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_LoanFacilityTrancheTwoMember" abstract="true" name="LoanFacilityTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember" abstract="true" name="SeriesERedeemableConvertiblePreferredStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_CommonStockWarrantsMember" abstract="true" name="CommonStockWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_Customer1Member" abstract="true" name="Customer1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_OperatingLeaseLiabilityAndLongTermDebt" abstract="false" name="OperatingLeaseLiabilityAndLongTermDebt" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense" abstract="false" name="FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" abstract="true" name="IncentiveStockOptionsAndNonqualifiedStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_InitialPublicOfferingAbstract" abstract="true" name="InitialPublicOfferingAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="prct_TemporaryEquityDividends" abstract="false" name="TemporaryEquityDividends" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent" abstract="false" name="LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn" abstract="false" name="LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_OperatingLeaseLiabilityAndLongTermDebtCurrent" abstract="false" name="OperatingLeaseLiabilityAndLongTermDebtCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock" abstract="false" name="RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo" abstract="false" name="OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_LineOfCreditFacilityFinalPaymentFeePercentage" abstract="false" name="LineOfCreditFacilityFinalPaymentFeePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="prct_HandPiecesAndOtherConsumablesMember" abstract="true" name="HandPiecesAndOtherConsumablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn" abstract="false" name="LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_TemporaryEquityAmountConversionOfConvertibleSecurities" abstract="false" name="TemporaryEquityAmountConversionOfConvertibleSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_DebtInstrumentInterestOnlyPeriod" abstract="false" name="DebtInstrumentInterestOnlyPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prct_SeriesGRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesGRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_SystemSalesAndRentalsMember" abstract="true" name="SystemSalesAndRentalsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" abstract="false" name="LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_InterestAndOtherIncomeExpense" abstract="false" name="InterestAndOtherIncomeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent" abstract="false" name="DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="prct_OutsideTheUnitedStatesMember" abstract="true" name="OutsideTheUnitedStatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_LoanFacilityMember" abstract="true" name="LoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="prct_WarrantsAndRightsOutstandingWeightedAverageTerm" abstract="false" name="WarrantsAndRightsOutstandingWeightedAverageTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract" abstract="true" name="OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount" abstract="false" name="OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn" abstract="false" name="DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="prct_Customer2Member" abstract="true" name="Customer2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>prct-20210930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:05140f27-a3ec-43bc-a461-9ef7bd6589c5,g:c5500a2c-3da2-4c15-b44b-608117d5a861-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_40c6223a-05b9-4f50-9abd-e2d5224ba4e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_87b481b8-8a01-4922-a2b2-80e7fbf12217" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40c6223a-05b9-4f50-9abd-e2d5224ba4e5" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_87b481b8-8a01-4922-a2b2-80e7fbf12217" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_fc6a1210-96a4-4c7f-a3da-4a7414fe8283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40c6223a-05b9-4f50-9abd-e2d5224ba4e5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_fc6a1210-96a4-4c7f-a3da-4a7414fe8283" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3e7b9cfe-c1c5-4817-a554-3c9d3038bc40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40c6223a-05b9-4f50-9abd-e2d5224ba4e5" xlink:to="loc_us-gaap_AssetsCurrent_3e7b9cfe-c1c5-4817-a554-3c9d3038bc40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_17c969ec-eb3c-45c3-bf30-866170d2a02a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40c6223a-05b9-4f50-9abd-e2d5224ba4e5" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_17c969ec-eb3c-45c3-bf30-866170d2a02a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ac066cf6-fc20-4863-8738-1c315d1f98bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_40c6223a-05b9-4f50-9abd-e2d5224ba4e5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ac066cf6-fc20-4863-8738-1c315d1f98bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2df2337c-2205-4b96-9511-ed3aad1e5246" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a74680d7-b757-4b70-9ff0-1a8d158ee5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2df2337c-2205-4b96-9511-ed3aad1e5246" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a74680d7-b757-4b70-9ff0-1a8d158ee5fd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_a663f586-c0dd-494e-843f-54b5232084c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2df2337c-2205-4b96-9511-ed3aad1e5246" xlink:to="loc_us-gaap_PreferredStockValue_a663f586-c0dd-494e-843f-54b5232084c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_91ce643f-a5a2-4872-8dd6-58b84c81115d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2df2337c-2205-4b96-9511-ed3aad1e5246" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_91ce643f-a5a2-4872-8dd6-58b84c81115d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_5cbf2996-0326-4994-bf29-00caffbacc24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2df2337c-2205-4b96-9511-ed3aad1e5246" xlink:to="loc_us-gaap_CommonStockValue_5cbf2996-0326-4994-bf29-00caffbacc24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e00c7c76-00b8-4038-b46e-7fafdbac5734" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_2df2337c-2205-4b96-9511-ed3aad1e5246" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e00c7c76-00b8-4038-b46e-7fafdbac5734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_14532f2f-ed69-4f21-bb13-08814e2059c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5a43fdef-3963-4f88-9f29-5314f08a4eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14532f2f-ed69-4f21-bb13-08814e2059c9" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5a43fdef-3963-4f88-9f29-5314f08a4eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7ffcaf07-2243-4d44-8882-e91135d7f72e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14532f2f-ed69-4f21-bb13-08814e2059c9" xlink:to="loc_us-gaap_InventoryNet_7ffcaf07-2243-4d44-8882-e91135d7f72e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b128bb51-ce44-41ae-8fe8-a2916142db36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14532f2f-ed69-4f21-bb13-08814e2059c9" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b128bb51-ce44-41ae-8fe8-a2916142db36" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a652c917-817c-4d35-88ff-032a8448e946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14532f2f-ed69-4f21-bb13-08814e2059c9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a652c917-817c-4d35-88ff-032a8448e946" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_adb718ec-9775-4ba5-a1d5-7560e783ad2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_9b912dbd-ae6d-4c67-821a-0af427e3fe10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_adb718ec-9775-4ba5-a1d5-7560e783ad2e" xlink:to="loc_us-gaap_StockholdersEquity_9b912dbd-ae6d-4c67-821a-0af427e3fe10" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c97495a2-7d27-4fbb-9fcb-43a711b6a813" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_adb718ec-9775-4ba5-a1d5-7560e783ad2e" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_c97495a2-7d27-4fbb-9fcb-43a711b6a813" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4f3ef1fc-674f-4899-b522-f108466ec1e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_adb718ec-9775-4ba5-a1d5-7560e783ad2e" xlink:to="loc_us-gaap_Liabilities_4f3ef1fc-674f-4899-b522-f108466ec1e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_79183616-7d78-4cc3-bfb4-d0eac93b4c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_adb718ec-9775-4ba5-a1d5-7560e783ad2e" xlink:to="loc_us-gaap_CommitmentsAndContingencies_79183616-7d78-4cc3-bfb4-d0eac93b4c89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_495d460f-5950-470e-8715-d1a81c5c9ecb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_10551f0b-941e-40af-b4f3-c88e545d87b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_495d460f-5950-470e-8715-d1a81c5c9ecb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_10551f0b-941e-40af-b4f3-c88e545d87b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0b5492ec-9fce-4c1b-b836-b7c7aff8e1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_495d460f-5950-470e-8715-d1a81c5c9ecb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0b5492ec-9fce-4c1b-b836-b7c7aff8e1d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_7f707902-0d83-4929-b029-e6c210f90dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_495d460f-5950-470e-8715-d1a81c5c9ecb" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_7f707902-0d83-4929-b029-e6c210f90dc7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_56e8ac26-1937-4fc2-897d-1bc87b429ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_495d460f-5950-470e-8715-d1a81c5c9ecb" xlink:to="loc_us-gaap_LiabilitiesCurrent_56e8ac26-1937-4fc2-897d-1bc87b429ca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_07531177-5c4e-43cc-a6e7-97eaa0996d21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_495d460f-5950-470e-8715-d1a81c5c9ecb" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_07531177-5c4e-43cc-a6e7-97eaa0996d21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b46678c8-bbfe-4ab3-8b1f-4e9d25ab173f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4858f492-21f2-4412-b1c4-6c59f57cbc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b46678c8-bbfe-4ab3-8b1f-4e9d25ab173f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4858f492-21f2-4412-b1c4-6c59f57cbc5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d993dadf-f235-4d60-8018-c696aa3672f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b46678c8-bbfe-4ab3-8b1f-4e9d25ab173f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d993dadf-f235-4d60-8018-c696aa3672f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_e5494e1d-cc63-4bf2-bc0a-853b9d9abe4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b46678c8-bbfe-4ab3-8b1f-4e9d25ab173f" xlink:to="loc_us-gaap_LongTermDebtCurrent_e5494e1d-cc63-4bf2-bc0a-853b9d9abe4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4965fd0a-d53a-4e9d-be7f-c8b6209cd37e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b46678c8-bbfe-4ab3-8b1f-4e9d25ab173f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_4965fd0a-d53a-4e9d-be7f-c8b6209cd37e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_150e18a1-b548-4ae3-840b-ba96f8067f68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b46678c8-bbfe-4ab3-8b1f-4e9d25ab173f" xlink:to="loc_us-gaap_AccruedSalariesCurrent_150e18a1-b548-4ae3-840b-ba96f8067f68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_560552a6-3138-445f-943b-83f6bf5237b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b46678c8-bbfe-4ab3-8b1f-4e9d25ab173f" xlink:to="loc_us-gaap_AccountsPayableCurrent_560552a6-3138-445f-943b-83f6bf5237b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_74df342c-2b1b-48ad-b59b-466b2630edd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_b46678c8-bbfe-4ab3-8b1f-4e9d25ab173f" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_74df342c-2b1b-48ad-b59b-466b2630edd2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8a5d26d4-41a0-4a93-b8c6-acf4d652e8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_47c25865-df25-4894-966a-3ff72ada1a34" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8a5d26d4-41a0-4a93-b8c6-acf4d652e8ec" xlink:to="loc_us-gaap_OperatingExpenses_47c25865-df25-4894-966a-3ff72ada1a34" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_311c5348-0a20-44da-95bc-147bad5636f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8a5d26d4-41a0-4a93-b8c6-acf4d652e8ec" xlink:to="loc_us-gaap_GrossProfit_311c5348-0a20-44da-95bc-147bad5636f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_21ead1b5-3f32-48e5-a1c0-8c27fa904992" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_710dc8d4-4b6a-410f-8c03-630169a90b0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_21ead1b5-3f32-48e5-a1c0-8c27fa904992" xlink:to="loc_us-gaap_CostOfRevenue_710dc8d4-4b6a-410f-8c03-630169a90b0c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_501cc4e8-6682-4233-a99e-afd3ca4a5b95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_21ead1b5-3f32-48e5-a1c0-8c27fa904992" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_501cc4e8-6682-4233-a99e-afd3ca4a5b95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_64df1494-06f5-426b-b078-7889fae51352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6ce2780d-21e0-4ec3-ba2f-323ef6ddc149" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_64df1494-06f5-426b-b078-7889fae51352" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6ce2780d-21e0-4ec3-ba2f-323ef6ddc149" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ac7789e4-4353-4b5f-ae41-4143de6a6845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_64df1494-06f5-426b-b078-7889fae51352" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ac7789e4-4353-4b5f-ae41-4143de6a6845" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2742a4e3-bff7-4e2d-8f23-09fca9f431e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32d3354e-31a4-40be-9df7-18af1180548d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2742a4e3-bff7-4e2d-8f23-09fca9f431e2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_32d3354e-31a4-40be-9df7-18af1180548d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_54aa4002-cd47-4800-ad40-249d36d648fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2742a4e3-bff7-4e2d-8f23-09fca9f431e2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_54aa4002-cd47-4800-ad40-249d36d648fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_af4eedaf-0a9e-4511-b792-3dc07bd689d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_93343d5b-20ab-47af-b176-b78aabd82964" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_af4eedaf-0a9e-4511-b792-3dc07bd689d9" xlink:to="loc_us-gaap_OperatingIncomeLoss_93343d5b-20ab-47af-b176-b78aabd82964" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e2aa7822-ac52-4acb-840a-b587a9565d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_af4eedaf-0a9e-4511-b792-3dc07bd689d9" xlink:to="loc_us-gaap_InterestExpense_e2aa7822-ac52-4acb-840a-b587a9565d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_InterestAndOtherIncomeExpense_f77dae32-4bcd-4556-87ee-4bc360ff015f" xlink:href="prct-20210930.xsd#prct_InterestAndOtherIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_af4eedaf-0a9e-4511-b792-3dc07bd689d9" xlink:to="loc_prct_InterestAndOtherIncomeExpense_f77dae32-4bcd-4556-87ee-4bc360ff015f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5a6663df-896f-4ac5-b3c7-9f2c5fa127ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2f213d91-7bff-45bd-bd31-a38ea176bc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5a6663df-896f-4ac5-b3c7-9f2c5fa127ce" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2f213d91-7bff-45bd-bd31-a38ea176bc1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca088125-b89c-4633-880c-e04f0dd0073c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts_968136b5-7b93-41c8-a4e1-97e6341d2692" xlink:href="prct-20210930.xsd#prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca088125-b89c-4633-880c-e04f0dd0073c" xlink:to="loc_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts_968136b5-7b93-41c8-a4e1-97e6341d2692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_b9ad2ff6-1138-4b3c-9b55-028ab7ebeb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca088125-b89c-4633-880c-e04f0dd0073c" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_b9ad2ff6-1138-4b3c-9b55-028ab7ebeb5f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_ec2550f5-1309-40cd-832d-8ef9472a6b83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca088125-b89c-4633-880c-e04f0dd0073c" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_ec2550f5-1309-40cd-832d-8ef9472a6b83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_c65d692e-11f1-48b5-94fd-ffe0b26a5d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca088125-b89c-4633-880c-e04f0dd0073c" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_c65d692e-11f1-48b5-94fd-ffe0b26a5d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_94ae95c5-bc2f-4e58-9a25-5dbb8b01af5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca088125-b89c-4633-880c-e04f0dd0073c" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_94ae95c5-bc2f-4e58-9a25-5dbb8b01af5b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5ffb8cc2-1da6-4ffe-a8c1-93c57dd38bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5ffb8cc2-1da6-4ffe-a8c1-93c57dd38bbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax_7f0f2867-d11a-4a84-80dd-322f1648c653" xlink:href="prct-20210930.xsd#prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax_7f0f2867-d11a-4a84-80dd-322f1648c653" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_f83a7e27-3ac7-4fa3-94fb-bfd68aa69d07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_ShareBasedCompensation_f83a7e27-3ac7-4fa3-94fb-bfd68aa69d07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23e9a3d7-1292-4bf5-89be-4a2248110764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_NetIncomeLoss_23e9a3d7-1292-4bf5-89be-4a2248110764" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_NonCashLeaseAccretionExpense_ea12adee-9836-48d9-b385-c0ebd921c4f0" xlink:href="prct-20210930.xsd#prct_NonCashLeaseAccretionExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_prct_NonCashLeaseAccretionExpense_ea12adee-9836-48d9-b385-c0ebd921c4f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ed4e6d30-cc1e-47e4-95a5-c1cf7c807019" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ed4e6d30-cc1e-47e4-95a5-c1cf7c807019" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c488d5ea-404d-4a0d-ba00-d0425741be07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c488d5ea-404d-4a0d-ba00-d0425741be07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_fb0925ca-54c5-4a89-82c7-af58304fb513" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_InventoryWriteDown_fb0925ca-54c5-4a89-82c7-af58304fb513" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_50453b44-e4e5-408a-8e31-b172dd6f068b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_50453b44-e4e5-408a-8e31-b172dd6f068b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_2afa4526-a69b-4ec0-a5dc-2e3d257b85e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_2afa4526-a69b-4ec0-a5dc-2e3d257b85e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_289da557-ecd1-486e-94a2-9eff99638509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_289da557-ecd1-486e-94a2-9eff99638509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0c8d36b6-1786-4468-ba0f-3867974b0321" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0c8d36b6-1786-4468-ba0f-3867974b0321" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_0115967c-4164-4a40-a379-0ef7e14a172f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_0115967c-4164-4a40-a379-0ef7e14a172f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_cc024142-ee49-4ded-8671-eac32c3ee46c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b7523bc4-76cb-487f-b27d-753711c2f345" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_cc024142-ee49-4ded-8671-eac32c3ee46c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64549340-8216-4020-8e64-643d378a148d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62b0cd73-363d-498c-8454-9084b9663b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64549340-8216-4020-8e64-643d378a148d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_62b0cd73-363d-498c-8454-9084b9663b8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17bf7625-458b-4896-b67c-f10881354b57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64549340-8216-4020-8e64-643d378a148d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_17bf7625-458b-4896-b67c-f10881354b57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38e7d072-3244-4426-840a-804fbce19049" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_64549340-8216-4020-8e64-643d378a148d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_38e7d072-3244-4426-840a-804fbce19049" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c34a48f5-c2ac-4886-84aa-24e837ab81c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_24122033-9bc9-4a96-8f06-9d7f72468e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c34a48f5-c2ac-4886-84aa-24e837ab81c2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_24122033-9bc9-4a96-8f06-9d7f72468e0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_08b1df3a-eb90-4eda-a610-62760404e388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c34a48f5-c2ac-4886-84aa-24e837ab81c2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_08b1df3a-eb90-4eda-a610-62760404e388" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_318c0aac-707b-4a69-913c-539a2c888add" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_f34777e4-b19b-4cdc-a938-8f49be8c98d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_318c0aac-707b-4a69-913c-539a2c888add" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_f34777e4-b19b-4cdc-a938-8f49be8c98d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_b6bbb470-fd10-483e-b7a9-1ecb4282da7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_318c0aac-707b-4a69-913c-539a2c888add" xlink:to="loc_us-gaap_Cash_b6bbb470-fd10-483e-b7a9-1ecb4282da7d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_33ba47ea-56cd-4c22-b41f-5fb4e2c365d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_39db91ea-2ee6-4d65-bee8-05ddd2133eca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_33ba47ea-56cd-4c22-b41f-5fb4e2c365d1" xlink:to="loc_us-gaap_InventoryWorkInProcess_39db91ea-2ee6-4d65-bee8-05ddd2133eca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_c617610c-9e10-4d72-88a7-752495d330b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_33ba47ea-56cd-4c22-b41f-5fb4e2c365d1" xlink:to="loc_us-gaap_InventoryRawMaterials_c617610c-9e10-4d72-88a7-752495d330b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_126de70f-b00b-4ff3-aff8-596e03cd94fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_33ba47ea-56cd-4c22-b41f-5fb4e2c365d1" xlink:to="loc_us-gaap_InventoryFinishedGoods_126de70f-b00b-4ff3-aff8-596e03cd94fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6fc5189f-c432-4c06-b4f1-e100334da9db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_2c0e908f-a94f-4ff5-a0ee-ab7c1e4616a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6fc5189f-c432-4c06-b4f1-e100334da9db" xlink:to="loc_us-gaap_PrepaidInsurance_2c0e908f-a94f-4ff5-a0ee-ab7c1e4616a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_db9856ef-0aab-46aa-83cd-bf617a6b07d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6fc5189f-c432-4c06-b4f1-e100334da9db" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_db9856ef-0aab-46aa-83cd-bf617a6b07d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_PrepaidInventory_9c8607e2-d88c-4aa9-b5ef-2c4df6c8eab7" xlink:href="prct-20210930.xsd#prct_PrepaidInventory"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6fc5189f-c432-4c06-b4f1-e100334da9db" xlink:to="loc_prct_PrepaidInventory_9c8607e2-d88c-4aa9-b5ef-2c4df6c8eab7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_PrepaidSoftware_46e9f502-565a-452a-8197-cb3d5b15e0c5" xlink:href="prct-20210930.xsd#prct_PrepaidSoftware"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6fc5189f-c432-4c06-b4f1-e100334da9db" xlink:to="loc_prct_PrepaidSoftware_46e9f502-565a-452a-8197-cb3d5b15e0c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_f3493b84-1ac6-426f-ab82-0f0fa13ae2d6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6fc5189f-c432-4c06-b4f1-e100334da9db" xlink:to="loc_us-gaap_PrepaidRent_f3493b84-1ac6-426f-ab82-0f0fa13ae2d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_bf9aa7b8-f29c-437e-8370-8cf13aaa2c03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_cf462f47-8aa7-4286-9f22-4885e5e13fac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_bf9aa7b8-f29c-437e-8370-8cf13aaa2c03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_cf462f47-8aa7-4286-9f22-4885e5e13fac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55266b49-72a8-442e-8d95-5d4220a6a2d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_bf9aa7b8-f29c-437e-8370-8cf13aaa2c03" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_55266b49-72a8-442e-8d95-5d4220a6a2d8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_4d4d7c43-6b99-43c7-a8fc-2ff5635b6cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_6499366e-4eb5-4183-abb6-559d1847186d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4d4d7c43-6b99-43c7-a8fc-2ff5635b6cc1" xlink:to="loc_us-gaap_InterestPayableCurrent_6499366e-4eb5-4183-abb6-559d1847186d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_AccruedClinicalTrialExpenses_d3c4a050-bc9c-443d-8214-712dce1c39d5" xlink:href="prct-20210930.xsd#prct_AccruedClinicalTrialExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4d4d7c43-6b99-43c7-a8fc-2ff5635b6cc1" xlink:to="loc_prct_AccruedClinicalTrialExpenses_d3c4a050-bc9c-443d-8214-712dce1c39d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e00b4f3f-a60b-462b-8874-6580b4937aad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4d4d7c43-6b99-43c7-a8fc-2ff5635b6cc1" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e00b4f3f-a60b-462b-8874-6580b4937aad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bce64d39-cab6-4fa7-8ea9-e3649a6c394e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4d4d7c43-6b99-43c7-a8fc-2ff5635b6cc1" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_bce64d39-cab6-4fa7-8ea9-e3649a6c394e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_46bb9c61-78f5-4e2b-9d5a-cd4a1a066b30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4d4d7c43-6b99-43c7-a8fc-2ff5635b6cc1" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_46bb9c61-78f5-4e2b-9d5a-cd4a1a066b30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_AccruedPurchases_611c81e6-d1de-4f50-9636-2df6ec80add7" xlink:href="prct-20210930.xsd#prct_AccruedPurchases"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_4d4d7c43-6b99-43c7-a8fc-2ff5635b6cc1" xlink:to="loc_prct_AccruedPurchases_611c81e6-d1de-4f50-9636-2df6ec80add7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails"/>
  <link:calculationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prct_InterestAndOtherIncomeExpense_55dcfb2c-68e0-4355-8bc1-aa6945cb2d20" xlink:href="prct-20210930.xsd#prct_InterestAndOtherIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d1a3e8d6-4dc0-47c2-9ccd-eaf3c0ac0c78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prct_InterestAndOtherIncomeExpense_55dcfb2c-68e0-4355-8bc1-aa6945cb2d20" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_d1a3e8d6-4dc0-47c2-9ccd-eaf3c0ac0c78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_320934c9-bed0-40ec-a2c8-fc00dae4874a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prct_InterestAndOtherIncomeExpense_55dcfb2c-68e0-4355-8bc1-aa6945cb2d20" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_320934c9-bed0-40ec-a2c8-fc00dae4874a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_4a921a37-d4c2-4077-8845-b55c0e622da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prct_InterestAndOtherIncomeExpense_55dcfb2c-68e0-4355-8bc1-aa6945cb2d20" xlink:to="loc_us-gaap_InvestmentIncomeInterest_4a921a37-d4c2-4077-8845-b55c0e622da6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_cbfe45ad-a84d-4577-b2a6-5a9b2806bfc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prct_InterestAndOtherIncomeExpense_55dcfb2c-68e0-4355-8bc1-aa6945cb2d20" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_cbfe45ad-a84d-4577-b2a6-5a9b2806bfc2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebt_ef1657cd-11cd-435e-80f8-ebd2a99b2185" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent_76ad2a55-4302-487b-a7fb-fdcb12e7a064" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebt_ef1657cd-11cd-435e-80f8-ebd2a99b2185" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent_76ad2a55-4302-487b-a7fb-fdcb12e7a064" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities_4ec786fe-0cf6-4406-8c45-2e6946839c35" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebt_ef1657cd-11cd-435e-80f8-ebd2a99b2185" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities_4ec786fe-0cf6-4406-8c45-2e6946839c35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_71686d94-224e-4864-a731-957ece3618e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ef1fc778-a5fe-4b0c-8805-5b238998e917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_71686d94-224e-4864-a731-957ece3618e2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ef1fc778-a5fe-4b0c-8805-5b238998e917" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7af96432-b360-4ee8-a199-74b9593ffb60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_71686d94-224e-4864-a731-957ece3618e2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7af96432-b360-4ee8-a199-74b9593ffb60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b1f6ff11-31d1-4377-8eb9-1e9e8b7ee406" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_71686d94-224e-4864-a731-957ece3618e2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_b1f6ff11-31d1-4377-8eb9-1e9e8b7ee406" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_adf26bd5-a91c-41dd-9a11-5ae5be755524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_71686d94-224e-4864-a731-957ece3618e2" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_adf26bd5-a91c-41dd-9a11-5ae5be755524" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ef03cacb-02cb-477f-a26c-bd3b1836bd29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_340870b3-1a3f-49fe-a938-7031bee29340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ef03cacb-02cb-477f-a26c-bd3b1836bd29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_340870b3-1a3f-49fe-a938-7031bee29340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e50702be-2ed7-45a3-bf4d-043cde8c0c29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ef03cacb-02cb-477f-a26c-bd3b1836bd29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e50702be-2ed7-45a3-bf4d-043cde8c0c29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_761eb0c6-0f88-4e6d-86ba-753a7ca8a48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ef03cacb-02cb-477f-a26c-bd3b1836bd29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_761eb0c6-0f88-4e6d-86ba-753a7ca8a48d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9e808306-6807-4c63-aa7d-3e3fb780f985" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ef03cacb-02cb-477f-a26c-bd3b1836bd29" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9e808306-6807-4c63-aa7d-3e3fb780f985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c634425a-f75b-4a72-b72a-110603150a90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_d36fac47-dfa1-42a5-9b12-f5a8b15cf430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c634425a-f75b-4a72-b72a-110603150a90" xlink:to="loc_us-gaap_LongTermDebtCurrent_d36fac47-dfa1-42a5-9b12-f5a8b15cf430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_5f7e5d9c-c2de-4d8e-8656-0c5cabac43d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_c634425a-f75b-4a72-b72a-110603150a90" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_5f7e5d9c-c2de-4d8e-8656-0c5cabac43d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_4fb2e607-dabc-42f9-8656-d4eb3025aef7" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear_de21c054-7120-4ee4-b7a1-a2d5f8ee5abb" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_4fb2e607-dabc-42f9-8656-d4eb3025aef7" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear_de21c054-7120-4ee4-b7a1-a2d5f8ee5abb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo_00d3e374-e6ef-41ec-a814-429e86dffb37" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_4fb2e607-dabc-42f9-8656-d4eb3025aef7" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo_00d3e374-e6ef-41ec-a814-429e86dffb37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne_9bdd3ae2-7694-4734-a293-ebf9fcaa95cb" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_4fb2e607-dabc-42f9-8656-d4eb3025aef7" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne_9bdd3ae2-7694-4734-a293-ebf9fcaa95cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree_95f43ad8-ad0d-4d35-8c4c-0aaa7ed1f5ca" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_4fb2e607-dabc-42f9-8656-d4eb3025aef7" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree_95f43ad8-ad0d-4d35-8c4c-0aaa7ed1f5ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_aee05b3b-f7f6-4362-b40f-a614d93043ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_24e6908a-e476-44f1-bc66-32cd929a1462" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_aee05b3b-f7f6-4362-b40f-a614d93043ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_24e6908a-e476-44f1-bc66-32cd929a1462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b97e9c6c-df3c-443e-aeb9-a52c73060eeb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_aee05b3b-f7f6-4362-b40f-a614d93043ab" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_b97e9c6c-df3c-443e-aeb9-a52c73060eeb" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>prct-20210930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:05140f27-a3ec-43bc-a461-9ef7bd6589c5,g:c5500a2c-3da2-4c15-b44b-608117d5a861-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="i89d2e8f7cb1049958251cfaf81cb4463_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41640aec-88b9-4e98-8f02-2eaddebd56db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41640aec-88b9-4e98-8f02-2eaddebd56db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e14dd36d-2aca-4cb7-bfbf-251949d76ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e14dd36d-2aca-4cb7-bfbf-251949d76ebf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4c4adbea-3a90-4ffd-83c4-6ebf5c412f65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:to="loc_us-gaap_InventoryNet_4c4adbea-3a90-4ffd-83c4-6ebf5c412f65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_537f9c57-92df-4462-ac17-3a8752f0b5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_537f9c57-92df-4462-ac17-3a8752f0b5d1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_70b4cef3-51df-4e48-af45-039a8e38d5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:to="loc_us-gaap_AssetsCurrent_70b4cef3-51df-4e48-af45-039a8e38d5f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0925ff85-11ce-46f5-9565-8aaeccc4a3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0925ff85-11ce-46f5-9565-8aaeccc4a3f2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4671befe-398c-4fce-a023-9291d67e28c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4671befe-398c-4fce-a023-9291d67e28c7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bce3b614-8bb0-4dd3-80b7-86b0e147035b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bce3b614-8bb0-4dd3-80b7-86b0e147035b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_52e34f1e-3419-4746-825e-1e0e72759a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_52e34f1e-3419-4746-825e-1e0e72759a6a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_825a7114-d4f9-4317-8bc5-177a736f549c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_Assets_825a7114-d4f9-4317-8bc5-177a736f549c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bea7e1ad-f06b-4e8a-934e-65ba5e8300b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_AccountsPayableCurrent_bea7e1ad-f06b-4e8a-934e-65ba5e8300b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_40545e95-5e2c-4750-bdb3-7374bab7e980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_AccruedSalariesCurrent_40545e95-5e2c-4750-bdb3-7374bab7e980" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_606ad777-c5e5-4795-a1d9-213b56f8a079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_LongTermDebtCurrent_606ad777-c5e5-4795-a1d9-213b56f8a079" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15727819-e44a-4771-b7d2-9d2511d4044a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15727819-e44a-4771-b7d2-9d2511d4044a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_da1fa415-390b-4fb2-ad0c-8f4d2790cadc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_da1fa415-390b-4fb2-ad0c-8f4d2790cadc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_70b22332-baf6-45e6-8110-c6977dbd1a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_70b22332-baf6-45e6-8110-c6977dbd1a09" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2added7c-e0e7-433d-bc2d-5409829b1b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2added7c-e0e7-433d-bc2d-5409829b1b9e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_27745939-9c63-4b39-a317-4b93de97a1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_LiabilitiesCurrent_27745939-9c63-4b39-a317-4b93de97a1ef" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8f369a9b-4da7-4cfc-8487-e52a9dcdc829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8f369a9b-4da7-4cfc-8487-e52a9dcdc829" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c688532d-f8a6-4f46-a54e-de91676ff474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c688532d-f8a6-4f46-a54e-de91676ff474" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7fa51ce1-87e9-4181-888f-e23b404296cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7fa51ce1-87e9-4181-888f-e23b404296cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3caf9d4f-ba2b-456b-9021-cb8a439e495c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3caf9d4f-ba2b-456b-9021-cb8a439e495c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5d23a5ad-8f6d-4796-b0c6-f3484a00cbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_Liabilities_5d23a5ad-8f6d-4796-b0c6-f3484a00cbb1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fbb45346-770b-4157-8ea5-04a67f35bd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fbb45346-770b-4157-8ea5-04a67f35bd3a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_ec7fe7fa-7874-45b6-9247-62a8eca23123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_ec7fe7fa-7874-45b6-9247-62a8eca23123" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_724c2e11-662e-4bcc-bb9d-db9045051f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_PreferredStockValue_724c2e11-662e-4bcc-bb9d-db9045051f29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e98e1fcb-efb2-4120-9866-28e26907d599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_CommonStockValue_e98e1fcb-efb2-4120-9866-28e26907d599" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f476db3d-1a35-44bb-b974-85a75a2a0fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f476db3d-1a35-44bb-b974-85a75a2a0fd1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3a87aa25-fda8-4948-a893-0e434d8b3f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3a87aa25-fda8-4948-a893-0e434d8b3f84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1014e97b-50db-457d-94c8-212a7da4dc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1014e97b-50db-457d-94c8-212a7da4dc1b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5c348336-a9d6-4aa7-95d0-f5d5f6e71d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_StockholdersEquity_5c348336-a9d6-4aa7-95d0-f5d5f6e71d47" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f37620ac-c8f7-45d1-9ce7-8a99dc7ecadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f37620ac-c8f7-45d1-9ce7-8a99dc7ecadd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_04762a82-d13c-4eff-b809-80b00982e95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_04762a82-d13c-4eff-b809-80b00982e95e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_9511e41d-c986-4137-91f2-f5883024fde0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_9511e41d-c986-4137-91f2-f5883024fde0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_1f80f522-1b18-4a30-9dee-d6de078a9500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_1f80f522-1b18-4a30-9dee-d6de078a9500" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_af5dd838-ca39-4d98-8925-5dda53e9f35c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_StatementTable_af5dd838-ca39-4d98-8925-5dda53e9f35c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1cf6b7fb-1111-4dd3-aae1-4ca932bcb506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_af5dd838-ca39-4d98-8925-5dda53e9f35c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1cf6b7fb-1111-4dd3-aae1-4ca932bcb506" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1cf6b7fb-1111-4dd3-aae1-4ca932bcb506_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1cf6b7fb-1111-4dd3-aae1-4ca932bcb506" xlink:to="loc_us-gaap_ClassOfStockDomain_1cf6b7fb-1111-4dd3-aae1-4ca932bcb506_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e2316513-cfa3-49f0-9860-c94d3ca9e079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1cf6b7fb-1111-4dd3-aae1-4ca932bcb506" xlink:to="loc_us-gaap_ClassOfStockDomain_e2316513-cfa3-49f0-9860-c94d3ca9e079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_96362092-3459-4587-88b1-54ff5d59e828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e2316513-cfa3-49f0-9860-c94d3ca9e079" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_96362092-3459-4587-88b1-54ff5d59e828" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="i5c5ad2d42b3f4b2684a548e38d89d5e6_CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ec45293e-2d6d-4a20-b81f-8e6fcd8904fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec45293e-2d6d-4a20-b81f-8e6fcd8904fe" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_172a955c-ee97-45e7-945e-f0ee60bc7f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_172a955c-ee97-45e7-945e-f0ee60bc7f2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_78da63e3-a2c7-478c-b77d-ab3967af57e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_78da63e3-a2c7-478c-b77d-ab3967af57e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_a3763d7c-9dc3-46c1-be09-2fc08f75aaeb" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_a3763d7c-9dc3-46c1-be09-2fc08f75aaeb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises_3724a892-6714-45f6-b495-85d860545e68" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises_3724a892-6714-45f6-b495-85d860545e68" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c65d939b-3f6f-45bd-9c59-c07887f781df" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c65d939b-3f6f-45bd-9c59-c07887f781df" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_44d327bf-9bec-473c-ba98-c475ba0594f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_44d327bf-9bec-473c-ba98-c475ba0594f2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquitySharesConversionOfConvertibleSecurities_c626212d-50e0-45cd-9239-1b34f85e44cb" xlink:href="prct-20210930.xsd#prct_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_prct_TemporaryEquitySharesConversionOfConvertibleSecurities_c626212d-50e0-45cd-9239-1b34f85e44cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityAmountConversionOfConvertibleSecurities_a152f219-73e5-47a2-aecf-c477c360ebad" xlink:href="prct-20210930.xsd#prct_TemporaryEquityAmountConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_prct_TemporaryEquityAmountConversionOfConvertibleSecurities_a152f219-73e5-47a2-aecf-c477c360ebad" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1a390e43-c44f-464c-aa1e-87f7bdc1f5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12279d04-c30b-4095-b53e-ba08559240ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ec45293e-2d6d-4a20-b81f-8e6fcd8904fe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d3e25477-3a25-4b57-9198-43c3fc2d8157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_SharesOutstanding_d3e25477-3a25-4b57-9198-43c3fc2d8157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_20369fa4-444b-461e-b9b3-aae84df4d7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockholdersEquity_20369fa4-444b-461e-b9b3-aae84df4d7ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a8f9c079-f20a-4ad9-bf6e-c46796137cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a8f9c079-f20a-4ad9-bf6e-c46796137cca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c9f06a76-a230-4abf-96d2-7f8c1b110415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c9f06a76-a230-4abf-96d2-7f8c1b110415" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition_d50b39cd-4a88-4da3-a315-6e8d606b3ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition_d50b39cd-4a88-4da3-a315-6e8d606b3ac4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_74c2ac16-1b14-4d17-b94d-b51d24902a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_74c2ac16-1b14-4d17-b94d-b51d24902a50" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_631c400b-85ca-4941-bcb3-793973698ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_631c400b-85ca-4941-bcb3-793973698ac7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3997ffe0-90a1-469f-85e1-a72193e367ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3997ffe0-90a1-469f-85e1-a72193e367ca" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df64d60d-4aa9-4a86-8023-fe00ad36235f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df64d60d-4aa9-4a86-8023-fe00ad36235f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cdaa2292-45c5-4318-aaf8-cc2919725931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cdaa2292-45c5-4318-aaf8-cc2919725931" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_41a29a49-87d4-4551-ba70-19acec4ab8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_NetIncomeLoss_41a29a49-87d4-4551-ba70-19acec4ab8ff" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_23087399-0286-4768-9a7d-db43ff516c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4321c93e-b69f-4d47-a7e1-098811aac780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0e0ed48f-954c-4a45-8f0e-219d971658b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ec45293e-2d6d-4a20-b81f-8e6fcd8904fe" xlink:to="loc_us-gaap_StatementTable_0e0ed48f-954c-4a45-8f0e-219d971658b6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2922ed30-f4fc-40d7-92b3-1d6c00e5a784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0e0ed48f-954c-4a45-8f0e-219d971658b6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2922ed30-f4fc-40d7-92b3-1d6c00e5a784" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2922ed30-f4fc-40d7-92b3-1d6c00e5a784_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2922ed30-f4fc-40d7-92b3-1d6c00e5a784" xlink:to="loc_us-gaap_EquityComponentDomain_2922ed30-f4fc-40d7-92b3-1d6c00e5a784_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2922ed30-f4fc-40d7-92b3-1d6c00e5a784" xlink:to="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b4f4a4b9-366b-4cd7-8420-7b36fe5163e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:to="loc_us-gaap_CommonStockMember_b4f4a4b9-366b-4cd7-8420-7b36fe5163e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c8dabe77-9f32-4142-8cb7-3cb9620ca2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c8dabe77-9f32-4142-8cb7-3cb9620ca2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_05f7e922-17fe-4a7f-be05-722cfedd70f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_05f7e922-17fe-4a7f-be05-722cfedd70f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_58753f50-f1f0-4066-a93a-9432e8c6a329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:to="loc_us-gaap_RetainedEarningsMember_58753f50-f1f0-4066-a93a-9432e8c6a329" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended" id="ibc337a4e950f4a31a840c0c9d7d98d9c_CondensedConsolidatedStatementsofCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39018fdf-024b-4ff6-b950-e1b980121288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39018fdf-024b-4ff6-b950-e1b980121288" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b217159a-549d-4ef9-899d-5ed362897ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39018fdf-024b-4ff6-b950-e1b980121288" xlink:to="loc_us-gaap_NetIncomeLoss_b217159a-549d-4ef9-899d-5ed362897ad8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39018fdf-024b-4ff6-b950-e1b980121288" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4ab8725d-c02b-4a2d-9ae8-b56f157870b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4ab8725d-c02b-4a2d-9ae8-b56f157870b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a1983700-ff32-43bb-bfb0-f380d15e86cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_us-gaap_ShareBasedCompensation_a1983700-ff32-43bb-bfb0-f380d15e86cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax_278f3ac8-bc71-43ed-8ec9-d885eb56399b" xlink:href="prct-20210930.xsd#prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax_278f3ac8-bc71-43ed-8ec9-d885eb56399b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_NonCashLeaseAccretionExpense_7ff04d9f-4a52-41cf-b844-3edfe761b1d5" xlink:href="prct-20210930.xsd#prct_NonCashLeaseAccretionExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_prct_NonCashLeaseAccretionExpense_7ff04d9f-4a52-41cf-b844-3edfe761b1d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f6827b35-a190-45ad-962f-0c6b8729eeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_us-gaap_InventoryWriteDown_f6827b35-a190-45ad-962f-0c6b8729eeb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a628a8b6-97e7-4919-81b1-8bcd31826b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a628a8b6-97e7-4919-81b1-8bcd31826b5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_400c408b-0267-474f-bcd5-b2725df70b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_400c408b-0267-474f-bcd5-b2725df70b8d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d28b2128-3d06-4066-956e-eee1c024ee02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d28b2128-3d06-4066-956e-eee1c024ee02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5076124e-bc36-4783-8b3d-6f30ec85e1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5076124e-bc36-4783-8b3d-6f30ec85e1c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_4f2cbdde-a642-466f-b13e-2e0b056091e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_4f2cbdde-a642-466f-b13e-2e0b056091e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_3e70cf4c-0958-4053-b8be-af212a87d0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_3e70cf4c-0958-4053-b8be-af212a87d0ab" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46e0c258-f551-4333-915d-e923385026a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46e0c258-f551-4333-915d-e923385026a5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b088f0ee-03a6-48ce-a155-e618debf08cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b088f0ee-03a6-48ce-a155-e618debf08cd" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8adb756e-7309-4e02-a430-d410752eb7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39018fdf-024b-4ff6-b950-e1b980121288" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8adb756e-7309-4e02-a430-d410752eb7d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_145b3d1c-2e45-4923-90fe-5de13e78a2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_145b3d1c-2e45-4923-90fe-5de13e78a2f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0e5fc7c6-7f12-4a59-ac0f-fe86227c989f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_145b3d1c-2e45-4923-90fe-5de13e78a2f2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0e5fc7c6-7f12-4a59-ac0f-fe86227c989f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8dbeaf6c-785f-443a-9a38-734862b17098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_145b3d1c-2e45-4923-90fe-5de13e78a2f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8dbeaf6c-785f-443a-9a38-734862b17098" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e156e38c-08fd-4160-a4c7-ca888d03aa51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e156e38c-08fd-4160-a4c7-ca888d03aa51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2c887168-f340-4e1a-ac90-cfa72419a57d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2c887168-f340-4e1a-ac90-cfa72419a57d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7fda89f0-18ac-4c66-a6e4-1c6c83869104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7fda89f0-18ac-4c66-a6e4-1c6c83869104" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts_0cb4ea64-f68e-406d-912a-533214a1733c" xlink:href="prct-20210930.xsd#prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts_0cb4ea64-f68e-406d-912a-533214a1733c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_cf015a93-3e18-4d2f-9e92-2b770689d7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_cf015a93-3e18-4d2f-9e92-2b770689d7c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20522928-8f0e-48bd-9790-bf5e8c04c3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20522928-8f0e-48bd-9790-bf5e8c04c3e9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b3a87c0-7ffd-4b36-99d3-3178507e3788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b3a87c0-7ffd-4b36-99d3-3178507e3788" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5730f97a-f795-42ce-9ff8-c15ac3d4aedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5730f97a-f795-42ce-9ff8-c15ac3d4aedd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f93cdbd-6a3e-4cd7-b410-f89ef8747c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b26e669f-5685-4b0c-b861-e7f5f6c3ddc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b26e669f-5685-4b0c-b861-e7f5f6c3ddc6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_199c30eb-6e4f-42b1-98e8-dd67805cbf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b26e669f-5685-4b0c-b861-e7f5f6c3ddc6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_199c30eb-6e4f-42b1-98e8-dd67805cbf9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a45e6692-58bc-46d4-8db3-61653b50de4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b26e669f-5685-4b0c-b861-e7f5f6c3ddc6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a45e6692-58bc-46d4-8db3-61653b50de4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e72d3a05-232a-4f10-a130-99a81fe9b799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfa39b1-44db-4777-b582-b856cf1b3c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfa39b1-44db-4777-b582-b856cf1b3c7e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c3b7cde7-a26f-40c5-ac49-ec6fcaff7967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfa39b1-44db-4777-b582-b856cf1b3c7e" xlink:to="loc_us-gaap_InterestPaidNet_c3b7cde7-a26f-40c5-ac49-ec6fcaff7967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab91bb18-e8fb-4b7d-809c-3cef469effd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfa39b1-44db-4777-b582-b856cf1b3c7e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab91bb18-e8fb-4b7d-809c-3cef469effd0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TransferFromInventoryToPropertyAndEquipmentNet_323ba7a0-d096-4666-95f9-9793c8c7ffe2" xlink:href="prct-20210930.xsd#prct_TransferFromInventoryToPropertyAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab91bb18-e8fb-4b7d-809c-3cef469effd0" xlink:to="loc_prct_TransferFromInventoryToPropertyAndEquipmentNet_323ba7a0-d096-4666-95f9-9793c8c7ffe2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_98a8d086-cd78-41d1-b22a-9748088afb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab91bb18-e8fb-4b7d-809c-3cef469effd0" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_98a8d086-cd78-41d1-b22a-9748088afb7d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_12023c86-afb0-4082-8f42-256b515b7a77" xlink:href="prct-20210930.xsd#prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab91bb18-e8fb-4b7d-809c-3cef469effd0" xlink:to="loc_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_12023c86-afb0-4082-8f42-256b515b7a77" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0d05711-2233-49c8-b109-13ab53f20b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_StatementTable_f0d05711-2233-49c8-b109-13ab53f20b8a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c3198473-70a5-40b1-9df6-091adb0a9a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f0d05711-2233-49c8-b109-13ab53f20b8a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c3198473-70a5-40b1-9df6-091adb0a9a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_c3198473-70a5-40b1-9df6-091adb0a9a5b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c3198473-70a5-40b1-9df6-091adb0a9a5b" xlink:to="loc_us-gaap_ClassOfStockDomain_c3198473-70a5-40b1-9df6-091adb0a9a5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca6bdef1-ad42-47d8-9a86-74562f7a04c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c3198473-70a5-40b1-9df6-091adb0a9a5b" xlink:to="loc_us-gaap_ClassOfStockDomain_ca6bdef1-ad42-47d8-9a86-74562f7a04c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_05e3f02b-ae73-4170-aec2-c129f2f1bbb2" xlink:href="prct-20210930.xsd#prct_SeriesFRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ca6bdef1-ad42-47d8-9a86-74562f7a04c3" xlink:to="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_05e3f02b-ae73-4170-aec2-c129f2f1bbb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_6e2ad737-e372-4387-8457-6344bd3104cd" xlink:href="prct-20210930.xsd#prct_SeriesGRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_ca6bdef1-ad42-47d8-9a86-74562f7a04c3" xlink:to="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_6e2ad737-e372-4387-8457-6344bd3104cd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/OrganizationDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#OrganizationDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/OrganizationDetails" xlink:type="extended" id="if5083c0dce1a4bb983a0281f504833ce_OrganizationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_9f939ff4-b18d-4d42-b56c-7b5ab55ce6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8482272-8b7b-477a-a1c5-a568a12c9586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9f939ff4-b18d-4d42-b56c-7b5ab55ce6cf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8482272-8b7b-477a-a1c5-a568a12c9586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_abf7b972-5b7e-496c-afa4-e7502068f44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9f939ff4-b18d-4d42-b56c-7b5ab55ce6cf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_abf7b972-5b7e-496c-afa4-e7502068f44f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_InitialPublicOfferingAbstract_5d29e560-140d-4534-97ef-136f73867749" xlink:href="prct-20210930.xsd#prct_InitialPublicOfferingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9f939ff4-b18d-4d42-b56c-7b5ab55ce6cf" xlink:to="loc_prct_InitialPublicOfferingAbstract_5d29e560-140d-4534-97ef-136f73867749" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_57b28b98-16fc-4c0b-b853-65505091b009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prct_InitialPublicOfferingAbstract_5d29e560-140d-4534-97ef-136f73867749" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_57b28b98-16fc-4c0b-b853-65505091b009" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_658f6436-deaf-4d48-8447-b3c36958ccda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9f939ff4-b18d-4d42-b56c-7b5ab55ce6cf" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_658f6436-deaf-4d48-8447-b3c36958ccda" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b1b37e-4df3-4aae-860e-36eb264e6ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_658f6436-deaf-4d48-8447-b3c36958ccda" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b1b37e-4df3-4aae-860e-36eb264e6ba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a0b1b37e-4df3-4aae-860e-36eb264e6ba2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b1b37e-4df3-4aae-860e-36eb264e6ba2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_a0b1b37e-4df3-4aae-860e-36eb264e6ba2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239aa202-c67a-4a90-b18b-1b97a4787156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b1b37e-4df3-4aae-860e-36eb264e6ba2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239aa202-c67a-4a90-b18b-1b97a4787156" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6888b57f-67e2-421c-b104-9e107976f4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239aa202-c67a-4a90-b18b-1b97a4787156" xlink:to="loc_us-gaap_IPOMember_6888b57f-67e2-421c-b104-9e107976f4b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f8ca4ae1-5cad-4e2c-83e1-a797063db59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_658f6436-deaf-4d48-8447-b3c36958ccda" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f8ca4ae1-5cad-4e2c-83e1-a797063db59a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_f8ca4ae1-5cad-4e2c-83e1-a797063db59a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f8ca4ae1-5cad-4e2c-83e1-a797063db59a" xlink:to="loc_us-gaap_ClassOfStockDomain_f8ca4ae1-5cad-4e2c-83e1-a797063db59a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_714adb8d-9d8c-498f-910a-c84aae678776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f8ca4ae1-5cad-4e2c-83e1-a797063db59a" xlink:to="loc_us-gaap_ClassOfStockDomain_714adb8d-9d8c-498f-910a-c84aae678776" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f6572414-92f9-4d08-8257-5eaff5f7ff7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_714adb8d-9d8c-498f-910a-c84aae678776" xlink:to="loc_us-gaap_CommonStockMember_f6572414-92f9-4d08-8257-5eaff5f7ff7c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="ie76d4330861b45248ed5c20c7494d7f7_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_74878ebc-0e80-4a33-901f-a92dd13fa08a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_74878ebc-0e80-4a33-901f-a92dd13fa08a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3de0a617-3a8e-441c-8946-18dfb940b520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3de0a617-3a8e-441c-8946-18dfb940b520" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_35852c74-c3b7-4d4b-9bdc-aede429f389e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_35852c74-c3b7-4d4b-9bdc-aede429f389e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1056305d-66f1-47be-a738-85913d923a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1056305d-66f1-47be-a738-85913d923a6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_ed86ef64-f4e6-4ca1-805f-1aa4f8d3cb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_ed86ef64-f4e6-4ca1-805f-1aa4f8d3cb49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_42b087dd-a16f-4c06-9433-949a256ba514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_42b087dd-a16f-4c06-9433-949a256ba514" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_56a902e3-1487-4b5b-b042-320b0d617936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_56a902e3-1487-4b5b-b042-320b0d617936" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_49a2a973-9320-4882-b830-49d2b92e4bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_49a2a973-9320-4882-b830-49d2b92e4bae" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c25c3b74-8525-487a-b596-c304672642f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c25c3b74-8525-487a-b596-c304672642f8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b680c9d-0cae-4f4d-842d-5dd9765d5dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b680c9d-0cae-4f4d-842d-5dd9765d5dd0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_3dc6b395-8663-4400-a441-2b7f054e64bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_DeferredOfferingCosts_3dc6b395-8663-4400-a441-2b7f054e64bb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ProductWarrantyTerm_f5cdf295-cbda-4d69-a888-d0631aacce04" xlink:href="prct-20210930.xsd#prct_ProductWarrantyTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_prct_ProductWarrantyTerm_f5cdf295-cbda-4d69-a888-d0631aacce04" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ServiceAgreementAmortizationPeriod_c4e768c1-f00e-417e-afe2-d4bc1f459de0" xlink:href="prct-20210930.xsd#prct_ServiceAgreementAmortizationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_prct_ServiceAgreementAmortizationPeriod_c4e768c1-f00e-417e-afe2-d4bc1f459de0" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ab9d07a9-c90a-4e7e-91f6-d6db1770b4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ab9d07a9-c90a-4e7e-91f6-d6db1770b4e0" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0c9fd274-a933-4a54-9498-b6d61641ce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_OperatingLeaseLiability_0c9fd274-a933-4a54-9498-b6d61641ce4e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4cf20689-0737-4149-ac3a-ff72531cf61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4cf20689-0737-4149-ac3a-ff72531cf61e" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_298143db-d512-4aca-b98c-913c9327e311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_298143db-d512-4aca-b98c-913c9327e311" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_270f230b-97ea-44bd-8951-c5c48eb2bd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_270f230b-97ea-44bd-8951-c5c48eb2bd4b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_470772c3-71f0-4b51-a2b9-f5ed80e2eec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_470772c3-71f0-4b51-a2b9-f5ed80e2eec1" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_08892bba-9d07-4fe3-842c-e18a00a1de38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_08892bba-9d07-4fe3-842c-e18a00a1de38" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_adb36713-a379-4ba0-b898-38b0c1efa21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_adb36713-a379-4ba0-b898-38b0c1efa21d" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_46702e65-13e0-4814-a3d8-9e6beed4a421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_StatementClassOfStockAxis_46702e65-13e0-4814-a3d8-9e6beed4a421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_46702e65-13e0-4814-a3d8-9e6beed4a421_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46702e65-13e0-4814-a3d8-9e6beed4a421" xlink:to="loc_us-gaap_ClassOfStockDomain_46702e65-13e0-4814-a3d8-9e6beed4a421_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_156b0000-4f76-4b54-9dfc-f2227bec0ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46702e65-13e0-4814-a3d8-9e6beed4a421" xlink:to="loc_us-gaap_ClassOfStockDomain_156b0000-4f76-4b54-9dfc-f2227bec0ee0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e9159667-87af-40f3-9eaf-5c012b509f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_156b0000-4f76-4b54-9dfc-f2227bec0ee0" xlink:to="loc_us-gaap_CommonStockMember_e9159667-87af-40f3-9eaf-5c012b509f3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8dbb281a-46a6-496e-8616-ffbbd058e143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8dbb281a-46a6-496e-8616-ffbbd058e143" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8dbb281a-46a6-496e-8616-ffbbd058e143_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8dbb281a-46a6-496e-8616-ffbbd058e143" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_8dbb281a-46a6-496e-8616-ffbbd058e143_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9563d695-3e11-4554-8fd9-3998a714a6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8dbb281a-46a6-496e-8616-ffbbd058e143" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9563d695-3e11-4554-8fd9-3998a714a6ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_ac20f5c5-bdc2-48f7-aba5-bf4e2f487ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9563d695-3e11-4554-8fd9-3998a714a6ac" xlink:to="loc_us-gaap_IPOMember_ac20f5c5-bdc2-48f7-aba5-bf4e2f487ebf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_6917a34a-5a29-4069-b221-635ae019a8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9563d695-3e11-4554-8fd9-3998a714a6ac" xlink:to="loc_us-gaap_OverAllotmentOptionMember_6917a34a-5a29-4069-b221-635ae019a8e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_a8dce356-2ef1-46ab-9c34-9ff46ea03922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9563d695-3e11-4554-8fd9-3998a714a6ac" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_a8dce356-2ef1-46ab-9c34-9ff46ea03922" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28509fda-884d-4fcd-bbf4-e24b12270369" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_srt_RangeAxis_28509fda-884d-4fcd-bbf4-e24b12270369" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_28509fda-884d-4fcd-bbf4-e24b12270369_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_28509fda-884d-4fcd-bbf4-e24b12270369" xlink:to="loc_srt_RangeMember_28509fda-884d-4fcd-bbf4-e24b12270369_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_269362ca-81c9-46dd-8674-c1224a402eb8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_28509fda-884d-4fcd-bbf4-e24b12270369" xlink:to="loc_srt_RangeMember_269362ca-81c9-46dd-8674-c1224a402eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37c1bd15-20e4-42bb-b98f-fd11b0667e84" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_269362ca-81c9-46dd-8674-c1224a402eb8" xlink:to="loc_srt_MinimumMember_37c1bd15-20e4-42bb-b98f-fd11b0667e84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_38e3257f-51eb-476c-8192-41040007cdea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_269362ca-81c9-46dd-8674-c1224a402eb8" xlink:to="loc_srt_MaximumMember_38e3257f-51eb-476c-8192-41040007cdea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_458bab53-9357-48d7-a188-4f3d65db1bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_458bab53-9357-48d7-a188-4f3d65db1bf7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_458bab53-9357-48d7-a188-4f3d65db1bf7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_458bab53-9357-48d7-a188-4f3d65db1bf7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_458bab53-9357-48d7-a188-4f3d65db1bf7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a4c144e0-d912-40f6-b6c0-7a0654be9bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_458bab53-9357-48d7-a188-4f3d65db1bf7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a4c144e0-d912-40f6-b6c0-7a0654be9bb9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_38ddb4bd-fff4-4339-bd93-9bb1646676b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a4c144e0-d912-40f6-b6c0-7a0654be9bb9" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_38ddb4bd-fff4-4339-bd93-9bb1646676b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_65f29895-64a7-4119-989e-4b8b6b64dac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_65f29895-64a7-4119-989e-4b8b6b64dac2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_65f29895-64a7-4119-989e-4b8b6b64dac2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65f29895-64a7-4119-989e-4b8b6b64dac2" xlink:to="loc_us-gaap_EquityComponentDomain_65f29895-64a7-4119-989e-4b8b6b64dac2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f9fff0af-ea45-4bf5-8114-c6798ddbd140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65f29895-64a7-4119-989e-4b8b6b64dac2" xlink:to="loc_us-gaap_EquityComponentDomain_f9fff0af-ea45-4bf5-8114-c6798ddbd140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3aef21f2-5c66-4576-8108-db0dad9b87d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f9fff0af-ea45-4bf5-8114-c6798ddbd140" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3aef21f2-5c66-4576-8108-db0dad9b87d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8c666aeb-f251-41d9-b377-d5ff5747f305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f9fff0af-ea45-4bf5-8114-c6798ddbd140" xlink:to="loc_us-gaap_WarrantMember_8c666aeb-f251-41d9-b377-d5ff5747f305" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6af3e8c3-52f1-4647-a20b-c7b87f213aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6af3e8c3-52f1-4647-a20b-c7b87f213aae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6af3e8c3-52f1-4647-a20b-c7b87f213aae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6af3e8c3-52f1-4647-a20b-c7b87f213aae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6af3e8c3-52f1-4647-a20b-c7b87f213aae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4cfe7003-e19a-490e-9b6a-bc2c99380348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6af3e8c3-52f1-4647-a20b-c7b87f213aae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4cfe7003-e19a-490e-9b6a-bc2c99380348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_a37e1776-4c4f-43ed-86e7-dd94169f8ac8" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4cfe7003-e19a-490e-9b6a-bc2c99380348" xlink:to="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_a37e1776-4c4f-43ed-86e7-dd94169f8ac8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails" xlink:type="extended" id="i8714ce7d830e4678b223420a449d1fe2_SummaryofSignificantAccountingPoliciesFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_a34eaecc-c5dc-45f7-97be-13423c437204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_Cash_a34eaecc-c5dc-45f7-97be-13423c437204" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_d5f61dde-6f4d-412a-85a4-c303c1e1eba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_d5f61dde-6f4d-412a-85a4-c303c1e1eba4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5644f76e-b926-4bdd-ae74-9ad2c107469f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5644f76e-b926-4bdd-ae74-9ad2c107469f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_ab30ffd7-283a-418a-8d14-66c0426edf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_ab30ffd7-283a-418a-8d14-66c0426edf9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_2395844e-c679-4f48-9722-b1ce247d9693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_DerivativeLiabilities_2395844e-c679-4f48-9722-b1ce247d9693" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5b29f900-2f72-471f-a5d7-9286726d50b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5b29f900-2f72-471f-a5d7-9286726d50b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ed29c9-3b58-436a-b3c9-609b11dc36eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5b29f900-2f72-471f-a5d7-9286726d50b9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ed29c9-3b58-436a-b3c9-609b11dc36eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0ed29c9-3b58-436a-b3c9-609b11dc36eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ed29c9-3b58-436a-b3c9-609b11dc36eb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_a0ed29c9-3b58-436a-b3c9-609b11dc36eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_349523b1-3ecb-4033-8f6c-ae8ec41f771f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ed29c9-3b58-436a-b3c9-609b11dc36eb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_349523b1-3ecb-4033-8f6c-ae8ec41f771f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_04293da3-3170-4678-9cc9-f6513fe4dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_349523b1-3ecb-4033-8f6c-ae8ec41f771f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_04293da3-3170-4678-9cc9-f6513fe4dcce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef93e4d3-a220-47ea-a0ee-83cf31a1cf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5b29f900-2f72-471f-a5d7-9286726d50b9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef93e4d3-a220-47ea-a0ee-83cf31a1cf89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef93e4d3-a220-47ea-a0ee-83cf31a1cf89_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef93e4d3-a220-47ea-a0ee-83cf31a1cf89" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ef93e4d3-a220-47ea-a0ee-83cf31a1cf89_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc4f77ed-7437-4c6f-afe5-2e112ce4e27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef93e4d3-a220-47ea-a0ee-83cf31a1cf89" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc4f77ed-7437-4c6f-afe5-2e112ce4e27e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8d386c3a-1d96-4dc8-8925-7a65a982697b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc4f77ed-7437-4c6f-afe5-2e112ce4e27e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8d386c3a-1d96-4dc8-8925-7a65a982697b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a36e689b-82f7-41da-b7f6-2885eaa712b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc4f77ed-7437-4c6f-afe5-2e112ce4e27e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a36e689b-82f7-41da-b7f6-2885eaa712b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3f752050-64fb-43ea-a45c-0577ec272054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc4f77ed-7437-4c6f-afe5-2e112ce4e27e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3f752050-64fb-43ea-a45c-0577ec272054" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails" xlink:type="extended" id="i47d8eabedaa24a96b93dd3cb18a415a2_SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_187166be-0958-4aa0-89be-a6d381e89e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_187166be-0958-4aa0-89be-a6d381e89e30" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_230fc578-679a-4bb2-9210-f27a7db7cb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_230fc578-679a-4bb2-9210-f27a7db7cb98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_df630261-0207-4376-9ccd-4557bda92a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_df630261-0207-4376-9ccd-4557bda92a1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_da27d5c0-64f8-4d3f-b516-bd4584b6f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_da27d5c0-64f8-4d3f-b516-bd4584b6f5e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9fb65009-f7d2-4c30-a1de-cf2957bc5aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9fb65009-f7d2-4c30-a1de-cf2957bc5aa5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4da41967-f9ea-4ee3-b7ee-705f9b3eb004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceca4bdb-bca7-4685-a7a1-24e4107340ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_187166be-0958-4aa0-89be-a6d381e89e30" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceca4bdb-bca7-4685-a7a1-24e4107340ce" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6d292bc5-1de6-438a-bb2d-0893da6c33c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceca4bdb-bca7-4685-a7a1-24e4107340ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6d292bc5-1de6-438a-bb2d-0893da6c33c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_6d292bc5-1de6-438a-bb2d-0893da6c33c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6d292bc5-1de6-438a-bb2d-0893da6c33c4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_6d292bc5-1de6-438a-bb2d-0893da6c33c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f4e5da04-3ce1-4274-9a53-4f03c65d0983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6d292bc5-1de6-438a-bb2d-0893da6c33c4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f4e5da04-3ce1-4274-9a53-4f03c65d0983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_c6f2db58-94dc-4a82-9ae4-a6476917ca04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f4e5da04-3ce1-4274-9a53-4f03c65d0983" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_c6f2db58-94dc-4a82-9ae4-a6476917ca04" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails" xlink:type="extended" id="i022b1a2dd9fd479fafaa00a3b0d08d1b_SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_bb80bace-4b5b-4495-a535-9d4997a1f39e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_WarrantsAndRightsOutstandingWeightedAverageTerm_7c3fae89-13a9-4964-a4e1-ab49a49f7f37" xlink:href="prct-20210930.xsd#prct_WarrantsAndRightsOutstandingWeightedAverageTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_bb80bace-4b5b-4495-a535-9d4997a1f39e" xlink:to="loc_prct_WarrantsAndRightsOutstandingWeightedAverageTerm_7c3fae89-13a9-4964-a4e1-ab49a49f7f37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_63a2968d-d782-4635-8938-f2905c5817b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_bb80bace-4b5b-4495-a535-9d4997a1f39e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_63a2968d-d782-4635-8938-f2905c5817b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cc4dd1cf-758d-4aae-b00a-2adffe569557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_bb80bace-4b5b-4495-a535-9d4997a1f39e" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cc4dd1cf-758d-4aae-b00a-2adffe569557" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_640a207b-1234-4286-b778-11e5480319f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cc4dd1cf-758d-4aae-b00a-2adffe569557" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_640a207b-1234-4286-b778-11e5480319f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_640a207b-1234-4286-b778-11e5480319f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_640a207b-1234-4286-b778-11e5480319f5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_640a207b-1234-4286-b778-11e5480319f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3fd855b6-0847-44c4-8802-c6887add0935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_640a207b-1234-4286-b778-11e5480319f5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3fd855b6-0847-44c4-8802-c6887add0935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_78b29cad-d0e6-4b69-aa77-47573e168fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3fd855b6-0847-44c4-8802-c6887add0935" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_78b29cad-d0e6-4b69-aa77-47573e168fa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_df3c0242-99b8-4cd5-b260-ff96cd18d7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cc4dd1cf-758d-4aae-b00a-2adffe569557" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_df3c0242-99b8-4cd5-b260-ff96cd18d7e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_df3c0242-99b8-4cd5-b260-ff96cd18d7e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_df3c0242-99b8-4cd5-b260-ff96cd18d7e8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_df3c0242-99b8-4cd5-b260-ff96cd18d7e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_285910e4-0b60-436d-b007-cb073136e306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_df3c0242-99b8-4cd5-b260-ff96cd18d7e8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_285910e4-0b60-436d-b007-cb073136e306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_580a1daa-9e55-4f68-af69-a53a6f334182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285910e4-0b60-436d-b007-cb073136e306" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_580a1daa-9e55-4f68-af69-a53a6f334182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e1e1f7f2-2bf2-4430-8c95-bd4be9c7496a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285910e4-0b60-436d-b007-cb073136e306" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e1e1f7f2-2bf2-4430-8c95-bd4be9c7496a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_134274ae-e78f-4445-940d-13974d820923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285910e4-0b60-436d-b007-cb073136e306" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_134274ae-e78f-4445-940d-13974d820923" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails" xlink:type="extended" id="i5e16d4b05ebd420299d2775d141fbf0f_SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_b8025347-8458-4f7a-9fca-f85a9ef7afab" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_b8025347-8458-4f7a-9fca-f85a9ef7afab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_39924f5c-41fb-4d03-a05d-5ea0933f93de" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_39924f5c-41fb-4d03-a05d-5ea0933f93de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_4eaf5ef0-09c4-4993-979b-c3045a672a07" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_4eaf5ef0-09c4-4993-979b-c3045a672a07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_3f9af5b4-867c-453d-92ce-5db9a89ae595" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_3f9af5b4-867c-453d-92ce-5db9a89ae595" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_f0ac4c18-56d5-4f0b-a918-320de529bfde" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_f0ac4c18-56d5-4f0b-a918-320de529bfde" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4558540f-4d29-41be-87b7-e074597dcf97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4558540f-4d29-41be-87b7-e074597dcf97" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMeasurementInput_965bea53-8696-4899-ba20-36689b1b9683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_us-gaap_LongTermDebtMeasurementInput_965bea53-8696-4899-ba20-36689b1b9683" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_93267a32-11db-4768-8b9c-3f4bd42cba00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_93267a32-11db-4768-8b9c-3f4bd42cba00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_c091d078-0787-42e9-9ee7-9d7991c7d280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_c091d078-0787-42e9-9ee7-9d7991c7d280" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_6b23145d-75d1-4848-833a-2ebe4c8f3a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_6b23145d-75d1-4848-833a-2ebe4c8f3a6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_d2993de3-2912-4ac3-8e42-4d62f65a180d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_d2993de3-2912-4ac3-8e42-4d62f65a180d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_ff427898-80ca-4d5c-ae34-c13f49d57542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8d70e0b-577f-47f3-81a0-1b639d00a17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8d70e0b-577f-47f3-81a0-1b639d00a17f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8d70e0b-577f-47f3-81a0-1b639d00a17f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8d70e0b-577f-47f3-81a0-1b639d00a17f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e8d70e0b-577f-47f3-81a0-1b639d00a17f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d89679b0-004d-4187-89d9-ce0b25737d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8d70e0b-577f-47f3-81a0-1b639d00a17f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d89679b0-004d-4187-89d9-ce0b25737d40" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6eb6170a-fda7-4c32-9dd8-84c6c96763df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d89679b0-004d-4187-89d9-ce0b25737d40" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6eb6170a-fda7-4c32-9dd8-84c6c96763df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2fc3081a-eae2-437c-9b56-3b25e1a57778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:to="loc_us-gaap_DebtInstrumentAxis_2fc3081a-eae2-437c-9b56-3b25e1a57778" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_2fc3081a-eae2-437c-9b56-3b25e1a57778_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fc3081a-eae2-437c-9b56-3b25e1a57778" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_2fc3081a-eae2-437c-9b56-3b25e1a57778_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e6da12dc-2715-49c0-9c85-2e9e8e13f89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fc3081a-eae2-437c-9b56-3b25e1a57778" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e6da12dc-2715-49c0-9c85-2e9e8e13f89f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityMember_b02b4f0c-5483-4e1e-b3c9-50fcf2ba0247" xlink:href="prct-20210930.xsd#prct_LoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e6da12dc-2715-49c0-9c85-2e9e8e13f89f" xlink:to="loc_prct_LoanFacilityMember_b02b4f0c-5483-4e1e-b3c9-50fcf2ba0247" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_5cc70425-0871-468e-a0c6-d1186e94e944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:to="loc_us-gaap_ValuationTechniqueAxis_5cc70425-0871-468e-a0c6-d1186e94e944" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_5cc70425-0871-468e-a0c6-d1186e94e944_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_5cc70425-0871-468e-a0c6-d1186e94e944" xlink:to="loc_us-gaap_ValuationTechniqueDomain_5cc70425-0871-468e-a0c6-d1186e94e944_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_d32c03cd-b0b0-4787-975b-872fe7123cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_5cc70425-0871-468e-a0c6-d1186e94e944" xlink:to="loc_us-gaap_ValuationTechniqueDomain_d32c03cd-b0b0-4787-975b-872fe7123cc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_1cdf8182-ec4b-40af-83f4-b5ee4b2315f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_d32c03cd-b0b0-4787-975b-872fe7123cc3" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_1cdf8182-ec4b-40af-83f4-b5ee4b2315f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ee214e-bb5e-4f27-a33c-ab798bbe6218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ee214e-bb5e-4f27-a33c-ab798bbe6218" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3ee214e-bb5e-4f27-a33c-ab798bbe6218_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ee214e-bb5e-4f27-a33c-ab798bbe6218" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f3ee214e-bb5e-4f27-a33c-ab798bbe6218_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_67819bc8-3230-4cae-8a3d-22d469a24ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ee214e-bb5e-4f27-a33c-ab798bbe6218" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_67819bc8-3230-4cae-8a3d-22d469a24ea5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e02ed0f6-8ea7-45ec-ae8e-c7f7cd6aeed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_67819bc8-3230-4cae-8a3d-22d469a24ea5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e02ed0f6-8ea7-45ec-ae8e-c7f7cd6aeed8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails" xlink:type="extended" id="if718e1bdf7ba43e38c860bf3d8ad4550_SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c217d751-3f8c-43d7-80b6-6eb93ed9eec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f340c48c-46ff-4219-be04-61fec1775077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c217d751-3f8c-43d7-80b6-6eb93ed9eec4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f340c48c-46ff-4219-be04-61fec1775077" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a2e44ea9-2e74-402e-a3a8-f6e99af5b411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c217d751-3f8c-43d7-80b6-6eb93ed9eec4" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a2e44ea9-2e74-402e-a3a8-f6e99af5b411" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0ddf98d6-f94b-4a7c-bc73-8545f70446ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2e44ea9-2e74-402e-a3a8-f6e99af5b411" xlink:to="loc_srt_StatementGeographicalAxis_0ddf98d6-f94b-4a7c-bc73-8545f70446ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_0ddf98d6-f94b-4a7c-bc73-8545f70446ad_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0ddf98d6-f94b-4a7c-bc73-8545f70446ad" xlink:to="loc_srt_SegmentGeographicalDomain_0ddf98d6-f94b-4a7c-bc73-8545f70446ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3a2c65bd-899d-43ef-8c22-cbc35507063a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0ddf98d6-f94b-4a7c-bc73-8545f70446ad" xlink:to="loc_srt_SegmentGeographicalDomain_3a2c65bd-899d-43ef-8c22-cbc35507063a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_20720eff-c346-4bb4-a756-6e3d2afee0c1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3a2c65bd-899d-43ef-8c22-cbc35507063a" xlink:to="loc_country_US_20720eff-c346-4bb4-a756-6e3d2afee0c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OutsideTheUnitedStatesMember_c5744af6-208e-400b-9af1-0465fee59eb7" xlink:href="prct-20210930.xsd#prct_OutsideTheUnitedStatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3a2c65bd-899d-43ef-8c22-cbc35507063a" xlink:to="loc_prct_OutsideTheUnitedStatesMember_c5744af6-208e-400b-9af1-0465fee59eb7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_238a1227-33b9-43f0-94d8-32a57fa5c1a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2e44ea9-2e74-402e-a3a8-f6e99af5b411" xlink:to="loc_srt_ProductOrServiceAxis_238a1227-33b9-43f0-94d8-32a57fa5c1a1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_238a1227-33b9-43f0-94d8-32a57fa5c1a1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_238a1227-33b9-43f0-94d8-32a57fa5c1a1" xlink:to="loc_srt_ProductsAndServicesDomain_238a1227-33b9-43f0-94d8-32a57fa5c1a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35feba81-2db7-451b-832f-68e8b2253827" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_238a1227-33b9-43f0-94d8-32a57fa5c1a1" xlink:to="loc_srt_ProductsAndServicesDomain_35feba81-2db7-451b-832f-68e8b2253827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SystemSalesAndRentalsMember_74be693e-3588-493f-aa90-8058798841d2" xlink:href="prct-20210930.xsd#prct_SystemSalesAndRentalsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35feba81-2db7-451b-832f-68e8b2253827" xlink:to="loc_prct_SystemSalesAndRentalsMember_74be693e-3588-493f-aa90-8058798841d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_HandPiecesAndOtherConsumablesMember_1bb485f1-f9ef-49d1-afd6-ab037c036429" xlink:href="prct-20210930.xsd#prct_HandPiecesAndOtherConsumablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35feba81-2db7-451b-832f-68e8b2253827" xlink:to="loc_prct_HandPiecesAndOtherConsumablesMember_1bb485f1-f9ef-49d1-afd6-ab037c036429" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ServiceRevenueMember_821a14c8-667f-4b6a-bce5-616ec1ccfcc3" xlink:href="prct-20210930.xsd#prct_ServiceRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_35feba81-2db7-451b-832f-68e8b2253827" xlink:to="loc_prct_ServiceRevenueMember_821a14c8-667f-4b6a-bce5-616ec1ccfcc3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails" xlink:type="extended" id="id101777494c54bdf93a9fc199bffc889_SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8605ffd6-b0bf-4e01-95fb-effdebbb7844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2a5314a6-bd3f-4efd-911d-eb9ed1a886b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8605ffd6-b0bf-4e01-95fb-effdebbb7844" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2a5314a6-bd3f-4efd-911d-eb9ed1a886b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8605ffd6-b0bf-4e01-95fb-effdebbb7844" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59e4fc78-cd8a-4c85-820a-2dfc02913d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59e4fc78-cd8a-4c85-820a-2dfc02913d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_59e4fc78-cd8a-4c85-820a-2dfc02913d0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59e4fc78-cd8a-4c85-820a-2dfc02913d0a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_59e4fc78-cd8a-4c85-820a-2dfc02913d0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ce42f2d4-6f39-4e21-93b8-e4494d8d16bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59e4fc78-cd8a-4c85-820a-2dfc02913d0a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ce42f2d4-6f39-4e21-93b8-e4494d8d16bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_ff258d94-89d1-48c7-9626-b57783fe0424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ce42f2d4-6f39-4e21-93b8-e4494d8d16bc" xlink:to="loc_us-gaap_SalesRevenueNetMember_ff258d94-89d1-48c7-9626-b57783fe0424" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b95135ff-af4b-44a0-8f36-9387af152dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b95135ff-af4b-44a0-8f36-9387af152dfb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_b95135ff-af4b-44a0-8f36-9387af152dfb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b95135ff-af4b-44a0-8f36-9387af152dfb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_b95135ff-af4b-44a0-8f36-9387af152dfb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_aa3361f6-c38a-49b4-a45c-ad4c07f91cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b95135ff-af4b-44a0-8f36-9387af152dfb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_aa3361f6-c38a-49b4-a45c-ad4c07f91cd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_faf0978a-3915-4daf-9bdf-a960a5e23b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_aa3361f6-c38a-49b4-a45c-ad4c07f91cd1" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_faf0978a-3915-4daf-9bdf-a960a5e23b9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cfc0ad10-afb1-4a0c-b5ec-7d2f6eb66cd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:to="loc_srt_StatementGeographicalAxis_cfc0ad10-afb1-4a0c-b5ec-7d2f6eb66cd3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_cfc0ad10-afb1-4a0c-b5ec-7d2f6eb66cd3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_cfc0ad10-afb1-4a0c-b5ec-7d2f6eb66cd3" xlink:to="loc_srt_SegmentGeographicalDomain_cfc0ad10-afb1-4a0c-b5ec-7d2f6eb66cd3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8d14683f-c372-46dd-b767-d39c63fd5651" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_cfc0ad10-afb1-4a0c-b5ec-7d2f6eb66cd3" xlink:to="loc_srt_SegmentGeographicalDomain_8d14683f-c372-46dd-b767-d39c63fd5651" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_04309eb9-0c33-4dc0-a2a8-1a10df20ec17" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_8d14683f-c372-46dd-b767-d39c63fd5651" xlink:to="loc_country_DE_04309eb9-0c33-4dc0-a2a8-1a10df20ec17" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i97b2aac4ea534a72bc797b8adfa628b6_SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_51abbdcd-c736-4f51-8590-a02518f2d42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0e20d21-cef0-434a-a4ef-7cb926043da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_51abbdcd-c736-4f51-8590-a02518f2d42d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0e20d21-cef0-434a-a4ef-7cb926043da1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47e534a4-4515-4c36-87a7-422a304f686d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_51abbdcd-c736-4f51-8590-a02518f2d42d" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47e534a4-4515-4c36-87a7-422a304f686d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_307c7611-3b85-42a3-85e5-7f5e2fbb622b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47e534a4-4515-4c36-87a7-422a304f686d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_307c7611-3b85-42a3-85e5-7f5e2fbb622b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307c7611-3b85-42a3-85e5-7f5e2fbb622b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_307c7611-3b85-42a3-85e5-7f5e2fbb622b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_307c7611-3b85-42a3-85e5-7f5e2fbb622b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_307c7611-3b85-42a3-85e5-7f5e2fbb622b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_5ad09438-9c2f-4fba-bf10-3b539077c146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_5ad09438-9c2f-4fba-bf10-3b539077c146" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedeemableConvertiblePreferredStockWarrantsMember_79070de0-c1d9-41a8-903d-9ba539199ba5" xlink:href="prct-20210930.xsd#prct_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:to="loc_prct_RedeemableConvertiblePreferredStockWarrantsMember_79070de0-c1d9-41a8-903d-9ba539199ba5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_CommonStockWarrantsMember_e001b8ba-21b0-4e9d-bddf-dfd5f2285fec" xlink:href="prct-20210930.xsd#prct_CommonStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:to="loc_prct_CommonStockWarrantsMember_e001b8ba-21b0-4e9d-bddf-dfd5f2285fec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e8c54320-d91d-4c18-ae09-19ef4e48cb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e8c54320-d91d-4c18-ae09-19ef4e48cb7b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails" xlink:type="extended" id="i8d0ef03d273e4f1299ab05b71dd3df02_SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_e22bf59d-e177-483f-9803-94759b8057eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1f14a660-8f25-4eab-bb24-d623deff1fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_e22bf59d-e177-483f-9803-94759b8057eb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1f14a660-8f25-4eab-bb24-d623deff1fe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_e22bf59d-e177-483f-9803-94759b8057eb" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_17d6248a-5b1d-4d95-a111-54eaa87bf5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_17d6248a-5b1d-4d95-a111-54eaa87bf5e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_17d6248a-5b1d-4d95-a111-54eaa87bf5e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_17d6248a-5b1d-4d95-a111-54eaa87bf5e6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_17d6248a-5b1d-4d95-a111-54eaa87bf5e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a13761b-f121-4b10-806f-977b9baec199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_17d6248a-5b1d-4d95-a111-54eaa87bf5e6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a13761b-f121-4b10-806f-977b9baec199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_42462814-fd70-4e2c-a97e-5caa77d73696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a13761b-f121-4b10-806f-977b9baec199" xlink:to="loc_us-gaap_SalesRevenueNetMember_42462814-fd70-4e2c-a97e-5caa77d73696" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_fa0d2ebd-7c7f-4963-ab53-615066a2fe79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a13761b-f121-4b10-806f-977b9baec199" xlink:to="loc_us-gaap_AccountsReceivableMember_fa0d2ebd-7c7f-4963-ab53-615066a2fe79" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_22f6ee6f-a702-419b-9c4e-77e2dd93eeca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_22f6ee6f-a702-419b-9c4e-77e2dd93eeca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_22f6ee6f-a702-419b-9c4e-77e2dd93eeca_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_22f6ee6f-a702-419b-9c4e-77e2dd93eeca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_22f6ee6f-a702-419b-9c4e-77e2dd93eeca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2553d860-e4f8-4288-96e6-0ab27c6083d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_22f6ee6f-a702-419b-9c4e-77e2dd93eeca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2553d860-e4f8-4288-96e6-0ab27c6083d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_45f0e9f8-62e2-4ff7-81b7-b71bf3d7eb68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2553d860-e4f8-4288-96e6-0ab27c6083d8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_45f0e9f8-62e2-4ff7-81b7-b71bf3d7eb68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b2acb3d2-4ff2-4a63-ba1f-fcc324c3cfe8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:to="loc_srt_MajorCustomersAxis_b2acb3d2-4ff2-4a63-ba1f-fcc324c3cfe8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b2acb3d2-4ff2-4a63-ba1f-fcc324c3cfe8_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_b2acb3d2-4ff2-4a63-ba1f-fcc324c3cfe8" xlink:to="loc_srt_NameOfMajorCustomerDomain_b2acb3d2-4ff2-4a63-ba1f-fcc324c3cfe8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2b4ddca3-4849-4348-a30b-69c90553bc73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_b2acb3d2-4ff2-4a63-ba1f-fcc324c3cfe8" xlink:to="loc_srt_NameOfMajorCustomerDomain_2b4ddca3-4849-4348-a30b-69c90553bc73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_Customer1Member_40ce02e8-0399-477e-bf35-d608fe9b91c1" xlink:href="prct-20210930.xsd#prct_Customer1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b4ddca3-4849-4348-a30b-69c90553bc73" xlink:to="loc_prct_Customer1Member_40ce02e8-0399-477e-bf35-d608fe9b91c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_Customer2Member_3aacf3e9-df29-480d-8482-19c2703dc3cb" xlink:href="prct-20210930.xsd#prct_Customer2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b4ddca3-4849-4348-a30b-69c90553bc73" xlink:to="loc_prct_Customer2Member_3aacf3e9-df29-480d-8482-19c2703dc3cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_Customer3Member_73ddbf32-1dc8-4e10-a15a-d7a325a835ab" xlink:href="prct-20210930.xsd#prct_Customer3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b4ddca3-4849-4348-a30b-69c90553bc73" xlink:to="loc_prct_Customer3Member_73ddbf32-1dc8-4e10-a15a-d7a325a835ab" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails" xlink:type="extended" id="i9292d61b616f45748f05dda23d8c14cf_CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4ef1ecb-6101-4a9c-96b1-d05e4f3686e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d3ff5607-2ece-4601-8da0-f582a2ac1f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4ef1ecb-6101-4a9c-96b1-d05e4f3686e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d3ff5607-2ece-4601-8da0-f582a2ac1f89" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_84db2bd7-1b10-4e67-9e07-7ca5e0d01c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4ef1ecb-6101-4a9c-96b1-d05e4f3686e6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_84db2bd7-1b10-4e67-9e07-7ca5e0d01c23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_82304338-762d-4868-b1e4-eb9793f7fbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4ef1ecb-6101-4a9c-96b1-d05e4f3686e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_82304338-762d-4868-b1e4-eb9793f7fbd6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61c54093-a056-487c-8813-8678c2a69f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4ef1ecb-6101-4a9c-96b1-d05e4f3686e6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61c54093-a056-487c-8813-8678c2a69f92" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0fe7b747-4c14-4778-9f67-5f2e7cf0d38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61c54093-a056-487c-8813-8678c2a69f92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0fe7b747-4c14-4778-9f67-5f2e7cf0d38b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fe7b747-4c14-4778-9f67-5f2e7cf0d38b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0fe7b747-4c14-4778-9f67-5f2e7cf0d38b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0fe7b747-4c14-4778-9f67-5f2e7cf0d38b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0fe7b747-4c14-4778-9f67-5f2e7cf0d38b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LaboratoryAndManufacturingEquipmentMember_20ff8add-602a-48e3-8560-5862434727ee" xlink:href="prct-20210930.xsd#prct_LaboratoryAndManufacturingEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:to="loc_prct_LaboratoryAndManufacturingEquipmentMember_20ff8add-602a-48e3-8560-5862434727ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_a1539a05-c286-44b8-9bd8-1cdafb85c884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:to="loc_us-gaap_EquipmentMember_a1539a05-c286-44b8-9bd8-1cdafb85c884" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4cd63c87-fcbd-4843-997b-f84886b0c99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4cd63c87-fcbd-4843-997b-f84886b0c99f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_EvaluationUnitsMember_0e142bae-d161-475d-82f4-0e26c6a78f62" xlink:href="prct-20210930.xsd#prct_EvaluationUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:to="loc_prct_EvaluationUnitsMember_0e142bae-d161-475d-82f4-0e26c6a78f62" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/LoanFacilityDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#LoanFacilityDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/LoanFacilityDetails" xlink:type="extended" id="ieaf12631d3614f00bb9f9012df2c7b30_LoanFacilityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_583f5be1-2bc4-4a6e-9e35-ccf32da24f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_583f5be1-2bc4-4a6e-9e35-ccf32da24f77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityNumberOfInstallments_6132b060-83cf-43ce-bcdd-b47d5fc65558" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityNumberOfInstallments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityNumberOfInstallments_6132b060-83cf-43ce-bcdd-b47d5fc65558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_46382bc4-d8b6-4216-9b8b-4ec69ec438bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_46382bc4-d8b6-4216-9b8b-4ec69ec438bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_573a9734-28b4-416b-8879-296ded7e36e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_573a9734-28b4-416b-8879-296ded7e36e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget_418e15d3-b06d-4de8-9d8b-8bcec9273521" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget_418e15d3-b06d-4de8-9d8b-8bcec9273521" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_a684a9dc-cb28-454c-96f4-dd23a2d6b710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_a684a9dc-cb28-454c-96f4-dd23a2d6b710" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_13492cb5-e95b-4b27-9a89-13dbd8d3f1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_13492cb5-e95b-4b27-9a89-13dbd8d3f1ff" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0cd450fa-3bfc-4d08-ab90-f5fad277845e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0cd450fa-3bfc-4d08-ab90-f5fad277845e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e66fc5bd-4a67-4bf6-a8a1-a457f85be6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_DebtInstrumentTerm_e66fc5bd-4a67-4bf6-a8a1-a457f85be6b5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentInterestOnlyPeriod_64a22fbe-8352-4616-bf62-22db1bbef2d8" xlink:href="prct-20210930.xsd#prct_DebtInstrumentInterestOnlyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentInterestOnlyPeriod_64a22fbe-8352-4616-bf62-22db1bbef2d8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentPrincipalAndInterestPeriod_a69dd38d-72ce-448d-ad51-28e00e070d96" xlink:href="prct-20210930.xsd#prct_DebtInstrumentPrincipalAndInterestPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentPrincipalAndInterestPeriod_a69dd38d-72ce-448d-ad51-28e00e070d96" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod_52da46e1-488f-49ee-bc45-cae88d1b61bc" xlink:href="prct-20210930.xsd#prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod_52da46e1-488f-49ee-bc45-cae88d1b61bc" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod_b79ca912-bf6a-4629-8c8b-601f7b357137" xlink:href="prct-20210930.xsd#prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod_b79ca912-bf6a-4629-8c8b-601f7b357137" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_364b60fd-8490-4627-a547-97dc8808c5a7" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_364b60fd-8490-4627-a547-97dc8808c5a7" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod_1b73a2a8-6943-41ea-93dd-384f213e59a8" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod_1b73a2a8-6943-41ea-93dd-384f213e59a8" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod_c04928a3-28eb-4cdb-8501-e8a0332ccf48" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod_c04928a3-28eb-4cdb-8501-e8a0332ccf48" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent_2e98682e-a5db-452d-9371-ed9a012993cd" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent_2e98682e-a5db-452d-9371-ed9a012993cd" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly_9ec1d1ed-000f-4eae-9d84-d83429a3b7a2" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly_9ec1d1ed-000f-4eae-9d84-d83429a3b7a2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly_ce059a0c-d5e0-46b6-a997-f67e8542da67" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly_ce059a0c-d5e0-46b6-a997-f67e8542da67" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn_c3a2a0a1-3cf0-40b8-9bef-6f4a879d267b" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn_c3a2a0a1-3cf0-40b8-9bef-6f4a879d267b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityFinalPaymentFeePercentage_b1fa39bf-17db-43f1-8234-699c08d683e5" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityFinalPaymentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityFinalPaymentFeePercentage_b1fa39bf-17db-43f1-8234-699c08d683e5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_daee7512-5961-4dbb-a962-0e59869ae8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_daee7512-5961-4dbb-a962-0e59869ae8fc" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent_ed17418f-2e8c-48a0-b385-e2dc9c00b8e4" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent_ed17418f-2e8c-48a0-b385-e2dc9c00b8e4" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent_85fa6a8a-38fc-41fc-9d7f-ec984dd9859e" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent_85fa6a8a-38fc-41fc-9d7f-ec984dd9859e" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent_d78966c8-dede-41bb-a290-daae7bfd502f" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent_d78966c8-dede-41bb-a290-daae7bfd502f" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_6fa5643e-44ab-40c2-a9d6-ac9b55d637b9" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_6fa5643e-44ab-40c2-a9d6-ac9b55d637b9" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_9337e318-d33f-4846-910c-4aaebe194630" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_9337e318-d33f-4846-910c-4aaebe194630" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_3e0971b7-eb79-46a3-a336-77e7592986b2" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_3e0971b7-eb79-46a3-a336-77e7592986b2" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_f1764a0f-46c3-4191-8f2a-e056e10cdafc" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_f1764a0f-46c3-4191-8f2a-e056e10cdafc" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_e2beb84a-1c18-48f5-935b-1bebc209105e" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_e2beb84a-1c18-48f5-935b-1bebc209105e" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dcdcc189-9c91-4d25-b039-a2c903373bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:to="loc_us-gaap_DebtInstrumentAxis_dcdcc189-9c91-4d25-b039-a2c903373bf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_dcdcc189-9c91-4d25-b039-a2c903373bf6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_dcdcc189-9c91-4d25-b039-a2c903373bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_dcdcc189-9c91-4d25-b039-a2c903373bf6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf272f88-0466-448a-9d50-ece84f8c7159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_dcdcc189-9c91-4d25-b039-a2c903373bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf272f88-0466-448a-9d50-ece84f8c7159" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:href="prct-20210930.xsd#prct_LoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf272f88-0466-448a-9d50-ece84f8c7159" xlink:to="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheOneMember_22e8787d-3c3c-4b69-a33f-8703562d0d15" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:to="loc_prct_LoanFacilityTrancheOneMember_22e8787d-3c3c-4b69-a33f-8703562d0d15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheTwoMember_0730e31d-9c4b-4f2a-8c4c-3c24d225e5a0" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:to="loc_prct_LoanFacilityTrancheTwoMember_0730e31d-9c4b-4f2a-8c4c-3c24d225e5a0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheThreeMember_a6609ff8-52d6-474c-b87b-96e3832e59b9" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:to="loc_prct_LoanFacilityTrancheThreeMember_a6609ff8-52d6-474c-b87b-96e3832e59b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheFourMember_4e59ccfd-2f61-4419-b4b9-6b09a1554ad6" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:to="loc_prct_LoanFacilityTrancheFourMember_4e59ccfd-2f61-4419-b4b9-6b09a1554ad6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e91ad8de-ebdc-4f52-be1d-0a5aa20786ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:to="loc_us-gaap_CreditFacilityAxis_e91ad8de-ebdc-4f52-be1d-0a5aa20786ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e91ad8de-ebdc-4f52-be1d-0a5aa20786ac_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_e91ad8de-ebdc-4f52-be1d-0a5aa20786ac" xlink:to="loc_us-gaap_CreditFacilityDomain_e91ad8de-ebdc-4f52-be1d-0a5aa20786ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e3e0c7f5-c831-454d-b7e9-4ff1abc2ecf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_e91ad8de-ebdc-4f52-be1d-0a5aa20786ac" xlink:to="loc_us-gaap_CreditFacilityDomain_e3e0c7f5-c831-454d-b7e9-4ff1abc2ecf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_19ba185c-e824-48d4-ab6c-5e0e6cab74bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_e3e0c7f5-c831-454d-b7e9-4ff1abc2ecf7" xlink:to="loc_us-gaap_LineOfCreditMember_19ba185c-e824-48d4-ab6c-5e0e6cab74bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_1ffce5b2-8261-429f-99fc-d6755af8946b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:to="loc_us-gaap_VariableRateAxis_1ffce5b2-8261-429f-99fc-d6755af8946b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_1ffce5b2-8261-429f-99fc-d6755af8946b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_1ffce5b2-8261-429f-99fc-d6755af8946b" xlink:to="loc_us-gaap_VariableRateDomain_1ffce5b2-8261-429f-99fc-d6755af8946b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_05b5dd76-c9cc-4466-b3eb-7cb57dd1ccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_1ffce5b2-8261-429f-99fc-d6755af8946b" xlink:to="loc_us-gaap_VariableRateDomain_05b5dd76-c9cc-4466-b3eb-7cb57dd1ccd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_c43fb9c1-599b-474c-bcb9-17b6de9686e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_05b5dd76-c9cc-4466-b3eb-7cb57dd1ccd0" xlink:to="loc_us-gaap_BaseRateMember_c43fb9c1-599b-474c-bcb9-17b6de9686e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_05973c33-f1f7-4b73-a406-c1b8e3e5133d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_05b5dd76-c9cc-4466-b3eb-7cb57dd1ccd0" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_05973c33-f1f7-4b73-a406-c1b8e3e5133d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_814b5778-f0d0-4e23-bafb-0175b6de366a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_814b5778-f0d0-4e23-bafb-0175b6de366a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_814b5778-f0d0-4e23-bafb-0175b6de366a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_814b5778-f0d0-4e23-bafb-0175b6de366a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_814b5778-f0d0-4e23-bafb-0175b6de366a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_87a2c8e8-cbb1-4a96-bd44-ed01605c593c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_814b5778-f0d0-4e23-bafb-0175b6de366a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_87a2c8e8-cbb1-4a96-bd44-ed01605c593c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ebf17717-799e-4ea5-bfac-1deecad3ba53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_87a2c8e8-cbb1-4a96-bd44-ed01605c593c" xlink:to="loc_us-gaap_LineOfCreditMember_ebf17717-799e-4ea5-bfac-1deecad3ba53" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails" xlink:type="extended" id="i2fa841ed8b284fde952e5acc64774376_RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_f0c5f08e-e248-4ace-b87b-6ec913407fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a73ec9da-b05c-4be8-abb0-d69778523f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f0c5f08e-e248-4ace-b87b-6ec913407fd9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a73ec9da-b05c-4be8-abb0-d69778523f25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_23466034-fe25-479c-841d-27f341c87a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f0c5f08e-e248-4ace-b87b-6ec913407fd9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_23466034-fe25-479c-841d-27f341c87a59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_74131d12-584c-4ef9-8aea-33082ec4eb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f0c5f08e-e248-4ace-b87b-6ec913407fd9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_74131d12-584c-4ef9-8aea-33082ec4eb08" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e3d22cf9-3c21-4c55-b438-03a27f1e3af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f0c5f08e-e248-4ace-b87b-6ec913407fd9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e3d22cf9-3c21-4c55-b438-03a27f1e3af7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ec3f993c-7887-42bb-9eba-22a467b02c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e3d22cf9-3c21-4c55-b438-03a27f1e3af7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ec3f993c-7887-42bb-9eba-22a467b02c01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_ec3f993c-7887-42bb-9eba-22a467b02c01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ec3f993c-7887-42bb-9eba-22a467b02c01" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_ec3f993c-7887-42bb-9eba-22a467b02c01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0dad1e54-f855-45e1-b1e7-15e2c371b434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ec3f993c-7887-42bb-9eba-22a467b02c01" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0dad1e54-f855-45e1-b1e7-15e2c371b434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_2e07eef6-fd97-4d50-8acd-7fc4eb9495a6" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0dad1e54-f855-45e1-b1e7-15e2c371b434" xlink:to="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_2e07eef6-fd97-4d50-8acd-7fc4eb9495a6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails" xlink:type="extended" id="ie1d7314ec505468e9e09459cd5cf4965_RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6e18b106-8af3-49f1-8a67-370825e32f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6e18b106-8af3-49f1-8a67-370825e32f32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_579f7174-89bf-424b-8577-9975fde03e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_579f7174-89bf-424b-8577-9975fde03e27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_52e8416a-c933-4a66-912d-c5ab78878f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_52e8416a-c933-4a66-912d-c5ab78878f13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_86dbfcc0-3d33-455f-8ea4-868188e9ad5c" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_86dbfcc0-3d33-455f-8ea4-868188e9ad5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f9d964c5-5ac8-4552-aa30-0b92d5de4994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f9d964c5-5ac8-4552-aa30-0b92d5de4994" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4859b2a1-852d-44f1-ba51-af6db8a68c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4859b2a1-852d-44f1-ba51-af6db8a68c45" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_33604754-4f32-40ee-9e07-fa9f198384d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4859b2a1-852d-44f1-ba51-af6db8a68c45" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_33604754-4f32-40ee-9e07-fa9f198384d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_33604754-4f32-40ee-9e07-fa9f198384d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_33604754-4f32-40ee-9e07-fa9f198384d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_33604754-4f32-40ee-9e07-fa9f198384d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5d4ec8de-c595-49c5-be26-7abdc2054a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_33604754-4f32-40ee-9e07-fa9f198384d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5d4ec8de-c595-49c5-be26-7abdc2054a38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_9d31c8dd-1fbf-4101-93d1-105edf592279" xlink:href="prct-20210930.xsd#prct_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5d4ec8de-c595-49c5-be26-7abdc2054a38" xlink:to="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_9d31c8dd-1fbf-4101-93d1-105edf592279" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_9d656dea-5d8a-486f-b401-571e20fcadef" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5d4ec8de-c595-49c5-be26-7abdc2054a38" xlink:to="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_9d656dea-5d8a-486f-b401-571e20fcadef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99528703-20f1-4f19-aa8a-a8e923fdaf68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4859b2a1-852d-44f1-ba51-af6db8a68c45" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_99528703-20f1-4f19-aa8a-a8e923fdaf68" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_99528703-20f1-4f19-aa8a-a8e923fdaf68_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99528703-20f1-4f19-aa8a-a8e923fdaf68" xlink:to="loc_us-gaap_EquityComponentDomain_99528703-20f1-4f19-aa8a-a8e923fdaf68_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a49b4ef4-123e-4a40-bee3-f2bd068c265f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99528703-20f1-4f19-aa8a-a8e923fdaf68" xlink:to="loc_us-gaap_EquityComponentDomain_a49b4ef4-123e-4a40-bee3-f2bd068c265f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c213dcde-ca7d-4e92-869a-ff947ce30027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a49b4ef4-123e-4a40-bee3-f2bd068c265f" xlink:to="loc_us-gaap_WarrantMember_c213dcde-ca7d-4e92-869a-ff947ce30027" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails" xlink:type="extended" id="ia5ca3db2c9f9487b9f8fd89ea0a844ed_RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_7c9e75b4-587a-43a4-b5ae-412c9d4f127f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_3ae0b703-6210-431d-9830-cca4b03f7537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7c9e75b4-587a-43a4-b5ae-412c9d4f127f" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_3ae0b703-6210-431d-9830-cca4b03f7537" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ae86888c-6920-4fbd-9e6e-8cabfdeb2946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7c9e75b4-587a-43a4-b5ae-412c9d4f127f" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ae86888c-6920-4fbd-9e6e-8cabfdeb2946" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_baec56ee-db94-4a3e-be8c-a9a30ff2e018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7c9e75b4-587a-43a4-b5ae-412c9d4f127f" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_baec56ee-db94-4a3e-be8c-a9a30ff2e018" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_4276ac14-df2d-490d-8a46-a4ac1e6e77f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7c9e75b4-587a-43a4-b5ae-412c9d4f127f" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_4276ac14-df2d-490d-8a46-a4ac1e6e77f5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5853aeca-c23a-4a96-9974-6f58eed74628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_4276ac14-df2d-490d-8a46-a4ac1e6e77f5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5853aeca-c23a-4a96-9974-6f58eed74628" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_5853aeca-c23a-4a96-9974-6f58eed74628_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5853aeca-c23a-4a96-9974-6f58eed74628" xlink:to="loc_us-gaap_ClassOfStockDomain_5853aeca-c23a-4a96-9974-6f58eed74628_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5853aeca-c23a-4a96-9974-6f58eed74628" xlink:to="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesARedeemableConvertiblePreferredStockMember_d650c6b2-42f1-4e0b-8482-aca68ff8c368" xlink:href="prct-20210930.xsd#prct_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesARedeemableConvertiblePreferredStockMember_d650c6b2-42f1-4e0b-8482-aca68ff8c368" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesBRedeemableConvertiblePreferredStockMember_0c2716b2-a11e-4f75-98f9-74b8b963c6a5" xlink:href="prct-20210930.xsd#prct_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesBRedeemableConvertiblePreferredStockMember_0c2716b2-a11e-4f75-98f9-74b8b963c6a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesCRedeemableConvertiblePreferredStockMember_3c7bf7b3-dc8c-4c63-9508-b136a07324b3" xlink:href="prct-20210930.xsd#prct_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesCRedeemableConvertiblePreferredStockMember_3c7bf7b3-dc8c-4c63-9508-b136a07324b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_9d657946-6ac7-4c5f-9e0e-da7ac32abf3a" xlink:href="prct-20210930.xsd#prct_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_9d657946-6ac7-4c5f-9e0e-da7ac32abf3a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_ba0365c1-7e13-41f9-a84a-44328885f2f3" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_ba0365c1-7e13-41f9-a84a-44328885f2f3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_b976cc17-48d4-46e4-84dd-1b428ec63a1c" xlink:href="prct-20210930.xsd#prct_SeriesFRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_b976cc17-48d4-46e4-84dd-1b428ec63a1c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_6c3f3f08-b3d5-4f3d-b4d6-87060fea1b2f" xlink:href="prct-20210930.xsd#prct_SeriesGRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_6c3f3f08-b3d5-4f3d-b4d6-87060fea1b2f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="extended" id="i633334038f694097a18d28ef878a8e5f_RedeemableConvertiblePreferredStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4368a2c3-7c0d-4d31-965c-d131e26e6069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4368a2c3-7c0d-4d31-965c-d131e26e6069" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_e3cce0ae-d4ee-45d7-b118-690677872e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_e3cce0ae-d4ee-45d7-b118-690677872e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_e98caf60-c1bc-427c-8a72-8b3cc651fad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_e98caf60-c1bc-427c-8a72-8b3cc651fad9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_0b85795c-5bbe-42de-b24f-96546d3f27da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_0b85795c-5bbe-42de-b24f-96546d3f27da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_8d9ef3fb-e997-4330-932a-433edb4d7a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_8d9ef3fb-e997-4330-932a-433edb4d7a3c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityDividends_a7602434-0fb8-451a-8785-088af0294a64" xlink:href="prct-20210930.xsd#prct_TemporaryEquityDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_prct_TemporaryEquityDividends_a7602434-0fb8-451a-8785-088af0294a64" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_597aa4e0-0754-4689-93c9-8748b490bac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_597aa4e0-0754-4689-93c9-8748b490bac9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted_23b09567-d105-44cd-9211-ab13fe7b888b" xlink:href="prct-20210930.xsd#prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted_23b09567-d105-44cd-9211-ab13fe7b888b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_73a39122-18c0-43d1-b5f9-9985b4abb3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_73a39122-18c0-43d1-b5f9-9985b4abb3b9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4cd5a963-75f9-42ac-9d15-90f965db0c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_73a39122-18c0-43d1-b5f9-9985b4abb3b9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4cd5a963-75f9-42ac-9d15-90f965db0c50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4cd5a963-75f9-42ac-9d15-90f965db0c50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4cd5a963-75f9-42ac-9d15-90f965db0c50" xlink:to="loc_us-gaap_ClassOfStockDomain_4cd5a963-75f9-42ac-9d15-90f965db0c50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4cd5a963-75f9-42ac-9d15-90f965db0c50" xlink:to="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_286fb7c3-4ac4-4828-b971-6b5e3f93882a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:to="loc_us-gaap_CommonStockMember_286fb7c3-4ac4-4828-b971-6b5e3f93882a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_5f83828f-ffc9-4146-8f0c-14b01cc00838" xlink:href="prct-20210930.xsd#prct_SeriesGRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:to="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_5f83828f-ffc9-4146-8f0c-14b01cc00838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_e87e9882-1026-4baa-8bd7-ed476f198a9f" xlink:href="prct-20210930.xsd#prct_SeriesFRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:to="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_e87e9882-1026-4baa-8bd7-ed476f198a9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedeemableConvertiblePreferredStockWarrantsMember_5b0a4419-01cf-4aa4-81aa-1ae49516cb6e" xlink:href="prct-20210930.xsd#prct_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:to="loc_prct_RedeemableConvertiblePreferredStockWarrantsMember_5b0a4419-01cf-4aa4-81aa-1ae49516cb6e" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails" xlink:type="extended" id="i04a1d1a04b9949fa80fd2dda9f81c99b_RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_149a95a1-11ac-4261-979e-add615761fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_b8c3f952-7192-4034-b804-15166c787262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_149a95a1-11ac-4261-979e-add615761fb0" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_b8c3f952-7192-4034-b804-15166c787262" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityDividends_b5849c51-4547-452e-95dd-fe0572b0c565" xlink:href="prct-20210930.xsd#prct_TemporaryEquityDividends"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_149a95a1-11ac-4261-979e-add615761fb0" xlink:to="loc_prct_TemporaryEquityDividends_b5849c51-4547-452e-95dd-fe0572b0c565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_dbe3e2a6-d868-410b-a654-d4a68c6e934d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_149a95a1-11ac-4261-979e-add615761fb0" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_dbe3e2a6-d868-410b-a654-d4a68c6e934d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0fb73845-8b2c-48b5-acb3-86aa3b2da78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_dbe3e2a6-d868-410b-a654-d4a68c6e934d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0fb73845-8b2c-48b5-acb3-86aa3b2da78a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0fb73845-8b2c-48b5-acb3-86aa3b2da78a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0fb73845-8b2c-48b5-acb3-86aa3b2da78a" xlink:to="loc_us-gaap_ClassOfStockDomain_0fb73845-8b2c-48b5-acb3-86aa3b2da78a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0fb73845-8b2c-48b5-acb3-86aa3b2da78a" xlink:to="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesARedeemableConvertiblePreferredStockMember_480d95b5-6083-4370-9a83-71863b4dfadb" xlink:href="prct-20210930.xsd#prct_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesARedeemableConvertiblePreferredStockMember_480d95b5-6083-4370-9a83-71863b4dfadb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesBRedeemableConvertiblePreferredStockMember_4f1ef967-0d50-4978-80c1-b1070f36894f" xlink:href="prct-20210930.xsd#prct_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesBRedeemableConvertiblePreferredStockMember_4f1ef967-0d50-4978-80c1-b1070f36894f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesCRedeemableConvertiblePreferredStockMember_4f1b98fd-b781-402f-9834-e7ccb3f47361" xlink:href="prct-20210930.xsd#prct_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesCRedeemableConvertiblePreferredStockMember_4f1b98fd-b781-402f-9834-e7ccb3f47361" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_b44de328-4310-4b8b-9df5-f4a3368c9abb" xlink:href="prct-20210930.xsd#prct_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_b44de328-4310-4b8b-9df5-f4a3368c9abb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_84cc81a4-26dd-4b83-a55a-434e76528ab7" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_84cc81a4-26dd-4b83-a55a-434e76528ab7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_d933519e-5217-415a-90b9-5a522099a40a" xlink:href="prct-20210930.xsd#prct_SeriesFRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_d933519e-5217-415a-90b9-5a522099a40a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_20d7f53e-814e-46e1-a5bf-03d3f5568f4d" xlink:href="prct-20210930.xsd#prct_SeriesGRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_20d7f53e-814e-46e1-a5bf-03d3f5568f4d" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended" id="ic18accaf6abe415684d4324a1518bdc9_StockholdersEquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_03c8ccfe-dabe-46f9-ac27-aaa64cb11fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_03c8ccfe-dabe-46f9-ac27-aaa64cb11fea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ceb5f462-1045-4886-9a52-d962bbc02b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ceb5f462-1045-4886-9a52-d962bbc02b2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7df7e25b-3194-4c8c-9bb1-5b6b8245a145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7df7e25b-3194-4c8c-9bb1-5b6b8245a145" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3f38a69c-f61c-4879-820c-3aa717c9257b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3f38a69c-f61c-4879-820c-3aa717c9257b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d12dd28f-d8ff-4479-9c5c-1fa64caff3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d12dd28f-d8ff-4479-9c5c-1fa64caff3f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_29f91e0a-62cf-4f1b-9a49-db2753c41c0d" xlink:href="prct-20210930.xsd#prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_29f91e0a-62cf-4f1b-9a49-db2753c41c0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b4ce51f1-68c9-4e55-bbad-7d70907a4f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b4ce51f1-68c9-4e55-bbad-7d70907a4f0a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_640bdffa-21c2-4aac-9c1a-52faf7bcf138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_640bdffa-21c2-4aac-9c1a-52faf7bcf138" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2f8b9641-6ee6-43ce-adf7-11b256a89eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2f8b9641-6ee6-43ce-adf7-11b256a89eaf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_83d27181-834b-4dde-a8cc-acbae325e029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_83d27181-834b-4dde-a8cc-acbae325e029" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_89679d91-ea3c-4c7b-a1b8-bdc4448e523b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_89679d91-ea3c-4c7b-a1b8-bdc4448e523b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_91fa3d89-5d2b-44f8-9b64-7c0b2f18442d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_91fa3d89-5d2b-44f8-9b64-7c0b2f18442d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c5b27821-b971-433a-be19-73e651d1991b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c5b27821-b971-433a-be19-73e651d1991b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c21fba8f-5ae7-4d00-b89e-73e3955cfcca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c21fba8f-5ae7-4d00-b89e-73e3955cfcca" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2d05528c-3cc1-46d1-8f4b-14b4a5100b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2d05528c-3cc1-46d1-8f4b-14b4a5100b94" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_cfa2d155-ae38-42c7-b554-acc129f095fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_cfa2d155-ae38-42c7-b554-acc129f095fe" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_c74644be-ae29-44fe-9cb0-e2b27e6148a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_c74644be-ae29-44fe-9cb0-e2b27e6148a3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_885aa8f4-78e3-4691-bde2-1a2e0668594c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_us-gaap_PlanNameAxis_885aa8f4-78e3-4691-bde2-1a2e0668594c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_885aa8f4-78e3-4691-bde2-1a2e0668594c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_885aa8f4-78e3-4691-bde2-1a2e0668594c" xlink:to="loc_us-gaap_PlanNameDomain_885aa8f4-78e3-4691-bde2-1a2e0668594c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8330e63a-97dc-41e0-8a55-a7716aa3ae60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_885aa8f4-78e3-4691-bde2-1a2e0668594c" xlink:to="loc_us-gaap_PlanNameDomain_8330e63a-97dc-41e0-8a55-a7716aa3ae60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_A2021EquityIncentiveAwardPlanMember_3ef3fcbc-79d4-4125-bc4c-c448b28feed5" xlink:href="prct-20210930.xsd#prct_A2021EquityIncentiveAwardPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8330e63a-97dc-41e0-8a55-a7716aa3ae60" xlink:to="loc_prct_A2021EquityIncentiveAwardPlanMember_3ef3fcbc-79d4-4125-bc4c-c448b28feed5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_A2008StockPlanMember_8af54e52-a549-48b0-8d16-cfc2a628bc7e" xlink:href="prct-20210930.xsd#prct_A2008StockPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8330e63a-97dc-41e0-8a55-a7716aa3ae60" xlink:to="loc_prct_A2008StockPlanMember_8af54e52-a549-48b0-8d16-cfc2a628bc7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_A2021EmployeeStockPurchasePlanMember_a72fb0f4-aa69-4efb-9f9d-9461e3e29cb9" xlink:href="prct-20210930.xsd#prct_A2021EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_8330e63a-97dc-41e0-8a55-a7716aa3ae60" xlink:to="loc_prct_A2021EmployeeStockPurchasePlanMember_a72fb0f4-aa69-4efb-9f9d-9461e3e29cb9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1a4003e7-57a8-480b-94b4-0e2dc5e370c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_us-gaap_AwardTypeAxis_1a4003e7-57a8-480b-94b4-0e2dc5e370c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a4003e7-57a8-480b-94b4-0e2dc5e370c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1a4003e7-57a8-480b-94b4-0e2dc5e370c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1a4003e7-57a8-480b-94b4-0e2dc5e370c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f046f56f-94d9-4cda-a431-bccb070bd253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1a4003e7-57a8-480b-94b4-0e2dc5e370c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f046f56f-94d9-4cda-a431-bccb070bd253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_09ce872c-83f9-417b-8091-c708e0efc699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f046f56f-94d9-4cda-a431-bccb070bd253" xlink:to="loc_us-gaap_EmployeeStockMember_09ce872c-83f9-417b-8091-c708e0efc699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_77a202a6-12be-4f4f-9944-064f7f73d2d4" xlink:href="prct-20210930.xsd#prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockMember_09ce872c-83f9-417b-8091-c708e0efc699" xlink:to="loc_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_77a202a6-12be-4f4f-9944-064f7f73d2d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_44e663cd-94a9-45f8-bd4a-af606258751f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f046f56f-94d9-4cda-a431-bccb070bd253" xlink:to="loc_us-gaap_EmployeeStockOptionMember_44e663cd-94a9-45f8-bd4a-af606258751f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3b65010e-8975-4cdf-a102-849ba3eab715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f046f56f-94d9-4cda-a431-bccb070bd253" xlink:to="loc_us-gaap_WarrantMember_3b65010e-8975-4cdf-a102-849ba3eab715" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90f19e6b-81a0-4f8b-ba1c-4cb1d47080bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_srt_RangeAxis_90f19e6b-81a0-4f8b-ba1c-4cb1d47080bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_90f19e6b-81a0-4f8b-ba1c-4cb1d47080bb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_90f19e6b-81a0-4f8b-ba1c-4cb1d47080bb" xlink:to="loc_srt_RangeMember_90f19e6b-81a0-4f8b-ba1c-4cb1d47080bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa1a3de6-7353-439d-9ccc-45144926338b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_90f19e6b-81a0-4f8b-ba1c-4cb1d47080bb" xlink:to="loc_srt_RangeMember_fa1a3de6-7353-439d-9ccc-45144926338b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4b467fc-0688-460e-b239-33a2806a83a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa1a3de6-7353-439d-9ccc-45144926338b" xlink:to="loc_srt_MinimumMember_b4b467fc-0688-460e-b239-33a2806a83a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_812a07f1-7624-4d54-a0e8-0a0a470802d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_fa1a3de6-7353-439d-9ccc-45144926338b" xlink:to="loc_srt_MaximumMember_812a07f1-7624-4d54-a0e8-0a0a470802d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ba3e15b8-ec8c-4d41-850f-98d07e9f6806" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_srt_OwnershipAxis_ba3e15b8-ec8c-4d41-850f-98d07e9f6806" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_ba3e15b8-ec8c-4d41-850f-98d07e9f6806_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_ba3e15b8-ec8c-4d41-850f-98d07e9f6806" xlink:to="loc_srt_OwnershipDomain_ba3e15b8-ec8c-4d41-850f-98d07e9f6806_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d599da0c-3b6e-40f5-9575-f98dd1db0c56" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_ba3e15b8-ec8c-4d41-850f-98d07e9f6806" xlink:to="loc_srt_OwnershipDomain_d599da0c-3b6e-40f5-9575-f98dd1db0c56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ShareholderOfTenPercentOwnershipOrGreaterMember_bc7c6da1-a178-4f90-a0d8-8bbbf98b9018" xlink:href="prct-20210930.xsd#prct_ShareholderOfTenPercentOwnershipOrGreaterMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_d599da0c-3b6e-40f5-9575-f98dd1db0c56" xlink:to="loc_prct_ShareholderOfTenPercentOwnershipOrGreaterMember_bc7c6da1-a178-4f90-a0d8-8bbbf98b9018" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8d5365ae-ce34-41ba-bd04-f499309d49f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_srt_StatementScenarioAxis_8d5365ae-ce34-41ba-bd04-f499309d49f3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8d5365ae-ce34-41ba-bd04-f499309d49f3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_8d5365ae-ce34-41ba-bd04-f499309d49f3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8d5365ae-ce34-41ba-bd04-f499309d49f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0da8ee70-638a-4977-8591-f2052ca0bb35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_8d5365ae-ce34-41ba-bd04-f499309d49f3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0da8ee70-638a-4977-8591-f2052ca0bb35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6f385e0d-f2b2-4352-8437-654955bfd433" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0da8ee70-638a-4977-8591-f2052ca0bb35" xlink:to="loc_srt_ScenarioForecastMember_6f385e0d-f2b2-4352-8437-654955bfd433" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6854518d-5275-432a-98d2-7ea9dd47e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6854518d-5275-432a-98d2-7ea9dd47e6c3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6854518d-5275-432a-98d2-7ea9dd47e6c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6854518d-5275-432a-98d2-7ea9dd47e6c3" xlink:to="loc_us-gaap_EquityComponentDomain_6854518d-5275-432a-98d2-7ea9dd47e6c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5d170730-83aa-4f6f-87ee-db0dc4283215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6854518d-5275-432a-98d2-7ea9dd47e6c3" xlink:to="loc_us-gaap_EquityComponentDomain_5d170730-83aa-4f6f-87ee-db0dc4283215" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_95f53b0d-f194-461e-a7b7-d851b836abcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5d170730-83aa-4f6f-87ee-db0dc4283215" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_95f53b0d-f194-461e-a7b7-d851b836abcb" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#StockholdersEquityScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="extended" id="if2bee19437d446eca5602a3c3535ee6a_StockholdersEquityScheduleofStockOptionActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_388c3a2a-c8d6-40f7-9fbe-a7b05a46c260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_388c3a2a-c8d6-40f7-9fbe-a7b05a46c260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5fa5683-5f48-414f-b6ba-73fbb44df0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5fa5683-5f48-414f-b6ba-73fbb44df0b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5da03b54-cd00-4efc-a727-491b7f000d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5da03b54-cd00-4efc-a727-491b7f000d46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b62704b9-2049-4c52-ab20-0df9afd35cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b62704b9-2049-4c52-ab20-0df9afd35cf0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3c95025b-a085-483d-bded-e3d7589a81fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3c95025b-a085-483d-bded-e3d7589a81fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4bb974d8-b2ae-4b20-a80f-060c09c5db93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_97a86b7c-7681-46dd-af9f-c7c7c87f1378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_97a86b7c-7681-46dd-af9f-c7c7c87f1378" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d7273cb1-8fb5-4eba-a7cf-209d1fe1bb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d7273cb1-8fb5-4eba-a7cf-209d1fe1bb72" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_388c3a2a-c8d6-40f7-9fbe-a7b05a46c260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_58bb9a4c-86e3-4288-828e-0f4d5d1e1a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_58bb9a4c-86e3-4288-828e-0f4d5d1e1a4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9f3c9bb8-1d14-4bc6-8688-94ba35231d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9f3c9bb8-1d14-4bc6-8688-94ba35231d65" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f3172182-9fd5-4e37-9fe4-9d355007d3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f3172182-9fd5-4e37-9fe4-9d355007d3c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7449d7c6-307e-4fd6-9ddf-c1229751bde4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7449d7c6-307e-4fd6-9ddf-c1229751bde4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e39a5d58-334f-4583-a427-0e8015dfc353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_889c0c7c-c12b-4062-af3f-3fb13d29c245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_889c0c7c-c12b-4062-af3f-3fb13d29c245" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_45274a15-a6ea-4b11-bf06-aede0af1c5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_45274a15-a6ea-4b11-bf06-aede0af1c5a3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3389332a-3ccf-480d-ba16-f2ac353930fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_388c3a2a-c8d6-40f7-9fbe-a7b05a46c260" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3389332a-3ccf-480d-ba16-f2ac353930fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da9cdb74-e714-4e53-bedc-aad87491a1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3389332a-3ccf-480d-ba16-f2ac353930fb" xlink:to="loc_us-gaap_AwardTypeAxis_da9cdb74-e714-4e53-bedc-aad87491a1df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da9cdb74-e714-4e53-bedc-aad87491a1df_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_da9cdb74-e714-4e53-bedc-aad87491a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_da9cdb74-e714-4e53-bedc-aad87491a1df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70ffa05d-9d07-4adc-b4ac-0865d249c99e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_da9cdb74-e714-4e53-bedc-aad87491a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70ffa05d-9d07-4adc-b4ac-0865d249c99e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3920f456-6385-464c-a829-7194b6dca65d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70ffa05d-9d07-4adc-b4ac-0865d249c99e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3920f456-6385-464c-a829-7194b6dca65d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended" id="i5407312760ee43f8bab50c12e7099260_StockholdersEquityScheduleofShareBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_593aea4d-aec5-4c5c-bc1d-b620900978c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_430a175e-c1fb-4322-b9c5-d6d0712ad830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_593aea4d-aec5-4c5c-bc1d-b620900978c8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_430a175e-c1fb-4322-b9c5-d6d0712ad830" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23cc07cc-4ed9-4126-8b4b-39e6f7361cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_593aea4d-aec5-4c5c-bc1d-b620900978c8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23cc07cc-4ed9-4126-8b4b-39e6f7361cad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f2fe8f63-ec5a-410a-9e24-9f0d246d7701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23cc07cc-4ed9-4126-8b4b-39e6f7361cad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f2fe8f63-ec5a-410a-9e24-9f0d246d7701" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f2fe8f63-ec5a-410a-9e24-9f0d246d7701_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2fe8f63-ec5a-410a-9e24-9f0d246d7701" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f2fe8f63-ec5a-410a-9e24-9f0d246d7701_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7b96da40-a986-4186-a10e-56f77210c1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2fe8f63-ec5a-410a-9e24-9f0d246d7701" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7b96da40-a986-4186-a10e-56f77210c1fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_455e9838-5a45-445a-a973-b1ca5217857b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7b96da40-a986-4186-a10e-56f77210c1fc" xlink:to="loc_us-gaap_CostOfSalesMember_455e9838-5a45-445a-a973-b1ca5217857b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5ce295b9-f40a-479f-9122-b92facc7a00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7b96da40-a986-4186-a10e-56f77210c1fc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5ce295b9-f40a-479f-9122-b92facc7a00f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_921ff843-2702-4056-b5dc-fd7bbb3dd9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7b96da40-a986-4186-a10e-56f77210c1fc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_921ff843-2702-4056-b5dc-fd7bbb3dd9d0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#StockholdersEquityFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails" xlink:type="extended" id="i3950ea9e383a4c62902823ac53daca59_StockholdersEquityFairValueAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2f24e4a3-8cff-4a9b-9748-c247d2c6daaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2f24e4a3-8cff-4a9b-9748-c247d2c6daaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_90e871b3-b20d-4ac4-9f3f-368727dbe480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_90e871b3-b20d-4ac4-9f3f-368727dbe480" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59ae8b90-6720-49c0-af23-293def28592f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59ae8b90-6720-49c0-af23-293def28592f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5030ac17-6114-4d68-a3ec-5aa80f8090f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5030ac17-6114-4d68-a3ec-5aa80f8090f3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_01d5f6b6-5a93-420a-8457-5beb734dbe52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_01d5f6b6-5a93-420a-8457-5beb734dbe52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e3587e9-b6ff-460e-b88f-dcf87138626d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e3587e9-b6ff-460e-b88f-dcf87138626d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_41110e01-db96-49c6-9209-4a5a2a76573d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e3587e9-b6ff-460e-b88f-dcf87138626d" xlink:to="loc_us-gaap_AwardTypeAxis_41110e01-db96-49c6-9209-4a5a2a76573d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41110e01-db96-49c6-9209-4a5a2a76573d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_41110e01-db96-49c6-9209-4a5a2a76573d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_41110e01-db96-49c6-9209-4a5a2a76573d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2a6865f-080d-4396-9eec-e09924c027b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_41110e01-db96-49c6-9209-4a5a2a76573d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2a6865f-080d-4396-9eec-e09924c027b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1866190a-de20-4bc0-9195-94d0e5fd8c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2a6865f-080d-4396-9eec-e09924c027b1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1866190a-de20-4bc0-9195-94d0e5fd8c8e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended" id="i3f1374ff7a0c4afebe4336082e6f3b21_CommitmentsandContingenciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a5633c6c-6961-43eb-aef3-18178ff41151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a5633c6c-6961-43eb-aef3-18178ff41151" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c65c20a8-dd00-441a-8946-67a2e778dede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c65c20a8-dd00-441a-8946-67a2e778dede" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dbc3ffbe-2fac-4135-a2f4-51e21ce5c7af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dbc3ffbe-2fac-4135-a2f4-51e21ce5c7af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f4ea1bd6-69fd-48d0-a0b5-f42fcd806e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_OperatingLeaseLiability_f4ea1bd6-69fd-48d0-a0b5-f42fcd806e5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_abf60913-0bca-4409-be85-8f00652faa46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_ContractWithCustomerLiability_abf60913-0bca-4409-be85-8f00652faa46" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ef842d26-8b63-45fe-83bd-afd5175f3429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ef842d26-8b63-45fe-83bd-afd5175f3429" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1bac7f41-7965-421c-aa14-cf57502382f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1bac7f41-7965-421c-aa14-cf57502382f8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_0fd4a676-bb96-45f5-ae4b-5169e10013a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_OperatingLeaseExpense_0fd4a676-bb96-45f5-ae4b-5169e10013a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_2efb7fa4-f3b0-4fc1-a2a2-aac6fdc3ee06" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_2efb7fa4-f3b0-4fc1-a2a2-aac6fdc3ee06" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentInterestOnlyPeriod_ac14b93b-4275-4a98-9623-7f280fa90abc" xlink:href="prct-20210930.xsd#prct_DebtInstrumentInterestOnlyPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_prct_DebtInstrumentInterestOnlyPeriod_ac14b93b-4275-4a98-9623-7f280fa90abc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_80c9788d-8006-4a60-a1af-0cdcdb56d512" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_80c9788d-8006-4a60-a1af-0cdcdb56d512" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fbb0e17b-ce62-48e0-8af5-193f2294ba1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_us-gaap_CreditFacilityAxis_fbb0e17b-ce62-48e0-8af5-193f2294ba1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fbb0e17b-ce62-48e0-8af5-193f2294ba1a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_fbb0e17b-ce62-48e0-8af5-193f2294ba1a" xlink:to="loc_us-gaap_CreditFacilityDomain_fbb0e17b-ce62-48e0-8af5-193f2294ba1a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5c9a9856-f98e-4dc2-b9fd-39f2026420cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_fbb0e17b-ce62-48e0-8af5-193f2294ba1a" xlink:to="loc_us-gaap_CreditFacilityDomain_5c9a9856-f98e-4dc2-b9fd-39f2026420cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_8bd2ab26-c626-4822-bb6f-bd7b188d021c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_5c9a9856-f98e-4dc2-b9fd-39f2026420cf" xlink:to="loc_us-gaap_LineOfCreditMember_8bd2ab26-c626-4822-bb6f-bd7b188d021c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_962282b5-832c-4221-addd-a486f1078e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_us-gaap_DebtInstrumentAxis_962282b5-832c-4221-addd-a486f1078e88" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_962282b5-832c-4221-addd-a486f1078e88_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_962282b5-832c-4221-addd-a486f1078e88" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_962282b5-832c-4221-addd-a486f1078e88_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_11a36025-3b7b-48a1-8eff-1638c339cb24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_962282b5-832c-4221-addd-a486f1078e88" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_11a36025-3b7b-48a1-8eff-1638c339cb24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityMember_f26157dc-01d0-4064-8ad6-5dd5e3490a98" xlink:href="prct-20210930.xsd#prct_LoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_11a36025-3b7b-48a1-8eff-1638c339cb24" xlink:to="loc_prct_LoanFacilityMember_f26157dc-01d0-4064-8ad6-5dd5e3490a98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f25f602b-c2e3-47f0-81ad-513e0e68b9c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_srt_StatementGeographicalAxis_f25f602b-c2e3-47f0-81ad-513e0e68b9c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_f25f602b-c2e3-47f0-81ad-513e0e68b9c1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_f25f602b-c2e3-47f0-81ad-513e0e68b9c1" xlink:to="loc_srt_SegmentGeographicalDomain_f25f602b-c2e3-47f0-81ad-513e0e68b9c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_42305c66-ff56-4573-802e-2411bb533426" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_f25f602b-c2e3-47f0-81ad-513e0e68b9c1" xlink:to="loc_srt_SegmentGeographicalDomain_42305c66-ff56-4573-802e-2411bb533426" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedwoodCityCAMember_86732078-e658-474d-84f4-f0e2c339fff9" xlink:href="prct-20210930.xsd#prct_RedwoodCityCAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_42305c66-ff56-4573-802e-2411bb533426" xlink:to="loc_prct_RedwoodCityCAMember_86732078-e658-474d-84f4-f0e2c339fff9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_37cf4e66-43ba-4e94-8ea1-e7a79e1b06d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_37cf4e66-43ba-4e94-8ea1-e7a79e1b06d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_37cf4e66-43ba-4e94-8ea1-e7a79e1b06d3_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_37cf4e66-43ba-4e94-8ea1-e7a79e1b06d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_37cf4e66-43ba-4e94-8ea1-e7a79e1b06d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_91b59455-dbe0-4fc3-a9ee-767a7fefaa55" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_37cf4e66-43ba-4e94-8ea1-e7a79e1b06d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_91b59455-dbe0-4fc3-a9ee-767a7fefaa55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_ccbc7fa8-14dd-4fcc-9c30-c2fd89f8bb7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_91b59455-dbe0-4fc3-a9ee-767a7fefaa55" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_ccbc7fa8-14dd-4fcc-9c30-c2fd89f8bb7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_af5271eb-1cf8-4442-a6d9-b96ba285ef8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_af5271eb-1cf8-4442-a6d9-b96ba285ef8f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_af5271eb-1cf8-4442-a6d9-b96ba285ef8f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_af5271eb-1cf8-4442-a6d9-b96ba285ef8f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_af5271eb-1cf8-4442-a6d9-b96ba285ef8f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_e294cad7-72cb-438a-95bd-b84c4076b11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_af5271eb-1cf8-4442-a6d9-b96ba285ef8f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_e294cad7-72cb-438a-95bd-b84c4076b11e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_45a89ca1-28ce-4916-a68a-599c888b82c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_e294cad7-72cb-438a-95bd-b84c4076b11e" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_45a89ca1-28ce-4916-a68a-599c888b82c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>prct-20210930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:05140f27-a3ec-43bc-a461-9ef7bd6589c5,g:c5500a2c-3da2-4c15-b44b-608117d5a861-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_d65b18bd-a884-4a55-801a-a61bea4aa38f_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of redeemable convertible preferred stock warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LoanFacilityMember_f7606fb9-f90a-4a8a-9ee9-c9f3f14f22c1_terseLabel_en-US" xlink:label="lab_prct_LoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility</link:label>
    <link:label id="lab_prct_LoanFacilityMember_label_en-US" xlink:label="lab_prct_LoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility [Member]</link:label>
    <link:label id="lab_prct_LoanFacilityMember_documentation_en-US" xlink:label="lab_prct_LoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityMember" xlink:href="prct-20210930.xsd#prct_LoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LoanFacilityMember" xlink:to="lab_prct_LoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_71a0e1b1-3a50-4e69-8fdd-1c8164f3e4d6_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_88ff7719-ae50-4fa0-bb2e-c9cabfa7ecd5_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_56600ce1-edd3-4b1a-a4a1-84edd5653f62_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_d1d5a8cb-9381-47ea-aaa9-051b26a54c01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_2679eccb-ff8a-44f5-a4af-6c64e9cebc45_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent_c45e91cd-189c-4ac4-aef2-ec43f141b166_negatedTerseLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent_label_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt, Current</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent_documentation_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent" xlink:to="lab_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_c95ba8af-598e-429c-a4d0-63f64f8ea661_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5b606d6d-3815-494f-bccf-c86e662b6f3d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_55725f42-dc4d-4afc-8b6f-f1bee2e0e97e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_76e71063-4004-4316-a7cc-fdcb872f4ec7_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_146446ff-7257-4925-84e8-2f6519d5720e_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_906d1bf9-9051-497c-899c-6297f7e6f93e_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_25dde0f4-cae3-477a-827d-278212ef091e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_ShareholderOfTenPercentOwnershipOrGreaterMember_c6c19a53-48ba-4fc4-a1e0-9e05dc8155c2_terseLabel_en-US" xlink:label="lab_prct_ShareholderOfTenPercentOwnershipOrGreaterMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder of Ten Percent Ownership or Greater</link:label>
    <link:label id="lab_prct_ShareholderOfTenPercentOwnershipOrGreaterMember_label_en-US" xlink:label="lab_prct_ShareholderOfTenPercentOwnershipOrGreaterMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder of Ten Percent Ownership or Greater [Member]</link:label>
    <link:label id="lab_prct_ShareholderOfTenPercentOwnershipOrGreaterMember_documentation_en-US" xlink:label="lab_prct_ShareholderOfTenPercentOwnershipOrGreaterMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholder of Ten Percent Ownership or Greater</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ShareholderOfTenPercentOwnershipOrGreaterMember" xlink:href="prct-20210930.xsd#prct_ShareholderOfTenPercentOwnershipOrGreaterMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_ShareholderOfTenPercentOwnershipOrGreaterMember" xlink:to="lab_prct_ShareholderOfTenPercentOwnershipOrGreaterMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_89f965e4-e77b-4800-8d4e-48e618131320_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear_fd92c18f-dba2-4f7a-a78a-1bd65b87081b_terseLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear_label_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Remainder of Fiscal year</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear_documentation_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Remainder of Fiscal year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear" xlink:to="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_5e9e8134-5819-4e47-9e92-063f8cee3185_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts" xlink:to="lab_us-gaap_DeferredOfferingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7992367c-e0f7-495c-a6f8-d79620bf23fb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_fec29306-e66b-44bd-9fa2-fb7735b29ee5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_a391b966-4986-4e0d-81e3-b41618ba16cb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_00c520fc-fa66-4f4b-97aa-c60d8d124f10_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_955e7048-ff51-44d2-8efb-9045bf99486c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_ProductWarrantyTerm_6ec9b262-6ef8-46a5-b342-9230505d5e49_terseLabel_en-US" xlink:label="lab_prct_ProductWarrantyTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product warranty period (in years)</link:label>
    <link:label id="lab_prct_ProductWarrantyTerm_label_en-US" xlink:label="lab_prct_ProductWarrantyTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Term</link:label>
    <link:label id="lab_prct_ProductWarrantyTerm_documentation_en-US" xlink:label="lab_prct_ProductWarrantyTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Warranty Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ProductWarrantyTerm" xlink:href="prct-20210930.xsd#prct_ProductWarrantyTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_ProductWarrantyTerm" xlink:to="lab_prct_ProductWarrantyTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_132e0dc6-c80d-42d4-9e22-20612e4be859_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan facility derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6dc26c1c-4375-4677-9a05-335a6021c203_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment, Geographical and Customer Concentration</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_7d3bfdc9-2346-4082-81e8-8b97a0c3b343_terseLabel_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales tax</link:label>
    <link:label id="lab_us-gaap_SalesAndExciseTaxPayableCurrent_label_en-US" xlink:label="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales and Excise Tax Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:to="lab_us-gaap_SalesAndExciseTaxPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_InitialPublicOfferingAbstract_65c23032-5550-4c34-a359-80850334a5e4_terseLabel_en-US" xlink:label="lab_prct_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:label id="lab_prct_InitialPublicOfferingAbstract_label_en-US" xlink:label="lab_prct_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering [Abstract]</link:label>
    <link:label id="lab_prct_InitialPublicOfferingAbstract_documentation_en-US" xlink:label="lab_prct_InitialPublicOfferingAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_InitialPublicOfferingAbstract" xlink:href="prct-20210930.xsd#prct_InitialPublicOfferingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_InitialPublicOfferingAbstract" xlink:to="lab_prct_InitialPublicOfferingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c25f4ac7-9573-4a60-a630-f83666bc60ce_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_fe7db5f0-1a99-4330-9bd9-6d72b4c5f5da_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_0c3484e7-9c2c-4490-b2cc-aa501afc5e90_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining operating lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_401c5a47-033a-427f-bb37-442c53ed79cc_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_7ed9904f-126b-4ad3-8e02-5fdcfce74b12_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_1aef69ab-097b-48bb-94cc-7553ae99bded_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end f the period (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_d802c9eb-c8b7-41f9-8310-6bdf268b36d1_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued and Outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff9f1c19-0ba6-40e9-aabd-daf340c3bd95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_CommonStockValuationPolicyPolicyTextBlock_69cd6159-0eee-4051-a017-d4b9f0381c6f_terseLabel_en-US" xlink:label="lab_prct_CommonStockValuationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Valuation</link:label>
    <link:label id="lab_prct_CommonStockValuationPolicyPolicyTextBlock_label_en-US" xlink:label="lab_prct_CommonStockValuationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Valuation Policy [Policy Text Block]</link:label>
    <link:label id="lab_prct_CommonStockValuationPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_prct_CommonStockValuationPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Valuation Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_CommonStockValuationPolicyPolicyTextBlock" xlink:href="prct-20210930.xsd#prct_CommonStockValuationPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_CommonStockValuationPolicyPolicyTextBlock" xlink:to="lab_prct_CommonStockValuationPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_08cbd6b2-b1bd-4b99-99f7-d1c6edc8d280_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility Derivative Liability</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_a4b4bd4a-8a24-4fd4-bc62-11bf18353c93_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedSalaries_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_1ba9fc4d-685b-442c-87d2-ea0dbea74ae0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_f0c65dad-60ba-43f2-ab4b-89d747693297_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_41096acf-939d-4bc7-8450-1b3c8abedfd1_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ca2e14eb-1c78-427e-ac99-e1e59568da4e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_ab5cad63-dd65-4981-be88-9f075a79ec95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Interest and Other Income (Expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_3c0250a9-0870-4795-a2e7-ba41c5ce29bc_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_8080dd41-9348-4ddf-8be3-029880c71b14_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_7a21d271-c0d5-40a5-b44c-18ec33fa8661_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised in the period, intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_532c0221-d66c-4b39-8c8c-e8ced3225914_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_701130e8-eec2-4910-82ad-631c04ffea63_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of success fee</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_ce919f95-3c18-4b61-95a4-245b414af204_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_13fc8a5c-bb5a-4a1d-8742-a9fc142ef7d0_terseLabel_en-US" xlink:label="lab_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_label_en-US" xlink:label="lab_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Policy [Policy Text Block]</link:label>
    <link:label id="lab_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:href="prct-20210930.xsd#prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:to="lab_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6fa86eac-a0b3-46d7-91ea-cc7a9fd0eb22_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_607f6886-0e25-4367-9191-98c72f764ce0_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_13deef9b-a6e0-4031-8a0a-2e5908e3e1bd_terseLabel_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Repayments</link:label>
    <link:label id="lab_us-gaap_MaturitiesOfLongTermDebtAbstract_label_en-US" xlink:label="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of Long-term Debt [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:to="lab_us-gaap_MaturitiesOfLongTermDebtAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_4d908f34-7d5e-43b9-860e-e0e699103c91_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b52c0f35-154c-4d24-a536-8bbc88a9f790_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2b6a04c8-8db4-4711-9d33-11f612b0ec31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6c9760e6-66ca-497c-980d-dbb5ead92e19_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LoanFacilityTrancheTwoMember_48edffbe-7504-4791-9187-2b8515d78031_terseLabel_en-US" xlink:label="lab_prct_LoanFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche Two</link:label>
    <link:label id="lab_prct_LoanFacilityTrancheTwoMember_label_en-US" xlink:label="lab_prct_LoanFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche Two [Member]</link:label>
    <link:label id="lab_prct_LoanFacilityTrancheTwoMember_documentation_en-US" xlink:label="lab_prct_LoanFacilityTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheTwoMember" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LoanFacilityTrancheTwoMember" xlink:to="lab_prct_LoanFacilityTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_73724b68-e20d-425e-a21a-c680fa974c15_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_1f3a0c11-cab3-4763-a615-c660c6c3e0c2_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_c309dc22-c193-401d-a489-5dc66ca73465_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidRent_0018fdff-d597-4ff1-9bef-8fb93881fa94_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent</link:label>
    <link:label id="lab_us-gaap_PrepaidRent_label_en-US" xlink:label="lab_us-gaap_PrepaidRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidRent" xlink:to="lab_us-gaap_PrepaidRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_73b70a1a-e716-494d-864a-578c97e37542_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse stock split, conversion ratio</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="lab_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_9cc19455-ab50-43ef-8693-2234b7f49001_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_642481dd-69f7-4f31-8cf0-92cb66912d4f_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_0ce7e4c8-634c-483c-9bb0-3d2e7fe99f58_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued interest expense</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInterestPayableNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Interest Payable, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:to="lab_us-gaap_IncreaseDecreaseInInterestPayableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_53d57a08-af6f-4960-853b-53808ee72e61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_ab468b9d-4fcf-4a4e-9b39-d8de080fbf0b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_85ec6af8-e4f3-43b5-b379-1abf763e71f7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_f95184cf-9224-48b7-91de-20f4b00e5f71_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_918b90e2-d14e-47dc-ab4e-7b8e01901d97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_fbf94dd4-0808-452b-950c-1389012c8469_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_PrepaidSoftware_6a7aa7ce-2371-4452-a640-f75b9cb5d84f_terseLabel_en-US" xlink:label="lab_prct_PrepaidSoftware" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Software</link:label>
    <link:label id="lab_prct_PrepaidSoftware_label_en-US" xlink:label="lab_prct_PrepaidSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Software</link:label>
    <link:label id="lab_prct_PrepaidSoftware_documentation_en-US" xlink:label="lab_prct_PrepaidSoftware" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_PrepaidSoftware" xlink:href="prct-20210930.xsd#prct_PrepaidSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_PrepaidSoftware" xlink:to="lab_prct_PrepaidSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_2d981847-ff62-4a8d-813e-03288c2fcdf4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue by significant geographical locations outside the United States</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_99d09be6-6e32-40d7-9ec4-e4551e037311_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b548069b-5a93-44d9-896d-95a9d71a90cc_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000 and none shares authorized, no shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_287830cb-f828-457d-b21d-c425d5b4aaa7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment and Intangible Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_942be123-d94a-4e6b-8853-7f13a109657f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_edb1a67b-4e39-4a07-84cc-90a3fb229a01_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_bcb16920-24be-4d1f-bc30-f688ede737b9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_254ff118-3859-4de5-9aee-00b883b6d996_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree_66d8b5ab-6d17-4a35-8b36-9a7d38379fa8_terseLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree_label_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Year Three</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree_documentation_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree" xlink:to="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ab273481-6d5e-4aa0-9f72-cc0f628bc33e_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IPOMember_87b36e73-82b7-4350-8eec-264aa3c104c0_terseLabel_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO</link:label>
    <link:label id="lab_us-gaap_IPOMember_label_en-US" xlink:label="lab_us-gaap_IPOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IPO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IPOMember" xlink:to="lab_us-gaap_IPOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_A2021EmployeeStockPurchasePlanMember_6a2e6b90-d27e-410b-a69a-3368695a02b4_terseLabel_en-US" xlink:label="lab_prct_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:label id="lab_prct_A2021EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_prct_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_prct_A2021EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_prct_A2021EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_A2021EmployeeStockPurchasePlanMember" xlink:href="prct-20210930.xsd#prct_A2021EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_A2021EmployeeStockPurchasePlanMember" xlink:to="lab_prct_A2021EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_cdaf0a77-64bc-456b-93fc-f52e085a9afc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_93e215c8-93f3-4dd4-9062-c930610755e1_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_TransferFromInventoryToPropertyAndEquipmentNet_16136e9f-a47f-4369-a0cc-250b4969175f_terseLabel_en-US" xlink:label="lab_prct_TransferFromInventoryToPropertyAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer of evaluation units from inventory to property and equipment, net</link:label>
    <link:label id="lab_prct_TransferFromInventoryToPropertyAndEquipmentNet_label_en-US" xlink:label="lab_prct_TransferFromInventoryToPropertyAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer From Inventory to Property and Equipment, Net</link:label>
    <link:label id="lab_prct_TransferFromInventoryToPropertyAndEquipmentNet_documentation_en-US" xlink:label="lab_prct_TransferFromInventoryToPropertyAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Transfer From Inventory to Property and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TransferFromInventoryToPropertyAndEquipmentNet" xlink:href="prct-20210930.xsd#prct_TransferFromInventoryToPropertyAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_TransferFromInventoryToPropertyAndEquipmentNet" xlink:to="lab_prct_TransferFromInventoryToPropertyAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_a0d3ab1d-3bf7-49f5-9c1b-4719a4bc11ec_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod_817b8342-3832-4a25-bbc4-3aee870a9971_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant compliance, IPO capital raised in threshold amount achieved, extended interest only period (in months)</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod_label_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount Achieved, Extended Interest Only Period</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod_documentation_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount Achieved, Extended Interest Only Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod" xlink:to="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_39d83c69-dbd4-4c69-ae21-f38e3533dcf8_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_70fc7325-1df2-4049-a434-59cef386809a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_AccruedClinicalTrialExpenses_d3e22fe3-a9a7-43ac-9678-3ed0689d8c40_terseLabel_en-US" xlink:label="lab_prct_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trial expenses</link:label>
    <link:label id="lab_prct_AccruedClinicalTrialExpenses_label_en-US" xlink:label="lab_prct_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_prct_AccruedClinicalTrialExpenses_documentation_en-US" xlink:label="lab_prct_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_AccruedClinicalTrialExpenses" xlink:href="prct-20210930.xsd#prct_AccruedClinicalTrialExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_AccruedClinicalTrialExpenses" xlink:to="lab_prct_AccruedClinicalTrialExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_EvaluationUnitsMember_60d80f95-b41a-43ac-813b-090cf9df2ea0_terseLabel_en-US" xlink:label="lab_prct_EvaluationUnitsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evaluation units</link:label>
    <link:label id="lab_prct_EvaluationUnitsMember_label_en-US" xlink:label="lab_prct_EvaluationUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evaluation Units [Member]</link:label>
    <link:label id="lab_prct_EvaluationUnitsMember_documentation_en-US" xlink:label="lab_prct_EvaluationUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evaluation Units</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_EvaluationUnitsMember" xlink:href="prct-20210930.xsd#prct_EvaluationUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_EvaluationUnitsMember" xlink:to="lab_prct_EvaluationUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_234962a6-ab46-43db-aed6-ed2e1cab7640_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_7b853b22-9184-4c5a-9923-c205ac696041_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_149b4964-46b6-41f7-aa0d-f73c0db3bbc0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_af8889dd-eda1-4288-bc6a-452e4665e606_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_b288700f-ed23-4713-87fb-900af9e7a0b4_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_country_DE_8d1829c6-f2ef-4e69-acf9-498a033d1f41_terseLabel_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Germany</link:label>
    <link:label id="lab_country_DE_label_en-US" xlink:label="lab_country_DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GERMANY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_DE" xlink:to="lab_country_DE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_61c998ce-a166-4ded-a702-9408cf3b58de_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_0bda87bd-9174-4430-ba45-27fb404f2a87_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4cf25cd3-5e36-4bc2-9dbc-bef0947fc42b_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_b24031b3-26eb-4e68-b160-7a55feb01f45_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_4b629619-26b5-4238-8082-8ebc93586be2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_536732a3-1d56-4b79-a91c-abb7b7a20359_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_1512f700-dc2e-4f6e-99eb-b11194c3d52a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent_55f70038-41ae-469f-ae7e-76fe3c3e9a70_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant compliance, revenue forecast for commensurate period, percent</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent_label_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Revenue Forecast for Commensurate Period, Percent</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent_documentation_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Revenue Forecast for Commensurate Period, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent" xlink:to="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f4c458b3-afec-48c8-b869-83862a7ef292_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_f40a069d-c7bc-4acd-884d-d64d0fade6e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3cf0d4e0-6a41-4501-a610-4c1b71ca323c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_67c3d95b-623a-4e5b-a2b6-590dedeeda72_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_24d25df2-144b-46c9-9479-e52796dee380_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly_5b5994d6-3995-4b0a-81a6-471066b15dc8_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant compliance, revenue forecast amount, first two installments only</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly_label_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Revenue Forecast Amount, First Two Installments Only</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly_documentation_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Revenue Forecast Amount, First Two Installments Only</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly" xlink:to="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_a20afa22-c76f-4d2c-926d-c5a9b2187404_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_5fd8f063-ee57-4a28-91f1-95d7ec6d1c60_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_A2021EquityIncentiveAwardPlanMember_b78248f6-297d-4d6c-b3a4-a41f402a5599_terseLabel_en-US" xlink:label="lab_prct_A2021EquityIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Equity Incentive Award Plan</link:label>
    <link:label id="lab_prct_A2021EquityIncentiveAwardPlanMember_label_en-US" xlink:label="lab_prct_A2021EquityIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Equity Incentive Award Plan [Member]</link:label>
    <link:label id="lab_prct_A2021EquityIncentiveAwardPlanMember_documentation_en-US" xlink:label="lab_prct_A2021EquityIncentiveAwardPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Equity Incentive Award Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_A2021EquityIncentiveAwardPlanMember" xlink:href="prct-20210930.xsd#prct_A2021EquityIncentiveAwardPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_A2021EquityIncentiveAwardPlanMember" xlink:to="lab_prct_A2021EquityIncentiveAwardPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_d6ac2565-2298-405f-95c9-630c90c4a10f_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_HandPiecesAndOtherConsumablesMember_53fc1d80-051d-46f6-8a34-081d5dde51e8_terseLabel_en-US" xlink:label="lab_prct_HandPiecesAndOtherConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Handpieces and other consumables</link:label>
    <link:label id="lab_prct_HandPiecesAndOtherConsumablesMember_label_en-US" xlink:label="lab_prct_HandPiecesAndOtherConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hand Pieces and Other Consumables [Member]</link:label>
    <link:label id="lab_prct_HandPiecesAndOtherConsumablesMember_documentation_en-US" xlink:label="lab_prct_HandPiecesAndOtherConsumablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hand Pieces and Other Consumables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_HandPiecesAndOtherConsumablesMember" xlink:href="prct-20210930.xsd#prct_HandPiecesAndOtherConsumablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_HandPiecesAndOtherConsumablesMember" xlink:to="lab_prct_HandPiecesAndOtherConsumablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense_77ef4ba7-18b5-45b9-8520-dc2c77cda01c_terseLabel_en-US" xlink:label="lab_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected annual amortization expense</link:label>
    <link:label id="lab_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense_label_en-US" xlink:label="lab_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Annual Amortization Expense</link:label>
    <link:label id="lab_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense_documentation_en-US" xlink:label="lab_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Annual Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense" xlink:href="prct-20210930.xsd#prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense" xlink:to="lab_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_8a5bc90e-4b73-4422-89c3-3bffc96aea5d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_a0935cad-edc4-4dce-ad53-82ad866f4e9a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_b74a7d2f-8061-4f61-bfc1-ab5bb9dcaf50_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_edc9f7b6-b88c-49c2-8792-0328b23b746a_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee if all four installments are drawn</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Four Installments Drawn</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Four Installments Drawn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn" xlink:to="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_2bcd0de0-d36c-417a-a2b9-ff9060c9556b_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_8f7102a2-99a4-4e83-bfd2-e12c301bcf93_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options vested in the period, fair value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_50f7a83d-4667-4c17-b828-70c3d438f721_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_7605470a-874a-4180-b598-2d108eec08d9_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future payments</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget_9a8a3b07-4c94-4127-b052-7a9fe4c60586_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing six months revenue target</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Compliance, Contingent Trailing Six Twelve Month Revenue Target</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Compliance, Contingent Trailing Six Twelve Month Revenue Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" xlink:to="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_0696bf47-1206-4903-b234-ac2b961c193a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_febdf474-d6ce-44f7-abc5-dfb32d11afb1_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_58470b7a-a46e-43db-8749-bbf9c0fc46f5_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_e060967a-3e34-4583-b57a-b4944864743a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_b6f508a2-f197-450c-898f-5ac185cf7eba_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c86a6d09-790f-434d-b25a-0e13be828957_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted_8277b1d9-edf4-4d86-a7bd-acc2b3a2278f_terseLabel_en-US" xlink:label="lab_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock voting rights, number of votes (per share)</link:label>
    <link:label id="lab_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted_label_en-US" xlink:label="lab_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Voting Rights, Number Of Votes Per Share Of Common Stock If Converted</link:label>
    <link:label id="lab_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted_documentation_en-US" xlink:label="lab_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Voting Rights, Number Of Votes Per Share Of Common Stock If Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted" xlink:href="prct-20210930.xsd#prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted" xlink:to="lab_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b9708c62-16c0-4611-ab21-ed6e360ad3c6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_SeriesCRedeemableConvertiblePreferredStockMember_54cca578-a9b3-4c62-822c-abb169aec473_terseLabel_en-US" xlink:label="lab_prct_SeriesCRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C</link:label>
    <link:label id="lab_prct_SeriesCRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_prct_SeriesCRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_prct_SeriesCRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_prct_SeriesCRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesCRedeemableConvertiblePreferredStockMember" xlink:href="prct-20210930.xsd#prct_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_SeriesCRedeemableConvertiblePreferredStockMember" xlink:to="lab_prct_SeriesCRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_619fd09d-ebd7-4d43-89a2-fc7ef0b34b92_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_SeriesGRedeemableConvertiblePreferredStockMember_a97f81ac-a9b1-47a6-808a-4c717d88e17e_terseLabel_en-US" xlink:label="lab_prct_SeriesGRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series G</link:label>
    <link:label id="lab_prct_SeriesGRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_prct_SeriesGRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series G Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_prct_SeriesGRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_prct_SeriesGRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series G Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember" xlink:href="prct-20210930.xsd#prct_SeriesGRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember" xlink:to="lab_prct_SeriesGRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_66f4497c-64ec-4fad-93a3-cd3d5262eaad_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_b76579d1-4b16-47e4-80fb-e761b207b136_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_2661350c-6bfe-4e2a-b339-441fe64f3402_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9dcf91fa-a5e7-48f9-ab34-cac96816ada7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_5187a9fb-cef1-4228-b3f7-3563704ef4e9_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1a36c442-0c67-4de8-a657-e5b1b447df23_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_702e0da0-4679-45c5-aed6-d108e07af656_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance Initial Public Offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="lab_us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_b44a7cc4-a0fc-4472-8325-268a386e1682_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_1e2d765d-7374-42d6-a831-49ff302015a2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMeasurementInput_1e2f1fdc-35d7-4bef-9ff6-2f3d042d7dee_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow discount</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMeasurementInput_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMeasurementInput" xlink:to="lab_us-gaap_LongTermDebtMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_8492fcef-4e65-486f-9726-6683b78c4e47_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_b470e0bd-abe5-405b-9de1-e5b73f758a16_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_0e1d8255-f7d9-4681-b780-684558db155f_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Composition of Certain Consolidated Financial Statement Items</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c454e274-b593-4ed9-a37a-ffafce846bc1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance upon exercise of options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_0ce2df7c-f607-40f4-a019-8b68410990ce_terseLabel_en-US" xlink:label="lab_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E, Redeemable Convertible Preferred Stock Warrants</link:label>
    <link:label id="lab_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_9d52a863-a358-45b2-88d3-314bb9b38b5f_verboseLabel_en-US" xlink:label="lab_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E</link:label>
    <link:label id="lab_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_label_en-US" xlink:label="lab_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Redeemable Convertible Preferred Stock Warrants [Member]</link:label>
    <link:label id="lab_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_documentation_en-US" xlink:label="lab_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Redeemable Convertible Preferred Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember" xlink:to="lab_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_3b83350a-3785-4d9b-8537-80ae96ab90b2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax_e55fc557-8839-4e8d-909e-68de9290e7da_terseLabel_en-US" xlink:label="lab_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of redeemable convertible preferred stock warrants and derivative liability</link:label>
    <link:label id="lab_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants and Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:label id="lab_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax_documentation_en-US" xlink:label="lab_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants and Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax" xlink:href="prct-20210930.xsd#prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_6d22ad40-39ba-48a9-af02-0ee5c829050d_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f7100055-ff39-4dd0-a742-4191a28d9e0b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_afccc650-ea87-4137-9b29-d19317e189d6_terseLabel_en-US" xlink:label="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_label_en-US" xlink:label="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Warrant Exercises</link:label>
    <link:label id="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_documentation_en-US" xlink:label="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xlink:to="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_55073ae8-549d-41b5-838b-d1432c734fa2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_c5cd5267-1837-47e8-8ef5-d9ab09d7d024_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1554aa1b-a5b0-4dcb-9695-7a511bed7d4a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_863c9bbd-c028-492d-aafd-83fd904b47e7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LoanFacilityTrancheThreeMember_fbc7925a-d5fc-4495-a9e3-ba6435f560d3_terseLabel_en-US" xlink:label="lab_prct_LoanFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche Three</link:label>
    <link:label id="lab_prct_LoanFacilityTrancheThreeMember_label_en-US" xlink:label="lab_prct_LoanFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche Three [Member]</link:label>
    <link:label id="lab_prct_LoanFacilityTrancheThreeMember_documentation_en-US" xlink:label="lab_prct_LoanFacilityTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheThreeMember" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LoanFacilityTrancheThreeMember" xlink:to="lab_prct_LoanFacilityTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_d324f88f-e818-463b-a142-130fe7b5da7f_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAxis_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e56b019a-9cac-4feb-9d69-3fae338badb8_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a11028fa-dc08-4230-a183-b422004a4a08_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_521c0ac3-6ec6-438e-a6c3-fcb7aacd5cd8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock Option Activity and Related Information</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_f4eac04d-a6ff-40a7-bd06-859e18cba834_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_55b2cf42-63ba-495b-8634-c3f628a94d49_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon initial public offering, net of underwriting discounts, commissions and offering expenses of $16,076</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_0b934e58-062a-4522-883c-829fb64e8ecb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_c04cf831-22ad-429d-929d-962d87e42166_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_62da7c36-e894-444c-9134-6782a9f00af5_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_12eb255e-3331-4682-870c-f25e80a5f84d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_7a01ddd6-ae93-4e50-87d0-c169d14d19d8_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_87f981bf-c371-4dd2-a304-afbaaa221d1c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_b32ac44c-4ffd-4222-8372-19a8c27e4cbc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount_b1297373-1127-4246-8fe1-b50be7c23fcf_negatedTerseLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amount representing interest/unamortized debt discount</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount_label_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Unamortized Debt Discount</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount_documentation_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Unamortized Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount" xlink:to="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_95e0b3ad-590f-4e32-92a9-d7585b5cd0d3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_39bd5367-3ca1-43b9-a585-7db645cd7a48_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c27871bd-9cf2-45f0-9916-6d389f969e8c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon Initial public offering, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_981875ac-5cc9-417e-9e55-c81c4d05ec56_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Professional services</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e5d3278a-7037-46a2-90cd-92594e782fa9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_6ebf7438-7d50-457c-8283-ef72af89c7f5_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_3a250629-077f-4c41-91af-cc73faed80a8_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_c141be1f-5b5b-4165-a01f-7acd7da5f865_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_1231a12f-c645-40ea-8fec-0337f7f69227_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value: 300,000 and 40,000 shares authorized, 43472 and 4,713 shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_317631ee-bd63-43b5-8505-008ab8e35b2f_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ac2d3cf7-cd4f-484c-a982-46176d6ff74c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average vesting period for unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentInterestOnlyPeriod_70fb07af-96cf-4193-a04c-eba7781974ab_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest only period</link:label>
    <link:label id="lab_prct_DebtInstrumentInterestOnlyPeriod_label_en-US" xlink:label="lab_prct_DebtInstrumentInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Interest Only Period</link:label>
    <link:label id="lab_prct_DebtInstrumentInterestOnlyPeriod_documentation_en-US" xlink:label="lab_prct_DebtInstrumentInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Interest Only Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentInterestOnlyPeriod" xlink:href="prct-20210930.xsd#prct_DebtInstrumentInterestOnlyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentInterestOnlyPeriod" xlink:to="lab_prct_DebtInstrumentInterestOnlyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_63b69052-35ed-4f2c-8d8c-153cf219111e_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_898759c4-c833-48f5-94ab-4ca4310167bb_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_c1103ea9-ab0d-483d-95af-8cb7b9a6e2f2_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee if first three installments drawn</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Three Installments Drawn</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Three Installments Drawn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn" xlink:to="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_847499aa-9566-4cbd-92af-3e9e6425014a_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (see Note 9)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_d3b57aa7-d008-44ed-bc45-693a079c881a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1f12dcde-4091-481a-84c4-1dc4856c4983_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_96f4ce28-a6a8-485b-9507-2c166ac489d6_terseLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_label_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity [Abstract]</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_documentation_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract" xlink:to="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_0dd6bc2e-24c5-4005-94ed-1166d18a6d2d_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of note payable, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:to="lab_us-gaap_ProceedsFromDebtNetOfIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebt_2e1997dc-0ce8-4f3c-bf14-1fa29c7aa0b4_totalLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Present value of future payments</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebt_label_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebt_documentation_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebt" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebt" xlink:to="lab_prct_OperatingLeaseLiabilityAndLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_7f9245d8-32b6-49dd-bac2-7d0cfdcb8ab8_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of the period</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_78cf193e-74bc-4ee4-82dc-638f57e61a80_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of the period</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_45c020cb-21a0-49ad-8649-655adf71b398_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_ea1f9a44-84c8-4f91-b40c-9d4473946fe8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_4fe0288f-5c77-4d06-bea3-39c35b886283_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent_95156a89-b05f-47dd-aa18-1563a1ef6806_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early repayment fee, twenty four months thereafter, percent</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Early Repayment Fee, Twenty Four Months Thru Maturity, Percent</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Early Repayment Fee, Twenty Four Months Thru Maturity, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent" xlink:to="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipAxis_4be70ef9-e434-46c9-a1ff-86c7a72e94a3_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_label_en-US" xlink:label="lab_srt_OwnershipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis" xlink:to="lab_srt_OwnershipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_01400464-4fb2-41e1-9484-b1656dd1f277_terseLabel_en-US" xlink:label="lab_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options and Nonqualified Stock Options</link:label>
    <link:label id="lab_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_label_en-US" xlink:label="lab_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options and Nonqualified Stock Options [Member]</link:label>
    <link:label id="lab_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_documentation_en-US" xlink:label="lab_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incentive Stock Options and Nonqualified Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:href="prct-20210930.xsd#prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:to="lab_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_77b88fca-e34c-4ba2-83fb-661e097f08d7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_4015d007-3535-4652-b097-93c9d8e3e37e_terseLabel_en-US" xlink:label="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)</link:label>
    <link:label id="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:label id="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_documentation_en-US" xlink:label="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_a42d27be-6fa0-445f-aca2-aa6dcbf52ac3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityNumberOfInstallments_773e85e3-0694-4acd-ad1d-f9b7251e958d_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of installments</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityNumberOfInstallments_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Installments</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityNumberOfInstallments_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityNumberOfInstallments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Number of Installments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityNumberOfInstallments" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityNumberOfInstallments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityNumberOfInstallments" xlink:to="lab_prct_LineOfCreditFacilityNumberOfInstallments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_9da326b3-4787-449c-a307-b6fe2ecbe08a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_de4d85c6-1b97-487b-8b1f-087c81b89410_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_660034e7-e307-4cad-8ad9-4e9d3e6b98ed_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption, Adjusted Balance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_030421be-3b0d-4461-85fc-55b1b1f8e2be_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_b1595a39-a1d3-47ea-abff-4fb10ac13215_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_fad2fbcd-5e4d-4b48-b03d-feb9e2288abb_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_SeriesFRedeemableConvertiblePreferredStockMember_28f38665-2158-4ac4-926b-af7801115e32_terseLabel_en-US" xlink:label="lab_prct_SeriesFRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series F</link:label>
    <link:label id="lab_prct_SeriesFRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_prct_SeriesFRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series F Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_prct_SeriesFRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_prct_SeriesFRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series F Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember" xlink:href="prct-20210930.xsd#prct_SeriesFRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember" xlink:to="lab_prct_SeriesFRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6d68083b-dbb1-4ff5-b359-fb9d88bde5fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amount representing interest/unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_8cb6d171-ab19-42e5-a550-2fa2737d57d0_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:label id="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_label_en-US" xlink:label="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="lab_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_50da4dce-60d3-493e-9717-34a4dd62a115_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, consideration received on transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_14f00167-90b2-4e08-9cc9-4ebce93113df_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_da050d3e-8192-4192-a31c-e69a37bbcb3b_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_1cc463ae-aea0-4d41-9c17-da74f4b40002_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_ab1b6116-1968-4b39-9c9d-8da0f92f96b4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_f5d27b11-1725-4f2a-a002-4cbf999054ff_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock issuable in series, $0.00001 par value;</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b3652c02-2a19-4cbc-86cd-51062d12a1e7_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_e9ad06e9-efee-4c01-94d5-231eb3c0fe06_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_575bf1bb-25f3-4e46-987b-b00a5f0382b0_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_79e3aaf0-3cf0-4d9e-bf19-9f7187a44d69_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_960b4f4b-e9a1-41d5-abb1-f5208300b8c3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_022fd544-85e6-4d88-856b-c6d142c4733c_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation Preference Per Share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Liquidation Preference Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreferencePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_3f7855cf-23c1-4a84-bd4a-3e7bff097d7d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_ce2ce588-eea2-410a-add2-37f5a751c93c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued, value</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_330db4d7-0403-45a7-af08-b0f5a646c545_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_7b8589cd-c2b1-4c30-b6d2-14980599932d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in fair value of preferred stock warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_42abef9e-f7f9-4ac6-9e3d-d62b265fe175_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_b2534bf3-dd27-4f73-b8a2-ff876bfb946c_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_1e905718-b4b1-465f-a65a-b78f9ffa015e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_7f420261-e231-4a3d-a2e5-c1284913436c_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_d66e16ed-3414-4284-a74d-46de2e171925_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4476469d-8c0e-49ac-b023-0135c38af82f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_f8d7c66d-4af9-4616-91b4-f03cc3fd2259_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease &#8211; current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d4caa943-0056-4f65-986a-1ffa4d4c52e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_a3ebc2a3-18ce-435e-ae07-005f6f87f972_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_15427d33-94b3-402e-a700-24482ca1379d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_bc727f49-1631-4e3c-989b-1ea0dcad863d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_692de503-fd24-4556-9d2e-997e88a21f24_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2ceea94b-bf6e-4570-a2b9-952cbbaf7c3c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_e7d8cc23-6e8b-4d06-aecc-b2a8ddd47a29_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d5d52888-3215-475e-800c-14281aea56f6_totalLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_5c20b4a2-60d5-4872-9f25-e75ebaccbf8d_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_62f222eb-5787-4537-b52e-5ed0f320a185_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued</link:label>
    <link:label id="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_label_en-US" xlink:label="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:to="lab_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_PrepaidInventory_cddb7e77-c2bc-4dab-be19-6fafca39065d_terseLabel_en-US" xlink:label="lab_prct_PrepaidInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Inventory</link:label>
    <link:label id="lab_prct_PrepaidInventory_label_en-US" xlink:label="lab_prct_PrepaidInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Inventory</link:label>
    <link:label id="lab_prct_PrepaidInventory_documentation_en-US" xlink:label="lab_prct_PrepaidInventory" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_PrepaidInventory" xlink:href="prct-20210930.xsd#prct_PrepaidInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_PrepaidInventory" xlink:to="lab_prct_PrepaidInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_07881843-d143-4784-b620-ec41437f8124_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease (increase) in fair value of loan facility derivative liability</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f1b1fe87-5226-45c2-971a-2fd18a29ad2e_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants exercised for redeemable convertible preferred stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_AccruedPurchases_361b3e2e-dd6a-4a14-93fb-a257f376329f_terseLabel_en-US" xlink:label="lab_prct_AccruedPurchases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued purchases</link:label>
    <link:label id="lab_prct_AccruedPurchases_label_en-US" xlink:label="lab_prct_AccruedPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchases</link:label>
    <link:label id="lab_prct_AccruedPurchases_documentation_en-US" xlink:label="lab_prct_AccruedPurchases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_AccruedPurchases" xlink:href="prct-20210930.xsd#prct_AccruedPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_AccruedPurchases" xlink:to="lab_prct_AccruedPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_InterestAndOtherIncomeExpense_6c94f279-b079-4ece-8f33-e59803162867_terseLabel_en-US" xlink:label="lab_prct_InterestAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_prct_InterestAndOtherIncomeExpense_427b9262-254b-4274-bc7e-b4cda5508c11_totalLabel_en-US" xlink:label="lab_prct_InterestAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total interest and other income (expense), net</link:label>
    <link:label id="lab_prct_InterestAndOtherIncomeExpense_label_en-US" xlink:label="lab_prct_InterestAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Other Income (Expense)</link:label>
    <link:label id="lab_prct_InterestAndOtherIncomeExpense_documentation_en-US" xlink:label="lab_prct_InterestAndOtherIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest And Other Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_InterestAndOtherIncomeExpense" xlink:href="prct-20210930.xsd#prct_InterestAndOtherIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_InterestAndOtherIncomeExpense" xlink:to="lab_prct_InterestAndOtherIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_569b73d7-810d-49a6-925c-4ea590be01be_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and other income, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_22083877-95d1-49d0-90de-ed45ac7522aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentPrincipalAndInterestPeriod_f3becbc8-64db-48a0-af56-1ce96f302154_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal and interest period (in months)</link:label>
    <link:label id="lab_prct_DebtInstrumentPrincipalAndInterestPeriod_label_en-US" xlink:label="lab_prct_DebtInstrumentPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Principal and Interest Period</link:label>
    <link:label id="lab_prct_DebtInstrumentPrincipalAndInterestPeriod_documentation_en-US" xlink:label="lab_prct_DebtInstrumentPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Principal and Interest Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentPrincipalAndInterestPeriod" xlink:href="prct-20210930.xsd#prct_DebtInstrumentPrincipalAndInterestPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentPrincipalAndInterestPeriod" xlink:to="lab_prct_DebtInstrumentPrincipalAndInterestPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidInsurance_44f0ad02-5713-4a08-997b-32be75942e40_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:label id="lab_us-gaap_PrepaidInsurance_label_en-US" xlink:label="lab_us-gaap_PrepaidInsurance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Insurance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_cf3979b3-ad80-4a01-b990-918f26d62d9c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_ae92de3f-f12b-483a-b0ca-dc93786f5fb1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5722001f-fa6b-4107-9777-5f037fecc679_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_0af92e45-57a6-4564-9b95-7907a840ad5b_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_724ed40b-d767-4c03-bf42-8dd812d26a7a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility interest rate at period end (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_440ffb53-d22e-4bf3-aebf-cd867e2149a0_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee if first two installments drawn</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Two Installments Drawn</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Two Installments Drawn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn" xlink:to="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_f2908adf-af07-41bd-b1f3-481134689c38_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_f7ac607d-8f21-47ae-a61c-741c9ae5625a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_548decba-a5ea-40e7-bf1b-74ae59d97ebf_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_9bc0264a-76e8-4ea0-b048-b0a837981c3f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGuaranteeObligationsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Guarantor Obligations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:to="lab_us-gaap_ScheduleOfGuaranteeObligationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_02ccb559-230d-4f74-9f70-952a8262ebb1_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fad3155e-80c5-4076-adcf-b9a63350ed1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_052308f1-14df-4f18-aec3-72165fc10af3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_17f6f7c8-02f1-4c96-96a9-e84ad43a4b98_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_46af5276-c89c-4696-8592-5a26fd772196_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_5de3b3a4-51a4-47ff-a6ed-aa4b5db67b2a_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_c7b05fb3-df3d-4e76-8ece-d91a410b527e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2b4bafa0-3734-4c66-9e8a-407dcfb743ba_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0651b48e-818a-4311-bad7-5613e6451716_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_1d4365a7-c834-4503-9ff1-f23339e1ba2f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_9b985617-e6ad-46fe-8c51-b9e7a17ad3fc_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputOptionVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Option Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputOptionVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputOptionVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_5ab1fda9-df03-4ca7-8ee3-e6644f31c45e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c360f6e3-1d6d-4a89-84fc-56fbd2eefaba_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_c501ee44-26d1-4786-9542-3db816fc3615_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_e797e40f-fc70-493b-8b06-731f05f8b8e1_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_528ccf3b-00b9-45f4-980b-3d83be1ca5a7_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_1fc16fec-ac84-428e-9408-8d402ef6f6fc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_373195e6-73be-4ad7-b10f-11d829d824ae_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_a531a850-a9e1-4b59-90a5-aaa8372bad51_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1764b49a-fa5d-4548-bafb-417a6a5f2d34_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease &#8211; non-current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_318b7b0b-5265-42c9-b57d-d1780826efdf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_f59f7d24-9d79-42e5-ac1b-5562686589a6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7184164e-80d7-4fb3-a996-5112490c68a0_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_4d89f380-7002-43d5-9201-5ced1dff037a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_8b7888bd-cd92-4f9f-b69a-bb718f419b1e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bdc7d1ac-8378-4b20-9fc0-ca2d2ff8e230_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0e28b4c2-2e69-460d-b601-e73e9361bdab_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1cc87169-fcfc-4413-adbe-45b9fb248553_negatedLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_127087e7-04f7-49cb-b870-58337fd3bbf1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease term (in years)</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_9f8f5e46-2dbf-496d-9285-4dcffa6e76d8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_Customer2Member_fe5bd568-0ad5-4794-8926-60f94311a1de_terseLabel_en-US" xlink:label="lab_prct_Customer2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2</link:label>
    <link:label id="lab_prct_Customer2Member_label_en-US" xlink:label="lab_prct_Customer2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2 [Member]</link:label>
    <link:label id="lab_prct_Customer2Member_documentation_en-US" xlink:label="lab_prct_Customer2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 2</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_Customer2Member" xlink:href="prct-20210930.xsd#prct_Customer2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_Customer2Member" xlink:to="lab_prct_Customer2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_148fece9-61f0-430a-95e8-e7d9567878fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_8923dab3-3a3b-4b15-8e31-cf20ed3317db_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_8bb8fe1c-85b5-4aa3-a59c-326f26fecd51_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash to balance sheets:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_0a5f1c7c-4626-4242-a227-735a381a8d54_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_fe14cf21-6702-45df-9cbc-c8e00c66d6cc_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee on first installment drawn</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Terms, Liquidity Occurrence, One Installment Drawn</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Terms, Liquidity Occurrence, One Installment Drawn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn" xlink:to="lab_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_18537f3d-cc2e-455d-9411-1f191b333a25_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_3dd2bc2a-1f5c-4be8-bb7f-a361f3052edf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_ServiceRevenueMember_2785f85e-7d15-40b8-b38f-ff4cc5e1fe94_terseLabel_en-US" xlink:label="lab_prct_ServiceRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service</link:label>
    <link:label id="lab_prct_ServiceRevenueMember_label_en-US" xlink:label="lab_prct_ServiceRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Revenue [Member]</link:label>
    <link:label id="lab_prct_ServiceRevenueMember_documentation_en-US" xlink:label="lab_prct_ServiceRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ServiceRevenueMember" xlink:href="prct-20210930.xsd#prct_ServiceRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_ServiceRevenueMember" xlink:to="lab_prct_ServiceRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_7d210dee-f926-451e-8502-0febd290809c_terseLabel_en-US" xlink:label="lab_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award cliff vesting period (in years)</link:label>
    <link:label id="lab_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_label_en-US" xlink:label="lab_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Cliff Vesting Period</link:label>
    <link:label id="lab_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_documentation_en-US" xlink:label="lab_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Cliff Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:href="prct-20210930.xsd#prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:to="lab_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_bc9a1def-9d41-420e-a690-34428b07377c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_a10f9a5e-c17e-4e11-b4b9-15a04e51ec63_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_9e7e0798-2058-4405-9f77-028bef1a707b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_TemporaryEquityAmountConversionOfConvertibleSecurities_2e8dc76a-2ce8-4ffd-aebc-372379e27c4b_negatedTerseLabel_en-US" xlink:label="lab_prct_TemporaryEquityAmountConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_prct_TemporaryEquityAmountConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_prct_TemporaryEquityAmountConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Amount, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_prct_TemporaryEquityAmountConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_prct_TemporaryEquityAmountConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Amount, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityAmountConversionOfConvertibleSecurities" xlink:href="prct-20210930.xsd#prct_TemporaryEquityAmountConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_TemporaryEquityAmountConversionOfConvertibleSecurities" xlink:to="lab_prct_TemporaryEquityAmountConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_56c5538f-2fbc-4b8a-9042-b673fce5436e_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_JobsActAccountingElectionPolicyTextBlock_c9d50e42-a5d0-4364-aa66-1e3ecd28314b_terseLabel_en-US" xlink:label="lab_prct_JobsActAccountingElectionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jobs Act Accounting Election</link:label>
    <link:label id="lab_prct_JobsActAccountingElectionPolicyTextBlock_label_en-US" xlink:label="lab_prct_JobsActAccountingElectionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jobs Act Accounting Election [Policy Text Block]</link:label>
    <link:label id="lab_prct_JobsActAccountingElectionPolicyTextBlock_documentation_en-US" xlink:label="lab_prct_JobsActAccountingElectionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jobs Act Accounting Election</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_JobsActAccountingElectionPolicyTextBlock" xlink:href="prct-20210930.xsd#prct_JobsActAccountingElectionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_JobsActAccountingElectionPolicyTextBlock" xlink:to="lab_prct_JobsActAccountingElectionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_a8422c4b-9c63-4745-8577-cbea6227e6c9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_46dae984-81b9-4bad-a520-16000e5e3204_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_cfc44c19-b2fd-4d5d-8f3b-0e38b9e34253_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_3cbad528-c281-42a8-a4e5-d08f2984c08e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_c952ec32-fe59-4a76-a001-7e81143166d6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_aae61bab-d2bc-41fa-bcee-786dca1f11de_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_83579afb-5b3c-4ac5-b79c-c4df13e9e7f1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share attributable to common shareholders</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_65f78e10-48ca-4c3a-8ad3-4fdbce00f4c3_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_577e2e1a-8efe-409d-9d30-bf462967536f_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_755f1e7c-270d-4b15-ba67-5aef0eba98f0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_d08d514e-14c3-40d3-8d84-452b892588a7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_bde3bdb6-5ca0-4af8-9e55-cfffe8719fda_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_31402b77-83dd-4cd9-b41c-dd0eebaebb63_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_b8844d4f-04a8-4e5f-ac17-821771e4c485_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_94f6e81d-e12b-40eb-8dd7-690fbb371e98_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_36074bc0-2f22-4f72-aa8a-3d85c3bc0057_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_75bd0e06-ee54-441f-a62e-257cdab3ee95_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_708e79c9-c45c-41a3-904c-7599be5eb797_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_53a91c88-2386-4bda-90ed-2859840167a2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_17fb5c58-6be7-4a2e-be61-86b1ff4aef35_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_127812f4-9d38-482e-acb3-da840ccdb783_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_12a60d49-a52e-4f6e-9fff-487495b8cb9a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_RedeemableConvertiblePreferredStockWarrantsMember_609955ba-f6e7-4cbe-a214-4f404665e6bc_terseLabel_en-US" xlink:label="lab_prct_RedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock warrants</link:label>
    <link:label id="lab_prct_RedeemableConvertiblePreferredStockWarrantsMember_label_en-US" xlink:label="lab_prct_RedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrants [Member]</link:label>
    <link:label id="lab_prct_RedeemableConvertiblePreferredStockWarrantsMember_documentation_en-US" xlink:label="lab_prct_RedeemableConvertiblePreferredStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedeemableConvertiblePreferredStockWarrantsMember" xlink:href="prct-20210930.xsd#prct_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_RedeemableConvertiblePreferredStockWarrantsMember" xlink:to="lab_prct_RedeemableConvertiblePreferredStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_6b71347e-511a-4d5d-af58-2728c434b51f_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_0ec5a8b2-b7b7-427f-9ea1-4e341a281b49_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_3f2a0f5d-8193-47b8-91d0-9237656c9879_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises_d6f05c33-a34d-4621-8e70-0444976a2ec3_terseLabel_en-US" xlink:label="lab_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance upon exercise of warrants</link:label>
    <link:label id="lab_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises_label_en-US" xlink:label="lab_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:label id="lab_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises_documentation_en-US" xlink:label="lab_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Stock Issued During Period, Value, Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" xlink:to="lab_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_SeriesDRedeemableConvertiblePreferredStockMember_35fff5ff-8a66-44fe-8d98-f42a3cc74c00_terseLabel_en-US" xlink:label="lab_prct_SeriesDRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D, Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_prct_SeriesDRedeemableConvertiblePreferredStockMember_b18699d1-6729-41c3-be30-591053ead306_verboseLabel_en-US" xlink:label="lab_prct_SeriesDRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D</link:label>
    <link:label id="lab_prct_SeriesDRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_prct_SeriesDRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_prct_SeriesDRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_prct_SeriesDRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember" xlink:href="prct-20210930.xsd#prct_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember" xlink:to="lab_prct_SeriesDRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_b2fc010d-c124-4e6e-b987-fee85fd064c9_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_e58d19a3-9003-4a73-b395-66577bdc4a71_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_196c96ca-321f-40eb-9d3e-1f7a968c70c6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_5d49d71f-38a7-4bdc-8392-d130ccdfa065_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent" xlink:to="lab_us-gaap_RestrictedCashNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_19781120-c7ac-49c4-bbc0-968e26e1c003_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent_91a8e450-7025-4bf9-8ab9-e9de0d298c01_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early repayment fee second twelve month period, percent</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Early Repayment Fee Second Twelve Month Period, Percent</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Early Repayment Fee Second Twelve Month Period, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent" xlink:to="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_dd91a28f-091c-40ec-83b7-78de64831fc1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_076f4e07-e389-4f3a-85a2-8c5a38300a5b_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value Assumptions</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_f3845c9e-9370-45e4-8de5-96ee6ddc89aa_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price of common stock, percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_37017ccb-798d-46d1-a04b-02e250ba929f_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for Doubtful Accounts</link:label>
    <link:label id="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_label_en-US" xlink:label="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:to="lab_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_ba69350c-e625-4ca5-b117-0371b23a034a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_395a9777-574b-468f-9b22-3e69232e84d8_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Standards Update [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f38d3826-84ca-4771-8d6d-a94b3d81208b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_3e370ab4-f006-48c5-8a90-b1114c29c1f2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_6bbb5a2c-3045-4564-89f9-8f671deca3ab_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="lab_us-gaap_SubsidiarySaleOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_a6cf5cb0-8ca9-4d04-af82-bf6be002e497_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_648e3b50-6a7b-41ae-bb99-78ea6524e5d0_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5b702ba4-77c1-4ce2-8bcc-8679185d9dbf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_252eea2a-9cd7-4a22-a69d-401fff496a20_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_c1695588-7156-45c9-a98d-72954d46f658_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_ae93cead-9bba-4643-b0c6-4b77202f4864_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_0a6be65f-b116-4ad4-a546-47e54b716b1e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_A2008StockPlanMember_1f4c22ed-bef4-46cc-af27-62e0e405ef9d_terseLabel_en-US" xlink:label="lab_prct_A2008StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Stock Plan</link:label>
    <link:label id="lab_prct_A2008StockPlanMember_label_en-US" xlink:label="lab_prct_A2008StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Stock Plan [Member]</link:label>
    <link:label id="lab_prct_A2008StockPlanMember_documentation_en-US" xlink:label="lab_prct_A2008StockPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2008 Stock Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_A2008StockPlanMember" xlink:href="prct-20210930.xsd#prct_A2008StockPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_A2008StockPlanMember" xlink:to="lab_prct_A2008StockPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_59b4948e-e01d-4e72-902f-8eb09fb7e654_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_WarrantsAndRightsOutstandingWeightedAverageTerm_4de189a5-f918-47ed-9ff4-e302308c52f7_terseLabel_en-US" xlink:label="lab_prct_WarrantsAndRightsOutstandingWeightedAverageTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant term (in years)</link:label>
    <link:label id="lab_prct_WarrantsAndRightsOutstandingWeightedAverageTerm_label_en-US" xlink:label="lab_prct_WarrantsAndRightsOutstandingWeightedAverageTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Weighted Average Term</link:label>
    <link:label id="lab_prct_WarrantsAndRightsOutstandingWeightedAverageTerm_documentation_en-US" xlink:label="lab_prct_WarrantsAndRightsOutstandingWeightedAverageTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Weighted Average Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_WarrantsAndRightsOutstandingWeightedAverageTerm" xlink:href="prct-20210930.xsd#prct_WarrantsAndRightsOutstandingWeightedAverageTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_WarrantsAndRightsOutstandingWeightedAverageTerm" xlink:to="lab_prct_WarrantsAndRightsOutstandingWeightedAverageTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_182fe854-3dec-457b-9501-ad3ac6c209a8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn_04b2fc5f-f273-4cc2-905d-3ed9f94f17cf_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant compliance, revenue forecast amount, all installments</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn_label_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Revenue Forecast Amount, All Installments Drawn</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn_documentation_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Revenue Forecast Amount, All Installments Drawn</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn" xlink:to="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b0263eff-242d-4ccb-b9c5-86c94f8e710b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityFinalPaymentFeePercentage_b830d487-ab96-44a7-9e62-73695a88c045_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityFinalPaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Final payment fee, percentage</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityFinalPaymentFeePercentage_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityFinalPaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Final Payment Fee, Percentage</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityFinalPaymentFeePercentage_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityFinalPaymentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Final Payment Fee, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityFinalPaymentFeePercentage" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityFinalPaymentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityFinalPaymentFeePercentage" xlink:to="lab_prct_LineOfCreditFacilityFinalPaymentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_bdeda4d9-3f76-4f5a-bde7-9cf5824de9ec_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_ed393916-0abc-40a1-bc21-a1eded3d4215_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_b298a964-deae-4e3c-93a3-a4ab29ecf693_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_6a48beb2-de25-4919-a86b-21af8aab73b8_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuaranteeObligationsLineItems_918ec7e4-a47c-49ec-a198-5465069da710_terseLabel_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations</link:label>
    <link:label id="lab_us-gaap_GuaranteeObligationsLineItems_label_en-US" xlink:label="lab_us-gaap_GuaranteeObligationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Guarantor Obligations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems" xlink:to="lab_us-gaap_GuaranteeObligationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_07fc158c-1eb2-4f95-a65e-8d1e30a2c6e8_terseLabel_en-US" xlink:label="lab_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred offering costs included in accounts payable and other current liabilities</link:label>
    <link:label id="lab_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_label_en-US" xlink:label="lab_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:label id="lab_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_documentation_en-US" xlink:label="lab_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:href="prct-20210930.xsd#prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:to="lab_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod_d56493b8-8132-4869-b2bf-67af3395beb4_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended principal and interest period (in months)</link:label>
    <link:label id="lab_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod_label_en-US" xlink:label="lab_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Contingent Borrowing, Extended Principal and Interest Period</link:label>
    <link:label id="lab_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod_documentation_en-US" xlink:label="lab_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Contingent Borrowing, Extended Principal and Interest Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod" xlink:href="prct-20210930.xsd#prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod" xlink:to="lab_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_80d079cc-85d7-4df8-b450-ab540e7f3b9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_adaaff7e-ea57-4d63-9835-26c2e43fd3ad_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_3b78f11d-8665-47dc-ac9d-4f0c045e43bd_terseLabel_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:label id="lab_srt_CumulativeEffectPeriodOfAdoptionDomain_label_en-US" xlink:label="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Effect, Period of Adoption [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:to="lab_srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_56d79fc4-eec6-4f5e-b000-69f17995afaf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_720cc322-15eb-4d5d-86f7-2cd92685af2b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_a4e243ee-85de-46a8-9180-c294aea869df_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock outstanding</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_fdf483b6-badf-4cc8-b769-314dd979747d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_1805bdf3-c8d1-4e19-bc3b-cbefdba3f436_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:label id="lab_us-gaap_DeferredChargesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Charges, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredChargesPolicyTextBlock" xlink:to="lab_us-gaap_DeferredChargesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo_2cb003a3-b387-473e-aa54-be711537384d_terseLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo_label_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Year Two</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo_documentation_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo" xlink:to="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_73a906b9-7310-4c56-90a9-e2f8b4b1bdba_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_10cc23cb-9358-4f87-8802-1af288c0d71a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cfaecd1c-823a-4a8c-9e3b-cb3c42d1f8ca_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common stock outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_e1a24fd8-7ee2-445e-aecc-f630d103288c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_fcc0742b-3701-4a8e-abfa-29497a0ad128_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne_5b772dfe-ba92-4a6d-87eb-e55ebe6903ee_terseLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne_label_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Year One</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne_documentation_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne" xlink:to="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_ad5c3e34-0045-48d2-a59f-ddb6646d58bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod_19be1e81-0fb3-4f04-96a8-48fcf83c46fe_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extended interest only period (in months)</link:label>
    <link:label id="lab_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod_label_en-US" xlink:label="lab_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Contingent Borrowing, Extended Interest Only Period</link:label>
    <link:label id="lab_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod_documentation_en-US" xlink:label="lab_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, Contingent Borrowing, Extended Interest Only Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod" xlink:href="prct-20210930.xsd#prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod" xlink:to="lab_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_a60528b1-59f3-4ffd-bfeb-9da540bc7b14_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_e3d9dd98-d00e-4852-97ab-4512e366d387_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_0ee504f6-abd9-478b-9464-23fcf0d590b1_verboseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfRevenue_682798d3-fe43-4825-8954-630f08217383_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfRevenue_label_en-US" xlink:label="lab_us-gaap_CostOfRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfRevenue" xlink:to="lab_us-gaap_CostOfRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1d21bd33-a8f9-4c64-8b33-8c28c5fa2575_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_bac15a45-18d4-42ec-aab2-d71d77ce1f64_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_3fb955e7-d02c-46a0-a8e2-17a3f7b72743_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition_abc5e9cc-d130-4fea-ac5a-b63a9e349a52_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7717afd9-4995-4df1-a57a-ee9fa6ee2334_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly_343fd96e-3905-4d87-b853-b1e0f3cb4bf0_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant compliance, revenue forecast amount, first three installments only</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly_label_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Revenue Forecast Amount, First Three Installments Only</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly_documentation_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Revenue Forecast Amount, First Three Installments Only</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly" xlink:to="lab_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LoanFacilityTrancheOneMember_a88671e5-b892-43c4-8f0b-5b48fabddd1e_terseLabel_en-US" xlink:label="lab_prct_LoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche One</link:label>
    <link:label id="lab_prct_LoanFacilityTrancheOneMember_label_en-US" xlink:label="lab_prct_LoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche One [Member]</link:label>
    <link:label id="lab_prct_LoanFacilityTrancheOneMember_documentation_en-US" xlink:label="lab_prct_LoanFacilityTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheOneMember" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LoanFacilityTrancheOneMember" xlink:to="lab_prct_LoanFacilityTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_8be9aa1f-23fc-478f-89ab-fff4a17df65c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_be4cf2c3-afad-49a5-af30-66a68ab02b34_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan facility derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_RedwoodCityCAMember_2391b6fe-7f10-4802-b571-3d14620d851e_terseLabel_en-US" xlink:label="lab_prct_RedwoodCityCAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redwood City, CA</link:label>
    <link:label id="lab_prct_RedwoodCityCAMember_label_en-US" xlink:label="lab_prct_RedwoodCityCAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redwood City, CA [Member]</link:label>
    <link:label id="lab_prct_RedwoodCityCAMember_documentation_en-US" xlink:label="lab_prct_RedwoodCityCAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redwood City, CA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedwoodCityCAMember" xlink:href="prct-20210930.xsd#prct_RedwoodCityCAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_RedwoodCityCAMember" xlink:to="lab_prct_RedwoodCityCAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_eab523c0-99c3-4037-926d-733e4b762ded_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_84d0b32f-883c-4bb8-ae0e-d3e07df004e7_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OutsideTheUnitedStatesMember_edb78e9f-d805-4d2a-bc8e-d99561ead964_terseLabel_en-US" xlink:label="lab_prct_OutsideTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of U.S.</link:label>
    <link:label id="lab_prct_OutsideTheUnitedStatesMember_label_en-US" xlink:label="lab_prct_OutsideTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside the United States [Member]</link:label>
    <link:label id="lab_prct_OutsideTheUnitedStatesMember_documentation_en-US" xlink:label="lab_prct_OutsideTheUnitedStatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside the United States</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OutsideTheUnitedStatesMember" xlink:href="prct-20210930.xsd#prct_OutsideTheUnitedStatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OutsideTheUnitedStatesMember" xlink:to="lab_prct_OutsideTheUnitedStatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_85cb947b-c7ec-4186-8d3a-0aeb5943566e_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_SystemSalesAndRentalsMember_aa01af84-ead7-4adb-9520-591737de4d60_terseLabel_en-US" xlink:label="lab_prct_SystemSalesAndRentalsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">System sales and rentals</link:label>
    <link:label id="lab_prct_SystemSalesAndRentalsMember_label_en-US" xlink:label="lab_prct_SystemSalesAndRentalsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">System Sales and Rentals [Member]</link:label>
    <link:label id="lab_prct_SystemSalesAndRentalsMember_documentation_en-US" xlink:label="lab_prct_SystemSalesAndRentalsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">System Sales and Rentals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SystemSalesAndRentalsMember" xlink:href="prct-20210930.xsd#prct_SystemSalesAndRentalsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_SystemSalesAndRentalsMember" xlink:to="lab_prct_SystemSalesAndRentalsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_42b7955f-4407-4f98-b40a-79fd5dccd73b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_4d032e5c-dddd-4664-a9b8-ed9a8056b958_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_a0221093-745a-4c63-a7cc-ae230cd8d9cd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term lines of credit</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Long-term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LaboratoryAndManufacturingEquipmentMember_d40701d7-c0fe-4ed7-885b-b64afedd9bfd_terseLabel_en-US" xlink:label="lab_prct_LaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory, manufacturing and computer equipment and furniture</link:label>
    <link:label id="lab_prct_LaboratoryAndManufacturingEquipmentMember_label_en-US" xlink:label="lab_prct_LaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and Manufacturing Equipment [Member]</link:label>
    <link:label id="lab_prct_LaboratoryAndManufacturingEquipmentMember_documentation_en-US" xlink:label="lab_prct_LaboratoryAndManufacturingEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and Manufacturing Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LaboratoryAndManufacturingEquipmentMember" xlink:href="prct-20210930.xsd#prct_LaboratoryAndManufacturingEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LaboratoryAndManufacturingEquipmentMember" xlink:to="lab_prct_LaboratoryAndManufacturingEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_3a8aff14-7ffe-490e-8ccb-e20761b70f95_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_4d12d196-c097-4a4f-8d5d-a04525c36f33_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_12484fe8-f786-496c-845e-be947377a51d_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends declared and payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_DividendsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_62a7bcfb-e89c-4a6c-b8e0-05164d973114_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_0d5f5950-5cda-4717-bc7e-b8f68e590097_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_3d59af64-8f9e-4e80-9c50-cfee7dc7fb24_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_fc44e206-0ba2-4df0-a766-b757cbc4ed81_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_eff8fc9b-d2ca-4963-9649-b77a4906fc05_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d67f116b-8207-4999-a385-e9ae4a700d85_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on cash equivalents</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_115d964b-b0ad-4bfb-a0a2-27884adb175f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_e26f541e-e375-48cd-8f8b-931b7e2faf75_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f9a16adb-7696-4837-9ee8-dbf2b6d19f75_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_2b881002-d9d2-4fd4-8456-73fd24eb46cc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility term (in years)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_1314d70b-68fb-4300-9fed-35df862bb7b6_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_50a4132f-dd8c-4549-9cfe-48b6b3c7c1d4_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_label_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_17db7587-224e-4ed7-918b-1fbbbb9bd65f_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_eb2a3e79-3e07-4bd4-addf-efc17c841026_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_4bfd94a2-15c9-4547-8bdf-0f58aba6b9c7_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_ef384c17-e507-45fb-8ff5-03f9b2ab0fac_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:label id="lab_us-gaap_OtherPrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_6e3fe870-1c3a-4b5e-99e0-276768c8a80d_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_3735966a-9ba0-4f21-83c7-78a740558934_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders' Equity and Share-based Payments [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_b8047d58-79df-4e5c-b20b-84830e0f4062_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_76719086-316f-4287-8346-04f919c380c8_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable convertible preferred stock, liquidation preference</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_bf772092-592b-4d6f-ba3d-194901f52e1c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_963f8d1a-d3fb-41e4-a30c-15962c212c66_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_e0d7120b-0f49-4926-8b78-fa9f2b3fc7d3_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_9c2a7c27-2f4e-4873-86eb-f3eb92a36a9a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_cfe7ac61-d662-432c-b730-cfb8e7270c46_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rental equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_a93050d5-e683-4e6c-81e2-5eab8c918710_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowing amount</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_5017a26e-353d-44fc-b52b-f5d4571f4d55_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_161fdd27-77a8-4183-ac5e-30b22e930c0a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock_4f93cb79-75ea-4091-acd5-902e39811b67_terseLabel_en-US" xlink:label="lab_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrant Liability</link:label>
    <link:label id="lab_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock_label_en-US" xlink:label="lab_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrant Liability, Policy [Policy Text Block]</link:label>
    <link:label id="lab_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrant Liability, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock" xlink:href="prct-20210930.xsd#prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock" xlink:to="lab_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_605bc0ab-ce86-411e-a02d-cfdb2340eb34_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_930d11b4-6e3f-4971-bdbf-268b672222ad_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_07ad7bd3-ab2d-4694-9f14-9aa45b6bfab7_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18ddcc16-82aa-4b93-92c0-a60d84ac9f58_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_7e152ce8-bb4b-414f-aa2a-29032c294e9a_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e1b3c868-8d2e-4d16-8bd5-725abaacc4c4_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_458a1a38-fd4c-48a9-b832-b998468f81dc_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant term (in years)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorLeasesPolicyTextBlock_f76dc7d5-574f-49d7-89cb-f6e6f90a91b3_terseLabel_en-US" xlink:label="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LessorLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LessorLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_ServiceAgreementAmortizationPeriod_b7a360c3-f117-47e6-9960-4f202bee10d5_terseLabel_en-US" xlink:label="lab_prct_ServiceAgreementAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service agreement, amortization period</link:label>
    <link:label id="lab_prct_ServiceAgreementAmortizationPeriod_label_en-US" xlink:label="lab_prct_ServiceAgreementAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement, Amortization Period</link:label>
    <link:label id="lab_prct_ServiceAgreementAmortizationPeriod_documentation_en-US" xlink:label="lab_prct_ServiceAgreementAmortizationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Agreement, Amortization Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ServiceAgreementAmortizationPeriod" xlink:href="prct-20210930.xsd#prct_ServiceAgreementAmortizationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_ServiceAgreementAmortizationPeriod" xlink:to="lab_prct_ServiceAgreementAmortizationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_a4726993-2b61-4de7-ab11-c0a4fe2bde21_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f0e83362-a12e-40c9-b62a-bc373bc2ff41_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_1b6b5eb3-496e-46da-a32c-d605546abb4a_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesPolicyTextBlock" xlink:to="lab_us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_CommonStockWarrantsMember_9ecf7b55-9aeb-472f-a9dd-d11be497662c_terseLabel_en-US" xlink:label="lab_prct_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock warrants</link:label>
    <link:label id="lab_prct_CommonStockWarrantsMember_label_en-US" xlink:label="lab_prct_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:label id="lab_prct_CommonStockWarrantsMember_documentation_en-US" xlink:label="lab_prct_CommonStockWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_CommonStockWarrantsMember" xlink:href="prct-20210930.xsd#prct_CommonStockWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_CommonStockWarrantsMember" xlink:to="lab_prct_CommonStockWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_1b3e0ba6-a18e-400a-8b40-0368678737b5_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_6428d23b-56b5-491f-85f8-76c5117efd17_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trailing twelve month revenue target</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Compliance, Contingent Trailing Twelve Month Revenue Target</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Covenant Compliance, Contingent Trailing Twelve Month Revenue Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget" xlink:to="lab_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_4041fa70-6073-4840-808d-47203b80c421_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_d7191c0f-ef6b-4f2f-ad45-9d80ad1a8a5e_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership interest, percent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_cd50a45e-2ad3-4a42-8ebb-732c850e8c76_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_c58ef5a1-ba0b-4d75-b21e-193982d305f7_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock, shares, number of shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_3de566b6-c485-440d-8319-eea8201f578d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding and exercisable, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_666bd2c7-7888-4044-ad26-c13fb7ab2c7f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_TemporaryEquitySharesConversionOfConvertibleSecurities_97041e91-28fb-4667-b58a-703c6d916d5e_negatedTerseLabel_en-US" xlink:label="lab_prct_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of redeemable convertible preferred stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_prct_TemporaryEquitySharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_prct_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:label id="lab_prct_TemporaryEquitySharesConversionOfConvertibleSecurities_documentation_en-US" xlink:label="lab_prct_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares, Conversion Of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:href="prct-20210930.xsd#prct_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:to="lab_prct_TemporaryEquitySharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_15daf8ab-1b42-4c39-abc9-453868d36d92_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash- Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_24efe8e6-25c3-44e8-a927-72b0e5dda8c6_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash - End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a795666-9143-44fd-8a87-2e4d7bbb8c5f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash in balance sheets</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductInformationLineItems_bcdbcb57-59c1-477e-a06e-60530e4b4f0a_terseLabel_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductInformationLineItems_label_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_5924f077-e49f-4d48-88d2-6c34e7db4db5_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_311f285e-823f-47c9-ac5c-49e3b04e3df5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_de2b7480-e0d4-4328-8473-5a4b42aa4e5e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8815ae81-70a2-4c87-afbf-521d0f88ee84_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4b047bc8-382d-4fb7-90f5-06cc407aa5a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_TemporaryEquityDividends_ff899678-1074-4e1e-a422-605d5fbe2de0_terseLabel_en-US" xlink:label="lab_prct_TemporaryEquityDividends" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">8% Dividend Per Share</link:label>
    <link:label id="lab_prct_TemporaryEquityDividends_label_en-US" xlink:label="lab_prct_TemporaryEquityDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividends</link:label>
    <link:label id="lab_prct_TemporaryEquityDividends_documentation_en-US" xlink:label="lab_prct_TemporaryEquityDividends" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityDividends" xlink:href="prct-20210930.xsd#prct_TemporaryEquityDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_TemporaryEquityDividends" xlink:to="lab_prct_TemporaryEquityDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_b6207ad1-7db7-4900-bdef-ac1a5763e194_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_1da98fc0-6ff2-4a56-bb85-724c1db9ea60_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_054e7353-faa7-4770-95d8-91d35282ca11_terseLabel_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR)</link:label>
    <link:label id="lab_us-gaap_LondonInterbankOfferedRateLIBORMember_label_en-US" xlink:label="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="lab_us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_76057761-c4cc-4406-9a5c-ebd236c3cb38_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_4c1adb25-0a45-4623-81d6-6c49270063fe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LoanFacilityTrancheFourMember_3e7c721c-8a31-4ca1-b586-f695aa4fc919_terseLabel_en-US" xlink:label="lab_prct_LoanFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche Four</link:label>
    <link:label id="lab_prct_LoanFacilityTrancheFourMember_label_en-US" xlink:label="lab_prct_LoanFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche Four [Member]</link:label>
    <link:label id="lab_prct_LoanFacilityTrancheFourMember_documentation_en-US" xlink:label="lab_prct_LoanFacilityTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan Facility, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheFourMember" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LoanFacilityTrancheFourMember" xlink:to="lab_prct_LoanFacilityTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_f19ca482-a98e-4f55-9e72-26be39e59844_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Revenue and Cost of Sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_13fd407d-b14b-45d7-ac5d-8ebce4b58506_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of vested options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_1bf7f220-4a3b-44bf-b6f0-eed00affdc17_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f3491a80-cc2b-4e74-89bf-90a02bcae72b_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1ffdaaa7-de4b-45c7-8522-ded0b0c03b1b_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common stock outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_a589815d-b538-4bb0-9216-4fdce1e29958_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible preferred stock warrant liability</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_90e5aeee-fd88-4149-9a4c-aab809009857_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPayableCurrent_c73d9dfd-64ab-4b3e-9b01-b19993264810_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPayableCurrent_label_en-US" xlink:label="lab_us-gaap_InterestPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPayableCurrent" xlink:to="lab_us-gaap_InterestPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_45333cb1-fced-46fd-8b3a-6c81e724e3b8_terseLabel_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option</link:label>
    <link:label id="lab_us-gaap_OverAllotmentOptionMember_label_en-US" xlink:label="lab_us-gaap_OverAllotmentOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Over-Allotment Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OverAllotmentOptionMember" xlink:to="lab_us-gaap_OverAllotmentOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_7dded998-3856-475b-bc07-145301766b3a_terseLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_4b6da4f1-bb1c-4f68-ac56-72b4f0f931fc_totalLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total minimum payments</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_label_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Gross</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_documentation_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt Maturity, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross" xlink:to="lab_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_SeriesBRedeemableConvertiblePreferredStockMember_df01a7a6-4e7e-4dd7-a2f9-e53e60981616_terseLabel_en-US" xlink:label="lab_prct_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B</link:label>
    <link:label id="lab_prct_SeriesBRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_prct_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_prct_SeriesBRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_prct_SeriesBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesBRedeemableConvertiblePreferredStockMember" xlink:href="prct-20210930.xsd#prct_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="lab_prct_SeriesBRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_83ab5205-035c-4ba3-8519-fc6b19f401dd_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_ddbb3ae1-7bc1-497e-923c-7f75d743cf2a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_b8959919-71d8-4865-aa32-f2c927287241_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility interest, spread on base rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_087c7994-4128-4440-9e39-4fb8f186c865_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock Warrant Liability</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_de0b93ef-264b-4cce-9ad1-f28c61136c2c_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_ea8e820e-22b6-430d-8b73-fdb7e2647e09_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_169811e7-a158-4b9b-a4a5-a2676172a48b_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_3ad46078-f52d-4af4-96f2-685e47984cb6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_608a1437-d670-46e4-afc6-92934923f9de_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_3e2e49b3-a22d-45f6-b382-57709eb2b3b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_675085a3-5620-4f52-8990-c6921e6ca9c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized (loss) gain on cash equivalents</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_6dcf71cc-da7b-4cd5-bd7a-64979152353d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f66e7758-fc50-4220-9935-484f922f0fd3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c4fbb092-d420-4d71-9fd6-233488041e4b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_628b1ec9-e88f-42e7-8ac7-26aacfae0576_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_caf879e6-8942-4271-a0eb-3231c527586c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_2d74c70f-39f4-42af-bc62-ceec6533fba3_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_d1227189-0f67-4faa-a4db-52caa41cebab_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems" xlink:to="lab_us-gaap_TemporaryEquityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_Customer1Member_e073d637-c31a-4f27-9dc0-946561559680_terseLabel_en-US" xlink:label="lab_prct_Customer1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1</link:label>
    <link:label id="lab_prct_Customer1Member_label_en-US" xlink:label="lab_prct_Customer1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1 [Member]</link:label>
    <link:label id="lab_prct_Customer1Member_documentation_en-US" xlink:label="lab_prct_Customer1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 1</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_Customer1Member" xlink:href="prct-20210930.xsd#prct_Customer1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_Customer1Member" xlink:to="lab_prct_Customer1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_21a66a81-ba37-410e-bb14-3dfe5631e225_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loan facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForUnderwritingExpense_1ad80f69-55b8-4af5-b4b6-ccadd1cab90a_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for underwriting discount and commissions</link:label>
    <link:label id="lab_us-gaap_PaymentsForUnderwritingExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForUnderwritingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Underwriting Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForUnderwritingExpense" xlink:to="lab_us-gaap_PaymentsForUnderwritingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_e1a9ea0f-327b-426a-8a24-e74caaa18836_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_OwnershipDomain_98997f43-f5bd-45a9-90f7-fc5d67108193_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_label_en-US" xlink:label="lab_srt_OwnershipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain" xlink:to="lab_srt_OwnershipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_ff32eb4b-046d-4ee4-b9d2-617abee5946c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_fa8f9ce7-7345-4901-b3af-8536f2c00c83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of outstanding stock maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod_841a2802-2875-4510-a3bc-69bb982a6899_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant compliance, IPO capital raised in threshold amount achieved, extended principal and interest only period (in months)</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod_label_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount Achieved, Extended Principal and Interest Period</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod_documentation_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount Achieved, Extended Principal and Interest Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod" xlink:to="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_11386485-6c05-48a4-a832-cd4373039d70_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_ee150a34-8b1f-40ea-ac37-f76c6e2b6e2d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_2cde94af-4729-4465-9690-0581a2179ac1_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_4e4ba088-a361-45b6-a38c-7088db3a2b92_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_8bff59be-d342-438f-9ca9-8b076b7cde10_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c18f481f-72ad-4da1-a317-c2185faab835_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_14d1e313-55c3-45b9-afea-507ad54e328d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_SeriesARedeemableConvertiblePreferredStockMember_2bbece84-dde8-471e-a9fc-47a54402c26b_terseLabel_en-US" xlink:label="lab_prct_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_prct_SeriesARedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_prct_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_prct_SeriesARedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_prct_SeriesARedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesARedeemableConvertiblePreferredStockMember" xlink:href="prct-20210930.xsd#prct_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_SeriesARedeemableConvertiblePreferredStockMember" xlink:to="lab_prct_SeriesARedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_dfb54202-a9a5-4e50-b537-237761f20316_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, loan facility</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_NonCashLeaseAccretionExpense_cf8d23b6-28f0-42a5-be0f-52c2b22e67c4_negatedTerseLabel_en-US" xlink:label="lab_prct_NonCashLeaseAccretionExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_prct_NonCashLeaseAccretionExpense_label_en-US" xlink:label="lab_prct_NonCashLeaseAccretionExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Lease Accretion Expense</link:label>
    <link:label id="lab_prct_NonCashLeaseAccretionExpense_documentation_en-US" xlink:label="lab_prct_NonCashLeaseAccretionExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash Lease Accretion Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_NonCashLeaseAccretionExpense" xlink:href="prct-20210930.xsd#prct_NonCashLeaseAccretionExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_NonCashLeaseAccretionExpense" xlink:to="lab_prct_NonCashLeaseAccretionExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities_1b28a6c6-ab89-48e8-a5ad-fa33bf6e6859_terseLabel_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities_label_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt, Excluding Current Maturities</link:label>
    <link:label id="lab_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities_documentation_en-US" xlink:label="lab_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Liability and Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities" xlink:to="lab_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_1cbffe5c-40e0-4a25-8013-358ebee9fcc0_terseLabel_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Covenant compliance, IPO capital raised in threshold amount</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_label_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount</link:label>
    <link:label id="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_documentation_en-US" xlink:label="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount" xlink:to="lab_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_b37b6566-255d-4410-80f0-a18c1f4735dd_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_09612087-b527-44b7-8b50-62ebda52c648_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input (percent)</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_a1890103-dfa0-4ecb-aef6-3c5780da138e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_27ac2763-422d-493d-9352-6304dd8abff7_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_9c500409-1d58-472f-b089-a5bea83d7632_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_e147e913-b92b-479d-9f33-ef9be8ee9f6b_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_cf0f5fec-d298-48b4-aafe-b9a3aee2b4e9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: amount representing interest/unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_90862c13-8fee-4315-86b8-5907bad0be35_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility base interest rate (percent)</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Interest Rate During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_Customer3Member_c35a11f1-201e-4466-8ca3-5fba1039d287_terseLabel_en-US" xlink:label="lab_prct_Customer3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3</link:label>
    <link:label id="lab_prct_Customer3Member_label_en-US" xlink:label="lab_prct_Customer3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3 [Member]</link:label>
    <link:label id="lab_prct_Customer3Member_documentation_en-US" xlink:label="lab_prct_Customer3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer 3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_Customer3Member" xlink:href="prct-20210930.xsd#prct_Customer3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_Customer3Member" xlink:to="lab_prct_Customer3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent_686903ad-e7fc-4b3d-bdd7-19eca65890fa_terseLabel_en-US" xlink:label="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early repayment fee first twelve month, percent</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent_label_en-US" xlink:label="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Early Repayment Fee First Twelve Month, Percent</link:label>
    <link:label id="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent_documentation_en-US" xlink:label="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Early Repayment Fee First Twelve Month, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent" xlink:to="lab_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts_50789feb-f9c0-4a10-9de9-759480ca4749_terseLabel_en-US" xlink:label="lab_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label id="lab_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts_label_en-US" xlink:label="lab_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock, Net of Issuance Costs</link:label>
    <link:label id="lab_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts_documentation_en-US" xlink:label="lab_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock, Net of Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" xlink:href="prct-20210930.xsd#prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" xlink:to="lab_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>prct-20210930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:05140f27-a3ec-43bc-a461-9ef7bd6589c5,g:c5500a2c-3da2-4c15-b44b-608117d5a861-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/Coverpage" xlink:type="simple" xlink:href="prct-20210930.xsd#Coverpage"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/Coverpage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_0c32eb3e-af0a-4a09-a89e-6de2286f8b72" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_DocumentType_0c32eb3e-af0a-4a09-a89e-6de2286f8b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_c3892b76-67fb-497e-8986-7e9acb432604" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_DocumentQuarterlyReport_c3892b76-67fb-497e-8986-7e9acb432604" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f416f623-adcf-4122-9c5b-ee22e5f490db" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_DocumentPeriodEndDate_f416f623-adcf-4122-9c5b-ee22e5f490db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_33b41040-47cd-44b7-90e4-72fe6cc33067" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_DocumentTransitionReport_33b41040-47cd-44b7-90e4-72fe6cc33067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fcfdf7e1-2778-443f-b6b0-7982607c2882" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityFileNumber_fcfdf7e1-2778-443f-b6b0-7982607c2882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_3e43efa1-886f-4c06-b1f8-6927fbb1679e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityRegistrantName_3e43efa1-886f-4c06-b1f8-6927fbb1679e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_1b3c02fa-edea-42de-b0ce-b2f688cada6a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityIncorporationStateCountryCode_1b3c02fa-edea-42de-b0ce-b2f688cada6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_e0e990e6-31cd-4ab0-ba6a-921a5df5c96b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityTaxIdentificationNumber_e0e990e6-31cd-4ab0-ba6a-921a5df5c96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_5e1de0e6-fec6-4369-9e98-56324c58d574" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityAddressAddressLine1_5e1de0e6-fec6-4369-9e98-56324c58d574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_23ee9087-da53-4aa4-8bda-1983cb08c013" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityAddressCityOrTown_23ee9087-da53-4aa4-8bda-1983cb08c013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_54cdb780-1fa2-4853-a24a-328dea68be42" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityAddressStateOrProvince_54cdb780-1fa2-4853-a24a-328dea68be42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_8dcb989c-2d65-4c48-95f5-a0e7df229e3d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityAddressPostalZipCode_8dcb989c-2d65-4c48-95f5-a0e7df229e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_92a61987-01ed-480a-b8a3-90b55796f8f5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_CityAreaCode_92a61987-01ed-480a-b8a3-90b55796f8f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d4adf3e8-f3b1-4d31-a868-76fdb1f3a844" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_LocalPhoneNumber_d4adf3e8-f3b1-4d31-a868-76fdb1f3a844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b31f2e33-30be-4630-9013-e3da67889225" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_Security12bTitle_b31f2e33-30be-4630-9013-e3da67889225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_a7f3419a-1265-42e1-becb-b776113da9a3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_TradingSymbol_a7f3419a-1265-42e1-becb-b776113da9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_46050faa-a19f-4a17-80cc-4e20a59d31d6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_SecurityExchangeName_46050faa-a19f-4a17-80cc-4e20a59d31d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_9e44089d-1453-4a20-9ea4-b1c3b7abf398" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityCurrentReportingStatus_9e44089d-1453-4a20-9ea4-b1c3b7abf398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_50bf82de-1f24-4303-b3f1-1a0e972ff1f9" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityInteractiveDataCurrent_50bf82de-1f24-4303-b3f1-1a0e972ff1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_af2f7851-2ec7-434f-aba8-9925b4749d8e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityFilerCategory_af2f7851-2ec7-434f-aba8-9925b4749d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_31d14f64-c875-451c-838b-ade4615983da" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntitySmallBusiness_31d14f64-c875-451c-838b-ade4615983da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d59e21ad-1eac-492e-9799-75ff699cd105" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityEmergingGrowthCompany_d59e21ad-1eac-492e-9799-75ff699cd105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_145b69e5-5be4-4af9-bd82-69eafb327b0b" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityExTransitionPeriod_145b69e5-5be4-4af9-bd82-69eafb327b0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4741e88b-f435-4115-92d6-1cd379202e03" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityShellCompany_4741e88b-f435-4115-92d6-1cd379202e03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a5129dee-a72b-47c2-bc4c-7689bcb21fbd" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a5129dee-a72b-47c2-bc4c-7689bcb21fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_cae7075d-ab11-4297-9874-9a27de67ef27" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_EntityCentralIndexKey_cae7075d-ab11-4297-9874-9a27de67ef27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_9d86180b-3c38-404b-a50e-87d72bc84823" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_CurrentFiscalYearEndDate_9d86180b-3c38-404b-a50e-87d72bc84823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_522c12c7-6d7d-4ffc-82f4-f0627f79d649" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_DocumentFiscalYearFocus_522c12c7-6d7d-4ffc-82f4-f0627f79d649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4837779c-3aa7-44de-9fd7-f440902be07c" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_AmendmentFlag_4837779c-3aa7-44de-9fd7-f440902be07c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_a282a134-920a-436e-a455-34a0b26fa939" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_949a1024-e6eb-45dc-b46e-74b8ede6dd9a" xlink:to="loc_dei_DocumentFiscalPeriodFocus_a282a134-920a-436e-a455-34a0b26fa939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_920529dd-65dc-4a11-9798-ce18e3492881" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_af5dd838-ca39-4d98-8925-5dda53e9f35c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_920529dd-65dc-4a11-9798-ce18e3492881" xlink:to="loc_us-gaap_StatementTable_af5dd838-ca39-4d98-8925-5dda53e9f35c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1cf6b7fb-1111-4dd3-aae1-4ca932bcb506" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_af5dd838-ca39-4d98-8925-5dda53e9f35c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1cf6b7fb-1111-4dd3-aae1-4ca932bcb506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e2316513-cfa3-49f0-9860-c94d3ca9e079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1cf6b7fb-1111-4dd3-aae1-4ca932bcb506" xlink:to="loc_us-gaap_ClassOfStockDomain_e2316513-cfa3-49f0-9860-c94d3ca9e079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_96362092-3459-4587-88b1-54ff5d59e828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e2316513-cfa3-49f0-9860-c94d3ca9e079" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_96362092-3459-4587-88b1-54ff5d59e828" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_af5dd838-ca39-4d98-8925-5dda53e9f35c" xlink:to="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41640aec-88b9-4e98-8f02-2eaddebd56db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_41640aec-88b9-4e98-8f02-2eaddebd56db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e14dd36d-2aca-4cb7-bfbf-251949d76ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e14dd36d-2aca-4cb7-bfbf-251949d76ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4c4adbea-3a90-4ffd-83c4-6ebf5c412f65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:to="loc_us-gaap_InventoryNet_4c4adbea-3a90-4ffd-83c4-6ebf5c412f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_537f9c57-92df-4462-ac17-3a8752f0b5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_537f9c57-92df-4462-ac17-3a8752f0b5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_70b4cef3-51df-4e48-af45-039a8e38d5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_5fdac581-421d-41c6-91aa-fca4c517bd73" xlink:to="loc_us-gaap_AssetsCurrent_70b4cef3-51df-4e48-af45-039a8e38d5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_0925ff85-11ce-46f5-9565-8aaeccc4a3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_0925ff85-11ce-46f5-9565-8aaeccc4a3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4671befe-398c-4fce-a023-9291d67e28c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4671befe-398c-4fce-a023-9291d67e28c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_bce3b614-8bb0-4dd3-80b7-86b0e147035b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_bce3b614-8bb0-4dd3-80b7-86b0e147035b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_52e34f1e-3419-4746-825e-1e0e72759a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_52e34f1e-3419-4746-825e-1e0e72759a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_825a7114-d4f9-4317-8bc5-177a736f549c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_972907b5-9dee-4e8c-81e0-bb383be0379b" xlink:to="loc_us-gaap_Assets_825a7114-d4f9-4317-8bc5-177a736f549c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_bea7e1ad-f06b-4e8a-934e-65ba5e8300b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_AccountsPayableCurrent_bea7e1ad-f06b-4e8a-934e-65ba5e8300b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_40545e95-5e2c-4750-bdb3-7374bab7e980" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_AccruedSalariesCurrent_40545e95-5e2c-4750-bdb3-7374bab7e980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_606ad777-c5e5-4795-a1d9-213b56f8a079" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_LongTermDebtCurrent_606ad777-c5e5-4795-a1d9-213b56f8a079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_15727819-e44a-4771-b7d2-9d2511d4044a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_15727819-e44a-4771-b7d2-9d2511d4044a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_da1fa415-390b-4fb2-ad0c-8f4d2790cadc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_da1fa415-390b-4fb2-ad0c-8f4d2790cadc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_70b22332-baf6-45e6-8110-c6977dbd1a09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_70b22332-baf6-45e6-8110-c6977dbd1a09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2added7c-e0e7-433d-bc2d-5409829b1b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2added7c-e0e7-433d-bc2d-5409829b1b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_27745939-9c63-4b39-a317-4b93de97a1ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_79380540-a07f-4d04-b20a-3a268403225e" xlink:to="loc_us-gaap_LiabilitiesCurrent_27745939-9c63-4b39-a317-4b93de97a1ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_8f369a9b-4da7-4cfc-8487-e52a9dcdc829" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_8f369a9b-4da7-4cfc-8487-e52a9dcdc829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c688532d-f8a6-4f46-a54e-de91676ff474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c688532d-f8a6-4f46-a54e-de91676ff474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7fa51ce1-87e9-4181-888f-e23b404296cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7fa51ce1-87e9-4181-888f-e23b404296cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_3caf9d4f-ba2b-456b-9021-cb8a439e495c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_3caf9d4f-ba2b-456b-9021-cb8a439e495c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5d23a5ad-8f6d-4796-b0c6-f3484a00cbb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_Liabilities_5d23a5ad-8f6d-4796-b0c6-f3484a00cbb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_fbb45346-770b-4157-8ea5-04a67f35bd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_fbb45346-770b-4157-8ea5-04a67f35bd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_ec7fe7fa-7874-45b6-9247-62a8eca23123" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_ec7fe7fa-7874-45b6-9247-62a8eca23123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_724c2e11-662e-4bcc-bb9d-db9045051f29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_PreferredStockValue_724c2e11-662e-4bcc-bb9d-db9045051f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e98e1fcb-efb2-4120-9866-28e26907d599" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_CommonStockValue_e98e1fcb-efb2-4120-9866-28e26907d599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f476db3d-1a35-44bb-b974-85a75a2a0fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f476db3d-1a35-44bb-b974-85a75a2a0fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3a87aa25-fda8-4948-a893-0e434d8b3f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3a87aa25-fda8-4948-a893-0e434d8b3f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1014e97b-50db-457d-94c8-212a7da4dc1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1014e97b-50db-457d-94c8-212a7da4dc1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5c348336-a9d6-4aa7-95d0-f5d5f6e71d47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_79d754b0-9924-4bc2-9a33-ee75f359b758" xlink:to="loc_us-gaap_StockholdersEquity_5c348336-a9d6-4aa7-95d0-f5d5f6e71d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f37620ac-c8f7-45d1-9ce7-8a99dc7ecadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3e7d03a3-458c-46de-8ad6-35d1b92b6fb8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f37620ac-c8f7-45d1-9ce7-8a99dc7ecadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_04762a82-d13c-4eff-b809-80b00982e95e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_04762a82-d13c-4eff-b809-80b00982e95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_9511e41d-c986-4137-91f2-f5883024fde0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_9511e41d-c986-4137-91f2-f5883024fde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_1f80f522-1b18-4a30-9dee-d6de078a9500" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9e810686-d8cb-4f5d-9426-a2f39bd2d703" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_1f80f522-1b18-4a30-9dee-d6de078a9500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedBalanceSheetsParentheticals"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_925312db-f293-4c4a-b271-671df9954c28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_925312db-f293-4c4a-b271-671df9954c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_5ba7d6ed-c005-44dd-aa23-b7fc664c3be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_5ba7d6ed-c005-44dd-aa23-b7fc664c3be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_021fa654-c6ff-439e-97be-e09a581940f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_021fa654-c6ff-439e-97be-e09a581940f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_8c3b0b44-22cd-40ef-8215-50720fe26dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_8c3b0b44-22cd-40ef-8215-50720fe26dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_b967973f-352e-4e80-8cd1-e2a2d79674f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_b967973f-352e-4e80-8cd1-e2a2d79674f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_72d092ac-f4e8-42ed-b313-79404b8e2690" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_72d092ac-f4e8-42ed-b313-79404b8e2690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6b58b1a5-6996-46b0-9402-83466cf8db56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6b58b1a5-6996-46b0-9402-83466cf8db56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_d665ac65-346b-4a56-a675-0da005d89202" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_PreferredStockSharesIssued_d665ac65-346b-4a56-a675-0da005d89202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_d9b93be2-e50f-4709-8058-79e884a1fb74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_d9b93be2-e50f-4709-8058-79e884a1fb74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_90cb3d0f-a269-4855-a6a7-d2aa47341963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_90cb3d0f-a269-4855-a6a7-d2aa47341963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f31625b2-cea4-4306-9aad-83561d853afa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f31625b2-cea4-4306-9aad-83561d853afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_60c3f8f4-d9df-4282-a3f8-c35023799cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_CommonStockSharesIssued_60c3f8f4-d9df-4282-a3f8-c35023799cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7f813d1d-947f-4ae3-9cd9-eafb187c1ff1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_adb4493f-025c-4fb7-b902-5bcaa5ff10a9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7f813d1d-947f-4ae3-9cd9-eafb187c1ff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b6eda047-1bdb-4b66-81bb-543b19ad2a0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b6eda047-1bdb-4b66-81bb-543b19ad2a0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfRevenue_257e84f3-854e-436c-b216-736147b93200" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_CostOfRevenue_257e84f3-854e-436c-b216-736147b93200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_31ff2631-4b3b-4237-9d34-1ea4047235eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_GrossProfit_31ff2631-4b3b-4237-9d34-1ea4047235eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_3ccfa845-8add-4c9e-9a5c-dac045c813d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_3ccfa845-8add-4c9e-9a5c-dac045c813d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_7de056ed-598c-4f2a-9794-2e0f5c99801f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ccfa845-8add-4c9e-9a5c-dac045c813d4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_7de056ed-598c-4f2a-9794-2e0f5c99801f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8bf27d35-f738-4045-ab36-6099f8a16847" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ccfa845-8add-4c9e-9a5c-dac045c813d4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_8bf27d35-f738-4045-ab36-6099f8a16847" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b72602e8-7f37-4e9e-9c56-bd447753a76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_3ccfa845-8add-4c9e-9a5c-dac045c813d4" xlink:to="loc_us-gaap_OperatingExpenses_b72602e8-7f37-4e9e-9c56-bd447753a76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_106ea744-8b5c-4f5b-8edb-d5c930e5b7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_OperatingIncomeLoss_106ea744-8b5c-4f5b-8edb-d5c930e5b7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_bb4c1476-5230-4adc-a4e3-cd2c2df26ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_InterestExpense_bb4c1476-5230-4adc-a4e3-cd2c2df26ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_InterestAndOtherIncomeExpense_0501e666-b759-4f46-9b7e-282dde845a4d" xlink:href="prct-20210930.xsd#prct_InterestAndOtherIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_prct_InterestAndOtherIncomeExpense_0501e666-b759-4f46-9b7e-282dde845a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a0ac34c9-7142-4d9c-9773-1dcdbe770b12" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_NetIncomeLoss_a0ac34c9-7142-4d9c-9773-1dcdbe770b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_a2c552a4-b541-4d3a-ab74-0c87f2a6e7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_EarningsPerShareBasic_a2c552a4-b541-4d3a-ab74-0c87f2a6e7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0b82f9e1-5bc6-4bf3-b919-f9e071e2618c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0b82f9e1-5bc6-4bf3-b919-f9e071e2618c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c1ab88c9-6adf-44b9-becd-b1120edd4dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c1ab88c9-6adf-44b9-becd-b1120edd4dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6b50caef-ee05-4e32-a0fa-76faf0832b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c1ab88c9-6adf-44b9-becd-b1120edd4dbc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_6b50caef-ee05-4e32-a0fa-76faf0832b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d60557ed-982c-4c60-bb97-efac133d2484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_c1ab88c9-6adf-44b9-becd-b1120edd4dbc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d60557ed-982c-4c60-bb97-efac133d2484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b54f84e9-e7d6-48c9-9370-b8d34031269b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0b9fab03-8eea-4cf1-9220-849470e37efd" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b54f84e9-e7d6-48c9-9370-b8d34031269b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d90e58e9-0ac9-45f0-9ee7-85d90e16f5da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b54f84e9-e7d6-48c9-9370-b8d34031269b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_d90e58e9-0ac9-45f0-9ee7-85d90e16f5da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5dfa298d-53eb-47aa-9eee-7c1d09865998" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b54f84e9-e7d6-48c9-9370-b8d34031269b" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_5dfa298d-53eb-47aa-9eee-7c1d09865998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_7cf6d9cc-0e0d-46ba-874e-cd7da75cc1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_0e0ed48f-954c-4a45-8f0e-219d971658b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_7cf6d9cc-0e0d-46ba-874e-cd7da75cc1b0" xlink:to="loc_us-gaap_StatementTable_0e0ed48f-954c-4a45-8f0e-219d971658b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2922ed30-f4fc-40d7-92b3-1d6c00e5a784" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0e0ed48f-954c-4a45-8f0e-219d971658b6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2922ed30-f4fc-40d7-92b3-1d6c00e5a784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2922ed30-f4fc-40d7-92b3-1d6c00e5a784" xlink:to="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b4f4a4b9-366b-4cd7-8420-7b36fe5163e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:to="loc_us-gaap_CommonStockMember_b4f4a4b9-366b-4cd7-8420-7b36fe5163e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_c8dabe77-9f32-4142-8cb7-3cb9620ca2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_c8dabe77-9f32-4142-8cb7-3cb9620ca2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_05f7e922-17fe-4a7f-be05-722cfedd70f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_05f7e922-17fe-4a7f-be05-722cfedd70f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_58753f50-f1f0-4066-a93a-9432e8c6a329" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_96462353-0397-4540-b4df-a172bd16607b" xlink:to="loc_us-gaap_RetainedEarningsMember_58753f50-f1f0-4066-a93a-9432e8c6a329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ec45293e-2d6d-4a20-b81f-8e6fcd8904fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0e0ed48f-954c-4a45-8f0e-219d971658b6" xlink:to="loc_us-gaap_StatementLineItems_ec45293e-2d6d-4a20-b81f-8e6fcd8904fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec45293e-2d6d-4a20-b81f-8e6fcd8904fe" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_172a955c-ee97-45e7-945e-f0ee60bc7f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_172a955c-ee97-45e7-945e-f0ee60bc7f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_78da63e3-a2c7-478c-b77d-ab3967af57e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_78da63e3-a2c7-478c-b77d-ab3967af57e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_a3763d7c-9dc3-46c1-be09-2fc08f75aaeb" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_a3763d7c-9dc3-46c1-be09-2fc08f75aaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises_3724a892-6714-45f6-b495-85d860545e68" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises_3724a892-6714-45f6-b495-85d860545e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c65d939b-3f6f-45bd-9c59-c07887f781df" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues_c65d939b-3f6f-45bd-9c59-c07887f781df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_44d327bf-9bec-473c-ba98-c475ba0594f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues_44d327bf-9bec-473c-ba98-c475ba0594f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquitySharesConversionOfConvertibleSecurities_c626212d-50e0-45cd-9239-1b34f85e44cb" xlink:href="prct-20210930.xsd#prct_TemporaryEquitySharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_prct_TemporaryEquitySharesConversionOfConvertibleSecurities_c626212d-50e0-45cd-9239-1b34f85e44cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityAmountConversionOfConvertibleSecurities_a152f219-73e5-47a2-aecf-c477c360ebad" xlink:href="prct-20210930.xsd#prct_TemporaryEquityAmountConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_prct_TemporaryEquityAmountConversionOfConvertibleSecurities_a152f219-73e5-47a2-aecf-c477c360ebad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_1a390e43-c44f-464c-aa1e-87f7bdc1f5de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_1a390e43-c44f-464c-aa1e-87f7bdc1f5de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12279d04-c30b-4095-b53e-ba08559240ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_29dd4a8b-b488-4e53-a8fe-ce6dc70c11fa" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_12279d04-c30b-4095-b53e-ba08559240ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ec45293e-2d6d-4a20-b81f-8e6fcd8904fe" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_d3e25477-3a25-4b57-9198-43c3fc2d8157" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_SharesOutstanding_d3e25477-3a25-4b57-9198-43c3fc2d8157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_20369fa4-444b-461e-b9b3-aae84df4d7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockholdersEquity_20369fa4-444b-461e-b9b3-aae84df4d7ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a8f9c079-f20a-4ad9-bf6e-c46796137cca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a8f9c079-f20a-4ad9-bf6e-c46796137cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c9f06a76-a230-4abf-96d2-7f8c1b110415" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_c9f06a76-a230-4abf-96d2-7f8c1b110415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition_d50b39cd-4a88-4da3-a315-6e8d606b3ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition_d50b39cd-4a88-4da3-a315-6e8d606b3ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_74c2ac16-1b14-4d17-b94d-b51d24902a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_74c2ac16-1b14-4d17-b94d-b51d24902a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_631c400b-85ca-4941-bcb3-793973698ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_631c400b-85ca-4941-bcb3-793973698ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3997ffe0-90a1-469f-85e1-a72193e367ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_3997ffe0-90a1-469f-85e1-a72193e367ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df64d60d-4aa9-4a86-8023-fe00ad36235f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_df64d60d-4aa9-4a86-8023-fe00ad36235f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cdaa2292-45c5-4318-aaf8-cc2919725931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_cdaa2292-45c5-4318-aaf8-cc2919725931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_41a29a49-87d4-4551-ba70-19acec4ab8ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_NetIncomeLoss_41a29a49-87d4-4551-ba70-19acec4ab8ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_23087399-0286-4768-9a7d-db43ff516c63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_SharesOutstanding_23087399-0286-4768-9a7d-db43ff516c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_4321c93e-b69f-4d47-a7e1-098811aac780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_2bf264cb-15e1-409f-a5e1-03f29e26b1f8" xlink:to="loc_us-gaap_StockholdersEquity_4321c93e-b69f-4d47-a7e1-098811aac780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_322bde1e-f853-43ef-88ec-ab73c980538b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_34e48007-e2e1-4756-aca2-bc001c2794cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_322bde1e-f853-43ef-88ec-ab73c980538b" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_34e48007-e2e1-4756-aca2-bc001c2794cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="prct-20210930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_cafb2d76-d840-49cf-82a5-7eeaa770acb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0d05711-2233-49c8-b109-13ab53f20b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_cafb2d76-d840-49cf-82a5-7eeaa770acb0" xlink:to="loc_us-gaap_StatementTable_f0d05711-2233-49c8-b109-13ab53f20b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_c3198473-70a5-40b1-9df6-091adb0a9a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0d05711-2233-49c8-b109-13ab53f20b8a" xlink:to="loc_us-gaap_StatementClassOfStockAxis_c3198473-70a5-40b1-9df6-091adb0a9a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ca6bdef1-ad42-47d8-9a86-74562f7a04c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_c3198473-70a5-40b1-9df6-091adb0a9a5b" xlink:to="loc_us-gaap_ClassOfStockDomain_ca6bdef1-ad42-47d8-9a86-74562f7a04c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_05e3f02b-ae73-4170-aec2-c129f2f1bbb2" xlink:href="prct-20210930.xsd#prct_SeriesFRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ca6bdef1-ad42-47d8-9a86-74562f7a04c3" xlink:to="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_05e3f02b-ae73-4170-aec2-c129f2f1bbb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_6e2ad737-e372-4387-8457-6344bd3104cd" xlink:href="prct-20210930.xsd#prct_SeriesGRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_ca6bdef1-ad42-47d8-9a86-74562f7a04c3" xlink:to="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_6e2ad737-e372-4387-8457-6344bd3104cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0d05711-2233-49c8-b109-13ab53f20b8a" xlink:to="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39018fdf-024b-4ff6-b950-e1b980121288" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39018fdf-024b-4ff6-b950-e1b980121288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b217159a-549d-4ef9-899d-5ed362897ad8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39018fdf-024b-4ff6-b950-e1b980121288" xlink:to="loc_us-gaap_NetIncomeLoss_b217159a-549d-4ef9-899d-5ed362897ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39018fdf-024b-4ff6-b950-e1b980121288" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4ab8725d-c02b-4a2d-9ae8-b56f157870b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4ab8725d-c02b-4a2d-9ae8-b56f157870b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a1983700-ff32-43bb-bfb0-f380d15e86cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_us-gaap_ShareBasedCompensation_a1983700-ff32-43bb-bfb0-f380d15e86cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax_278f3ac8-bc71-43ed-8ec9-d885eb56399b" xlink:href="prct-20210930.xsd#prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax_278f3ac8-bc71-43ed-8ec9-d885eb56399b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_NonCashLeaseAccretionExpense_7ff04d9f-4a52-41cf-b844-3edfe761b1d5" xlink:href="prct-20210930.xsd#prct_NonCashLeaseAccretionExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_prct_NonCashLeaseAccretionExpense_7ff04d9f-4a52-41cf-b844-3edfe761b1d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_f6827b35-a190-45ad-962f-0c6b8729eeb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_us-gaap_InventoryWriteDown_f6827b35-a190-45ad-962f-0c6b8729eeb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_53576c74-d7d1-4d26-bcc7-8b4ca892ca66" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a628a8b6-97e7-4919-81b1-8bcd31826b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a628a8b6-97e7-4919-81b1-8bcd31826b5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_400c408b-0267-474f-bcd5-b2725df70b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_400c408b-0267-474f-bcd5-b2725df70b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d28b2128-3d06-4066-956e-eee1c024ee02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_d28b2128-3d06-4066-956e-eee1c024ee02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5076124e-bc36-4783-8b3d-6f30ec85e1c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_5076124e-bc36-4783-8b3d-6f30ec85e1c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_4f2cbdde-a642-466f-b13e-2e0b056091e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_4f2cbdde-a642-466f-b13e-2e0b056091e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_3e70cf4c-0958-4053-b8be-af212a87d0ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInterestPayableNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInInterestPayableNet_3e70cf4c-0958-4053-b8be-af212a87d0ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46e0c258-f551-4333-915d-e923385026a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_46e0c258-f551-4333-915d-e923385026a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b088f0ee-03a6-48ce-a155-e618debf08cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_d4d63e1f-0e98-4ef3-a684-2e52ff7eabbc" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b088f0ee-03a6-48ce-a155-e618debf08cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8adb756e-7309-4e02-a430-d410752eb7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_39018fdf-024b-4ff6-b950-e1b980121288" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8adb756e-7309-4e02-a430-d410752eb7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_145b3d1c-2e45-4923-90fe-5de13e78a2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_145b3d1c-2e45-4923-90fe-5de13e78a2f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0e5fc7c6-7f12-4a59-ac0f-fe86227c989f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_145b3d1c-2e45-4923-90fe-5de13e78a2f2" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0e5fc7c6-7f12-4a59-ac0f-fe86227c989f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8dbeaf6c-785f-443a-9a38-734862b17098" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_145b3d1c-2e45-4923-90fe-5de13e78a2f2" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_8dbeaf6c-785f-443a-9a38-734862b17098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_e156e38c-08fd-4160-a4c7-ca888d03aa51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_e156e38c-08fd-4160-a4c7-ca888d03aa51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2c887168-f340-4e1a-ac90-cfa72419a57d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDebtNetOfIssuanceCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_us-gaap_ProceedsFromDebtNetOfIssuanceCosts_2c887168-f340-4e1a-ac90-cfa72419a57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_7fda89f0-18ac-4c66-a6e4-1c6c83869104" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_7fda89f0-18ac-4c66-a6e4-1c6c83869104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts_0cb4ea64-f68e-406d-912a-533214a1733c" xlink:href="prct-20210930.xsd#prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts_0cb4ea64-f68e-406d-912a-533214a1733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_cf015a93-3e18-4d2f-9e92-2b770689d7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_us-gaap_ProceedsFromIssuanceInitialPublicOffering_cf015a93-3e18-4d2f-9e92-2b770689d7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20522928-8f0e-48bd-9790-bf5e8c04c3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_9951938d-1bfe-40e1-ac5c-6c2d47349ee9" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_20522928-8f0e-48bd-9790-bf5e8c04c3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b3a87c0-7ffd-4b36-99d3-3178507e3788" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_5b3a87c0-7ffd-4b36-99d3-3178507e3788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5730f97a-f795-42ce-9ff8-c15ac3d4aedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5730f97a-f795-42ce-9ff8-c15ac3d4aedd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f93cdbd-6a3e-4cd7-b410-f89ef8747c36" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8f93cdbd-6a3e-4cd7-b410-f89ef8747c36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b26e669f-5685-4b0c-b861-e7f5f6c3ddc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b26e669f-5685-4b0c-b861-e7f5f6c3ddc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_199c30eb-6e4f-42b1-98e8-dd67805cbf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b26e669f-5685-4b0c-b861-e7f5f6c3ddc6" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_199c30eb-6e4f-42b1-98e8-dd67805cbf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a45e6692-58bc-46d4-8db3-61653b50de4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b26e669f-5685-4b0c-b861-e7f5f6c3ddc6" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_a45e6692-58bc-46d4-8db3-61653b50de4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e72d3a05-232a-4f10-a130-99a81fe9b799" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b26e669f-5685-4b0c-b861-e7f5f6c3ddc6" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e72d3a05-232a-4f10-a130-99a81fe9b799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfa39b1-44db-4777-b582-b856cf1b3c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b049238b-eaed-4085-9b66-485fa5fe1245" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfa39b1-44db-4777-b582-b856cf1b3c7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_c3b7cde7-a26f-40c5-ac49-ec6fcaff7967" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfa39b1-44db-4777-b582-b856cf1b3c7e" xlink:to="loc_us-gaap_InterestPaidNet_c3b7cde7-a26f-40c5-ac49-ec6fcaff7967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab91bb18-e8fb-4b7d-809c-3cef469effd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6cfa39b1-44db-4777-b582-b856cf1b3c7e" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab91bb18-e8fb-4b7d-809c-3cef469effd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TransferFromInventoryToPropertyAndEquipmentNet_323ba7a0-d096-4666-95f9-9793c8c7ffe2" xlink:href="prct-20210930.xsd#prct_TransferFromInventoryToPropertyAndEquipmentNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab91bb18-e8fb-4b7d-809c-3cef469effd0" xlink:to="loc_prct_TransferFromInventoryToPropertyAndEquipmentNet_323ba7a0-d096-4666-95f9-9793c8c7ffe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_98a8d086-cd78-41d1-b22a-9748088afb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab91bb18-e8fb-4b7d-809c-3cef469effd0" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_98a8d086-cd78-41d1-b22a-9748088afb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_12023c86-afb0-4082-8f42-256b515b7a77" xlink:href="prct-20210930.xsd#prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ab91bb18-e8fb-4b7d-809c-3cef469effd0" xlink:to="loc_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction_12023c86-afb0-4082-8f42-256b515b7a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/Organization" xlink:type="simple" xlink:href="prct-20210930.xsd#Organization"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/Organization" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_350cea49-92c8-46dc-a990-9ec21233a209" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_46b88875-fca2-48a1-a7f7-20faa512e154" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_350cea49-92c8-46dc-a990-9ec21233a209" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_46b88875-fca2-48a1-a7f7-20faa512e154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/OrganizationDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#OrganizationDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/OrganizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0a15a3f3-7ca1-4ca2-bfa5-ebe273e268c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_658f6436-deaf-4d48-8447-b3c36958ccda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0a15a3f3-7ca1-4ca2-bfa5-ebe273e268c1" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_658f6436-deaf-4d48-8447-b3c36958ccda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b1b37e-4df3-4aae-860e-36eb264e6ba2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_658f6436-deaf-4d48-8447-b3c36958ccda" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b1b37e-4df3-4aae-860e-36eb264e6ba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239aa202-c67a-4a90-b18b-1b97a4787156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_a0b1b37e-4df3-4aae-860e-36eb264e6ba2" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239aa202-c67a-4a90-b18b-1b97a4787156" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_6888b57f-67e2-421c-b104-9e107976f4b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_239aa202-c67a-4a90-b18b-1b97a4787156" xlink:to="loc_us-gaap_IPOMember_6888b57f-67e2-421c-b104-9e107976f4b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_f8ca4ae1-5cad-4e2c-83e1-a797063db59a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_658f6436-deaf-4d48-8447-b3c36958ccda" xlink:to="loc_us-gaap_StatementClassOfStockAxis_f8ca4ae1-5cad-4e2c-83e1-a797063db59a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_714adb8d-9d8c-498f-910a-c84aae678776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_f8ca4ae1-5cad-4e2c-83e1-a797063db59a" xlink:to="loc_us-gaap_ClassOfStockDomain_714adb8d-9d8c-498f-910a-c84aae678776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f6572414-92f9-4d08-8257-5eaff5f7ff7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_714adb8d-9d8c-498f-910a-c84aae678776" xlink:to="loc_us-gaap_CommonStockMember_f6572414-92f9-4d08-8257-5eaff5f7ff7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_9f939ff4-b18d-4d42-b56c-7b5ab55ce6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_658f6436-deaf-4d48-8447-b3c36958ccda" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_9f939ff4-b18d-4d42-b56c-7b5ab55ce6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8482272-8b7b-477a-a1c5-a568a12c9586" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9f939ff4-b18d-4d42-b56c-7b5ab55ce6cf" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_f8482272-8b7b-477a-a1c5-a568a12c9586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_abf7b972-5b7e-496c-afa4-e7502068f44f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9f939ff4-b18d-4d42-b56c-7b5ab55ce6cf" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_abf7b972-5b7e-496c-afa4-e7502068f44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_InitialPublicOfferingAbstract_5d29e560-140d-4534-97ef-136f73867749" xlink:href="prct-20210930.xsd#prct_InitialPublicOfferingAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_9f939ff4-b18d-4d42-b56c-7b5ab55ce6cf" xlink:to="loc_prct_InitialPublicOfferingAbstract_5d29e560-140d-4534-97ef-136f73867749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_57b28b98-16fc-4c0b-b853-65505091b009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_InitialPublicOfferingAbstract_5d29e560-140d-4534-97ef-136f73867749" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_57b28b98-16fc-4c0b-b853-65505091b009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a268aba5-66e4-42b6-8a42-6e9a3759cf00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a9e41ea4-2ac5-42ee-aafd-77bf834849bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a268aba5-66e4-42b6-8a42-6e9a3759cf00" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_a9e41ea4-2ac5-42ee-aafd-77bf834849bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2c6b6b09-7682-44cb-89f0-7048a8c97691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_2c6b6b09-7682-44cb-89f0-7048a8c97691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_a817b797-459e-4925-84c4-a148b6df6a08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_UseOfEstimates_a817b797-459e-4925-84c4-a148b6df6a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f4b22c4b-5e2c-4251-8e71-272df1b77121" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_f4b22c4b-5e2c-4251-8e71-272df1b77121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6ff8afd1-dcb4-401f-8198-cb368c4420cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_6ff8afd1-dcb4-401f-8198-cb368c4420cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_fced29e5-f7ca-4cbd-9e10-8f848e189347" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_fced29e5-f7ca-4cbd-9e10-8f848e189347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_c1682fe3-5f1e-41ae-8573-84bb72da3298" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy_c1682fe3-5f1e-41ae-8573-84bb72da3298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_e97f134f-d506-4c69-a1bd-c3cacf95812e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_e97f134f-d506-4c69-a1bd-c3cacf95812e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a28626c7-d7f9-47bf-b304-9a14b5744b00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_a28626c7-d7f9-47bf-b304-9a14b5744b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_328b5e59-b2f7-4366-a300-ac11b4103ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_328b5e59-b2f7-4366-a300-ac11b4103ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredChargesPolicyTextBlock_4c2e6b5d-2003-4441-b981-58b2209a9de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredChargesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_DeferredChargesPolicyTextBlock_4c2e6b5d-2003-4441-b981-58b2209a9de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d1781748-34c8-4d68-b524-236ebd063303" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d1781748-34c8-4d68-b524-236ebd063303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_8d910872-76f8-45aa-8411-b4f8768db273" xlink:href="prct-20210930.xsd#prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock_8d910872-76f8-45aa-8411-b4f8768db273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock_fa904b65-3618-42e1-af4e-2a7862b50be5" xlink:href="prct-20210930.xsd#prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock_fa904b65-3618-42e1-af4e-2a7862b50be5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_424069bb-8e99-41ea-b93e-ffab5a76dc85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_424069bb-8e99-41ea-b93e-ffab5a76dc85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_cc9b4ad5-1458-4611-a38a-30d28dc35c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_cc9b4ad5-1458-4611-a38a-30d28dc35c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorLeasesPolicyTextBlock_54b48940-1332-4093-b02c-2147cbe71108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LessorLeasesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_LessorLeasesPolicyTextBlock_54b48940-1332-4093-b02c-2147cbe71108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_810841a5-6c9c-4678-9713-318d0fbc64d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_810841a5-6c9c-4678-9713-318d0fbc64d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesPolicyTextBlock_fcb17492-ab0b-4a8a-a956-55d3d64fc299" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_CostOfSalesPolicyTextBlock_fcb17492-ab0b-4a8a-a956-55d3d64fc299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3f9c69f9-15ff-410f-82cd-6ebb2f76ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3f9c69f9-15ff-410f-82cd-6ebb2f76ff67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0c771ed1-48c2-4112-b682-5e8ab397c8b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_0c771ed1-48c2-4112-b682-5e8ab397c8b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_CommonStockValuationPolicyPolicyTextBlock_f9e9064a-c1fb-447d-a981-2f3995b6dcb0" xlink:href="prct-20210930.xsd#prct_CommonStockValuationPolicyPolicyTextBlock"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_prct_CommonStockValuationPolicyPolicyTextBlock_f9e9064a-c1fb-447d-a981-2f3995b6dcb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_81109567-7cab-4702-af2e-3790618ead3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_81109567-7cab-4702-af2e-3790618ead3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_85a307fa-ff8a-4c5f-9230-48feb14610e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy_85a307fa-ff8a-4c5f-9230-48feb14610e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_950cb863-bf27-43ac-be59-205d8222e8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_950cb863-bf27-43ac-be59-205d8222e8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_a9274b8a-aa2b-4577-bda8-ca5d87875c05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_a9274b8a-aa2b-4577-bda8-ca5d87875c05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_46269eeb-c43d-4cd9-b28c-b9f5009f5764" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_46269eeb-c43d-4cd9-b28c-b9f5009f5764" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_JobsActAccountingElectionPolicyTextBlock_cf8f5b74-1cef-44b9-a110-cbafb7a829e3" xlink:href="prct-20210930.xsd#prct_JobsActAccountingElectionPolicyTextBlock"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_prct_JobsActAccountingElectionPolicyTextBlock_cf8f5b74-1cef-44b9-a110-cbafb7a829e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a451c673-2680-466f-9b17-6914c091e4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_343b2526-d670-4550-a0e2-7ad0118f7b86" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_a451c673-2680-466f-9b17-6914c091e4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_8956b52d-3c82-4d68-934e-eef5b1b5c14b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3171818b-2c36-459c-876f-a9d0fde349c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8956b52d-3c82-4d68-934e-eef5b1b5c14b" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3171818b-2c36-459c-876f-a9d0fde349c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_e6af35eb-16b9-4b82-9cac-2bba0bc928c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8956b52d-3c82-4d68-934e-eef5b1b5c14b" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_e6af35eb-16b9-4b82-9cac-2bba0bc928c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1d21c8bd-6e12-4c82-b99c-f1aa32599142" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8956b52d-3c82-4d68-934e-eef5b1b5c14b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_1d21c8bd-6e12-4c82-b99c-f1aa32599142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_b9bb5861-a5ab-49c0-95d7-a6538809813b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8956b52d-3c82-4d68-934e-eef5b1b5c14b" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_b9bb5861-a5ab-49c0-95d7-a6538809813b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6b3a09c5-2158-4edf-aeb5-4346ebc819cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8956b52d-3c82-4d68-934e-eef5b1b5c14b" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_6b3a09c5-2158-4edf-aeb5-4346ebc819cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_05035567-5e57-4af1-bff3-c0250a7569f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8956b52d-3c82-4d68-934e-eef5b1b5c14b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock_05035567-5e57-4af1-bff3-c0250a7569f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_d4cc25d1-a36a-4835-ac60-652e50d4a806" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8956b52d-3c82-4d68-934e-eef5b1b5c14b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock_d4cc25d1-a36a-4835-ac60-652e50d4a806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_018c9098-08fa-48bd-9528-c75030c0757e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8956b52d-3c82-4d68-934e-eef5b1b5c14b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_018c9098-08fa-48bd-9528-c75030c0757e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_dce1621f-26ae-4d5e-87f5-fbc5a3f56713" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_8956b52d-3c82-4d68-934e-eef5b1b5c14b" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_dce1621f-26ae-4d5e-87f5-fbc5a3f56713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7a98e5c9-abf4-48f5-aa74-a1599371e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7a98e5c9-abf4-48f5-aa74-a1599371e29d" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_46702e65-13e0-4814-a3d8-9e6beed4a421" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_StatementClassOfStockAxis_46702e65-13e0-4814-a3d8-9e6beed4a421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_156b0000-4f76-4b54-9dfc-f2227bec0ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46702e65-13e0-4814-a3d8-9e6beed4a421" xlink:to="loc_us-gaap_ClassOfStockDomain_156b0000-4f76-4b54-9dfc-f2227bec0ee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_e9159667-87af-40f3-9eaf-5c012b509f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_156b0000-4f76-4b54-9dfc-f2227bec0ee0" xlink:to="loc_us-gaap_CommonStockMember_e9159667-87af-40f3-9eaf-5c012b509f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_8dbb281a-46a6-496e-8616-ffbbd058e143" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_8dbb281a-46a6-496e-8616-ffbbd058e143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9563d695-3e11-4554-8fd9-3998a714a6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_8dbb281a-46a6-496e-8616-ffbbd058e143" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9563d695-3e11-4554-8fd9-3998a714a6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IPOMember_ac20f5c5-bdc2-48f7-aba5-bf4e2f487ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9563d695-3e11-4554-8fd9-3998a714a6ac" xlink:to="loc_us-gaap_IPOMember_ac20f5c5-bdc2-48f7-aba5-bf4e2f487ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OverAllotmentOptionMember_6917a34a-5a29-4069-b221-635ae019a8e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OverAllotmentOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9563d695-3e11-4554-8fd9-3998a714a6ac" xlink:to="loc_us-gaap_OverAllotmentOptionMember_6917a34a-5a29-4069-b221-635ae019a8e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_a8dce356-2ef1-46ab-9c34-9ff46ea03922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9563d695-3e11-4554-8fd9-3998a714a6ac" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_a8dce356-2ef1-46ab-9c34-9ff46ea03922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_28509fda-884d-4fcd-bbf4-e24b12270369" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_srt_RangeAxis_28509fda-884d-4fcd-bbf4-e24b12270369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_269362ca-81c9-46dd-8674-c1224a402eb8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_28509fda-884d-4fcd-bbf4-e24b12270369" xlink:to="loc_srt_RangeMember_269362ca-81c9-46dd-8674-c1224a402eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_37c1bd15-20e4-42bb-b98f-fd11b0667e84" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_269362ca-81c9-46dd-8674-c1224a402eb8" xlink:to="loc_srt_MinimumMember_37c1bd15-20e4-42bb-b98f-fd11b0667e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_38e3257f-51eb-476c-8192-41040007cdea" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_269362ca-81c9-46dd-8674-c1224a402eb8" xlink:to="loc_srt_MaximumMember_38e3257f-51eb-476c-8192-41040007cdea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_458bab53-9357-48d7-a188-4f3d65db1bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_458bab53-9357-48d7-a188-4f3d65db1bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_a4c144e0-d912-40f6-b6c0-7a0654be9bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_458bab53-9357-48d7-a188-4f3d65db1bf7" xlink:to="loc_us-gaap_TypeOfAdoptionMember_a4c144e0-d912-40f6-b6c0-7a0654be9bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_38ddb4bd-fff4-4339-bd93-9bb1646676b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_a4c144e0-d912-40f6-b6c0-7a0654be9bb9" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_38ddb4bd-fff4-4339-bd93-9bb1646676b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_65f29895-64a7-4119-989e-4b8b6b64dac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_65f29895-64a7-4119-989e-4b8b6b64dac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f9fff0af-ea45-4bf5-8114-c6798ddbd140" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_65f29895-64a7-4119-989e-4b8b6b64dac2" xlink:to="loc_us-gaap_EquityComponentDomain_f9fff0af-ea45-4bf5-8114-c6798ddbd140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_3aef21f2-5c66-4576-8108-db0dad9b87d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f9fff0af-ea45-4bf5-8114-c6798ddbd140" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_3aef21f2-5c66-4576-8108-db0dad9b87d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_8c666aeb-f251-41d9-b377-d5ff5747f305" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f9fff0af-ea45-4bf5-8114-c6798ddbd140" xlink:to="loc_us-gaap_WarrantMember_8c666aeb-f251-41d9-b377-d5ff5747f305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6af3e8c3-52f1-4647-a20b-c7b87f213aae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6af3e8c3-52f1-4647-a20b-c7b87f213aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_4cfe7003-e19a-490e-9b6a-bc2c99380348" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6af3e8c3-52f1-4647-a20b-c7b87f213aae" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_4cfe7003-e19a-490e-9b6a-bc2c99380348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_a37e1776-4c4f-43ed-86e7-dd94169f8ac8" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_4cfe7003-e19a-490e-9b6a-bc2c99380348" xlink:to="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_a37e1776-4c4f-43ed-86e7-dd94169f8ac8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_71c5432e-3d1d-4c22-932f-20fa4e7c1039" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_74878ebc-0e80-4a33-901f-a92dd13fa08a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_74878ebc-0e80-4a33-901f-a92dd13fa08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3de0a617-3a8e-441c-8946-18dfb940b520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_3de0a617-3a8e-441c-8946-18dfb940b520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_35852c74-c3b7-4d4b-9bdc-aede429f389e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_35852c74-c3b7-4d4b-9bdc-aede429f389e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1056305d-66f1-47be-a738-85913d923a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_1056305d-66f1-47be-a738-85913d923a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForUnderwritingExpense_ed86ef64-f4e6-4ca1-805f-1aa4f8d3cb49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForUnderwritingExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_PaymentsForUnderwritingExpense_ed86ef64-f4e6-4ca1-805f-1aa4f8d3cb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_42b087dd-a16f-4c06-9433-949a256ba514" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_42b087dd-a16f-4c06-9433-949a256ba514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_56a902e3-1487-4b5b-b042-320b0d617936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_56a902e3-1487-4b5b-b042-320b0d617936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_49a2a973-9320-4882-b830-49d2b92e4bae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_49a2a973-9320-4882-b830-49d2b92e4bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c25c3b74-8525-487a-b596-c304672642f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c25c3b74-8525-487a-b596-c304672642f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b680c9d-0cae-4f4d-842d-5dd9765d5dd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6b680c9d-0cae-4f4d-842d-5dd9765d5dd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredOfferingCosts_3dc6b395-8663-4400-a441-2b7f054e64bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredOfferingCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_DeferredOfferingCosts_3dc6b395-8663-4400-a441-2b7f054e64bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ProductWarrantyTerm_f5cdf295-cbda-4d69-a888-d0631aacce04" xlink:href="prct-20210930.xsd#prct_ProductWarrantyTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_prct_ProductWarrantyTerm_f5cdf295-cbda-4d69-a888-d0631aacce04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ServiceAgreementAmortizationPeriod_c4e768c1-f00e-417e-afe2-d4bc1f459de0" xlink:href="prct-20210930.xsd#prct_ServiceAgreementAmortizationPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_prct_ServiceAgreementAmortizationPeriod_c4e768c1-f00e-417e-afe2-d4bc1f459de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_ab9d07a9-c90a-4e7e-91f6-d6db1770b4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_ab9d07a9-c90a-4e7e-91f6-d6db1770b4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0c9fd274-a933-4a54-9498-b6d61641ce4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_OperatingLeaseLiability_0c9fd274-a933-4a54-9498-b6d61641ce4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_4cf20689-0737-4149-ac3a-ff72531cf61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_4cf20689-0737-4149-ac3a-ff72531cf61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_298143db-d512-4aca-b98c-913c9327e311" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_298143db-d512-4aca-b98c-913c9327e311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_270f230b-97ea-44bd-8951-c5c48eb2bd4b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_270f230b-97ea-44bd-8951-c5c48eb2bd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_470772c3-71f0-4b51-a2b9-f5ed80e2eec1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_470772c3-71f0-4b51-a2b9-f5ed80e2eec1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_08892bba-9d07-4fe3-842c-e18a00a1de38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_08892bba-9d07-4fe3-842c-e18a00a1de38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_adb36713-a379-4ba0-b898-38b0c1efa21d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_11d5cef4-ab7a-4ce0-80e7-ff254c929b2f" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_adb36713-a379-4ba0-b898-38b0c1efa21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68dccb78-0056-43a0-a67e-3902a1cb6366" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5b29f900-2f72-471f-a5d7-9286726d50b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68dccb78-0056-43a0-a67e-3902a1cb6366" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5b29f900-2f72-471f-a5d7-9286726d50b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ed29c9-3b58-436a-b3c9-609b11dc36eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5b29f900-2f72-471f-a5d7-9286726d50b9" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ed29c9-3b58-436a-b3c9-609b11dc36eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_349523b1-3ecb-4033-8f6c-ae8ec41f771f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_a0ed29c9-3b58-436a-b3c9-609b11dc36eb" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_349523b1-3ecb-4033-8f6c-ae8ec41f771f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_04293da3-3170-4678-9cc9-f6513fe4dcce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_349523b1-3ecb-4033-8f6c-ae8ec41f771f" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_04293da3-3170-4678-9cc9-f6513fe4dcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef93e4d3-a220-47ea-a0ee-83cf31a1cf89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5b29f900-2f72-471f-a5d7-9286726d50b9" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef93e4d3-a220-47ea-a0ee-83cf31a1cf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc4f77ed-7437-4c6f-afe5-2e112ce4e27e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ef93e4d3-a220-47ea-a0ee-83cf31a1cf89" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc4f77ed-7437-4c6f-afe5-2e112ce4e27e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_8d386c3a-1d96-4dc8-8925-7a65a982697b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc4f77ed-7437-4c6f-afe5-2e112ce4e27e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_8d386c3a-1d96-4dc8-8925-7a65a982697b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_a36e689b-82f7-41da-b7f6-2885eaa712b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc4f77ed-7437-4c6f-afe5-2e112ce4e27e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_a36e689b-82f7-41da-b7f6-2885eaa712b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3f752050-64fb-43ea-a45c-0577ec272054" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_cc4f77ed-7437-4c6f-afe5-2e112ce4e27e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3f752050-64fb-43ea-a45c-0577ec272054" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_5b29f900-2f72-471f-a5d7-9286726d50b9" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_a34eaecc-c5dc-45f7-97be-13423c437204" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_Cash_a34eaecc-c5dc-45f7-97be-13423c437204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_d5f61dde-6f4d-412a-85a4-c303c1e1eba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_d5f61dde-6f4d-412a-85a4-c303c1e1eba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5644f76e-b926-4bdd-ae74-9ad2c107469f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_5644f76e-b926-4bdd-ae74-9ad2c107469f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_ab30ffd7-283a-418a-8d14-66c0426edf9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_ab30ffd7-283a-418a-8d14-66c0426edf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_2395844e-c679-4f48-9722-b1ce247d9693" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_8795f6a7-06e1-4a9c-96a7-c9a129b03a1d" xlink:to="loc_us-gaap_DerivativeLiabilities_2395844e-c679-4f48-9722-b1ce247d9693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_17ffef36-ec77-4717-8ae6-673e49e4a083" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceca4bdb-bca7-4685-a7a1-24e4107340ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_17ffef36-ec77-4717-8ae6-673e49e4a083" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceca4bdb-bca7-4685-a7a1-24e4107340ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_6d292bc5-1de6-438a-bb2d-0893da6c33c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceca4bdb-bca7-4685-a7a1-24e4107340ce" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_6d292bc5-1de6-438a-bb2d-0893da6c33c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f4e5da04-3ce1-4274-9a53-4f03c65d0983" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_6d292bc5-1de6-438a-bb2d-0893da6c33c4" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f4e5da04-3ce1-4274-9a53-4f03c65d0983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_c6f2db58-94dc-4a82-9ae4-a6476917ca04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f4e5da04-3ce1-4274-9a53-4f03c65d0983" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_c6f2db58-94dc-4a82-9ae4-a6476917ca04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_187166be-0958-4aa0-89be-a6d381e89e30" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_ceca4bdb-bca7-4685-a7a1-24e4107340ce" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_187166be-0958-4aa0-89be-a6d381e89e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_187166be-0958-4aa0-89be-a6d381e89e30" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_230fc578-679a-4bb2-9210-f27a7db7cb98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_230fc578-679a-4bb2-9210-f27a7db7cb98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_df630261-0207-4376-9ccd-4557bda92a1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales_df630261-0207-4376-9ccd-4557bda92a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_da27d5c0-64f8-4d3f-b516-bd4584b6f5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_da27d5c0-64f8-4d3f-b516-bd4584b6f5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9fb65009-f7d2-4c30-a1de-cf2957bc5aa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_9fb65009-f7d2-4c30-a1de-cf2957bc5aa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4da41967-f9ea-4ee3-b7ee-705f9b3eb004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1c19aeaf-e0fb-4673-9c0b-5a096b23f787" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4da41967-f9ea-4ee3-b7ee-705f9b3eb004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fa113cfa-7177-48af-b1da-df645d81d5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cc4dd1cf-758d-4aae-b00a-2adffe569557" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fa113cfa-7177-48af-b1da-df645d81d5f1" xlink:to="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cc4dd1cf-758d-4aae-b00a-2adffe569557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_640a207b-1234-4286-b778-11e5480319f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cc4dd1cf-758d-4aae-b00a-2adffe569557" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_640a207b-1234-4286-b778-11e5480319f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_3fd855b6-0847-44c4-8802-c6887add0935" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_640a207b-1234-4286-b778-11e5480319f5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_3fd855b6-0847-44c4-8802-c6887add0935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_78b29cad-d0e6-4b69-aa77-47573e168fa3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_3fd855b6-0847-44c4-8802-c6887add0935" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_78b29cad-d0e6-4b69-aa77-47573e168fa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_df3c0242-99b8-4cd5-b260-ff96cd18d7e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cc4dd1cf-758d-4aae-b00a-2adffe569557" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_df3c0242-99b8-4cd5-b260-ff96cd18d7e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_285910e4-0b60-436d-b007-cb073136e306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_df3c0242-99b8-4cd5-b260-ff96cd18d7e8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_285910e4-0b60-436d-b007-cb073136e306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputOptionVolatilityMember_580a1daa-9e55-4f68-af69-a53a6f334182" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputOptionVolatilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285910e4-0b60-436d-b007-cb073136e306" xlink:to="loc_us-gaap_MeasurementInputOptionVolatilityMember_580a1daa-9e55-4f68-af69-a53a6f334182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e1e1f7f2-2bf2-4430-8c95-bd4be9c7496a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285910e4-0b60-436d-b007-cb073136e306" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_e1e1f7f2-2bf2-4430-8c95-bd4be9c7496a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_134274ae-e78f-4445-940d-13974d820923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_285910e4-0b60-436d-b007-cb073136e306" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_134274ae-e78f-4445-940d-13974d820923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockLineItems_bb80bace-4b5b-4495-a535-9d4997a1f39e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_cc4dd1cf-758d-4aae-b00a-2adffe569557" xlink:to="loc_us-gaap_SubsidiarySaleOfStockLineItems_bb80bace-4b5b-4495-a535-9d4997a1f39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_WarrantsAndRightsOutstandingWeightedAverageTerm_7c3fae89-13a9-4964-a4e1-ab49a49f7f37" xlink:href="prct-20210930.xsd#prct_WarrantsAndRightsOutstandingWeightedAverageTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_bb80bace-4b5b-4495-a535-9d4997a1f39e" xlink:to="loc_prct_WarrantsAndRightsOutstandingWeightedAverageTerm_7c3fae89-13a9-4964-a4e1-ab49a49f7f37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_63a2968d-d782-4635-8938-f2905c5817b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockLineItems_bb80bace-4b5b-4495-a535-9d4997a1f39e" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_63a2968d-d782-4635-8938-f2905c5817b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c9cd8ed2-885d-4598-bba2-8c22749c9c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c9cd8ed2-885d-4598-bba2-8c22749c9c1a" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8d70e0b-577f-47f3-81a0-1b639d00a17f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8d70e0b-577f-47f3-81a0-1b639d00a17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d89679b0-004d-4187-89d9-ce0b25737d40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e8d70e0b-577f-47f3-81a0-1b639d00a17f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d89679b0-004d-4187-89d9-ce0b25737d40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_6eb6170a-fda7-4c32-9dd8-84c6c96763df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d89679b0-004d-4187-89d9-ce0b25737d40" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_6eb6170a-fda7-4c32-9dd8-84c6c96763df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_2fc3081a-eae2-437c-9b56-3b25e1a57778" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:to="loc_us-gaap_DebtInstrumentAxis_2fc3081a-eae2-437c-9b56-3b25e1a57778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e6da12dc-2715-49c0-9c85-2e9e8e13f89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2fc3081a-eae2-437c-9b56-3b25e1a57778" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e6da12dc-2715-49c0-9c85-2e9e8e13f89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityMember_b02b4f0c-5483-4e1e-b3c9-50fcf2ba0247" xlink:href="prct-20210930.xsd#prct_LoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e6da12dc-2715-49c0-9c85-2e9e8e13f89f" xlink:to="loc_prct_LoanFacilityMember_b02b4f0c-5483-4e1e-b3c9-50fcf2ba0247" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_5cc70425-0871-468e-a0c6-d1186e94e944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:to="loc_us-gaap_ValuationTechniqueAxis_5cc70425-0871-468e-a0c6-d1186e94e944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_d32c03cd-b0b0-4787-975b-872fe7123cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_5cc70425-0871-468e-a0c6-d1186e94e944" xlink:to="loc_us-gaap_ValuationTechniqueDomain_d32c03cd-b0b0-4787-975b-872fe7123cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_1cdf8182-ec4b-40af-83f4-b5ee4b2315f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_d32c03cd-b0b0-4787-975b-872fe7123cc3" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_1cdf8182-ec4b-40af-83f4-b5ee4b2315f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ee214e-bb5e-4f27-a33c-ab798bbe6218" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ee214e-bb5e-4f27-a33c-ab798bbe6218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_67819bc8-3230-4cae-8a3d-22d469a24ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f3ee214e-bb5e-4f27-a33c-ab798bbe6218" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_67819bc8-3230-4cae-8a3d-22d469a24ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_e02ed0f6-8ea7-45ec-ae8e-c7f7cd6aeed8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_67819bc8-3230-4cae-8a3d-22d469a24ea5" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_e02ed0f6-8ea7-45ec-ae8e-c7f7cd6aeed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_b4ed7889-9337-43c3-a88f-a56281ee3c82" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_b8025347-8458-4f7a-9fca-f85a9ef7afab" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_b8025347-8458-4f7a-9fca-f85a9ef7afab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_39924f5c-41fb-4d03-a05d-5ea0933f93de" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_39924f5c-41fb-4d03-a05d-5ea0933f93de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_4eaf5ef0-09c4-4993-979b-c3045a672a07" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_4eaf5ef0-09c4-4993-979b-c3045a672a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_3f9af5b4-867c-453d-92ce-5db9a89ae595" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_3f9af5b4-867c-453d-92ce-5db9a89ae595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_f0ac4c18-56d5-4f0b-a918-320de529bfde" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_f0ac4c18-56d5-4f0b-a918-320de529bfde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4558540f-4d29-41be-87b7-e074597dcf97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_4558540f-4d29-41be-87b7-e074597dcf97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMeasurementInput_965bea53-8696-4899-ba20-36689b1b9683" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMeasurementInput"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_us-gaap_LongTermDebtMeasurementInput_965bea53-8696-4899-ba20-36689b1b9683" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_0fd42fbb-0b7b-4aa3-9a7a-3ac250fe18d9" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_93267a32-11db-4768-8b9c-3f4bd42cba00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_93267a32-11db-4768-8b9c-3f4bd42cba00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_c091d078-0787-42e9-9ee7-9d7991c7d280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues_c091d078-0787-42e9-9ee7-9d7991c7d280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_6b23145d-75d1-4848-833a-2ebe4c8f3a6e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings_6b23145d-75d1-4848-833a-2ebe4c8f3a6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_d2993de3-2912-4ac3-8e42-4d62f65a180d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements_d2993de3-2912-4ac3-8e42-4d62f65a180d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_ff427898-80ca-4d5c-ae34-c13f49d57542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward_686f824b-c486-499e-b7f3-4f395e5a1932" xlink:to="loc_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs_ff427898-80ca-4d5c-ae34-c13f49d57542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_2135861e-19ce-4aec-b7a6-5780e70c7f3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_a2e44ea9-2e74-402e-a3a8-f6e99af5b411" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_2135861e-19ce-4aec-b7a6-5780e70c7f3b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_a2e44ea9-2e74-402e-a3a8-f6e99af5b411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_0ddf98d6-f94b-4a7c-bc73-8545f70446ad" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2e44ea9-2e74-402e-a3a8-f6e99af5b411" xlink:to="loc_srt_StatementGeographicalAxis_0ddf98d6-f94b-4a7c-bc73-8545f70446ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3a2c65bd-899d-43ef-8c22-cbc35507063a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0ddf98d6-f94b-4a7c-bc73-8545f70446ad" xlink:to="loc_srt_SegmentGeographicalDomain_3a2c65bd-899d-43ef-8c22-cbc35507063a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_20720eff-c346-4bb4-a756-6e3d2afee0c1" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3a2c65bd-899d-43ef-8c22-cbc35507063a" xlink:to="loc_country_US_20720eff-c346-4bb4-a756-6e3d2afee0c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OutsideTheUnitedStatesMember_c5744af6-208e-400b-9af1-0465fee59eb7" xlink:href="prct-20210930.xsd#prct_OutsideTheUnitedStatesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3a2c65bd-899d-43ef-8c22-cbc35507063a" xlink:to="loc_prct_OutsideTheUnitedStatesMember_c5744af6-208e-400b-9af1-0465fee59eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_238a1227-33b9-43f0-94d8-32a57fa5c1a1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2e44ea9-2e74-402e-a3a8-f6e99af5b411" xlink:to="loc_srt_ProductOrServiceAxis_238a1227-33b9-43f0-94d8-32a57fa5c1a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_35feba81-2db7-451b-832f-68e8b2253827" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_238a1227-33b9-43f0-94d8-32a57fa5c1a1" xlink:to="loc_srt_ProductsAndServicesDomain_35feba81-2db7-451b-832f-68e8b2253827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SystemSalesAndRentalsMember_74be693e-3588-493f-aa90-8058798841d2" xlink:href="prct-20210930.xsd#prct_SystemSalesAndRentalsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35feba81-2db7-451b-832f-68e8b2253827" xlink:to="loc_prct_SystemSalesAndRentalsMember_74be693e-3588-493f-aa90-8058798841d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_HandPiecesAndOtherConsumablesMember_1bb485f1-f9ef-49d1-afd6-ab037c036429" xlink:href="prct-20210930.xsd#prct_HandPiecesAndOtherConsumablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35feba81-2db7-451b-832f-68e8b2253827" xlink:to="loc_prct_HandPiecesAndOtherConsumablesMember_1bb485f1-f9ef-49d1-afd6-ab037c036429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ServiceRevenueMember_821a14c8-667f-4b6a-bce5-616ec1ccfcc3" xlink:href="prct-20210930.xsd#prct_ServiceRevenueMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_35feba81-2db7-451b-832f-68e8b2253827" xlink:to="loc_prct_ServiceRevenueMember_821a14c8-667f-4b6a-bce5-616ec1ccfcc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_c217d751-3f8c-43d7-80b6-6eb93ed9eec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_a2e44ea9-2e74-402e-a3a8-f6e99af5b411" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_c217d751-3f8c-43d7-80b6-6eb93ed9eec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f340c48c-46ff-4219-be04-61fec1775077" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_c217d751-3f8c-43d7-80b6-6eb93ed9eec4" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f340c48c-46ff-4219-be04-61fec1775077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7f3a3dfe-5c14-4e7c-9ea5-da17b167a7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7f3a3dfe-5c14-4e7c-9ea5-da17b167a7fe" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59e4fc78-cd8a-4c85-820a-2dfc02913d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59e4fc78-cd8a-4c85-820a-2dfc02913d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ce42f2d4-6f39-4e21-93b8-e4494d8d16bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_59e4fc78-cd8a-4c85-820a-2dfc02913d0a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ce42f2d4-6f39-4e21-93b8-e4494d8d16bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_ff258d94-89d1-48c7-9626-b57783fe0424" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ce42f2d4-6f39-4e21-93b8-e4494d8d16bc" xlink:to="loc_us-gaap_SalesRevenueNetMember_ff258d94-89d1-48c7-9626-b57783fe0424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_b95135ff-af4b-44a0-8f36-9387af152dfb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_b95135ff-af4b-44a0-8f36-9387af152dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_aa3361f6-c38a-49b4-a45c-ad4c07f91cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_b95135ff-af4b-44a0-8f36-9387af152dfb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_aa3361f6-c38a-49b4-a45c-ad4c07f91cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_faf0978a-3915-4daf-9bdf-a960a5e23b9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeographicConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_aa3361f6-c38a-49b4-a45c-ad4c07f91cd1" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_faf0978a-3915-4daf-9bdf-a960a5e23b9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_cfc0ad10-afb1-4a0c-b5ec-7d2f6eb66cd3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:to="loc_srt_StatementGeographicalAxis_cfc0ad10-afb1-4a0c-b5ec-7d2f6eb66cd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_8d14683f-c372-46dd-b767-d39c63fd5651" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_cfc0ad10-afb1-4a0c-b5ec-7d2f6eb66cd3" xlink:to="loc_srt_SegmentGeographicalDomain_8d14683f-c372-46dd-b767-d39c63fd5651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_DE_04309eb9-0c33-4dc0-a2a8-1a10df20ec17" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_DE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_8d14683f-c372-46dd-b767-d39c63fd5651" xlink:to="loc_country_DE_04309eb9-0c33-4dc0-a2a8-1a10df20ec17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8605ffd6-b0bf-4e01-95fb-effdebbb7844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_056254cb-7655-49a8-9d29-b831a537dab0" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8605ffd6-b0bf-4e01-95fb-effdebbb7844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_2a5314a6-bd3f-4efd-911d-eb9ed1a886b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8605ffd6-b0bf-4e01-95fb-effdebbb7844" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_2a5314a6-bd3f-4efd-911d-eb9ed1a886b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesEarningPerShareDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesEarningPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesEarningPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_022170d1-2d35-4b1f-af5a-2e7b5393d4fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ddf42dbb-cebc-468f-85ec-c293bc40443d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_022170d1-2d35-4b1f-af5a-2e7b5393d4fd" xlink:to="loc_us-gaap_NetIncomeLoss_ddf42dbb-cebc-468f-85ec-c293bc40443d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b95a3d3b-5150-49f8-b933-0e8263a1d77d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_022170d1-2d35-4b1f-af5a-2e7b5393d4fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b95a3d3b-5150-49f8-b933-0e8263a1d77d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fd47543-6954-49ec-b874-92ed3a3f4310" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_022170d1-2d35-4b1f-af5a-2e7b5393d4fd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4fd47543-6954-49ec-b874-92ed3a3f4310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_7a17787b-a48e-407a-8124-27381f843ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_022170d1-2d35-4b1f-af5a-2e7b5393d4fd" xlink:to="loc_us-gaap_EarningsPerShareBasic_7a17787b-a48e-407a-8124-27381f843ee5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_2cb07a21-184c-471a-b1c2-9346543d1fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_022170d1-2d35-4b1f-af5a-2e7b5393d4fd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_2cb07a21-184c-471a-b1c2-9346543d1fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c4ec3de6-e003-4608-b8ee-131ce5a33e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47e534a4-4515-4c36-87a7-422a304f686d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c4ec3de6-e003-4608-b8ee-131ce5a33e8f" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47e534a4-4515-4c36-87a7-422a304f686d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_307c7611-3b85-42a3-85e5-7f5e2fbb622b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47e534a4-4515-4c36-87a7-422a304f686d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_307c7611-3b85-42a3-85e5-7f5e2fbb622b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_307c7611-3b85-42a3-85e5-7f5e2fbb622b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_5ad09438-9c2f-4fba-bf10-3b539077c146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_5ad09438-9c2f-4fba-bf10-3b539077c146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedeemableConvertiblePreferredStockWarrantsMember_79070de0-c1d9-41a8-903d-9ba539199ba5" xlink:href="prct-20210930.xsd#prct_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:to="loc_prct_RedeemableConvertiblePreferredStockWarrantsMember_79070de0-c1d9-41a8-903d-9ba539199ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_CommonStockWarrantsMember_e001b8ba-21b0-4e9d-bddf-dfd5f2285fec" xlink:href="prct-20210930.xsd#prct_CommonStockWarrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:to="loc_prct_CommonStockWarrantsMember_e001b8ba-21b0-4e9d-bddf-dfd5f2285fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e8c54320-d91d-4c18-ae09-19ef4e48cb7b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_70da0011-38da-446d-b8ae-cb6539477ca8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e8c54320-d91d-4c18-ae09-19ef4e48cb7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_51abbdcd-c736-4f51-8590-a02518f2d42d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_47e534a4-4515-4c36-87a7-422a304f686d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_51abbdcd-c736-4f51-8590-a02518f2d42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0e20d21-cef0-434a-a4ef-7cb926043da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_51abbdcd-c736-4f51-8590-a02518f2d42d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e0e20d21-cef0-434a-a4ef-7cb926043da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_73cce3db-3ab3-4dc8-8c5e-2b6afe86f16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_73cce3db-3ab3-4dc8-8c5e-2b6afe86f16b" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_17d6248a-5b1d-4d95-a111-54eaa87bf5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_17d6248a-5b1d-4d95-a111-54eaa87bf5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a13761b-f121-4b10-806f-977b9baec199" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_17d6248a-5b1d-4d95-a111-54eaa87bf5e6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a13761b-f121-4b10-806f-977b9baec199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_42462814-fd70-4e2c-a97e-5caa77d73696" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a13761b-f121-4b10-806f-977b9baec199" xlink:to="loc_us-gaap_SalesRevenueNetMember_42462814-fd70-4e2c-a97e-5caa77d73696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_fa0d2ebd-7c7f-4963-ab53-615066a2fe79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3a13761b-f121-4b10-806f-977b9baec199" xlink:to="loc_us-gaap_AccountsReceivableMember_fa0d2ebd-7c7f-4963-ab53-615066a2fe79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_22f6ee6f-a702-419b-9c4e-77e2dd93eeca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_22f6ee6f-a702-419b-9c4e-77e2dd93eeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2553d860-e4f8-4288-96e6-0ab27c6083d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_22f6ee6f-a702-419b-9c4e-77e2dd93eeca" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2553d860-e4f8-4288-96e6-0ab27c6083d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_45f0e9f8-62e2-4ff7-81b7-b71bf3d7eb68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_2553d860-e4f8-4288-96e6-0ab27c6083d8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_45f0e9f8-62e2-4ff7-81b7-b71bf3d7eb68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_b2acb3d2-4ff2-4a63-ba1f-fcc324c3cfe8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:to="loc_srt_MajorCustomersAxis_b2acb3d2-4ff2-4a63-ba1f-fcc324c3cfe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2b4ddca3-4849-4348-a30b-69c90553bc73" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_b2acb3d2-4ff2-4a63-ba1f-fcc324c3cfe8" xlink:to="loc_srt_NameOfMajorCustomerDomain_2b4ddca3-4849-4348-a30b-69c90553bc73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_Customer1Member_40ce02e8-0399-477e-bf35-d608fe9b91c1" xlink:href="prct-20210930.xsd#prct_Customer1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b4ddca3-4849-4348-a30b-69c90553bc73" xlink:to="loc_prct_Customer1Member_40ce02e8-0399-477e-bf35-d608fe9b91c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_Customer2Member_3aacf3e9-df29-480d-8482-19c2703dc3cb" xlink:href="prct-20210930.xsd#prct_Customer2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b4ddca3-4849-4348-a30b-69c90553bc73" xlink:to="loc_prct_Customer2Member_3aacf3e9-df29-480d-8482-19c2703dc3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_Customer3Member_73ddbf32-1dc8-4e10-a15a-d7a325a835ab" xlink:href="prct-20210930.xsd#prct_Customer3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_2b4ddca3-4849-4348-a30b-69c90553bc73" xlink:to="loc_prct_Customer3Member_73ddbf32-1dc8-4e10-a15a-d7a325a835ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_e22bf59d-e177-483f-9803-94759b8057eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_bef6dc0e-18e2-4858-80db-a587033b7e8f" xlink:to="loc_us-gaap_ProductInformationLineItems_e22bf59d-e177-483f-9803-94759b8057eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_1f14a660-8f25-4eab-bb24-d623deff1fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_e22bf59d-e177-483f-9803-94759b8057eb" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_1f14a660-8f25-4eab-bb24-d623deff1fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItems" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItems"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItems" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34a9078a-3197-42e5-98cd-b869cb7a7a47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_d95398ce-7ac8-4992-8017-158cafe56350" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_34a9078a-3197-42e5-98cd-b869cb7a7a47" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_d95398ce-7ac8-4992-8017-158cafe56350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsTables"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab82f4d0-16ac-4b03-b761-6d213f196aec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bee3f299-871e-4fe3-b202-fc70cb19a2dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab82f4d0-16ac-4b03-b761-6d213f196aec" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_bee3f299-871e-4fe3-b202-fc70cb19a2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_d4e43b44-1292-4954-82e0-6edd381d5166" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab82f4d0-16ac-4b03-b761-6d213f196aec" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_d4e43b44-1292-4954-82e0-6edd381d5166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1a249b4d-0e1f-4216-8d66-d626fc1a6f84" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab82f4d0-16ac-4b03-b761-6d213f196aec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1a249b4d-0e1f-4216-8d66-d626fc1a6f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_a732deac-034c-44d4-8310-09e3e3def6c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab82f4d0-16ac-4b03-b761-6d213f196aec" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_a732deac-034c-44d4-8310-09e3e3def6c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1a8b4ad9-ac7d-4c83-aa0a-33112b87ea39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab82f4d0-16ac-4b03-b761-6d213f196aec" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1a8b4ad9-ac7d-4c83-aa0a-33112b87ea39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73ef69ef-465f-48a3-87ed-d286cdcccabb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_979587bb-9395-4651-8298-720888e745de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73ef69ef-465f-48a3-87ed-d286cdcccabb" xlink:to="loc_us-gaap_InventoryRawMaterials_979587bb-9395-4651-8298-720888e745de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_a8496638-b802-4596-9b49-7ee5a5168e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73ef69ef-465f-48a3-87ed-d286cdcccabb" xlink:to="loc_us-gaap_InventoryWorkInProcess_a8496638-b802-4596-9b49-7ee5a5168e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_6212312d-508f-4139-8029-3f95738a52b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73ef69ef-465f-48a3-87ed-d286cdcccabb" xlink:to="loc_us-gaap_InventoryFinishedGoods_6212312d-508f-4139-8029-3f95738a52b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9b7d9ebc-24b9-444e-a7ff-f05f65d0c0a0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73ef69ef-465f-48a3-87ed-d286cdcccabb" xlink:to="loc_us-gaap_InventoryNet_9b7d9ebc-24b9-444e-a7ff-f05f65d0c0a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a45039a0-f47d-470c-8e05-fa0375ed44f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_PrepaidInventory_d9432aba-d287-4478-a140-217c2de04c4c" xlink:href="prct-20210930.xsd#prct_PrepaidInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a45039a0-f47d-470c-8e05-fa0375ed44f4" xlink:to="loc_prct_PrepaidInventory_d9432aba-d287-4478-a140-217c2de04c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_PrepaidSoftware_90a97a20-f1b1-43f5-ba77-9b98a2056119" xlink:href="prct-20210930.xsd#prct_PrepaidSoftware"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a45039a0-f47d-470c-8e05-fa0375ed44f4" xlink:to="loc_prct_PrepaidSoftware_90a97a20-f1b1-43f5-ba77-9b98a2056119" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidRent_7c258e9f-f665-465c-b192-9f8683e12f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidRent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a45039a0-f47d-470c-8e05-fa0375ed44f4" xlink:to="loc_us-gaap_PrepaidRent_7c258e9f-f665-465c-b192-9f8683e12f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidInsurance_cb1bf43d-16d6-46ff-90d2-a2459a1dd85f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a45039a0-f47d-470c-8e05-fa0375ed44f4" xlink:to="loc_us-gaap_PrepaidInsurance_cb1bf43d-16d6-46ff-90d2-a2459a1dd85f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_b29f3b0c-266b-4f00-8d1d-8f30428cce3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a45039a0-f47d-470c-8e05-fa0375ed44f4" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_b29f3b0c-266b-4f00-8d1d-8f30428cce3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37f7c798-5a90-4fd0-9066-c74160e529f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a45039a0-f47d-470c-8e05-fa0375ed44f4" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_37f7c798-5a90-4fd0-9066-c74160e529f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ae383e-5e9c-41b9-be9e-7eef393083a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61c54093-a056-487c-8813-8678c2a69f92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e8ae383e-5e9c-41b9-be9e-7eef393083a2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61c54093-a056-487c-8813-8678c2a69f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0fe7b747-4c14-4778-9f67-5f2e7cf0d38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61c54093-a056-487c-8813-8678c2a69f92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0fe7b747-4c14-4778-9f67-5f2e7cf0d38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0fe7b747-4c14-4778-9f67-5f2e7cf0d38b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LaboratoryAndManufacturingEquipmentMember_20ff8add-602a-48e3-8560-5862434727ee" xlink:href="prct-20210930.xsd#prct_LaboratoryAndManufacturingEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:to="loc_prct_LaboratoryAndManufacturingEquipmentMember_20ff8add-602a-48e3-8560-5862434727ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_a1539a05-c286-44b8-9bd8-1cdafb85c884" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:to="loc_us-gaap_EquipmentMember_a1539a05-c286-44b8-9bd8-1cdafb85c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4cd63c87-fcbd-4843-997b-f84886b0c99f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4cd63c87-fcbd-4843-997b-f84886b0c99f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_EvaluationUnitsMember_0e142bae-d161-475d-82f4-0e26c6a78f62" xlink:href="prct-20210930.xsd#prct_EvaluationUnitsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_33047cda-d30e-4d7a-b18f-6c02f061f994" xlink:to="loc_prct_EvaluationUnitsMember_0e142bae-d161-475d-82f4-0e26c6a78f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4ef1ecb-6101-4a9c-96b1-d05e4f3686e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61c54093-a056-487c-8813-8678c2a69f92" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4ef1ecb-6101-4a9c-96b1-d05e4f3686e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_d3ff5607-2ece-4601-8da0-f582a2ac1f89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4ef1ecb-6101-4a9c-96b1-d05e4f3686e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_d3ff5607-2ece-4601-8da0-f582a2ac1f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_84db2bd7-1b10-4e67-9e07-7ca5e0d01c23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4ef1ecb-6101-4a9c-96b1-d05e4f3686e6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_84db2bd7-1b10-4e67-9e07-7ca5e0d01c23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_82304338-762d-4868-b1e4-eb9793f7fbd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_c4ef1ecb-6101-4a9c-96b1-d05e4f3686e6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_82304338-762d-4868-b1e4-eb9793f7fbd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6880d93b-0677-4628-be9c-3264f60d65f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_AccruedPurchases_915e00ba-1ea2-4f4b-9898-85fa5b1f3546" xlink:href="prct-20210930.xsd#prct_AccruedPurchases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6880d93b-0677-4628-be9c-3264f60d65f2" xlink:to="loc_prct_AccruedPurchases_915e00ba-1ea2-4f4b-9898-85fa5b1f3546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPayableCurrent_306ce512-aebc-4684-8c86-0d10f47ae1d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6880d93b-0677-4628-be9c-3264f60d65f2" xlink:to="loc_us-gaap_InterestPayableCurrent_306ce512-aebc-4684-8c86-0d10f47ae1d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_b328a1a8-958f-44e2-857a-7031c47eb9bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6880d93b-0677-4628-be9c-3264f60d65f2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_b328a1a8-958f-44e2-857a-7031c47eb9bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesAndExciseTaxPayableCurrent_24d814f5-2872-481b-bc5f-439b4a6ef706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesAndExciseTaxPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6880d93b-0677-4628-be9c-3264f60d65f2" xlink:to="loc_us-gaap_SalesAndExciseTaxPayableCurrent_24d814f5-2872-481b-bc5f-439b4a6ef706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_AccruedClinicalTrialExpenses_aec2faee-c01d-4ae9-86fa-95cfe659a4a4" xlink:href="prct-20210930.xsd#prct_AccruedClinicalTrialExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6880d93b-0677-4628-be9c-3264f60d65f2" xlink:to="loc_prct_AccruedClinicalTrialExpenses_aec2faee-c01d-4ae9-86fa-95cfe659a4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ddd6d4be-470f-4df6-8c9e-24e059c32baf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6880d93b-0677-4628-be9c-3264f60d65f2" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_ddd6d4be-470f-4df6-8c9e-24e059c32baf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d16d0640-e277-4ccd-87e8-2f662789e4df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6880d93b-0677-4628-be9c-3264f60d65f2" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d16d0640-e277-4ccd-87e8-2f662789e4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f00da50b-123c-4ad3-88a2-52618ad3cf24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d18577bd-f06a-4b7b-bc40-e0a41cdc4273" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f00da50b-123c-4ad3-88a2-52618ad3cf24" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d18577bd-f06a-4b7b-bc40-e0a41cdc4273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_4808ea24-b85a-42b2-93cc-b26ef497dbc2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f00da50b-123c-4ad3-88a2-52618ad3cf24" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_4808ea24-b85a-42b2-93cc-b26ef497dbc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_0c9bbe2e-4204-47ee-bd13-7d6f2787ba87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f00da50b-123c-4ad3-88a2-52618ad3cf24" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_0c9bbe2e-4204-47ee-bd13-7d6f2787ba87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_a13aa4af-2a61-4d43-8e23-91a680c16b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f00da50b-123c-4ad3-88a2-52618ad3cf24" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_a13aa4af-2a61-4d43-8e23-91a680c16b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_InterestAndOtherIncomeExpense_9ad90472-68b6-4dc0-acfd-28daf4ba45ab" xlink:href="prct-20210930.xsd#prct_InterestAndOtherIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_f00da50b-123c-4ad3-88a2-52618ad3cf24" xlink:to="loc_prct_InterestAndOtherIncomeExpense_9ad90472-68b6-4dc0-acfd-28daf4ba45ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/IntangibleAssets" xlink:type="simple" xlink:href="prct-20210930.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_df385328-8316-463d-a6c9-68922d559ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_a77da622-db40-49e6-bedd-e55624f12823" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_df385328-8316-463d-a6c9-68922d559ce9" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_a77da622-db40-49e6-bedd-e55624f12823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/IntangibleAssetsDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#IntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/IntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00daeefd-1b33-40a0-8837-974d7986391e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_627d6d2d-8534-45ac-bf3c-a6bb3cee969b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00daeefd-1b33-40a0-8837-974d7986391e" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_627d6d2d-8534-45ac-bf3c-a6bb3cee969b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_225de386-985c-4bfc-b488-ad5384cce79e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00daeefd-1b33-40a0-8837-974d7986391e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_225de386-985c-4bfc-b488-ad5384cce79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense_1d92a042-b8cc-48dd-9afd-cd210642cfd5" xlink:href="prct-20210930.xsd#prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00daeefd-1b33-40a0-8837-974d7986391e" xlink:to="loc_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense_1d92a042-b8cc-48dd-9afd-cd210642cfd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_6b2c91a1-ec7c-4af2-93c8-fe95530952f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_00daeefd-1b33-40a0-8837-974d7986391e" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_6b2c91a1-ec7c-4af2-93c8-fe95530952f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/LoanFacility" xlink:type="simple" xlink:href="prct-20210930.xsd#LoanFacility"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/LoanFacility" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8adfd616-1c18-41af-b470-99c491769ecd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_490f8242-2cca-4984-83c4-31b074ed7ef0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8adfd616-1c18-41af-b470-99c491769ecd" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_490f8242-2cca-4984-83c4-31b074ed7ef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/LoanFacilityDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#LoanFacilityDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/LoanFacilityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_a1aa1b7c-f985-4994-b4cb-5d4ddfb86474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_a1aa1b7c-f985-4994-b4cb-5d4ddfb86474" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_dcdcc189-9c91-4d25-b039-a2c903373bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:to="loc_us-gaap_DebtInstrumentAxis_dcdcc189-9c91-4d25-b039-a2c903373bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bf272f88-0466-448a-9d50-ece84f8c7159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_dcdcc189-9c91-4d25-b039-a2c903373bf6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bf272f88-0466-448a-9d50-ece84f8c7159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:href="prct-20210930.xsd#prct_LoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_bf272f88-0466-448a-9d50-ece84f8c7159" xlink:to="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheOneMember_22e8787d-3c3c-4b69-a33f-8703562d0d15" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:to="loc_prct_LoanFacilityTrancheOneMember_22e8787d-3c3c-4b69-a33f-8703562d0d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheTwoMember_0730e31d-9c4b-4f2a-8c4c-3c24d225e5a0" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:to="loc_prct_LoanFacilityTrancheTwoMember_0730e31d-9c4b-4f2a-8c4c-3c24d225e5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheThreeMember_a6609ff8-52d6-474c-b87b-96e3832e59b9" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:to="loc_prct_LoanFacilityTrancheThreeMember_a6609ff8-52d6-474c-b87b-96e3832e59b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityTrancheFourMember_4e59ccfd-2f61-4419-b4b9-6b09a1554ad6" xlink:href="prct-20210930.xsd#prct_LoanFacilityTrancheFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_LoanFacilityMember_32ca8a13-6a3d-4bc1-92f5-0572e5bc53b9" xlink:to="loc_prct_LoanFacilityTrancheFourMember_4e59ccfd-2f61-4419-b4b9-6b09a1554ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_e91ad8de-ebdc-4f52-be1d-0a5aa20786ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:to="loc_us-gaap_CreditFacilityAxis_e91ad8de-ebdc-4f52-be1d-0a5aa20786ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e3e0c7f5-c831-454d-b7e9-4ff1abc2ecf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_e91ad8de-ebdc-4f52-be1d-0a5aa20786ac" xlink:to="loc_us-gaap_CreditFacilityDomain_e3e0c7f5-c831-454d-b7e9-4ff1abc2ecf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_19ba185c-e824-48d4-ab6c-5e0e6cab74bd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_e3e0c7f5-c831-454d-b7e9-4ff1abc2ecf7" xlink:to="loc_us-gaap_LineOfCreditMember_19ba185c-e824-48d4-ab6c-5e0e6cab74bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_1ffce5b2-8261-429f-99fc-d6755af8946b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:to="loc_us-gaap_VariableRateAxis_1ffce5b2-8261-429f-99fc-d6755af8946b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_05b5dd76-c9cc-4466-b3eb-7cb57dd1ccd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_1ffce5b2-8261-429f-99fc-d6755af8946b" xlink:to="loc_us-gaap_VariableRateDomain_05b5dd76-c9cc-4466-b3eb-7cb57dd1ccd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_c43fb9c1-599b-474c-bcb9-17b6de9686e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_05b5dd76-c9cc-4466-b3eb-7cb57dd1ccd0" xlink:to="loc_us-gaap_BaseRateMember_c43fb9c1-599b-474c-bcb9-17b6de9686e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_05973c33-f1f7-4b73-a406-c1b8e3e5133d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_05b5dd76-c9cc-4466-b3eb-7cb57dd1ccd0" xlink:to="loc_us-gaap_LondonInterbankOfferedRateLIBORMember_05973c33-f1f7-4b73-a406-c1b8e3e5133d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_814b5778-f0d0-4e23-bafb-0175b6de366a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_814b5778-f0d0-4e23-bafb-0175b6de366a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_87a2c8e8-cbb1-4a96-bd44-ed01605c593c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_814b5778-f0d0-4e23-bafb-0175b6de366a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_87a2c8e8-cbb1-4a96-bd44-ed01605c593c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ebf17717-799e-4ea5-bfac-1deecad3ba53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_87a2c8e8-cbb1-4a96-bd44-ed01605c593c" xlink:to="loc_us-gaap_LineOfCreditMember_ebf17717-799e-4ea5-bfac-1deecad3ba53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_a290273e-d5b3-4b03-8b4c-dd262c102004" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_583f5be1-2bc4-4a6e-9e35-ccf32da24f77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_583f5be1-2bc4-4a6e-9e35-ccf32da24f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityNumberOfInstallments_6132b060-83cf-43ce-bcdd-b47d5fc65558" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityNumberOfInstallments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityNumberOfInstallments_6132b060-83cf-43ce-bcdd-b47d5fc65558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_46382bc4-d8b6-4216-9b8b-4ec69ec438bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromLongTermLinesOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_ProceedsFromLongTermLinesOfCredit_46382bc4-d8b6-4216-9b8b-4ec69ec438bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_573a9734-28b4-416b-8879-296ded7e36e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_573a9734-28b4-416b-8879-296ded7e36e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget_418e15d3-b06d-4de8-9d8b-8bcec9273521" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget_418e15d3-b06d-4de8-9d8b-8bcec9273521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_a684a9dc-cb28-454c-96f4-dd23a2d6b710" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_a684a9dc-cb28-454c-96f4-dd23a2d6b710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_13492cb5-e95b-4b27-9a89-13dbd8d3f1ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateDuringPeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod_13492cb5-e95b-4b27-9a89-13dbd8d3f1ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0cd450fa-3bfc-4d08-ab90-f5fad277845e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_0cd450fa-3bfc-4d08-ab90-f5fad277845e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_e66fc5bd-4a67-4bf6-a8a1-a457f85be6b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_DebtInstrumentTerm_e66fc5bd-4a67-4bf6-a8a1-a457f85be6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentInterestOnlyPeriod_64a22fbe-8352-4616-bf62-22db1bbef2d8" xlink:href="prct-20210930.xsd#prct_DebtInstrumentInterestOnlyPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentInterestOnlyPeriod_64a22fbe-8352-4616-bf62-22db1bbef2d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentPrincipalAndInterestPeriod_a69dd38d-72ce-448d-ad51-28e00e070d96" xlink:href="prct-20210930.xsd#prct_DebtInstrumentPrincipalAndInterestPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentPrincipalAndInterestPeriod_a69dd38d-72ce-448d-ad51-28e00e070d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod_52da46e1-488f-49ee-bc45-cae88d1b61bc" xlink:href="prct-20210930.xsd#prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod_52da46e1-488f-49ee-bc45-cae88d1b61bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod_b79ca912-bf6a-4629-8c8b-601f7b357137" xlink:href="prct-20210930.xsd#prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod_b79ca912-bf6a-4629-8c8b-601f7b357137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_364b60fd-8490-4627-a547-97dc8808c5a7" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_364b60fd-8490-4627-a547-97dc8808c5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod_1b73a2a8-6943-41ea-93dd-384f213e59a8" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod_1b73a2a8-6943-41ea-93dd-384f213e59a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod_c04928a3-28eb-4cdb-8501-e8a0332ccf48" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod_c04928a3-28eb-4cdb-8501-e8a0332ccf48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent_2e98682e-a5db-452d-9371-ed9a012993cd" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent_2e98682e-a5db-452d-9371-ed9a012993cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly_9ec1d1ed-000f-4eae-9d84-d83429a3b7a2" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly_9ec1d1ed-000f-4eae-9d84-d83429a3b7a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly_ce059a0c-d5e0-46b6-a997-f67e8542da67" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly_ce059a0c-d5e0-46b6-a997-f67e8542da67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn_c3a2a0a1-3cf0-40b8-9bef-6f4a879d267b" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn_c3a2a0a1-3cf0-40b8-9bef-6f4a879d267b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityFinalPaymentFeePercentage_b1fa39bf-17db-43f1-8234-699c08d683e5" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityFinalPaymentFeePercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityFinalPaymentFeePercentage_b1fa39bf-17db-43f1-8234-699c08d683e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_daee7512-5961-4dbb-a962-0e59869ae8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_daee7512-5961-4dbb-a962-0e59869ae8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent_ed17418f-2e8c-48a0-b385-e2dc9c00b8e4" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent_ed17418f-2e8c-48a0-b385-e2dc9c00b8e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent_85fa6a8a-38fc-41fc-9d7f-ec984dd9859e" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent_85fa6a8a-38fc-41fc-9d7f-ec984dd9859e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent_d78966c8-dede-41bb-a290-daae7bfd502f" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent_d78966c8-dede-41bb-a290-daae7bfd502f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_6fa5643e-44ab-40c2-a9d6-ac9b55d637b9" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget_6fa5643e-44ab-40c2-a9d6-ac9b55d637b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_9337e318-d33f-4846-910c-4aaebe194630" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn_9337e318-d33f-4846-910c-4aaebe194630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_3e0971b7-eb79-46a3-a336-77e7592986b2" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn_3e0971b7-eb79-46a3-a336-77e7592986b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_f1764a0f-46c3-4191-8f2a-e056e10cdafc" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn_f1764a0f-46c3-4191-8f2a-e056e10cdafc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_e2beb84a-1c18-48f5-935b-1bebc209105e" xlink:href="prct-20210930.xsd#prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_195aa344-3054-453b-8367-6194720815b8" xlink:to="loc_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn_e2beb84a-1c18-48f5-935b-1bebc209105e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiability" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockWarrantLiability"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiability" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d07eeeb3-8f9c-4d15-933d-bc720e874780" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3ecf6410-903c-4f83-8070-4ca8acc5ab9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d07eeeb3-8f9c-4d15-933d-bc720e874780" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3ecf6410-903c-4f83-8070-4ca8acc5ab9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityTables" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockWarrantLiabilityTables"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ed85d50-e5e9-4b09-9f12-d9cb5ec84fed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_4283c83c-e02a-4adb-8d01-ad3dab41e0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ed85d50-e5e9-4b09-9f12-d9cb5ec84fed" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_4283c83c-e02a-4adb-8d01-ad3dab41e0bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_cbe49202-bad4-45e4-9180-9945952073a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_e3d22cf9-3c21-4c55-b438-03a27f1e3af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_cbe49202-bad4-45e4-9180-9945952073a5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_e3d22cf9-3c21-4c55-b438-03a27f1e3af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_ec3f993c-7887-42bb-9eba-22a467b02c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e3d22cf9-3c21-4c55-b438-03a27f1e3af7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_ec3f993c-7887-42bb-9eba-22a467b02c01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_0dad1e54-f855-45e1-b1e7-15e2c371b434" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_ec3f993c-7887-42bb-9eba-22a467b02c01" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_0dad1e54-f855-45e1-b1e7-15e2c371b434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_2e07eef6-fd97-4d50-8acd-7fc4eb9495a6" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_0dad1e54-f855-45e1-b1e7-15e2c371b434" xlink:to="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_2e07eef6-fd97-4d50-8acd-7fc4eb9495a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_f0c5f08e-e248-4ace-b87b-6ec913407fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_e3d22cf9-3c21-4c55-b438-03a27f1e3af7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_f0c5f08e-e248-4ace-b87b-6ec913407fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a73ec9da-b05c-4be8-abb0-d69778523f25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f0c5f08e-e248-4ace-b87b-6ec913407fd9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a73ec9da-b05c-4be8-abb0-d69778523f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_23466034-fe25-479c-841d-27f341c87a59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f0c5f08e-e248-4ace-b87b-6ec913407fd9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_23466034-fe25-479c-841d-27f341c87a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_74131d12-584c-4ef9-8aea-33082ec4eb08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_f0c5f08e-e248-4ace-b87b-6ec913407fd9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_74131d12-584c-4ef9-8aea-33082ec4eb08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_3676cb75-8ad5-4091-b86c-30307947180a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_4859b2a1-852d-44f1-ba51-af6db8a68c45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3676cb75-8ad5-4091-b86c-30307947180a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_4859b2a1-852d-44f1-ba51-af6db8a68c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_33604754-4f32-40ee-9e07-fa9f198384d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4859b2a1-852d-44f1-ba51-af6db8a68c45" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_33604754-4f32-40ee-9e07-fa9f198384d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_5d4ec8de-c595-49c5-be26-7abdc2054a38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_33604754-4f32-40ee-9e07-fa9f198384d1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_5d4ec8de-c595-49c5-be26-7abdc2054a38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_9d31c8dd-1fbf-4101-93d1-105edf592279" xlink:href="prct-20210930.xsd#prct_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5d4ec8de-c595-49c5-be26-7abdc2054a38" xlink:to="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_9d31c8dd-1fbf-4101-93d1-105edf592279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_9d656dea-5d8a-486f-b401-571e20fcadef" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_5d4ec8de-c595-49c5-be26-7abdc2054a38" xlink:to="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_9d656dea-5d8a-486f-b401-571e20fcadef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_99528703-20f1-4f19-aa8a-a8e923fdaf68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4859b2a1-852d-44f1-ba51-af6db8a68c45" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_99528703-20f1-4f19-aa8a-a8e923fdaf68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a49b4ef4-123e-4a40-bee3-f2bd068c265f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_99528703-20f1-4f19-aa8a-a8e923fdaf68" xlink:to="loc_us-gaap_EquityComponentDomain_a49b4ef4-123e-4a40-bee3-f2bd068c265f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c213dcde-ca7d-4e92-869a-ff947ce30027" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a49b4ef4-123e-4a40-bee3-f2bd068c265f" xlink:to="loc_us-gaap_WarrantMember_c213dcde-ca7d-4e92-869a-ff947ce30027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_4859b2a1-852d-44f1-ba51-af6db8a68c45" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6e18b106-8af3-49f1-8a67-370825e32f32" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_6e18b106-8af3-49f1-8a67-370825e32f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_579f7174-89bf-424b-8577-9975fde03e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_579f7174-89bf-424b-8577-9975fde03e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_52e8416a-c933-4a66-912d-c5ab78878f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_52e8416a-c933-4a66-912d-c5ab78878f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_86dbfcc0-3d33-455f-8ea4-868188e9ad5c" xlink:href="prct-20210930.xsd#prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises_86dbfcc0-3d33-455f-8ea4-868188e9ad5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f9d964c5-5ac8-4552-aa30-0b92d5de4994" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_e8149660-3605-4341-9152-864829cbb378" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_f9d964c5-5ac8-4552-aa30-0b92d5de4994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStock" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStock"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_71d242b3-a7d9-4aa3-a000-059da2e10f17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_10a7ce27-c2db-434d-9de8-fc7452c79221" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_71d242b3-a7d9-4aa3-a000-059da2e10f17" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_10a7ce27-c2db-434d-9de8-fc7452c79221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockTables" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockTables"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1108bde2-9667-4439-95ff-47d9e3170fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_fca20efa-3750-42b9-a91d-3b2b9d7e581f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1108bde2-9667-4439-95ff-47d9e3170fa1" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_fca20efa-3750-42b9-a91d-3b2b9d7e581f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_7f1fef3d-db85-488d-8ca5-9a207aecd828" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_4276ac14-df2d-490d-8a46-a4ac1e6e77f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_7f1fef3d-db85-488d-8ca5-9a207aecd828" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_4276ac14-df2d-490d-8a46-a4ac1e6e77f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5853aeca-c23a-4a96-9974-6f58eed74628" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_4276ac14-df2d-490d-8a46-a4ac1e6e77f5" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5853aeca-c23a-4a96-9974-6f58eed74628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5853aeca-c23a-4a96-9974-6f58eed74628" xlink:to="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesARedeemableConvertiblePreferredStockMember_d650c6b2-42f1-4e0b-8482-aca68ff8c368" xlink:href="prct-20210930.xsd#prct_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesARedeemableConvertiblePreferredStockMember_d650c6b2-42f1-4e0b-8482-aca68ff8c368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesBRedeemableConvertiblePreferredStockMember_0c2716b2-a11e-4f75-98f9-74b8b963c6a5" xlink:href="prct-20210930.xsd#prct_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesBRedeemableConvertiblePreferredStockMember_0c2716b2-a11e-4f75-98f9-74b8b963c6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesCRedeemableConvertiblePreferredStockMember_3c7bf7b3-dc8c-4c63-9508-b136a07324b3" xlink:href="prct-20210930.xsd#prct_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesCRedeemableConvertiblePreferredStockMember_3c7bf7b3-dc8c-4c63-9508-b136a07324b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_9d657946-6ac7-4c5f-9e0e-da7ac32abf3a" xlink:href="prct-20210930.xsd#prct_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_9d657946-6ac7-4c5f-9e0e-da7ac32abf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_ba0365c1-7e13-41f9-a84a-44328885f2f3" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_ba0365c1-7e13-41f9-a84a-44328885f2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_b976cc17-48d4-46e4-84dd-1b428ec63a1c" xlink:href="prct-20210930.xsd#prct_SeriesFRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_b976cc17-48d4-46e4-84dd-1b428ec63a1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_6c3f3f08-b3d5-4f3d-b4d6-87060fea1b2f" xlink:href="prct-20210930.xsd#prct_SeriesGRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_45974c77-a071-4b9d-804a-d62c9c4b72ce" xlink:to="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_6c3f3f08-b3d5-4f3d-b4d6-87060fea1b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_7c9e75b4-587a-43a4-b5ae-412c9d4f127f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_4276ac14-df2d-490d-8a46-a4ac1e6e77f5" xlink:to="loc_us-gaap_TemporaryEquityLineItems_7c9e75b4-587a-43a4-b5ae-412c9d4f127f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_3ae0b703-6210-431d-9830-cca4b03f7537" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7c9e75b4-587a-43a4-b5ae-412c9d4f127f" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_3ae0b703-6210-431d-9830-cca4b03f7537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_ae86888c-6920-4fbd-9e6e-8cabfdeb2946" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7c9e75b4-587a-43a4-b5ae-412c9d4f127f" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_ae86888c-6920-4fbd-9e6e-8cabfdeb2946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_baec56ee-db94-4a3e-be8c-a9a30ff2e018" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_7c9e75b4-587a-43a4-b5ae-412c9d4f127f" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_baec56ee-db94-4a3e-be8c-a9a30ff2e018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_66e55183-8321-4bb8-b99c-bea6b475fe59" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_73a39122-18c0-43d1-b5f9-9985b4abb3b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_66e55183-8321-4bb8-b99c-bea6b475fe59" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_73a39122-18c0-43d1-b5f9-9985b4abb3b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_4cd5a963-75f9-42ac-9d15-90f965db0c50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_73a39122-18c0-43d1-b5f9-9985b4abb3b9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_4cd5a963-75f9-42ac-9d15-90f965db0c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_4cd5a963-75f9-42ac-9d15-90f965db0c50" xlink:to="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_286fb7c3-4ac4-4828-b971-6b5e3f93882a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:to="loc_us-gaap_CommonStockMember_286fb7c3-4ac4-4828-b971-6b5e3f93882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_5f83828f-ffc9-4146-8f0c-14b01cc00838" xlink:href="prct-20210930.xsd#prct_SeriesGRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:to="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_5f83828f-ffc9-4146-8f0c-14b01cc00838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_e87e9882-1026-4baa-8bd7-ed476f198a9f" xlink:href="prct-20210930.xsd#prct_SeriesFRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:to="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_e87e9882-1026-4baa-8bd7-ed476f198a9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedeemableConvertiblePreferredStockWarrantsMember_5b0a4419-01cf-4aa4-81aa-1ae49516cb6e" xlink:href="prct-20210930.xsd#prct_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_184edfa0-15b0-48f6-b327-2c64f0e55af5" xlink:to="loc_prct_RedeemableConvertiblePreferredStockWarrantsMember_5b0a4419-01cf-4aa4-81aa-1ae49516cb6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_73a39122-18c0-43d1-b5f9-9985b4abb3b9" xlink:to="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4368a2c3-7c0d-4d31-965c-d131e26e6069" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_4368a2c3-7c0d-4d31-965c-d131e26e6069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_e3cce0ae-d4ee-45d7-b118-690677872e56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_e3cce0ae-d4ee-45d7-b118-690677872e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_e98caf60-c1bc-427c-8a72-8b3cc651fad9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_e98caf60-c1bc-427c-8a72-8b3cc651fad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_0b85795c-5bbe-42de-b24f-96546d3f27da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_0b85795c-5bbe-42de-b24f-96546d3f27da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_8d9ef3fb-e997-4330-932a-433edb4d7a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_8d9ef3fb-e997-4330-932a-433edb4d7a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityDividends_a7602434-0fb8-451a-8785-088af0294a64" xlink:href="prct-20210930.xsd#prct_TemporaryEquityDividends"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_prct_TemporaryEquityDividends_a7602434-0fb8-451a-8785-088af0294a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_597aa4e0-0754-4689-93c9-8748b490bac9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DividendsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_us-gaap_DividendsPayableCurrentAndNoncurrent_597aa4e0-0754-4689-93c9-8748b490bac9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted_23b09567-d105-44cd-9211-ab13fe7b888b" xlink:href="prct-20210930.xsd#prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_6a6bee16-5665-49f3-a628-52cad4274d4e" xlink:to="loc_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted_23b09567-d105-44cd-9211-ab13fe7b888b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_99520c2a-e94b-4096-866b-4b83c05cf75a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_dbe3e2a6-d868-410b-a654-d4a68c6e934d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_99520c2a-e94b-4096-866b-4b83c05cf75a" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_dbe3e2a6-d868-410b-a654-d4a68c6e934d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_0fb73845-8b2c-48b5-acb3-86aa3b2da78a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_dbe3e2a6-d868-410b-a654-d4a68c6e934d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_0fb73845-8b2c-48b5-acb3-86aa3b2da78a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_0fb73845-8b2c-48b5-acb3-86aa3b2da78a" xlink:to="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesARedeemableConvertiblePreferredStockMember_480d95b5-6083-4370-9a83-71863b4dfadb" xlink:href="prct-20210930.xsd#prct_SeriesARedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesARedeemableConvertiblePreferredStockMember_480d95b5-6083-4370-9a83-71863b4dfadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesBRedeemableConvertiblePreferredStockMember_4f1ef967-0d50-4978-80c1-b1070f36894f" xlink:href="prct-20210930.xsd#prct_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesBRedeemableConvertiblePreferredStockMember_4f1ef967-0d50-4978-80c1-b1070f36894f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesCRedeemableConvertiblePreferredStockMember_4f1b98fd-b781-402f-9834-e7ccb3f47361" xlink:href="prct-20210930.xsd#prct_SeriesCRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesCRedeemableConvertiblePreferredStockMember_4f1b98fd-b781-402f-9834-e7ccb3f47361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_b44de328-4310-4b8b-9df5-f4a3368c9abb" xlink:href="prct-20210930.xsd#prct_SeriesDRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesDRedeemableConvertiblePreferredStockMember_b44de328-4310-4b8b-9df5-f4a3368c9abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_84cc81a4-26dd-4b83-a55a-434e76528ab7" xlink:href="prct-20210930.xsd#prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember_84cc81a4-26dd-4b83-a55a-434e76528ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_d933519e-5217-415a-90b9-5a522099a40a" xlink:href="prct-20210930.xsd#prct_SeriesFRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesFRedeemableConvertiblePreferredStockMember_d933519e-5217-415a-90b9-5a522099a40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_20d7f53e-814e-46e1-a5bf-03d3f5568f4d" xlink:href="prct-20210930.xsd#prct_SeriesGRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b5b60a7-d55e-4451-b5a6-561d917fe94f" xlink:to="loc_prct_SeriesGRedeemableConvertiblePreferredStockMember_20d7f53e-814e-46e1-a5bf-03d3f5568f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLineItems_149a95a1-11ac-4261-979e-add615761fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_dbe3e2a6-d868-410b-a654-d4a68c6e934d" xlink:to="loc_us-gaap_TemporaryEquityLineItems_149a95a1-11ac-4261-979e-add615761fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_b8c3f952-7192-4034-b804-15166c787262" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreferencePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_149a95a1-11ac-4261-979e-add615761fb0" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreferencePerShare_b8c3f952-7192-4034-b804-15166c787262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_TemporaryEquityDividends_b5849c51-4547-452e-95dd-fe0572b0c565" xlink:href="prct-20210930.xsd#prct_TemporaryEquityDividends"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_149a95a1-11ac-4261-979e-add615761fb0" xlink:to="loc_prct_TemporaryEquityDividends_b5849c51-4547-452e-95dd-fe0572b0c565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/StockholdersEquity" xlink:type="simple" xlink:href="prct-20210930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_97130ff4-589b-4ff5-b8cd-9039e5ea16b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_21c7e22f-6535-48c0-a623-14ca2e847d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_97130ff4-589b-4ff5-b8cd-9039e5ea16b6" xlink:to="loc_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock_21c7e22f-6535-48c0-a623-14ca2e847d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="prct-20210930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f0b35e1-e3ca-4891-b595-f3fc33851d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_a282ab63-6f79-4657-8b90-e691d6a801b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f0b35e1-e3ca-4891-b595-f3fc33851d8e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock_a282ab63-6f79-4657-8b90-e691d6a801b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_45aba8c6-e6ba-4ba3-ae7a-d058baff36a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f0b35e1-e3ca-4891-b595-f3fc33851d8e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_45aba8c6-e6ba-4ba3-ae7a-d058baff36a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_802705cb-ea36-4fc7-97cf-f9246e3b3031" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0f0b35e1-e3ca-4891-b595-f3fc33851d8e" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_802705cb-ea36-4fc7-97cf-f9246e3b3031" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#StockholdersEquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8039877-190a-4cd7-8f80-58734b763ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a8039877-190a-4cd7-8f80-58734b763ae2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_885aa8f4-78e3-4691-bde2-1a2e0668594c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_us-gaap_PlanNameAxis_885aa8f4-78e3-4691-bde2-1a2e0668594c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_8330e63a-97dc-41e0-8a55-a7716aa3ae60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_885aa8f4-78e3-4691-bde2-1a2e0668594c" xlink:to="loc_us-gaap_PlanNameDomain_8330e63a-97dc-41e0-8a55-a7716aa3ae60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_A2021EquityIncentiveAwardPlanMember_3ef3fcbc-79d4-4125-bc4c-c448b28feed5" xlink:href="prct-20210930.xsd#prct_A2021EquityIncentiveAwardPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8330e63a-97dc-41e0-8a55-a7716aa3ae60" xlink:to="loc_prct_A2021EquityIncentiveAwardPlanMember_3ef3fcbc-79d4-4125-bc4c-c448b28feed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_A2008StockPlanMember_8af54e52-a549-48b0-8d16-cfc2a628bc7e" xlink:href="prct-20210930.xsd#prct_A2008StockPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8330e63a-97dc-41e0-8a55-a7716aa3ae60" xlink:to="loc_prct_A2008StockPlanMember_8af54e52-a549-48b0-8d16-cfc2a628bc7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_A2021EmployeeStockPurchasePlanMember_a72fb0f4-aa69-4efb-9f9d-9461e3e29cb9" xlink:href="prct-20210930.xsd#prct_A2021EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_8330e63a-97dc-41e0-8a55-a7716aa3ae60" xlink:to="loc_prct_A2021EmployeeStockPurchasePlanMember_a72fb0f4-aa69-4efb-9f9d-9461e3e29cb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_1a4003e7-57a8-480b-94b4-0e2dc5e370c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_us-gaap_AwardTypeAxis_1a4003e7-57a8-480b-94b4-0e2dc5e370c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f046f56f-94d9-4cda-a431-bccb070bd253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1a4003e7-57a8-480b-94b4-0e2dc5e370c7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f046f56f-94d9-4cda-a431-bccb070bd253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_09ce872c-83f9-417b-8091-c708e0efc699" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f046f56f-94d9-4cda-a431-bccb070bd253" xlink:to="loc_us-gaap_EmployeeStockMember_09ce872c-83f9-417b-8091-c708e0efc699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_77a202a6-12be-4f4f-9944-064f7f73d2d4" xlink:href="prct-20210930.xsd#prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockMember_09ce872c-83f9-417b-8091-c708e0efc699" xlink:to="loc_prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember_77a202a6-12be-4f4f-9944-064f7f73d2d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_44e663cd-94a9-45f8-bd4a-af606258751f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f046f56f-94d9-4cda-a431-bccb070bd253" xlink:to="loc_us-gaap_EmployeeStockOptionMember_44e663cd-94a9-45f8-bd4a-af606258751f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_3b65010e-8975-4cdf-a102-849ba3eab715" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f046f56f-94d9-4cda-a431-bccb070bd253" xlink:to="loc_us-gaap_WarrantMember_3b65010e-8975-4cdf-a102-849ba3eab715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_90f19e6b-81a0-4f8b-ba1c-4cb1d47080bb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_srt_RangeAxis_90f19e6b-81a0-4f8b-ba1c-4cb1d47080bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fa1a3de6-7353-439d-9ccc-45144926338b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_90f19e6b-81a0-4f8b-ba1c-4cb1d47080bb" xlink:to="loc_srt_RangeMember_fa1a3de6-7353-439d-9ccc-45144926338b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b4b467fc-0688-460e-b239-33a2806a83a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa1a3de6-7353-439d-9ccc-45144926338b" xlink:to="loc_srt_MinimumMember_b4b467fc-0688-460e-b239-33a2806a83a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_812a07f1-7624-4d54-a0e8-0a0a470802d9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_fa1a3de6-7353-439d-9ccc-45144926338b" xlink:to="loc_srt_MaximumMember_812a07f1-7624-4d54-a0e8-0a0a470802d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipAxis_ba3e15b8-ec8c-4d41-850f-98d07e9f6806" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_srt_OwnershipAxis_ba3e15b8-ec8c-4d41-850f-98d07e9f6806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_OwnershipDomain_d599da0c-3b6e-40f5-9575-f98dd1db0c56" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_OwnershipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_ba3e15b8-ec8c-4d41-850f-98d07e9f6806" xlink:to="loc_srt_OwnershipDomain_d599da0c-3b6e-40f5-9575-f98dd1db0c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ShareholderOfTenPercentOwnershipOrGreaterMember_bc7c6da1-a178-4f90-a0d8-8bbbf98b9018" xlink:href="prct-20210930.xsd#prct_ShareholderOfTenPercentOwnershipOrGreaterMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_d599da0c-3b6e-40f5-9575-f98dd1db0c56" xlink:to="loc_prct_ShareholderOfTenPercentOwnershipOrGreaterMember_bc7c6da1-a178-4f90-a0d8-8bbbf98b9018" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_8d5365ae-ce34-41ba-bd04-f499309d49f3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_srt_StatementScenarioAxis_8d5365ae-ce34-41ba-bd04-f499309d49f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0da8ee70-638a-4977-8591-f2052ca0bb35" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_8d5365ae-ce34-41ba-bd04-f499309d49f3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0da8ee70-638a-4977-8591-f2052ca0bb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_6f385e0d-f2b2-4352-8437-654955bfd433" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0da8ee70-638a-4977-8591-f2052ca0bb35" xlink:to="loc_srt_ScenarioForecastMember_6f385e0d-f2b2-4352-8437-654955bfd433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6854518d-5275-432a-98d2-7ea9dd47e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6854518d-5275-432a-98d2-7ea9dd47e6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5d170730-83aa-4f6f-87ee-db0dc4283215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6854518d-5275-432a-98d2-7ea9dd47e6c3" xlink:to="loc_us-gaap_EquityComponentDomain_5d170730-83aa-4f6f-87ee-db0dc4283215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_95f53b0d-f194-461e-a7b7-d851b836abcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5d170730-83aa-4f6f-87ee-db0dc4283215" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_95f53b0d-f194-461e-a7b7-d851b836abcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_23627ce3-7035-446e-85a7-3d51725d60de" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_03c8ccfe-dabe-46f9-ac27-aaa64cb11fea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_03c8ccfe-dabe-46f9-ac27-aaa64cb11fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ceb5f462-1045-4886-9a52-d962bbc02b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_ceb5f462-1045-4886-9a52-d962bbc02b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7df7e25b-3194-4c8c-9bb1-5b6b8245a145" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_7df7e25b-3194-4c8c-9bb1-5b6b8245a145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3f38a69c-f61c-4879-820c-3aa717c9257b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_3f38a69c-f61c-4879-820c-3aa717c9257b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d12dd28f-d8ff-4479-9c5c-1fa64caff3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_d12dd28f-d8ff-4479-9c5c-1fa64caff3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_29f91e0a-62cf-4f1b-9a49-db2753c41c0d" xlink:href="prct-20210930.xsd#prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod_29f91e0a-62cf-4f1b-9a49-db2753c41c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b4ce51f1-68c9-4e55-bbad-7d70907a4f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b4ce51f1-68c9-4e55-bbad-7d70907a4f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_640bdffa-21c2-4aac-9c1a-52faf7bcf138" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_640bdffa-21c2-4aac-9c1a-52faf7bcf138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2f8b9641-6ee6-43ce-adf7-11b256a89eaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_2f8b9641-6ee6-43ce-adf7-11b256a89eaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_83d27181-834b-4dde-a8cc-acbae325e029" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_83d27181-834b-4dde-a8cc-acbae325e029" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_89679d91-ea3c-4c7b-a1b8-bdc4448e523b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_89679d91-ea3c-4c7b-a1b8-bdc4448e523b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_91fa3d89-5d2b-44f8-9b64-7c0b2f18442d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_91fa3d89-5d2b-44f8-9b64-7c0b2f18442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c5b27821-b971-433a-be19-73e651d1991b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_c5b27821-b971-433a-be19-73e651d1991b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c21fba8f-5ae7-4d00-b89e-73e3955cfcca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c21fba8f-5ae7-4d00-b89e-73e3955cfcca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2d05528c-3cc1-46d1-8f4b-14b4a5100b94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_2d05528c-3cc1-46d1-8f4b-14b4a5100b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_cfa2d155-ae38-42c7-b554-acc129f095fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_cfa2d155-ae38-42c7-b554-acc129f095fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_c74644be-ae29-44fe-9cb0-e2b27e6148a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_fef8f823-d520-4223-a3af-9cbf06295416" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueIssuedForServices_c74644be-ae29-44fe-9cb0-e2b27e6148a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#StockholdersEquityScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_900fc3dd-16e5-4e0d-b2e1-a2c8d7e58d56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3389332a-3ccf-480d-ba16-f2ac353930fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_900fc3dd-16e5-4e0d-b2e1-a2c8d7e58d56" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3389332a-3ccf-480d-ba16-f2ac353930fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_da9cdb74-e714-4e53-bedc-aad87491a1df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3389332a-3ccf-480d-ba16-f2ac353930fb" xlink:to="loc_us-gaap_AwardTypeAxis_da9cdb74-e714-4e53-bedc-aad87491a1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70ffa05d-9d07-4adc-b4ac-0865d249c99e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_da9cdb74-e714-4e53-bedc-aad87491a1df" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70ffa05d-9d07-4adc-b4ac-0865d249c99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3920f456-6385-464c-a829-7194b6dca65d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_70ffa05d-9d07-4adc-b4ac-0865d249c99e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3920f456-6385-464c-a829-7194b6dca65d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_388c3a2a-c8d6-40f7-9fbe-a7b05a46c260" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3389332a-3ccf-480d-ba16-f2ac353930fb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_388c3a2a-c8d6-40f7-9fbe-a7b05a46c260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_388c3a2a-c8d6-40f7-9fbe-a7b05a46c260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5fa5683-5f48-414f-b6ba-73fbb44df0b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c5fa5683-5f48-414f-b6ba-73fbb44df0b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5da03b54-cd00-4efc-a727-491b7f000d46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_5da03b54-cd00-4efc-a727-491b7f000d46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b62704b9-2049-4c52-ab20-0df9afd35cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_b62704b9-2049-4c52-ab20-0df9afd35cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3c95025b-a085-483d-bded-e3d7589a81fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_3c95025b-a085-483d-bded-e3d7589a81fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4bb974d8-b2ae-4b20-a80f-060c09c5db93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4bb974d8-b2ae-4b20-a80f-060c09c5db93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_97a86b7c-7681-46dd-af9f-c7c7c87f1378" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_97a86b7c-7681-46dd-af9f-c7c7c87f1378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d7273cb1-8fb5-4eba-a7cf-209d1fe1bb72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5e2005c5-fc93-477c-a2f5-4b03fcd7ed9b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d7273cb1-8fb5-4eba-a7cf-209d1fe1bb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_388c3a2a-c8d6-40f7-9fbe-a7b05a46c260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_58bb9a4c-86e3-4288-828e-0f4d5d1e1a4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_58bb9a4c-86e3-4288-828e-0f4d5d1e1a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9f3c9bb8-1d14-4bc6-8688-94ba35231d65" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9f3c9bb8-1d14-4bc6-8688-94ba35231d65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f3172182-9fd5-4e37-9fe4-9d355007d3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_f3172182-9fd5-4e37-9fe4-9d355007d3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7449d7c6-307e-4fd6-9ddf-c1229751bde4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7449d7c6-307e-4fd6-9ddf-c1229751bde4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e39a5d58-334f-4583-a427-0e8015dfc353" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e39a5d58-334f-4583-a427-0e8015dfc353" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_889c0c7c-c12b-4062-af3f-3fb13d29c245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_889c0c7c-c12b-4062-af3f-3fb13d29c245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_45274a15-a6ea-4b11-bf06-aede0af1c5a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3bf2e387-366e-4e85-91df-2c7393d2ba78" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_45274a15-a6ea-4b11-bf06-aede0af1c5a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b91f24cc-a6e6-4cdc-87f1-78a722f38283" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23cc07cc-4ed9-4126-8b4b-39e6f7361cad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b91f24cc-a6e6-4cdc-87f1-78a722f38283" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23cc07cc-4ed9-4126-8b4b-39e6f7361cad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f2fe8f63-ec5a-410a-9e24-9f0d246d7701" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23cc07cc-4ed9-4126-8b4b-39e6f7361cad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f2fe8f63-ec5a-410a-9e24-9f0d246d7701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7b96da40-a986-4186-a10e-56f77210c1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f2fe8f63-ec5a-410a-9e24-9f0d246d7701" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7b96da40-a986-4186-a10e-56f77210c1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_455e9838-5a45-445a-a973-b1ca5217857b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7b96da40-a986-4186-a10e-56f77210c1fc" xlink:to="loc_us-gaap_CostOfSalesMember_455e9838-5a45-445a-a973-b1ca5217857b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5ce295b9-f40a-479f-9122-b92facc7a00f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7b96da40-a986-4186-a10e-56f77210c1fc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5ce295b9-f40a-479f-9122-b92facc7a00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_921ff843-2702-4056-b5dc-fd7bbb3dd9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7b96da40-a986-4186-a10e-56f77210c1fc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_921ff843-2702-4056-b5dc-fd7bbb3dd9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_593aea4d-aec5-4c5c-bc1d-b620900978c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_23cc07cc-4ed9-4126-8b4b-39e6f7361cad" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_593aea4d-aec5-4c5c-bc1d-b620900978c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_430a175e-c1fb-4322-b9c5-d6d0712ad830" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_593aea4d-aec5-4c5c-bc1d-b620900978c8" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_430a175e-c1fb-4322-b9c5-d6d0712ad830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#StockholdersEquityFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8616f038-10c8-48e2-a35d-aa3205d0521a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e3587e9-b6ff-460e-b88f-dcf87138626d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8616f038-10c8-48e2-a35d-aa3205d0521a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e3587e9-b6ff-460e-b88f-dcf87138626d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_41110e01-db96-49c6-9209-4a5a2a76573d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e3587e9-b6ff-460e-b88f-dcf87138626d" xlink:to="loc_us-gaap_AwardTypeAxis_41110e01-db96-49c6-9209-4a5a2a76573d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2a6865f-080d-4396-9eec-e09924c027b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_41110e01-db96-49c6-9209-4a5a2a76573d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2a6865f-080d-4396-9eec-e09924c027b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1866190a-de20-4bc0-9195-94d0e5fd8c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b2a6865f-080d-4396-9eec-e09924c027b1" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1866190a-de20-4bc0-9195-94d0e5fd8c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8e3587e9-b6ff-460e-b88f-dcf87138626d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2f24e4a3-8cff-4a9b-9748-c247d2c6daaf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2f24e4a3-8cff-4a9b-9748-c247d2c6daaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_90e871b3-b20d-4ac4-9f3f-368727dbe480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_90e871b3-b20d-4ac4-9f3f-368727dbe480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59ae8b90-6720-49c0-af23-293def28592f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_59ae8b90-6720-49c0-af23-293def28592f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5030ac17-6114-4d68-a3ec-5aa80f8090f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_5030ac17-6114-4d68-a3ec-5aa80f8090f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_01d5f6b6-5a93-420a-8457-5beb734dbe52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_93c79302-dcd9-414f-9d6b-8afe6ec823e0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_01d5f6b6-5a93-420a-8457-5beb734dbe52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="prct-20210930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa8b0aa9-bebd-436f-9cc9-0a97ec16ee79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6dcb400c-b3ae-499b-8fdd-eb6408d5a8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa8b0aa9-bebd-436f-9cc9-0a97ec16ee79" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_6dcb400c-b3ae-499b-8fdd-eb6408d5a8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_eec4f7c7-80df-4a2e-8ff3-4df02402b5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_aa8b0aa9-bebd-436f-9cc9-0a97ec16ee79" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_eec4f7c7-80df-4a2e-8ff3-4df02402b5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesTables" xlink:type="simple" xlink:href="prct-20210930.xsd#CommitmentsandContingenciesTables"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28be40c5-512f-40b9-9d81-d406a2eefc56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_abff140d-05ba-40c3-8fdb-657ae6f46c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28be40c5-512f-40b9-9d81-d406a2eefc56" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_abff140d-05ba-40c3-8fdb-657ae6f46c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9f4fd425-8b07-425b-9d8e-2a6169dc8ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_28be40c5-512f-40b9-9d81-d406a2eefc56" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_9f4fd425-8b07-425b-9d8e-2a6169dc8ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CommitmentsandContingenciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd61a0a8-aee9-4af1-933f-043bdf40397b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGuaranteeObligationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_cd61a0a8-aee9-4af1-933f-043bdf40397b" xlink:to="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fbb0e17b-ce62-48e0-8af5-193f2294ba1a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_us-gaap_CreditFacilityAxis_fbb0e17b-ce62-48e0-8af5-193f2294ba1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_5c9a9856-f98e-4dc2-b9fd-39f2026420cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_fbb0e17b-ce62-48e0-8af5-193f2294ba1a" xlink:to="loc_us-gaap_CreditFacilityDomain_5c9a9856-f98e-4dc2-b9fd-39f2026420cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_8bd2ab26-c626-4822-bb6f-bd7b188d021c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_5c9a9856-f98e-4dc2-b9fd-39f2026420cf" xlink:to="loc_us-gaap_LineOfCreditMember_8bd2ab26-c626-4822-bb6f-bd7b188d021c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_962282b5-832c-4221-addd-a486f1078e88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_us-gaap_DebtInstrumentAxis_962282b5-832c-4221-addd-a486f1078e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_11a36025-3b7b-48a1-8eff-1638c339cb24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_962282b5-832c-4221-addd-a486f1078e88" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_11a36025-3b7b-48a1-8eff-1638c339cb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_LoanFacilityMember_f26157dc-01d0-4064-8ad6-5dd5e3490a98" xlink:href="prct-20210930.xsd#prct_LoanFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_11a36025-3b7b-48a1-8eff-1638c339cb24" xlink:to="loc_prct_LoanFacilityMember_f26157dc-01d0-4064-8ad6-5dd5e3490a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_f25f602b-c2e3-47f0-81ad-513e0e68b9c1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_srt_StatementGeographicalAxis_f25f602b-c2e3-47f0-81ad-513e0e68b9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_42305c66-ff56-4573-802e-2411bb533426" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_f25f602b-c2e3-47f0-81ad-513e0e68b9c1" xlink:to="loc_srt_SegmentGeographicalDomain_42305c66-ff56-4573-802e-2411bb533426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_RedwoodCityCAMember_86732078-e658-474d-84f4-f0e2c339fff9" xlink:href="prct-20210930.xsd#prct_RedwoodCityCAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_42305c66-ff56-4573-802e-2411bb533426" xlink:to="loc_prct_RedwoodCityCAMember_86732078-e658-474d-84f4-f0e2c339fff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_37cf4e66-43ba-4e94-8ea1-e7a79e1b06d3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_37cf4e66-43ba-4e94-8ea1-e7a79e1b06d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_91b59455-dbe0-4fc3-a9ee-767a7fefaa55" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionAxis_37cf4e66-43ba-4e94-8ea1-e7a79e1b06d3" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_91b59455-dbe0-4fc3-a9ee-767a7fefaa55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_ccbc7fa8-14dd-4fcc-9c30-c2fd89f8bb7d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CumulativeEffectPeriodOfAdoptionDomain_91b59455-dbe0-4fc3-a9ee-767a7fefaa55" xlink:to="loc_srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember_ccbc7fa8-14dd-4fcc-9c30-c2fd89f8bb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_af5271eb-1cf8-4442-a6d9-b96ba285ef8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_af5271eb-1cf8-4442-a6d9-b96ba285ef8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfAdoptionMember_e294cad7-72cb-438a-95bd-b84c4076b11e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_af5271eb-1cf8-4442-a6d9-b96ba285ef8f" xlink:to="loc_us-gaap_TypeOfAdoptionMember_e294cad7-72cb-438a-95bd-b84c4076b11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_45a89ca1-28ce-4916-a68a-599c888b82c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_e294cad7-72cb-438a-95bd-b84c4076b11e" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_45a89ca1-28ce-4916-a68a-599c888b82c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GuaranteeObligationsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGuaranteeObligationsTable_3b2f785a-1acf-4b73-96a7-25eedf0cb408" xlink:to="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a5633c6c-6961-43eb-aef3-18178ff41151" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a5633c6c-6961-43eb-aef3-18178ff41151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c65c20a8-dd00-441a-8946-67a2e778dede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c65c20a8-dd00-441a-8946-67a2e778dede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dbc3ffbe-2fac-4135-a2f4-51e21ce5c7af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dbc3ffbe-2fac-4135-a2f4-51e21ce5c7af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_f4ea1bd6-69fd-48d0-a0b5-f42fcd806e5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_OperatingLeaseLiability_f4ea1bd6-69fd-48d0-a0b5-f42fcd806e5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_abf60913-0bca-4409-be85-8f00652faa46" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_ContractWithCustomerLiability_abf60913-0bca-4409-be85-8f00652faa46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ef842d26-8b63-45fe-83bd-afd5175f3429" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ef842d26-8b63-45fe-83bd-afd5175f3429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1bac7f41-7965-421c-aa14-cf57502382f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1bac7f41-7965-421c-aa14-cf57502382f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_0fd4a676-bb96-45f5-ae4b-5169e10013a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_us-gaap_OperatingLeaseExpense_0fd4a676-bb96-45f5-ae4b-5169e10013a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_2efb7fa4-f3b0-4fc1-a2a2-aac6fdc3ee06" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_2efb7fa4-f3b0-4fc1-a2a2-aac6fdc3ee06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentInterestOnlyPeriod_ac14b93b-4275-4a98-9623-7f280fa90abc" xlink:href="prct-20210930.xsd#prct_DebtInstrumentInterestOnlyPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_prct_DebtInstrumentInterestOnlyPeriod_ac14b93b-4275-4a98-9623-7f280fa90abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_80c9788d-8006-4a60-a1af-0cdcdb56d512" xlink:href="prct-20210930.xsd#prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GuaranteeObligationsLineItems_9200270f-1dfb-4837-bf20-58a5afd08526" xlink:to="loc_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount_80c9788d-8006-4a60-a1af-0cdcdb56d512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails" xlink:type="simple" xlink:href="prct-20210930.xsd#CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b030db4-2864-41d1-bd13-a3d542e246ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b030db4-2864-41d1-bd13-a3d542e246ec" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2e94a382-9f6b-4e63-8da6-8b8be4908fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2e94a382-9f6b-4e63-8da6-8b8be4908fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_05b6c567-83c7-4ad8-b2a7-a7313b80c0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_05b6c567-83c7-4ad8-b2a7-a7313b80c0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4bcd835a-0a84-4ede-b7c5-c2be709c1905" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4bcd835a-0a84-4ede-b7c5-c2be709c1905" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_139a1a75-ba28-43ef-96fc-ad4a33dd7bf3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_139a1a75-ba28-43ef-96fc-ad4a33dd7bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44cd62c8-0ab0-4211-8a6c-a34fdafbee60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_44cd62c8-0ab0-4211-8a6c-a34fdafbee60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e11ccaa9-0b00-4297-b255-fea98c01e344" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_e11ccaa9-0b00-4297-b255-fea98c01e344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_22f14bcb-95f1-4bd0-a9f7-346325eecfb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:to="loc_us-gaap_OperatingLeaseLiability_22f14bcb-95f1-4bd0-a9f7-346325eecfb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_e1cf0ff8-226b-4abb-933c-bc873db09c92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_e1cf0ff8-226b-4abb-933c-bc873db09c92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4f1026db-4c3f-4b10-9e12-c68d97f498d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_cd245f02-f043-425f-97cf-b655869cf3d2" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4f1026db-4c3f-4b10-9e12-c68d97f498d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MaturitiesOfLongTermDebtAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b030db4-2864-41d1-bd13-a3d542e246ec" xlink:to="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3a04ae87-48ba-4433-8b3d-6a69db31e9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_3a04ae87-48ba-4433-8b3d-6a69db31e9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9d0a82b8-cd15-4933-8994-db8bd2a469eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9d0a82b8-cd15-4933-8994-db8bd2a469eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_01fa5c4b-c3db-47e6-a2ef-a11b84a6f18d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_01fa5c4b-c3db-47e6-a2ef-a11b84a6f18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1d4e9279-1976-42b8-b8e0-fea6b773b2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_1d4e9279-1976-42b8-b8e0-fea6b773b2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_43522359-d9f0-4499-a93b-effc54d8de96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_43522359-d9f0-4499-a93b-effc54d8de96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4596d197-5756-4021-8cc1-5d09e5b0aa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_4596d197-5756-4021-8cc1-5d09e5b0aa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_228c62ae-158a-444e-80ab-ecd3d6d6ecad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:to="loc_us-gaap_LongTermDebt_228c62ae-158a-444e-80ab-ecd3d6d6ecad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_04cfa382-dcc6-44f2-8efb-70798de85243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:to="loc_us-gaap_LongTermDebtCurrent_04cfa382-dcc6-44f2-8efb-70798de85243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_715dbc3a-959a-4db2-8122-958d76b7b3b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MaturitiesOfLongTermDebtAbstract_7fab529a-918b-4b54-bc81-aaafd1214820" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_715dbc3a-959a-4db2-8122-958d76b7b3b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7b030db4-2864-41d1-bd13-a3d542e246ec" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear_114467a9-1dcb-4e26-8098-f717f364b36d" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear_114467a9-1dcb-4e26-8098-f717f364b36d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne_2c2dba30-9864-4eca-8ee5-4da6dcba34e5" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne_2c2dba30-9864-4eca-8ee5-4da6dcba34e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo_084c25d2-07d8-4ed9-8153-1080a4a8883a" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo_084c25d2-07d8-4ed9-8153-1080a4a8883a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree_0ed98c80-991e-4a21-8b41-f12a5cc242af" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree_0ed98c80-991e-4a21-8b41-f12a5cc242af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_65ada156-c35a-4a21-a28b-47cf92772648" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross_65ada156-c35a-4a21-a28b-47cf92772648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount_3a68e1b4-eecf-4c97-bb70-3f61f7366e84" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount_3a68e1b4-eecf-4c97-bb70-3f61f7366e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebt_8ffee3c3-e662-4dca-bb34-31fc7ccf5f14" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebt_8ffee3c3-e662-4dca-bb34-31fc7ccf5f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent_c75b5aa1-96bf-41c4-8ffd-68b52a7abd8d" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent_c75b5aa1-96bf-41c4-8ffd-68b52a7abd8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities_119f443d-3a62-4672-917b-b75aadfcfba2" xlink:href="prct-20210930.xsd#prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract_5500f4c0-8b1d-4b61-af2b-65f0fb4f9023" xlink:to="loc_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities_119f443d-3a62-4672-917b-b75aadfcfba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>prct-20210930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:prct="http://www.procept-biorobotics.com/20210930"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="prct-20210930.xsd" xlink:type="simple"/>
    <context id="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ife2115ee5766464a8a5a08c494796bcc_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i894ed293fa3742e3a04a1df94f575575_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i01918d59a04b4c499b05ee2466db1b59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i100c23f92bda49a28c0877949b1a0fbd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia55a781d4fc84f41a41fcb23206c4b8c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i565b2c3bc8fb41c3b592ad68c4361808_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69c82465ba6d48e6b9185da02a84e2b4_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="ie7eb6a1e27a14c97a0ea1c2cf23a8098_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i49c187172a454793b7a939d7e48946ac_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i35f6cea14ac0417b98a3dd1cea4a266d_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i4658dd5cdc744b40a5f591e4cd3f85e0_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i6d5816a787b74534b5f25f18a706ccf0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="if2cb5f33c9274d0097af2dc64d06de5c_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6de1f8c86cea46dc902859f13d99afc9_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2eec3bd752b2481d9dc300830ea16b5f_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ib9403ca6a5054b1f88c93a222d45cd64_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i2e13c67478f6478e8541be8a44bb1f4c_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i802e7d5b07ff4ca5b8093189adc87bb0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6e3cb976587c4b1d83bc6098c98b5efe_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i72403aeb9eb44de7b079046542387a2e_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ie60a74e01b9041ce961b1963ccfbf1d1_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0047bc2007a74490b97d13e8976d3dbf_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i3e1bb70ea6094ea29f8dc5001a1cdf43_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iaacff7f78ad74cae9c3705649ac848a3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i529b692fd02c440cb93775020fee3392_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i655db423d80146ba9a5fc4791da055de_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i2578d1ae003e4df39157ff0cedef50d3_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icad0956d1fac424f955531bf976553b6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iad55634ed8394953ba4771879c737291_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i77e0b2f826e241698ef40dc6384a75c7_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2f72d70743b3499b96f9d263ba7b8823_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia092c91a3f084cdcbfb9a7581c7384e8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2962c8287fb9466283c88ab19620b70a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ifa21a99062154fbdb875876427776118_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6bba4b69cf534b07bff7fadc5c5880e1_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i350149917e7c4dad952ac65149521110_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="ibfd71f7a814d4c54bda649dd20cbfc19_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i63de44b1b5764b5484ed75a0180e0f06_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="if86cc355897b4827abd740147e1208da_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="id8c4f5ac282a46bfb9afbc186bba95e2_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i207a558e6bf54b419ced15aa4da0802b_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="iee7a556f8ed44411b236ac803a34efa5_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i6ba09fbe2d8e41ae91b530bd0fd4aabf_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i28789e1867f6489181082ded2abe46bd_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i47808217616c42a1bde3b298ba31d9ec_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="if3221c2435d1479a8c4fbc3f096a5d50_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i8b07359bb1524f11b21ca2e21f932d05_I20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="i6b42bfa189674105a63a13810f164fee_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i9dc6976f7625478f8a1e700402e190e8_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i83a299a91bc0478bbe2f8a0bce7ff85b_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i74d430c7456149008291631a41455fb6_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ic0c1cb22a76846d88fe33bc3ec293fe5_D20200401-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="ibb23ec3142464357adefd10788d9dc21_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i3a5d7ddae2bf4b4c9ff977f94e8bf4df_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i43a77154c7e44d6c916d662730d39095_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i9c72799a37ef4b6996ae6377297e5d8b_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i406bac8d8e3c42e8ba906eba2383e727_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i82411be0df684d5999a14b0a6ad94e9a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i402b4853a118490284a4c268556e6aa9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f878035d2ed48dc9860fc0e9a488f55_D20200701-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i5ae4098982084df789f8c32460ce665d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3fc7c14ea459484dbff851cda6151300_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i333242aedc914ccab277eab2cc3188fe_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ib1af9fd0db1144ceb9953d270a352e2d_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="ic8aa66f1be4e40d5b3e68af93a816d5b_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i2eb4717194044992b7d6a3ba0a73a671_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i3e6d9aca39d64536ad610f06bc65f7f3_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i9679f5b41fb34cf6abfae1649202e1c5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if2b1c007cb5a4990af1e1f1d862c4d24_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3acfe77b8a2f44e79e9ac544b7465414_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesGRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a1b74e1acd043bda78eed560ea4270b_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i679a14a77cd0453ca47285769b9db2d0_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib8664e9a7cee4889bdb472916c610c7d_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i719157466752459aa43b7047e2f317c7_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="i55fff3d953504e32a8bb1767e17be163_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i685a759150ca4001b06e6ef8169b3a0a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia13ef5c367424e9b87f0aa0201302d21_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic790d5759ab443cba375a13c77efc8a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic53305bb04ab4021944c4163701dcd71_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib383b7e5ad6141079ebfdfb1678720a6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i372dc095e6bb4b4fab2fda830e21a778_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i26689b208bf84601a3e040e4ce73ce49_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i80cf655a5572442ab5b3157b560431bf_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i932b6afd06b54dfdbf042021f1fb619a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i735e2352ec40490980b3c86c7253982d_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i87940b64ee9940b29b568ac0a865184b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f0a6d3d6a5d41aabc418f290a24224b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5998e1db9c1d41c4b57ba2aac373504c_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i821880a0f0ea457fb74d98beb2145b75_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4acb9ad050634e849a2a2923e0940cae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide057d850a674c1faa90ee7654a9dcba_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ibf0b64a5bcea498e9f11e448dcbfd834_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputOptionVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i70cffcb762f444178b8ff9f5925b1a05_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i669bfb53914c4eb98abef7a0bb67beb4_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i149316ff5b004dd4a6c20c85ec67c952_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia44bb9ced3444ecab70c0374b5456e34_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3604760cd7da443ebd82948c1de89a0c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="iec7eb3e7ffce40f691737cf9a773acc7_I20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="i5706bc22431543fd88f03f8d8b69bf07_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i70e3fa6d51e049b29372b92a12097b3b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i552d18e694c74d6ea1105c6c060177c9_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5e3327002d624963bd45eaa1f8569e6c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c34540459ad463592472f93bf90d0d6_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i521f9bcdc3594f5cad2c4aaf7085a016_I20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="i886693e4845143ee9412596e575e4081_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic400b41cd47342848644ec9514f047c0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7b9ba7023422472682b16a20f5f463a1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1c26f250c925422aa863c70b7a19551d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7a170ab8421b4089a99080c2ea10af97_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="idabe1c5a57964ddb9bd5d12ab67202b8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d0c0948cc8f4e1280e0195a16e98801_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic44775719b294dc1913d8311a089ebaf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd2dcb59faa3426288a132975960e82e_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ie17f18e3e20e4d43aae76b23a39a3be8_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic89eb2bbd1924e0fb717bfba7cc199c8_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1d1f490ec27b47feb871022c21515bab_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id8353a9a7b034508bb8f01dbd8917e72_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ieeada33fd4aa4372b8bd11229fdf8032_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ac6cd3dce7f43fda61bce4f9ba59555_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="if05a3e115a3c4a69bedce4615d0524f0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idf79d1655d82439f9563d7390347f8f3_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i81c94b64a4fe411c90294df282895066_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibe009ff3d8a84467b238828dc96fa66e_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1a203d4671604af189dd4efe9cfc3f3c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib054ba1212a040a5ba7001b1a2bc8aaa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iad3a4897b0f74d93b212ccf2d92ceb95_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iaa5d2fc51a09454fb9410268366249f0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:SystemSalesAndRentalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9c6ae97130174160926aac368d44e969_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ff4ab44021547058325efd92af9bd8b_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i018b3765196146e48322f8a859dbb4d5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i52ad0f1364cd409c9f18e002b7381a5f_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:HandPiecesAndOtherConsumablesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="icfa97cb67f4c48af906ec7b00d213a04_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifd005e7d887548c48d2e442a699161c8_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i1b33b0f044bd43a19422b9118049e601_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee4ecb3e06be41628c57d8da452ede6d_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">prct:ServiceRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ia2968256b5824a29a2ac8033c768dcc5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6c940d5581a0431aaaeb6016386ef835_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9fde91df02034661a6ff9d0d3c072933_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2df0a857498b4af18745e51eab13a016_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:OutsideTheUnitedStatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5de6b566d9af4bbbbdb356901e72ac2f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i39c4d84b986e41378d377fdb579b0a86_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ifb2eba5a66004f438219847cad5c1e9a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">prct:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifb63ff2219e442f2819551ec884c0008_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">prct:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic982c9e58b554c3082d06d2c3a72e4fd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">prct:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i49ee07a01cc44074a4d6e760f58e4643_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">prct:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ibe92bd4b50d543f59cb5bba7fd59e5d6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib43d1b122a854476a24a6c9ee1ab3406_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i621e3ef4440f48c2b9f769e24af4620f_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">prct:Customer1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i9bfac2758f3446a3ad3a43b3803a084a_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">prct:Customer2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i8bc8fda665ae45fda75450551e6878fb_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">prct:Customer3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i7708603bb2ff47579ddc870b44b0fbb0_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i52f5aefc16b34dfda582cd7651908024_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:DE</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i62921dc1224a460e89216f894a1e2b07_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">prct:Customer1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ac307246bd746a78220da47930dbd09_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">prct:Customer2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="icec9f26499284935a6a375b0c451fdcb_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i39ecf903be504ecdaf949aece1345593_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prct:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ic86cf6a985714467a558f903d60ea686_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prct:LaboratoryAndManufacturingEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4cacff96a36941f49fc136cd9987bba8_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i56f7a99ae3cc46a48d7f360c4949ca50_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib0930250516e46df8adee1ddbea619bb_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id08e754d707e4d5ca56a878c541eb772_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia890f1a1f9ea4925ac24d0577d19ee3c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prct:EvaluationUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ia2daf6e575dd487a9593c9105221c75c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">prct:EvaluationUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i323691aee3ba4470beeb781efc9f7d5a_D20190301-20190331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="ic9df1ea4e38a48c3958b823d207dc494_I20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="ie747bb89dfe9448486f081a8d7c662b9_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i69e54cc3200146fb8da3275f099dcd86_D20200301-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheTwoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i9e17326bb20948edb8a8ca7d92913aaa_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id581c96bb97e44a48ba70ae2493b16db_D20210101-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="idc0b522093084b14a072138407b528ec_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheThreeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="i8d291c059d984acabb11a4e041ff93bc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i9578e35c34594195b4553614451e762d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id1237e90024844c78a16dad0cbdc499c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie2270b85069d4e108aafb93ea6264888_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i03b0c48c8ac947c3a489c6f136a47201_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iee83fb3442a945c89e3036e0c6098fdb_D20190901-20190930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="ifbe7a57a89de4a8285e98235fc3da48b_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <context id="ib126ee67697d4fdc82b80a04fe0cc629_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityTrancheFourMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7425a248d0c54625b60e82800726ba6e_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i37a93df4a20d471fa73a04fadd763398_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a6641bdf6a04d2a9f8abd5a3282a1c4_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="ib8ca34d460bd431e9f40af8ba7f4941d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if5da641970b84172a5c935038a6a1c8e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibecb2734dfdd4390b231ca7dcd3bc7eb_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="ifc65b7919fd243f887cb7aa91fed512f_I20150731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-31</instant>
        </period>
    </context>
    <context id="i869c38d090bb4baa8be1f5e855808baa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i103b94ebee224533bc1827781430d1ba_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i4d86103fd3bc4740a8b6c0bfaf50e9e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i90bf229ad34d4baba483ea11a398bc08_I20170630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="i927e6688e0294af2a421eef76a378dca_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i3019d42f68fb44eaa750274de9c831ec_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ied497de295f14e1f827bd811b22ff9f1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie352732829a944e8bcad696ed9555ae7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="id0c5306798ce4d5cbf19af58bc03c7b0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9144a17da8024a6fa09ae89276a70ce7_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i86acacb511a247ad99b9d153e72b9538_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i43040eb9775b4ce6978553e3936f3b76_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iea718991298743b4bf83f37c95537401_D20200701-20200731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-07-31</endDate>
        </period>
    </context>
    <context id="iffd69005bc104609a9a1664e72d42b12_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesGRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i60e32c082ec946839e6d084bceac21a6_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesGRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i0e1b4a8dca7145f3b32508e4106c7c5b_I20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-31</instant>
        </period>
    </context>
    <context id="ib4185c7d482a4d408c70efb88bc2655b_D20200701-20200831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="i7aa86dd5567043e78dbeaa1869e5a838_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i006123c4fa5d483a9e5463519395740b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8f4ede9a776146de87f610eeb9409d5d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i6f35ad14fa9c4afd9f180294ec2f5da1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7de321a1c268402ab2b16faea56fdb02_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0e48ea26dceb47ec879e15c92c50d98e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6e43455a41214ba3a21927edd8a4845d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i3a5a5773de0d4f218c0162ed76015607_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesDRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib4321f4042af4f5cb3cf13c10279d51d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4982cd5fdb3f431caecb3cf5474a994c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesERedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ice8d36bf1b564de9b741f74e90346ae9_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesFRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i74e05f7559ad44e2b03cdce92864389e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">prct:SeriesGRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ib06a5da95c7042d7b94adeb6559177b2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icbaeafd33bbd4e6888b366b6103f762f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4ece297f570a4b82a416279c7fdc8910_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">prct:ShareholderOfTenPercentOwnershipOrGreaterMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">prct:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i775e9da970104587a8e43c336154fd28_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">prct:IncentiveStockOptionsAndNonqualifiedStockOptionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i06d1766f867741e985119b9837680d50_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ecfd2799a3b484db31278a912812179_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EquityIncentiveAwardPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id017d7645c90419b8f85f400f2c78e30_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2008StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i29a3508d251b4bde9f8eb210f942bfaa_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10a6eebd2df541eca35c8a3094153817_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i12898071c0444fe7844142bb4d3cd49c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iccd781125894469891eb522580c6b2aa_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i0f72c2550a004f309da2bc458a30adfe_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i78b24385d55b4a209c528145906fa5ce_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i445258736c484e52b6ddb965454bb1ff_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9c80643e4da242ecbd5c44667621fad4_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i5f0e6e6c797846fa8312b60ebb59afb3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i190871b1575a4e8db9bd9f80d3702fa0_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="iffd4490b13ce46d8825d6f990c341beb_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6bd6c00e464c4f16bf14f0e616cee1d1_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i008a0e4e1310456bb44ece232d2da544_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i95da0a4005cc41b88796003dc99be3ea_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="ic2e662689b684020aedbed74e67c085f_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i09198490d2f441a08b39181593f1f255_D20200701-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-09-30</endDate>
        </period>
    </context>
    <context id="i90a0eaa9861b47338cef7b3ddc5fa8d1_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i147dde6bfea84bb5a5a2eab1578869ea_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7d2b70c21dbc4b32895eedfc71019388_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">prct:A2021EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i03b8cb9f698a47d698415757c8e483bf_D20150501-20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="i5398d7157b274e53afc37f43c4fb9f1a_D20150501-20150531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-05-01</startDate>
            <endDate>2015-05-31</endDate>
        </period>
    </context>
    <context id="id13f0093eaaa458181bd8b489d0fa71e_I20130731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:RedwoodCityCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-07-31</instant>
        </period>
    </context>
    <context id="i51e569731e334d18b46ce30b6992446f_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:RedwoodCityCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i0882844190cf46d882aec93c3be61895_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">prct:RedwoodCityCAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ibcde0d5c3d85476888c4854555b60153_I20200101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CumulativeEffectPeriodOfAdoptionAxis">srt:CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-01</instant>
        </period>
    </context>
    <context id="i6c89c558562342acb1a97bac5a006107_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9c6bcd3416cb4dff84912e6e977f510e_D20210101-20210131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001588978</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">prct:LoanFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="installment">
        <measure>prct:installment</measure>
    </unit>
    <unit id="customer">
        <measure>prct:customer</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NTMvZnJhZzoyNjQxY2Y5YjNjYWY0ZGVkODQzYjMzNzUzMTFhOGRhNC90YWJsZTowMzQ0ZTFkMjJkMWY0NjgzOGYxMGYwZDYzNDhhZjBmZi90YWJsZXJhbmdlOjAzNDRlMWQyMmQxZjQ2ODM4ZjEwZjBkNjM0OGFmMGZmXzAtMS0xLTEtNDExNzM_f85fb5e1-009d-40f3-a537-70b776a569d9">0001588978</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NTMvZnJhZzoyNjQxY2Y5YjNjYWY0ZGVkODQzYjMzNzUzMTFhOGRhNC90YWJsZTowMzQ0ZTFkMjJkMWY0NjgzOGYxMGYwZDYzNDhhZjBmZi90YWJsZXJhbmdlOjAzNDRlMWQyMmQxZjQ2ODM4ZjEwZjBkNjM0OGFmMGZmXzEtMS0xLTEtNDExNzM_ad6fc04d-8fd3-4b0f-b8e1-99125a7b0a3d">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NTMvZnJhZzoyNjQxY2Y5YjNjYWY0ZGVkODQzYjMzNzUzMTFhOGRhNC90YWJsZTowMzQ0ZTFkMjJkMWY0NjgzOGYxMGYwZDYzNDhhZjBmZi90YWJsZXJhbmdlOjAzNDRlMWQyMmQxZjQ2ODM4ZjEwZjBkNjM0OGFmMGZmXzItMS0xLTEtNDExNzM_2f7bd4c9-2bc4-4a8b-98f4-bb55a102c67a">2021</dei:DocumentFiscalYearFocus>
    <dei:AmendmentFlag
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NTMvZnJhZzoyNjQxY2Y5YjNjYWY0ZGVkODQzYjMzNzUzMTFhOGRhNC90YWJsZTowMzQ0ZTFkMjJkMWY0NjgzOGYxMGYwZDYzNDhhZjBmZi90YWJsZXJhbmdlOjAzNDRlMWQyMmQxZjQ2ODM4ZjEwZjBkNjM0OGFmMGZmXzMtMS0xLTEtNDExNzM_551c16b8-193c-461d-bc46-1a3ffb4b000b">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NTMvZnJhZzoyNjQxY2Y5YjNjYWY0ZGVkODQzYjMzNzUzMTFhOGRhNC90YWJsZTowMzQ0ZTFkMjJkMWY0NjgzOGYxMGYwZDYzNDhhZjBmZi90YWJsZXJhbmdlOjAzNDRlMWQyMmQxZjQ2ODM4ZjEwZjBkNjM0OGFmMGZmXzQtMS0xLTEtNDExNzM_c53787ca-6820-48b6-b182-5cb72f248748">Q3</dei:DocumentFiscalPeriodFocus>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="ib8664e9a7cee4889bdb472916c610c7d_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NzAvZnJhZzpkMjM2ODkxODQ4NDE0OGJhOTkwZGQwNTYxYWI5OTMyZi90YWJsZTo5NzZmYmI1ZTRiMDc0ZDU0YWJmNTYxYTBlNGNmOWVhNi90YWJsZXJhbmdlOjk3NmZiYjVlNGIwNzRkNTRhYmY1NjFhMGU0Y2Y5ZWE2XzItMS0xLTEtNDgxMzU_0e20ff93-c0f9-40be-be5c-bb2c1f48151f"
      unitRef="number">0.2105263158</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <dei:DocumentType
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2MzU_fbd5ba26-32c5-4e56-9742-7b092817bc70">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTphODVjZmNiMzE4ZDU0YzRjOTA4MGFjMWM4ZDA4MWRlZi90YWJsZXJhbmdlOmE4NWNmY2IzMThkNTRjNGM5MDgwYWMxYzhkMDgxZGVmXzAtMC0xLTEtNDA5Nzk_eb1c61e0-a2c8-46c4-b182-1c2a1544004a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzQzOTgwNDY1MzE3NjA_4e8526a5-9777-435d-9512-6cd379aa780d">2021-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTplNGYyN2Q1ZmFmNTM0MDQ0YTg3NzZjYjI0OGNhMWIxYy90YWJsZXJhbmdlOmU0ZjI3ZDVmYWY1MzQwNDRhODc3NmNiMjQ4Y2ExYjFjXzAtMC0xLTEtNDA5ODE_7e630ec0-3991-469c-9b50-3aae93970476">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NDQ_9a32c87e-aacf-4db5-b2dd-5f34879a74be">001-40797</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NDc_4a8f37de-801c-4ad2-b0df-3678026d7198">PROCEPT BioRobotics Corporation</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzAtMC0xLTEtNDA5ODg_2d915474-e45e-4b53-b3d1-2099da82c970">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzAtMy0xLTEtNDA5ODg_937963dd-23bc-420c-8421-0039fc022202">26-0199180</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzMtMC0xLTEtNDA5ODg_bb1fa591-f5fa-413a-8fde-764d9373780e">900 Island Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzMtMS0xLTEtNDA5ODg_33c7485d-857f-4f1e-a915-f2eac624bead">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzMtMi0xLTEtNDA5ODg_7b3c6391-fdfd-4202-8b86-77f49bc9b0ce">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTpjNWFiNWY5MjQ1ZDA0ZDdhYWU5ZWRiMWUyZjI0Yzk1Ni90YWJsZXJhbmdlOmM1YWI1ZjkyNDVkMDRkN2FhZTllZGIxZTJmMjRjOTU2XzMtMy0xLTEtNDA5ODg_3b2917ff-4caf-4ee6-bb2e-ad2b339b686d">94065</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2Mzc_c3b40839-8969-46c5-8285-b8bc11dddf1c">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NDE_36a43650-b9a3-4d96-bd5c-9cd6e818fd84">232-7200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTo1YmM0YzNmZGRmODM0N2VkYjA3ZTBlOWNiZWVhMTk3My90YWJsZXJhbmdlOjViYzRjM2ZkZGY4MzQ3ZWRiMDdlMGU5Y2JlZWExOTczXzEtMC0xLTEtNDEwMDA_5b420947-ec81-4474-b7a6-4c7e1c39334c">Common stock, $0.00001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTo1YmM0YzNmZGRmODM0N2VkYjA3ZTBlOWNiZWVhMTk3My90YWJsZXJhbmdlOjViYzRjM2ZkZGY4MzQ3ZWRiMDdlMGU5Y2JlZWExOTczXzEtMS0xLTEtNDEwMDA_fee7db68-e482-4772-8ee9-4eb165d23e2d">PRCT</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTo1YmM0YzNmZGRmODM0N2VkYjA3ZTBlOWNiZWVhMTk3My90YWJsZXJhbmdlOjViYzRjM2ZkZGY4MzQ3ZWRiMDdlMGU5Y2JlZWExOTczXzEtMi0xLTEtNDEwMDA_8d1bcf17-9c10-4cb6-923d-a274728f8d08">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTcxOTE_db321bff-d293-4ce5-8d5f-dcd746e688ce">No</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NDk_f09d210d-d168-47bc-be9c-cc91db3138ad">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTozOTI5YzE0YTQ2ZTM0MTdlYjY4ODk2ZWU1NjM5ZmEwNS90YWJsZXJhbmdlOjM5MjljMTRhNDZlMzQxN2ViNjg4OTZlZTU2MzlmYTA1XzEtMC0xLTEtNDYzNzM_8cdc8853-eeaa-4587-bd7b-a73524f412fd">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTozOTI5YzE0YTQ2ZTM0MTdlYjY4ODk2ZWU1NjM5ZmEwNS90YWJsZXJhbmdlOjM5MjljMTRhNDZlMzQxN2ViNjg4OTZlZTU2MzlmYTA1XzEtMy0xLTEtNDEwNzQ_3b53a470-aa4d-4339-b467-0701da822f91">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90YWJsZTozOTI5YzE0YTQ2ZTM0MTdlYjY4ODk2ZWU1NjM5ZmEwNS90YWJsZXJhbmdlOjM5MjljMTRhNDZlMzQxN2ViNjg4OTZlZTU2MzlmYTA1XzItMy0xLTEtNDEwNzQ_6bf1398b-3c35-4918-ab0b-4a02511b09e6">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NTA_bd02bc37-e735-4cc5-b78f-c09d0be3bf50">false</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzkzNDU4NDg4NTY2NTE_5cb291e0-638e-450b-b2ae-5c68c245f656">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="ife2115ee5766464a8a5a08c494796bcc_I20211031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF83NDYvZnJhZzowYjY0OGE3YmY1NTE0ZTUyOWZhNjhkNjU1OTRkYTk0My90ZXh0cmVnaW9uOjBiNjQ4YTdiZjU1MTRlNTI5ZmE2OGQ2NTU5NGRhOTQzXzQzOTgwNDY1MzE2Njg_07b3760a-1ff4-4357-8cf4-fd78fa808852"
      unitRef="shares">43496831</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNS0xLTEtMS0zNDQwMQ_c99fbdbd-687d-4c64-9eba-806f6eac9a28"
      unitRef="usd">320484000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNS0zLTEtMS0zNDQwMQ_7530e9d5-4a87-4d38-b42d-2ca5fb705cc2"
      unitRef="usd">100130000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNi0xLTEtMS0zNDQwMQ_b46a03dd-5aa4-4b05-8f95-f6a9aa5b164c"
      unitRef="usd">6353000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNi0zLTEtMS0zNDQwMQ_66f6eed7-f582-49b0-9cf7-f2bd99dc2ad8"
      unitRef="usd">1549000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNy0xLTEtMS0zNDQwMQ_6855e7ff-80f1-4a7d-be65-e92b927238b0"
      unitRef="usd">10401000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNy0zLTEtMS0zNDQwMQ_a015a155-4150-4fc9-8de2-da040ea47092"
      unitRef="usd">6924000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfOC0xLTEtMS0zNDQwMQ_d63623fe-5ac3-487d-9685-0a56b8eecad2"
      unitRef="usd">2232000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfOC0zLTEtMS0zNDQwMQ_ec286ab6-8d73-4a2b-bb61-2f7295303cc1"
      unitRef="usd">1653000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfOS0xLTEtMS0zNDQwMQ_b2b4c175-61d1-4d8d-96a6-c5b80b473218"
      unitRef="usd">339470000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfOS0zLTEtMS0zNDQwMQ_1d3ace37-984e-408b-b48e-86e29fb512c3"
      unitRef="usd">110256000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTAtMS0xLTEtMzQ0MDE_967da144-b4da-4300-b8f3-3fbffd8ba5d7"
      unitRef="usd">777000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTAtMy0xLTEtMzQ0MDE_34c26d43-2775-449f-a48f-b3fbbf1164d1"
      unitRef="usd">777000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTEtMS0xLTEtMzQ0MDE_7598835a-581c-4189-9c68-a1a1b999f4a9"
      unitRef="usd">5731000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTEtMy0xLTEtMzQ0MDE_a04eac76-1009-4a4c-a08a-2599fe01ba6f"
      unitRef="usd">8274000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTItMS0xLTEtMzQ0MDE_e1b6df23-7594-48b2-ae6d-7285d2d5b766"
      unitRef="usd">3667000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTItMy0xLTEtMzQ0MDE_dcd0798c-e3d6-43df-9e96-0c41b9b6b47a"
      unitRef="usd">4641000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTMtMS0xLTEtMzQ0MDE_3e071631-f1a2-47b2-be32-5461458fa277"
      unitRef="usd">1818000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTMtMy0xLTEtMzQ0MDE_3310b682-6a91-4403-a3c9-e76f5f7e5e2e"
      unitRef="usd">2023000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:Assets
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTUtMS0xLTEtMzQ0MDE_311ce768-d215-40c3-8470-d67e1ca176fc"
      unitRef="usd">351463000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTUtMy0xLTEtMzQ0MDE_2f91a78f-4096-41b0-8459-c9379c131ff3"
      unitRef="usd">125971000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTgtMS0xLTEtMzQ0MDE_b888b31e-2031-48ea-94c9-f868cb83172f"
      unitRef="usd">3590000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTgtMy0xLTEtMzQ0MDE_95cd4300-9d65-418c-8882-3b662d9930e9"
      unitRef="usd">1240000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTktMS0xLTEtMzQ0MDE_c04603e5-dd39-497e-8eea-2cb923e1e4f0"
      unitRef="usd">4875000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMTktMy0xLTEtMzQ0MDE_f3aa5745-c8c8-4a93-a77f-44e90a3aa486"
      unitRef="usd">4640000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjAtMS0xLTEtMzQ0MDE_6b928a7d-4cb2-432d-8bdd-fae2d78e3842"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjAtMy0xLTEtMzQ0MDE_01a418fd-db86-4a2b-a1fb-c4d7151f83f2"
      unitRef="usd">4551000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjEtMS0xLTEtMzQ0MDE_ec86a6cf-c466-4c8d-8d9c-393bc88dcd62"
      unitRef="usd">2032000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjEtMy0xLTEtMzQ0MDE_33a9b646-9036-439f-8679-dde9b645af7e"
      unitRef="usd">1708000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjItMS0xLTEtNDYwNDY_a231e80e-94af-48ad-b887-9bcdba174fb5"
      unitRef="usd">848000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjItMy0xLTEtNDYwNTM_b6b85640-1f67-4a1d-91c0-b462915eef1a"
      unitRef="usd">233000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjItMS0xLTEtMzQ0MDE_a8778c16-3477-48ee-88b0-350a48d17d0b"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjItMy0xLTEtMzQ0MDE_2ea898ad-a106-4c66-815b-dbf7e982acd1"
      unitRef="usd">177000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjMtMS0xLTEtMzQ0MDE_f9ee264e-73d2-47be-b1bc-3cd7921e1ef9"
      unitRef="usd">2834000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjMtMy0xLTEtMzQ0MDE_53c28d26-0bb9-433a-81d0-090dbaad6385"
      unitRef="usd">1977000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjQtMS0xLTEtMzQ0MDE_5db89b08-237a-45e5-a897-4837fc01615f"
      unitRef="usd">14179000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjQtMy0xLTEtMzQ0MDE_5649e46d-b591-4666-a74e-6123f3e32d3b"
      unitRef="usd">14526000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjUtMS0xLTEtMzQ0MDE_92bc053c-5e00-44fc-b233-3c4e81954a23"
      unitRef="usd">49762000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjUtMy0xLTEtMzQ0MDE_e91573b7-796c-4acc-836c-51fc75c54a32"
      unitRef="usd">44407000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjYtMS0xLTEtMzQ0MDE_f8b7317b-7141-4f23-8714-0ce28ba33ad4"
      unitRef="usd">2550000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjYtMy0xLTEtMzQ0MDE_96543532-ea86-4dc4-a62e-2930fa82b7c2"
      unitRef="usd">4096000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjctMS0xLTEtMzQ0MDE_f1c196fb-105a-46d8-8831-7460f1790e21"
      unitRef="usd">1460000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjctMy0xLTEtMzQ0MDE_02572d38-4bae-4c07-8c9e-82be138a772d"
      unitRef="usd">1782000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjktMS0xLTEtMzQ0MDE_6aae964f-0455-4462-8953-c6c161d130f3"
      unitRef="usd">200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMjktMy0xLTEtMzQ0MDE_e2939165-3eb1-44dc-8c80-82ac0a155fa5"
      unitRef="usd">200000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzAtMS0xLTEtMzQ0MDE_e01913e7-b75b-4dac-b4db-fcf14b69d2c9"
      unitRef="usd">68151000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzAtMy0xLTEtMzQ0MDE_79aa965a-5fea-497d-a4a6-aa2fe15884d9"
      unitRef="usd">65011000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzEtMS0xLTEtNDU3NjI_e5b5b907-a415-4ea8-bdc9-f3ec8a506a36"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzEtMy0xLTEtNDU3NjI_760f32cb-9f4e-46e3-bfd0-330117354b9a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzItMC0xLTEtMzQ3MTEvdGV4dHJlZ2lvbjpjMWIyZWM2MGVhY2Q0YTdiYjMxM2Q1YWVhNmRhOTBjZl8xNjQ5MjY3NDQxNzU0_12946eaa-339f-4e3a-b0ca-018e6a09b821"
      unitRef="usdPerShare">0.00001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquityParOrStatedValuePerShare
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzItMC0xLTEtMzQ3MTEvdGV4dHJlZ2lvbjpjMWIyZWM2MGVhY2Q0YTdiYjMxM2Q1YWVhNmRhOTBjZl8xNjQ5MjY3NDQxNzU0_7b4ba982-460e-4bd5-86ca-71feec0b24f2"
      unitRef="usdPerShare">0.00001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzMtMC0xLTEtMzQ3MjQvdGV4dHJlZ2lvbjphZjJhOWM1MjgxYjM0ZDA0ODFlMTlhZjVkZjYyZGUzZl80Mzk4MDQ2NTExMzAz_f322ee1c-1cce-4213-a0f8-a2b8dc6d72f9"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzMtMC0xLTEtMzQ3MjQvdGV4dHJlZ2lvbjphZjJhOWM1MjgxYjM0ZDA0ODFlMTlhZjVkZjYyZGUzZl80Mzk4MDQ2NTExMzY1_cb80277f-0606-41d0-b3b7-e62fbdb67df4"
      unitRef="shares">26984000</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzQtMC0xLTEtMzQ3NDQvdGV4dHJlZ2lvbjo0YWVhMzUzNzRmMjM0MDk1YTA3OTJjMmVhYTVkY2M0Ml8xNjQ5MjY3NDQxODIz_86bd8a12-5b04-422c-88e4-25c671c526f5"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzQtMC0xLTEtMzQ3NDQvdGV4dHJlZ2lvbjo0YWVhMzUzNzRmMjM0MDk1YTA3OTJjMmVhYTVkY2M0Ml8xNjQ5MjY3NDQxODIz_e6ac6332-049d-49d2-a6cc-f0b7480c165a"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzQtMC0xLTEtMzQ3NDQvdGV4dHJlZ2lvbjo0YWVhMzUzNzRmMjM0MDk1YTA3OTJjMmVhYTVkY2M0Ml80Mzk4MDQ2NTExMzY1_5cc24912-593b-44d3-b793-4de40152a91f"
      unitRef="shares">25402000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzQtMC0xLTEtMzQ3NDQvdGV4dHJlZ2lvbjo0YWVhMzUzNzRmMjM0MDk1YTA3OTJjMmVhYTVkY2M0Ml80Mzk4MDQ2NTExMzY1_c3e5de88-55cb-4cbd-805f-9917e72343c3"
      unitRef="shares">25402000</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzUtMC0xLTEtMzQ3NjQvdGV4dHJlZ2lvbjpjY2Q2Y2QwZGMzMjU0NjA5OGMyODNmODZhYTJjMDZiNF8xNjQ5MjY3NDQxODM4_b6b0cdd2-b8fe-4be0-a871-e8a02fca2f37"
      unitRef="usd">0</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityLiquidationPreference
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzUtMC0xLTEtMzQ3NjQvdGV4dHJlZ2lvbjpjY2Q2Y2QwZGMzMjU0NjA5OGMyODNmODZhYTJjMDZiNF80Mzk4MDQ2NTExMzgx_fb017473-6452-47a4-bb73-d5beb63da16a"
      unitRef="usd">245768000</us-gaap:TemporaryEquityLiquidationPreference>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzUtMS0xLTEtMzQ0MDE_bd11dcf9-04f4-4387-adcd-5ccc0ff425b6"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzUtMy0xLTEtMzQ0MDE_fa4aa41d-52a6-4c6e-b878-6bc82a7bc118"
      unitRef="usd">243854000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzctMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjozN2VjMTE0MGI1NmM0NjQyOWNlNWQ3ODVjNmFlOTY0MV80Mzk4MDQ2NTExMTUy_4d2b24ad-4741-4eff-abd3-4c82e5572b79"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzctMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjozN2VjMTE0MGI1NmM0NjQyOWNlNWQ3ODVjNmFlOTY0MV80Mzk4MDQ2NTExMTUy_725af891-d516-44e6-aa51-1f8bfdb31e27"
      unitRef="usdPerShare">0.00001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzgtMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZWZkZjE3M2E1N2M0YmEyOGZjYTA3MjNkOTU1N2JiMV80Mzk4MDQ2NTExMjQ1_cd7ff86a-383d-4322-af74-362f0bd92c63"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzgtMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZWZkZjE3M2E1N2M0YmEyOGZjYTA3MjNkOTU1N2JiMV80Mzk4MDQ2NTExMjQx_22d6d281-3941-4026-a6f1-18a28b219ef6"
      unitRef="shares">0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZjM4MWQ2MWI2NWU0MzI3OTQyODgzYjNjYjg3ZGNjOV80Mzk4MDQ2NTExMjQz_4523a8fa-ebb1-4d28-a296-4c34268815df"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZjM4MWQ2MWI2NWU0MzI3OTQyODgzYjNjYjg3ZGNjOV80Mzk4MDQ2NTExMjQz_574ddbf2-b45b-4008-828b-3a9839bd12ac"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZjM4MWQ2MWI2NWU0MzI3OTQyODgzYjNjYjg3ZGNjOV80Mzk4MDQ2NTExMjQz_6f53e6e3-4612-441c-aa51-e5b57162c1b6"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzg4NzMvdGV4dHJlZ2lvbjpjZjM4MWQ2MWI2NWU0MzI3OTQyODgzYjNjYjg3ZGNjOV80Mzk4MDQ2NTExMjQz_d96068cf-edc1-40e7-8d4e-da62de8b1910"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMS0xLTEtNDA0NTg_c90246e6-d251-46b5-b663-96a2800bdcfb"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMy0xLTEtNDA0NjU_b3213796-e625-4b46-87f1-b2eeef5fa783"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzctMC0xLTEtMzQ3ODIvdGV4dHJlZ2lvbjoxYTc0N2JiMjEyYTQ0MjExYjkwMjI0MzMzMWQwZDQ2Zl8xNjQ5MjY3NDQxNzA5_348b0320-4f5e-4c6a-bff8-6c7f74140145"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzctMC0xLTEtMzQ3ODIvdGV4dHJlZ2lvbjoxYTc0N2JiMjEyYTQ0MjExYjkwMjI0MzMzMWQwZDQ2Zl8xNjQ5MjY3NDQxNzA5_99bbc897-d54a-4367-835f-273b8b15f947"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzgtMC0xLTEtMzQ3ODgvdGV4dHJlZ2lvbjoxNTk2NzU3MjA0YTE0MmY3OGJkOThkYTYxNzJhYzhjYl8xNjQ5MjY3NDQxODA3_d0182880-efb3-4207-9046-c25b069a6b62"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzgtMC0xLTEtMzQ3ODgvdGV4dHJlZ2lvbjoxNTk2NzU3MjA0YTE0MmY3OGJkOThkYTYxNzJhYzhjYl80Mzk4MDQ2NTExMzA3_1756c1c7-5c74-44c6-af30-87178d69a985"
      unitRef="shares">40000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzQ4MDYvdGV4dHJlZ2lvbjpjNmRmNjIzNzBlNzA0ZDE3YmQ4Y2M5ZTEwODJlMWY1ZV8xNjQ5MjY3NDQxODEz_08bdbf17-42ee-4294-b1ff-6571aa8110f1"
      unitRef="shares">43472000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzQ4MDYvdGV4dHJlZ2lvbjpjNmRmNjIzNzBlNzA0ZDE3YmQ4Y2M5ZTEwODJlMWY1ZV8xNjQ5MjY3NDQxODEz_59a8b1b0-8706-4a12-96b4-6259ec3bfe55"
      unitRef="shares">43472000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzQ4MDYvdGV4dHJlZ2lvbjpjNmRmNjIzNzBlNzA0ZDE3YmQ4Y2M5ZTEwODJlMWY1ZV80Mzk4MDQ2NTExMzEz_820d4324-1a64-41cb-a1b8-2a9b558cfcb8"
      unitRef="shares">4713000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMC0xLTEtMzQ4MDYvdGV4dHJlZ2lvbjpjNmRmNjIzNzBlNzA0ZDE3YmQ4Y2M5ZTEwODJlMWY1ZV80Mzk4MDQ2NTExMzEz_ac325c52-46d4-4e3e-be15-bc8761e6af7b"
      unitRef="shares">4713000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMS0xLTEtMzQ0MDE_cb2a9be9-0f45-404e-9506-3aac75421dae"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfMzktMy0xLTEtMzQ0MDE_d19b26d2-4944-43a3-be4c-839802d385fd"
      unitRef="usd">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDAtMS0xLTEtMzQ0MDE_8000b5d2-b532-429e-a2c9-ba422308f798"
      unitRef="usd">526526000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDAtMy0xLTEtMzQ0MDE_c8b4b9f7-ee86-4c1a-b152-8cc90789f6fa"
      unitRef="usd">18788000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDEtMS0xLTEtMzQ0MDE_4f739b7d-d551-4c8e-931f-3c6d2344cb14"
      unitRef="usd">-41000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDEtMy0xLTEtMzQ0MDE_5a98b309-a8e3-48aa-a15d-8deefc813825"
      unitRef="usd">-14000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDItMS0xLTEtMzQ0MDE_45a42ddc-c6bd-4e4c-b9dd-288d29dfdf15"
      unitRef="usd">-243173000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDItMy0xLTEtMzQ0MDE_7c1c6862-b6a2-4218-a661-9478a8c19042"
      unitRef="usd">-201668000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDMtMS0xLTEtMzQ0MDE_11488a60-f4f8-4bf4-9387-b3155151a0a4"
      unitRef="usd">283312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDMtMy0xLTEtMzQ0MDE_bc6025d8-4df2-4c4f-86bb-36a40f035391"
      unitRef="usd">-182894000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDQtMS0xLTEtMzQ0MDE_8615aaec-764f-4d8d-a8af-99e1f74c44cf"
      unitRef="usd">351463000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8xOS9mcmFnOjIzN2Y4YjAwNzM0NjRiNjNhY2YyMzIxMWI1MjA2MjBjL3RhYmxlOjg3ZmI4YmIxNzVjNTQwNDJiMTYzOTM0MWVkZjQ2ODJiL3RhYmxlcmFuZ2U6ODdmYjhiYjE3NWM1NDA0MmIxNjM5MzQxZWRmNDY4MmJfNDQtMy0xLTEtMzQ0MDE_75961915-6bcd-4a67-b147-ff725f9fbc74"
      unitRef="usd">125971000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMy0xLTEtMS0zNDQwMQ_d7eeb5d2-c886-452c-b524-887af7ca1d8b"
      unitRef="usd">8668000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMy0zLTEtMS0zNDQwMQ_bdf111e3-d10f-458e-86a2-bd5ce0693954"
      unitRef="usd">2107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMy01LTEtMS0zNDQwMQ_93c6adbf-5e9b-4779-8ab0-fd6d22d05b2c"
      unitRef="usd">24335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMy03LTEtMS0zNDQwMQ_cd570f52-7478-4d53-a1ef-9143d0510660"
      unitRef="usd">4496000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfRevenue
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNC0xLTEtMS0zNDQwMQ_b67d3829-42aa-43ae-99aa-535e1736f960"
      unitRef="usd">4428000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNC0zLTEtMS0zNDQwMQ_a6866d21-be98-4adc-a291-14bbf50bd10d"
      unitRef="usd">2138000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNC01LTEtMS0zNDQwMQ_f0a29716-e453-4dfb-a90b-4f521fe29e14"
      unitRef="usd">12986000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNC03LTEtMS0zNDQwMQ_3b6007bf-9241-44d3-ab36-8635782b6e66"
      unitRef="usd">6221000</us-gaap:CostOfRevenue>
    <us-gaap:GrossProfit
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNS0xLTEtMS0zNDQwMQ_330662ff-d93d-4823-8ad8-67e2aec852d8"
      unitRef="usd">4240000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNS0zLTEtMS0zNDQwMQ_ac669d33-b89d-4137-9555-d94bd5b5a8d7"
      unitRef="usd">-31000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNS01LTEtMS0zNDQwMQ_fad64024-ffaa-44b0-8abe-9f5106f70e87"
      unitRef="usd">11349000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNS03LTEtMS0zNDQwMQ_1d344113-8387-4a68-8ffb-07550df174de"
      unitRef="usd">-1725000</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNy0xLTEtMS0zNDQwMQ_6eb8bece-860f-4839-84b0-0254834eb1d0"
      unitRef="usd">4919000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNy0zLTEtMS0zNDQwMQ_aadecadd-3532-42c5-8322-822a16758640"
      unitRef="usd">3893000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNy01LTEtMS0zNDQwMQ_b94f69b9-47a1-4d0a-b145-b631f2a56992"
      unitRef="usd">13917000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfNy03LTEtMS0zNDQwMQ_0b0ed51f-8841-43a5-893b-3e2e01804d5b"
      unitRef="usd">11732000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOC0xLTEtMS0zNDQwMQ_99e798ba-d1d1-4ea9-b9fc-bb80f68085e5"
      unitRef="usd">12118000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOC0zLTEtMS0zNDQwMQ_da07a493-fd8d-4492-a5dc-98a13bb171d9"
      unitRef="usd">7054000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOC01LTEtMS0zNDQwMQ_0f4b4764-6580-4c69-b6f7-ff132b7cb727"
      unitRef="usd">34765000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOC03LTEtMS0zNDQwMQ_74beeb2f-e036-45cf-9c93-0d80214127fd"
      unitRef="usd">21138000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOS0xLTEtMS0zNDQwMQ_52749bd2-7da3-4cdb-a94f-ddd37b0725e2"
      unitRef="usd">17037000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOS0zLTEtMS0zNDQwMQ_ab8c2e0b-139f-46d2-ad67-e8e1b36aed3a"
      unitRef="usd">10947000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOS01LTEtMS0zNDQwMQ_67130da0-2d01-447f-a281-352afdf64272"
      unitRef="usd">48682000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfOS03LTEtMS0zNDQwMQ_119300b4-092b-4b5e-933b-b54d1fedaabd"
      unitRef="usd">32870000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTAtMS0xLTEtMzQ0MDE_2c8907c7-b6f2-427b-ab49-b9900d426eeb"
      unitRef="usd">-12797000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTAtMy0xLTEtMzQ0MDE_dffb1b56-8c17-4fa9-8e52-70b75723b271"
      unitRef="usd">-10978000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTAtNS0xLTEtMzQ0MDE_b2b8fe73-1c6e-4fbd-ad0d-ccfda90a0aba"
      unitRef="usd">-37333000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTAtNy0xLTEtMzQ0MDE_bad8ca60-7c21-4fff-8fac-8e4b2a907898"
      unitRef="usd">-34595000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTEtMS0xLTEtMzQ0MDE_2138e7ce-a2c6-4b4c-a1c7-43591151552b"
      unitRef="usd">1469000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTEtMy0xLTEtMzQ0MDE_dd4272fe-f36a-45fa-bb0d-fc9c1fbf1a86"
      unitRef="usd">1387000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTEtNS0xLTEtMzQ0MDE_6344a636-7df9-40a7-917e-2affe86d27f4"
      unitRef="usd">4370000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTEtNy0xLTEtMzQ0MDE_a0765539-ea92-44b0-9ad6-f770946a6953"
      unitRef="usd">3490000</us-gaap:InterestExpense>
    <prct:InterestAndOtherIncomeExpense
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTItMS0xLTEtMzQ0MDE_6c358b60-8391-4806-86b1-62f51ff48011"
      unitRef="usd">163000</prct:InterestAndOtherIncomeExpense>
    <prct:InterestAndOtherIncomeExpense
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTItMy0xLTEtMzQ0MDE_9424f5a1-c84d-4423-8554-7b52dea357ba"
      unitRef="usd">357000</prct:InterestAndOtherIncomeExpense>
    <prct:InterestAndOtherIncomeExpense
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTItNS0xLTEtMzQ0MDE_d3f842ed-48be-4e1f-bda0-c8c50a30d0be"
      unitRef="usd">198000</prct:InterestAndOtherIncomeExpense>
    <prct:InterestAndOtherIncomeExpense
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTItNy0xLTEtMzQ0MDE_8b0e921a-363d-4675-9865-c9687ffffc1d"
      unitRef="usd">344000</prct:InterestAndOtherIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTMtMS0xLTEtMzQ0MDE_52b988ed-3aa7-4c4a-b9b9-828f1afadd70"
      unitRef="usd">-14103000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTMtMy0xLTEtMzQ0MDE_d34dfd23-ddac-414e-9b53-77bb8855fa8b"
      unitRef="usd">-12008000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTMtNS0xLTEtMzQ0MDE_a7890653-1663-4818-895b-a4e512f01b2d"
      unitRef="usd">-41505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTMtNy0xLTEtMzQ0MDE_92b9556d-19cf-4621-932c-d0f3e4bc92ee"
      unitRef="usd">-37741000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtMS0xLTEtMzQ0MDE_8fe0f799-6fa4-43cd-b015-8360b9964bee"
      unitRef="usdPerShare">-1.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtMS0xLTEtMzQ0MDE_941952fe-661c-4237-bfa9-b213cca81c56"
      unitRef="usdPerShare">-1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtMy0xLTEtMzQ0MDE_2ab8dbe6-cc32-41e0-a43c-700c2497a9a2"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtMy0xLTEtMzQ0MDE_4c1f0129-c4f5-4f1c-a347-622e7cbbda24"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtNS0xLTEtMzQ0MDE_17bfa606-6c1e-4184-af2f-6dff56b54421"
      unitRef="usdPerShare">-5.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtNS0xLTEtMzQ0MDE_d4b5f550-3859-4113-a089-cb096d5494e5"
      unitRef="usdPerShare">-5.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtNy0xLTEtMzQ0MDE_3168c2ef-ba15-41bc-8b1d-dfadab88ceb4"
      unitRef="usdPerShare">-11.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTQtNy0xLTEtMzQ0MDE_f8fb25f1-2482-4196-adaa-e2c33cc36a5e"
      unitRef="usdPerShare">-11.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctMS0xLTEtMzQ0MDE_3c9e6119-1713-4948-81e7-789cd8986ace"
      unitRef="shares">11580000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctMS0xLTEtMzQ0MDE_a9ff3ed0-39b1-450a-8602-6402be635e40"
      unitRef="shares">11580000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctMy0xLTEtMzQ0MDE_5bedbb54-fb28-4c85-93dc-8d04a754f7eb"
      unitRef="shares">4329000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctMy0xLTEtMzQ0MDE_90622652-1bf9-436a-8e70-2effe0a6ebd5"
      unitRef="shares">4329000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctNS0xLTEtMzQ0MDE_1e87593b-4d1e-48fe-a0f0-74c81b935bf2"
      unitRef="shares">7361000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctNS0xLTEtMzQ0MDE_a55aad25-9676-41ec-96e5-921b64619070"
      unitRef="shares">7361000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctNy0xLTEtMzQ0MDE_5660c2e0-c25f-41fb-a33f-c6fe7c9e7de4"
      unitRef="shares">3327000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTctNy0xLTEtMzQ0MDE_61ad7dbe-f8c9-4296-b37e-a1c01be2738f"
      unitRef="shares">3327000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTktMS0xLTEtMzQ0MDE_f16594ab-c52d-449f-8504-6496fde4e332"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTktMy0xLTEtMzQ0MDE_146f29a4-5b00-439a-b1d4-b0d01f747b0d"
      unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTktNS0xLTEtMzQ0MDE_688fdc19-7593-41a6-81d2-fd813453af96"
      unitRef="usd">-27000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMTktNy0xLTEtMzQ0MDE_01177d9e-8dfe-4b0b-9241-63c95347e75c"
      unitRef="usd">3000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMjAtMS0xLTEtMzQ0MDE_16193f2f-7eca-4e4a-8327-edc43bb870c1"
      unitRef="usd">-14105000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMjAtMy0xLTEtMzQ0MDE_bb4e2d63-f885-4a6e-9670-450f641d90d7"
      unitRef="usd">-12024000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMjAtNS0xLTEtMzQ0MDE_cd298a40-da03-4119-96ef-61e9af1dc1f9"
      unitRef="usd">-41532000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yMi9mcmFnOmY1MjgwYWNiY2Q4NzQ2MGY5NmI0MDk4ZWUzOGQzZTA1L3RhYmxlOmZjN2ZmYzZiMzQxYTQ3YTZhZDYzODY5ZGE3MDVmYzVjL3RhYmxlcmFuZ2U6ZmM3ZmZjNmIzNDFhNDdhNmFkNjM4NjlkYTcwNWZjNWNfMjAtNy0xLTEtMzQ0MDE_4b6bec44-e75e-4498-901c-d6a766bdc417"
      unitRef="usd">-37738000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMS0xLTEtMzQ0MDE_edf82d8b-c93b-4ef1-bf3c-b4dd3df7a8b1"
      unitRef="shares">25402000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMy0xLTEtMzQ0MDE_3873a59f-74a1-49b9-974a-f0a228f200fe"
      unitRef="usd">243854000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i01918d59a04b4c499b05ee2466db1b59_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtNi0xLTEtMzQ0MDE_2928052b-5cc6-4cf3-865d-57618967c48e"
      unitRef="shares">4713000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i01918d59a04b4c499b05ee2466db1b59_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtOC0xLTEtMzQ0MDE_58d59aff-22a6-40ae-be04-4c95ba7f1ff4"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i100c23f92bda49a28c0877949b1a0fbd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMTAtMS0xLTM0NDAx_276ed026-7cfc-4565-a1e8-fbd2fe3eda90"
      unitRef="usd">18788000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia55a781d4fc84f41a41fcb23206c4b8c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMTItMS0xLTM0NDAx_0a1a293f-425c-4c32-b28e-f543874df4ad"
      unitRef="usd">-14000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i565b2c3bc8fb41c3b592ad68c4361808_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMTQtMS0xLTM0NDAx_2f9c959e-6b6d-4116-ab0f-075a5954942f"
      unitRef="usd">-201668000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTYtMTYtMS0xLTM0NDAx_78616af4-9e63-41a3-86a3-aedd60e40f5d"
      unitRef="usd">-182894000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i69c82465ba6d48e6b9185da02a84e2b4_D20210101-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTgtNi0xLTEtMzQ0MDE_e3a84567-3af1-4243-bca0-37f0d7dbdf73"
      unitRef="shares">504000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie7eb6a1e27a14c97a0ea1c2cf23a8098_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTgtMTAtMS0xLTM0NDAx_0bd22731-74d3-4dbc-88ab-f1ae9047bdc5"
      unitRef="usd">1225000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i49c187172a454793b7a939d7e48946ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTgtMTYtMS0xLTM0NDAx_aa26e72d-bd1e-49f8-a2c1-b7548be70045"
      unitRef="usd">1225000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="ie7eb6a1e27a14c97a0ea1c2cf23a8098_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTktMTAtMS0xLTM0NDAx_980733ad-b353-4dc8-aea9-f6d627a87ccf"
      unitRef="usd">650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="i49c187172a454793b7a939d7e48946ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMTktMTYtMS0xLTM0NDAx_f3f32eb9-bcc9-4a65-8380-bc4b53752325"
      unitRef="usd">650000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i35f6cea14ac0417b98a3dd1cea4a266d_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjAtMTItMS0xLTM0NDAx_ad4db523-20d3-4a84-bf6a-7c31ebd6f858"
      unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i49c187172a454793b7a939d7e48946ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjAtMTYtMS0xLTM0NDAx_ffaafde8-6b71-48a9-8606-2ebb838114d5"
      unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i4658dd5cdc744b40a5f591e4cd3f85e0_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjEtMTQtMS0xLTM0NDAx_3e5a0642-2c51-4c01-a1a4-3f149e0b81db"
      unitRef="usd">-12822000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i49c187172a454793b7a939d7e48946ac_D20210101-20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjEtMTYtMS0xLTM0NDAx_f3ded4f5-44c3-4e65-92f0-f068c4ad132b"
      unitRef="usd">-12822000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6d5816a787b74534b5f25f18a706ccf0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMS0xLTEtNDQ1ODg_106498dd-8865-49f5-b989-b53821379316"
      unitRef="shares">25402000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i6d5816a787b74534b5f25f18a706ccf0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMy0xLTEtNDQ2MDQ_de8dc772-ec6f-47f9-80b1-e429013a2f68"
      unitRef="usd">243854000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="if2cb5f33c9274d0097af2dc64d06de5c_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtNi0xLTEtNDQ2MjY_e0f41428-9358-4cfb-a422-ba8ac151534f"
      unitRef="shares">5217000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if2cb5f33c9274d0097af2dc64d06de5c_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtOC0xLTEtNDQ2Mzg_5f003a5f-7b85-4970-8828-f9eff9eebbec"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6de1f8c86cea46dc902859f13d99afc9_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMTAtMS0xLTQ0NjUw_f0c29b77-5d59-4788-b17d-07e695e00c48"
      unitRef="usd">20663000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2eec3bd752b2481d9dc300830ea16b5f_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMTItMS0xLTQ0NjYx_38268d92-e388-4974-9c70-98916eacccae"
      unitRef="usd">-30000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib9403ca6a5054b1f88c93a222d45cd64_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMTQtMS0xLTQ0Njcy_ae6ab071-14e8-4d26-b4ab-26cca5b493ae"
      unitRef="usd">-214490000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d5816a787b74534b5f25f18a706ccf0_I20210331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjQtMTYtMS0xLTQ0Njgz_68fe633f-37e2-4e4e-8c3a-7f58891e6b23"
      unitRef="usd">-193857000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i2e13c67478f6478e8541be8a44bb1f4c_D20210601-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjctMC0xLTEtNDU4NjAvdGV4dHJlZ2lvbjowYzVkNTg0ZjYyNzA0Y2YyOTI2N2IyMDUxMTVmZjc5M180Mzk4MDQ2NTExMTg5_f0f8cdcb-2f7c-4fad-9fee-7cfe6406e2be"
      unitRef="usd">290000</us-gaap:PaymentsOfStockIssuanceCosts>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjYtMS0xLTEtNDQ1ODg_41385773-e50c-4a7a-b9b4-e8abe139424c"
      unitRef="shares">4448000</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises
      contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjYtMy0xLTEtNDQ2MDQ_7c2541e5-0774-49d0-952c-9e9e19ffc458"
      unitRef="usd">84710000</prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i802e7d5b07ff4ca5b8093189adc87bb0_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjgtNi0xLTEtNDQ2MjY_0503dd26-df9e-474f-844c-1d77340e010a"
      unitRef="shares">575000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6e3cb976587c4b1d83bc6098c98b5efe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjgtMTAtMS0xLTQ0NjUw_13622901-f59c-4296-b735-9b88723a5d70"
      unitRef="usd">1415000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjgtMTYtMS0xLTQ0Njgz_d8aa4fe2-5b4f-42f7-a914-0c390ac9e751"
      unitRef="usd">1415000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="i6e3cb976587c4b1d83bc6098c98b5efe_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjktMTAtMS0xLTQ0NjUw_5bde4faa-c2b1-431c-a28e-75f530694abb"
      unitRef="usd">725000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjktMTYtMS0xLTQ0Njgz_fba6d21a-a166-47b3-97ea-6fcaa1c72bdc"
      unitRef="usd">725000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i72403aeb9eb44de7b079046542387a2e_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzAtMTItMS0xLTQ0NjYx_850e5f7f-222c-41ed-833a-3a212ac05bc3"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzAtMTYtMS0xLTQ0Njgz_f16bee4d-59d3-4dd5-a049-2d7c53aeb125"
      unitRef="usd">-9000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ie60a74e01b9041ce961b1963ccfbf1d1_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzEtMTQtMS0xLTQ0Njcy_24592525-5a11-4515-ad14-a92663dc7947"
      unitRef="usd">-14580000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ibbb4e8b5166d4e0fa063487a29064278_D20210401-20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzEtMTYtMS0xLTQ0Njgz_0a0faa08-bcaf-442f-b55a-f563475ea0aa"
      unitRef="usd">-14580000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i0047bc2007a74490b97d13e8976d3dbf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMS0xLTEtNDQ1ODg_34137368-47b6-432f-8661-808e97465e03"
      unitRef="shares">29850000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i0047bc2007a74490b97d13e8976d3dbf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMy0xLTEtNDQ2MDQ_cb5bbe6d-5aa7-4c39-a7cb-c4e0b98acb7b"
      unitRef="usd">328564000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i3e1bb70ea6094ea29f8dc5001a1cdf43_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItNi0xLTEtNDQ2MjY_98456088-4702-4786-8e53-0a3284c0f62f"
      unitRef="shares">5792000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3e1bb70ea6094ea29f8dc5001a1cdf43_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItOC0xLTEtNDQ2Mzg_ea6fa476-adc8-4a4e-832c-cf827136a17a"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaacff7f78ad74cae9c3705649ac848a3_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTAtMS0xLTQ0NjUw_a2506d10-eb5a-49e4-a552-1b0cac0f222f"
      unitRef="usd">22803000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i529b692fd02c440cb93775020fee3392_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTItMS0xLTQ0NjYx_17d0aa7d-b5ad-4d85-8fa4-c01e3dc9055a"
      unitRef="usd">-39000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i655db423d80146ba9a5fc4791da055de_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTQtMS0xLTQ0Njcy_f8861ee7-f767-428f-995c-d0f00a701a49"
      unitRef="usd">-229070000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0047bc2007a74490b97d13e8976d3dbf_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTYtMS0xLTQ0Njgz_509ecc53-d001-45de-a0c7-0ca9b07a359c"
      unitRef="usd">-206306000</us-gaap:StockholdersEquity>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMS0xLTEtNDQ1ODg_f60aa7f5-ceef-4a2b-a3ab-a32fc90305e4"
      unitRef="shares">62000</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMy0xLTEtNDQ2MDQ_15327acd-e580-4729-92ce-514379c750b8"
      unitRef="usd">970000</prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises>
    <prct:TemporaryEquitySharesConversionOfConvertibleSecurities
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMS0xLTEtNDQ4NzQ_c20bdcbc-052c-4356-b847-6fd610345e2a"
      unitRef="shares">29912000</prct:TemporaryEquitySharesConversionOfConvertibleSecurities>
    <prct:TemporaryEquityAmountConversionOfConvertibleSecurities
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMy0xLTEtNDQ4ODE_2e5e63a8-fc81-4fe3-b7dc-54fb68ba899a"
      unitRef="usd">329534000</prct:TemporaryEquityAmountConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i2578d1ae003e4df39157ff0cedef50d3_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctNi0xLTEtNDQ4ODg_356f6373-fd52-41c6-9e63-11b9c7934ca6"
      unitRef="shares">29912000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTAtMS0xLTQ0OTAy_9ca9ccb7-f936-4b97-b817-376e131e21d6"
      unitRef="usd">329534000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTYtMS0xLTQ0OTIz_1d120d26-e481-4a35-8cf2-4ee330365ffd"
      unitRef="usd">329534000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzgtMC0xLTEtNDU5NTYvdGV4dHJlZ2lvbjo2M2UyZDcyZmVhMjc0ODU4YTcwMDRlNzMxNGUxZGMxYV80Mzk4MDQ2NTExMTk1_bd494c4d-94d2-44c4-b85e-a031e36d6fdd"
      unitRef="usd">16076000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="i2578d1ae003e4df39157ff0cedef50d3_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzUtNi0xLTEtNDQ2MjY_ad2e379b-0e0b-4813-b0bc-2a7b312d8bd0"
      unitRef="shares">7539000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzUtMTAtMS0xLTQ0NjUw_da87cd9d-3878-4818-804c-17ccb223dfd2"
      unitRef="usd">172409000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzUtMTYtMS0xLTQ0Njgz_34f72f0a-414a-422f-b539-ce266c7bce11"
      unitRef="usd">172409000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2578d1ae003e4df39157ff0cedef50d3_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzYtNi0xLTEtNDQ2MjY_e376e369-2ba2-4112-969e-072df6f26fed"
      unitRef="shares">229000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzYtMTAtMS0xLTQ0NjUw_059f2dff-bf41-4413-9500-5a5909663d01"
      unitRef="usd">855000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzYtMTYtMS0xLTQ0Njgz_f4bce0a3-e60d-4ca7-a356-4cd6e3920034"
      unitRef="usd">855000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTAtMS0xLTQ0NjUw_e121fa5b-a0c5-4959-9f1b-3e345b747377"
      unitRef="usd">925000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTYtMS0xLTQ0Njgz_7309ddb6-202e-4dc6-9b12-a5eb1e0ee7c7"
      unitRef="usd">925000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="icad0956d1fac424f955531bf976553b6_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzgtMTItMS0xLTQ0NjYx_28d44b0d-4b94-4516-868e-1b1dccbfe97d"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzgtMTYtMS0xLTQ0Njgz_e2a546cf-6649-4956-9621-5bece43c8d2d"
      unitRef="usd">-2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iad55634ed8394953ba4771879c737291_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzktMTQtMS0xLTQ0Njcy_89a21618-9f88-4f4a-bdf9-9bc7894750e5"
      unitRef="usd">-14103000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzktMTYtMS0xLTQ0Njgz_4430ddfe-cbba-4664-82f0-ce7e427edfe4"
      unitRef="usd">-14103000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMS0xLTEtMzQ0MDE_a7fabd60-e6a1-4862-9732-36c7121c5aea"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMy0xLTEtMzQ0MDE_e8f17828-77d5-44b6-b159-d5b2f967cbec"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i77e0b2f826e241698ef40dc6384a75c7_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItNi0xLTEtMzQ0MDE_53d094d7-3f1e-41a0-8c8c-408edfa2f822"
      unitRef="shares">43472000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i77e0b2f826e241698ef40dc6384a75c7_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItOC0xLTEtMzQ0MDE_09b64c74-0c1f-4560-bdab-40687db523ff"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2f72d70743b3499b96f9d263ba7b8823_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMTAtMS0xLTM0NDAx_83b0d7e1-c657-4dc3-804e-7f2c7c5d0d2d"
      unitRef="usd">526526000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia092c91a3f084cdcbfb9a7581c7384e8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMTItMS0xLTM0NDAx_1d95778c-6818-4171-9af7-2a3506326c1a"
      unitRef="usd">-41000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2962c8287fb9466283c88ab19620b70a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMTQtMS0xLTM0NDAx_55c9a452-fbf6-412d-aec1-918d9dc763d4"
      unitRef="usd">-243173000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjItMTYtMS0xLTM0NDAx_d3ef1d2a-c54a-4250-a927-fded96b9cc81"
      unitRef="usd">283312000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ifa21a99062154fbdb875876427776118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMS0xLTEtMzQ0MDE_d6b1c240-9799-4053-92c9-ec16b1072c25"
      unitRef="shares">20998000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ifa21a99062154fbdb875876427776118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMy0xLTEtMzQ0MDE_94ae636d-f815-4933-8fda-93aba9cea16c"
      unitRef="usd">173068000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i6bba4b69cf534b07bff7fadc5c5880e1_I20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtNi0xLTEtMzQ0MDE_8502530a-969d-4363-82c2-d7b6d9fee288"
      unitRef="shares">2290000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i6bba4b69cf534b07bff7fadc5c5880e1_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtOC0xLTEtMzQ0MDE_02ac711e-8063-4d24-9139-cbede02a2c29"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i350149917e7c4dad952ac65149521110_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMTAtMS0xLTM0NDAx_f0827d90-5a01-4e0a-8872-76568fcc2dd5"
      unitRef="usd">4808000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibfd71f7a814d4c54bda649dd20cbfc19_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMTItMS0xLTM0NDAx_e0300ebf-ca17-4b0e-9bae-f156220dbeba"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i63de44b1b5764b5484ed75a0180e0f06_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMTQtMS0xLTM0NDAx_1fd80342-ee16-49fd-a7b6-10a52125ef4a"
      unitRef="usd">-148649000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifa21a99062154fbdb875876427776118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjUtMTYtMS0xLTM0NDAx_678e6127-dbb8-48fa-9f31-a52b413cb761"
      unitRef="usd">-143837000</us-gaap:StockholdersEquity>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjctMS0xLTEtMzQ0MDE_127bd6c4-72bc-44a2-b7f6-0f101c53eee1"
      unitRef="shares">75000</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises
      contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjctMy0xLTEtMzQ0MDE_6e5308c4-4db8-441c-ae25-fa0a0ca9e824"
      unitRef="usd">379000</prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="if86cc355897b4827abd740147e1208da_D20200101-20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjktNi0xLTEtMzQ0MDE_745a8c63-91a8-4fcf-a09f-2a63ff479853"
      unitRef="shares">602000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="id8c4f5ac282a46bfb9afbc186bba95e2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjktMTAtMS0xLTM0NDAx_5296e94f-c93b-4fb2-a9d0-2067096a813c"
      unitRef="usd">1024000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMjktMTYtMS0xLTM0NDAx_900b3457-a633-4dfb-beaa-666afe89a633"
      unitRef="usd">1024000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="id8c4f5ac282a46bfb9afbc186bba95e2_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzAtMTAtMS0xLTM0NDAx_3f33334d-32b6-4d36-b7cf-12dc2852e3cf"
      unitRef="usd">561000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzAtMTYtMS0xLTM0NDAx_533dc9cd-5a2b-47f8-b308-a128e0c6c7f2"
      unitRef="usd">561000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i207a558e6bf54b419ced15aa4da0802b_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzEtMTItMS0xLTM0NDAx_6569451f-1af3-491d-aea9-5713272df587"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzEtMTYtMS0xLTM0NDAx_35977e41-f120-497e-beac-f307cb7c6f97"
      unitRef="usd">-7000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="iee7a556f8ed44411b236ac803a34efa5_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTQtMS0xLTM0NDAx_5127308d-6dd8-4538-a578-fd6ee35a3fd2"
      unitRef="usd">-13126000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i33765b1a92a74ef19800e242dae1e333_D20200101-20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzItMTYtMS0xLTM0NDAx_ff1b2071-86ac-489a-9a37-e99ef1294f84"
      unitRef="usd">-13126000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i6ba09fbe2d8e41ae91b530bd0fd4aabf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMS0xLTEtNDE1MTM_73f800f9-7d05-4531-b7cc-6c464c1c139f"
      unitRef="shares">21073000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i6ba09fbe2d8e41ae91b530bd0fd4aabf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMy0xLTEtNDE1NDU_67bc49c9-5200-4e13-939f-8d93488725b4"
      unitRef="usd">173447000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i28789e1867f6489181082ded2abe46bd_I20200331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtNi0xLTEtNDE1NTY_b718d985-1dc2-491e-83d1-009b0a47e49d"
      unitRef="shares">2892000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i28789e1867f6489181082ded2abe46bd_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtOC0xLTEtNDE1NjQ_3d9f8049-526f-49ab-9089-5d0f7feecf48"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i47808217616c42a1bde3b298ba31d9ec_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTAtMS0xLTQxNTc4_9414a443-9e7d-44c5-88e3-38fcd5ca74fa"
      unitRef="usd">6393000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if3221c2435d1479a8c4fbc3f096a5d50_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTItMS0xLTQxNTky_8b1c29c4-c663-4ca8-899f-686fb3f3fa0f"
      unitRef="usd">-3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b07359bb1524f11b21ca2e21f932d05_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTQtMS0xLTQxNjA2_94814cf2-5306-4c17-a930-53db2b694047"
      unitRef="usd">-161775000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ba09fbe2d8e41ae91b530bd0fd4aabf_I20200331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTYtMS0xLTQxNjIw_f5f88240-de9c-4f0e-9afa-267481640d9d"
      unitRef="usd">-155385000</us-gaap:StockholdersEquity>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzUtMS0xLTEtNDE1MzE_f22edc9a-06f5-4e4a-a6b9-603888b94b49"
      unitRef="shares">45000</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises
      contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzUtMy0xLTEtNDE1NDU_9c6999b0-47f3-46ac-b001-6d2d95010897"
      unitRef="usd">230000</prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i9dc6976f7625478f8a1e700402e190e8_D20200401-20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctNi0xLTEtNDE1NTY_1614e504-88b2-462b-9213-a732b33fbdf9"
      unitRef="shares">218000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i83a299a91bc0478bbe2f8a0bce7ff85b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTAtMS0xLTQxNTc4_63643435-6427-4802-b8a9-5ebcd58dc2ee"
      unitRef="usd">979000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzctMTYtMS0xLTQxNjIw_7af5395b-7997-4576-b2f0-e968db6392b1"
      unitRef="usd">979000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="i83a299a91bc0478bbe2f8a0bce7ff85b_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzgtMTAtMS0xLTQxNTc4_cd0bfbf3-2995-4dcf-8884-ec560115d981"
      unitRef="usd">445000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzgtMTYtMS0xLTQxNjIw_bd99faa9-0471-41f9-9dc8-c1d9fa8f0fdf"
      unitRef="usd">445000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i74d430c7456149008291631a41455fb6_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzktMTItMS0xLTQxNTky_133b0d2d-4ac7-4b2d-bba5-9913e5606d8e"
      unitRef="usd">26000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzktMTYtMS0xLTQxNjIw_c6e1873e-fce3-454f-b8bf-89ac7b071de9"
      unitRef="usd">26000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ic0c1cb22a76846d88fe33bc3ec293fe5_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDAtMTQtMS0xLTQxNjA2_5f59491e-cd1c-45cb-8b3a-d35cde539839"
      unitRef="usd">-12606000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6b42bfa189674105a63a13810f164fee_D20200401-20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDAtMTYtMS0xLTQxNjIw_b9c5217b-d3f1-4c55-8518-88536fd5851e"
      unitRef="usd">-12606000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ibb23ec3142464357adefd10788d9dc21_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMS0xLTEtNDE1MzE_45e6ff51-0a7f-4d2b-913f-0555186c229a"
      unitRef="shares">21118000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ibb23ec3142464357adefd10788d9dc21_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMy0xLTEtNDE1NDU_bbc1acab-a1b2-4fbe-b423-6ec987b8fc58"
      unitRef="usd">173677000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="i3a5d7ddae2bf4b4c9ff977f94e8bf4df_I20200630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtNi0xLTEtNDE1NTY_3cd66d82-2c7a-47de-9c34-441fda5d6d8b"
      unitRef="shares">3110000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i3a5d7ddae2bf4b4c9ff977f94e8bf4df_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtOC0xLTEtNDE1NjQ_9e78ad0b-e406-473f-87b8-2d36b917cf06"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i43a77154c7e44d6c916d662730d39095_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMTAtMS0xLTQxNTc4_7b80d588-7472-4340-8fd4-49f083e3af97"
      unitRef="usd">7817000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9c72799a37ef4b6996ae6377297e5d8b_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMTItMS0xLTQxNTky_78792078-5424-4542-b8d8-5b58de28c011"
      unitRef="usd">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i406bac8d8e3c42e8ba906eba2383e727_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMTQtMS0xLTQxNjA2_27cdd6a9-b10e-44b9-9dc8-5b9678ca6a02"
      unitRef="usd">-174381000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ibb23ec3142464357adefd10788d9dc21_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDEtMTYtMS0xLTQxNjIw_c1facf88-803a-4d3b-ae22-ffd489467b8f"
      unitRef="usd">-166541000</us-gaap:StockholdersEquity>
    <prct:TemporaryEquitySharesConversionOfConvertibleSecurities
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDItMS0xLTEtNDE1MzE_d6bb6319-d7b3-440f-a31b-410aa4af595a"
      unitRef="shares">1474000</prct:TemporaryEquitySharesConversionOfConvertibleSecurities>
    <prct:TemporaryEquityAmountConversionOfConvertibleSecurities
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDItMy0xLTEtNDE1NDU_e1b64536-0041-454c-ac0e-a138fda7315f"
      unitRef="usd">9520000</prct:TemporaryEquityAmountConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i82411be0df684d5999a14b0a6ad94e9a_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDItNi0xLTEtNDE1NTY_18713bbd-0e2e-4d08-bced-85535f4ccdc0"
      unitRef="shares">1474000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i402b4853a118490284a4c268556e6aa9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDItMTAtMS0xLTQxNTc4_6b69af9c-3f44-4e55-809d-a7dbcd8d4b0f"
      unitRef="usd">9520000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDItMTYtMS0xLTQxNjIw_fb3addf2-145c-427a-a7f4-b5f051751e05"
      unitRef="usd">9520000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDMtMS0xLTEtNDE1MzE_462c4006-14ca-48cc-916e-5fb70f512bb3"
      unitRef="shares">531000</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDMtMy0xLTEtNDE1NDU_e7df037b-8382-4f23-bd1e-4d2c540dbf12"
      unitRef="usd">3209000</prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i5f878035d2ed48dc9860fc0e9a488f55_D20200701-20200831"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNjUtMC0xLTEtNDcyNjAvdGV4dHJlZ2lvbjo1YTA4YTI1MzZmNTY0NjVlYTJiMjcwY2FlY2UxOTc2NF80Mzk4MDQ2NTExMTg5_99790780-2782-4014-a635-b66eb625820d"
      unitRef="usd">496000</us-gaap:PaymentsOfStockIssuanceCosts>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDQtMS0xLTEtNDE1MzE_edf5e390-e126-4956-aab2-7077a7e268b5"
      unitRef="shares">5227000</prct:TemporaryEquityStockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDQtMy0xLTEtNDE1NDU_2fe39cb5-d05d-4166-aa0d-6edd1e23ff8c"
      unitRef="usd">76486000</us-gaap:TemporaryEquityStockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i82411be0df684d5999a14b0a6ad94e9a_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDUtNi0xLTEtNDE1NTY_1058745f-f60b-4391-908d-35f62d321608"
      unitRef="shares">36000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i402b4853a118490284a4c268556e6aa9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDUtMTAtMS0xLTQxNTc4_ce2efd3c-2954-4d74-8a52-701ace7c65ca"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDUtMTYtMS0xLTQxNjIw_35c79501-1e65-4177-8484-a61126ec2cb1"
      unitRef="usd">51000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="i402b4853a118490284a4c268556e6aa9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDYtMTAtMS0xLTQxNTc4_c4eccb85-dd6a-435e-bae0-28031736f864"
      unitRef="usd">563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDYtMTYtMS0xLTQxNjIw_50be2fe7-9921-46d6-b29b-2692a78114a3"
      unitRef="usd">563000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i5ae4098982084df789f8c32460ce665d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDctMTItMS0xLTQxNTky_8b3168fe-a64e-4a12-9f12-66a0caf4b3d1"
      unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDctMTYtMS0xLTQxNjIw_c724d3eb-5e9f-445e-addd-c0ba93c3b9e0"
      unitRef="usd">-16000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="i3fc7c14ea459484dbff851cda6151300_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDgtMTQtMS0xLTQxNjA2_62cade76-606a-4d4e-ab96-8c3e44a61eea"
      unitRef="usd">-12008000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfNDgtMTYtMS0xLTQxNjIw_b9dd4663-1ee2-4ede-bf44-ae4b38a570fc"
      unitRef="usd">-12008000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMS0xLTEtMzQ0MDE_a7772c56-d630-4853-90d0-5228dd8f1dee"
      unitRef="shares">25402000</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMy0xLTEtMzQ0MDE_3a0d731a-a13c-4437-ba1e-21a3a04d53f4"
      unitRef="usd">243852000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="ib1af9fd0db1144ceb9953d270a352e2d_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtNi0xLTEtMzQ0MDE_dc8e206f-849b-47d2-b3e0-40c4d32df27b"
      unitRef="shares">4620000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib1af9fd0db1144ceb9953d270a352e2d_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtOC0xLTEtMzQ0MDE_f631060d-d380-40cc-9af6-00b43a788202"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic8aa66f1be4e40d5b3e68af93a816d5b_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTAtMS0xLTM0NDAx_5a0037f3-2c21-4b2d-86ce-87e739b9f872"
      unitRef="usd">17951000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2eb4717194044992b7d6a3ba0a73a671_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTItMS0xLTM0NDAx_96986387-f002-4075-8f61-227affca7e6d"
      unitRef="usd">7000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3e6d9aca39d64536ad610f06bc65f7f3_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTQtMS0xLTM0NDAx_98bb66cd-9a42-400f-8ee4-31b0bb331eff"
      unitRef="usd">-186389000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yNS9mcmFnOjQ5NDMxNTdmZjEzOTQxNWY5MzA4MmU5ZDQ4OWViN2VhL3RhYmxlOjZhMDVjZDc4NTkyNDQxYzE4ZjM0MWRlN2FhZmZhNTQ1L3RhYmxlcmFuZ2U6NmEwNWNkNzg1OTI0NDFjMThmMzQxZGU3YWFmZmE1NDVfMzMtMTYtMS0xLTM0NDAx_61318c2e-9744-432d-9143-45e64be9323c"
      unitRef="usd">-168431000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNC0xLTEtMS0zNDQwMQ_00688956-a41d-4df8-b894-0d43a6b7f7b0"
      unitRef="usd">-41505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNC0zLTEtMS0zNDQwMQ_0785b95e-2da8-45ed-a1f4-887e0055cecb"
      unitRef="usd">-37741000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNi0xLTEtMS0zNDQwMQ_37e16b1b-52dd-4e72-b57d-ca4e5e2d8d1f"
      unitRef="usd">2561000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNi0zLTEtMS0zNDQwMQ_d991bf7e-b3d4-41bd-8099-26254895bc16"
      unitRef="usd">2145000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNy0xLTEtMS0zNDQwMQ_7099de4b-38fb-4df9-bc7d-f1041aa508a5"
      unitRef="usd">2300000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNy0zLTEtMS0zNDQwMQ_cfd24697-c444-46e1-ae7e-a33c13addc53"
      unitRef="usd">1569000</us-gaap:ShareBasedCompensation>
    <prct:FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfOC0xLTEtMS0zNDQwMQ_5437c044-a40c-42d8-96d3-38fbeb5d426f"
      unitRef="usd">-235000</prct:FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax>
    <prct:FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfOC0zLTEtMS0zNDQwMQ_8de469a7-a488-4ee5-813a-cfc604d8b96b"
      unitRef="usd">-408000</prct:FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax>
    <prct:NonCashLeaseAccretionExpense
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfOS0xLTEtMS0zNDQwMQ_1270ed96-2e64-404d-a16e-892470a0282c"
      unitRef="usd">249000</prct:NonCashLeaseAccretionExpense>
    <prct:NonCashLeaseAccretionExpense
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfOS0zLTEtMS0zNDQwMQ_74c25ec6-433e-4371-b293-af049adf836a"
      unitRef="usd">82000</prct:NonCashLeaseAccretionExpense>
    <us-gaap:InventoryWriteDown
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTAtMS0xLTEtMzQ0MDE_556b4e3f-41b4-4376-8922-5ff139ad81a2"
      unitRef="usd">537000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTAtMy0xLTEtMzQ0MDE_5831e311-8a11-4f58-95d8-f06a50a09acf"
      unitRef="usd">22000</us-gaap:InventoryWriteDown>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTQtMS0xLTEtMzQ0MDE_98a0c7be-9cdd-4596-bd32-898ba66a8926"
      unitRef="usd">4804000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTQtMy0xLTEtMzQ0MDE_3f18231e-23ee-4533-9da5-9315706265e7"
      unitRef="usd">729000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTUtMS0xLTEtMzQ0MDE_da12a3ac-54ae-49d6-a6f8-fce59287e659"
      unitRef="usd">3580000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTUtMy0xLTEtMzQ0MDE_773bc180-0e31-4dde-8142-6df9d04165ff"
      unitRef="usd">895000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTYtMS0xLTEtMzQ0MDE_dec53793-00db-4c29-9e5b-77ce548ce341"
      unitRef="usd">606000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTYtMy0xLTEtMzQ0MDE_7cf6d52f-4c53-4078-8029-802136d4c276"
      unitRef="usd">200000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTctMS0xLTEtMzQ0MDE_304e1cef-c825-44b2-aec3-7b2dd2214b02"
      unitRef="usd">2362000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTctMy0xLTEtMzQ0MDE_743f2cff-9d2a-4c47-a895-69ae55fdfeee"
      unitRef="usd">-262000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTgtMS0xLTEtMzQ0MDE_61a6c0ad-a8c2-43d1-8dd3-3b60479dee18"
      unitRef="usd">235000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInAccruedSalaries
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTgtMy0xLTEtMzQ0MDE_3046d8fb-fdd1-47a6-918e-29d639a7414f"
      unitRef="usd">1307000</us-gaap:IncreaseDecreaseInAccruedSalaries>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTktMS0xLTEtMzQ0MDE_51024a22-a2f4-4830-8b04-0df49144cfe8"
      unitRef="usd">804000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInInterestPayableNet
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMTktMy0xLTEtMzQ0MDE_5e408a97-6c16-4cdf-8189-c00c446c51a7"
      unitRef="usd">866000</us-gaap:IncreaseDecreaseInInterestPayableNet>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjAtMS0xLTEtMzQ0MDE_2641f452-a02d-47c9-9e45-c4db8b3ace2d"
      unitRef="usd">615000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjAtMy0xLTEtMzQ0MDE_b3cd3304-6b72-46b4-850c-b0d68dcdc8af"
      unitRef="usd">182000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjItMS0xLTEtMzQ0MDE_408d12d5-3323-4b73-a62b-f7858f566329"
      unitRef="usd">707000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjItMy0xLTEtMzQ0MDE_a49433c2-e0cc-4657-a6dd-0e7781704e77"
      unitRef="usd">-672000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjMtMS0xLTEtMzQ0MDE_b74b8bb1-febf-43c3-b129-62e64f35132f"
      unitRef="usd">-40858000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjMtMy0xLTEtMzQ0MDE_3961a1fa-bedf-43cc-b2f3-6948c7fd06ec"
      unitRef="usd">-34898000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjctMS0xLTEtMzQ0MDE_b6a4e776-e463-44dc-ac86-c640da2898fd"
      unitRef="usd">260000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjctMy0xLTEtMzQ0MDE_53a28071-8ca6-47de-83fb-e40f990576fc"
      unitRef="usd">224000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjgtMS0xLTEtMzQ0MDE_58377d22-7fe1-4fef-af93-c91cf979982c"
      unitRef="usd">-260000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMjgtMy0xLTEtMzQ0MDE_430c65e8-1b78-4571-a9d3-32a7f2b0c02e"
      unitRef="usd">-224000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzAtMS0xLTEtMzQ0MDE_1de441f0-7531-4a1c-8c78-438d11bf34f4"
      unitRef="usd">3495000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzAtMy0xLTEtMzQ0MDE_3a6b4ffb-4d88-48b4-8976-7cc41d2ae2bb"
      unitRef="usd">2051000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzEtMS0xLTEtMzQ0MDE_3ee9e80d-85d1-44a8-b1e5-2f33ac84e58c"
      unitRef="usd">0</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromDebtNetOfIssuanceCosts
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzEtMy0xLTEtMzQ0MDE_8ca6ed8b-de8f-401b-8131-a914134a74f3"
      unitRef="usd">24685000</us-gaap:ProceedsFromDebtNetOfIssuanceCosts>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzItMS0xLTEtMzQ0MDE_74811ed7-1f18-455d-b35d-fc86fa96eb64"
      unitRef="usd">858000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzItMy0xLTEtMzQ0MDE_0ed77289-ad89-45d9-97ac-0ed86e3938e3"
      unitRef="usd">3310000</us-gaap:ProceedsFromWarrantExercises>
    <prct:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts
      contextRef="i9679f5b41fb34cf6abfae1649202e1c5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzMtMS0xLTEtMzQ0MDE_79451d09-fc98-49ad-ab25-e3a6b31d1171"
      unitRef="usd">0</prct:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts>
    <prct:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts
      contextRef="if2b1c007cb5a4990af1e1f1d862c4d24_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzMtMy0xLTEtMzQ0MDE_16f2319d-1920-42be-838b-4f86ffe8dd48"
      unitRef="usd">76488000</prct:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts>
    <prct:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts
      contextRef="i3acfe77b8a2f44e79e9ac544b7465414_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzQtMS0xLTEtMzQ0MDE_46ab3d01-5c53-49e1-9e60-190d49661b17"
      unitRef="usd">84710000</prct:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzUtMS0xLTEtNDQxMDE_90d6e1fa-3875-493d-80a8-4ecd605676df"
      unitRef="usd">172409000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzUtMy0xLTEtNDQxMDk_176d8675-bf07-4b03-8ecf-cd471657f1da"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzUtMS0xLTEtMzQ0MDE_6b49a94e-983b-4773-9ff0-05109ab747e0"
      unitRef="usd">261472000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzUtMy0xLTEtMzQ0MDE_8c5e0cf1-ba02-4188-b7c7-c5142935c59e"
      unitRef="usd">106534000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzYtMS0xLTEtMzQ0MDE_4d609376-94a5-44a9-b693-9960e5af4652"
      unitRef="usd">220354000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzYtMy0xLTEtMzQ0MDE_b16cf68c-158c-41f0-91aa-fe872644ef11"
      unitRef="usd">71412000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzgtMS0xLTEtMzQ0MDE_afdaf566-0948-4afe-aae2-f2db2c5888ce"
      unitRef="usd">100907000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ifa21a99062154fbdb875876427776118_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzgtMy0xLTEtMzQ0MDE_3494c8ae-e5ea-4ebd-bac3-b122a78c1676"
      unitRef="usd">42712000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzktMS0xLTEtMzQ0MDE_f17de370-1a36-471e-9518-14ec5a79feb8"
      unitRef="usd">321261000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfMzktMy0xLTEtMzQ0MDE_3b4ceece-a120-4898-b119-08df6bb70146"
      unitRef="usd">114124000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDEtMS0xLTEtMzQ0MDE_f109a9c3-9f6c-4b1c-a0f7-01800fbee8fd"
      unitRef="usd">320484000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDEtMy0xLTEtMzQ0MDE_eaa3d2ad-dd5e-4bfe-b57e-395e8be96745"
      unitRef="usd">113347000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDItMS0xLTEtMzQ0MDE_f090a1b9-d620-40eb-b8e5-ed87623d995d"
      unitRef="usd">777000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDItMy0xLTEtMzQ0MDE_a177adff-016a-4179-aaf4-8707f187f84d"
      unitRef="usd">777000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDMtMS0xLTEtMzQ0MDE_47ba6685-5952-46c8-a9f9-bc2d69bcaab9"
      unitRef="usd">321261000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i333242aedc914ccab277eab2cc3188fe_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDMtMy0xLTEtMzQ0MDE_734f51f3-3101-4aa6-9559-1cc39c839a26"
      unitRef="usd">114124000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDUtMS0xLTEtMzQ0MDE_9bb63cc0-c197-41ea-8316-3ad6f8f61bd6"
      unitRef="usd">3566000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDUtMy0xLTEtMzQ0MDE_1b22e90d-438a-4cb3-9153-6eab4c6ba6ef"
      unitRef="usd">2785000</us-gaap:InterestPaidNet>
    <prct:TransferFromInventoryToPropertyAndEquipmentNet
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDgtMS0xLTEtMzQ0MDE_9769a5a7-02bb-418f-991a-b6c272c4de23"
      unitRef="usd">-1227000</prct:TransferFromInventoryToPropertyAndEquipmentNet>
    <prct:TransferFromInventoryToPropertyAndEquipmentNet
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDgtMy0xLTEtMzQ0MDE_df48ab6f-3e04-4927-a0e2-a9e62c375dc0"
      unitRef="usd">1470000</prct:TransferFromInventoryToPropertyAndEquipmentNet>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDktMS0xLTEtMzQ0MDE_fa61bf32-3e2d-423c-a099-060832d42f5f"
      unitRef="usd">200000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNDktMy0xLTEtMzQ0MDE_82a96600-1f42-4e85-ac1e-6de543b6c694"
      unitRef="usd">200000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <prct:DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNTAtMS0xLTEtMzQ0MDE_112bbd5f-414c-4913-bb10-14f77d920f23"
      unitRef="usd">819000</prct:DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <prct:DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8yOC9mcmFnOmNlN2QyZWE4NjM2YTQxNGM5Y2YzNDM4NGIxYjJiZTZmL3RhYmxlOjcyZWY1NTYzNzQ5ZjRmYzc4ZjkwMzllMWNjNDU5OGZkL3RhYmxlcmFuZ2U6NzJlZjU1NjM3NDlmNGZjNzhmOTAzOWUxY2M0NTk4ZmRfNTAtMy0xLTEtMzQ0MDE_6af7b1d9-d59c-4953-b345-327522d30b6f"
      unitRef="usd">0</prct:DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfOTM0NTg0ODgzODk2MQ_f391b0b5-6e91-4b35-b093-f9bb635b812e">Organization &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Description of Business &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;PROCEPT BioRobotics Corporation (the &#x201c;Company&#x201d;) was incorporated in the state of California in 2007 and its headquarters are located in Redwood City, California. In April 2021, the Company re-incorporated in the state of Delaware. The Company received U.S. Food and Drug Administration clearance in December 2017 to market its AquaBeam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Robotic System, an automated surgical robot providing tissue removal for the treatment of benign prostatic hyperplasia, a prostate gland enlargement condition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, the Company had cash and cash equivalents of $320.5 million and $100.1 million, respectively, and an accumulated deficit of $243.2 million and $201.7 million, respectively. In September 2021, the Company completed its initial public offering (&#x201c;IPO&#x201d;) for net proceeds of approximately $172.4 million, after deducting underwriting discounts and commissions, and offering expenses. Since its inception, the Company has financed its operations with a combination of debt and equity financing arrangements. The Company expects its cash and cash equivalents, revenue and available debt financing arrangements will be sufficient to fund its operations through at least the next twelve months from the issuance date of these financial statements. The Company has not achieved positive cashflow from operations to date and expects to continue incurring losses for the foreseeable future as it focuses on growing its business.&lt;/span&gt;&lt;/div&gt;The COVID-19 pandemic and the resulting economic downturn are affecting business conditions in the industry in which the Company operates. In response to the pandemic, many state and local governments in the United States issued orders that temporarily precluded elective medical procedures in order to conserve scarce health system resources. The Company has taken necessary precautions to safeguard its employees, patients, customers, and other stakeholders from the COVID-19 pandemic, while maintaining business continuity to support its patients, customers and employees. The timing, extent and continuation of any increase in procedures, and any corresponding increase in sales of the Company&#x2019;s products, and whether there could be a future decrease in the current level of procedures as a result of the COVID-19 pandemic or otherwise, remain uncertain and are subject to a variety of factors.</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfNDM5ODA0NjUxMzc4Mw_2f902dc9-a6f4-4d19-a5bd-86ea09e924fd"
      unitRef="usd">320500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfMTY0OTI2NzQ0MzkwOA_1834702a-7622-409c-a035-1af073a3c64e"
      unitRef="usd">100100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfNDM5ODA0NjUxMzc5OA_04187b1b-c6ac-4448-ac5b-22593ab18300"
      unitRef="usd">-243200000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfMTY0OTI2NzQ0Mzk0Mg_1267c55a-18c9-4fec-8f84-152d86ce2cc4"
      unitRef="usd">-201700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i0a1b74e1acd043bda78eed560ea4270b_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNC9mcmFnOmM3NjIxYjY4ZGY2MjQ4ODY4MjQzNTIzY2EwZGI1YjE4L3RleHRyZWdpb246Yzc2MjFiNjhkZjYyNDg4NjgyNDM1MjNjYTBkYjViMThfNDM5ODA0NjUxNDExOA_bd2cff67-5d08-478d-841a-08455518fe3b"
      unitRef="usd">172400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NjY5MA_3dc39f8f-6374-4d97-924c-3abc19099184">Summary of Significant Accounting Policies &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Preparation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). These consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements. Management uses significant judgment when making estimates related to its common stock valuation in periods before the Company&#x2019;s IPO and related stock-based compensation, right-of-use lease asset, lease liability, the valuations of the redeemable convertible preferred stock warrant liability and loan facility derivative liability, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reverse Stock Split &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Board of Directors and stockholders approved, and the Company filed, an amended and restated certificate of incorporation effecting a 1-for-4.75 reverse stock split of common stock and all redeemable convertible preferred stock. The par value of the common and redeemable convertible preferred stock was not adjusted as a result of the reverse stock split. All authorized, issued and outstanding common stock, redeemable convertible preferred stock, warrants for preferred stock, stock options and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Initial Public Offering&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company completed its IPO by issuing 6,556,000 shares of common stock, and the exercise of the underwriters option for 983,400 shares, at an offering price of $25.00 per share, for total net proceeds of approximately $172.4 million, after deducting underwriting discounts and commissions of $13.2 million and offering expenses of $2.9 million. Offering costs are capitalized, and consist of fees and expenses incurred in connection with the sale of common stock in its IPO, including legal, accounting, printing and other IPO-related costs. Upon completion of its IPO, these deferred offering costs were reclassified to stockholders&#x2019; equity and recorded against the proceeds from the offering. In addition, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock and it reclassified $329.5 million of redeemable convertible preferred stock to additional paid-in capital on its condensed consolidated balance sheet. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unaudited Interim Financial Statements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying balance sheet as of September&#160;30, 2021, the statements of operations and comprehensive loss for the three and nine months ended September 30, 2021 and 2020, cash flows for the nine months ended September 30, 2021 and 2020, and the statements of redeemable convertible preferred stock and stockholders&#x2019; equity (deficit) as of September&#160;30, 2021 and 2020, are unaudited. The financial data and other information disclosed in these notes to the financial statements related to September&#160;30, 2021, and the three and nine months ended September 30, 2021 and 2020, are also unaudited. The accompanying balance sheet as of December&#160;31, 2020 has been derived from the audited consolidated financial statements included in the Company&#x2019;s Registration Statement on Form S-1 filed with the Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to a fair statement of the Company&#x2019;s financial position as of September&#160;30, 2021, and the results of its operations for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. The results for the three and nine months ended September 30, 2021, are not necessarily indicative of results to be expected for the year ending December&#160;31, 2021, or for any other interim period or for any future year and should be read in conjunction with the annual consolidated financial statements included in the Company&#x2019;s Registration Statement on Form S-1.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Par Value and Shares Authorized Change &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Board of Directors and stockholders approved, and the Company filed, an amended and restated certificate of incorporation effecting a change in par value from $0.001 to $0.00001 per share of common stock and all redeemable convertible preferred stock. All issued and outstanding common stock and redeemable convertible preferred stock contained in the financial statements have been retroactively corrected to reflect this immaterial change in par value for all periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, 10.0 million shares of preferred stock was authorized and the shares of common stock authorized was increased to 300.0 million shares, both having a par value of $0.00001 per share. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash in banks and highly liquid securities, which are readily convertible to cash, that mature within 90 days or less from the original date of purchase, to be cash equivalents, which include money market funds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. Unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders&#x2019; equity (deficit). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash is related to the Company&#x2019;s letter of credit for the lease of its corporate headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash and cash equivalents, and accounts receivable, accounts payable and accrued liabilities, which approximate fair value due to their relatively short maturities as well as the redeemable convertible preferred stock warrant liability and loan facility derivative liability. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt"&gt;Observable inputs such as quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt"&gt;Other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt"&gt;Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Preferred stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Loan facility derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents consist primarily of money market funds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers in and out of Level 3 during the nine months ended September 30, 2021 and year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Redeemable Convertible Preferred Stock Warrants &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the estimated fair value of the Company&#x2019;s redeemable convertible preferred stock warrants, which represents financial instruments with valuations classified as &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. However, Level 3 financial instruments typically include, in addition to the unobservable inputs, observable inputs (that is, components that are actively quoted and can be validated to external sources). Accordingly, the gain or loss in the table below includes changes in fair value due in part to observable factors that are part of the Level 3 methodology recognized in the statement of operations as a component of interest and other income or expense as appropriate (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the completion of the Company&#x2019;s IPO in September 2021, warrants exercised for redeemable convertible preferred stock were automatically converted into 62,454 shares of common stock and the remaining unexercised warrants expired, therefore no warrants outstanding at September&#160;30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the redeemable convertible preferred stock warrant liability was determined using the Black-Scholes option pricing model using the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Loan facility derivative liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s loan facility, the Company is obligated to pay a fee upon the earlier occurrence of a defined liquidity event, including but not limited to, a merger or sale of our assets or voting stock, or achieving a $200.0&#160;million trailing twelve months revenue target, in each case, by September 2029&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fee is calculated at the time of the liquidity event occurrence to be $1.0&#160;million if only the first installment has been drawn, $2.0 million if the first two installments have been drawn, $2.4 million if the first three installments have been drawn, or $3.0 million if all four installments have been drawn, in each case, upon the occurrence of the liquidity event. The Company has determined this fee is a freestanding derivative instrument. The $1.4 million fair value of this loan facility derivative was recorded as a debt discount and liability on the date of issuance in connection with obtaining additional financing as applicable and will be revalued every reporting period until the earlier occurrence of a defined liquidity event or achieving a revenue target by September 2029 or termination of such fee arrangement.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the estimated fair value of the Company&#x2019;s loan facility derivative liability, classified as Level 3 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of success fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the loan facility derivative liability was determined using a discounted cash flow calculation discounted at 10%. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents and, to a lesser extent, accounts receivable. The Company believes that credit risk in its accounts receivable is mitigated by its credit evaluation process, relatively short collection terms and diversity of its customer base. The Company generally does not require collateral and losses on accounts receivable have historically been within management&#x2019;s expectations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings, as well as corporate debt or commercial paper issued by the highest quality financial and non-financial companies, and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash and cash equivalents and issuers of investments to the extent recorded on the balance sheets. The Company has limited its credit risk associated with cash and cash equivalents by placing its investments with banks it believes are highly creditworthy and with highly rated investments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Allowance for Doubtful Accounts &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company provides for uncollectible accounts receivable by recording an allowance for doubtful accounts for balances deemed uncollectible. The Company evaluates the collectability of its accounts receivable based on known collection risks and historical experience. In circumstances where the Company is aware of a specific customer&#x2019;s inability to meet its financial obligations to the Company (e.g., bankruptcy filings, substantial downgrading of credit ratings), the Company records a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount it reasonably believes will be collected. The Company has not experienced any significant collection issues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are valued at the lower of cost, computed on a first-in, first-out basis, or net realizable value. The allocation of production overhead to inventory costs is based on normal production capacity. Abnormal amounts of idle facility expense, freight, handling costs, and consumption are expensed as incurred, and not included in overhead. The Company maintains provisions for excess and obsolete inventory based on management&#x2019;s estimates of forecasted demand and, where applicable, product expiration. The Company has initiated voluntary recalls for a limited number of handpieces due to certain issues related to supply chain and manufacturing processes, of which the provision recognized was not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment and Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment and Intangible Assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization for property and equipment are determined using the straight-line method over the estimated useful lives of the respective assets, generally 3 to 5 years. The Company reclassifies inventory used at customer sites for evaluation purposes to property and equipment due to a limited history of sales of evaluation units. Amortization of intangible assets are determined using the straight-line method over the estimated useful lives, generally through the patent expiration date. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Maintenance and repairs are charged to operating expenses as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist primarily of property and equipment and intangible assets, net, and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that a long-lived asset be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated by the asset group to the carrying amount of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;asset group. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. The Company determines fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. The Company&#x2019;s cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors. Since inception, the Company has not recorded impairment charges on its long-lived assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Offering Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes, within other assets, certain legal, accounting and other third-party fees that are directly related to the Company&#x2019;s in-process equity financings, including its recent initial public offering, until such financings are consummated. After consummation of the equity financing, these costs are recorded to additional paid in capital as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses. There were no deferred offering costs as of September&#160;30, 2021 and December&#160;31, 2020. Upon the completion of the Company&#x2019;s IPO in September 2021, all deferred offering costs were reclassified to cost of issuance in additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue will be recognized subsequent to invoicing. Service agreements are generally invoiced annually at the beginning of each coverage period and recorded as deferred revenue and recognized as revenue ratably over the coverage period. Deferred revenue that will be recognized during the twelve months following the balance sheet date is recorded as the current portion of deferred revenue, and the remaining portion, if any, would be recorded as non-current. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records redeemable convertible preferred stock at fair value on the date of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because it contains liquidation features that are not solely within the Company&#x2019;s control. The Company determined that the carrying values of the redeemable convertible preferred stock should not be adjusted to the liquidation preferences because it is uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock. Subsequent adjustments to the carrying values of the redeemable convertible preferred stock to the liquidation preferences will be made only when it is probable that the redeemable convertible preferred stock will become redeemable. Upon the completion of the Company&#x2019;s IPO in September 2021, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock and it reclassified $329.5 million of redeemable convertible preferred stock to additional paid-in capital on its condensed consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redeemable Convertible Preferred Stock Warrant Liability &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued freestanding warrants to purchase shares of redeemable convertible preferred stock to investors in connection with sales of certain of its redeemable convertible preferred stock. The Company classified these warrants as a derivative liability because they create a conditional obligation for the Company to repurchase its own shares for cash or other assets. The fair value of the warrants are recorded on the consolidated balance sheets at the issuance of the warrants and remeasured to fair value at each financial reporting date. The changes in the fair value of the warrants are recorded in the statement of operations as a component of interest and other income or expense as appropriate. The Company will continue to adjust the carrying value of the redeemable convertible preferred stock warrant liability for changes in the fair value of the warrants until the earlier of: the exercise of the warrants, at which time the liability will be reclassified to temporary equity or the expiration of the warrant, at which time the entire amount would be reversed and reflected in the consolidated statements of operations and comprehensive loss. Upon the completion of the Company&#x2019;s IPO in September 2021, warrants exercised for redeemable convertible preferred stock were automatically converted into 62,454 shares of common stock and the remaining unexercised warrants expired.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loan Facility Derivative Liability&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that its obligation to pay success fees to a lender upon a successful liquidation event or achieving a revenue target represents freestanding financial instruments. The instruments are classified as a non-current liability in the consolidated balance sheets and are subject to remeasurement at each financial reporting date. Any change in fair value was recognized through other income (expense) in the condensed consolidated statements of operations and comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements with a term of more than twelve months, the Company determines if an agreement contains a lease at inception. Operating lease liabilities represent an obligation to make lease payments arising from the lease agreement. Operating lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the remaining lease term. In determining the present value of lease payments, the Company estimates its incremental borrowing rate as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, of an amount equal to the lease payments in a similar economic environment. Operating lease liabilities are included in the Company&#x2019;s consolidated balance sheet. Right-of-use assets represent our right to use an underlying asset for the lease term and are classified as non-current assets. Lease expense is recognized on a straight-line basis over the expected lease term in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December&#160;31, 2019, the Company recorded the difference between rent paid and the straight-line rent as a deferred rent liability and leasehold improvements funded by landlord incentives or allowances are recorded as leasehold improvement assets and a corresponding deferred rent liability. Upon adoption of Accounting Standards Codification (&#x201c;ASC 842&#x201d;) on January 1, 2020, the unamortized deferred rent liability has been reclassified to reduce the right-of-use asset.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not elected to separate lease and non-lease components for any leases within its existing classes of assets and, as a result, records a right-of-use asset and lease liability based on the present value of the future minimum lease payments over the term at commencement date. Variable lease payments are expensed as incurred. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has lessor arrangements with customers for a fixed monthly fee with no non-lease components, typically for 3-12 months. These arrangements are accounted for as an operating lease in accordance with ASC 842. These arrangements and related revenue are immaterial to the periods presented. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is derived primarily from the sales of the AquaBeam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Robotic Systems, and handpieces that are for one-time use during each surgery using the AquaBeam Robotic System. The AquaBeam Robotic System contains both software and non-software components that are delivered together as a single product and generally contain a one-year warranty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), the Company performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct based on the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contracts are typically in the form of an agreement and a purchase order from the customer. The Company&#x2019;s AquaBeam Robotic System sales generally contain multiple products and services and can include a combination of the following performance obligations: robotic system, handpieces and consumables, and service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the transaction price it expects to be entitled to in exchange for transferring the promised product to the customer, which is based on the invoiced price for the products. All prices are at fixed amounts per the sales agreement with the customer and there are generally no discounts, rebates or other price concessions or a right of return, once the agreement is signed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations at the following points in time:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AquaBeam Robotic Systems&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the time of delivery. Systems rented for a fixed monthly fee during an evaluation period, typically 3-12 months, are recognized as revenue straight-line during the lease term, in accordance with ASC 842, and are not material. For systems sold following an evaluation period, revenue is recognized generally once sales terms are mutually agreed (as the system is already install at the customer site). For systems sold through distributors, revenue is recognized generally at the time of delivery. The Company&#x2019;s system arrangements generally do not provide a right of return. The systems are generally covered by a one-year service agreement. The service agreements have a stand alone selling price and are typically recognized as deferred revenue and amortized over the one-year service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hand pieces and other consumables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Revenue from sales of handpieces and other consumables is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also occurs at the time of delivery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Service&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Service revenue, inclusive of the amounts associated with the AquaBeam Robotic System warranties, is recognized over the term of the service period, as the customer benefits from the services throughout the service period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that certain promises in the multiple-element arrangements, such as installation, training and certain ancillary products, are immaterial, and/or do not represent separate performance obligations for which transaction price is allocated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue is recognized subsequent to invoicing, such as service contracts, which are recognized ratably as revenue over the performance period, which is not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s typical payment terms are between approximately 30 to 90 days. The Company expenses shipping and handling costs as incurred and includes them in the cost of sales. In those cases where shipping and handling costs are billed to customers, the Company classifies the amounts billed as a component of revenue. Taxes collected from customers and remitted to governmental authorities are excluded from revenue. The Company expenses any incremental costs of obtaining a contract, including but not limited to, sales commissions, as and when &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;incurred as the expected amortization period of the incremental costs would have been less than one year and are reported in selling, general and administrative expense in the statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue disaggregated by type and geography (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;System sales and rentals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Handpieces and other consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside of U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;System sales and rentals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Handpieces and other consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total outside of U.S. revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Sales &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of sales consists primarily of manufacturing overhead costs, material costs and direct labor, including stock-based compensation. A significant portion of the Company&#x2019;s cost of sales currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of sales also includes depreciation expense for production equipment, warranty and field service costs, and purchased intangibles and certain direct costs such as shipping costs. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development costs are expensed as incurred. Research and development costs consist primarily of engineering, product development, and regulatory affairs, consulting services, materials, depreciation and other costs associated with products and technologies being developed, including employee and non-employee compensation, stock-based compensation, supplies, quality assurance expenses, related travel expenses and facilities expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a payment equity incentive plan to provide long-term incentives for employees, consultants and members of the board of directors. The plan allows for the issuance of non-statutory and incentive stock options to employees and non-statutory stock options to consultants and non-employee directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to determine the fair value of equity incentive awards and recognize compensation expense for all equity incentive awards made to employees and directors, including employee stock options. Stock-based compensation expense is recognized over the requisite service period in the statements of operations and comprehensive loss. The Company uses the straight-line method for expense attribution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation model used for calculating the fair value of awards for stock-based compensation expense is the Black-Scholes option-pricing model (the &#x201c;Black-Scholes model&#x201d;). The Black-Scholes model requires the Company to make assumptions and judgments about the variables used in the calculation, including the fair value of the Company&#x2019;s common stock, the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate and an expected dividend rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s common stock underlying the stock options has historically been determined by the Company&#x2019;s board of directors (&#x201c;Board&#x201d;). Because there was no public market for the Company&#x2019;s common &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;stock prior to the IPO, the Board determined the fair value of the Company&#x2019;s common stock at the time of grant of the option by considering a number of objective and subjective factors, including valuations of comparable companies, sales of the Company&#x2019;s redeemable convertible preferred stock, operating and financial performance and the general and industry-specific economic outlook. The Company used the &#x201c;simplified method&#x201d; to determine the expected term of the stock option. Expected volatility is based on an average of the historical volatilities of the common stock of publicly-traded companies with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected term of the option. The Company has elected to account for forfeitures when they occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intent has been to grant all options with an exercise price not less than the fair value of its common stock underlying those options on the date of grant. Prior to its IPO, the Company has determined the estimated fair value of its common stock at each valuation date in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the &#x201c;Practice Aid&#x201d;). The Company&#x2019;s board of directors, with the assistance of management, developed these valuations using significant judgment and taking into account numerous factors, including:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;valuations of its common stock with the assistance of independent third-party valuation specialists;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the stage of development and business strategy, including the status of research and development efforts, of its products and product candidates, and the material risks related to its business and industry;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the results of operations and financial position, including its levels of available capital resources;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the valuation of publicly traded companies in the life sciences and medical device sectors, as well as recently completed mergers and acquisitions of peer companies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the prices of its redeemable convertible preferred stock sold to investors in arm&#x2019;s length transactions and the rights, preferences, and privileges of its redeemable convertible preferred stock relative to those of its common stock;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering or a sale of the Company given prevailing market conditions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the inability of the Company&#x2019;s stockholders to freely trade its common stock in the public markets, resulting in a discount to reflect the lack of marketability of the Company&#x2019;s common stock based on the weighted-average expected time to liquidity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;trends and developments in its industry; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;external market conditions affecting the life sciences and medical device industry sectors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s board of directors determined the fair value of its common stock by first determining the enterprise value of the Company&#x2019;s business using the market approach, income approach or from the value implied by the latest round of equity financing, and then allocating the value among the various classes of its equity securities to derive a per share value of its common stock. The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all option granted prior to the Company&#x2019;s IPO in September 2021, the Board allocated the enterprise value based on the option pricing method (&#x201c;OPM&#x201d;). OPM treats the rights of the holders of preferred and common stock as equivalent to call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders of preferred stock, as well as their rights to participation and conversion. Thus, the estimated value of the common stock can be determined by estimating the value of its portion of each of these call option rights. When valuing options granted round the time of an equity financing that is considered arms-&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;length, OPM derived the Company&#x2019;s equity value of a company from the price of the securities issued by the Company in the equity financing. Following the completion of the Company&#x2019;s IPO in September 2021, the fair value of the Company&#x2019;s common stock is determined based on the closing price of its common stock on The Nasdaq Global Market. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expenses &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were not significant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Defined Contribution Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their annual compensation on a pre-tax basis. The Company is authorized to make matching contributions but has not made such contributions for the three and nine months ended September 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established when necessary to reduce deferred tax assets to the amounts expected to be realized. Currently, the Company has recorded a full valuation allowance against its deferred tax assets and there is no provision for income taxes, as the Company has incurred operating losses to-date. The Company&#x2019;s policy is to record interest and penalties expense related to uncertain tax positions as a component of income tax expense in the statement of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalent shares from dilutive stock options and common stock warrants outstanding during the period. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods as all potentially dilutive securities were antidilutive in those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company&#x2019;s redeemable convertible preferred stock participated in any dividends declared by the Company and were therefore considered to be participating securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the completion of the Company&#x2019;s IPO in September 2021, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share was determined as follows (in thousands, except per share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding have been excluded from the computations of weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable convertible preferred stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable convertible preferred stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Comprehensive Loss &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Comprehensive loss consists of net loss and changes in unrealized gains and losses on cash equivalents and available-for-sale marketable securities. Accumulated other comprehensive income (loss) is presented in the accompanying balance sheets, when applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment, Geographical and Customer Concentration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. The Company&#x2019;s assets are primarily based in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No customers accounted for more than 10% of revenue during the three and nine months ended September 30, 2021. Three customers accounted for 16%, 13% and 13% of revenue during the three months ended September 30, 2020. No customers accounted for more than 10% of revenue during the nine months ended September 30, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by significant geographical locations outside the United States for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Less than 10% of total net revenues for the period indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; No customers accounted for more than 10% of accounts receivable at September&#160;30, 2021. Two customers each accounted for 22% and 13% of accounts receivable at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;JOBS Act Accounting Election &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to avail itself of this exemption and, therefore, for new or revised accounting standards applicable to public companies, the Company will be subject to an extended transition period until those standards would otherwise apply to private companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2018-13&#x201d;). The amendments on changes in unrealized gains and losses recognized in other comprehensive income categorized within Level 3, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively in the initial fiscal year of adoption. All other amendments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;should be applied retrospectively to all periods presented upon their effective date. The Company adopted ASU 2018-13 as of January 1, 2020, which did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (&#x201c;ASU 2018-11&#x201d;). ASU 2018-11 provided an alternative implementation method in addition to the current modified retrospective transition method for ASU No. 2016-2, Leases: Amendments to the FASB Accounting Standards Codification (&#x201c;ASU 2016-2&#x201d;), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-2, a lessee is required to recognize assets and liabilities for leases with lease terms of more than twelve months. ASU 2016-2 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted ASC Topic 842, Leases, on January 1, 2020 using the modified retrospective transition method. In addition, the Company elected certain practical expedients permitted under the transition guidance, which allowed it to carryforward its historical long-term lease classification, its assessment on whether a contract is or contains a lease and the treatment of its initial direct costs for any leases that existed prior to the adoption of Topic 842. In determining the lease term at commencement date, any renewal or termination options are considered if they are reasonably assured of exercise. The Company has elected to exclude from its consolidated balance sheet any leases having a term of 12 months or less. The Company recorded a right-of-use leased asset of approximately $6.0 million and a corresponding lease liability of $7.4 million in its adoption of Topic 842. In addition, as of the adoption date, the Company derecognized a deferred rent obligation of $1.4 million. There was no cumulative effect adjustment upon the adoption of Topic 842.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;), which requires an entity to utilize a new impairment model known as the current expected credit loss (&#x201c;CECL&#x201d;) model to estimate its lifetime &#x201c;expected credit loss&#x201d; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. This standard is effective for fiscal periods beginning after December 15, 2021, and for fiscal years beginning after December 15, 2020 for public business entities. The Company adopted ASU 2019-12, effective of January 1, 2021, and the adoption did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NjY4Nw_a818a4ed-e32b-40f5-bf1a-5bb7bb792876">Basis of Preparation The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#x201c;U.S. GAAP&#x201d;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;). These consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NjY4OA_d7c4aa6c-88ad-4d40-b22e-b9e497f1c567">Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements. Management uses significant judgment when making estimates related to its common stock valuation in periods before the Company&#x2019;s IPO and related stock-based compensation, right-of-use lease asset, lease liability, the valuations of the redeemable convertible preferred stock warrant liability and loan facility derivative liability, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.</us-gaap:UseOfEstimates>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i0a1b74e1acd043bda78eed560ea4270b_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MTk3Nw_d855d22f-f2e4-413e-a62f-a840812e51b9"
      unitRef="shares">6556000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i679a14a77cd0453ca47285769b9db2d0_D20210901-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MjA1Mw_7418820b-4a90-4a28-9c77-85d26771e95a"
      unitRef="shares">983400</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MjA4OQ_350adf67-0ea1-4007-87d7-107107722a86"
      unitRef="usdPerShare">25.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i0a1b74e1acd043bda78eed560ea4270b_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MjE0NA_bd2cff67-5d08-478d-841a-08455518fe3b"
      unitRef="usd">172400000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:PaymentsForUnderwritingExpense
      contextRef="ib8664e9a7cee4889bdb472916c610c7d_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NDc0Nw_8858eed4-fcdc-49e3-a2c1-c889581b0ec5"
      unitRef="usd">13200000</us-gaap:PaymentsForUnderwritingExpense>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ib8664e9a7cee4889bdb472916c610c7d_D20210901-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NDc1MA_e3815d76-9118-4c14-8061-0a72e160e34e"
      unitRef="usd">2900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NjEyOA_080bcfa1-af45-4252-af29-85b40683fa55"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NjEyOA_c67bb575-5e73-493b-9fee-a555ef693c48"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NjEzMg_080bcfa1-af45-4252-af29-85b40683fa55"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NjEzMg_c67bb575-5e73-493b-9fee-a555ef693c48"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MzE1NQ_d5a4071a-8dff-415f-99a3-daf3c6f22d7c"
      unitRef="usd">329500000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i719157466752459aa43b7047e2f317c7_I20210531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjM1NQ_f6a9e743-0f8d-424b-9e95-27fd4181a547"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i55fff3d953504e32a8bb1767e17be163_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjM2OA_14a8107b-ceba-4a0f-8342-096924cf05c6"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2NzYyOQ_cd7ff86a-383d-4322-af74-362f0bd92c63"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDk0NzgwMjM4NzE5NQ_d0182880-efb3-4207-9046-c25b069a6b62"
      unitRef="shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i55fff3d953504e32a8bb1767e17be163_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2Nzc5Mg_14a8107b-ceba-4a0f-8342-096924cf05c6"
      unitRef="usdPerShare">0.00001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY0NQ_d0d303a4-9153-4965-a092-e4e8dd46592e">Cash, Cash Equivalents and Restricted Cash &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash in banks and highly liquid securities, which are readily convertible to cash, that mature within 90 days or less from the original date of purchase, to be cash equivalents, which include money market funds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. Unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders&#x2019; equity (deficit). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash is related to the Company&#x2019;s letter of credit for the lease of its corporate headquarters.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY0Ng_0404d571-54c1-4a14-8f81-cc873f762f45">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value of Financial Instruments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash and cash equivalents, and accounts receivable, accounts payable and accrued liabilities, which approximate fair value due to their relatively short maturities as well as the redeemable convertible preferred stock warrant liability and loan facility derivative liability. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt"&gt;Observable inputs such as quoted prices (unadjusted) for identical assets or liabilities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt"&gt;Other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3-&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt"&gt;Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions.&lt;/span&gt;&lt;/div&gt;The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY0Nw_b7261d71-b2af-4774-86ed-6b569dc54813">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.432%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.433%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;179,797&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,502&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;140,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;98,628&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;320,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;100,130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Preferred stock warrant liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Loan facility derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:Cash
      contextRef="i685a759150ca4001b06e6ef8169b3a0a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS0xLTEtMS0zNDQwMQ_a446648d-8ad4-44d9-94d7-7251db5fe5d0"
      unitRef="usd">179797000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS0zLTEtMS0zNDQwMQ_214d4766-e5d9-4665-84a2-dd602173a200"
      unitRef="usd">0</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS01LTEtMS0zNDQwMQ_dc6f41dc-99ad-47be-bdf1-a7c908351c6e"
      unitRef="usd">0</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="ia13ef5c367424e9b87f0aa0201302d21_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS03LTEtMS0zNDQwMQ_63e1d909-03f4-4fe1-abad-86edb38edf9a"
      unitRef="usd">179797000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="ic790d5759ab443cba375a13c77efc8a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS05LTEtMS0zNDQwMQ_26708850-975b-4713-ab69-cfb8d6811813"
      unitRef="usd">1502000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS0xMS0xLTEtMzQ0MDE_8feee18f-22ac-4ca1-b769-1bdecc5eba93"
      unitRef="usd">0</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS0xMy0xLTEtMzQ0MDE_93bf7ec3-a249-4991-8ecd-3a70b89e3ee6"
      unitRef="usd">0</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="ic53305bb04ab4021944c4163701dcd71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNS0xNS0xLTEtMzQ0MDE_dfd0ae39-0bb0-448f-ac41-68c08f36e746"
      unitRef="usd">1502000</us-gaap:Cash>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i685a759150ca4001b06e6ef8169b3a0a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi0xLTEtMS0zNDQwMQ_b8df0734-3cb1-4a9e-9390-34b65debd77c"
      unitRef="usd">140687000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi0zLTEtMS0zNDQwMQ_a64f1abc-292c-451c-8d7d-d589b5c5b364"
      unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi01LTEtMS0zNDQwMQ_59ae9035-56a5-403d-8242-8cf3850099cc"
      unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ia13ef5c367424e9b87f0aa0201302d21_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi03LTEtMS0zNDQwMQ_28388b1b-6519-41e7-a806-7367cef425c2"
      unitRef="usd">140687000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ic790d5759ab443cba375a13c77efc8a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi05LTEtMS0zNDQwMQ_0c967c72-3079-4c52-beab-de0b8e4b86b3"
      unitRef="usd">98628000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi0xMS0xLTEtMzQ0MDE_8ed374f4-c24d-4b15-8609-9cc95217caf0"
      unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi0xMy0xLTEtMzQ0MDE_43cbf6ae-a2b2-4df9-bc29-27a4eb691ee0"
      unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ic53305bb04ab4021944c4163701dcd71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNi0xNS0xLTEtMzQ0MDE_0e64aad9-7ce6-42d9-9327-0f3d488fff5d"
      unitRef="usd">98628000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i685a759150ca4001b06e6ef8169b3a0a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy0xLTEtMS0zNDQwMQ_1fe68c7c-44f1-4237-9a41-c06a66f8b96f"
      unitRef="usd">320484000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy0zLTEtMS0zNDQwMQ_5db6bb00-df62-4228-89f6-05ca9a19c67d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy01LTEtMS0zNDQwMQ_92bfff50-0b29-4e3d-b17c-9a945574a0e6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia13ef5c367424e9b87f0aa0201302d21_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy03LTEtMS0zNDQwMQ_e8ce6a30-74be-4d1f-83ce-e5fba78815b3"
      unitRef="usd">320484000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic790d5759ab443cba375a13c77efc8a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy05LTEtMS0zNDQwMQ_0f167121-fe91-4939-9803-fe555bb53a20"
      unitRef="usd">100130000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy0xMS0xLTEtMzQ0MDE_b6c1dca7-328a-40fa-ab60-6102a23c8e0c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy0xMy0xLTEtMzQ0MDE_5ccc6f25-2344-47fa-81cf-bc85447e03b0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic53305bb04ab4021944c4163701dcd71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfNy0xNS0xLTEtMzQ0MDE_b6645f06-25f5-439a-a7a6-08ece9220beb"
      unitRef="usd">100130000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i685a759150ca4001b06e6ef8169b3a0a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS0xLTEtMS0zNDQwMQ_f37a33fc-0daf-4912-82d5-46378d80e1bc"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS0zLTEtMS0zNDQwMQ_4394e12a-93d9-4113-9386-d467e8b578c2"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS01LTEtMS0zNDQwMQ_bfc98592-0be7-4a2b-bc99-4add8216c50b"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ia13ef5c367424e9b87f0aa0201302d21_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS03LTEtMS0zNDQwMQ_80e1388d-ccdc-4c21-863d-de7b2eebd54b"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ic790d5759ab443cba375a13c77efc8a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS05LTEtMS0zNDQwMQ_2da02a59-3a57-42c3-bce2-9a0adaeb32cb"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS0xMS0xLTEtMzQ0MDE_927d6779-0c6f-469f-b53a-7120e72039ba"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS0xMy0xLTEtMzQ0MDE_4e3b3da7-d6ef-4f21-8ade-197c75ef9ec9"
      unitRef="usd">177000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ic53305bb04ab4021944c4163701dcd71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfOS0xNS0xLTEtMzQ0MDE_87e072b2-faf6-4d50-a1f5-a575d3c0fa3d"
      unitRef="usd">177000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:DerivativeLiabilities
      contextRef="i685a759150ca4001b06e6ef8169b3a0a_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtMS0xLTEtMzQ0MDE_87ac83eb-c7d7-444b-beb6-c6732f187af2"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="idb98ad0de8504c78aba7432c1dbcbcc3_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtMy0xLTEtMzQ0MDE_f0faa565-5006-4124-ae13-494223437edf"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtNS0xLTEtMzQ0MDE_0a6783de-825d-4c8b-a035-4309c34024e6"
      unitRef="usd">1610000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia13ef5c367424e9b87f0aa0201302d21_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtNy0xLTEtMzQ0MDE_13c30e67-6111-4776-81bf-3d828e2e0120"
      unitRef="usd">1610000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic790d5759ab443cba375a13c77efc8a1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtOS0xLTEtMzQ0MDE_b264773c-52ea-4e27-93a6-64c64abdd42b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i86bbfe8de8ca4af9b977e0ffa121535c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtMTEtMS0xLTM0NDAx_579005a1-2e8e-4f8d-8a46-d7e2904facde"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtMTMtMS0xLTM0NDAx_9458b81f-a711-49bd-b961-dfc324c9fbaa"
      unitRef="usd">1782000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ic53305bb04ab4021944c4163701dcd71_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmE4NGY5MDQ2NjVkZTQ4NjRhMWIzMzVmY2VjNDI1Mzc2L3RhYmxlcmFuZ2U6YTg0ZjkwNDY2NWRlNDg2NGExYjMzNWZjZWM0MjUzNzZfMTAtMTUtMS0xLTM0NDAx_a7b03b49-1ba0-45cd-bcb3-c8ab1cacd047"
      unitRef="usd">1782000</us-gaap:DerivativeLiabilities>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4NQ_3ea082a5-3573-4e36-8037-01efb5d83882">The following table sets forth a summary of the changes in the estimated fair value of the Company&#x2019;s redeemable convertible preferred stock warrants, which represents financial instruments with valuations classified as &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. However, Level 3 financial instruments typically include, in addition to the unobservable inputs, observable inputs (that is, components that are actively quoted and can be validated to external sources). Accordingly, the gain or loss in the table below includes changes in fair value due in part to observable factors that are part of the Level 3 methodology recognized in the statement of operations as a component of interest and other income or expense as appropriate (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(112)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(532)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(653)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants to purchase shares of redeemable convertible preferred stock outstanding and exercisable are as follows (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.621%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shares Outstanding at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:10pt"&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Initial&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:10pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Series&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Jun 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Jun 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib383b7e5ad6141079ebfdfb1678720a6_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfMy0xLTEtMS0zNDQwMQ_4a925a41-fe4f-4fb1-bce8-09c11f69d287"
      unitRef="usd">129000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i372dc095e6bb4b4fab2fda830e21a778_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfMy0zLTEtMS0zNDQwMQ_274ed5dc-c5d4-475e-8586-25b0f146872f"
      unitRef="usd">749000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i26689b208bf84601a3e040e4ce73ce49_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfMy01LTEtMS0zNDQwMQ_460a317e-f105-4e86-abfc-070890ea3203"
      unitRef="usd">177000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i80cf655a5572442ab5b3157b560431bf_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfMy03LTEtMS0zNDQwMQ_88f8da77-21b2-43b9-818d-20947084a11e"
      unitRef="usd">870000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="i932b6afd06b54dfdbf042021f1fb619a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNC0xLTEtMS0zNDQwMQ_32f92f1c-0d9b-4ea9-982b-571727167327"
      unitRef="usd">112000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="i735e2352ec40490980b3c86c7253982d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNC0zLTEtMS0zNDQwMQ_237a8dd4-5d2c-4d2e-bec6-fc753f10fc3e"
      unitRef="usd">532000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="i87940b64ee9940b29b568ac0a865184b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNC01LTEtMS0zNDQwMQ_b39c34b3-5d8d-4277-b99a-756a26a0aec3"
      unitRef="usd">113000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales
      contextRef="i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNC03LTEtMS0zNDQwMQ_c8015c98-f0ca-4fe6-8d79-0952071b3098"
      unitRef="usd">653000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i932b6afd06b54dfdbf042021f1fb619a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS0xLTEtMS00MjUzMQ_b6d1611c-87c7-48e8-b56e-cc58b8989f4a"
      unitRef="usd">16000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i735e2352ec40490980b3c86c7253982d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS0zLTEtMS00MjUzMQ_0b7e9132-db2d-4dba-8522-1c67b4bb3345"
      unitRef="usd">22000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i87940b64ee9940b29b568ac0a865184b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS01LTEtMS00MjUzMQ_20248db6-6fc7-448a-8f44-49e1287d562a"
      unitRef="usd">16000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS03LTEtMS00MjUzMQ_634c6162-beb3-42dc-b9e0-c13b3ae19ecb"
      unitRef="usd">22000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i932b6afd06b54dfdbf042021f1fb619a_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS0xLTEtMS0zNDQwMQ_32ef6db8-d48c-4d54-84c0-41caaa77e871"
      unitRef="usd">-1000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i735e2352ec40490980b3c86c7253982d_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS0zLTEtMS0zNDQwMQ_8b76472f-442a-46e3-95c6-1a64a78e42e4"
      unitRef="usd">-67000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i87940b64ee9940b29b568ac0a865184b_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS01LTEtMS0zNDQwMQ_6542b8e6-fd2a-472a-9eef-f8d94a8959d3"
      unitRef="usd">-48000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNS03LTEtMS0zNDQwMQ_3556e9e7-e013-40ba-babd-a8b9949ed2f4"
      unitRef="usd">-67000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5f0a6d3d6a5d41aabc418f290a24224b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNi0xLTEtMS0zNDQwMQ_a7c9f030-3a8b-42f5-9447-d9ac60b96eff"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5998e1db9c1d41c4b57ba2aac373504c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNi0zLTEtMS0zNDQwMQ_afce97b6-5f1c-4b3b-b9c2-8dcee0efc8f5"
      unitRef="usd">128000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5f0a6d3d6a5d41aabc418f290a24224b_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNi01LTEtMS0zNDQwMQ_6ad933fb-e3aa-49b4-92e9-49f4e3895854"
      unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5998e1db9c1d41c4b57ba2aac373504c_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkMjc5NWMzNzM2YTQ1MGY5NzhhNTA3ZjZkNTEwYjQ0L3RhYmxlcmFuZ2U6YWQyNzk1YzM3MzZhNDUwZjk3OGE1MDdmNmQ1MTBiNDRfNi03LTEtMS0zNDQwMQ_8cc1a4cd-352f-4ec6-ab5a-e09747b69e7a"
      unitRef="usd">128000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i821880a0f0ea457fb74d98beb2145b75_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MTc2Mg_a79c51b0-7c59-4539-90a6-fb3299291210"
      unitRef="shares">62454</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i4acb9ad050634e849a2a2923e0940cae_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MTc2Mg_ce90b69b-fe8a-4a11-81d2-51c3d730e7c7"
      unitRef="shares">62454</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ide057d850a674c1faa90ee7654a9dcba_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3NDI5NA_750e6288-cab8-463a-882b-89c41a21962f"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4Ng_f7973e7e-da81-4deb-a40c-6d916c8a2ead">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the redeemable convertible preferred stock warrant liability was determined using the Black-Scholes option pricing model using the following assumptions: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.957%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <prct:WarrantsAndRightsOutstandingWeightedAverageTerm
      contextRef="i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjg3NzY4YmJhYjY4NTQzMjNiNmEzNjRlMjRiNTk0NDg1L3RhYmxlcmFuZ2U6ODc3NjhiYmFiNjg1NDMyM2I2YTM2NGUyNGI1OTQ0ODVfMy03LTEtMS0zNDQwMQ_82ebedf0-1408-4d93-9554-9b7becf362d0">P1Y4M24D</prct:WarrantsAndRightsOutstandingWeightedAverageTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="ibf0b64a5bcea498e9f11e448dcbfd834_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjg3NzY4YmJhYjY4NTQzMjNiNmEzNjRlMjRiNTk0NDg1L3RhYmxlcmFuZ2U6ODc3NjhiYmFiNjg1NDMyM2I2YTM2NGUyNGI1OTQ0ODVfNC03LTEtMS0zNDQwMQ_9c335750-b238-48cf-929d-425bcd744268"
      unitRef="number">0.80</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i70cffcb762f444178b8ff9f5925b1a05_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjg3NzY4YmJhYjY4NTQzMjNiNmEzNjRlMjRiNTk0NDg1L3RhYmxlcmFuZ2U6ODc3NjhiYmFiNjg1NDMyM2I2YTM2NGUyNGI1OTQ0ODVfNS03LTEtMS0zNDQwMQ_bd74ed93-c9cb-4721-9475-4ac20706b769"
      unitRef="number">0.001</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i669bfb53914c4eb98abef7a0bb67beb4_I20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjg3NzY4YmJhYjY4NTQzMjNiNmEzNjRlMjRiNTk0NDg1L3RhYmxlcmFuZ2U6ODc3NjhiYmFiNjg1NDMyM2I2YTM2NGUyNGI1OTQ0ODVfNi03LTEtMS0zNDQwMQ_630b8b19-1493-407b-8250-ea5a844328a4"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <prct:LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget
      contextRef="i149316ff5b004dd4a6c20c85ec67c952_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjM4Mw_b96b4f21-d237-4946-a05f-b57bcd82fb3b"
      unitRef="usd">200000000</prct:LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget>
    <prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn
      contextRef="ia44bb9ced3444ecab70c0374b5456e34_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjM5OQ_0042ca1b-1dcf-4693-b221-046fd82a0d2b"
      unitRef="usd">1000000</prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn>
    <prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn
      contextRef="ia44bb9ced3444ecab70c0374b5456e34_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQxNQ_990e6826-1761-438d-88f1-753a23eb00ef"
      unitRef="usd">2000000</prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn>
    <prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn
      contextRef="ia44bb9ced3444ecab70c0374b5456e34_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQzMQ_64f235f5-52c9-49b9-9292-89999d562ad8"
      unitRef="usd">2400000</prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn>
    <prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn
      contextRef="ia44bb9ced3444ecab70c0374b5456e34_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQ0NQ_4e8d348d-ce78-4020-9674-711a82bad25f"
      unitRef="usd">3000000</prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia44bb9ced3444ecab70c0374b5456e34_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQ2Mg_d17f782b-88eb-42d2-957e-b2a16a478167"
      unitRef="usd">1400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4Nw_76f1f637-e0f6-4ac7-b740-f03322f369e2">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth a summary of the changes in the estimated fair value of the Company&#x2019;s loan facility derivative liability, classified as Level 3 (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(177)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(172)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payment of success fee&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of the period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="i3604760cd7da443ebd82948c1de89a0c_I20210630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfMy0xLTEtMS0zNDQwMQ_8aa26d8c-057c-4f60-8be0-c111d8a84813"
      unitRef="usd">1787000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="iec7eb3e7ffce40f691737cf9a773acc7_I20200630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfMy0zLTEtMS0zNDQwMQ_df3d856b-7900-41ab-9a01-818118b3f77c"
      unitRef="usd">1698000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="i7f9fec37483f4d45b7fef4a5d9f2817d_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfMy01LTEtMS0zNDQwMQ_66433ea3-9145-4efe-9d2a-c1b5503aee8f"
      unitRef="usd">1782000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="i5706bc22431543fd88f03f8d8b69bf07_I20191231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfMy03LTEtMS0zNDQwMQ_33e46fae-1da6-47e0-beb8-414958cad98e"
      unitRef="usd">1482000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="i70e3fa6d51e049b29372b92a12097b3b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNC0xLTEtMS0zNDQwMQ_61d25dd5-6941-4476-a2dd-7d3fbbc29257"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="i552d18e694c74d6ea1105c6c060177c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNC0zLTEtMS0zNDQwMQ_ccfc161e-af8c-44e5-85c8-3049f7fa580b"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="i5e3327002d624963bd45eaa1f8569e6c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNC01LTEtMS0zNDQwMQ_5a32a245-0c49-4dde-bede-7ae41d67f25f"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
      contextRef="i3c34540459ad463592472f93bf90d0d6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNC03LTEtMS0zNDQwMQ_7c818806-26ab-4e8f-b74d-c46cc44ee1db"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="i70e3fa6d51e049b29372b92a12097b3b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNS0xLTEtMS0zNDQwMQ_c5923fa2-fa70-4e85-9d67-6b38c58617bd"
      unitRef="usd">177000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="i552d18e694c74d6ea1105c6c060177c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNS0zLTEtMS0zNDQwMQ_bebe7fd1-7408-4780-86a3-5b0b6746e8a5"
      unitRef="usd">175000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="i5e3327002d624963bd45eaa1f8569e6c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNS01LTEtMS0zNDQwMQ_cbd1cc5a-2a51-4965-8477-422d4fcc4404"
      unitRef="usd">172000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings
      contextRef="i3c34540459ad463592472f93bf90d0d6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNS03LTEtMS0zNDQwMQ_b6d09294-0512-4c40-94c4-a28eaf92f0da"
      unitRef="usd">-41000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
      contextRef="i70e3fa6d51e049b29372b92a12097b3b_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi0xLTEtMS00MjI4NQ_3aa22454-0a44-477a-9570-96b1cebe1bea"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
      contextRef="i552d18e694c74d6ea1105c6c060177c9_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi0zLTEtMS00MjI3OA_b3982194-257a-493a-bd75-487196a82f8b"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
      contextRef="i5e3327002d624963bd45eaa1f8569e6c_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi01LTEtMS00MjI3MQ_57e3cd94-af68-463b-9bfd-6b3f31aa5ffc"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements
      contextRef="i3c34540459ad463592472f93bf90d0d6_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi03LTEtMS00MjI2NA_75588e4b-a6ef-427f-b785-813e8ee287f7"
      unitRef="usd">0</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi0xLTEtMS0zNDQwMQ_26f0be7f-3768-4982-950c-633e2cf378c3"
      unitRef="usd">1610000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="i521f9bcdc3594f5cad2c4aaf7085a016_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi0zLTEtMS0zNDQwMQ_6390f140-e3d9-4899-9d68-3f27279cd331"
      unitRef="usd">1523000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="i1c8fdfa7196b4c45bae042046e2ae3e4_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi01LTEtMS0zNDQwMQ_84277c35-6a48-433e-876d-d906e6b38bf9"
      unitRef="usd">1610000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
      contextRef="i521f9bcdc3594f5cad2c4aaf7085a016_I20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmI1ZTEyOTdhNzNmYTRkMzJiZTEyMWZmZmU5OGYyZTI5L3RhYmxlcmFuZ2U6YjVlMTI5N2E3M2ZhNGQzMmJlMTIxZmZmZTk4ZjJlMjlfNi03LTEtMS0zNDQwMQ_5b0ac285-48a5-4a5f-9f77-ff4fa5b81b33"
      unitRef="usd">1523000</us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs>
    <us-gaap:LongTermDebtMeasurementInput
      contextRef="i886693e4845143ee9412596e575e4081_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQ2OQ_6e051b7d-965c-41d4-afc9-de999ae2858c"
      unitRef="number">0.10</us-gaap:LongTermDebtMeasurementInput>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2Mg_4f3f492e-65ae-4443-adf3-2ccb94e122a1">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents and, to a lesser extent, accounts receivable. The Company believes that credit risk in its accounts receivable is mitigated by its credit evaluation process, relatively short collection terms and diversity of its customer base. The Company generally does not require collateral and losses on accounts receivable have historically been within management&#x2019;s expectations. &lt;/span&gt;&lt;/div&gt;The Company&#x2019;s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings, as well as corporate debt or commercial paper issued by the highest quality financial and non-financial companies, and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash and cash equivalents and issuers of investments to the extent recorded on the balance sheets. The Company has limited its credit risk associated with cash and cash equivalents by placing its investments with banks it believes are highly creditworthy and with highly rated investments.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2Mw_eeda4d73-2582-401c-b13a-70c45ee4a7a4">Allowance for Doubtful Accounts The Company provides for uncollectible accounts receivable by recording an allowance for doubtful accounts for balances deemed uncollectible. The Company evaluates the collectability of its accounts receivable based on known collection risks and historical experience. In circumstances where the Company is aware of a specific customer&#x2019;s inability to meet its financial obligations to the Company (e.g., bankruptcy filings, substantial downgrading of credit ratings), the Company records a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount it reasonably believes will be collected. The Company has not experienced any significant collection issues.</us-gaap:ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2NA_ca0674a0-c760-4d55-ba0a-95c5584fff79">Inventory Inventories are valued at the lower of cost, computed on a first-in, first-out basis, or net realizable value. The allocation of production overhead to inventory costs is based on normal production capacity. Abnormal amounts of idle facility expense, freight, handling costs, and consumption are expensed as incurred, and not included in overhead. The Company maintains provisions for excess and obsolete inventory based on management&#x2019;s estimates of forecasted demand and, where applicable, product expiration. The Company has initiated voluntary recalls for a limited number of handpieces due to certain issues related to supply chain and manufacturing processes, of which the provision recognized was not material.</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2NQ_9a1ebb7f-f0fa-4a28-99e5-80f68d65dd39">Property and Equipment and Intangible AssetsProperty and equipment and Intangible Assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization for property and equipment are determined using the straight-line method over the estimated useful lives of the respective assets, generally 3 to 5 years. The Company reclassifies inventory used at customer sites for evaluation purposes to property and equipment due to a limited history of sales of evaluation units. Amortization of intangible assets are determined using the straight-line method over the estimated useful lives, generally through the patent expiration date. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Maintenance and repairs are charged to operating expenses as incurred.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ic400b41cd47342848644ec9514f047c0_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjQ4OA_f4a2cb27-cd91-4b98-9300-85633e335dd4">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i7b9ba7023422472682b16a20f5f463a1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2Ng_5b453c46-cc8d-40f1-a6aa-2fae33df87fb">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2Nw_4cb2dec3-6883-488f-80c0-6328ce7428e6">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist primarily of property and equipment and intangible assets, net, and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that a long-lived asset be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated by the asset group to the carrying amount of the &lt;/span&gt;&lt;/div&gt;asset group. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. The Company determines fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. The Company&#x2019;s cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors. Since inception, the Company has not recorded impairment charges on its long-lived assets.</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:DeferredChargesPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2OA_29064728-b92f-41a5-9148-31cede6717ab">Deferred Offering CostsThe Company capitalizes, within other assets, certain legal, accounting and other third-party fees that are directly related to the Company&#x2019;s in-process equity financings, including its recent initial public offering, until such financings are consummated. After consummation of the equity financing, these costs are recorded to additional paid in capital as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses.</us-gaap:DeferredChargesPolicyTextBlock>
    <us-gaap:DeferredOfferingCosts
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjIzNQ_60b370b4-7b98-4886-b9c9-11d8a5e4eb0f"
      unitRef="usd">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:DeferredOfferingCosts
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3MjIzNQ_ace9773f-1e79-4dc3-9fb0-ee908a9ebb94"
      unitRef="usd">0</us-gaap:DeferredOfferingCosts>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY2OQ_7f7ca6e8-7e16-4f33-ab70-3c53586bfc7a">Deferred RevenueThe timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue will be recognized subsequent to invoicing. Service agreements are generally invoiced annually at the beginning of each coverage period and recorded as deferred revenue and recognized as revenue ratably over the coverage period. Deferred revenue that will be recognized during the twelve months following the balance sheet date is recorded as the current portion of deferred revenue, and the remaining portion, if any, would be recorded as non-current.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <prct:RedeemableConvertiblePreferredStockPolicyPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3MA_9bdffed9-9684-4ff0-98f8-d5cc19380b16">Redeemable Convertible Preferred StockThe Company records redeemable convertible preferred stock at fair value on the date of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because it contains liquidation features that are not solely within the Company&#x2019;s control. The Company determined that the carrying values of the redeemable convertible preferred stock should not be adjusted to the liquidation preferences because it is uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock. Subsequent adjustments to the carrying values of the redeemable convertible preferred stock to the liquidation preferences will be made only when it is probable that the redeemable convertible preferred stock will become redeemable.</prct:RedeemableConvertiblePreferredStockPolicyPolicyTextBlock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjA2MQ_080bcfa1-af45-4252-af29-85b40683fa55"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjA2MQ_c67bb575-5e73-493b-9fee-a555ef693c48"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjE2NA_080bcfa1-af45-4252-af29-85b40683fa55"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjE2NA_c67bb575-5e73-493b-9fee-a555ef693c48"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MzM1MA_d5a4071a-8dff-415f-99a3-daf3c6f22d7c"
      unitRef="usd">329500000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <prct:RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3MQ_b643e0b1-57b1-492e-8ff2-b26ac781e01f">Redeemable Convertible Preferred Stock Warrant Liability The Company has issued freestanding warrants to purchase shares of redeemable convertible preferred stock to investors in connection with sales of certain of its redeemable convertible preferred stock. The Company classified these warrants as a derivative liability because they create a conditional obligation for the Company to repurchase its own shares for cash or other assets. The fair value of the warrants are recorded on the consolidated balance sheets at the issuance of the warrants and remeasured to fair value at each financial reporting date. The changes in the fair value of the warrants are recorded in the statement of operations as a component of interest and other income or expense as appropriate. The Company will continue to adjust the carrying value of the redeemable convertible preferred stock warrant liability for changes in the fair value of the warrants until the earlier of: the exercise of the warrants, at which time the liability will be reclassified to temporary equity or the expiration of the warrant, at which time the entire amount would be reversed and reflected in the consolidated statements of operations and comprehensive loss.</prct:RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i821880a0f0ea457fb74d98beb2145b75_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MTgxOA_a79c51b0-7c59-4539-90a6-fb3299291210"
      unitRef="shares">62454</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i4acb9ad050634e849a2a2923e0940cae_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2MTgxOA_ce90b69b-fe8a-4a11-81d2-51c3d730e7c7"
      unitRef="shares">62454</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3Mg_fc03a0b9-1c25-4a5b-9f98-84cf15008964">Loan Facility Derivative LiabilityThe Company has determined that its obligation to pay success fees to a lender upon a successful liquidation event or achieving a revenue target represents freestanding financial instruments. The instruments are classified as a non-current liability in the consolidated balance sheets and are subject to remeasurement at each financial reporting date. Any change in fair value was recognized through other income (expense) in the condensed consolidated statements of operations and comprehensive loss.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3Mw_b0c41cce-0395-4a5c-8769-b8619e4c1c64">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For agreements with a term of more than twelve months, the Company determines if an agreement contains a lease at inception. Operating lease liabilities represent an obligation to make lease payments arising from the lease agreement. Operating lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the remaining lease term. In determining the present value of lease payments, the Company estimates its incremental borrowing rate as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, of an amount equal to the lease payments in a similar economic environment. Operating lease liabilities are included in the Company&#x2019;s consolidated balance sheet. Right-of-use assets represent our right to use an underlying asset for the lease term and are classified as non-current assets. Lease expense is recognized on a straight-line basis over the expected lease term in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Through December&#160;31, 2019, the Company recorded the difference between rent paid and the straight-line rent as a deferred rent liability and leasehold improvements funded by landlord incentives or allowances are recorded as leasehold improvement assets and a corresponding deferred rent liability. Upon adoption of Accounting Standards Codification (&#x201c;ASC 842&#x201d;) on January 1, 2020, the unamortized deferred rent liability has been reclassified to reduce the right-of-use asset.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has not elected to separate lease and non-lease components for any leases within its existing classes of assets and, as a result, records a right-of-use asset and lease liability based on the present value of the future minimum lease payments over the term at commencement date. Variable lease payments are expensed as incurred. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LessorLeasesPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg5NjkyNQ_68016953-f64c-4506-be4d-f9904e6d1a87">The Company has lessor arrangements with customers for a fixed monthly fee with no non-lease components, typically for 3-12 months. These arrangements are accounted for as an operating lease in accordance with ASC 842. These arrangements and related revenue are immaterial to the periods presented.</us-gaap:LessorLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3NQ_9c1cb9e7-2915-41d5-b3f1-74f0eac1e60e">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue Recognition &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is derived primarily from the sales of the AquaBeam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Robotic Systems, and handpieces that are for one-time use during each surgery using the AquaBeam Robotic System. The AquaBeam Robotic System contains both software and non-software components that are delivered together as a single product and generally contain a one-year warranty. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ASC 606&#x201d;), the Company performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct based on the contract. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contracts are typically in the form of an agreement and a purchase order from the customer. The Company&#x2019;s AquaBeam Robotic System sales generally contain multiple products and services and can include a combination of the following performance obligations: robotic system, handpieces and consumables, and service. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines the transaction price it expects to be entitled to in exchange for transferring the promised product to the customer, which is based on the invoiced price for the products. All prices are at fixed amounts per the sales agreement with the customer and there are generally no discounts, rebates or other price concessions or a right of return, once the agreement is signed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations at the following points in time:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AquaBeam Robotic Systems&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the time of delivery. Systems rented for a fixed monthly fee during an evaluation period, typically 3-12 months, are recognized as revenue straight-line during the lease term, in accordance with ASC 842, and are not material. For systems sold following an evaluation period, revenue is recognized generally once sales terms are mutually agreed (as the system is already install at the customer site). For systems sold through distributors, revenue is recognized generally at the time of delivery. The Company&#x2019;s system arrangements generally do not provide a right of return. The systems are generally covered by a one-year service agreement. The service agreements have a stand alone selling price and are typically recognized as deferred revenue and amortized over the one-year service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Hand pieces and other consumables&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Revenue from sales of handpieces and other consumables is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also occurs at the time of delivery.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Service&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - Service revenue, inclusive of the amounts associated with the AquaBeam Robotic System warranties, is recognized over the term of the service period, as the customer benefits from the services throughout the service period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that certain promises in the multiple-element arrangements, such as installation, training and certain ancillary products, are immaterial, and/or do not represent separate performance obligations for which transaction price is allocated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue is recognized subsequent to invoicing, such as service contracts, which are recognized ratably as revenue over the performance period, which is not material. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s typical payment terms are between approximately 30 to 90 days. The Company expenses shipping and handling costs as incurred and includes them in the cost of sales. In those cases where shipping and handling costs are billed to customers, the Company classifies the amounts billed as a component of revenue. Taxes collected from customers and remitted to governmental authorities are excluded from revenue. The Company expenses any incremental costs of obtaining a contract, including but not limited to, sales commissions, as and when &lt;/span&gt;&lt;/div&gt;incurred as the expected amortization period of the incremental costs would have been less than one year and are reported in selling, general and administrative expense in the statements of operations and comprehensive loss.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <prct:ProductWarrantyTerm
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4OA_a9f80850-1c41-496e-8baa-2d5fe7f7a4cf">P1Y</prct:ProductWarrantyTerm>
    <prct:ServiceAgreementAmortizationPeriod
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODkwMTY2OQ_6fdcad0d-b1bc-4cc0-8975-f66c65e1b9ae">P1Y</prct:ServiceAgreementAmortizationPeriod>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY5MA_17d01520-8256-40a7-bf4e-d675968441ca">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue disaggregated by type and geography (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;System sales and rentals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Handpieces and other consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside of U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;System sales and rentals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Handpieces and other consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total outside of U.S. revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY5MA_a3e10956-5a12-4b6a-8a1c-f79b4da2a48f">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue disaggregated by type and geography (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;System sales and rentals&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,038&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;646&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Handpieces and other consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total U.S. revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outside of U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;System sales and rentals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,111&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Handpieces and other consumables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total outside of U.S. revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents revenue by significant geographical locations outside the United States for the periods presented:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Germany&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;* Less than 10% of total net revenues for the period indicated.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c26f250c925422aa863c70b7a19551d_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNC0xLTEtMS0zNDQwMQ_24178f82-db19-476a-ac99-97471f3de8db"
      unitRef="usd">5038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a170ab8421b4089a99080c2ea10af97_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNC0zLTEtMS0zNDQwMQ_71c4f619-617a-4fe3-a614-98340ed11d75"
      unitRef="usd">646000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idabe1c5a57964ddb9bd5d12ab67202b8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNC01LTEtMS0zNDQwMQ_af419756-16d6-4361-a7df-49b090e27cbd"
      unitRef="usd">14368000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5d0c0948cc8f4e1280e0195a16e98801_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNC03LTEtMS0zNDQwMQ_361a2bf9-d8c6-4157-856b-98790c215f00"
      unitRef="usd">1106000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic44775719b294dc1913d8311a089ebaf_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNS0xLTEtMS0zNDQwMQ_322374bd-ee1e-41c7-b31a-fa74de042e77"
      unitRef="usd">2184000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd2dcb59faa3426288a132975960e82e_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNS0zLTEtMS0zNDQwMQ_517655f0-248c-4997-b24e-e399e34ccf9f"
      unitRef="usd">451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie17f18e3e20e4d43aae76b23a39a3be8_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNS01LTEtMS0zNDQwMQ_77c6a5f9-406d-4d46-adaf-1183f07e32c5"
      unitRef="usd">5458000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic89eb2bbd1924e0fb717bfba7cc199c8_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNS03LTEtMS0zNDQwMQ_3d90a8a7-211b-4f4f-9252-f92cac7cee2f"
      unitRef="usd">930000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d1f490ec27b47feb871022c21515bab_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNi0xLTEtMS0zNDQwMQ_9a812880-0fc4-4495-9570-261e4f6b214b"
      unitRef="usd">169000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8353a9a7b034508bb8f01dbd8917e72_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNi0zLTEtMS0zNDQwMQ_842c521c-f769-478f-8407-b7a196af8920"
      unitRef="usd">16000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieeada33fd4aa4372b8bd11229fdf8032_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNi01LTEtMS0zNDQwMQ_d0154268-b61c-42a7-bc94-ee77d1b2b340"
      unitRef="usd">378000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ac6cd3dce7f43fda61bce4f9ba59555_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNi03LTEtMS0zNDQwMQ_a2102bff-1421-48ea-9a89-2ab7874e8ac5"
      unitRef="usd">26000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if05a3e115a3c4a69bedce4615d0524f0_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNy0xLTEtMS0zNDQwMQ_7c73f487-5278-4786-b686-d90280489229"
      unitRef="usd">7391000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf79d1655d82439f9563d7390347f8f3_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNy0zLTEtMS0zNDQwMQ_894e54a9-9019-408b-83c3-a7c04e062001"
      unitRef="usd">1113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81c94b64a4fe411c90294df282895066_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNy01LTEtMS0zNDQwMQ_bd9ff3ca-6889-465e-8de7-1a62ea406606"
      unitRef="usd">20204000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe009ff3d8a84467b238828dc96fa66e_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfNy03LTEtMS0zNDQwMQ_39865880-1e7e-464c-bafc-983668b4c867"
      unitRef="usd">2062000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1a203d4671604af189dd4efe9cfc3f3c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfOS0xLTEtMS0zNDQwMQ_13c2279f-5dfe-4aac-8578-4638df9ea211"
      unitRef="usd">481000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib054ba1212a040a5ba7001b1a2bc8aaa_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfOS0zLTEtMS0zNDQwMQ_66cd3686-580c-45de-abfa-4acc1b6c4736"
      unitRef="usd">369000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad3a4897b0f74d93b212ccf2d92ceb95_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfOS01LTEtMS0zNDQwMQ_f891b011-b609-4ede-8391-b405b17a1792"
      unitRef="usd">1725000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa5d2fc51a09454fb9410268366249f0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfOS03LTEtMS0zNDQwMQ_58d5e856-79a4-4050-94e7-79ae93e6da69"
      unitRef="usd">1111000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c6ae97130174160926aac368d44e969_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTAtMS0xLTEtMzQ0MDE_0ab7dfed-45be-418b-bf0a-41169ff3fb27"
      unitRef="usd">666000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ff4ab44021547058325efd92af9bd8b_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTAtMy0xLTEtMzQ0MDE_be0c518c-06f4-462d-b93a-d6d727529297"
      unitRef="usd">596000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i018b3765196146e48322f8a859dbb4d5_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTAtNS0xLTEtMzQ0MDE_4f09b60f-1534-4075-a69d-d75463c62a14"
      unitRef="usd">2159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i52ad0f1364cd409c9f18e002b7381a5f_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTAtNy0xLTEtMzQ0MDE_b5ea5d3c-1180-4ca4-8219-06a674186d1b"
      unitRef="usd">1278000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfa97cb67f4c48af906ec7b00d213a04_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTEtMS0xLTEtMzQ0MDE_819e47a6-1fdc-4361-ac04-3250f96eebcb"
      unitRef="usd">130000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd005e7d887548c48d2e442a699161c8_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTEtMy0xLTEtMzQ0MDE_16e8976c-2b53-447e-9a97-27fb01c65dda"
      unitRef="usd">29000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b33b0f044bd43a19422b9118049e601_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTEtNS0xLTEtMzQ0MDE_84dd35c1-a307-456c-8d37-d3eadcc1bc03"
      unitRef="usd">247000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee4ecb3e06be41628c57d8da452ede6d_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTEtNy0xLTEtMzQ0MDE_eccdbee3-c677-4d8c-8a94-cea28f905f0f"
      unitRef="usd">45000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia2968256b5824a29a2ac8033c768dcc5_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTItMS0xLTEtMzQ0MDE_27fe747c-729f-4836-be85-4b9a7de8c73f"
      unitRef="usd">1277000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6c940d5581a0431aaaeb6016386ef835_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTItMy0xLTEtMzQ0MDE_4feb1dea-eb0a-4450-bcda-427c0a101e00"
      unitRef="usd">994000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fde91df02034661a6ff9d0d3c072933_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTItNS0xLTEtMzQ0MDE_8fb27dbe-9575-43e7-8c54-917869189dbd"
      unitRef="usd">4131000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2df0a857498b4af18745e51eab13a016_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTItNy0xLTEtMzQ0MDE_82820a12-a8cb-4d20-b1b2-e5b7023cf498"
      unitRef="usd">2434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTMtMS0xLTEtMzQ0MDE_37b15083-951d-40c4-85ef-d1f24b6cee70"
      unitRef="usd">8668000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTMtMy0xLTEtMzQ0MDE_68525fb4-7d47-4c4e-b9e2-6760bfe2bacb"
      unitRef="usd">2107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTMtNS0xLTEtMzQ0MDE_0e76fa5a-155b-4180-a057-42caa1c0d76c"
      unitRef="usd">24335000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmU0ZjQ3N2MwY2NlZTQyNzVhMzhmZjNmYjY2YTEyNTFkL3RhYmxlcmFuZ2U6ZTRmNDc3YzBjY2VlNDI3NWEzOGZmM2ZiNjZhMTI1MWRfMTMtNy0xLTEtMzQ0MDE_3ff5df78-052a-450d-9d10-3aa87b64c7c7"
      unitRef="usd">4496000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfSalesPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3Ng_a1c80d63-4360-4f4a-856a-d9b23db3aafe">Cost of Sales Cost of sales consists primarily of manufacturing overhead costs, material costs and direct labor, including stock-based compensation. A significant portion of the Company&#x2019;s cost of sales currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of sales also includes depreciation expense for production equipment, warranty and field service costs, and purchased intangibles and certain direct costs such as shipping costs.</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3Nw_d9325d17-6d7e-467c-a735-5d81ce510da5">Research and Development Research and development costs are expensed as incurred. Research and development costs consist primarily of engineering, product development, and regulatory affairs, consulting services, materials, depreciation and other costs associated with products and technologies being developed, including employee and non-employee compensation, stock-based compensation, supplies, quality assurance expenses, related travel expenses and facilities expenses.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3OA_032cd9a1-39d8-4819-834b-2e50c4cd4dd6">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains a payment equity incentive plan to provide long-term incentives for employees, consultants and members of the board of directors. The plan allows for the issuance of non-statutory and incentive stock options to employees and non-statutory stock options to consultants and non-employee directors. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to determine the fair value of equity incentive awards and recognize compensation expense for all equity incentive awards made to employees and directors, including employee stock options. Stock-based compensation expense is recognized over the requisite service period in the statements of operations and comprehensive loss. The Company uses the straight-line method for expense attribution.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation model used for calculating the fair value of awards for stock-based compensation expense is the Black-Scholes option-pricing model (the &#x201c;Black-Scholes model&#x201d;). The Black-Scholes model requires the Company to make assumptions and judgments about the variables used in the calculation, including the fair value of the Company&#x2019;s common stock, the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate and an expected dividend rate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the Company&#x2019;s common stock underlying the stock options has historically been determined by the Company&#x2019;s board of directors (&#x201c;Board&#x201d;). Because there was no public market for the Company&#x2019;s common &lt;/span&gt;&lt;/div&gt;stock prior to the IPO, the Board determined the fair value of the Company&#x2019;s common stock at the time of grant of the option by considering a number of objective and subjective factors, including valuations of comparable companies, sales of the Company&#x2019;s redeemable convertible preferred stock, operating and financial performance and the general and industry-specific economic outlook. The Company used the &#x201c;simplified method&#x201d; to determine the expected term of the stock option. Expected volatility is based on an average of the historical volatilities of the common stock of publicly-traded companies with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected term of the option. The Company has elected to account for forfeitures when they occur.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <prct:CommonStockValuationPolicyPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY3OQ_7582bbf7-bbc5-4aef-9e36-48911e9de571">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Valuation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s intent has been to grant all options with an exercise price not less than the fair value of its common stock underlying those options on the date of grant. Prior to its IPO, the Company has determined the estimated fair value of its common stock at each valuation date in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Valuation of Privately-Held-Company Equity Securities Issued as Compensation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(the &#x201c;Practice Aid&#x201d;). The Company&#x2019;s board of directors, with the assistance of management, developed these valuations using significant judgment and taking into account numerous factors, including:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;valuations of its common stock with the assistance of independent third-party valuation specialists;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the stage of development and business strategy, including the status of research and development efforts, of its products and product candidates, and the material risks related to its business and industry;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the results of operations and financial position, including its levels of available capital resources;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the valuation of publicly traded companies in the life sciences and medical device sectors, as well as recently completed mergers and acquisitions of peer companies;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the prices of its redeemable convertible preferred stock sold to investors in arm&#x2019;s length transactions and the rights, preferences, and privileges of its redeemable convertible preferred stock relative to those of its common stock;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering or a sale of the Company given prevailing market conditions;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the inability of the Company&#x2019;s stockholders to freely trade its common stock in the public markets, resulting in a discount to reflect the lack of marketability of the Company&#x2019;s common stock based on the weighted-average expected time to liquidity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;trends and developments in its industry; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;external market conditions affecting the life sciences and medical device industry sectors.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s board of directors determined the fair value of its common stock by first determining the enterprise value of the Company&#x2019;s business using the market approach, income approach or from the value implied by the latest round of equity financing, and then allocating the value among the various classes of its equity securities to derive a per share value of its common stock. The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all option granted prior to the Company&#x2019;s IPO in September 2021, the Board allocated the enterprise value based on the option pricing method (&#x201c;OPM&#x201d;). OPM treats the rights of the holders of preferred and common stock as equivalent to call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders of preferred stock, as well as their rights to participation and conversion. Thus, the estimated value of the common stock can be determined by estimating the value of its portion of each of these call option rights. When valuing options granted round the time of an equity financing that is considered arms-&lt;/span&gt;&lt;/div&gt;length, OPM derived the Company&#x2019;s equity value of a company from the price of the securities issued by the Company in the equity financing. Following the completion of the Company&#x2019;s IPO in September 2021, the fair value of the Company&#x2019;s common stock is determined based on the closing price of its common stock on The Nasdaq Global Market.</prct:CommonStockValuationPolicyPolicyTextBlock>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4MA_5d72a835-7c8c-42c9-b251-64a6645cbb73">Advertising Expenses The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were not significant.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4MQ_c696f16a-c701-4a31-a027-21a37302f616">Defined Contribution PlanThe Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their annual compensation on a pre-tax basis.</us-gaap:PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4Mg_81d4cb19-b602-4f39-82de-1ef468b7fc5b">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established when necessary to reduce deferred tax assets to the amounts expected to be realized. Currently, the Company has recorded a full valuation allowance against its deferred tax assets and there is no provision for income taxes, as the Company has incurred operating losses to-date. The Company&#x2019;s policy is to record interest and penalties expense related to uncertain tax positions as a component of income tax expense in the statement of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg5NjkyNg_5a16d820-0a56-49d7-a68f-5b2309920dfa">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Loss Per Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalent shares from dilutive stock options and common stock warrants outstanding during the period. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods as all potentially dilutive securities were antidilutive in those periods.&lt;/span&gt;&lt;/div&gt;The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company&#x2019;s redeemable convertible preferred stock participated in any dividends declared by the Company and were therefore considered to be participating securities.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjY2Mg_080bcfa1-af45-4252-af29-85b40683fa55"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3MjY2Mg_c67bb575-5e73-493b-9fee-a555ef693c48"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3Mjc2NQ_080bcfa1-af45-4252-af29-85b40683fa55"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU3Mjc2NQ_c67bb575-5e73-493b-9fee-a555ef693c48"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY5Mw_02f341be-ad34-46ad-878d-3e7c3d5348eb">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share was determined as follows (in thousands, except per share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY5Mw_a884cdb4-b3cd-443b-be4d-b8c99b44069f">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net loss per share was determined as follows (in thousands, except per share amounts): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14,103)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,008)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41,505)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37,741)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.64)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicByCommonClassTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfMy0xLTEtMS0zNDQwMQ_4d2794ba-1b3c-4098-9471-791f6da8a5b2"
      unitRef="usd">-14103000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfMy0zLTEtMS0zNDQwMQ_2d028043-5036-40fc-a289-6c40c8a64319"
      unitRef="usd">-12008000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfMy01LTEtMS0zNDQwMQ_5b159ebb-4162-4d23-a45e-b51610acce25"
      unitRef="usd">-41505000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfMy03LTEtMS0zNDQwMQ_e726fdae-6822-480a-94fd-6857130a761e"
      unitRef="usd">-37741000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC0xLTEtMS0zNDQwMQ_89e1e34e-1d3c-414f-b093-48e9d0a10ef6"
      unitRef="shares">11580000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC0xLTEtMS0zNDQwMQ_adf39b38-6544-403a-b27e-d68be620d580"
      unitRef="shares">11580000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC0zLTEtMS0zNDQwMQ_324c98f1-b9b9-4c3f-a31e-5d510ff9cba5"
      unitRef="shares">4329000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC0zLTEtMS0zNDQwMQ_b09392b6-6337-4d88-bd83-d484b2c5893a"
      unitRef="shares">4329000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC01LTEtMS0zNDQwMQ_2309d38a-1bbb-4c50-91ee-ff63be3a8569"
      unitRef="shares">7361000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC01LTEtMS0zNDQwMQ_659b361b-9336-4cd0-a6df-f5ac2abc96f4"
      unitRef="shares">7361000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC03LTEtMS0zNDQwMQ_8922e589-e8b5-4294-a002-b693fadac5c5"
      unitRef="shares">3327000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNC03LTEtMS0zNDQwMQ_d53b85b9-d85b-499a-a025-01dfe46a571d"
      unitRef="shares">3327000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS0xLTEtMS0zNDQwMQ_030aee9f-41e0-4613-a893-6264d0155090"
      unitRef="usdPerShare">-1.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS0xLTEtMS0zNDQwMQ_fd4ef9bd-5648-429f-945e-4d41afb0e925"
      unitRef="usdPerShare">-1.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS0zLTEtMS0zNDQwMQ_67d1b832-7193-422c-bfcc-a186487fc782"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS0zLTEtMS0zNDQwMQ_b7e46c66-c7a8-4db0-836a-62a4ec935d06"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS01LTEtMS0zNDQwMQ_274b2b0b-f7ce-4fb1-ba72-60ba461457fd"
      unitRef="usdPerShare">-5.64</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS01LTEtMS0zNDQwMQ_285fe056-6d49-4a00-b6f0-e25ffc06b666"
      unitRef="usdPerShare">-5.64</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS03LTEtMS0zNDQwMQ_4927145d-ff6f-40eb-ba08-79b9baea24b5"
      unitRef="usdPerShare">-11.34</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOmFkYTNmZGViMzJjNDQ0MDY5NmRmYmFmMmU1ZmFmODEwL3RhYmxlcmFuZ2U6YWRhM2ZkZWIzMmM0NDQwNjk2ZGZiYWYyZTVmYWY4MTBfNS03LTEtMS0zNDQwMQ_4b06c655-a679-47f7-a4c0-93c2c00876a4"
      unitRef="usdPerShare">-11.34</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzcxNw_913e9c6c-7f4a-4259-9139-b50de56299d4">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following potentially dilutive securities outstanding have been excluded from the computations of weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable convertible preferred stock outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Redeemable convertible preferred stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5de6b566d9af4bbbbdb356901e72ac2f_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfMy0xLTEtMS0zNDQwMQ_1fcb0f98-3e87-441c-8b55-174dde97539c"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i39c4d84b986e41378d377fdb579b0a86_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfMy0zLTEtMS0zNDQwMQ_ed24625b-a1b0-4093-9b92-a60577ec8dd0"
      unitRef="shares">25402000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifb2eba5a66004f438219847cad5c1e9a_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNC0xLTEtMS0zNDQwMQ_f3d92a1b-582d-42bb-ba70-b8c029bab222"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ifb63ff2219e442f2819551ec884c0008_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNC0zLTEtMS0zNDQwMQ_65c166ae-a243-44f8-930a-3a48a9c7c4bb"
      unitRef="shares">72000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic982c9e58b554c3082d06d2c3a72e4fd_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNS0xLTEtMS0zNDQwMQ_85fce5f8-ac33-4ffe-95f6-340918342331"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i49ee07a01cc44074a4d6e760f58e4643_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNS0zLTEtMS0zNDQwMQ_7987709e-952c-4697-ace1-9dea8d2b31d1"
      unitRef="shares">12000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ibe92bd4b50d543f59cb5bba7fd59e5d6_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNi0xLTEtMS0zNDQwMQ_99bbf775-a686-4839-b2d9-920140160303"
      unitRef="shares">6607000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib43d1b122a854476a24a6c9ee1ab3406_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNi0zLTEtMS0zNDQwMQ_70205049-faf5-4619-a0bc-09692bc96da6"
      unitRef="shares">6143000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNy0xLTEtMS0zNDQwMQ_5d3bfc07-8eab-487c-a8e0-b9927504f92b"
      unitRef="shares">6607000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjk3NTdiZmFhZjI1ODQ5MTliOGNjZThmNGUxYTUxYzIzL3RhYmxlcmFuZ2U6OTc1N2JmYWFmMjU4NDkxOWI4Y2NlOGY0ZTFhNTFjMjNfNy0zLTEtMS0zNDQwMQ_7d2001b8-87a4-4517-beac-d0e8a9d6b180"
      unitRef="shares">31629000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4Mw_e079b64f-c1cd-4c7e-881a-8d8631ddb22b">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Segment, Geographical and Customer Concentration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as a single operating segment. The Company&#x2019;s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. The Company&#x2019;s assets are primarily based in the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i621e3ef4440f48c2b9f769e24af4620f_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2Mzg2OA_5301e594-6534-42d2-a1c5-1452dece9eca"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i9bfac2758f3446a3ad3a43b3803a084a_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2Mzg3Mw_1e9bfc52-0f4c-431f-b3a5-f09a075faca8"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8bc8fda665ae45fda75450551e6878fb_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfNDM5ODA0NjU2Mzg4MQ_8666f45e-6403-4feb-9cbf-a2a0174ac856"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7708603bb2ff47579ddc870b44b0fbb0_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjMwMzdlYTIzNzRiYjQ4ZGZhMjBhNGUwOTM5ZjZiMTdiL3RhYmxlcmFuZ2U6MzAzN2VhMjM3NGJiNDhkZmEyMGE0ZTA5MzlmNmIxN2JfMy0zLTEtMS00MjQ1MQ_c1b54428-8e9f-4919-94a1-ef8a02d36142"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i52f5aefc16b34dfda582cd7651908024_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RhYmxlOjMwMzdlYTIzNzRiYjQ4ZGZhMjBhNGUwOTM5ZjZiMTdiL3RhYmxlcmFuZ2U6MzAzN2VhMjM3NGJiNDhkZmEyMGE0ZTA5MzlmNmIxN2JfMy03LTEtMS00MjQ1Nw_b6f7e5de-6d46-4a49-a94c-a3589ce7b784"
      unitRef="number">0.32</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i62921dc1224a460e89216f894a1e2b07_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3Mjg3NQ_99cd408f-b3ed-436b-bd53-492c4c2dfa31"
      unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0ac307246bd746a78220da47930dbd09_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3Mjg4MQ_c7a935bb-1c8d-4d3d-baab-0aa8ebe6d9c5"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <prct:JobsActAccountingElectionPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NzY4NA_0d93582a-c29d-4968-abae-a3914f86f215">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;JOBS Act Accounting Election &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to avail itself of this exemption and, therefore, for new or revised accounting standards applicable to public companies, the Company will be subject to an extended transition period until those standards would otherwise apply to private companies.&lt;/span&gt;&lt;/div&gt;</prct:JobsActAccountingElectionPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfOTM0NTg0ODg4NjY4OQ_7d0a5a83-be99-4628-b30f-69c564212a77">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2018-13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurement (Topic 820): Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(&#x201c;ASU 2018-13&#x201d;). The amendments on changes in unrealized gains and losses recognized in other comprehensive income categorized within Level 3, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively in the initial fiscal year of adoption. All other amendments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;should be applied retrospectively to all periods presented upon their effective date. The Company adopted ASU 2018-13 as of January 1, 2020, which did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (&#x201c;ASU 2018-11&#x201d;). ASU 2018-11 provided an alternative implementation method in addition to the current modified retrospective transition method for ASU No. 2016-2, Leases: Amendments to the FASB Accounting Standards Codification (&#x201c;ASU 2016-2&#x201d;), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-2, a lessee is required to recognize assets and liabilities for leases with lease terms of more than twelve months. ASU 2016-2 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted ASC Topic 842, Leases, on January 1, 2020 using the modified retrospective transition method. In addition, the Company elected certain practical expedients permitted under the transition guidance, which allowed it to carryforward its historical long-term lease classification, its assessment on whether a contract is or contains a lease and the treatment of its initial direct costs for any leases that existed prior to the adoption of Topic 842. In determining the lease term at commencement date, any renewal or termination options are considered if they are reasonably assured of exercise. The Company has elected to exclude from its consolidated balance sheet any leases having a term of 12 months or less. The Company recorded a right-of-use leased asset of approximately $6.0 million and a corresponding lease liability of $7.4 million in its adoption of Topic 842. In addition, as of the adoption date, the Company derecognized a deferred rent obligation of $1.4 million. There was no cumulative effect adjustment upon the adoption of Topic 842.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#x2014;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (&#x201c;ASU 2016-13&#x201d;), which requires an entity to utilize a new impairment model known as the current expected credit loss (&#x201c;CECL&#x201d;) model to estimate its lifetime &#x201c;expected credit loss&#x201d; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments&#x2014;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. This standard is effective for fiscal periods beginning after December 15, 2021, and for fiscal years beginning after December 15, 2020 for public business entities. The Company adopted ASU 2019-12, effective of January 1, 2021, and the adoption did not have a material impact on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="icec9f26499284935a6a375b0c451fdcb_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3Mjk0Mw_98b24172-f871-4b57-b637-60baa9decd12"
      unitRef="usd">6000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="icec9f26499284935a6a375b0c451fdcb_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3Mjk1OQ_65270e02-53a5-4309-9b1f-0bb0a364af6c"
      unitRef="usd">7400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="icec9f26499284935a6a375b0c451fdcb_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF8zNy9mcmFnOjRjOWY1YWU4NjNhZTQ0NmRhOTc3NWEyMjgzZTkzZjJiL3RleHRyZWdpb246NGM5ZjVhZTg2M2FlNDQ2ZGE5Nzc1YTIyODNlOTNmMmJfMTA5OTUxMTY3Mjk3NQ_ee847e22-9b0b-41b0-b07f-c5985d3d9e2f"
      unitRef="usd">-1400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzMg_5f77ea1b-672d-4edb-a7c6-5bd3a32718d0">Composition of Certain Consolidated Financial Statement Items &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory, manufacturing and computer equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rental equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evaluation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, other non-current liabilities consisted of an asset retirement obligation for the facility lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest and Other Income (Expense), net (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease (increase) in fair value of preferred stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease (increase) in fair value of loan facility derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest and other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzNw_b64c7fff-4065-44cb-9ce6-ee5128f90b04">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventory (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfMy0xLTEtMS0zNDQwMQ_137d8c0b-f062-451d-af4c-67a34fee5e80"
      unitRef="usd">4602000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfMy0zLTEtMS0zNDQwMQ_1a07f994-65d2-48c2-b174-e3d08d17cc8f"
      unitRef="usd">2647000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNC0xLTEtMS0zNDQwMQ_f219c7ed-536a-4f08-bc64-b3c9e0dfd385"
      unitRef="usd">612000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNC0zLTEtMS0zNDQwMQ_eee95bb4-c88e-48b0-9d17-3133b20bbbb2"
      unitRef="usd">51000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNS0xLTEtMS0zNDQwMQ_16153de8-9875-4ddc-8f0a-7735beab684e"
      unitRef="usd">5187000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNS0zLTEtMS0zNDQwMQ_7523f6a9-7877-4cb6-8ac4-baea4cee1672"
      unitRef="usd">4226000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryNet
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNi0xLTEtMS0zNDQwMQ_54fa2212-baaa-406e-b260-f6f2ed41ca44"
      unitRef="usd">10401000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjE1NThhNTFmOTQwZDRhNmFiNThhYTNmODU2M2Q4OGQ3L3RhYmxlcmFuZ2U6MTU1OGE1MWY5NDBkNGE2YWI1OGFhM2Y4NTYzZDg4ZDdfNi0zLTEtMS0zNDQwMQ_17f3cb9c-7679-4751-bb46-2bf4ac4fedfa"
      unitRef="usd">6924000</us-gaap:InventoryNet>
    <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzNA_1232030a-7988-408f-814a-a03b642efc97">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;310&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rent&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;245&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Insurance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
    <prct:PrepaidInventory
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfMy0xLTEtMS0zNDQwMQ_84a3cecf-c19b-499a-baf9-0fb9c6e6e8b0"
      unitRef="usd">310000</prct:PrepaidInventory>
    <prct:PrepaidInventory
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfMy0zLTEtMS0zNDQwMQ_0a88c0ee-06ed-4378-847e-7b1fba0e0b20"
      unitRef="usd">553000</prct:PrepaidInventory>
    <prct:PrepaidSoftware
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNC0xLTEtMS0zNDQwMQ_c7a87fd6-d007-4035-9492-5d730cbe2a9c"
      unitRef="usd">580000</prct:PrepaidSoftware>
    <prct:PrepaidSoftware
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNC0zLTEtMS0zNDQwMQ_ad55820f-d775-469e-a285-b1565108167e"
      unitRef="usd">375000</prct:PrepaidSoftware>
    <us-gaap:PrepaidRent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNS0xLTEtMS0zNDQwMQ_4038008b-3f28-404c-9e93-f27926a464d0"
      unitRef="usd">252000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidRent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNS0zLTEtMS0zNDQwMQ_12f3ff16-9130-4b29-928b-b544bf4876f5"
      unitRef="usd">245000</us-gaap:PrepaidRent>
    <us-gaap:PrepaidInsurance
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNi0xLTEtMS0zNDQwMQ_fdd75a2d-8419-4c89-b579-5ddddc1285b9"
      unitRef="usd">447000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNi0zLTEtMS0zNDQwMQ_08480654-fdcb-4da4-927c-4d03d0639825"
      unitRef="usd">124000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNy0xLTEtMS0zNDQwMQ_d875548e-38dd-4564-b18a-471b1c36fee5"
      unitRef="usd">643000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfNy0zLTEtMS0zNDQwMQ_9f2f2c6b-443e-4607-ba5c-8b5524c73df9"
      unitRef="usd">356000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfOC0xLTEtMS0zNDQwMQ_d867ba8c-4673-4a94-b4e2-5f5a786a4111"
      unitRef="usd">2232000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjY1N2ZiNjdhMWE0MjRiZDJhYzllMDRmZTQwMGE1NzYyL3RhYmxlcmFuZ2U6NjU3ZmI2N2ExYTQyNGJkMmFjOWUwNGZlNDAwYTU3NjJfOC0zLTEtMS0zNDQwMQ_42baaedf-7aec-429a-aecf-14af2d73b2c5"
      unitRef="usd">1653000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzNQ_edc65a2b-d2a3-443f-b661-0a9142ddb159">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory, manufacturing and computer equipment and furniture&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rental equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Evaluation units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,062&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,788)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i39ecf903be504ecdaf949aece1345593_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNC0xLTEtMS0zNDQwMQ_2949ce60-5a3a-4eb3-926e-dc9956d53aad"
      unitRef="usd">2911000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic86cf6a985714467a558f903d60ea686_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNC0zLTEtMS0zNDQwMQ_f61722c3-cfa1-4776-918d-3946a4981b41"
      unitRef="usd">2645000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4cacff96a36941f49fc136cd9987bba8_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNi0xLTEtMS0zNDQwMQ_cb5fe1e7-92a2-4319-aa83-12b269fa5281"
      unitRef="usd">821000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i56f7a99ae3cc46a48d7f360c4949ca50_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNi0zLTEtMS0zNDQwMQ_8f6ca15f-4178-4012-9252-9243a0c15f11"
      unitRef="usd">1247000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib0930250516e46df8adee1ddbea619bb_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNy0xLTEtMS0zNDQwMQ_46120463-48da-481f-babf-2e4b8880dca3"
      unitRef="usd">4941000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id08e754d707e4d5ca56a878c541eb772_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfNy0zLTEtMS0zNDQwMQ_d55495a8-8d6e-4f56-9c6d-709c4e6524c2"
      unitRef="usd">4941000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia890f1a1f9ea4925ac24d0577d19ee3c_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfOC0xLTEtMS0zNDQwMQ_732a198f-be64-47b5-afa3-38f07f1fa0d0"
      unitRef="usd">3492000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia2daf6e575dd487a9593c9105221c75c_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfOC0zLTEtMS0zNDQwMQ_894152d3-0049-4fb2-b0ea-2d085eaf15ad"
      unitRef="usd">4229000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfOS0xLTEtMS0zNDQwMQ_0df8e0fd-34e7-497d-a0f0-623b88fdb981"
      unitRef="usd">12165000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfOS0zLTEtMS0zNDQwMQ_e07a7a2b-259d-4add-8368-6e20a672a3d0"
      unitRef="usd">13062000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfMTAtMS0xLTEtMzQ0MDE_18facadd-cada-4cdd-9ca0-3fd98de58789"
      unitRef="usd">6434000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfMTAtMy0xLTEtMzQ0MDE_f3a58492-3884-400a-85fd-f05c367ae0fb"
      unitRef="usd">4788000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfMTEtMS0xLTEtMzQ0MDE_dc685417-88cf-4344-bca9-53e8e7c79dc7"
      unitRef="usd">5731000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjQ3ZTE5MmRlNDhiYzRkNmY4NWQ5OTFjYWIzZjBjMDk4L3RhYmxlcmFuZ2U6NDdlMTkyZGU0OGJjNGQ2Zjg1ZDk5MWNhYjNmMGMwOThfMTEtMy0xLTEtMzQ0MDE_ca61d579-e14d-4479-a363-4003a178749c"
      unitRef="usd">8274000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzNg_a672d2fc-583d-447d-8ba8-41a4af64cb3b">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Current Liabilities (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.224%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued purchases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;403&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Professional services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trial expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <prct:AccruedPurchases
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMy0xLTEtMS0zNDQwMQ_e099ddcb-4cef-4032-9ae4-4a6b104a20ef"
      unitRef="usd">134000</prct:AccruedPurchases>
    <prct:AccruedPurchases
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMy0zLTEtMS0zNDQwMQ_3ff60dbb-adb7-4f68-80f6-7028e9666759"
      unitRef="usd">432000</prct:AccruedPurchases>
    <us-gaap:InterestPayableCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNC0xLTEtMS0zNDQwMQ_627a3d83-5199-457d-9685-d5e8cb2a1289"
      unitRef="usd">390000</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNC0zLTEtMS0zNDQwMQ_368993af-3900-4a25-a647-bb027e8be006"
      unitRef="usd">403000</us-gaap:InterestPayableCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNS0xLTEtMS0zNDQwMQ_4629f339-fde0-49d1-99cc-ea45ea02f6c5"
      unitRef="usd">579000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNS0zLTEtMS0zNDQwMQ_8f6218c3-adf9-4e60-a6a4-b6dab180e08a"
      unitRef="usd">339000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNi0xLTEtMS0zNDQwMQ_df57d97c-40a5-4f8c-ba42-ca15988393e6"
      unitRef="usd">482000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <us-gaap:SalesAndExciseTaxPayableCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfNi0zLTEtMS0zNDQwMQ_4ac46d47-5689-486c-a49a-2288747030a9"
      unitRef="usd">302000</us-gaap:SalesAndExciseTaxPayableCurrent>
    <prct:AccruedClinicalTrialExpenses
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfOC0xLTEtMS0zNDQwMQ_32528439-2c55-4325-98d2-4348b12dc430"
      unitRef="usd">117000</prct:AccruedClinicalTrialExpenses>
    <prct:AccruedClinicalTrialExpenses
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfOC0zLTEtMS0zNDQwMQ_1c5aa8be-f6c4-4dae-b799-7d59a7da1543"
      unitRef="usd">47000</prct:AccruedClinicalTrialExpenses>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMTItMS0xLTEtMzQ0MDE_f525d78f-06bf-469e-b790-8f9da98ba67e"
      unitRef="usd">1132000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMTItMy0xLTEtMzQ0MDE_2d0daa81-6a77-4574-bf56-a287db361462"
      unitRef="usd">454000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMTMtMS0xLTEtMzQ0MDE_8729920d-7431-4ece-9fc1-1b6e0586f326"
      unitRef="usd">2834000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjhiMjkzOWE2MGU3MjRiMTFiYTIyMGUzMzk4Mjg2YjkxL3RhYmxlcmFuZ2U6OGIyOTM5YTYwZTcyNGIxMWJhMjIwZTMzOTgyODZiOTFfMTMtMy0xLTEtMzQ0MDE_e0f959ee-5d58-4482-9ea5-ab94cebd77a2"
      unitRef="usd">1977000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RleHRyZWdpb246ZjMyYTg0OWYyOTUyNGJkYWIyNjMwOGQ4OTI2YmQyNWFfOTM0NTg0ODgzNjgzOQ_761323a8-f112-4f8a-8d2a-1b797dbdcc8d">&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Interest and Other Income (Expense), net (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease (increase) in fair value of preferred stock warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decrease (increase) in fair value of loan facility derivative liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;158&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(87)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total interest and other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfMy0xLTEtMS0zNDQwMQ_b1299a52-a9bd-4253-b292-3bb9fcf30703"
      unitRef="usd">22000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfMy0zLTEtMS0zNDQwMQ_14e6fb0f-a15c-44f6-ad9b-6f062217eedc"
      unitRef="usd">23000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfMy01LTEtMS0zNDQwMQ_53a56366-4523-49c2-8a00-7e22da6456fd"
      unitRef="usd">49000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfMy03LTEtMS0zNDQwMQ_c7d63d6e-e301-4d04-90a9-0b4340e415ba"
      unitRef="usd">161000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNC0xLTEtMS0zNDQwMQ_09b055b8-5fcd-46a7-9b00-1c70ac4ff303"
      unitRef="usd">-16000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNC0zLTEtMS0zNDQwMQ_8eba6215-148b-4b6c-b6a2-0ae4c1c1c3fc"
      unitRef="usd">-142000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNC01LTEtMS0zNDQwMQ_4206eb4e-be18-4bec-bdab-b95986c1af70"
      unitRef="usd">-78000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNC03LTEtMS0zNDQwMQ_c37d7df3-9f2a-4338-82a3-e68bcf918e97"
      unitRef="usd">-233000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNS0xLTEtMS0zNDQwMQ_89762a6b-3bd8-4f11-a8c7-aa7fcb1e631b"
      unitRef="usd">177000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNS0zLTEtMS0zNDQwMQ_1ba0c8ea-5b1c-437d-b47b-8af2ba4f23c8"
      unitRef="usd">174000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNS01LTEtMS0zNDQwMQ_4cab714c-3e9d-4d2b-8c6c-5f50bac29a3e"
      unitRef="usd">158000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNS03LTEtMS0zNDQwMQ_c226cb6c-4859-41c2-9775-f6237a79763d"
      unitRef="usd">-41000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNi0xLTEtMS0zNDQwMQ_a53a9839-5eb7-4514-bb82-694dc9e3dcac"
      unitRef="usd">-52000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNi0zLTEtMS0zNDQwMQ_111dbc41-9488-45c0-accd-8b89ce5f6055"
      unitRef="usd">18000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNi01LTEtMS0zNDQwMQ_d02f2582-1363-48bf-86a8-564c8eab1ebb"
      unitRef="usd">-87000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNi03LTEtMS0zNDQwMQ_c523300b-ea70-4908-9106-6edb383d64e9"
      unitRef="usd">-9000</us-gaap:OtherNonoperatingIncomeExpense>
    <prct:InterestAndOtherIncomeExpense
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNy0xLTEtMS0zNDQwMQ_9dc4a486-7e17-432d-a95a-cfe5878dc6c9"
      unitRef="usd">163000</prct:InterestAndOtherIncomeExpense>
    <prct:InterestAndOtherIncomeExpense
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNy0zLTEtMS0zNDQwMQ_95983e6e-4558-4619-b871-ad7bcce2654c"
      unitRef="usd">357000</prct:InterestAndOtherIncomeExpense>
    <prct:InterestAndOtherIncomeExpense
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNy01LTEtMS0zNDQwMQ_4768f2f5-8f64-413f-aa8c-7a6722aaf123"
      unitRef="usd">198000</prct:InterestAndOtherIncomeExpense>
    <prct:InterestAndOtherIncomeExpense
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80MC9mcmFnOmYzMmE4NDlmMjk1MjRiZGFiMjYzMDhkODkyNmJkMjVhL3RhYmxlOjcxNjlmNDUyZTkxMzQzM2Q5YTlhNGZmMGE1NGEzNWEyL3RhYmxlcmFuZ2U6NzE2OWY0NTJlOTEzNDMzZDlhOWE0ZmYwYTU0YTM1YTJfNy03LTEtMS0zNDQwMQ_b9eb81e4-c608-4777-b5c4-0eca49de4cbd"
      unitRef="usd">344000</prct:InterestAndOtherIncomeExpense>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfOTM0NTg0ODgzODQ0NQ_e7de680b-059d-4d1a-9e93-631f4d32a828">Intangible Assets &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, the Company entered into a license agreement with HydroCision, Inc. This agreement grants the Company an exclusive, perpetual, irrevocable, worldwide, fully paid-up license to develop, manufacture and commercialize products in the field of urology using the patented technology and know-how controlled by HydroCision as of the effective date and as well as new patented technology developed by HydroCision that cover certain activities and improvements that relate to the use of fluid jet technology in connection with the licensed products during the period commencing on the effective date and ending on the earlier of the date that the Company ceases to use HydroCision&#x2019;s existing contract manufacturers and the third anniversary of the effective date. Also included is the right to utilize HydroCision&#x2019;s contract manufacturers, if desired. The consideration paid was a one-time upfront payment of $2.5 million, as well as allowing HydroCision (a reciprocal license) to use any new patented technology and know-how developed by the Company relating to the HydroCision patented technology and know-how in the field of urology for HydroCision use outside the field of urology. HydroCision will pay for any patent maintenance fees on HydroCision&#x2019;s licensed patents. As of September&#160;30, 2021 and December&#160;31, 2020, accumulated amortization was $0.7 million and $0.5 million, respectively, and the net carrying amount is expected to be amortized at a rate of $0.3 million per year until fully amortized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense for intangible assets was $0.1 million for each of the three months ended September 30, 2021 and 2020, and $0.2 million for each of the nine months ended September 30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i323691aee3ba4470beeb781efc9f7d5a_D20190301-20190331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfMTA5OTUxMTYyOTU2Nw_b3d11ab4-daf7-45ba-acfc-3f8c03c49eca"
      unitRef="usd">2500000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfNDM5ODA0NjUxMzQ1Nw_8509a7c8-7c03-4550-a03b-44653a5f073c"
      unitRef="usd">700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfMTA5OTUxMTYyOTYyMA_b77d432b-1f88-409b-a6d6-d31362149317"
      unitRef="usd">500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <prct:FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfMTA5OTUxMTYyOTY1Mw_95b80278-2644-4265-a1b6-1c60bd23e656"
      unitRef="usd">300000</prct:FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfNDM5ODA0NjUxMzQ4OA_141db712-5cde-491d-b8dc-1855d673a140"
      unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfNDM5ODA0NjUxMzQ4OA_6dc52d08-f60e-4d6c-a246-5afa8b16b044"
      unitRef="usd">100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfNDM5ODA0NjUxMzUwOA_237358cc-525d-428d-975c-11e041404419"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80My9mcmFnOjgwOGM1YjkzZmE5NTRmNjFhMmI0ZWY3OTUxNzUwMGM1L3RleHRyZWdpb246ODA4YzViOTNmYTk1NGY2MWEyYjRlZjc5NTE3NTAwYzVfNDM5ODA0NjUxMzUwOA_2c9a86a4-b0ae-46b9-a1b4-58d92c68c014"
      unitRef="usd">200000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTI3MQ_9b027d63-3ef9-4025-985a-11e3b7a7f4b9">Loan Facility In September 2019, the Company entered into a loan facility for up to $75 million available in four installments. The Company borrowed $25 million in September 2019. An additional $25 million was borrowed in March 2020. The third installment of $10 million was originally available for draw through March 31, 2021 contingent upon achieving $20 million in trailing six months revenue. In January 2021, the third installment was amended to be available for draw through June 30, 2021 contingent upon achieving $6.4 million trailing six months revenue. The remaining $15 million was originally available for draw through June 30, 2021 and is contingent upon achieving $25&#160;million in trailing six months revenue. In January 2021, this installment was amended to be available for draw through June 30, 2022. The facility bears an interest rate of 9.37%, which is 7.17% plus the greater of 2.2% or 30-day LIBOR. The initial term of the facility is 60 months with interest-only payments each month for 24 months followed by 36 months amortization of principal and interest. In January 2021, the interest-only period was amended to 36 months followed by 24 months amortization (principal and interest) beginning October 1, 2022 since the amended trailing six months target revenue of $6.4 million was achieved, and accordingly, the current portion of the amount due was reclassified to non-current. Upon drawing the final $15 million tranche, interest-only period is extended 12 months followed by 24 months amortization of principal and interest. Upon the completion of the Company raising over $50 million in its IPO in September 2021, interest-only payments were extended an additional 12 months followed by 12 months amortization of principal and interest. Substantially all assets of the Company are pledged as collateral. Commencing with the earlier of June 30, 2021 and the month following the funding of either the third or final installment, the Company is required to achieve revenues for the previous six months ended equal to the greater of (1) 70% of the forecast for the commensurate period, (2) $15 million if neither third or final &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;installments have been drawn, (3) $20 million if the third but not final installment has been drawn and (4) $25 million if both the third and final installments have been drawn.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The loan facility includes certain fees payable to the lender recorded as a loan discount that are accrued and amortized to interest expense during the loan term. A 6% final payment fee of each funded tranche is payable at the earlier of prepayment or loan maturity and a 0.25% facility fee paid at each funded tranche. A prepayment fee was originally payable if the loan is paid before maturity in the amount of 3% of loans outstanding if paid in full during first 12 months, 2% if loan is paid in full during second 12 months, or 1% if loan is paid in full thereafter before maturity. In January 2021, the prepayment fee was removed as part of the amendments. In addition, the Company should pay the lender&#x2019;s loan initiation fees and a fee upon the earlier occurrence of a defined liquidity event, including but not limited to, a merger or sale of the Company&#x2019;s assets or voting stock, or achieving a $200 million trailing twelve months revenue target, in each case, by September 2029&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The success fees are calculated at the time of the liquidity event occurrence to be $1.0 million if only the first installment has been drawn, $2.0 million if the first two installments have been drawn, $2.4 million if the first three installments have been drawn, or $3.0 million if all four installments have been drawn, in each case, upon the occurrence of the defined liquidity event. The Company determined that this obligation to pay success fees represents freestanding financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amendments in January 2021 were accounted for as a debt modification under ASC 470-50-40 as the changes in the debt terms are not considered substantial, and thus no gain or loss was recorded and a new effective interest rate was established based on the carrying value of the loan and the revised cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="ic9df1ea4e38a48c3958b823d207dc494_I20190930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTg3MA_c6e7cedd-7f7d-4802-bfdf-76c674401bc4"
      unitRef="usd">75000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <prct:LineOfCreditFacilityNumberOfInstallments
      contextRef="ic9df1ea4e38a48c3958b823d207dc494_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4Nw_2dfdc7f1-7b9b-4b59-adba-617c99f3b213"
      unitRef="installment">4</prct:LineOfCreditFacilityNumberOfInstallments>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="ie747bb89dfe9448486f081a8d7c662b9_D20210901-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTg4NQ_1cc652f3-ce8d-443f-8fff-8f1277f568c1"
      unitRef="usd">25000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLongTermLinesOfCredit
      contextRef="i69e54cc3200146fb8da3275f099dcd86_D20200301-20200331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTkwMA_3c78ebad-9b55-440d-80d4-c9fe63e61f34"
      unitRef="usd">25000000</us-gaap:ProceedsFromLongTermLinesOfCredit>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i9e17326bb20948edb8a8ca7d92913aaa_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTkxNQ_783ec568-2b1b-4395-8bc4-03ad5c2cd874"
      unitRef="usd">10000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget
      contextRef="id581c96bb97e44a48ba70ae2493b16db_D20210101-20210331"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTkzMA_0bfeb69b-1221-4453-86b7-8fddf2da2951"
      unitRef="usd">20000000</prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget>
    <prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget
      contextRef="idc0b522093084b14a072138407b528ec_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTk1NA_ee387057-f7f9-4ec3-ae0c-8a0ee33ea2da"
      unitRef="usd">6400000</prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i8d291c059d984acabb11a4e041ff93bc_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTk3OQ_64d6260b-384b-4dd4-a523-be8dde369365"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget
      contextRef="i9578e35c34594195b4553614451e762d_D20210101-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMTk5NA_a66cf3b5-964d-452d-9c1b-18f1c049168d"
      unitRef="usd">25000000</prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget>
    <us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd
      contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMjAxMw_728fcc21-c776-4008-ba43-22b198eaed56"
      unitRef="number">0.0937</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
    <us-gaap:LineOfCreditFacilityInterestRateDuringPeriod
      contextRef="ie2270b85069d4e108aafb93ea6264888_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMjAyMQ_795e385b-28f1-4b32-91f9-4b6d9121406c"
      unitRef="number">0.0717</us-gaap:LineOfCreditFacilityInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i03b0c48c8ac947c3a489c6f136a47201_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTA5OTUxMTYzMjAyOA_0de70838-1bc5-4930-914f-e4d3e73f0504"
      unitRef="number">0.022</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentTerm
      contextRef="iee83fb3442a945c89e3036e0c6098fdb_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4MQ_eef1f59a-1aa2-48ac-9b31-2dc353a818d3">P60M</us-gaap:DebtInstrumentTerm>
    <prct:DebtInstrumentInterestOnlyPeriod
      contextRef="iee83fb3442a945c89e3036e0c6098fdb_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4MA_7cea175e-c37c-498e-9649-00556f5e114e">P24M</prct:DebtInstrumentInterestOnlyPeriod>
    <prct:DebtInstrumentPrincipalAndInterestPeriod
      contextRef="iee83fb3442a945c89e3036e0c6098fdb_D20190901-20190930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA5OA_e34c87e8-52f1-4bd3-b98b-41205d5535f4">P36M</prct:DebtInstrumentPrincipalAndInterestPeriod>
    <prct:DebtInstrumentInterestOnlyPeriod
      contextRef="ifbe7a57a89de4a8285e98235fc3da48b_D20210101-20210131"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4Mg_4875ec98-31a6-4a82-9b5d-4aea83793d73">P36M</prct:DebtInstrumentInterestOnlyPeriod>
    <prct:DebtInstrumentPrincipalAndInterestPeriod
      contextRef="ifbe7a57a89de4a8285e98235fc3da48b_D20210101-20210131"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA5OQ_83c4c6e3-a5d6-457c-97fa-dbd4957bc54d">P24M</prct:DebtInstrumentPrincipalAndInterestPeriod>
    <prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget
      contextRef="idc0b522093084b14a072138407b528ec_D20210101-20210131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NTk2MQ_2618ab9d-778c-4b75-8e23-c83b552802cb"
      unitRef="usd">6400000</prct:LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i8d291c059d984acabb11a4e041ff93bc_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NTk4NA_81670ef8-547f-4c09-be87-0c22ea44bfa0"
      unitRef="usd">15000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <prct:DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod
      contextRef="ib126ee67697d4fdc82b80a04fe0cc629_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4Mw_5e003efb-f749-4b8a-85b4-62aff2e0966e">P12M</prct:DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod>
    <prct:DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod
      contextRef="ib126ee67697d4fdc82b80a04fe0cc629_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTEwMA_9e2ed306-08a4-411a-8b02-f37abd2fb5f3">P24M</prct:DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod>
    <prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount
      contextRef="i7425a248d0c54625b60e82800726ba6e_D20210901-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjAwOQ_6a77f5ea-34ce-4852-8864-21b4cbcd6463"
      unitRef="usd">50000000</prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount>
    <prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod
      contextRef="i7425a248d0c54625b60e82800726ba6e_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTA4NA_a3ac46e7-fa16-4516-a82f-5ba7e123a9d6">P12M</prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod>
    <prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod
      contextRef="i7425a248d0c54625b60e82800726ba6e_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfOTM0NTg0ODg0MTEwMQ_b9994148-b02c-42ad-9649-e627ecebe66b">P12M</prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod>
    <prct:DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent
      contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjAzNA_946acc19-28bf-4d20-9ba2-8506d8f881d3"
      unitRef="number">0.70</prct:DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent>
    <prct:DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly
      contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA0Nw_248410ca-3c52-42d1-a9e1-bb004ed8581c"
      unitRef="usd">15000000</prct:DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly>
    <prct:DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly
      contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA2NQ_fee79478-3552-4e64-863e-c31a063527da"
      unitRef="usd">20000000</prct:DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly>
    <prct:DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn
      contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA4MA_51c84e38-aa36-4482-a032-600d13b54a5d"
      unitRef="usd">25000000</prct:DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn>
    <prct:LineOfCreditFacilityFinalPaymentFeePercentage
      contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA4Ng_1839a3e6-9981-4bc5-8ed1-c347fa7e0475"
      unitRef="number">0.06</prct:LineOfCreditFacilityFinalPaymentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i37a93df4a20d471fa73a04fadd763398_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA5NA_357ce054-fc6b-48f2-9071-3685a9ae6ced"
      unitRef="number">0.0025</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <prct:LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent
      contextRef="ic9df1ea4e38a48c3958b823d207dc494_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjA5OQ_96a5e5df-7171-44d1-bf36-eee3a24139ec"
      unitRef="number">0.03</prct:LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent>
    <prct:LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent
      contextRef="ic9df1ea4e38a48c3958b823d207dc494_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjEwOQ_098b0c26-c3e6-455f-b2ef-c5afcafc07df"
      unitRef="number">0.02</prct:LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent>
    <prct:LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent
      contextRef="ic9df1ea4e38a48c3958b823d207dc494_I20190930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjExOQ_f90f0195-594a-4fee-8d0f-4f27b3bafa9a"
      unitRef="number">0.01</prct:LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent>
    <prct:LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget
      contextRef="i37a93df4a20d471fa73a04fadd763398_D20210101-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjEzNQ_df69b854-41dc-45ed-9910-9196253355fe"
      unitRef="usd">200000000</prct:LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget>
    <prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn
      contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjQxOQ_123912d6-489d-4f56-9cf2-3cada7ffd8ed"
      unitRef="usd">1000000</prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn>
    <prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn
      contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjQzMw_7c3bb320-2567-43de-b8ac-7886b3cdfba5"
      unitRef="usd">2000000</prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn>
    <prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn
      contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjQ0OQ_6e27bebc-039f-41ec-8d6f-5c9d45644bf7"
      unitRef="usd">2400000</prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn>
    <prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn
      contextRef="id1237e90024844c78a16dad0cbdc499c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80Ni9mcmFnOmY0MmVkMDBkYWQxYjRjYWNhMGQ5ZGRlZjkxNjllYmNlL3RleHRyZWdpb246ZjQyZWQwMGRhZDFiNGNhY2EwZDlkZGVmOTE2OWViY2VfMTY0OTI2NzQ0NjQ2Mw_1dd9c9b5-8779-4026-aafc-fb10f54ccce5"
      unitRef="usd">3000000</prct:LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfOTM0NTg0ODgzOTgxOQ_8ac2b1ee-9d8f-492e-90d9-937c8e183951">Redeemable Convertible Preferred Stock Warrant Liability &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Warrants to purchase shares of redeemable convertible preferred stock outstanding and exercisable are as follows (in thousands, except per share data):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.621%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.484%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.473%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.523%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.477%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shares Outstanding at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value at&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:10pt"&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Dates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Initial&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:10pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Issuance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Series&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Jun 2017&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Jun 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2015, in connection with the issuance of convertible notes, the Company issued 869,842 redeemable convertible preferred stock warrants that were exercisable into Series D redeemable convertible preferred stock immediately, with $5.08 exercise price and expiration in five years. During the three and nine months ended September 30, 2020, warrants for 531,423 and 651,328 shares were exercised, respectively, and none were outstanding at December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, in connection with the issuance of convertible notes, the Company issued 108,145 redeemable convertible preferred stock warrants that were exercisable into Series E or the next round of redeemable convertible preferred stock. During the and three and nine months ended September 30, 2021, 62,454 warrants were exercised and the remaining unexercised warrants expired, none were outstanding at September&#160;30, 2021. During the three and nine months ended September 30, 2020, no warrants were exercised.&lt;/span&gt;&lt;/div&gt;Redeemable Convertible Preferred Stock &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s redeemable convertible preferred stock are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Series&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shares &lt;br/&gt;Issued and Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying &lt;br/&gt;Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,243,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,104,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,841,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,543,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,564,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,564,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;8,245,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,547,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;36,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;8,825,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;8,414,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;115,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,263,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,226,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;76,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26,983,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;25,402,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;243,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon the completion of the Company&#x2019;s IPO in September 2021, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock and it reclassified $329.5 million of redeemable convertible preferred stock to additional paid-in capital on our condensed consolidated balance sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2020, an aggregate of $1.5 million shares of redeemable convertible preferred stock was converted to common stock as requested by the holder. The corresponding carrying value was reclassified from redeemable convertible preferred stock to common stock and additional paid in capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series G Redeemable Convertible Preferred Stock &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021, the Company issued 4,447,530&#160;shares of Series&#160;G redeemable convertible preferred stock for gross proceeds of $85.0 million. Issuance costs totaled $0.3 million and were recorded as an offset to gross proceeds.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Series F Redeemable Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July and August 2020, the Company issued 5,226,969 shares of Series F redeemable convertible preferred stock for gross proceeds of $77.0 million. Issuance costs totaled $0.5 million and were recorded as an offset to gross proceeds. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s redeemable convertible preferred stock terms were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Series&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation&lt;br/&gt;Preference&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8%&lt;br/&gt;Dividend&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs. A redemption event would only occur upon the liquidation or winding up of the Company, a greater than 50% change in control, or sale of substantially all of the assets of the Company. As the redemption event was outside the control of the Company, all shares of redeemable convertible preferred stock were presented outside of permanent equity. Further, the Company had determined the carrying values of the redeemable convertible preferred stock should not be adjusted to the redemption value of such shares, since it was uncertain whether or when a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;redemption event would occur. Subsequent adjustments to increase the carrying values of the redeemable convertible preferred stock to the redemption values would have been made when it became probable that such redemption would occur. As of September&#160;30, 2021, no shares of redeemable convertible preferred stock were outstanding, and as of December&#160;31, 2020, it was not probable that such redemption would occur.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Dividends &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The holders of the Series D, E, F and G redeemable convertible preferred stock, in preference to the holders of Series A, B and C redeemable convertible preferred stock and common stock, were entitled to receive noncumulative dividends at the rate of 8% per share of the original issuance price, when and as declared by the board of directors. After the payment of any dividends to holders of Series D, E, F and G redeemable convertible preferred stock, and in preference to the holders of common stock, the holders of Series A, B, and C redeemable convertible preferred stock would have been entitled to receive noncumulative dividends at the rate of 8% per share of the original issuance price, when and as declared by the board of directors. No dividends were declared and payable for the nine months ended September 30, 2021 and year ended December&#160;31, 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the event of any liquidation, dissolution, or winding-up of the Company, including a merger, acquisition, or sale of assets, as defined in the certificate of incorporation, each holder of Series G redeemable convertible preferred stock was entitled to receive a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C, D, E or F redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series G redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the full payment of the liquidation preference to the holders of Series G redeemable convertible preferred stock, each holder of Series F redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C, D or E redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series F redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the full payment of the liquidation preference to the holders of Series F redeemable convertible preferred stock, each holder of Series E redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C or D redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series E redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the full payment of the liquidation preference to the holders of Series E redeemable convertible preferred stock, each holder of Series D redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B or C redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series D redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the full payment of the liquidation preference to the holders of Series D redeemable convertible preferred stock, each holder of Series A, B and C redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of common stock. If the assets of the Company were insufficient to make payment in full to all holders of Series A, B or C redeemable convertible preferred stock, then the assets or consideration would have been distributed ratably among &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;After the payment of the full liquidation preference to holders of redeemable convertible preferred stock, the remaining assets of the Company legally available for distribution would have been distributed ratably to the holders of the common stock. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Voting &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each holder had the right to one vote for each share of common stock into which such redeemable convertible preferred stock would have been converted. So long as any shares of redeemable convertible preferred stock were outstanding, the Company was prohibited, without first obtaining the approval of more than 50% of the holders of redeemable convertible preferred stock then outstanding, voting together as a separate class to (a) amend certificate of incorporation in any way that would materially and adversely alter or change the rights, preferences, or privileges of the series preferred stock or (b) increase the total number of authorized shares of any Series Preferred stock. Additionally, the vote of at least a majority of the holders of Series D, E, F and G redeemable convertible preferred stock was needed to materially and adversely affect the rights of such holders of each series, including increasing or decreasing the number of authorized shares of Series D, E, F and G redeemable convertible preferred stock, as applicable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Redemption &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The redeemable convertible preferred shares were not mandatorily redeemable. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Conversion &lt;/span&gt;&lt;/div&gt;Upon the completion of the Company&#x2019;s IPO in September 2021, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock and it reclassified $329.5 million of redeemable convertible preferred stock to additional paid-in capital on our condensed consolidated balance sheet.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i0a6641bdf6a04d2a9f8abd5a3282a1c4_I20150731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC04LTEtMS0zNDQwMQ_11ba3427-7f9f-4863-becc-2131cc8bb163"
      unitRef="usdPerShare">13.73</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ib8ca34d460bd431e9f40af8ba7f4941d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC0xMC0xLTEtMzQ0MDE_9665bd98-ec0b-4fe0-a2a3-76a5113c9289"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="if5da641970b84172a5c935038a6a1c8e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC0xMi0xLTEtMzQ0MDE_0c470a4d-01e9-4195-a34a-db9c2291992f"
      unitRef="shares">72000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ibecb2734dfdd4390b231ca7dcd3bc7eb_I20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC0xNi0xLTEtMzQ0MDE_be5995b8-8b14-4679-98c4-6a81273214cb"
      unitRef="usd">763000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="ib8ca34d460bd431e9f40af8ba7f4941d_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC0xOC0xLTEtMzQ0MDE_a7554b3a-eb93-43bc-b818-62c4cee971e3"
      unitRef="usd">0</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="if5da641970b84172a5c935038a6a1c8e_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RhYmxlOjkwMTlkMGE4NWIzODQ2MWZhOWVjZTU5Yzg3NWM2NjY2L3RhYmxlcmFuZ2U6OTAxOWQwYTg1YjM4NDYxZmE5ZWNlNTljODc1YzY2NjZfNC0yMC0xLTEtMzQ0MDE_0ca8c1b7-b9e2-4127-bfb7-012113ed7c2f"
      unitRef="usd">177000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="ifc65b7919fd243f887cb7aa91fed512f_I20150731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfMTA5OTUxMTYyOTY2Mw_b8fa5185-8dc2-4d0b-ab84-f6bdc816d18c"
      unitRef="shares">869842</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="ifc65b7919fd243f887cb7aa91fed512f_I20150731"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfMTA5OTUxMTYyOTY3MQ_f351feae-eb5e-44ec-8d5a-16705adf5d9e"
      unitRef="usdPerShare">5.08</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="ifc65b7919fd243f887cb7aa91fed512f_I20150731"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfOTM0NTg0ODgzOTgxNg_b72c731d-1f7e-4951-9bb7-c42e25348290">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i869c38d090bb4baa8be1f5e855808baa_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDgzMQ_7f635955-d7b1-419c-9da0-604a34fbd54d"
      unitRef="shares">531423</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i103b94ebee224533bc1827781430d1ba_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfMTA5OTUxMTYyOTcxMA_4d81142f-8544-447e-af57-53cce89b75ee"
      unitRef="shares">651328</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i4d86103fd3bc4740a8b6c0bfaf50e9e0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxMzc4Ng_bf6a398c-6d51-41bf-87d2-a6f84e81b60b"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i90bf229ad34d4baba483ea11a398bc08_I20170630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfMTA5OTUxMTYyOTcyMA_dcf4a815-c638-450d-842a-5275b6f9e3df"
      unitRef="shares">108145</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i821880a0f0ea457fb74d98beb2145b75_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDgxNg_a79c51b0-7c59-4539-90a6-fb3299291210"
      unitRef="shares">62454</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i4acb9ad050634e849a2a2923e0940cae_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDgxNg_ce90b69b-fe8a-4a11-81d2-51c3d730e7c7"
      unitRef="shares">62454</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ide057d850a674c1faa90ee7654a9dcba_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDgzNQ_750e6288-cab8-463a-882b-89c41a21962f"
      unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i927e6688e0294af2a421eef76a378dca_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDY5Nw_1e4c64d4-a08e-4c75-b979-1a254fafbb10"
      unitRef="shares">0</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises
      contextRef="i3019d42f68fb44eaa750274de9c831ec_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF80OS9mcmFnOjViMjQ1ZDg2OTFkMTQyZGQ5ZGRhZTMzMzY1ZDQxZTM1L3RleHRyZWdpb246NWIyNDVkODY5MWQxNDJkZDlkZGFlMzMzNjVkNDFlMzVfNDM5ODA0NjUxNDY5Nw_3e40aa1b-f056-4806-9b4b-fd2d659cded0"
      unitRef="shares">0</prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises>
    <us-gaap:TemporaryEquityTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfOTM0NTg0ODg0Njg5NA_a097f9b7-ee41-4fae-81fe-d8855fd099d1">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s redeemable convertible preferred stock are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.156%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Series&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shares&lt;br/&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Shares &lt;br/&gt;Issued and Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Carrying &lt;br/&gt;Value &lt;br/&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,243,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,104,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;2,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,841,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,543,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,564,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;1,564,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,073&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;8,245,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;7,547,542&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;36,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;8,825,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;8,414,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;115,229&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,263,157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;5,226,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;76,488&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;26,983,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;25,402,402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"&gt;243,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s redeemable convertible preferred stock terms were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Series&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Liquidation&lt;br/&gt;Preference&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;8%&lt;br/&gt;Dividend&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;A&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.5175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;B&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;C&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;D&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.0825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;E&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;F&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;G&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.1116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ied497de295f14e1f827bd811b22ff9f1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMy03LTEtMS0zNDQwMQ_880b0e92-93a3-4805-b8e9-99589d721a4d"
      unitRef="shares">1243223</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ied497de295f14e1f827bd811b22ff9f1_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMy05LTEtMS0zNDQwMQ_fcb70220-08ff-4dd7-b091-c7eb4874eb60"
      unitRef="shares">1104728</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ied497de295f14e1f827bd811b22ff9f1_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMy0xMS0xLTEtMzQ0MDE_027b234a-9584-4564-9f08-101777ff9e32"
      unitRef="usd">2781000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="ie352732829a944e8bcad696ed9555ae7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNC03LTEtMS0zNDQwMQ_a08d9678-3389-4837-938c-b5713859cf26"
      unitRef="shares">1841805</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ie352732829a944e8bcad696ed9555ae7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNC05LTEtMS0zNDQwMQ_6528e1f7-8ca0-435c-a93f-57c42385d02b"
      unitRef="shares">1543804</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ie352732829a944e8bcad696ed9555ae7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNC0xMS0xLTEtMzQ0MDE_416555f2-f8c8-4805-abb1-d8fd7ff86b78"
      unitRef="usd">5404000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="id0c5306798ce4d5cbf19af58bc03c7b0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNS03LTEtMS0zNDQwMQ_6ff4fe39-1d06-4b9e-8b70-248ceffd71b8"
      unitRef="shares">1564851</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="id0c5306798ce4d5cbf19af58bc03c7b0_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNS05LTEtMS0zNDQwMQ_ca658b3d-b6bc-4208-b629-621cd1d90652"
      unitRef="shares">1564851</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="id0c5306798ce4d5cbf19af58bc03c7b0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNS0xMS0xLTEtMzQ0MDE_75e71ac8-9b90-4df1-a88a-f98c62ec720e"
      unitRef="usd">7073000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i9144a17da8024a6fa09ae89276a70ce7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNi03LTEtMS0zNDQwMQ_9dc536df-5a99-42e6-9a32-9cae8801e191"
      unitRef="shares">8245295</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i9144a17da8024a6fa09ae89276a70ce7_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNi05LTEtMS0zNDQwMQ_d38023d1-36bd-4106-be38-2e420059e16d"
      unitRef="shares">7547542</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i9144a17da8024a6fa09ae89276a70ce7_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNi0xMS0xLTEtMzQ0MDE_9ea328e1-972c-460f-bfd9-bd321bc7ec4c"
      unitRef="usd">36879000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i86acacb511a247ad99b9d153e72b9538_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNy03LTEtMS0zNDQwMQ_4813201e-2f5f-41f3-a114-5f520536aaa0"
      unitRef="shares">8825653</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i86acacb511a247ad99b9d153e72b9538_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNy05LTEtMS0zNDQwMQ_36adcec8-9c63-43c5-937e-c55075f7a68e"
      unitRef="shares">8414496</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i86acacb511a247ad99b9d153e72b9538_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfNy0xMS0xLTEtMzQ0MDE_3ebd8b70-f0e4-4e09-b198-88393a3efc50"
      unitRef="usd">115229000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i43040eb9775b4ce6978553e3936f3b76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfOC03LTEtMS0zNDQwMQ_30cca840-ca7c-449f-91b8-add0c290d4e4"
      unitRef="shares">5263157</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i43040eb9775b4ce6978553e3936f3b76_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfOC05LTEtMS0zNDQwMQ_e07c03df-d3c4-4c59-b68c-46717346d67f"
      unitRef="shares">5226981</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i43040eb9775b4ce6978553e3936f3b76_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfOC0xMS0xLTEtMzQ0MDE_249a0865-a8c1-4854-8818-24b32f28e3a6"
      unitRef="usd">76488000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:TemporaryEquitySharesAuthorized
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMTAtNy0xLTEtMzQ0MDE_4c09698a-89d3-4e70-95cc-1d4ce7598c24"
      unitRef="shares">26983984</us-gaap:TemporaryEquitySharesAuthorized>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMTAtOS0xLTEtMzQ0MDE_9f68defa-462a-4940-abd7-f8f455741741"
      unitRef="shares">25402402</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMTAtOS0xLTEtMzQ0MDE_e7a343b3-13ba-4bc5-877a-a5f740d2203b"
      unitRef="shares">25402402</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOmQ2MDg4YTBlMjg1NTRiZThiZDJlODI2ZTAxMDU0Y2M4L3RhYmxlcmFuZ2U6ZDYwODhhMGUyODU1NGJlOGJkMmU4MjZlMDEwNTRjYzhfMTAtMTEtMS0xLTM0NDAx_28f729e1-91d6-4573-b36b-5e9cb0ac4a78"
      unitRef="usd">243854000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMjIyMg_080bcfa1-af45-4252-af29-85b40683fa55"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMjIyMg_c67bb575-5e73-493b-9fee-a555ef693c48"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMjMyNQ_080bcfa1-af45-4252-af29-85b40683fa55"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMjMyNQ_c67bb575-5e73-493b-9fee-a555ef693c48"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyNjI2MQ_d5a4071a-8dff-415f-99a3-daf3c6f22d7c"
      unitRef="usd">329500000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ReclassificationsOfTemporaryToPermanentEquity
      contextRef="iea718991298743b4bf83f37c95537401_D20200701-20200731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMTA5OTUxMTYzNjczMw_c9929d62-b504-430f-8df9-ec2031da5e17"
      unitRef="usd">1500000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="iffd69005bc104609a9a1664e72d42b12_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMDkwMQ_349faa5a-de3a-4e26-80f1-71f3ca30aa65"
      unitRef="shares">4447530</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="i60e32c082ec946839e6d084bceac21a6_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMDk4NQ_f601c554-fa78-44ba-beec-198589810da6"
      unitRef="usd">85000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i60e32c082ec946839e6d084bceac21a6_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyNjI1MQ_921a44a1-d492-43e8-bd02-2c6df92c5e95"
      unitRef="usd">300000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:TemporaryEquitySharesIssued
      contextRef="i0e1b4a8dca7145f3b32508e4106c7c5b_I20200831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMTA5OTUxMTYzNjc0Ng_0bac72af-e7aa-444a-827c-0f252a5cb732"
      unitRef="shares">5226969</us-gaap:TemporaryEquitySharesIssued>
    <us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock
      contextRef="ib4185c7d482a4d408c70efb88bc2655b_D20200701-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMTA5OTUxMTYzNjc2Mg_83117bb6-69b6-4bc1-8e92-39b8ed8c9a4f"
      unitRef="usd">77000000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="ib4185c7d482a4d408c70efb88bc2655b_D20200701-20200831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyNjI1Ng_da9d1072-0ce4-4829-afe7-d6f9d454248f"
      unitRef="usd">500000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="i7aa86dd5567043e78dbeaa1869e5a838_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMS0xLTEtMS0zNDQwMQ_831d70ad-9ec6-4d8f-a42e-44b8f474c9e2"
      unitRef="usdPerShare">2517.5000</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <prct:TemporaryEquityDividends
      contextRef="i006123c4fa5d483a9e5463519395740b_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMS0zLTEtMS0zNDQwMQ_e89108e4-7ad7-4f00-83d0-e160b0bfd13c"
      unitRef="usdPerShare">201.4000</prct:TemporaryEquityDividends>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="i8f4ede9a776146de87f610eeb9409d5d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMi0xLTEtMS0zNDQwMQ_ed0a1d67-72a7-4586-8cdd-d72bdbe15c75"
      unitRef="usdPerShare">3237.6000</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <prct:TemporaryEquityDividends
      contextRef="i6f35ad14fa9c4afd9f180294ec2f5da1_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMi0zLTEtMS0zNDQwMQ_fde5a5cd-2fe6-4cd2-8814-c7c48d790dde"
      unitRef="usdPerShare">259</prct:TemporaryEquityDividends>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="i7de321a1c268402ab2b16faea56fdb02_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMy0xLTEtMS0zNDQwMQ_bff7d634-e66a-4ec8-8d05-2e4a8242ac13"
      unitRef="usdPerShare">4560</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <prct:TemporaryEquityDividends
      contextRef="i0e48ea26dceb47ec879e15c92c50d98e_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfMy0zLTEtMS0zNDQwMQ_c719cb51-f403-45c4-bd28-d8612d066450"
      unitRef="usdPerShare">364.8000</prct:TemporaryEquityDividends>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="i6e43455a41214ba3a21927edd8a4845d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNC0xLTEtMS0zNDQwMQ_3a1b500d-b22c-4efc-9007-8acad1ba21f0"
      unitRef="usdPerShare">5082.5000</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <prct:TemporaryEquityDividends
      contextRef="i3a5a5773de0d4f218c0162ed76015607_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNC0zLTEtMS0zNDQwMQ_14e8abc2-582a-43c8-a9b6-3bebe677092c"
      unitRef="usdPerShare">406.6000</prct:TemporaryEquityDividends>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="ib4321f4042af4f5cb3cf13c10279d51d_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNS0xLTEtMS0zNDQwMQ_e422c51e-67a8-44f3-acc6-17e2454318f9"
      unitRef="usdPerShare">13727.5000</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <prct:TemporaryEquityDividends
      contextRef="i4982cd5fdb3f431caecb3cf5474a994c_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNS0zLTEtMS0zNDQwMQ_feef5276-2c82-4073-88d9-a0085fa63fdd"
      unitRef="usdPerShare">1098.2000</prct:TemporaryEquityDividends>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="ice8d36bf1b564de9b741f74e90346ae9_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNi0xLTEtMS0zNDQwMQ_da701938-172c-48b3-a92f-ef8b8ef67629"
      unitRef="usdPerShare">14727.9000</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <prct:TemporaryEquityDividends
      contextRef="i9679f5b41fb34cf6abfae1649202e1c5_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNi0zLTEtMS0zNDQwMQ_61be8d50-10bb-4813-8c02-e5035057fccf"
      unitRef="usdPerShare">1178.2000</prct:TemporaryEquityDividends>
    <us-gaap:TemporaryEquityLiquidationPreferencePerShare
      contextRef="i74e05f7559ad44e2b03cdce92864389e_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNy0xLTEtMS0zNDQwMQ_6e874511-718b-48b2-a38d-9a7c2d376ce9"
      unitRef="usdPerShare">19111.6000</us-gaap:TemporaryEquityLiquidationPreferencePerShare>
    <prct:TemporaryEquityDividends
      contextRef="i3acfe77b8a2f44e79e9ac544b7465414_D20210101-20210930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RhYmxlOjczYjZmNTBjOWE5NjRlYTRhNzVmZTQwMjZlOGNhMGE0L3RhYmxlcmFuZ2U6NzNiNmY1MGM5YTk2NGVhNGE3NWZlNDAyNmU4Y2EwYTRfNy0zLTEtMS0zNDQwMQ_3a0a24ec-abd5-4f85-a7a0-005097a71bc6"
      unitRef="usdPerShare">1528.9000</prct:TemporaryEquityDividends>
    <prct:TemporaryEquityDividends
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMTA5OTUxMTYzNjgzMA_18a8e75a-568b-47c8-88cb-6f4f84807b5a"
      unitRef="usdPerShare">0.08</prct:TemporaryEquityDividends>
    <prct:TemporaryEquityDividends
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMTA5OTUxMTYzNjgzNQ_f6a900e4-b569-4b88-942b-c24ace890866"
      unitRef="usdPerShare">0.08</prct:TemporaryEquityDividends>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMjc0ODc3OTA3ODU0NA_884a4f45-53df-4cd3-b946-38b341bfb9f5"
      unitRef="usd">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <us-gaap:DividendsPayableCurrentAndNoncurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfMjc0ODc3OTA3ODU0NA_f91d7324-ea0b-4688-ac28-a307eea9edfe"
      unitRef="usd">0</us-gaap:DividendsPayableCurrentAndNoncurrent>
    <prct:TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfOTM0NTg0ODg0Njg5NQ_d4a17b0c-6d31-42ab-baae-b31ab5153aea"
      unitRef="customer">1</prct:TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMzUyOQ_080bcfa1-af45-4252-af29-85b40683fa55"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMzUyOQ_c67bb575-5e73-493b-9fee-a555ef693c48"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMzYzMg_080bcfa1-af45-4252-af29-85b40683fa55"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyMzYzMg_c67bb575-5e73-493b-9fee-a555ef693c48"
      unitRef="shares">29912264</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i7f3200e0d7344d89bcb322d6dd52c6bd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81Mi9mcmFnOjMyNjlkOWY0NjE5NDQ3ODRiNWMzOWYyODI3ODJiNjAwL3RleHRyZWdpb246MzI2OWQ5ZjQ2MTk0NDc4NGI1YzM5ZjI4Mjc4MmI2MDBfNDM5ODA0NjUyNjI2NQ_d5a4071a-8dff-415f-99a3-daf3c6f22d7c"
      unitRef="usd">329500000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfOTg5NTYwNDY3MDUzNw_6a9ecb3e-564d-4369-a764-7acbb99b4775">Stockholder&#x2019;s Equity &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Equity Incentive Award Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company adopted the 2021 Equity Incentive Award Plan (the &#x201c;2021 Plan&#x201d;), which allows for the granting of stock options and stock purchase rights to the employees, members of the board of directors, and consultants of the Company. A total of 3,303,910 shares of common stock were initially reserved for issuance under the 2021 Plan. Options granted under the 2021 Plan may be either incentive stock options (&#x201c;ISOs&#x201d;) or nonqualified stock options (&#x201c;NSOs&#x201d;). ISOs may be granted only to the Company&#x2019;s employees, including officers and directors who are also employees. NSOs may be granted to employees and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Options under the 2021 Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Granted options for newly hired employees usually vest over four years monthly with a one-year cliff vesting, and follow-on options vest monthly over four years with no cliff vesting. Options granted to consultants have various vesting schedules depending on the underlying consulting arrangement and anticipated period of service. As of September&#160;30, 2021, 3.2 million shares are available for grant under the 2021 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2008 Stock Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company ceased making awards under the 2008 Stock Plan upon the effective date of the Company&#x2019;s IPO. In 2008, the Company adopted the 2008 Stock Plan (the &#x201c;2008 Plan&#x201d;), which allows for the granting of stock options and stock purchase rights to the employees, members of the board of directors, and consultants of the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company. Options granted under the 2008 Plan may be either incentive stock options (&#x201c;ISOs&#x201d;) or nonqualified stock options (&#x201c;NSOs&#x201d;). ISOs may be granted only to the Company&#x2019;s employees, including officers and directors who are also employees. NSOs may be granted to employees and consultants. Options granted under the 2008 Plan will start expiring in August 2021. Options outstanding under the 2008 Plan will expire upon forfeiture. As of September&#160;30, 2021, 6.5 million options were outstanding under the 2008 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity and related information are as follows (options in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, the aggregate pre-tax intrinsic value of options outstanding and exercisable was $98.7 million and $6.9 million, respectively, and options outstanding were $218.5 million and $9.9 million, respectively. The aggregate pre-tax intrinsic value of options exercised was $5.1 million and $1.8 million during the nine months ended September&#160;30, 2021 and 2020, respectively. The aggregate pre-tax intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. The total fair value of options vested was $2.4 million and $1.2 million during the nine months ended September&#160;30, 2021 and 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company estimates the fair value of stock-based compensation on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model determines the fair value of stock-based payment awards based on the fair market value of the Company&#x2019;s common stock on the date of grant and is affected by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the fair market value of the Company&#x2019;s common stock, volatility over the expected term of the awards and actual and projected employee stock option exercise behaviors. The Company has opted to use the &#x201c;simplified method&#x201d; for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Due to the Company&#x2019;s limited operating history and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company generally selected companies with comparable characteristics to it, including enterprise value, stages of clinical development, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies&#x2019; shares during the equivalent period of the calculated expected term of the share-based payments. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company&#x2019;s common stock becomes available. The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company&#x2019;s stock options. The expected dividend assumption is based on the Company&#x2019;s history of not paying dividends and its expectation that it will not declare dividends for the foreseeable future. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation recognized, before taxes, is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amount of unearned stock-based compensation related to unvested employee stock-based payment awards as of September&#160;30, 2021 and December&#160;31, 2020 is $9.7 million and $6.5 million, respectively. The weighted-average period over which the unearned stock-based compensation is expected to be recognized as of September&#160;30, 2021 and December&#160;31, 2020 is 2.9 years for both periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the options granted to employees or directors was estimated as of the grant date using the Black-Scholes model assuming the weighted-average assumptions listed in the following table: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2021 Employee Stock Purchase Plan &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, the Company adopted the 2021 Employee Stock Purchase Plan (the &#x201c;2021 ESPP&#x201d;). The 2021 ESPP became effective on the effective date of the IPO. A total of 412,988 shares were initially reserved for issuance under the 2021 ESPP. Additionally, the number of shares of common stock reserved for issuance under the 2021 ESPP will increase automatically each year, beginning on January&#160;1, 2022, and continuing through and including January&#160;1, 2031, by the lesser of (1) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; or (2) such lesser number as determined by the Company&#x2019;s board of directors. The number of shares that may be issued under the 2021 ESPP shall not exceed a total of 10,526,315 shares. As of September 30, 2021, the Company has not implemented the 2021 ESPP. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Common Stock Warrants &lt;/span&gt;&lt;/div&gt;In May 2015, the Company issued warrants to purchase 12,308 shares of the Company&#x2019;s common stock in exchange for recruiting services. These warrants are exercisable immediately and expire on April 30, 2025. These common stock warrants of $15,000 were recorded as general and administrative expense and additional paid-in capital, as this warrant met the equity classification requirements. In November 2020, these warrants were fully exercised.</us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="ib06a5da95c7042d7b94adeb6559177b2_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUzMTY3Nw_c3d68eef-9080-4bfc-93ca-371bc367fdd8"
      unitRef="shares">3303910</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="icbaeafd33bbd4e6888b366b6103f762f_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTcwNQ_4c296e57-ad44-477c-bb20-ae6618347225">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="icbaeafd33bbd4e6888b366b6103f762f_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTcxMw_a90a7811-1525-4a41-8a39-51ed86259dbf"
      unitRef="number">1</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="i4ece297f570a4b82a416279c7fdc8910_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTcxOQ_6d0fe349-d171-4ee6-ad39-f5873553066b"
      unitRef="number">0.10</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="i775e9da970104587a8e43c336154fd28_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTcyNg_b3079ff4-9b45-4de4-a06f-47e102a39502"
      unitRef="number">1.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i06d1766f867741e985119b9837680d50_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTczOQ_be3de5b5-1a3b-41e1-9c47-90106ca1f233">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <prct:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod
      contextRef="i06d1766f867741e985119b9837680d50_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfOTg5NTYwNDY3MDUzOQ_5cf5522c-8176-4ee8-a9b4-78a40024f859">P1Y</prct:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i06d1766f867741e985119b9837680d50_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTc2MA_83ac284d-95c2-4074-ab4d-0ecc040d1276">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i1ecfd2799a3b484db31278a912812179_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxNzg4MQ_a8a54f9d-7ec9-4e20-b572-055c90a4b577"
      unitRef="shares">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="id017d7645c90419b8f85f400f2c78e30_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUzMTM4Nw_0a75e29a-8d17-4eff-a5bf-c62b07321128"
      unitRef="shares">6500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfOTM0NTg0ODg1NjY2Mw_b9ad5378-0d84-439e-a538-4875738231e8">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s stock option activity and related information are as follows (options in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,307)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(104)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i29a3508d251b4bde9f8eb210f942bfaa_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNC0xLTEtMS0zNDQwMQ_eaef181f-f33a-4465-bb93-d487d058c247"
      unitRef="shares">6507000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i29a3508d251b4bde9f8eb210f942bfaa_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNC0zLTEtMS0zNDQwMQ_7d63f4f8-3f59-4486-80df-e19d575fa3c4"
      unitRef="usdPerShare">3.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNS0xLTEtMS0zNDQwMQ_113a176b-f2d3-4801-b9a2-b811325eb15f"
      unitRef="shares">1511000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNS0zLTEtMS0zNDQwMQ_dd629a5e-2c55-4845-8c74-f433b5da3728"
      unitRef="usdPerShare">8.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNi0xLTEtMS0zNDQwMQ_f6045098-1f37-4182-a747-34efd4ad5d36"
      unitRef="shares">1307000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNi0zLTEtMS0zNDQwMQ_732b3e2b-4e2c-4ece-8837-e0545907015d"
      unitRef="usdPerShare">2.70</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNy0xLTEtMS0zNDQwMQ_8492448b-85cc-4689-a775-be53a276fc52"
      unitRef="shares">104000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfNy0zLTEtMS0zNDQwMQ_08632432-2f8d-4d2f-999f-5de361672c5c"
      unitRef="usdPerShare">6.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfOC0xLTEtMS0zNDQwMQ_3a39f25f-f1a4-4a7f-8ffe-07e167d2d03b"
      unitRef="shares">6607000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfOC0zLTEtMS0zNDQwMQ_f0cfeef6-6c02-4304-addf-f2b6034089fa"
      unitRef="usdPerShare">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfOS0xLTEtMS0zNDQwMQ_d5b18eb2-f837-4305-8544-c5727d4388ca"
      unitRef="shares">6607000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfOS0zLTEtMS0zNDQwMQ_209396ad-95da-4f6e-97ac-b4ebf497aa44"
      unitRef="usdPerShare">5.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfMTAtMS0xLTEtMzQ0MDE_53bd64dc-96da-471a-a68d-cadb387b6716"
      unitRef="shares">2885000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i10a6eebd2df541eca35c8a3094153817_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjlhNmRiZTcyMmU1ODRmOGJhOWZmMjUxYWJlMTkyMjdhL3RhYmxlcmFuZ2U6OWE2ZGJlNzIyZTU4NGY4YmE5ZmYyNTFhYmUxOTIyN2FfMTAtMy0xLTEtMzQ0MDE_3dbc46b8-887a-49a6-9e9d-4045a80557e2"
      unitRef="usdPerShare">3.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxNzkxMg_2f27d068-86e2-4546-866d-276a6db4977c"
      unitRef="usd">98700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTgyMg_84ba2973-86a1-4f8d-9fd7-98874e933872"
      unitRef="usd">6900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxNzkyNQ_459d7019-48ca-489d-ab0c-c50f12f4086c"
      unitRef="usd">218500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTg2OA_1a3ed788-6a24-462f-979e-6821fec8e84a"
      unitRef="usd">9900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTk0Mw_4c26ae1e-c989-4b33-9f25-31a1d34ddc88"
      unitRef="usd">5100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxODExMw_b55a49a6-ceb0-4101-9d22-9c04cfca2750"
      unitRef="usd">1800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxODE5NA_45884f6e-d486-41d0-95a3-d6e52d312c1f"
      unitRef="usd">2400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NTk3Mw_b73416d8-0ea7-471f-9012-a79ff36bc503"
      unitRef="usd">1200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfOTM0NTg0ODg1NjY2NA_5f1efe7e-8b06-4616-92ea-f760f84d72f9">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total stock-based compensation recognized, before taxes, is as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;689&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i12898071c0444fe7844142bb4d3cd49c_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfMy0xLTEtMS0zNDQwMQ_4432d410-a692-4d13-99e8-c715fd33b9e0"
      unitRef="usd">62000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iccd781125894469891eb522580c6b2aa_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfMy0zLTEtMS0zNDQwMQ_22152434-b5ce-4aa1-b288-228bbdf4a61f"
      unitRef="usd">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f72c2550a004f309da2bc458a30adfe_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfMy01LTEtMS0zNDQwMQ_d19390a7-1f22-468b-b59f-c76d8860e511"
      unitRef="usd">135000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i78b24385d55b4a209c528145906fa5ce_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfMy03LTEtMS0zNDQwMQ_2ec075c4-0ddd-4fb3-8dc7-28aadd2769ff"
      unitRef="usd">68000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i445258736c484e52b6ddb965454bb1ff_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNC0xLTEtMS0zNDQwMQ_bc6365ad-ede9-428f-9c74-b3a0c6bd9f02"
      unitRef="usd">174000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9c80643e4da242ecbd5c44667621fad4_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNC0zLTEtMS0zNDQwMQ_8bac306f-3277-40c9-8e9e-ffef511f4cc3"
      unitRef="usd">134000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5f0e6e6c797846fa8312b60ebb59afb3_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNC01LTEtMS0zNDQwMQ_e451badc-1cbf-46a2-9c55-83d5489b164a"
      unitRef="usd">482000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i190871b1575a4e8db9bd9f80d3702fa0_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNC03LTEtMS0zNDQwMQ_e36014ee-730a-4db3-b1a5-2eea833ae016"
      unitRef="usd">397000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iffd4490b13ce46d8825d6f990c341beb_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNS0xLTEtMS0zNDQwMQ_d5ed210b-3fa1-4ee7-b73b-fa4c8eb15291"
      unitRef="usd">689000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6bd6c00e464c4f16bf14f0e616cee1d1_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNS0zLTEtMS0zNDQwMQ_9a7efcd5-fbc3-4674-85a1-bccc838645c6"
      unitRef="usd">411000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i008a0e4e1310456bb44ece232d2da544_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNS01LTEtMS0zNDQwMQ_ae0100c3-633c-4c94-82e4-5ac1561f2fa7"
      unitRef="usd">1683000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i95da0a4005cc41b88796003dc99be3ea_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNS03LTEtMS0zNDQwMQ_e7295d58-e5b4-45a2-98fb-4396fcba82ba"
      unitRef="usd">1104000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNi0xLTEtMS0zNDQwMQ_c2a66db0-2319-4f71-ad14-53909cbd4fa9"
      unitRef="usd">925000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNi0zLTEtMS0zNDQwMQ_52dd6feb-15ce-4c21-8074-4c4d55cbf729"
      unitRef="usd">563000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNi01LTEtMS0zNDQwMQ_f38d4f2a-df1c-48c7-88e2-c42e606b13be"
      unitRef="usd">2300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOjNkNTRhMzhkODZhNTQ1MjdiMzMxYmQwMzY3OTNmYjMwL3RhYmxlcmFuZ2U6M2Q1NGEzOGQ4NmE1NDUyN2IzMzFiZDAzNjc5M2ZiMzBfNi03LTEtMS0zNDQwMQ_ec7bec39-29ef-4fbe-a0e0-f0299d40f1ef"
      unitRef="usd">1569000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NjAzNA_7dbc8570-af67-4e7c-b50a-1f44916e67f4"
      unitRef="usd">9700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUxODIzMQ_5ad4fb42-afde-460a-908a-c252f2040254"
      unitRef="usd">6500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ic2e662689b684020aedbed74e67c085f_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NjA2MQ_6d4d9dc9-8226-4ed9-bfb7-1e2b844e7f2f">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NjA2MQ_8f153139-236a-405a-b327-4867990f2393">P2Y10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfOTM0NTg0ODg1NjY2NQ_7938c9e5-7961-43ff-9867-7dd12cd5825f">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the options granted to employees or directors was estimated as of the grant date using the Black-Scholes model assuming the weighted-average assumptions listed in the following table: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.207%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2019&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend rate &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfMy0xLTEtMS0zNDQwMQ_3f010d6a-e2db-4924-a091-70e8848a17ad">P5Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i09198490d2f441a08b39181593f1f255_D20200701-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfMy0zLTEtMS0zNDQwMQ_e53f949b-1241-4187-8071-a1e863c67a88">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfMy01LTEtMS0zNDQwMQ_bda8b246-f601-45b5-90b9-ac97f7a3c2da">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfMy03LTEtMS0zNDQwMQ_9336cc65-6f6a-4fe4-ba80-0b90820520a6">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNC0xLTEtMS0zNDQwMQ_b4b6e10c-32d0-4700-a7f9-181139e9d43e"
      unitRef="number">0.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i09198490d2f441a08b39181593f1f255_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNC0zLTEtMS0zNDQwMQ_5e372d50-28f4-4331-81d7-aa3ca27e2ffd"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNC01LTEtMS0zNDQwMQ_0d38bfc2-0a7f-4875-a02c-f2ec1bbb80e8"
      unitRef="number">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNC03LTEtMS0zNDQwMQ_aa3e4073-1f11-4b1a-bae9-cc228292ce9a"
      unitRef="number">0.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNS0xLTEtMS0zNDQwMQ_062d582f-524d-4fe1-83ee-5c289092204f"
      unitRef="number">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i09198490d2f441a08b39181593f1f255_D20200701-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNS0zLTEtMS0zNDQwMQ_4cad327d-5792-4a55-88a4-fbdd21de74cd"
      unitRef="number">0.003</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNS01LTEtMS0zNDQwMQ_198591f8-7cea-4310-80d0-97a86086b8f9"
      unitRef="number">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNS03LTEtMS0zNDQwMQ_cbcd63b5-8c52-4759-8dae-52b72bf1e7c6"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNi0xLTEtMS0zNDQwMQ_5bc1680a-ca71-43ad-829c-d4a1885e37f0"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i09198490d2f441a08b39181593f1f255_D20200701-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNi0zLTEtMS0zNDQwMQ_5bc93d95-ab9d-43f5-9c60-4ca226b2b74d"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNi01LTEtMS0zNDQwMQ_53eca202-8e86-4ab0-aba3-1320edd331a8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNi03LTEtMS0zNDQwMQ_e5144c75-eaee-4f6b-a927-ad546d67c4c8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNy0xLTEtMS0zNDQwMQ_df76d7c3-954f-4f76-ab09-6fada56be3c4"
      unitRef="usdPerShare">7.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i09198490d2f441a08b39181593f1f255_D20200701-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNy0zLTEtMS0zNDQwMQ_8d024542-4f7b-42fc-adbc-b6b00061198a"
      unitRef="usdPerShare">2.41</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i69d76d77405240c68aef85b1fc24420e_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNy01LTEtMS0zNDQwMQ_3e7924c4-3672-466b-a78b-6c16e76e0414"
      unitRef="usdPerShare">3.88</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="i86de76510a264cb7ad9bf8117ff207ff_D20200101-20200930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RhYmxlOmJiMzczNTE1ODk2YjQ2OTM5MjVlNjM5ZjkxNjczOGJmL3RhYmxlcmFuZ2U6YmIzNzM1MTU4OTZiNDY5MzkyNWU2MzlmOTE2NzM4YmZfNy03LTEtMS0zNDQwMQ_9f5671bf-f56d-4a7b-bd60-3dcbb210cb8c"
      unitRef="usdPerShare">1.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i90a0eaa9861b47338cef7b3ddc5fa8d1_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUzMTY4OA_7fc3a503-41ba-4418-b9ae-ffd6982cc069"
      unitRef="shares">412988</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="i147dde6bfea84bb5a5a2eab1578869ea_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUzMTczMQ_db7d4db0-6223-465a-9ed6-b248da662586"
      unitRef="number">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7d2b70c21dbc4b32895eedfc71019388_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfNDM5ODA0NjUzMTc1MA_232d47b4-2fb1-4dce-a143-55992d04e9c7"
      unitRef="shares">10526315</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="i03b8cb9f698a47d698415757c8e483bf_D20150501-20150531"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NjA4NA_b1213f54-dec3-44ed-8221-5f38e4f7d3cc"
      unitRef="shares">12308</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="i5398d7157b274e53afc37f43c4fb9f1a_D20150501-20150531"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81NS9mcmFnOmRkYzExYzBlMmJjMTQ3ZmFiOGEwYjMyMTZmODkzZTA0L3RleHRyZWdpb246ZGRjMTFjMGUyYmMxNDdmYWI4YTBiMzIxNmY4OTNlMDRfMjc0ODc3OTA3NjA5OA_b6649c30-c063-4547-96f0-d4e1772d73df"
      unitRef="usd">15000</us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDEzMQ_81623619-fa47-453e-b42e-71bd94c881e6">Commitments and Contingencies &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantees and Indemnifications  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September&#160;30, 2021 and December&#160;31, 2020, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Facility Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2013, the Company entered into a three-year lease agreement for its current facility located in Redwood City, California. In 2018, the Company expanded the lease space and extended the lease agreement through October 2023. The lease agreement provides for an escalation of rent payments each year and the Company records rent expense on a straight-line basis over the term of the lease. Rent is payable monthly. As of September&#160;30, 2021 and December&#160;31, 2020, the remaining future minimum lease payments under this lease is $5.1 million and $6.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s adoption of ASC Topic 842, Leases, on January 1, 2020, the Company recorded a right-of-use leased asset of $6.0 million and a corresponding lease liability of $7.4 million and derecognized a deferred rent obligation of $1.4 million. The Company used its borrowing rate of 10% as its discount rate and the remaining operating lease term was 3.8 years. The results for the year ended December&#160;31, 2020 subsequent periods are presented under Topic 842.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense recognized under the lease, including additional rent charges for utilities, parking, maintenance, and real estate taxes, was $0.5 million for each of the three months ended September 30, 2021 and 2020, and $1.5 million for each of the nine months ended September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, the Company has future commitments of $55.1 million and $56.7 million from debt repayments and office space under a non-cancelable operating lease expiring October 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum annual operating lease and debt repayments are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest/unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest/unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, the Company&#x2019;s security deposit is in the form of, and recorded as, restricted cash. In January 2021, in connection with the Company&#x2019;s amended loan agreement with modified terms, the interest-only period was modified from 24 months beginning October 1, 2021 to 36 months &lt;/span&gt;&lt;/div&gt;beginning October 1, 2022, and accordingly, the current portion of the amount due was reclassified to non-current. Upon the completion of the Company raising over $50 million in its IPO in September 2021, interest-only payments were extended an additional 12 months followed by 12 months of amortization of principal and interest.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDEzMw_33d7ea78-808f-40a4-8a08-cfd657a22ef6">Commitments and Contingencies &lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Guarantees and Indemnifications  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#x2019;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September&#160;30, 2021 and December&#160;31, 2020, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Facility Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2013, the Company entered into a three-year lease agreement for its current facility located in Redwood City, California. In 2018, the Company expanded the lease space and extended the lease agreement through October 2023. The lease agreement provides for an escalation of rent payments each year and the Company records rent expense on a straight-line basis over the term of the lease. Rent is payable monthly. As of September&#160;30, 2021 and December&#160;31, 2020, the remaining future minimum lease payments under this lease is $5.1 million and $6.7 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Company&#x2019;s adoption of ASC Topic 842, Leases, on January 1, 2020, the Company recorded a right-of-use leased asset of $6.0 million and a corresponding lease liability of $7.4 million and derecognized a deferred rent obligation of $1.4 million. The Company used its borrowing rate of 10% as its discount rate and the remaining operating lease term was 3.8 years. The results for the year ended December&#160;31, 2020 subsequent periods are presented under Topic 842.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Rent expense recognized under the lease, including additional rent charges for utilities, parking, maintenance, and real estate taxes, was $0.5 million for each of the three months ended September 30, 2021 and 2020, and $1.5 million for each of the nine months ended September 30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, the Company has future commitments of $55.1 million and $56.7 million from debt repayments and office space under a non-cancelable operating lease expiring October 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum annual operating lease and debt repayments are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest/unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest/unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2021 and December&#160;31, 2020, the Company&#x2019;s security deposit is in the form of, and recorded as, restricted cash. In January 2021, in connection with the Company&#x2019;s amended loan agreement with modified terms, the interest-only period was modified from 24 months beginning October 1, 2021 to 36 months &lt;/span&gt;&lt;/div&gt;beginning October 1, 2022, and accordingly, the current portion of the amount due was reclassified to non-current. Upon the completion of the Company raising over $50 million in its IPO in September 2021, interest-only payments were extended an additional 12 months followed by 12 months of amortization of principal and interest.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="id13f0093eaaa458181bd8b489d0fa71e_I20130731"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDI5OA_55ec6fe8-defb-46b7-8b84-85627cc00697">P3Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i51e569731e334d18b46ce30b6992446f_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfNDM5ODA0NjUxNDkwNw_5eb6e195-07f5-4e0f-92c1-58d80e7dddbc"
      unitRef="usd">5100000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i0882844190cf46d882aec93c3be61895_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTE0MQ_c65558e3-9150-4b81-97fd-edeae409ce0c"
      unitRef="usd">6700000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibcde0d5c3d85476888c4854555b60153_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTMxMw_b52d336f-1d23-4fe0-b1f7-df6f7c34390d"
      unitRef="usd">6000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibcde0d5c3d85476888c4854555b60153_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTMyOA_1c4e9317-e252-4695-90ea-4a6e88c0a06d"
      unitRef="usd">7400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ibcde0d5c3d85476888c4854555b60153_I20200101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTM0Mw_d6598a22-ba08-4b78-8149-8704f3d59327"
      unitRef="usd">-1400000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTM1Mg_00dc5f65-b94f-4dc6-b52d-7b5e86a863c2"
      unitRef="number">0.10</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDI4NA_57d32ff8-7d65-46ae-8359-d1b34d77655f">P3Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseExpense
      contextRef="i03c93ab9afcc45e7ab42fe99738fb141_D20200701-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTQwMw_18d4ab6a-3710-40e3-8365-6d16cba6ae55"
      unitRef="usd">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTQwMw_c9eba0ea-2c5c-4349-a579-1ba2e343d38c"
      unitRef="usd">500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfNDM5ODA0NjUxNTI3MQ_aadeb2d1-bac6-4ac3-bce6-af82ea636d15"
      unitRef="usd">1500000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="i696d38fd73924a4483f8e27b5e98bfcc_D20200101-20200930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfNDM5ODA0NjUxNTI3MQ_d694bdc8-ac52-45ab-89f0-b596bbfbe3f0"
      unitRef="usd">1500000</us-gaap:OperatingLeaseExpense>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfNDM5ODA0NjUxNTA3Ng_cabfa55e-b95f-4ef9-aa52-82f309d1b3ea"
      unitRef="usd">55100000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfMTA5OTUxMTYzMTQ3NA_330a618c-cb22-41b2-ae79-64e501669b62"
      unitRef="usd">56700000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDEzNQ_38f61a79-19bc-4672-94d5-4751ef3a549a">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum annual operating lease and debt repayments are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest/unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest/unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDEzNQ_964a0d8b-17b1-4c76-b7ff-14145524d05e">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Future minimum annual operating lease and debt repayments are as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest/unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(559)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(238)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(797)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,032)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.791%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.842%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.843%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Minimum Lease Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Debt Repayments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,695&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total minimum payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,716&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: amount representing interest/unamortized debt discount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(912)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,042)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,954)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Present value of future payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,259)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,096&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMS0xLTEtMS00MzAxMA_4eb5c2eb-6943-4ae8-b186-bebae51bd44f"
      unitRef="usd">604000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMS0zLTEtMS00MzQzNA_0f6021ac-d9f2-4d48-a8b1-28e53fa2d52a"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMS01LTEtMS00MzQzOQ_9f0cd5ff-ad60-4bab-a104-6a0a39539394"
      unitRef="usd">604000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMi0xLTEtMS00MzAxMA_3788c145-dad9-4fa4-a0d4-ac706f397b04"
      unitRef="usd">2445000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMi0zLTEtMS00MzQzNA_f069e5d7-6d57-4e3b-bca8-1cc25005b0fb"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMi01LTEtMS00MzQzOQ_ab2b5c80-69d0-4c26-859f-9c2812b6dffe"
      unitRef="usd">2445000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMy0xLTEtMS00MzAxMA_5b51138b-222f-42e3-84eb-ef3f637ab7b5"
      unitRef="usd">2092000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMy0zLTEtMS00MzQzNA_d1cca2b9-272f-4136-b187-17b8964d41ed"
      unitRef="usd">12500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfMy01LTEtMS00MzQzOQ_1611ca6d-1683-40fa-a862-eb23d98e5528"
      unitRef="usd">14592000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNC0xLTEtMS00MzAxMA_44edd4b1-e648-44e1-9368-589107f9e243"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNC0zLTEtMS00MzQzNA_bf5c25e4-c541-4a93-9242-12dbb7e3a794"
      unitRef="usd">37500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNC01LTEtMS00MzQzOQ_c98cff6e-9212-4b96-ad70-3425d9f5b1cf"
      unitRef="usd">37500000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNS0xLTEtMS00MzAxMA_42ff0971-d9b1-4ed1-a65e-ea6af02e6a9a"
      unitRef="usd">5141000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNS0zLTEtMS00MzQzNA_e3e89e47-e30c-43ed-a59d-c368d6cc12db"
      unitRef="usd">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNS01LTEtMS00MzQzOQ_06077f6d-15d2-4654-9c27-d88216e5d140"
      unitRef="usd">55141000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNi0xLTEtMS00MzAxMA_f931f5c8-b475-4cf6-8bdf-478940d0ee1c"
      unitRef="usd">559000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNi0zLTEtMS00MzQzNA_d5fd863c-0def-4167-a1a9-22be451684eb"
      unitRef="usd">238000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNi01LTEtMS00MzQzOQ_aa465ec9-a291-4b93-b326-09b8b3adc673"
      unitRef="usd">797000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNy0xLTEtMS00MzAxMA_08ca80c3-524b-45dd-a399-1285dca66f77"
      unitRef="usd">4582000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LongTermDebt
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNy0zLTEtMS00MzQzNA_ced637d5-c536-4d5a-a8d0-7fda2835983d"
      unitRef="usd">49762000</us-gaap:LongTermDebt>
    <prct:OperatingLeaseLiabilityAndLongTermDebt
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfNy01LTEtMS00MzQzOQ_774cae75-1fbd-4fd9-9a59-0428583224f2"
      unitRef="usd">54344000</prct:OperatingLeaseLiabilityAndLongTermDebt>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOC0xLTEtMS00MzAxMA_e26fd55c-fc5a-4bf9-9068-c96662c573db"
      unitRef="usd">2032000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOC0zLTEtMS00MzQzNA_a254b81f-3082-4a5d-9bc5-a48dc3a9e059"
      unitRef="usd">0</us-gaap:LongTermDebtCurrent>
    <prct:OperatingLeaseLiabilityAndLongTermDebtCurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOC01LTEtMS00MzQzOQ_f3d6bf78-e620-4026-a850-4b5506e10f3e"
      unitRef="usd">2032000</prct:OperatingLeaseLiabilityAndLongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOS0xLTEtMS00MzAxMA_59fa4b63-d3a5-40a4-8aab-3ac432641c1f"
      unitRef="usd">2550000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOS0zLTEtMS00MzQzNA_87c6d59d-90f4-4069-92f1-d71a5d26fa90"
      unitRef="usd">49762000</us-gaap:LongTermDebtNoncurrent>
    <prct:OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities
      contextRef="i06ef5a3561da4e20a7b17f4ed74847c6_I20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOmMwYzcwOWQ5MmI2MjQ3YjhhOTI5ODJhNTEyZWQzMmFmL3RhYmxlcmFuZ2U6YzBjNzA5ZDkyYjYyNDdiOGE5Mjk4MmE1MTJlZDMyYWZfOS01LTEtMS00MzQzOQ_52704f6a-37d2-4f19-b9fa-39aa325d8d55"
      unitRef="usd">52312000</prct:OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMS0xLTEtMS0zNDQwMQ_683341c6-4e16-4798-ab24-d61d4fffce92"
      unitRef="usd">2179000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMS0zLTEtMS0zNDQwMQ_1940ca92-d3af-45a3-b0a6-85b3dea48714"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMS01LTEtMS0zNDQwMQ_e01dc8a7-d746-47a8-88b5-aac81e30d0c1"
      unitRef="usd">2179000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMi0xLTEtMS0zNDQwMQ_996515fd-c936-4fc0-b898-c0be0d862b8c"
      unitRef="usd">2445000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMi0zLTEtMS0zNDQwMQ_44e5a509-c1d2-4655-98bc-884e85edbce6"
      unitRef="usd">6250000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMi01LTEtMS0zNDQwMQ_0bfef07c-217a-4f6e-a268-d5a64bee9020"
      unitRef="usd">8695000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMy0xLTEtMS0zNDQwMQ_76604ccf-3337-43a7-9c7e-733d451f040c"
      unitRef="usd">2092000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMy0zLTEtMS0zNDQwMQ_8e97c37d-0a82-45df-ab4d-36b0f4c8e8ff"
      unitRef="usd">25000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfMy01LTEtMS0zNDQwMQ_9d9b0a06-d832-4218-8698-b15a8e84f584"
      unitRef="usd">27092000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNC0xLTEtMS0zNDQwMQ_683d141b-2ce5-4b58-affc-4f48817c60a7"
      unitRef="usd">0</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNC0zLTEtMS0zNDQwMQ_21c932bb-7914-45e5-97d7-78619b40f97e"
      unitRef="usd">18750000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNC01LTEtMS0zNDQwMQ_759150ab-01ce-48c2-829f-0714a4997827"
      unitRef="usd">18750000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNS0xLTEtMS0zNDQwMQ_0bf551ae-5339-4a19-bd50-64f682efd441"
      unitRef="usd">6716000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNS0zLTEtMS0zNDQwMQ_f069df29-2eea-4051-bc25-b660d3e3322c"
      unitRef="usd">50000000</us-gaap:DebtInstrumentCarryingAmount>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNS01LTEtMS0zNDQwMQ_44e47bb8-d36b-4f9b-8ebe-fc6caaf9c970"
      unitRef="usd">56716000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityGross>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNi0xLTEtMS0zNDQwMQ_fb8fdbd3-36e6-41fe-af6d-6460e1a2dec7"
      unitRef="usd">912000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNi0zLTEtMS0zNDQwMQ_f4f3add5-4cab-4345-a698-fdfe02689912"
      unitRef="usd">1042000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <prct:OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNi01LTEtMS0zNDQwMQ_a752189b-aa46-4948-bb69-c09136eb458b"
      unitRef="usd">1954000</prct:OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNy0xLTEtMS0zNDQwMQ_44fcfc4d-f45d-43db-8263-185e195ade4a"
      unitRef="usd">5804000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LongTermDebt
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNy0zLTEtMS0zNDQwMQ_66b6e8bc-5a38-40c5-9883-a9750dd88beb"
      unitRef="usd">48958000</us-gaap:LongTermDebt>
    <prct:OperatingLeaseLiabilityAndLongTermDebt
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfNy01LTEtMS0zNDQwMQ_481e9f34-ba56-42f1-85a7-3685530d3695"
      unitRef="usd">54762000</prct:OperatingLeaseLiabilityAndLongTermDebt>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOC0xLTEtMS0zNDQwMQ_3b6aec82-9409-49b9-8f65-9f2109bf88b5"
      unitRef="usd">1708000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOC0zLTEtMS0zNDQwMQ_c53a258d-b3cf-4df4-a8cc-0db957a3b7c1"
      unitRef="usd">4551000</us-gaap:LongTermDebtCurrent>
    <prct:OperatingLeaseLiabilityAndLongTermDebtCurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOC01LTEtMS0zNDQwMQ_ae6d2093-4ff0-46d7-aa03-b0d6aa4b3694"
      unitRef="usd">6259000</prct:OperatingLeaseLiabilityAndLongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOS0xLTEtMS0zNDQwMQ_ec5c51a3-29cf-43a5-9584-4d3b231031b8"
      unitRef="usd">4096000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOS0zLTEtMS0zNDQwMQ_ab39ea0b-d858-4346-bfa1-c4c15134e0f9"
      unitRef="usd">44407000</us-gaap:LongTermDebtNoncurrent>
    <prct:OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities
      contextRef="i894ed293fa3742e3a04a1df94f575575_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RhYmxlOjBmNmRhOTIzZDBhYjQwMTliOTU1MmE4MDQyY2RkMjgxL3RhYmxlcmFuZ2U6MGY2ZGE5MjNkMGFiNDAxOWI5NTUyYTgwNDJjZGQyODFfOS01LTEtMS0zNDQwMQ_514a85b5-783f-4b37-8340-326f80edfa5e"
      unitRef="usd">48503000</prct:OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities>
    <prct:DebtInstrumentInterestOnlyPeriod
      contextRef="i6c89c558562342acb1a97bac5a006107_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDI4NQ_f393b504-375d-42e8-8b9d-c81f22b6adc1">P24M</prct:DebtInstrumentInterestOnlyPeriod>
    <prct:DebtInstrumentInterestOnlyPeriod
      contextRef="i9c6bcd3416cb4dff84912e6e977f510e_D20210101-20210131"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfOTM0NTg0ODg0MDI4Ng_b6afac38-4666-4f77-a2d3-db7e21812ba5">P36M</prct:DebtInstrumentInterestOnlyPeriod>
    <prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount
      contextRef="i7425a248d0c54625b60e82800726ba6e_D20210901-20210930"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmQ2ODk2ZGJkMjIxYTQ3MTQ4NWNlMTQ5MTk2ZmJjZjQ0L3NlYzpkNjg5NmRiZDIyMWE0NzE0ODVjZTE0OTE5NmZiY2Y0NF81OC9mcmFnOmU0NzE1NTRiNzJhMzQwYmU5NDIxYmU5MzBmYThlNDQ4L3RleHRyZWdpb246ZTQ3MTU1NGI3MmEzNDBiZTk0MjFiZTkzMGZhOGU0NDhfNDM5ODA0NjUxNTM2MA_6a77f5ea-34ce-4852-8864-21b4cbcd6463"
      unitRef="usd">50000000</prct:DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278656616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40797<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROCEPT BioRobotics Corporation<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">26-0199180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">900 Island Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">232-7200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, $0.00001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PRCT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,496,831<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001588978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871281963576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 320,484<span></span>
</td>
<td class="nump">$ 100,130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">6,353<span></span>
</td>
<td class="nump">1,549<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">10,401<span></span>
</td>
<td class="nump">6,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,232<span></span>
</td>
<td class="nump">1,653<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">339,470<span></span>
</td>
<td class="nump">110,256<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">5,731<span></span>
</td>
<td class="nump">8,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="nump">4,641<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">1,818<span></span>
</td>
<td class="nump">2,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">351,463<span></span>
</td>
<td class="nump">125,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,590<span></span>
</td>
<td class="nump">1,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">4,875<span></span>
</td>
<td class="nump">4,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease &#8211; current portion</a></td>
<td class="nump">2,032<span></span>
</td>
<td class="nump">1,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">848<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Convertible preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">2,834<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">14,179<span></span>
</td>
<td class="nump">14,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion</a></td>
<td class="nump">49,762<span></span>
</td>
<td class="nump">44,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease &#8211; non-current portion</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">4,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Loan facility derivative liability</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">68,151<span></span>
</td>
<td class="nump">65,011<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock issuable in series, $0.00001 par value;</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">243,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000 and none shares authorized, no shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value: 300,000 and 40,000 shares authorized, 43472 and 4,713 shares issued and outstanding as of September&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">526,526<span></span>
</td>
<td class="nump">18,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(41)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(243,173)<span></span>
</td>
<td class="num">(201,668)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">283,312<span></span>
</td>
<td class="num">(182,894)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">$ 351,463<span></span>
</td>
<td class="nump">$ 125,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,983,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,402,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,402,402<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282609032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - Parentheticals - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,983,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,402,402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,402,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation preference</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 245,768<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred Stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">43,472,000<span></span>
</td>
<td class="nump">4,713,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">43,472,000<span></span>
</td>
<td class="nump">4,713,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871359537832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 8,668<span></span>
</td>
<td class="nump">$ 2,107<span></span>
</td>
<td class="nump">$ 24,335<span></span>
</td>
<td class="nump">$ 4,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of sales</a></td>
<td class="nump">4,428<span></span>
</td>
<td class="nump">2,138<span></span>
</td>
<td class="nump">12,986<span></span>
</td>
<td class="nump">6,221<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">4,240<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="nump">11,349<span></span>
</td>
<td class="num">(1,725)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,919<span></span>
</td>
<td class="nump">3,893<span></span>
</td>
<td class="nump">13,917<span></span>
</td>
<td class="nump">11,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">12,118<span></span>
</td>
<td class="nump">7,054<span></span>
</td>
<td class="nump">34,765<span></span>
</td>
<td class="nump">21,138<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">17,037<span></span>
</td>
<td class="nump">10,947<span></span>
</td>
<td class="nump">48,682<span></span>
</td>
<td class="nump">32,870<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(12,797)<span></span>
</td>
<td class="num">(10,978)<span></span>
</td>
<td class="num">(37,333)<span></span>
</td>
<td class="num">(34,595)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(1,469)<span></span>
</td>
<td class="num">(1,387)<span></span>
</td>
<td class="num">(4,370)<span></span>
</td>
<td class="num">(3,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_InterestAndOtherIncomeExpense', window );">Interest and other income, net</a></td>
<td class="nump">163<span></span>
</td>
<td class="nump">357<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,103)<span></span>
</td>
<td class="num">$ (12,008)<span></span>
</td>
<td class="num">$ (41,505)<span></span>
</td>
<td class="num">$ (37,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="num">$ (5.64)<span></span>
</td>
<td class="num">$ (11.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="num">$ (5.64)<span></span>
</td>
<td class="num">$ (11.34)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average shares used in computing net loss per share attributable to common shareholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">11,580,000<span></span>
</td>
<td class="nump">4,329,000<span></span>
</td>
<td class="nump">7,361,000<span></span>
</td>
<td class="nump">3,327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">11,580,000<span></span>
</td>
<td class="nump">4,329,000<span></span>
</td>
<td class="nump">7,361,000<span></span>
</td>
<td class="nump">3,327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized (loss) gain on cash equivalents</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="num">$ (16)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (14,105)<span></span>
</td>
<td class="num">$ (12,024)<span></span>
</td>
<td class="num">$ (41,532)<span></span>
</td>
<td class="num">$ (37,738)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_InterestAndOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest And Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_InterestAndOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871270898216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">20,998,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the beginning of the period at Dec. 31, 2019</a></td>
<td class="nump">$ 173,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance upon exercise of warrants (in shares)</a></td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises', window );">Issuance upon exercise of warrants</a></td>
<td class="nump">$ 379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the end f the period (in shares) at Mar. 31, 2020</a></td>
<td class="nump">21,073,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the end of the period at Mar. 31, 2020</a></td>
<td class="nump">$ 173,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Dec. 31, 2019</a></td>
<td class="num">(143,837)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4,808<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">$ (148,649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of vested options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon exercise of options</a></td>
<td class="nump">1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on cash equivalents</a></td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(13,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(13,126)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Mar. 31, 2020</a></td>
<td class="num">$ (155,385)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,393<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(161,775)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2019</a></td>
<td class="nump">20,998,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the beginning of the period at Dec. 31, 2019</a></td>
<td class="nump">$ 173,068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the end f the period (in shares) at Sep. 30, 2020</a></td>
<td class="nump">25,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the end of the period at Sep. 30, 2020</a></td>
<td class="nump">$ 243,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Dec. 31, 2019</a></td>
<td class="num">(143,837)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,808<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="num">(148,649)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(37,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Sep. 30, 2020</a></td>
<td class="num">$ (168,431)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,951<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(186,389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the beginning of the period (in shares) at Mar. 31, 2020</a></td>
<td class="nump">21,073,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the beginning of the period at Mar. 31, 2020</a></td>
<td class="nump">$ 173,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance upon exercise of warrants (in shares)</a></td>
<td class="nump">45,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises', window );">Issuance upon exercise of warrants</a></td>
<td class="nump">$ 230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the end f the period (in shares) at Jun. 30, 2020</a></td>
<td class="nump">21,118,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the end of the period at Jun. 30, 2020</a></td>
<td class="nump">$ 173,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning of the period (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,892,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Mar. 31, 2020</a></td>
<td class="num">(155,385)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">6,393<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="num">(161,775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of vested options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon exercise of options</a></td>
<td class="nump">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on cash equivalents</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,606)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,606)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Jun. 30, 2020</a></td>
<td class="num">$ (166,541)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">7,817<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="num">(174,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance upon exercise of warrants (in shares)</a></td>
<td class="nump">531,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises', window );">Issuance upon exercise of warrants</a></td>
<td class="nump">$ 3,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)</a></td>
<td class="nump">5,227,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="nump">$ 76,486<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquitySharesConversionOfConvertibleSecurities', window );">Issuance of redeemable convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="num">(1,474,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityAmountConversionOfConvertibleSecurities', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="num">$ (9,520)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the end f the period (in shares) at Sep. 30, 2020</a></td>
<td class="nump">25,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the end of the period at Sep. 30, 2020</a></td>
<td class="nump">$ 243,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of vested options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon exercise of options</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on cash equivalents</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,474,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="nump">9,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,008)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,620,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Sep. 30, 2020</a></td>
<td class="num">$ (168,431)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">17,951<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(186,389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">25,402,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the beginning of the period at Dec. 31, 2020</a></td>
<td class="nump">$ 243,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the end f the period (in shares) at Mar. 31, 2021</a></td>
<td class="nump">25,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the end of the period at Mar. 31, 2021</a></td>
<td class="nump">$ 243,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,713,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Dec. 31, 2020</a></td>
<td class="num">(182,894)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">18,788<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(201,668)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of vested options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">504,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon exercise of options</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on cash equivalents</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(12,822)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,822)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Mar. 31, 2021</a></td>
<td class="num">$ (193,857)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">20,663<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(214,490)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2020</a></td>
<td class="nump">25,402,402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the beginning of the period at Dec. 31, 2020</a></td>
<td class="nump">$ 243,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the end f the period (in shares) at Sep. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the end of the period at Sep. 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning of the period (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,713,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Dec. 31, 2020</a></td>
<td class="num">(182,894)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">18,788<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(201,668)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(41,505)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Sep. 30, 2021</a></td>
<td class="nump">$ 283,312<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">526,526<span></span>
</td>
<td class="num">(41)<span></span>
</td>
<td class="num">(243,173)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the beginning of the period (in shares) at Mar. 31, 2021</a></td>
<td class="nump">25,402,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the beginning of the period at Mar. 31, 2021</a></td>
<td class="nump">$ 243,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance upon exercise of warrants (in shares)</a></td>
<td class="nump">4,448,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises', window );">Issuance upon exercise of warrants</a></td>
<td class="nump">$ 84,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the end f the period (in shares) at Jun. 30, 2021</a></td>
<td class="nump">29,850,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the end of the period at Jun. 30, 2021</a></td>
<td class="nump">$ 328,564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the beginning of the period (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,217,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning of the period at Mar. 31, 2021</a></td>
<td class="num">(193,857)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">20,663<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="num">(214,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of vested options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon exercise of options</a></td>
<td class="nump">1,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on cash equivalents</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,580)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,580)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,792,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Jun. 30, 2021</a></td>
<td class="num">$ (206,306)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">22,803<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(229,070)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance upon exercise of warrants (in shares)</a></td>
<td class="nump">62,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises', window );">Issuance upon exercise of warrants</a></td>
<td class="nump">$ 970<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquitySharesConversionOfConvertibleSecurities', window );">Issuance of redeemable convertible preferred stock, net of issuance costs (in shares)</a></td>
<td class="num">(29,912,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityAmountConversionOfConvertibleSecurities', window );">Issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="num">$ (329,534)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance at the end f the period (in shares) at Sep. 30, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance at the end of the period at Sep. 30, 2021</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of vested options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">229,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon exercise of options</a></td>
<td class="nump">855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">855<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition', window );">Stock-based compensation expense</a></td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on cash equivalents</a></td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,912,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="nump">329,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock upon Initial public offering, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,539,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock upon initial public offering, net of underwriting discounts, commissions and offering expenses of $16,076</a></td>
<td class="nump">172,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(14,103)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,103)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance at the end of the period (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,472,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end of the period at Sep. 30, 2021</a></td>
<td class="nump">$ 283,312<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 526,526<span></span>
</td>
<td class="num">$ (41)<span></span>
</td>
<td class="num">$ (243,173)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_TemporaryEquityAmountConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Amount, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_TemporaryEquityAmountConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_TemporaryEquitySharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Shares, Conversion Of Convertible Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_TemporaryEquitySharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, New Issues</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Value, Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of new stock classified as temporary equity issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278435816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (41,505)<span></span>
</td>
<td class="num">$ (37,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,561<span></span>
</td>
<td class="nump">2,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">1,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax', window );">Change in fair value of redeemable convertible preferred stock warrants and derivative liability</a></td>
<td class="num">(235)<span></span>
</td>
<td class="num">(408)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_NonCashLeaseAccretionExpense', window );">Non-cash lease expense</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(82)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(4,804)<span></span>
</td>
<td class="num">(729)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(3,580)<span></span>
</td>
<td class="num">(895)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(606)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,362<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">Accrued compensation</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">1,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInterestPayableNet', window );">Accrued interest expense</a></td>
<td class="nump">804<span></span>
</td>
<td class="nump">866<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">707<span></span>
</td>
<td class="num">(672)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(40,858)<span></span>
</td>
<td class="num">(34,898)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(260)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock from the exercise of stock options</a></td>
<td class="nump">3,495<span></span>
</td>
<td class="nump">2,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts', window );">Proceeds from issuance of note payable, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from the exercise of redeemable convertible preferred stock warrants</a></td>
<td class="nump">858<span></span>
</td>
<td class="nump">3,310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses</a></td>
<td class="nump">172,409<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">261,472<span></span>
</td>
<td class="nump">106,534<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents, and restricted cash</a></td>
<td class="nump">220,354<span></span>
</td>
<td class="nump">71,412<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash- Beginning of period</a></td>
<td class="nump">100,907<span></span>
</td>
<td class="nump">42,712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash - End of period</a></td>
<td class="nump">321,261<span></span>
</td>
<td class="nump">114,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">320,484<span></span>
</td>
<td class="nump">113,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="nump">777<span></span>
</td>
<td class="nump">777<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash in balance sheets</a></td>
<td class="nump">321,261<span></span>
</td>
<td class="nump">114,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">3,566<span></span>
</td>
<td class="nump">2,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TransferFromInventoryToPropertyAndEquipmentNet', window );">Transfer of evaluation units from inventory to property and equipment, net</a></td>
<td class="num">(1,227)<span></span>
</td>
<td class="nump">1,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment included in accounts payable and accrued expenses</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction', window );">Deferred offering costs included in accounts payable and other current liabilities</a></td>
<td class="nump">819<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember', window );">Series F</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 76,488<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesGRedeemableConvertiblePreferredStockMember', window );">Series G</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="nump">$ 84,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Offering Costs Incurred During Noncash or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Adjustment of Warrants and Gain (Loss) on Derivative Instruments, Net, Pretax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_NonCashLeaseAccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non-cash Lease Accretion Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_NonCashLeaseAccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Issuance of Redeemable Convertible Preferred Stock, Net of Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_TransferFromInventoryToPropertyAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer From Inventory to Property and Equipment, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_TransferFromInventoryToPropertyAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInterestPayableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInterestPayableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDebtNetOfIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDebtNetOfIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesGRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesGRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282248584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Parenthetical - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">$ 16,076<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871275191016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization</a></td>
<td class="text">Organization <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Description of Business </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PROCEPT BioRobotics Corporation (the &#8220;Company&#8221;) was incorporated in the state of California in 2007 and its headquarters are located in Redwood City, California. In April 2021, the Company re-incorporated in the state of Delaware. The Company received U.S. Food and Drug Administration clearance in December 2017 to market its AquaBeam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Robotic System, an automated surgical robot providing tissue removal for the treatment of benign prostatic hyperplasia, a prostate gland enlargement condition. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company had cash and cash equivalents of $320.5 million and $100.1 million, respectively, and an accumulated deficit of $243.2 million and $201.7 million, respectively. In September 2021, the Company completed its initial public offering (&#8220;IPO&#8221;) for net proceeds of approximately $172.4 million, after deducting underwriting discounts and commissions, and offering expenses. Since its inception, the Company has financed its operations with a combination of debt and equity financing arrangements. The Company expects its cash and cash equivalents, revenue and available debt financing arrangements will be sufficient to fund its operations through at least the next twelve months from the issuance date of these financial statements. The Company has not achieved positive cashflow from operations to date and expects to continue incurring losses for the foreseeable future as it focuses on growing its business.</span></div>The COVID-19 pandemic and the resulting economic downturn are affecting business conditions in the industry in which the Company operates. In response to the pandemic, many state and local governments in the United States issued orders that temporarily precluded elective medical procedures in order to conserve scarce health system resources. The Company has taken necessary precautions to safeguard its employees, patients, customers, and other stakeholders from the COVID-19 pandemic, while maintaining business continuity to support its patients, customers and employees. The timing, extent and continuation of any increase in procedures, and any corresponding increase in sales of the Company&#8217;s products, and whether there could be a future decrease in the current level of procedures as a result of the COVID-19 pandemic or otherwise, remain uncertain and are subject to a variety of factors.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278362824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Preparation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). These consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements. Management uses significant judgment when making estimates related to its common stock valuation in periods before the Company&#8217;s IPO and related stock-based compensation, right-of-use lease asset, lease liability, the valuations of the redeemable convertible preferred stock warrant liability and loan facility derivative liability, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reverse Stock Split </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Board of Directors and stockholders approved, and the Company filed, an amended and restated certificate of incorporation effecting a 1-for-4.75 reverse stock split of common stock and all redeemable convertible preferred stock. The par value of the common and redeemable convertible preferred stock was not adjusted as a result of the reverse stock split. All authorized, issued and outstanding common stock, redeemable convertible preferred stock, warrants for preferred stock, stock options and per share amounts contained in the financial statements have been retroactively adjusted to reflect this reverse stock split for all periods presented.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Initial Public Offering</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company completed its IPO by issuing 6,556,000 shares of common stock, and the exercise of the underwriters option for 983,400 shares, at an offering price of $25.00 per share, for total net proceeds of approximately $172.4 million, after deducting underwriting discounts and commissions of $13.2 million and offering expenses of $2.9 million. Offering costs are capitalized, and consist of fees and expenses incurred in connection with the sale of common stock in its IPO, including legal, accounting, printing and other IPO-related costs. Upon completion of its IPO, these deferred offering costs were reclassified to stockholders&#8217; equity and recorded against the proceeds from the offering. In addition, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock and it reclassified $329.5 million of redeemable convertible preferred stock to additional paid-in capital on its condensed consolidated balance sheet. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Financial Statements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying balance sheet as of September&#160;30, 2021, the statements of operations and comprehensive loss for the three and nine months ended September 30, 2021 and 2020, cash flows for the nine months ended September 30, 2021 and 2020, and the statements of redeemable convertible preferred stock and stockholders&#8217; equity (deficit) as of September&#160;30, 2021 and 2020, are unaudited. The financial data and other information disclosed in these notes to the financial statements related to September&#160;30, 2021, and the three and nine months ended September 30, 2021 and 2020, are also unaudited. The accompanying balance sheet as of December&#160;31, 2020 has been derived from the audited consolidated financial statements included in the Company&#8217;s Registration Statement on Form S-1 filed with the Securities and Exchange Commission.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unaudited interim financial statements have been prepared on the same basis as the annual financial statements and, in the opinion of management, reflect all adjustments, which include only normal recurring adjustments, necessary to a fair statement of the Company&#8217;s financial position as of September&#160;30, 2021, and the results of its operations for the three and nine months ended September 30, 2021 and 2020, and cash flows for the nine months ended September 30, 2021 and 2020. The results for the three and nine months ended September 30, 2021, are not necessarily indicative of results to be expected for the year ending December&#160;31, 2021, or for any other interim period or for any future year and should be read in conjunction with the annual consolidated financial statements included in the Company&#8217;s Registration Statement on Form S-1.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Par Value and Shares Authorized Change </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Board of Directors and stockholders approved, and the Company filed, an amended and restated certificate of incorporation effecting a change in par value from $0.001 to $0.00001 per share of common stock and all redeemable convertible preferred stock. All issued and outstanding common stock and redeemable convertible preferred stock contained in the financial statements have been retroactively corrected to reflect this immaterial change in par value for all periods presented. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, 10.0 million shares of preferred stock was authorized and the shares of common stock authorized was increased to 300.0 million shares, both having a par value of $0.00001 per share. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in banks and highly liquid securities, which are readily convertible to cash, that mature within 90 days or less from the original date of purchase, to be cash equivalents, which include money market funds. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. Unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity (deficit). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash is related to the Company&#8217;s letter of credit for the lease of its corporate headquarters.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash and cash equivalents, and accounts receivable, accounts payable and accrued liabilities, which approximate fair value due to their relatively short maturities as well as the redeemable convertible preferred stock warrant liability and loan facility derivative liability. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: </span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt">Observable inputs such as quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt">Other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt">Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.433%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320,484&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320,484&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Preferred stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Loan facility derivative liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents consist primarily of money market funds. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers in and out of Level 3 during the nine months ended September 30, 2021 and year ended December&#160;31, 2020. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Redeemable Convertible Preferred Stock Warrants </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the estimated fair value of the Company&#8217;s redeemable convertible preferred stock warrants, which represents financial instruments with valuations classified as </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. However, Level 3 financial instruments typically include, in addition to the unobservable inputs, observable inputs (that is, components that are actively quoted and can be validated to external sources). Accordingly, the gain or loss in the table below includes changes in fair value due in part to observable factors that are part of the Level 3 methodology recognized in the statement of operations as a component of interest and other income or expense as appropriate (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the Company&#8217;s IPO in September 2021, warrants exercised for redeemable convertible preferred stock were automatically converted into 62,454 shares of common stock and the remaining unexercised warrants expired, therefore no warrants outstanding at September&#160;30, 2021.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the redeemable convertible preferred stock warrant liability was determined using the Black-Scholes option pricing model using the following assumptions: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loan facility derivative liability </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s loan facility, the Company is obligated to pay a fee upon the earlier occurrence of a defined liquidity event, including but not limited to, a merger or sale of our assets or voting stock, or achieving a $200.0&#160;million trailing twelve months revenue target, in each case, by September 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fee is calculated at the time of the liquidity event occurrence to be $1.0&#160;million if only the first installment has been drawn, $2.0 million if the first two installments have been drawn, $2.4 million if the first three installments have been drawn, or $3.0 million if all four installments have been drawn, in each case, upon the occurrence of the liquidity event. The Company has determined this fee is a freestanding derivative instrument. The $1.4 million fair value of this loan facility derivative was recorded as a debt discount and liability on the date of issuance in connection with obtaining additional financing as applicable and will be revalued every reporting period until the earlier occurrence of a defined liquidity event or achieving a revenue target by September 2029 or termination of such fee arrangement.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the estimated fair value of the Company&#8217;s loan facility derivative liability, classified as Level 3 (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of success fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the loan facility derivative liability was determined using a discounted cash flow calculation discounted at 10%. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents and, to a lesser extent, accounts receivable. The Company believes that credit risk in its accounts receivable is mitigated by its credit evaluation process, relatively short collection terms and diversity of its customer base. The Company generally does not require collateral and losses on accounts receivable have historically been within management&#8217;s expectations. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings, as well as corporate debt or commercial paper issued by the highest quality financial and non-financial companies, and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash and cash equivalents and issuers of investments to the extent recorded on the balance sheets. The Company has limited its credit risk associated with cash and cash equivalents by placing its investments with banks it believes are highly creditworthy and with highly rated investments. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Allowance for Doubtful Accounts </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides for uncollectible accounts receivable by recording an allowance for doubtful accounts for balances deemed uncollectible. The Company evaluates the collectability of its accounts receivable based on known collection risks and historical experience. In circumstances where the Company is aware of a specific customer&#8217;s inability to meet its financial obligations to the Company (e.g., bankruptcy filings, substantial downgrading of credit ratings), the Company records a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount it reasonably believes will be collected. The Company has not experienced any significant collection issues. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are valued at the lower of cost, computed on a first-in, first-out basis, or net realizable value. The allocation of production overhead to inventory costs is based on normal production capacity. Abnormal amounts of idle facility expense, freight, handling costs, and consumption are expensed as incurred, and not included in overhead. The Company maintains provisions for excess and obsolete inventory based on management&#8217;s estimates of forecasted demand and, where applicable, product expiration. The Company has initiated voluntary recalls for a limited number of handpieces due to certain issues related to supply chain and manufacturing processes, of which the provision recognized was not material. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment and Intangible Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment and Intangible Assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization for property and equipment are determined using the straight-line method over the estimated useful lives of the respective assets, generally 3 to 5 years. The Company reclassifies inventory used at customer sites for evaluation purposes to property and equipment due to a limited history of sales of evaluation units. Amortization of intangible assets are determined using the straight-line method over the estimated useful lives, generally through the patent expiration date. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Maintenance and repairs are charged to operating expenses as incurred. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist primarily of property and equipment and intangible assets, net, and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that a long-lived asset be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated by the asset group to the carrying amount of the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">asset group. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. The Company determines fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. The Company&#8217;s cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors. Since inception, the Company has not recorded impairment charges on its long-lived assets. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Offering Costs</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes, within other assets, certain legal, accounting and other third-party fees that are directly related to the Company&#8217;s in-process equity financings, including its recent initial public offering, until such financings are consummated. After consummation of the equity financing, these costs are recorded to additional paid in capital as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses. There were no deferred offering costs as of September&#160;30, 2021 and December&#160;31, 2020. Upon the completion of the Company&#8217;s IPO in September 2021, all deferred offering costs were reclassified to cost of issuance in additional paid in capital.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue will be recognized subsequent to invoicing. Service agreements are generally invoiced annually at the beginning of each coverage period and recorded as deferred revenue and recognized as revenue ratably over the coverage period. Deferred revenue that will be recognized during the twelve months following the balance sheet date is recorded as the current portion of deferred revenue, and the remaining portion, if any, would be recorded as non-current. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records redeemable convertible preferred stock at fair value on the date of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because it contains liquidation features that are not solely within the Company&#8217;s control. The Company determined that the carrying values of the redeemable convertible preferred stock should not be adjusted to the liquidation preferences because it is uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock. Subsequent adjustments to the carrying values of the redeemable convertible preferred stock to the liquidation preferences will be made only when it is probable that the redeemable convertible preferred stock will become redeemable. Upon the completion of the Company&#8217;s IPO in September 2021, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock and it reclassified $329.5 million of redeemable convertible preferred stock to additional paid-in capital on its condensed consolidated balance sheet.  </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redeemable Convertible Preferred Stock Warrant Liability </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued freestanding warrants to purchase shares of redeemable convertible preferred stock to investors in connection with sales of certain of its redeemable convertible preferred stock. The Company classified these warrants as a derivative liability because they create a conditional obligation for the Company to repurchase its own shares for cash or other assets. The fair value of the warrants are recorded on the consolidated balance sheets at the issuance of the warrants and remeasured to fair value at each financial reporting date. The changes in the fair value of the warrants are recorded in the statement of operations as a component of interest and other income or expense as appropriate. The Company will continue to adjust the carrying value of the redeemable convertible preferred stock warrant liability for changes in the fair value of the warrants until the earlier of: the exercise of the warrants, at which time the liability will be reclassified to temporary equity or the expiration of the warrant, at which time the entire amount would be reversed and reflected in the consolidated statements of operations and comprehensive loss. Upon the completion of the Company&#8217;s IPO in September 2021, warrants exercised for redeemable convertible preferred stock were automatically converted into 62,454 shares of common stock and the remaining unexercised warrants expired.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loan Facility Derivative Liability</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that its obligation to pay success fees to a lender upon a successful liquidation event or achieving a revenue target represents freestanding financial instruments. The instruments are classified as a non-current liability in the consolidated balance sheets and are subject to remeasurement at each financial reporting date. Any change in fair value was recognized through other income (expense) in the condensed consolidated statements of operations and comprehensive loss. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements with a term of more than twelve months, the Company determines if an agreement contains a lease at inception. Operating lease liabilities represent an obligation to make lease payments arising from the lease agreement. Operating lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the remaining lease term. In determining the present value of lease payments, the Company estimates its incremental borrowing rate as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, of an amount equal to the lease payments in a similar economic environment. Operating lease liabilities are included in the Company&#8217;s consolidated balance sheet. Right-of-use assets represent our right to use an underlying asset for the lease term and are classified as non-current assets. Lease expense is recognized on a straight-line basis over the expected lease term in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2019, the Company recorded the difference between rent paid and the straight-line rent as a deferred rent liability and leasehold improvements funded by landlord incentives or allowances are recorded as leasehold improvement assets and a corresponding deferred rent liability. Upon adoption of Accounting Standards Codification (&#8220;ASC 842&#8221;) on January 1, 2020, the unamortized deferred rent liability has been reclassified to reduce the right-of-use asset.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not elected to separate lease and non-lease components for any leases within its existing classes of assets and, as a result, records a right-of-use asset and lease liability based on the present value of the future minimum lease payments over the term at commencement date. Variable lease payments are expensed as incurred. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has lessor arrangements with customers for a fixed monthly fee with no non-lease components, typically for 3-12 months. These arrangements are accounted for as an operating lease in accordance with ASC 842. These arrangements and related revenue are immaterial to the periods presented. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is derived primarily from the sales of the AquaBeam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Robotic Systems, and handpieces that are for one-time use during each surgery using the AquaBeam Robotic System. The AquaBeam Robotic System contains both software and non-software components that are delivered together as a single product and generally contain a one-year warranty. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), the Company performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct based on the contract. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contracts are typically in the form of an agreement and a purchase order from the customer. The Company&#8217;s AquaBeam Robotic System sales generally contain multiple products and services and can include a combination of the following performance obligations: robotic system, handpieces and consumables, and service. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the transaction price it expects to be entitled to in exchange for transferring the promised product to the customer, which is based on the invoiced price for the products. All prices are at fixed amounts per the sales agreement with the customer and there are generally no discounts, rebates or other price concessions or a right of return, once the agreement is signed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations at the following points in time:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AquaBeam Robotic Systems</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the time of delivery. Systems rented for a fixed monthly fee during an evaluation period, typically 3-12 months, are recognized as revenue straight-line during the lease term, in accordance with ASC 842, and are not material. For systems sold following an evaluation period, revenue is recognized generally once sales terms are mutually agreed (as the system is already install at the customer site). For systems sold through distributors, revenue is recognized generally at the time of delivery. The Company&#8217;s system arrangements generally do not provide a right of return. The systems are generally covered by a one-year service agreement. The service agreements have a stand alone selling price and are typically recognized as deferred revenue and amortized over the one-year service period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hand pieces and other consumables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Revenue from sales of handpieces and other consumables is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also occurs at the time of delivery.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Service revenue, inclusive of the amounts associated with the AquaBeam Robotic System warranties, is recognized over the term of the service period, as the customer benefits from the services throughout the service period. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that certain promises in the multiple-element arrangements, such as installation, training and certain ancillary products, are immaterial, and/or do not represent separate performance obligations for which transaction price is allocated. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue is recognized subsequent to invoicing, such as service contracts, which are recognized ratably as revenue over the performance period, which is not material. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s typical payment terms are between approximately 30 to 90 days. The Company expenses shipping and handling costs as incurred and includes them in the cost of sales. In those cases where shipping and handling costs are billed to customers, the Company classifies the amounts billed as a component of revenue. Taxes collected from customers and remitted to governmental authorities are excluded from revenue. The Company expenses any incremental costs of obtaining a contract, including but not limited to, sales commissions, as and when </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">incurred as the expected amortization period of the incremental costs would have been less than one year and are reported in selling, general and administrative expense in the statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue disaggregated by type and geography (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System sales and rentals</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Handpieces and other consumables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System sales and rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Handpieces and other consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outside of U.S. revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of sales consists primarily of manufacturing overhead costs, material costs and direct labor, including stock-based compensation. A significant portion of the Company&#8217;s cost of sales currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of sales also includes depreciation expense for production equipment, warranty and field service costs, and purchased intangibles and certain direct costs such as shipping costs. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred. Research and development costs consist primarily of engineering, product development, and regulatory affairs, consulting services, materials, depreciation and other costs associated with products and technologies being developed, including employee and non-employee compensation, stock-based compensation, supplies, quality assurance expenses, related travel expenses and facilities expenses. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a payment equity incentive plan to provide long-term incentives for employees, consultants and members of the board of directors. The plan allows for the issuance of non-statutory and incentive stock options to employees and non-statutory stock options to consultants and non-employee directors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to determine the fair value of equity incentive awards and recognize compensation expense for all equity incentive awards made to employees and directors, including employee stock options. Stock-based compensation expense is recognized over the requisite service period in the statements of operations and comprehensive loss. The Company uses the straight-line method for expense attribution.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation model used for calculating the fair value of awards for stock-based compensation expense is the Black-Scholes option-pricing model (the &#8220;Black-Scholes model&#8221;). The Black-Scholes model requires the Company to make assumptions and judgments about the variables used in the calculation, including the fair value of the Company&#8217;s common stock, the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate and an expected dividend rate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s common stock underlying the stock options has historically been determined by the Company&#8217;s board of directors (&#8220;Board&#8221;). Because there was no public market for the Company&#8217;s common </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">stock prior to the IPO, the Board determined the fair value of the Company&#8217;s common stock at the time of grant of the option by considering a number of objective and subjective factors, including valuations of comparable companies, sales of the Company&#8217;s redeemable convertible preferred stock, operating and financial performance and the general and industry-specific economic outlook. The Company used the &#8220;simplified method&#8221; to determine the expected term of the stock option. Expected volatility is based on an average of the historical volatilities of the common stock of publicly-traded companies with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected term of the option. The Company has elected to account for forfeitures when they occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Valuation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intent has been to grant all options with an exercise price not less than the fair value of its common stock underlying those options on the date of grant. Prior to its IPO, the Company has determined the estimated fair value of its common stock at each valuation date in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Practice Aid&#8221;). The Company&#8217;s board of directors, with the assistance of management, developed these valuations using significant judgment and taking into account numerous factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">valuations of its common stock with the assistance of independent third-party valuation specialists;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the stage of development and business strategy, including the status of research and development efforts, of its products and product candidates, and the material risks related to its business and industry;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of operations and financial position, including its levels of available capital resources;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the valuation of publicly traded companies in the life sciences and medical device sectors, as well as recently completed mergers and acquisitions of peer companies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prices of its redeemable convertible preferred stock sold to investors in arm&#8217;s length transactions and the rights, preferences, and privileges of its redeemable convertible preferred stock relative to those of its common stock;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering or a sale of the Company given prevailing market conditions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of the Company&#8217;s stockholders to freely trade its common stock in the public markets, resulting in a discount to reflect the lack of marketability of the Company&#8217;s common stock based on the weighted-average expected time to liquidity. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trends and developments in its industry; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external market conditions affecting the life sciences and medical device industry sectors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s board of directors determined the fair value of its common stock by first determining the enterprise value of the Company&#8217;s business using the market approach, income approach or from the value implied by the latest round of equity financing, and then allocating the value among the various classes of its equity securities to derive a per share value of its common stock. The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all option granted prior to the Company&#8217;s IPO in September 2021, the Board allocated the enterprise value based on the option pricing method (&#8220;OPM&#8221;). OPM treats the rights of the holders of preferred and common stock as equivalent to call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders of preferred stock, as well as their rights to participation and conversion. Thus, the estimated value of the common stock can be determined by estimating the value of its portion of each of these call option rights. When valuing options granted round the time of an equity financing that is considered arms-</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">length, OPM derived the Company&#8217;s equity value of a company from the price of the securities issued by the Company in the equity financing. Following the completion of the Company&#8217;s IPO in September 2021, the fair value of the Company&#8217;s common stock is determined based on the closing price of its common stock on The Nasdaq Global Market. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were not significant. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Defined Contribution Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their annual compensation on a pre-tax basis. The Company is authorized to make matching contributions but has not made such contributions for the three and nine months ended September 30, 2021 and 2020.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established when necessary to reduce deferred tax assets to the amounts expected to be realized. Currently, the Company has recorded a full valuation allowance against its deferred tax assets and there is no provision for income taxes, as the Company has incurred operating losses to-date. The Company&#8217;s policy is to record interest and penalties expense related to uncertain tax positions as a component of income tax expense in the statement of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalent shares from dilutive stock options and common stock warrants outstanding during the period. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods as all potentially dilutive securities were antidilutive in those periods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company&#8217;s redeemable convertible preferred stock participated in any dividends declared by the Company and were therefore considered to be participating securities. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the Company&#8217;s IPO in September 2021, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share was determined as follows (in thousands, except per share amounts): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,008)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,505)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.77)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computations of weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comprehensive Loss </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Comprehensive loss consists of net loss and changes in unrealized gains and losses on cash equivalents and available-for-sale marketable securities. Accumulated other comprehensive income (loss) is presented in the accompanying balance sheets, when applicable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment, Geographical and Customer Concentration </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. The Company&#8217;s assets are primarily based in the United States.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No customers accounted for more than 10% of revenue during the three and nine months ended September 30, 2021. Three customers accounted for 16%, 13% and 13% of revenue during the three months ended September 30, 2020. No customers accounted for more than 10% of revenue during the nine months ended September 30, 2020. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by significant geographical locations outside the United States for the periods presented:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Less than 10% of total net revenues for the period indicated.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> No customers accounted for more than 10% of accounts receivable at September&#160;30, 2021. Two customers each accounted for 22% and 13% of accounts receivable at December&#160;31, 2020.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act Accounting Election </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to avail itself of this exemption and, therefore, for new or revised accounting standards applicable to public companies, the Company will be subject to an extended transition period until those standards would otherwise apply to private companies.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2018-13&#8221;). The amendments on changes in unrealized gains and losses recognized in other comprehensive income categorized within Level 3, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively in the initial fiscal year of adoption. All other amendments </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should be applied retrospectively to all periods presented upon their effective date. The Company adopted ASU 2018-13 as of January 1, 2020, which did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (&#8220;ASU 2018-11&#8221;). ASU 2018-11 provided an alternative implementation method in addition to the current modified retrospective transition method for ASU No. 2016-2, Leases: Amendments to the FASB Accounting Standards Codification (&#8220;ASU 2016-2&#8221;), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-2, a lessee is required to recognize assets and liabilities for leases with lease terms of more than twelve months. ASU 2016-2 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted ASC Topic 842, Leases, on January 1, 2020 using the modified retrospective transition method. In addition, the Company elected certain practical expedients permitted under the transition guidance, which allowed it to carryforward its historical long-term lease classification, its assessment on whether a contract is or contains a lease and the treatment of its initial direct costs for any leases that existed prior to the adoption of Topic 842. In determining the lease term at commencement date, any renewal or termination options are considered if they are reasonably assured of exercise. The Company has elected to exclude from its consolidated balance sheet any leases having a term of 12 months or less. The Company recorded a right-of-use leased asset of approximately $6.0 million and a corresponding lease liability of $7.4 million in its adoption of Topic 842. In addition, as of the adoption date, the Company derecognized a deferred rent obligation of $1.4 million. There was no cumulative effect adjustment upon the adoption of Topic 842.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;), which requires an entity to utilize a new impairment model known as the current expected credit loss (&#8220;CECL&#8221;) model to estimate its lifetime &#8220;expected credit loss&#8221; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. This standard is effective for fiscal periods beginning after December 15, 2021, and for fiscal years beginning after December 15, 2020 for public business entities. The Company adopted ASU 2019-12, effective of January 1, 2021, and the adoption did not have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278317176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Consolidated Financial Statement Items<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Composition of Certain Consolidated Financial Statement Items</a></td>
<td class="text">Composition of Certain Consolidated Financial Statement Items <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"/><td style="width:65.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.224%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"/><td style="width:65.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.224%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"/><td style="width:65.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.224%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory, manufacturing and computer equipment and furniture</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluation units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,788)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"/><td style="width:65.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.224%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued purchases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, other non-current liabilities consisted of an asset retirement obligation for the facility lease.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income (Expense), net (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in fair value of preferred stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in fair value of loan facility derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest and other income (expense), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871276751960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets Disclosure</a></td>
<td class="text">Intangible Assets <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, the Company entered into a license agreement with HydroCision, Inc. This agreement grants the Company an exclusive, perpetual, irrevocable, worldwide, fully paid-up license to develop, manufacture and commercialize products in the field of urology using the patented technology and know-how controlled by HydroCision as of the effective date and as well as new patented technology developed by HydroCision that cover certain activities and improvements that relate to the use of fluid jet technology in connection with the licensed products during the period commencing on the effective date and ending on the earlier of the date that the Company ceases to use HydroCision&#8217;s existing contract manufacturers and the third anniversary of the effective date. Also included is the right to utilize HydroCision&#8217;s contract manufacturers, if desired. The consideration paid was a one-time upfront payment of $2.5 million, as well as allowing HydroCision (a reciprocal license) to use any new patented technology and know-how developed by the Company relating to the HydroCision patented technology and know-how in the field of urology for HydroCision use outside the field of urology. HydroCision will pay for any patent maintenance fees on HydroCision&#8217;s licensed patents. As of September&#160;30, 2021 and December&#160;31, 2020, accumulated amortization was $0.7 million and $0.5 million, respectively, and the net carrying amount is expected to be amortized at a rate of $0.3 million per year until fully amortized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense for intangible assets was $0.1 million for each of the three months ended September 30, 2021 and 2020, and $0.2 million for each of the nine months ended September 30, 2021 and 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871274922808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Facility<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure</a></td>
<td class="text">Loan Facility In September 2019, the Company entered into a loan facility for up to $75 million available in four installments. The Company borrowed $25 million in September 2019. An additional $25 million was borrowed in March 2020. The third installment of $10 million was originally available for draw through March 31, 2021 contingent upon achieving $20 million in trailing six months revenue. In January 2021, the third installment was amended to be available for draw through June 30, 2021 contingent upon achieving $6.4 million trailing six months revenue. The remaining $15 million was originally available for draw through June 30, 2021 and is contingent upon achieving $25&#160;million in trailing six months revenue. In January 2021, this installment was amended to be available for draw through June 30, 2022. The facility bears an interest rate of 9.37%, which is 7.17% plus the greater of 2.2% or 30-day LIBOR. The initial term of the facility is 60 months with interest-only payments each month for 24 months followed by 36 months amortization of principal and interest. In January 2021, the interest-only period was amended to 36 months followed by 24 months amortization (principal and interest) beginning October 1, 2022 since the amended trailing six months target revenue of $6.4 million was achieved, and accordingly, the current portion of the amount due was reclassified to non-current. Upon drawing the final $15 million tranche, interest-only period is extended 12 months followed by 24 months amortization of principal and interest. Upon the completion of the Company raising over $50 million in its IPO in September 2021, interest-only payments were extended an additional 12 months followed by 12 months amortization of principal and interest. Substantially all assets of the Company are pledged as collateral. Commencing with the earlier of June 30, 2021 and the month following the funding of either the third or final installment, the Company is required to achieve revenues for the previous six months ended equal to the greater of (1) 70% of the forecast for the commensurate period, (2) $15 million if neither third or final <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">installments have been drawn, (3) $20 million if the third but not final installment has been drawn and (4) $25 million if both the third and final installments have been drawn.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The loan facility includes certain fees payable to the lender recorded as a loan discount that are accrued and amortized to interest expense during the loan term. A 6% final payment fee of each funded tranche is payable at the earlier of prepayment or loan maturity and a 0.25% facility fee paid at each funded tranche. A prepayment fee was originally payable if the loan is paid before maturity in the amount of 3% of loans outstanding if paid in full during first 12 months, 2% if loan is paid in full during second 12 months, or 1% if loan is paid in full thereafter before maturity. In January 2021, the prepayment fee was removed as part of the amendments. In addition, the Company should pay the lender&#8217;s loan initiation fees and a fee upon the earlier occurrence of a defined liquidity event, including but not limited to, a merger or sale of the Company&#8217;s assets or voting stock, or achieving a $200 million trailing twelve months revenue target, in each case, by September 2029</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success fees are calculated at the time of the liquidity event occurrence to be $1.0 million if only the first installment has been drawn, $2.0 million if the first two installments have been drawn, $2.4 million if the first three installments have been drawn, or $3.0 million if all four installments have been drawn, in each case, upon the occurrence of the defined liquidity event. The Company determined that this obligation to pay success fees represents freestanding financial instruments. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amendments in January 2021 were accounted for as a debt modification under ASC 470-50-40 as the changes in the debt terms are not considered substantial, and thus no gain or loss was recorded and a new effective interest rate was established based on the carrying value of the loan and the revised cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871276624296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock Warrant Liability<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock Warrant Liability</a></td>
<td class="text">Redeemable Convertible Preferred Stock Warrant Liability <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase shares of redeemable convertible preferred stock outstanding and exercisable are as follows (in thousands, except per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.621%"><tr><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.477%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares Outstanding at</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:10pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:10pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, in connection with the issuance of convertible notes, the Company issued 869,842 redeemable convertible preferred stock warrants that were exercisable into Series D redeemable convertible preferred stock immediately, with $5.08 exercise price and expiration in five years. During the three and nine months ended September 30, 2020, warrants for 531,423 and 651,328 shares were exercised, respectively, and none were outstanding at December&#160;31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, in connection with the issuance of convertible notes, the Company issued 108,145 redeemable convertible preferred stock warrants that were exercisable into Series E or the next round of redeemable convertible preferred stock. During the and three and nine months ended September 30, 2021, 62,454 warrants were exercised and the remaining unexercised warrants expired, none were outstanding at September&#160;30, 2021. During the three and nine months ended September 30, 2020, no warrants were exercised.</span></div>Redeemable Convertible Preferred Stock <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s redeemable convertible preferred stock are as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares<br/>Authorized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares <br/>Issued and Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying <br/>Value <br/>(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,243,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,104,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,841,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,543,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,564,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,564,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">D</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,245,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,547,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">36,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">E</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,825,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,414,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">115,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">F</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,263,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,226,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">76,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26,983,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25,402,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">243,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the Company&#8217;s IPO in September 2021, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock and it reclassified $329.5 million of redeemable convertible preferred stock to additional paid-in capital on our condensed consolidated balance sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, an aggregate of $1.5 million shares of redeemable convertible preferred stock was converted to common stock as requested by the holder. The corresponding carrying value was reclassified from redeemable convertible preferred stock to common stock and additional paid in capital.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series G Redeemable Convertible Preferred Stock </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company issued 4,447,530&#160;shares of Series&#160;G redeemable convertible preferred stock for gross proceeds of $85.0 million. Issuance costs totaled $0.3 million and were recorded as an offset to gross proceeds.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series F Redeemable Convertible Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July and August 2020, the Company issued 5,226,969 shares of Series F redeemable convertible preferred stock for gross proceeds of $77.0 million. Issuance costs totaled $0.5 million and were recorded as an offset to gross proceeds. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s redeemable convertible preferred stock terms were as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Preference<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8%<br/>Dividend<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs. A redemption event would only occur upon the liquidation or winding up of the Company, a greater than 50% change in control, or sale of substantially all of the assets of the Company. As the redemption event was outside the control of the Company, all shares of redeemable convertible preferred stock were presented outside of permanent equity. Further, the Company had determined the carrying values of the redeemable convertible preferred stock should not be adjusted to the redemption value of such shares, since it was uncertain whether or when a </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redemption event would occur. Subsequent adjustments to increase the carrying values of the redeemable convertible preferred stock to the redemption values would have been made when it became probable that such redemption would occur. As of September&#160;30, 2021, no shares of redeemable convertible preferred stock were outstanding, and as of December&#160;31, 2020, it was not probable that such redemption would occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Series D, E, F and G redeemable convertible preferred stock, in preference to the holders of Series A, B and C redeemable convertible preferred stock and common stock, were entitled to receive noncumulative dividends at the rate of 8% per share of the original issuance price, when and as declared by the board of directors. After the payment of any dividends to holders of Series D, E, F and G redeemable convertible preferred stock, and in preference to the holders of common stock, the holders of Series A, B, and C redeemable convertible preferred stock would have been entitled to receive noncumulative dividends at the rate of 8% per share of the original issuance price, when and as declared by the board of directors. No dividends were declared and payable for the nine months ended September 30, 2021 and year ended December&#160;31, 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of any liquidation, dissolution, or winding-up of the Company, including a merger, acquisition, or sale of assets, as defined in the certificate of incorporation, each holder of Series G redeemable convertible preferred stock was entitled to receive a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C, D, E or F redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series G redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series G redeemable convertible preferred stock, each holder of Series F redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C, D or E redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series F redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series F redeemable convertible preferred stock, each holder of Series E redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C or D redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series E redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series E redeemable convertible preferred stock, each holder of Series D redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B or C redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series D redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series D redeemable convertible preferred stock, each holder of Series A, B and C redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of common stock. If the assets of the Company were insufficient to make payment in full to all holders of Series A, B or C redeemable convertible preferred stock, then the assets or consideration would have been distributed ratably among </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the payment of the full liquidation preference to holders of redeemable convertible preferred stock, the remaining assets of the Company legally available for distribution would have been distributed ratably to the holders of the common stock. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder had the right to one vote for each share of common stock into which such redeemable convertible preferred stock would have been converted. So long as any shares of redeemable convertible preferred stock were outstanding, the Company was prohibited, without first obtaining the approval of more than 50% of the holders of redeemable convertible preferred stock then outstanding, voting together as a separate class to (a) amend certificate of incorporation in any way that would materially and adversely alter or change the rights, preferences, or privileges of the series preferred stock or (b) increase the total number of authorized shares of any Series Preferred stock. Additionally, the vote of at least a majority of the holders of Series D, E, F and G redeemable convertible preferred stock was needed to materially and adversely affect the rights of such holders of each series, including increasing or decreasing the number of authorized shares of Series D, E, F and G redeemable convertible preferred stock, as applicable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable convertible preferred shares were not mandatorily redeemable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion </span></div>Upon the completion of the Company&#8217;s IPO in September 2021, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock and it reclassified $329.5 million of redeemable convertible preferred stock to additional paid-in capital on our condensed consolidated balance sheet.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871276599784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">Redeemable Convertible Preferred Stock Warrant Liability <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase shares of redeemable convertible preferred stock outstanding and exercisable are as follows (in thousands, except per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.621%"><tr><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.477%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares Outstanding at</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:10pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:10pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2015, in connection with the issuance of convertible notes, the Company issued 869,842 redeemable convertible preferred stock warrants that were exercisable into Series D redeemable convertible preferred stock immediately, with $5.08 exercise price and expiration in five years. During the three and nine months ended September 30, 2020, warrants for 531,423 and 651,328 shares were exercised, respectively, and none were outstanding at December&#160;31, 2020.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, in connection with the issuance of convertible notes, the Company issued 108,145 redeemable convertible preferred stock warrants that were exercisable into Series E or the next round of redeemable convertible preferred stock. During the and three and nine months ended September 30, 2021, 62,454 warrants were exercised and the remaining unexercised warrants expired, none were outstanding at September&#160;30, 2021. During the three and nine months ended September 30, 2020, no warrants were exercised.</span></div>Redeemable Convertible Preferred Stock <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s redeemable convertible preferred stock are as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares<br/>Authorized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares <br/>Issued and Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying <br/>Value <br/>(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,243,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,104,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,841,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,543,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,564,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,564,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">D</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,245,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,547,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">36,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">E</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,825,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,414,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">115,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">F</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,263,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,226,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">76,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26,983,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25,402,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">243,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the completion of the Company&#8217;s IPO in September 2021, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock and it reclassified $329.5 million of redeemable convertible preferred stock to additional paid-in capital on our condensed consolidated balance sheet.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2020, an aggregate of $1.5 million shares of redeemable convertible preferred stock was converted to common stock as requested by the holder. The corresponding carrying value was reclassified from redeemable convertible preferred stock to common stock and additional paid in capital.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series G Redeemable Convertible Preferred Stock </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021, the Company issued 4,447,530&#160;shares of Series&#160;G redeemable convertible preferred stock for gross proceeds of $85.0 million. Issuance costs totaled $0.3 million and were recorded as an offset to gross proceeds.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Series F Redeemable Convertible Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July and August 2020, the Company issued 5,226,969 shares of Series F redeemable convertible preferred stock for gross proceeds of $77.0 million. Issuance costs totaled $0.5 million and were recorded as an offset to gross proceeds. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s redeemable convertible preferred stock terms were as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Preference<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8%<br/>Dividend<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded its redeemable convertible preferred stock at fair value on the dates of issuance, net of issuance costs. A redemption event would only occur upon the liquidation or winding up of the Company, a greater than 50% change in control, or sale of substantially all of the assets of the Company. As the redemption event was outside the control of the Company, all shares of redeemable convertible preferred stock were presented outside of permanent equity. Further, the Company had determined the carrying values of the redeemable convertible preferred stock should not be adjusted to the redemption value of such shares, since it was uncertain whether or when a </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redemption event would occur. Subsequent adjustments to increase the carrying values of the redeemable convertible preferred stock to the redemption values would have been made when it became probable that such redemption would occur. As of September&#160;30, 2021, no shares of redeemable convertible preferred stock were outstanding, and as of December&#160;31, 2020, it was not probable that such redemption would occur.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holders of the Series D, E, F and G redeemable convertible preferred stock, in preference to the holders of Series A, B and C redeemable convertible preferred stock and common stock, were entitled to receive noncumulative dividends at the rate of 8% per share of the original issuance price, when and as declared by the board of directors. After the payment of any dividends to holders of Series D, E, F and G redeemable convertible preferred stock, and in preference to the holders of common stock, the holders of Series A, B, and C redeemable convertible preferred stock would have been entitled to receive noncumulative dividends at the rate of 8% per share of the original issuance price, when and as declared by the board of directors. No dividends were declared and payable for the nine months ended September 30, 2021 and year ended December&#160;31, 2020. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event of any liquidation, dissolution, or winding-up of the Company, including a merger, acquisition, or sale of assets, as defined in the certificate of incorporation, each holder of Series G redeemable convertible preferred stock was entitled to receive a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C, D, E or F redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series G redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series G redeemable convertible preferred stock, each holder of Series F redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C, D or E redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series F redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series F redeemable convertible preferred stock, each holder of Series E redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B, C or D redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series E redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series E redeemable convertible preferred stock, each holder of Series D redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of Series A, B or C redeemable convertible preferred stock and common stock. If the assets of the Company were insufficient to make payment in full to all Series D redeemable convertible preferred stockholders, then the assets or consideration would have been distributed ratably among such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the full payment of the liquidation preference to the holders of Series D redeemable convertible preferred stock, each holder of Series A, B and C redeemable convertible preferred stock would have been entitled to be paid a liquidation preference amount, plus any dividends declared but unpaid before any payments to holders of common stock. If the assets of the Company were insufficient to make payment in full to all holders of Series A, B or C redeemable convertible preferred stock, then the assets or consideration would have been distributed ratably among </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such holders in proportion to the full liquidation preference amounts to which the holders would otherwise have been entitled to.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the payment of the full liquidation preference to holders of redeemable convertible preferred stock, the remaining assets of the Company legally available for distribution would have been distributed ratably to the holders of the common stock. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Voting </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each holder had the right to one vote for each share of common stock into which such redeemable convertible preferred stock would have been converted. So long as any shares of redeemable convertible preferred stock were outstanding, the Company was prohibited, without first obtaining the approval of more than 50% of the holders of redeemable convertible preferred stock then outstanding, voting together as a separate class to (a) amend certificate of incorporation in any way that would materially and adversely alter or change the rights, preferences, or privileges of the series preferred stock or (b) increase the total number of authorized shares of any Series Preferred stock. Additionally, the vote of at least a majority of the holders of Series D, E, F and G redeemable convertible preferred stock was needed to materially and adversely affect the rights of such holders of each series, including increasing or decreasing the number of authorized shares of Series D, E, F and G redeemable convertible preferred stock, as applicable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Redemption </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The redeemable convertible preferred shares were not mandatorily redeemable. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Conversion </span></div>Upon the completion of the Company&#8217;s IPO in September 2021, all 29,912,264 shares of its then-outstanding redeemable convertible preferred stock automatically converted into 29,912,264 shares of common stock and it reclassified $329.5 million of redeemable convertible preferred stock to additional paid-in capital on our condensed consolidated balance sheet.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278751208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholder&#8217;s Equity <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Equity Incentive Award Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company adopted the 2021 Equity Incentive Award Plan (the &#8220;2021 Plan&#8221;), which allows for the granting of stock options and stock purchase rights to the employees, members of the board of directors, and consultants of the Company. A total of 3,303,910 shares of common stock were initially reserved for issuance under the 2021 Plan. Options granted under the 2021 Plan may be either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options (&#8220;NSOs&#8221;). ISOs may be granted only to the Company&#8217;s employees, including officers and directors who are also employees. NSOs may be granted to employees and consultants. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options under the 2021 Plan may be granted for periods of up to 10 years and at prices no less than 100% of the estimated fair value of the shares on the date of grant as determined by the board of directors, provided, however, that the exercise price of an ISO and NSO granted to a 10% shareholder shall not be less than 110% of the estimated fair value of the shares on the date of grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted options for newly hired employees usually vest over four years monthly with a one-year cliff vesting, and follow-on options vest monthly over four years with no cliff vesting. Options granted to consultants have various vesting schedules depending on the underlying consulting arrangement and anticipated period of service. As of September&#160;30, 2021, 3.2 million shares are available for grant under the 2021 Plan.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2008 Stock Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company ceased making awards under the 2008 Stock Plan upon the effective date of the Company&#8217;s IPO. In 2008, the Company adopted the 2008 Stock Plan (the &#8220;2008 Plan&#8221;), which allows for the granting of stock options and stock purchase rights to the employees, members of the board of directors, and consultants of the </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company. Options granted under the 2008 Plan may be either incentive stock options (&#8220;ISOs&#8221;) or nonqualified stock options (&#8220;NSOs&#8221;). ISOs may be granted only to the Company&#8217;s employees, including officers and directors who are also employees. NSOs may be granted to employees and consultants. Options granted under the 2008 Plan will start expiring in August 2021. Options outstanding under the 2008 Plan will expire upon forfeiture. As of September&#160;30, 2021, 6.5 million options were outstanding under the 2008 Plan. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information are as follows (options in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the aggregate pre-tax intrinsic value of options outstanding and exercisable was $98.7 million and $6.9 million, respectively, and options outstanding were $218.5 million and $9.9 million, respectively. The aggregate pre-tax intrinsic value of options exercised was $5.1 million and $1.8 million during the nine months ended September&#160;30, 2021 and 2020, respectively. The aggregate pre-tax intrinsic value was calculated as the difference between the exercise prices of the underlying options and the estimated fair value of the common stock on the date of exercise. The total fair value of options vested was $2.4 million and $1.2 million during the nine months ended September&#160;30, 2021 and 2020, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company estimates the fair value of stock-based compensation on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes model determines the fair value of stock-based payment awards based on the fair market value of the Company&#8217;s common stock on the date of grant and is affected by assumptions regarding a number of highly complex and subjective variables. These variables include, but are not limited to, the fair market value of the Company&#8217;s common stock, volatility over the expected term of the awards and actual and projected employee stock option exercise behaviors. The Company has opted to use the &#8220;simplified method&#8221; for estimating the expected term of options, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option. Due to the Company&#8217;s limited operating history and a lack of company specific historical and implied volatility data, the Company has based its estimate of expected volatility on the historical volatility of a group of similar companies that are publicly traded. When selecting these public companies on which it has based its expected stock price volatility, the Company generally selected companies with comparable characteristics to it, including enterprise value, stages of clinical development, risk profiles, position within the industry and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies&#8217; shares during the equivalent period of the calculated expected term of the share-based payments. The Company will continue to analyze the historical stock price volatility and expected term assumptions as more historical data for the Company&#8217;s common stock becomes available. The risk-free rate assumption is based on the U.S. Treasury instruments with maturities similar to the expected term of the Company&#8217;s stock options. The expected dividend assumption is based on the Company&#8217;s history of not paying dividends and its expectation that it will not declare dividends for the foreseeable future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation recognized, before taxes, is as follows (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of unearned stock-based compensation related to unvested employee stock-based payment awards as of September&#160;30, 2021 and December&#160;31, 2020 is $9.7 million and $6.5 million, respectively. The weighted-average period over which the unearned stock-based compensation is expected to be recognized as of September&#160;30, 2021 and December&#160;31, 2020 is 2.9 years for both periods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the options granted to employees or directors was estimated as of the grant date using the Black-Scholes model assuming the weighted-average assumptions listed in the following table: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2021 Employee Stock Purchase Plan </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, the Company adopted the 2021 Employee Stock Purchase Plan (the &#8220;2021 ESPP&#8221;). The 2021 ESPP became effective on the effective date of the IPO. A total of 412,988 shares were initially reserved for issuance under the 2021 ESPP. Additionally, the number of shares of common stock reserved for issuance under the 2021 ESPP will increase automatically each year, beginning on January&#160;1, 2022, and continuing through and including January&#160;1, 2031, by the lesser of (1) 1% of the total number of shares of common stock outstanding on December 31 of the preceding calendar year; or (2) such lesser number as determined by the Company&#8217;s board of directors. The number of shares that may be issued under the 2021 ESPP shall not exceed a total of 10,526,315 shares. As of September 30, 2021, the Company has not implemented the 2021 ESPP. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Warrants </span></div>In May 2015, the Company issued warrants to purchase 12,308 shares of the Company&#8217;s common stock in exchange for recruiting services. These warrants are exercisable immediately and expire on April 30, 2025. These common stock warrants of $15,000 were recorded as general and administrative expense and additional paid-in capital, as this warrant met the equity classification requirements. In November 2020, these warrants were fully exercised.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871274940232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September&#160;30, 2021 and December&#160;31, 2020, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Facility Lease </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2013, the Company entered into a three-year lease agreement for its current facility located in Redwood City, California. In 2018, the Company expanded the lease space and extended the lease agreement through October 2023. The lease agreement provides for an escalation of rent payments each year and the Company records rent expense on a straight-line basis over the term of the lease. Rent is payable monthly. As of September&#160;30, 2021 and December&#160;31, 2020, the remaining future minimum lease payments under this lease is $5.1 million and $6.7 million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s adoption of ASC Topic 842, Leases, on January 1, 2020, the Company recorded a right-of-use leased asset of $6.0 million and a corresponding lease liability of $7.4 million and derecognized a deferred rent obligation of $1.4 million. The Company used its borrowing rate of 10% as its discount rate and the remaining operating lease term was 3.8 years. The results for the year ended December&#160;31, 2020 subsequent periods are presented under Topic 842.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense recognized under the lease, including additional rent charges for utilities, parking, maintenance, and real estate taxes, was $0.5 million for each of the three months ended September 30, 2021 and 2020, and $1.5 million for each of the nine months ended September 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company has future commitments of $55.1 million and $56.7 million from debt repayments and office space under a non-cancelable operating lease expiring October 2023, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum annual operating lease and debt repayments are as follows (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;30, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Repayments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest/unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31, 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Repayments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest/unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s security deposit is in the form of, and recorded as, restricted cash. In January 2021, in connection with the Company&#8217;s amended loan agreement with modified terms, the interest-only period was modified from 24 months beginning October 1, 2021 to 36 months </span></div>beginning October 1, 2022, and accordingly, the current portion of the amount due was reclassified to non-current. Upon the completion of the Company raising over $50 million in its IPO in September 2021, interest-only payments were extended an additional 12 months followed by 12 months of amortization of principal and interest.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guarantees and Indemnifications  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, the Company enters into agreements that contain a variety of representations and provide for general indemnification. The Company&#8217;s exposure under these agreements is unknown because it involves claims that may be made against the Company in the future. To date, the Company has not paid any claims or been required to defend any action related to its indemnification obligations. As of September&#160;30, 2021 and December&#160;31, 2020, the Company does not have any material indemnification claims that were probable or reasonably possible and consequently has not recorded related liabilities. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Facility Lease </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2013, the Company entered into a three-year lease agreement for its current facility located in Redwood City, California. In 2018, the Company expanded the lease space and extended the lease agreement through October 2023. The lease agreement provides for an escalation of rent payments each year and the Company records rent expense on a straight-line basis over the term of the lease. Rent is payable monthly. As of September&#160;30, 2021 and December&#160;31, 2020, the remaining future minimum lease payments under this lease is $5.1 million and $6.7 million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Company&#8217;s adoption of ASC Topic 842, Leases, on January 1, 2020, the Company recorded a right-of-use leased asset of $6.0 million and a corresponding lease liability of $7.4 million and derecognized a deferred rent obligation of $1.4 million. The Company used its borrowing rate of 10% as its discount rate and the remaining operating lease term was 3.8 years. The results for the year ended December&#160;31, 2020 subsequent periods are presented under Topic 842.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rent expense recognized under the lease, including additional rent charges for utilities, parking, maintenance, and real estate taxes, was $0.5 million for each of the three months ended September 30, 2021 and 2020, and $1.5 million for each of the nine months ended September 30, 2021 and 2020, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company has future commitments of $55.1 million and $56.7 million from debt repayments and office space under a non-cancelable operating lease expiring October 2023, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum annual operating lease and debt repayments are as follows (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;30, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Repayments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest/unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31, 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Repayments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest/unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2021 and December&#160;31, 2020, the Company&#8217;s security deposit is in the form of, and recorded as, restricted cash. In January 2021, in connection with the Company&#8217;s amended loan agreement with modified terms, the interest-only period was modified from 24 months beginning October 1, 2021 to 36 months </span></div>beginning October 1, 2022, and accordingly, the current portion of the amount due was reclassified to non-current. Upon the completion of the Company raising over $50 million in its IPO in September 2021, interest-only payments were extended an additional 12 months followed by 12 months of amortization of principal and interest.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282916264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">Basis of Preparation The condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;). These consolidated financial statements include the accounts of the Company and its consolidated subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts and disclosures reported in the consolidated financial statements. Management uses significant judgment when making estimates related to its common stock valuation in periods before the Company&#8217;s IPO and related stock-based compensation, right-of-use lease asset, lease liability, the valuations of the redeemable convertible preferred stock warrant liability and loan facility derivative liability, as well as certain accrued liabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash, Cash Equivalents and Restricted Cash</a></td>
<td class="text">Cash, Cash Equivalents and Restricted Cash <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash in banks and highly liquid securities, which are readily convertible to cash, that mature within 90 days or less from the original date of purchase, to be cash equivalents, which include money market funds. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash equivalents are considered available-for-sale marketable securities and are recorded at fair value, based on quoted market prices. Unrealized gains and losses are recorded in other comprehensive income (loss) and included as a separate component of stockholders&#8217; equity (deficit). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash is related to the Company&#8217;s letter of credit for the lease of its corporate headquarters.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain financial assets and liabilities at fair value on a recurring basis, including cash and cash equivalents, and accounts receivable, accounts payable and accrued liabilities, which approximate fair value due to their relatively short maturities as well as the redeemable convertible preferred stock warrant liability and loan facility derivative liability. Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or a liability. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value: </span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt">Observable inputs such as quoted prices (unadjusted) for identical assets or liabilities in active markets.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt">Other inputs that are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant inputs are observable in the market or can be derived from observable market data.</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:20.44pt">Unobservable inputs that are supported by little or no market activities, which would require the Company to develop its own assumptions.</span></div>The fair value hierarchy also requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash, cash equivalents and, to a lesser extent, accounts receivable. The Company believes that credit risk in its accounts receivable is mitigated by its credit evaluation process, relatively short collection terms and diversity of its customer base. The Company generally does not require collateral and losses on accounts receivable have historically been within management&#8217;s expectations. </span></div>The Company&#8217;s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies, and institutions with investment-grade credit ratings, as well as corporate debt or commercial paper issued by the highest quality financial and non-financial companies, and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash and cash equivalents and issuers of investments to the extent recorded on the balance sheets. The Company has limited its credit risk associated with cash and cash equivalents by placing its investments with banks it believes are highly creditworthy and with highly rated investments.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy', window );">Allowance for Doubtful Accounts</a></td>
<td class="text">Allowance for Doubtful Accounts The Company provides for uncollectible accounts receivable by recording an allowance for doubtful accounts for balances deemed uncollectible. The Company evaluates the collectability of its accounts receivable based on known collection risks and historical experience. In circumstances where the Company is aware of a specific customer&#8217;s inability to meet its financial obligations to the Company (e.g., bankruptcy filings, substantial downgrading of credit ratings), the Company records a specific allowance for bad debts against amounts due to reduce the carrying amount of accounts receivable to the amount it reasonably believes will be collected. The Company has not experienced any significant collection issues.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text">Inventory Inventories are valued at the lower of cost, computed on a first-in, first-out basis, or net realizable value. The allocation of production overhead to inventory costs is based on normal production capacity. Abnormal amounts of idle facility expense, freight, handling costs, and consumption are expensed as incurred, and not included in overhead. The Company maintains provisions for excess and obsolete inventory based on management&#8217;s estimates of forecasted demand and, where applicable, product expiration. The Company has initiated voluntary recalls for a limited number of handpieces due to certain issues related to supply chain and manufacturing processes, of which the provision recognized was not material.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment and Intangible Assets</a></td>
<td class="text">Property and Equipment and Intangible AssetsProperty and equipment and Intangible Assets are stated at cost, less accumulated depreciation and amortization. Depreciation and amortization for property and equipment are determined using the straight-line method over the estimated useful lives of the respective assets, generally 3 to 5 years. The Company reclassifies inventory used at customer sites for evaluation purposes to property and equipment due to a limited history of sales of evaluation units. Amortization of intangible assets are determined using the straight-line method over the estimated useful lives, generally through the patent expiration date. Leasehold improvements are amortized on a straight-line basis over the shorter of their estimated useful lives or the term of the lease. Maintenance and repairs are charged to operating expenses as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist primarily of property and equipment and intangible assets, net, and are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If circumstances require that a long-lived asset be tested for possible impairment, the Company compares the undiscounted cash flows expected to be generated by the asset group to the carrying amount of the </span></div>asset group. If the carrying amount of the long-lived asset is not recoverable on an undiscounted cash flow basis, an impairment is recognized to the extent that the carrying amount exceeds its fair value. The Company determines fair value using the income approach based on the present value of expected future cash flows or other appropriate measures of estimated fair value. The Company&#8217;s cash flow assumptions consider historical and forecasted revenue and operating costs and other relevant factors. Since inception, the Company has not recorded impairment charges on its long-lived assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredChargesPolicyTextBlock', window );">Deferred Offering Costs</a></td>
<td class="text">Deferred Offering CostsThe Company capitalizes, within other assets, certain legal, accounting and other third-party fees that are directly related to the Company&#8217;s in-process equity financings, including its recent initial public offering, until such financings are consummated. After consummation of the equity financing, these costs are recorded to additional paid in capital as a reduction of the proceeds received as a result of the offering. Should a planned equity financing be abandoned, terminated or significantly delayed, the deferred offering costs are immediately written off to operating expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Deferred Revenue and Cost of Sales</a></td>
<td class="text">Deferred RevenueThe timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue will be recognized subsequent to invoicing. Service agreements are generally invoiced annually at the beginning of each coverage period and recorded as deferred revenue and recognized as revenue ratably over the coverage period. Deferred revenue that will be recognized during the twelve months following the balance sheet date is recorded as the current portion of deferred revenue, and the remaining portion, if any, would be recorded as non-current.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock', window );">Redeemable Convertible Preferred Stock</a></td>
<td class="text">Redeemable Convertible Preferred StockThe Company records redeemable convertible preferred stock at fair value on the date of issuance, net of issuance costs. The redeemable convertible preferred stock is recorded outside of permanent equity because it contains liquidation features that are not solely within the Company&#8217;s control. The Company determined that the carrying values of the redeemable convertible preferred stock should not be adjusted to the liquidation preferences because it is uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of redeemable convertible preferred stock. Subsequent adjustments to the carrying values of the redeemable convertible preferred stock to the liquidation preferences will be made only when it is probable that the redeemable convertible preferred stock will become redeemable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock', window );">Redeemable Convertible Preferred Stock Warrant Liability</a></td>
<td class="text">Redeemable Convertible Preferred Stock Warrant Liability The Company has issued freestanding warrants to purchase shares of redeemable convertible preferred stock to investors in connection with sales of certain of its redeemable convertible preferred stock. The Company classified these warrants as a derivative liability because they create a conditional obligation for the Company to repurchase its own shares for cash or other assets. The fair value of the warrants are recorded on the consolidated balance sheets at the issuance of the warrants and remeasured to fair value at each financial reporting date. The changes in the fair value of the warrants are recorded in the statement of operations as a component of interest and other income or expense as appropriate. The Company will continue to adjust the carrying value of the redeemable convertible preferred stock warrant liability for changes in the fair value of the warrants until the earlier of: the exercise of the warrants, at which time the liability will be reclassified to temporary equity or the expiration of the warrant, at which time the entire amount would be reversed and reflected in the consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Loan Facility Derivative Liability</a></td>
<td class="text">Loan Facility Derivative LiabilityThe Company has determined that its obligation to pay success fees to a lender upon a successful liquidation event or achieving a revenue target represents freestanding financial instruments. The instruments are classified as a non-current liability in the consolidated balance sheets and are subject to remeasurement at each financial reporting date. Any change in fair value was recognized through other income (expense) in the condensed consolidated statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For agreements with a term of more than twelve months, the Company determines if an agreement contains a lease at inception. Operating lease liabilities represent an obligation to make lease payments arising from the lease agreement. Operating lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the remaining lease term. In determining the present value of lease payments, the Company estimates its incremental borrowing rate as the rate of interest that the Company would have to pay to borrow on a collateralized basis over a similar term, of an amount equal to the lease payments in a similar economic environment. Operating lease liabilities are included in the Company&#8217;s consolidated balance sheet. Right-of-use assets represent our right to use an underlying asset for the lease term and are classified as non-current assets. Lease expense is recognized on a straight-line basis over the expected lease term in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through December&#160;31, 2019, the Company recorded the difference between rent paid and the straight-line rent as a deferred rent liability and leasehold improvements funded by landlord incentives or allowances are recorded as leasehold improvement assets and a corresponding deferred rent liability. Upon adoption of Accounting Standards Codification (&#8220;ASC 842&#8221;) on January 1, 2020, the unamortized deferred rent liability has been reclassified to reduce the right-of-use asset.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not elected to separate lease and non-lease components for any leases within its existing classes of assets and, as a result, records a right-of-use asset and lease liability based on the present value of the future minimum lease payments over the term at commencement date. Variable lease payments are expensed as incurred. The Company has also elected to not apply the recognition requirement to any leases within its existing classes of assets with a term of 12 months or less and does not include an option to purchase the underlying asset that the Company is reasonably certain to exercise.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">The Company has lessor arrangements with customers for a fixed monthly fee with no non-lease components, typically for 3-12 months. These arrangements are accounted for as an operating lease in accordance with ASC 842. These arrangements and related revenue are immaterial to the periods presented.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is derived primarily from the sales of the AquaBeam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Robotic Systems, and handpieces that are for one-time use during each surgery using the AquaBeam Robotic System. The AquaBeam Robotic System contains both software and non-software components that are delivered together as a single product and generally contain a one-year warranty. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To determine revenue recognition for arrangements that the Company determines are within the scope of ASC Topic 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ASC 606&#8221;), the Company performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when, or as, the Company satisfies the performance obligations. The Company only applies the five-step model to contracts when it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance obligations and assesses whether each promised good or service is distinct based on the contract. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contracts are typically in the form of an agreement and a purchase order from the customer. The Company&#8217;s AquaBeam Robotic System sales generally contain multiple products and services and can include a combination of the following performance obligations: robotic system, handpieces and consumables, and service. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines the transaction price it expects to be entitled to in exchange for transferring the promised product to the customer, which is based on the invoiced price for the products. All prices are at fixed amounts per the sales agreement with the customer and there are generally no discounts, rebates or other price concessions or a right of return, once the agreement is signed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the products or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the products and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue as the performance obligations are satisfied by transferring control of the product or service to a customer. The Company generally recognizes revenue for the performance obligations at the following points in time:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AquaBeam Robotic Systems</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - For systems (including system components and system accessories) sold directly to end customers, revenue is recognized when the Company transfers control to the customer, which is generally at the time of delivery. Systems rented for a fixed monthly fee during an evaluation period, typically 3-12 months, are recognized as revenue straight-line during the lease term, in accordance with ASC 842, and are not material. For systems sold following an evaluation period, revenue is recognized generally once sales terms are mutually agreed (as the system is already install at the customer site). For systems sold through distributors, revenue is recognized generally at the time of delivery. The Company&#8217;s system arrangements generally do not provide a right of return. The systems are generally covered by a one-year service agreement. The service agreements have a stand alone selling price and are typically recognized as deferred revenue and amortized over the one-year service period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Hand pieces and other consumables</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Revenue from sales of handpieces and other consumables is recognized when control is transferred to the customers, which generally occurs at the time of shipment but also occurs at the time of delivery.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Service</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - Service revenue, inclusive of the amounts associated with the AquaBeam Robotic System warranties, is recognized over the term of the service period, as the customer benefits from the services throughout the service period. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that certain promises in the multiple-element arrangements, such as installation, training and certain ancillary products, are immaterial, and/or do not represent separate performance obligations for which transaction price is allocated. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The timing of revenue recognition may differ from the timing of invoicing to customers. The Company records deferred revenue when revenue is recognized subsequent to invoicing, such as service contracts, which are recognized ratably as revenue over the performance period, which is not material. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s typical payment terms are between approximately 30 to 90 days. The Company expenses shipping and handling costs as incurred and includes them in the cost of sales. In those cases where shipping and handling costs are billed to customers, the Company classifies the amounts billed as a component of revenue. Taxes collected from customers and remitted to governmental authorities are excluded from revenue. The Company expenses any incremental costs of obtaining a contract, including but not limited to, sales commissions, as and when </span></div>incurred as the expected amortization period of the incremental costs would have been less than one year and are reported in selling, general and administrative expense in the statements of operations and comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Sales</a></td>
<td class="text">Cost of Sales Cost of sales consists primarily of manufacturing overhead costs, material costs and direct labor, including stock-based compensation. A significant portion of the Company&#8217;s cost of sales currently consists of manufacturing overhead costs. These overhead costs include the cost of quality assurance, material procurement, inventory control, facilities, equipment and operations supervision and management. Cost of sales also includes depreciation expense for production equipment, warranty and field service costs, and purchased intangibles and certain direct costs such as shipping costs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text">Research and Development Research and development costs are expensed as incurred. Research and development costs consist primarily of engineering, product development, and regulatory affairs, consulting services, materials, depreciation and other costs associated with products and technologies being developed, including employee and non-employee compensation, stock-based compensation, supplies, quality assurance expenses, related travel expenses and facilities expenses.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains a payment equity incentive plan to provide long-term incentives for employees, consultants and members of the board of directors. The plan allows for the issuance of non-statutory and incentive stock options to employees and non-statutory stock options to consultants and non-employee directors. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to determine the fair value of equity incentive awards and recognize compensation expense for all equity incentive awards made to employees and directors, including employee stock options. Stock-based compensation expense is recognized over the requisite service period in the statements of operations and comprehensive loss. The Company uses the straight-line method for expense attribution.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation model used for calculating the fair value of awards for stock-based compensation expense is the Black-Scholes option-pricing model (the &#8220;Black-Scholes model&#8221;). The Black-Scholes model requires the Company to make assumptions and judgments about the variables used in the calculation, including the fair value of the Company&#8217;s common stock, the expected term (weighted-average period of time that the options granted are expected to be outstanding), the expected volatility of common stock, an assumed risk-free interest rate and an expected dividend rate. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the Company&#8217;s common stock underlying the stock options has historically been determined by the Company&#8217;s board of directors (&#8220;Board&#8221;). Because there was no public market for the Company&#8217;s common </span></div>stock prior to the IPO, the Board determined the fair value of the Company&#8217;s common stock at the time of grant of the option by considering a number of objective and subjective factors, including valuations of comparable companies, sales of the Company&#8217;s redeemable convertible preferred stock, operating and financial performance and the general and industry-specific economic outlook. The Company used the &#8220;simplified method&#8221; to determine the expected term of the stock option. Expected volatility is based on an average of the historical volatilities of the common stock of publicly-traded companies with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected term of the option. The Company has elected to account for forfeitures when they occur.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_CommonStockValuationPolicyPolicyTextBlock', window );">Common Stock Valuation</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Common Stock Valuation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s intent has been to grant all options with an exercise price not less than the fair value of its common stock underlying those options on the date of grant. Prior to its IPO, the Company has determined the estimated fair value of its common stock at each valuation date in accordance with the guidelines outlined in the American Institute of Certified Public Accountants Practice Aid, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Valuation of Privately-Held-Company Equity Securities Issued as Compensation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(the &#8220;Practice Aid&#8221;). The Company&#8217;s board of directors, with the assistance of management, developed these valuations using significant judgment and taking into account numerous factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">valuations of its common stock with the assistance of independent third-party valuation specialists;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the stage of development and business strategy, including the status of research and development efforts, of its products and product candidates, and the material risks related to its business and industry;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of operations and financial position, including its levels of available capital resources;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the valuation of publicly traded companies in the life sciences and medical device sectors, as well as recently completed mergers and acquisitions of peer companies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prices of its redeemable convertible preferred stock sold to investors in arm&#8217;s length transactions and the rights, preferences, and privileges of its redeemable convertible preferred stock relative to those of its common stock;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the likelihood of achieving a liquidity event for the holders of its common stock, such as an initial public offering or a sale of the Company given prevailing market conditions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of the Company&#8217;s stockholders to freely trade its common stock in the public markets, resulting in a discount to reflect the lack of marketability of the Company&#8217;s common stock based on the weighted-average expected time to liquidity. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">trends and developments in its industry; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">external market conditions affecting the life sciences and medical device industry sectors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s board of directors determined the fair value of its common stock by first determining the enterprise value of the Company&#8217;s business using the market approach, income approach or from the value implied by the latest round of equity financing, and then allocating the value among the various classes of its equity securities to derive a per share value of its common stock. The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all option granted prior to the Company&#8217;s IPO in September 2021, the Board allocated the enterprise value based on the option pricing method (&#8220;OPM&#8221;). OPM treats the rights of the holders of preferred and common stock as equivalent to call options on any value of the enterprise above certain break points of value based upon the liquidation preferences of the holders of preferred stock, as well as their rights to participation and conversion. Thus, the estimated value of the common stock can be determined by estimating the value of its portion of each of these call option rights. When valuing options granted round the time of an equity financing that is considered arms-</span></div>length, OPM derived the Company&#8217;s equity value of a company from the price of the securities issued by the Company in the equity financing. Following the completion of the Company&#8217;s IPO in September 2021, the fair value of the Company&#8217;s common stock is determined based on the closing price of its common stock on The Nasdaq Global Market.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expenses</a></td>
<td class="text">Advertising Expenses The Company expenses the costs of advertising, including promotional expenses, as incurred. Advertising expenses were not significant.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy', window );">Defined Contribution Plan</a></td>
<td class="text">Defined Contribution PlanThe Company has a defined contribution retirement savings plan under Section 401(k) of the Internal Revenue Code. This plan allows eligible employees to defer a portion of their annual compensation on a pre-tax basis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for income taxes under the liability method. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates that will be in effect when the differences are expected to reverse. Valuation allowances against deferred tax assets are established when necessary to reduce deferred tax assets to the amounts expected to be realized. Currently, the Company has recorded a full valuation allowance against its deferred tax assets and there is no provision for income taxes, as the Company has incurred operating losses to-date. The Company&#8217;s policy is to record interest and penalties expense related to uncertain tax positions as a component of income tax expense in the statement of operations. To date, there have been no interest or penalties charged in relation to the unrecognized tax benefits.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing the net loss by the weighted-average number of shares of common stock and common stock equivalent shares from dilutive stock options and common stock warrants outstanding during the period. Because the Company has reported a net loss for all periods presented, diluted net loss per share is the same as basic net loss per share for those periods as all potentially dilutive securities were antidilutive in those periods.</span></div>The Company allocates no loss to participating securities because they have no contractual obligation to share in the losses of the Company. The shares of the Company&#8217;s redeemable convertible preferred stock participated in any dividends declared by the Company and were therefore considered to be participating securities.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment, Geographical and Customer Concentration</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment, Geographical and Customer Concentration </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as a single operating segment. The Company&#8217;s chief operating decision maker, its Chief Executive Officer, reviews financial information on an aggregate basis for the purposes of allocating resources and evaluating financial performance. The Company&#8217;s assets are primarily based in the United States.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_JobsActAccountingElectionPolicyTextBlock', window );">Jobs Act Accounting Election</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">JOBS Act Accounting Election </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to avail itself of this exemption and, therefore, for new or revised accounting standards applicable to public companies, the Company will be subject to an extended transition period until those standards would otherwise apply to private companies.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2018-13, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurement (Topic 820): Disclosure Framework&#8212;Changes to the Disclosure Requirements for Fair Value Measurement </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;ASU 2018-13&#8221;). The amendments on changes in unrealized gains and losses recognized in other comprehensive income categorized within Level 3, the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and the narrative description of measurement uncertainty should be applied prospectively in the initial fiscal year of adoption. All other amendments </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">should be applied retrospectively to all periods presented upon their effective date. The Company adopted ASU 2018-13 as of January 1, 2020, which did not have a material impact on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the FASB issued ASU No. 2018-11, Leases (Topic 842): Targeted Improvements (&#8220;ASU 2018-11&#8221;). ASU 2018-11 provided an alternative implementation method in addition to the current modified retrospective transition method for ASU No. 2016-2, Leases: Amendments to the FASB Accounting Standards Codification (&#8220;ASU 2016-2&#8221;), issued in February 2016. Under ASU 2018-11, an entity may elect to initially apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. Under ASU 2016-2, a lessee is required to recognize assets and liabilities for leases with lease terms of more than twelve months. ASU 2016-2 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company adopted ASC Topic 842, Leases, on January 1, 2020 using the modified retrospective transition method. In addition, the Company elected certain practical expedients permitted under the transition guidance, which allowed it to carryforward its historical long-term lease classification, its assessment on whether a contract is or contains a lease and the treatment of its initial direct costs for any leases that existed prior to the adoption of Topic 842. In determining the lease term at commencement date, any renewal or termination options are considered if they are reasonably assured of exercise. The Company has elected to exclude from its consolidated balance sheet any leases having a term of 12 months or less. The Company recorded a right-of-use leased asset of approximately $6.0 million and a corresponding lease liability of $7.4 million in its adoption of Topic 842. In addition, as of the adoption date, the Company derecognized a deferred rent obligation of $1.4 million. There was no cumulative effect adjustment upon the adoption of Topic 842.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments&#8212;Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (&#8220;ASU 2016-13&#8221;), which requires an entity to utilize a new impairment model known as the current expected credit loss (&#8220;CECL&#8221;) model to estimate its lifetime &#8220;expected credit loss&#8221; and record an allowance that, when deducted from the amortized cost basis of the financial assets and certain other instruments, including but not limited to available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. ASU 2016-13 requires a cumulative effect adjustment to the balance sheet as of the beginning of the first reporting period in which the guidance is effective. In November 2019, the FASB issued ASU 2019-10, Financial Instruments&#8212;Credit Losses (Topic 326), Derivatives and Hedging (Topic 815) and Leases (Topic 842): Effective Dates, which defers the effective date of ASU 2016-13 to fiscal years beginning after December 15, 2022 for all entities except SEC reporting companies that are not smaller reporting companies. ASU 2016-13 will be effective for the Company beginning January 1, 2023. The Company is currently evaluating the impact of the adoption of ASU 2016-13 on its consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740), which simplifies the accounting for income taxes, primarily by eliminating certain exceptions to ASC 740. This standard is effective for fiscal periods beginning after December 15, 2021, and for fiscal years beginning after December 15, 2020 for public business entities. The Company adopted ASU 2019-12, effective of January 1, 2021, and the adoption did not have a material impact on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_CommonStockValuationPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Valuation Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_CommonStockValuationPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_JobsActAccountingElectionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Jobs Act Accounting Election</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_JobsActAccountingElectionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Convertible Preferred Stock Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Redeemable Convertible Preferred Stock Warrant Liability, Policy</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredChargesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferral and amortization of significant deferred charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredChargesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangements entered into by lessor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919352-209981<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL117410129-209981<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL119206284-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235144<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235172<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5144-111524<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282046472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of assets and liabilities measured at fair value on a recurring basis (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:34.156%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.433%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash and cash equivalents:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">179,797&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,502&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">140,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">98,628&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total cash and cash equivalents</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320,484&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">320,484&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">100,130&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Preferred stock warrant liability</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Loan facility derivative liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Redeemable Convertible Preferred Stock Warrants</a></td>
<td class="text">The following table sets forth a summary of the changes in the estimated fair value of the Company&#8217;s redeemable convertible preferred stock warrants, which represents financial instruments with valuations classified as <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. However, Level 3 financial instruments typically include, in addition to the unobservable inputs, observable inputs (that is, components that are actively quoted and can be validated to external sources). Accordingly, the gain or loss in the table below includes changes in fair value due in part to observable factors that are part of the Level 3 methodology recognized in the statement of operations as a component of interest and other income or expense as appropriate (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase shares of redeemable convertible preferred stock outstanding and exercisable are as follows (in thousands, except per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.621%"><tr><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.477%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares Outstanding at</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:10pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:10pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the redeemable convertible preferred stock warrant liability was determined using the Black-Scholes option pricing model using the following assumptions: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.957%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend rate</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth a summary of the changes in the estimated fair value of the Company&#8217;s loan facility derivative liability, classified as Level 3 (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,787&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,782&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,482&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(177)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(172)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payment of success fee</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Revenue from External Customers by Products and Services</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue disaggregated by type and geography (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System sales and rentals</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Handpieces and other consumables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System sales and rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Handpieces and other consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outside of U.S. revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock', window );">Schedule of Earnings Per Share, Basic</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share was determined as follows (in thousands, except per share amounts): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,008)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,505)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.77)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock', window );">Schedule of Earnings Per Share, Diluted</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss per share was determined as follows (in thousands, except per share amounts): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14,103)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,008)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,505)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,741)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common stock outstanding</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,329&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,327&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.22)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.77)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.64)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.34)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities outstanding have been excluded from the computations of weighted-average shares outstanding because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares, in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock outstanding</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,402&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Redeemable convertible preferred stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,629&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue disaggregated by type and geography (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System sales and rentals</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,038&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">646&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Handpieces and other consumables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,458&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total U.S. revenue</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,391&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">System sales and rentals</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,725&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,111&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Handpieces and other consumables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,278&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total outside of U.S. revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,277&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,131&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,668&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,335&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents revenue by significant geographical locations outside the United States for the periods presented:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Germany</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Less than 10% of total net revenues for the period indicated.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on basic earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1278-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871276571944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Consolidated Financial Statement Items (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventory (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"/><td style="width:65.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.224%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,602&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,187&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventory</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,401&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,924&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"/><td style="width:65.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.224%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">310&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rent</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">245&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,653&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"/><td style="width:65.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.224%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory, manufacturing and computer equipment and furniture</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,911&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,645&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rental equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,941&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Evaluation units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,492&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,229&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,165&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,062&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,434)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,788)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property and equipment, net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Other Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Current Liabilities (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.416%"><tr><td style="width:1.0%"/><td style="width:65.504%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.222%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.550%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.224%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued purchases</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">432&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">403&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Professional services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">302&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,834&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,977&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Interest and Other Income (Expense), net</a></td>
<td class="text"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest and Other Income (Expense), net (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in fair value of preferred stock warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease (increase) in fair value of loan facility derivative liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(87)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total interest and other income (expense), net</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871274921960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock Warrant Liability (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights</a></td>
<td class="text">The following table sets forth a summary of the changes in the estimated fair value of the Company&#8217;s redeemable convertible preferred stock warrants, which represents financial instruments with valuations classified as <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3. When a determination is made to classify a financial instrument within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. However, Level 3 financial instruments typically include, in addition to the unobservable inputs, observable inputs (that is, components that are actively quoted and can be validated to external sources). Accordingly, the gain or loss in the table below includes changes in fair value due in part to observable factors that are part of the Level 3 methodology recognized in the statement of operations as a component of interest and other income or expense as appropriate (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of the period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(112)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(532)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of the period</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Warrants to purchase shares of redeemable convertible preferred stock outstanding and exercisable are as follows (in thousands, except per share data):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.621%"><tr><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.484%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.473%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.523%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.477%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares Outstanding at</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value at</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:10pt"><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Dates</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Exercise<br/>Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Initial<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:10pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Issuance</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Expiration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jun 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">E</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.73&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">763&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">177&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871277210952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Schedule of Redeemable Convertible Preferred Stock</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s redeemable convertible preferred stock are as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.156%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares<br/>Authorized</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Shares <br/>Issued and Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Carrying <br/>Value <br/>(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">A</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,243,223&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,104,728&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">2,781&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">B</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,841,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,543,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,404&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">C</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,564,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">1,564,851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,073&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">D</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,245,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">7,547,542&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">36,879&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">E</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,825,653&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">8,414,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">115,229&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">F</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,263,157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">5,226,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">76,488&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">26,983,984&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">25,402,402&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">243,854&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s redeemable convertible preferred stock terms were as follows: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Series</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Liquidation<br/>Preference<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">8%<br/>Dividend<br/>Per Share</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.5175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2014&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">B</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">C</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.0825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7275&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7279&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">G</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.1116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871274899880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock', window );">Schedule of Stock Option Activity and Related Information</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s stock option activity and related information are as follows (options in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Price</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, beginning of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,507&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,511&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,307)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(104)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding, end of period</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,607&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.08&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercisable</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation recognized, before taxes, is as follows (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">689&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">411&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,569&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Schedule of Fair Value Assumptions</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the options granted to employees or directors was estimated as of the grant date using the Black-Scholes model assuming the weighted-average assumptions listed in the following table: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.207%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.844%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (years)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend rate </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871275058856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Future minimum lease payments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum annual operating lease and debt repayments are as follows (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;30, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Repayments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest/unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31, 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Repayments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest/unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Future minimum annual operating lease and debt repayments are as follows (in thousands): </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September&#160;30, 2021</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Repayments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest/unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(559)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(238)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(797)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,582&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,344&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,032)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,762&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,312&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.842%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.843%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31, 2020</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Minimum Lease Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Repayments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,695&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total minimum payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,716&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: amount representing interest/unamortized debt discount</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(912)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,042)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,954)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Present value of future payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,958&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,762&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,259)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,096&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,503&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282133688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 320,484<span></span>
</td>
<td class="nump">$ 100,130<span></span>
</td>
<td class="nump">$ 113,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">243,173<span></span>
</td>
<td class="nump">$ 201,668<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_InitialPublicOfferingAbstract', window );"><strong>Initial Public Offering</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 172,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_InitialPublicOfferingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial Public Offering</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_InitialPublicOfferingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871281288184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 01, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split, conversion ratio</a></td>
<td class="nump">0.2105263158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForUnderwritingExpense', window );">Payments for underwriting discount and commissions</a></td>
<td class="nump">$ 13,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">$ 16,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares, number of shares issued upon conversion (in shares) | shares</a></td>
<td class="nump">29,912,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,912,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,912,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Deferred offering costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_ProductWarrantyTerm', window );">Product warranty period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_ServiceAgreementAmortizationPeriod', window );">Service agreement, amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future payments</a></td>
<td class="nump">$ 4,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">$ 1,415<span></span>
</td>
<td class="nump">$ 1,225<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="nump">$ 1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, shares authorized (in shares) | shares</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember', window );">Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 329,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,520<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance upon exercise of options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 855<span></span>
</td>
<td class="nump">$ 1,415<span></span>
</td>
<td class="nump">$ 1,225<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="nump">$ 979<span></span>
</td>
<td class="nump">$ 1,024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.00001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">6,556,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Sale of stock, consideration received on transaction</a></td>
<td class="nump">$ 172,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock | Over-Allotment Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">983,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_ProductWarrantyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Product Warranty Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_ProductWarrantyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_ServiceAgreementAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Service Agreement, Amortization Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_ServiceAgreementAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=122040515&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForUnderwritingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForUnderwritingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871358553224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 320,484<span></span>
</td>
<td class="nump">$ 100,130<span></span>
</td>
<td class="nump">$ 113,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Convertible preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">179,797<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">140,687<span></span>
</td>
<td class="nump">98,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">320,484<span></span>
</td>
<td class="nump">100,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Convertible preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Loan facility derivative liability</a></td>
<td class="nump">1,610<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">179,797<span></span>
</td>
<td class="nump">1,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">140,687<span></span>
</td>
<td class="nump">98,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">320,484<span></span>
</td>
<td class="nump">100,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Convertible preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Loan facility derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Convertible preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Loan facility derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Convertible preferred stock warrant liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Loan facility derivative liability</a></td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="nump">$ 1,782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282137528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value Rollforward (Details) - Redeemable convertible preferred stock outstanding - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning of the period</a></td>
<td class="nump">$ 129<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">$ 177<span></span>
</td>
<td class="nump">$ 870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales', window );">Exercised</a></td>
<td class="num">(112)<span></span>
</td>
<td class="num">(532)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">(653)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Cancelled</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">End of the period</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282764088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock Assumptions (Details) - Redeemable convertible preferred stock outstanding<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_WarrantsAndRightsOutstandingWeightedAverageTerm', window );">Warrant term (in years)</a></td>
<td class="text">1 year 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input (percent)</a></td>
<td class="nump">0.80<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input (percent)</a></td>
<td class="nump">0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input (percent)</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_WarrantsAndRightsOutstandingWeightedAverageTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants and Rights Outstanding, Weighted Average Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_WarrantsAndRightsOutstandingWeightedAverageTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputOptionVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282034696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Loan Facility Derivative Liability (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember', window );">Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget', window );">Trailing twelve month revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn', window );">Fee on first installment drawn</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn', window );">Fee if first two installments drawn</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn', window );">Fee if first three installments drawn</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn', window );">Fee if all four installments are drawn</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, loan facility</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward', window );"><strong>Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">Beginning of the period</a></td>
<td class="nump">1,787<span></span>
</td>
<td class="nump">$ 1,698<span></span>
</td>
<td class="nump">1,782<span></span>
</td>
<td class="nump">$ 1,482<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues', window );">Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="num">(177)<span></span>
</td>
<td class="num">(175)<span></span>
</td>
<td class="num">(172)<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements', window );">Payment of success fee</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs', window );">End of the period</a></td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="nump">$ 1,523<span></span>
</td>
<td class="nump">$ 1,610<span></span>
</td>
<td class="nump">$ 1,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Valuation Technique, Discounted Cash Flow | Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMeasurementInput', window );">Cash flow discount</a></td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Compliance, Contingent Trailing Twelve Month Revenue Target</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Four Installments Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Terms, Liquidity Occurrence, One Installment Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Three Installments Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Two Installments Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278759432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Revenue by Type and Geographic Location (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 8,668<span></span>
</td>
<td class="nump">$ 2,107<span></span>
</td>
<td class="nump">$ 24,335<span></span>
</td>
<td class="nump">$ 4,496<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">7,391<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">20,204<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | System sales and rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">5,038<span></span>
</td>
<td class="nump">646<span></span>
</td>
<td class="nump">14,368<span></span>
</td>
<td class="nump">1,106<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Handpieces and other consumables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="nump">5,458<span></span>
</td>
<td class="nump">930<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=prct_OutsideTheUnitedStatesMember', window );">Outside of U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">1,277<span></span>
</td>
<td class="nump">994<span></span>
</td>
<td class="nump">4,131<span></span>
</td>
<td class="nump">2,434<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=prct_OutsideTheUnitedStatesMember', window );">Outside of U.S. | System sales and rentals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">481<span></span>
</td>
<td class="nump">369<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
<td class="nump">1,111<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=prct_OutsideTheUnitedStatesMember', window );">Outside of U.S. | Handpieces and other consumables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">666<span></span>
</td>
<td class="nump">596<span></span>
</td>
<td class="nump">2,159<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=prct_OutsideTheUnitedStatesMember', window );">Outside of U.S. | Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 130<span></span>
</td>
<td class="nump">$ 29<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=prct_SystemSalesAndRentalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=prct_SystemSalesAndRentalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=prct_HandPiecesAndOtherConsumablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=prct_HandPiecesAndOtherConsumablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=prct_ServiceRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=prct_ServiceRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=prct_OutsideTheUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=prct_OutsideTheUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871276563768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Significant Geographical Locations Outside the United States (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Geographic Concentration Risk | Germany</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Revenue by significant geographical locations outside the United States</a></td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_DE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_DE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871281701544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Earning Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (14,103)<span></span>
</td>
<td class="num">$ (14,580)<span></span>
</td>
<td class="num">$ (12,822)<span></span>
</td>
<td class="num">$ (12,008)<span></span>
</td>
<td class="num">$ (12,606)<span></span>
</td>
<td class="num">$ (13,126)<span></span>
</td>
<td class="num">$ (41,505)<span></span>
</td>
<td class="num">$ (37,741)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common stock outstanding, basic (in shares)</a></td>
<td class="nump">11,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,361,000<span></span>
</td>
<td class="nump">3,327,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common stock outstanding, diluted (in shares)</a></td>
<td class="nump">11,580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,329,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,361,000<span></span>
</td>
<td class="nump">3,327,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5.64)<span></span>
</td>
<td class="num">$ (11.34)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (1.22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5.64)<span></span>
</td>
<td class="num">$ (11.34)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282995432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">6,607,000<span></span>
</td>
<td class="nump">31,629,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Redeemable convertible preferred stock outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,402,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=prct_RedeemableConvertiblePreferredStockWarrantsMember', window );">Redeemable convertible preferred stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=prct_CommonStockWarrantsMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share, amount (in shares)</a></td>
<td class="nump">6,607,000<span></span>
</td>
<td class="nump">6,143,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=prct_RedeemableConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=prct_RedeemableConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=prct_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=prct_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282953672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Customer Concentration (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark | Customer 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable | Customer 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=prct_Customer1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=prct_Customer1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=prct_Customer2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=prct_Customer2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=prct_Customer3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=prct_Customer3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278122008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Consolidated Financial Statement Items - Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 4,602<span></span>
</td>
<td class="nump">$ 2,647<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">612<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">5,187<span></span>
</td>
<td class="nump">4,226<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventory</a></td>
<td class="nump">$ 10,401<span></span>
</td>
<td class="nump">$ 6,924<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282919528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Consolidated Financial Statement Items - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_PrepaidInventory', window );">Prepaid Inventory</a></td>
<td class="nump">$ 310<span></span>
</td>
<td class="nump">$ 553<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_PrepaidSoftware', window );">Prepaid Software</a></td>
<td class="nump">580<span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidRent', window );">Prepaid Rent</a></td>
<td class="nump">252<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid Insurance</a></td>
<td class="nump">447<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other Prepaid Expense, Current</a></td>
<td class="nump">643<span></span>
</td>
<td class="nump">356<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 2,232<span></span>
</td>
<td class="nump">$ 1,653<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_PrepaidInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Inventory</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_PrepaidInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_PrepaidSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid Software</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_PrepaidSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278615912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Consolidated Financial Statement Items - Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 12,165<span></span>
</td>
<td class="nump">$ 13,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(6,434)<span></span>
</td>
<td class="num">(4,788)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">5,731<span></span>
</td>
<td class="nump">8,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prct_LaboratoryAndManufacturingEquipmentMember', window );">Laboratory, manufacturing and computer equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">2,911<span></span>
</td>
<td class="nump">2,645<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Rental equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">821<span></span>
</td>
<td class="nump">1,247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">4,941<span></span>
</td>
<td class="nump">4,941<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prct_EvaluationUnitsMember', window );">Evaluation units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 3,492<span></span>
</td>
<td class="nump">$ 4,229<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prct_LaboratoryAndManufacturingEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=prct_LaboratoryAndManufacturingEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=prct_EvaluationUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=prct_EvaluationUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871370748824">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Composition of Certain Consolidated Financial Statement Items - Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_AccruedPurchases', window );">Accrued purchases</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="nump">$ 432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPayableCurrent', window );">Interest</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">403<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional services</a></td>
<td class="nump">579<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesAndExciseTaxPayableCurrent', window );">Sales tax</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_AccruedClinicalTrialExpenses', window );">Clinical trial expenses</a></td>
<td class="nump">117<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">1,132<span></span>
</td>
<td class="nump">454<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total other current liabilities</a></td>
<td class="nump">$ 2,834<span></span>
</td>
<td class="nump">$ 1,977<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_AccruedClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expenses</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_AccruedClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_AccruedPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Purchases</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_AccruedPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesAndExciseTaxPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesAndExciseTaxPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282863880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Composition of Certain Consolidated Financial Statement Items - Interest and Other Income (Expense), net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Decrease (increase) in fair value of preferred stock warrants</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">78<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Decrease (increase) in fair value of loan facility derivative liability</a></td>
<td class="nump">177<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="nump">158<span></span>
</td>
<td class="num">(41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Interest and other income, net</a></td>
<td class="num">(52)<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_InterestAndOtherIncomeExpense', window );">Total interest and other income (expense), net</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">$ 344<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_InterestAndOtherIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest And Other Income (Expense)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_InterestAndOtherIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871283728904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Payments to acquire intangible assets</a></td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense', window );">Expected annual amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Expected Annual Amortization Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871359487288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan Facility (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($) </div>
<div>installment</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember', window );">Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget', window );">Trailing twelve month revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn', window );">Fee on first installment drawn</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn', window );">Fee if first two installments drawn</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn', window );">Fee if first three installments drawn</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn', window );">Fee if all four installments are drawn</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember', window );">Loan Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentInterestOnlyPeriod', window );">Interest only period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember', window );">Loan Facility | Line of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Loan facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityNumberOfInstallments', window );">Number of installments | installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Facility interest rate at period end (percent)</a></td>
<td class="nump">9.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.37%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Facility term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentInterestOnlyPeriod', window );">Interest only period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentPrincipalAndInterestPeriod', window );">Principal and interest period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount', window );">Covenant compliance, IPO capital raised in threshold amount</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod', window );">Covenant compliance, IPO capital raised in threshold amount achieved, extended interest only period (in months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod', window );">Covenant compliance, IPO capital raised in threshold amount achieved, extended principal and interest only period (in months)</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent', window );">Covenant compliance, revenue forecast for commensurate period, percent</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly', window );">Covenant compliance, revenue forecast amount, first two installments only</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly', window );">Covenant compliance, revenue forecast amount, first three installments only</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn', window );">Covenant compliance, revenue forecast amount, all installments</a></td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityFinalPaymentFeePercentage', window );">Final payment fee, percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent', window );">Early repayment fee first twelve month, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent', window );">Early repayment fee second twelve month period, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent', window );">Early repayment fee, twenty four months thereafter, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget', window );">Trailing twelve month revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn', window );">Fee on first installment drawn</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn', window );">Fee if first two installments drawn</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn', window );">Fee if first three installments drawn</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn', window );">Fee if all four installments are drawn</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember', window );">Loan Facility | Line of Credit | Base Rate | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod', window );">Facility base interest rate (percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.17%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember', window );">Loan Facility | Line of Credit | London Interbank Offered Rate (LIBOR) | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Facility interest, spread on base rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheOneMember', window );">Loan Facility, Tranche One | Line of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from long-term lines of credit</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheTwoMember', window );">Loan Facility, Tranche Two | Line of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLongTermLinesOfCredit', window );">Proceeds from long-term lines of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheThreeMember', window );">Loan Facility, Tranche Three | Line of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing amount</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget', window );">Trailing six months revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheFourMember', window );">Loan Facility, Tranche Four | Line of Credit | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing amount</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget', window );">Trailing six months revenue target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod', window );">Extended interest only period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod', window );">Extended principal and interest period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Contingent Borrowing, Extended Interest Only Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Contingent Borrowing, Extended Principal and Interest Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount Achieved, Extended Interest Only Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount Achieved, Extended Principal and Interest Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Revenue Forecast Amount, All Installments Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Revenue Forecast Amount, First Three Installments Only</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Revenue Forecast Amount, First Two Installments Only</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant Compliance, Revenue Forecast for Commensurate Period, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentInterestOnlyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Interest Only Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentInterestOnlyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentPrincipalAndInterestPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Principal and Interest Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentPrincipalAndInterestPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Compliance, Contingent Trailing Six Twelve Month Revenue Target</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Compliance, Contingent Trailing Twelve Month Revenue Target</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Four Installments Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Terms, Liquidity Occurrence, One Installment Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Three Installments Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Two Installments Drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Early Repayment Fee First Twelve Month, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Early Repayment Fee Second Twelve Month Period, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Early Repayment Fee, Twenty Four Months Thru Maturity, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityFinalPaymentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Final Payment Fee, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityFinalPaymentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_LineOfCreditFacilityNumberOfInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Number of Installments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_LineOfCreditFacilityNumberOfInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prct_LoanFacilityTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871282447064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock Warrant Liability - Schedule of Warrants to Purchase Shares of Redeemable Convertible Preferred Stock (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Convertible preferred stock warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember', window );">Series E, Redeemable Convertible Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Convertible preferred stock warrant liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 177,000<span></span>
</td>
<td class="nump">$ 763,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871281244984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock Warrant Liability - Narrative (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Jul. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance upon exercise of warrants (in shares)</a></td>
<td class="nump">62,000<span></span>
</td>
<td class="nump">4,448,000<span></span>
</td>
<td class="nump">531,000<span></span>
</td>
<td class="nump">45,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D, Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants exercised for redeemable convertible preferred stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,145<span></span>
</td>
<td class="nump">869,842<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrant term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D, Redeemable Convertible Preferred Stock | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance upon exercise of warrants (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">531,423<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">651,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember', window );">Series E, Redeemable Convertible Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.73<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember', window );">Series E, Redeemable Convertible Preferred Stock Warrants | Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises', window );">Issuance upon exercise of warrants (in shares)</a></td>
<td class="nump">62,454<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,454<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Stock Issued During Period, Shares, Warrant Exercises</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871277648616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Schedule of Temporary Equity by Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Mar. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,983,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Issued and Outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,850,000<span></span>
</td>
<td class="nump">25,402,000<span></span>
</td>
<td class="nump">25,402,402<span></span>
</td>
<td class="nump">25,402,000<span></span>
</td>
<td class="nump">21,118,000<span></span>
</td>
<td class="nump">21,073,000<span></span>
</td>
<td class="nump">20,998,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 328,564<span></span>
</td>
<td class="nump">$ 243,854<span></span>
</td>
<td class="nump">$ 243,854<span></span>
</td>
<td class="nump">$ 243,852<span></span>
</td>
<td class="nump">$ 173,677<span></span>
</td>
<td class="nump">$ 173,447<span></span>
</td>
<td class="nump">$ 173,068<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Issued and Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,104,728<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,841,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Issued and Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,543,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,564,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Issued and Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,564,851<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,245,295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Issued and Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,547,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember', window );">Series E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,825,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Issued and Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,414,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember', window );">Series F</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Shares Issued and Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,226,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871435715336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>customer </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>customer </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>customer </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock, shares, number of shares issued upon conversion (in shares) | shares</a></td>
<td class="nump">29,912,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,912,264<span></span>
</td>
<td class="nump">29,912,264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,402,402<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">$ 16,076<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrentAndNoncurrent', window );">Dividends declared and payable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted', window );">Common stock voting rights, number of votes (per share) | customer</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of redeemable convertible preferred stock to common stock upon initial public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesGRedeemableConvertiblePreferredStockMember', window );">Series G</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,447,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,528.9000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember', window );">Series F</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,226,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,178.2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_TemporaryEquityDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Dividends</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_TemporaryEquityDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Voting Rights, Number Of Votes Per Share Of Common Stock If Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90193-114008<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=SL6540498-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesGRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesGRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871381788424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Redeemable Convertible Preferred Stock - Schedule of Liquidation Preference (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share</a></td>
<td class="nump">0.08<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation Preference Per Share (in dollars per share)</a></td>
<td class="nump">$ 2,517.5000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share</a></td>
<td class="nump">201.4000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation Preference Per Share (in dollars per share)</a></td>
<td class="nump">$ 3,237.6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share</a></td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation Preference Per Share (in dollars per share)</a></td>
<td class="nump">$ 4,560<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share</a></td>
<td class="nump">364.8000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesDRedeemableConvertiblePreferredStockMember', window );">Series D</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation Preference Per Share (in dollars per share)</a></td>
<td class="nump">$ 5,082.5000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share</a></td>
<td class="nump">406.6000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember', window );">Series E</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation Preference Per Share (in dollars per share)</a></td>
<td class="nump">$ 13,727.5000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share</a></td>
<td class="nump">1,098.2000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember', window );">Series F</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation Preference Per Share (in dollars per share)</a></td>
<td class="nump">$ 14,727.9000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share</a></td>
<td class="nump">1,178.2000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=prct_SeriesGRedeemableConvertiblePreferredStockMember', window );">Series G</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLineItems', window );"><strong>Temporary Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare', window );">Liquidation Preference Per Share (in dollars per share)</a></td>
<td class="nump">$ 19,111.6000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_TemporaryEquityDividends', window );">8% Dividend Per Share</a></td>
<td class="nump">1,528.9000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_TemporaryEquityDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity, Dividends</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_TemporaryEquityDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreferencePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreferencePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesDRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesDRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesFRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=prct_SeriesGRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=prct_SeriesGRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871359509432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 31, 2015</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options outstanding and exercisable, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Options exercised in the period, intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Options vested in the period, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Average vesting period for unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,607,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,507,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Warrants issued (in shares)</a></td>
<td class="nump">12,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember', window );">Common Stock Warrants | Additional Paid-in Capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Warrants issued, value</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prct_A2021EquityIncentiveAwardPlanMember', window );">2021 Equity Incentive Award Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,303,910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prct_A2021EquityIncentiveAwardPlanMember', window );">2021 Equity Incentive Award Plan | Employee stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod', window );">Award cliff vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prct_A2021EquityIncentiveAwardPlanMember', window );">2021 Equity Incentive Award Plan | Incentive Stock Options and Nonqualified Stock Options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prct_A2021EquityIncentiveAwardPlanMember', window );">2021 Equity Incentive Award Plan | Incentive Stock Options and Nonqualified Stock Options | Minimum | Shareholder of Ten Percent Ownership or Greater</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Ownership interest, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prct_A2021EquityIncentiveAwardPlanMember', window );">2021 Equity Incentive Award Plan | Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Award contractual life (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prct_A2008StockPlanMember', window );">2008 Stock Plan | Common stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prct_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">412,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prct_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding stock maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=prct_A2021EmployeeStockPurchasePlanMember', window );">2021 Employee Stock Purchase Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,526,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Award Cliff Vesting Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prct_A2021EquityIncentiveAwardPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prct_A2021EquityIncentiveAwardPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=prct_ShareholderOfTenPercentOwnershipOrGreaterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=prct_ShareholderOfTenPercentOwnershipOrGreaterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prct_A2008StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prct_A2008StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=prct_A2021EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=prct_A2021EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278321016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Stock Option Activity (Details) - Common stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the beginning of the period (in shares)</a></td>
<td class="nump">6,507,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,511,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(1,307,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(104,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at the end of the period (in shares)</a></td>
<td class="nump">6,607,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">6,607,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,885,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 3.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">8.03<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">6.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at the end of the period (in dollars per share)</a></td>
<td class="nump">5.08<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">5.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 3.95<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278359400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Share Base d Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 925<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 1,569<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">62<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">174<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="nump">482<span></span>
</td>
<td class="nump">397<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 689<span></span>
</td>
<td class="nump">$ 411<span></span>
</td>
<td class="nump">$ 1,683<span></span>
</td>
<td class="nump">$ 1,104<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278374840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Fair Value Assumptions (Details) - Common stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
<td class="text">5 years 10 months 24 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average fair value (in dollars per share)</a></td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="nump">$ 2.41<span></span>
</td>
<td class="nump">$ 3.88<span></span>
</td>
<td class="nump">$ 1.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871277597144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Jul. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,582<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining operating lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross', window );">Total minimum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,141<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56,716<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember', window );">Cumulative Effect, Period of Adoption, Adjusted Balance | Accounting Standards Update 2016-02</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=prct_RedwoodCityCAMember', window );">Redwood City, CA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit | Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GuaranteeObligationsLineItems', window );"><strong>Guarantor Obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_DebtInstrumentInterestOnlyPeriod', window );">Interest only period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_DebtInstrumentInterestOnlyPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, Interest Only Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_DebtInstrumentInterestOnlyPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt Maturity, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuaranteeObligationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuaranteeObligationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CumulativeEffectPeriodOfAdoptionAxis=srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=prct_RedwoodCityCAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=prct_RedwoodCityCAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=prct_LoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139871278416744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Lease Payments and Long-Term Debt Maturities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Minimum Lease Payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 604<span></span>
</td>
<td class="nump">$ 2,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">2,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">2,092<span></span>
</td>
<td class="nump">2,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum payments</a></td>
<td class="nump">5,141<span></span>
</td>
<td class="nump">6,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: amount representing interest/unamortized debt discount</a></td>
<td class="num">(559)<span></span>
</td>
<td class="num">(912)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of future payments</a></td>
<td class="nump">4,582<span></span>
</td>
<td class="nump">5,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="num">(2,032)<span></span>
</td>
<td class="num">(1,708)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current portion</a></td>
<td class="nump">2,550<span></span>
</td>
<td class="nump">4,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MaturitiesOfLongTermDebtAbstract', window );"><strong>Debt Repayments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2023</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="nump">25,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2024</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total minimum payments</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: amount representing interest/unamortized debt discount</a></td>
<td class="num">(238)<span></span>
</td>
<td class="num">(1,042)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Present value of future payments</a></td>
<td class="nump">49,762<span></span>
</td>
<td class="nump">48,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion</a></td>
<td class="nump">49,762<span></span>
</td>
<td class="nump">44,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract', window );"><strong>Total</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">604<span></span>
</td>
<td class="nump">2,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne', window );">2022</a></td>
<td class="nump">2,445<span></span>
</td>
<td class="nump">8,695<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo', window );">2023</a></td>
<td class="nump">14,592<span></span>
</td>
<td class="nump">27,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree', window );">2024</a></td>
<td class="nump">37,500<span></span>
</td>
<td class="nump">18,750<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross', window );">Total minimum payments</a></td>
<td class="nump">55,141<span></span>
</td>
<td class="nump">56,716<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount', window );">Less: amount representing interest/unamortized debt discount</a></td>
<td class="num">(797)<span></span>
</td>
<td class="num">(1,954)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebt', window );">Present value of future payments</a></td>
<td class="nump">54,344<span></span>
</td>
<td class="nump">54,762<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent', window );">Less: current portion</a></td>
<td class="num">(2,032)<span></span>
</td>
<td class="num">(6,259)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities', window );">Non-current portion</a></td>
<td class="nump">$ 52,312<span></span>
</td>
<td class="nump">$ 48,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt, Excluding Current Maturities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt Maturity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt Maturity, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt Maturity, Remainder of Fiscal year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt Maturity, Unamortized Debt Discount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt Maturity, Year One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt Maturity, Year Three</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liability and Long-Term Debt Maturity, Year Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>prct_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaturitiesOfLongTermDebtAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaturitiesOfLongTermDebtAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>64
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( (Z!95,'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " ".@653+LM#UNX    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M3L,P#(9?!>7>NLF 0]3E N*T24A, G&+'&^+:-HH,6KW]K1EZX3@ 3C&_O/Y
ML^0:H\8NT7/J(B7VE&^&T+198UR+(W/4 !F/%&PNQT0[-O=="I;'9SI M/AA
M#P2JJNXA$%MGV<($+.)"%*9VJ#&1Y2Z=\0X7?/Q,S0QS"-10H)8SR%*",-/$
M>!J:&JZ "<:40OXND%N(<_5/[-P!<4X.V2^ION_+?C7GQATDO&TW+_.ZA6\S
MVQ9I_)6]YE.DM;A,?ET]/.Z>A%&5DH64176W4Y662LO;]\GUA]]5.'3.[_T_
M-KX(FAI^W87Y E!+ P04    " ".@653F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M (Z!95/I4W,M4@4   46   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MI5A;<^(V%'[>_@H-TX=V)L2VS'4G808<LF6ZFQ!(V]EV^B!L 9ZU+2K)D/S[
M'ME@D]0<N[-Y"+[H?/YT)'WG<G,0\IO:<J[)2QPEZK:UU7KWT;*4O^4Q4]=B
MQQ-XLQ8R9AINY<92.\E9D!G%D45MNV?%+$Q:HYOLV5R.;D2JHS#A<TE4&L=,
MODYX) ZW+:=U>K (-UMM'EBCFQW;\"77O^WF$NZL B4(8YZH4"1$\O5M:^Q\
M]%S7&&0C?@_Y09U=$S.5E1#?S,TLN&W9AA&/N*\-!(.?/?=X%!DDX/'/$;15
M?-,8GE^?T.^SR<-D5DQQ3T1_A('>WK8&+1+P-4LCO1"'7_AQ0EV#YXM(9?_)
M(1_;Z;2(GRHMXJ,Q,(C#)/]E+T='G!NX%PSHT8"^,W N?<$]&F2>LW)FV;3N
MF&:C&RD.1)K1@&8N,M]DUC";,#'+N-02WH9@IT>>V'-)S(J1-E%;)KFZL30
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MIAUQ*+C?@O),'-L]B'E'XG-9KIJA6"V5U2<_DV*:EDD]#L]Q4<3U^FY-&C0
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M5;YLJDO?Y565SYN/CTFL%E\MH/Y^G^?5]H>Z8/6N:/K5_P%02P,$%     @
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MUY6(_(V:Q9GE;5<5VK2#\P LJ6ZRWA:52!OO#*;.SD#9R?8'#4W%%%?WN:Y
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M1U!Q#B0I8BDIM=CB/ 0@:('@P SD58+H816/Q9\80>"AQH<XJ1[/VG0_@;$
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MI-8P4D;P!U-V0+"HRT-4<LQ?3S#S)_B'(3'$5;MNZFXE=)J1X>0YC (D6,,
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MX;Z5'RM<<#F( =9+[]/^10(,5^;+?P%02P,$%     @ CH%E4\ T<'Z5!P
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M/)Q?#X2+'[;B1;!K_IB$IAYLP3]S)9%#6H#G2VM#<T$;M%\7[_\-4$L#!!0
M   ( (Z!95.EG3D9+0L  ,HL   9    >&PO=V]R:W-H965T<R]S:&5E=#$S
M+GAM;.U:;7/;-A+^*QB?>]/.,+)(D7I)D\PXCM/FIKUFXK3]<',?(!*2T)"$
M"H!6=+_^G@4@BK(MAT[27N:F'V3S!=A=//OL8@'PR4;I=V8EA&7OJ[(V3T]6
MUJX?GYV9?"4J;@9J+6J\62A=<8M;O3PS:RUXX3I5Y5DR'([/*B[KDV=/W+/7
M^MD3U=A2UN*U9J:I*JZWST6I-D]/XI/=@S=RN;+TX.S9DS5?BBMA?UZ_UK@[
M:Z44LA*UD:IF6BR>GIS'CY^GU-XU^$6*C>E<,QK)7*EW=/.J>'HR)(-$*7)+
M$CC^78L+498D"&;\'F2>M"JI8_=Z)_VE&SO&,N=&7*CR5UG8U=.3Z0DKQ((W
MI7VC-M^+,)Z,Y.6J-.XOV_BVV>2$Y8VQJ@J=84$E:_^?OP\X=#I,AT<Z)*%#
MXNSVBIR5+[CESYYHM6&:6D,:7;BANMXP3M;DE"NK\5:BGWWV1A0";IZ7@EVH
M^EIH*^GZ-; 16HN"75F5OV._<JUY;=D/DL]E*>WVR9F%=I)QE@=-S[VFY(BF
M&?M1U79EV&5=B.*P_QFL;DU/=J8_3^X5>"76 S8:1BP9)O$]\D8M%",G;W1$
MWN7O#0;&_G4^-U:#+?^^1V;:RDR=S/1/@/=>312\C\V:Y^+I":+3"'TM3CY:
M_>Z)85:Q=:/S%8C/S(I#,E,+1&,K-^_(7;=RC9.+)& LKPM9+QG^,?%>Z%P:
MUP^B&#=LH4KD!<.^EC6S*]48M#,16N9B;=E::*^5%2#W-X_9E3?AIZY@RUYR
MJ=DOO&P$W2$.T.32ZQ(,-+&BFD,2<>6%R,--'+%7M;22E_<V,:;A=2X@;RTU
M=YGD2F@)#40[^C/L7/VCJ7$13\)%DK!+%H\&DQ'[^]^F29Q\RR8)FXQ'[+1]
M<,KBR02FH$NYI<Y9Q  &<*U#YMI(NP(X@LF=,7!!%_=:8<21:W*AJC6OMZXI
M_# =SZ)IFO1UV*9U^PI ;@2 [_I,UJ!#&/V+OC)E58E"PB?E-O)#.<T&P^E.
M,'60&)+G1XLQ$%@@7;.MX-H,V(M&DZ]IA':EA6]>(P18Y9.*H*1RPY'DD6@_
M)LQ@+(-/TV3DNH^S.!HETQVMNZ,5183AF;5P<P89[O0IZ'/-U"'_#AA#6@?>
MGVA.9/B,_HR'TRA.LS_ GY<,\)#&6KRW3*L& ^X=Z0<.(J@>Y"2 -DZB-$OW
M]AXZ(X@4L(;J#%($;-NW;2_''_+=44_=UOU)W*K5,9,'['Q7Z!",'5>ZN)]\
M:_KZ\#!1/KY-MIT'0VX,_RY@UY;&=<[B*$E'40+:QU$\3*,)2'_*DF@RC=ES
M/)NF^ TS7&5H-QVF+(M2_+V@)^,TFF9QYVH2#9'.7K II&91,LOP)$OIE[#1
M.)I.9N#2-)HF633.1KA*XS1*9V,6([,ER8R]A/AD/(KB;$)7R3B:P9#).$JG
M4_96621D]VR$7\H2LB6A']E,]H$G/Z]5[3#-@6DI7%0=0?G5ZY\H_/;>\X3C
M);3,HEF<P):T,[5)%RVB?M1E3E]7-2C7D+]R2-_N6N*MB[,[M<%^D&S7';R3
MB#V1E]P8N9#H>CI*9H,,E5]9AD'VM 4:>5%(@@: KKDL'E$6XFM) ).H1I.
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ME>"P#S7 ^X4"L<(-#=!^FOST/U!+ P04    " ".@6531?E+\=8+  ##(P
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MGU5KF:J7 X1;I>R=&G1)__4OLR2^?%[Y#5A3X?Y]F4(JN+NXWD@+D7-98E!
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M=),]W61/-]G33?9TDSW=9$\WV=--]G23/=UD3S?9TTWV=)/]OV^RHX.OX+5
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M^)P#)S[AJH%5P/&68!<+XXE"6KDJ3H(;3M:(!XP/E?6QAY7U/NJ-47L[.)#
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MF".+B3Y:U@4(FLZQ>79.&5/OTB$_$>]FCQNB#QM\;[>#8:/)CL8_J"4I+'
M(.-.U@ZTZVF;<1.IMDE1XE84][[&@"6N37W;6U![U'0*H2HF)#$@26^DF7=
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MX*N*D60R43ECY&>Y+$DFE3"2@GS)\IR4X5E2"(+@":M*06)P&0(5!7A!@9^
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MRM*KR2W7]$Q%S0KT^U(I>]AP@/;A._T74$L#!!0    ( (Z!95-KZ+QVQ@,
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MII^R'OGU1HN-&X(KH<U(=<O"W)(H;8!YGPNA]QLKT-Z[DW]02P,$%     @
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M#3RP)"N<)_*)[?\F98?N=+Z8):+X#_8E-O! G O)TC)8,4AI=OC%O\I"' 7
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M+I@IN^>JRGH?T4$7-KGT8(.Q!=4?M$Q>:%P!HDL% OP!QZC[;)OK]P]D1Q(
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M*H("9V*IZ,FLO^,VH7//EQOEPA76V[U)!/G2D2FW8%902EW?Q>O6B#U UOT
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M7#3"PL3IPF8FF)=X7A=V;X0Y3M*%/1AAD1-U88\FF _ +FQN@ 5NZ(1=V,(
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MN%GJX@9>2$24 .A?<:[>*Z6#YLTU_1M02P,$%     @ CH%E4\\R(38S P
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M971S+W-H965T,S<N>&ULO5?;CM,P$/T5*^(!I&43)VG2KMI*T 6!!%*UY?*
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M+W-H965T,SDN>&ULI59-;]LX$/TKA-!# J21+<D?"6P#B>5B<R@:U.WV4/1
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MC(&>7W.N]ATC4#['AO\ 4$L#!!0    ( (Z!95,'SI)1OP<  $0K   9
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MY_O.Y3O.R;3DXDEF  J]Y)3)F9,I55R[KDPRR+$<\ *8/MERD6.EMV+GRD(
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MN6<SVSB;=I2&U'%E$XC?96Q@4JY 6@R.E/8A#[P53R+)X'4EK^D \2-?^DZ
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MCU2Q:Q%_Y9%>G@\F Q2Q.<UB_4EL_F+EA$;&7RABE?]%FW*L-T!AIK1(2F-
MD/"T^$^?2B)V#,!/LP$I#<B> 1FW&/BE@;\?(6@Q"$J#8-^@+<*H-!CUA30N
M#<8Y]P59.=,W5-.+,RDV2)K1X,U<Y,N56P/!/#69]: E_,K!3E\\:!%^6XHX
M8E+]@6Z_9UP_HW?H Y62FC5';VZ8ICQ6;^'IEX<;].:WM^@WQ%/T>2DR1=-(
MG0TU #'NAF$9]*H(2EJ"8G0O4KU4Z#:-6-1@?^VVGW;9WW;$)PX'0V"PHI%L
M:;PB3H_W]!GY^ @1#X^:YN.V?F"K8^1[QIS@!O.;_N9>$QMN\QL6'I?@"6DP
MO^MO[CFH]*N,]'-_?MMLEE2R=T8M(G0M$I!017,1NH243!<,9$TK1YR@BA/D
M<8*6.!]7QJM"(+=*0Q[S=('@'V)/3(9<T<>8'2&Z6$BVH)I!QFO)05!#M*9Q
MQIH6N8@WSN,915]?3"<G'G"RWF6S/FH\W1GT8BZC:BZCU\[EE=@+_Z,=5 1/
M1C7P]6'35O#C"ORX%_B2>%AV4!>]9&C%)!?141_XXQJN$=X'?S.N,8\G;>!/
M*O GO<"OF=)UY'/*93OHDSKG00WT21TT:0,]J4!/G*"_I)*%8I'R?P!RN/N.
MA4+I)JB3>FK7,[L^:#QJ@SJMH$Z=4"_73$*'D_-KWM""600M%<I>/0MW*(*>
M&94*80\E174@ 8KH<U.!N_LEKEXP@CU;LCVG=U!%\(J4*=U(% GH<KS3"^"#
M2B\F-A)YM?B^@9='&03J;6-+0&JORWCL01;NIV'3P-'+@2]1V\J$_3[$YST3
M^FI:I X^;"W"P6&9MY4"NTO%%C;B2F40S<WZ%:XK/B:^-VFATFH^=HM^(Y7H
M![J,(FXF3F,THSQZ!^BNZ8IK&KMF;]4:GQR69RNQV*VQ>SP?M9:!*US73=-$
M-O)K91-W*!!TDMMV_GT:PK1,,W^YH3)"LYBFKI[7"A'Q#LHFL<I$<'_)@UQE
M<LV**C#/="99SC*%>7:I2!EG-Y]]W_.GN$4<B)4TXI:T+L8AN6^352R>&>LM
MW<1*$SELUTRL5!%WWUS,:*\>&];SDM=,NMMC4)BZT%EY(VYY*]"%,9_/7XG1
M[1?GIBZ(5OJ(6_KRI5*(KF%;;789>1HOC%AT)F^]S?6A&6RM;,3J(G&WL3V2
MUSXN1'M;PLV>Z8-(OV<42.>0?B]__H'N><J3+'%Q9U653 Z;YE9 B5M 9YD,
MEQ 'K20'61%STV)6&G1DDLKPT;A,;L\8>\>>][MKJVP5V'>W@O_#NL%5SGKQ
MD<@0\9FE:%9,'WW<I$RJ)5\A2.(_)8/MINLM\:WB^X?M17TKW'Y'+UI- 3::
M#-X][5S=#F_=B[OS(<3=;O98W%=N!7RK\OYA&U+?*K;?2[%AFR1IJ"$;$>0C
MZU#K#I^P[^HJ*;[5:]^MU_]!"3H\8Z\S6:R"^UT*[DW*5_@G<\.*L']8$?:M
M"/MNJ?R);6+I<6_WUUXC ZNU01^MW;9P)=7;W.CHJ0.K>\%A=2^PNA>XE>J7
M]=1!?<,=8#*=M&P2 RN 01\!=# .67XG) OI_O>>EP%W/@D?5O4"JWJ!6Z'*
M^FD^;8&@[.9WL1X)?:HW3<77_ [/N$-2 BM\@5N>^M!_WX3S93PK8<%A-^>!
M5;# O3G_=:D_J7\>\49D[-=V\,.=,[J$R45^FJJ@E&2I+@Y'JJ?5B>UE?DZY
M]_P:G][@AN>W^/2N.(^U[HOCX7LJ%QQ4-&9S".4=GP!<69RX%C=:K/(3PD>A
MM4CRRR6CT.V9 ?#[7 B]O3$!JG/OBW\!4$L#!!0    ( (Z!95.M7*/^8@,
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MQ0B%I4KE= ?JT.!%P5@T),M-1?3"I*JOS&.B:FS@.D"]7S(F#PV=H*K:QW\
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MM/6=2!_UZ:,^ULN%C*L/%L?MDYC#/=(DB:(XQC(Z'CL5C+&\Q3%\W6R8-O#
MXD"DU^4:GVV\0O;7 3:G^RH$&RE>B=A(\5P#XLX;>"2)>[:Q.."!S0)6.Q#?
M'0=JRNT313"KF#9L!>-(DF (U**[1N,8R4X,'_?\8*LDBI+$C0#F5A!%& *K
M$4<P!: !0Z*H>@[N/(^"]7,JV/R!/_H+4$L#!!0    ( (Z!95.7BKL<P
M !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6
MH@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.
MD4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,
M<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW'
M]I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ CH%E
M4]CAD[;M P  !2,   \   !X;"]W;W)K8F]O:RYX;6S%FEUOVS84AO\*H9ME
M%YTMB78^4!=HDZ8+,+1!7>0V8"3:)B*1+DD[:W[]*!GNCE;CQ6X.=&6)DJA'
MI,F'YTAO7YQ_?G+N6?S=-C8LLDV,VZO))%0;W:KPA]MJFXZLG&]53+M^/0E;
MKU4=-EK'MID4T^E\TBICLW=OCW7=^PG=<5%7T3B;"KN"!Z-?PK_'NUVQ-\$\
MF<;$'XNLWVYT)EIC36M>=;W(IID(&_?RI_/FU=FHFF7E7=,LLOQPX$'[:*I?
MBI<=Y#?U%/J2J)Z^J@2RR.;35.'*^!#[,_KZ56+<ZW3R86\7W:UIHO8W*NI/
MWNVVQJZ[:M)33,AC].UP_#TTXI7_/\WH5BM3Z1M7[5IMXZ$=O6XZ0!LV9ALR
M856K%]FUVVLOMFJMNX=*=[FK#P\8$QEI+G]ET@%_5_>,G#RVUC;H6J2MX!I3
M)XY:?%"-LI46!+( D,6(D(\%@2P!9#D*Y++#29<22 D@Y8B0@Y:< <C9F) E
M@9P#R/F8D)) G@/(<U[(+WZMK'GM#Q"B"T!TP4NTW+6M\C^$6XFE65N3+E,V
MBO=5Y78V&@)Y"2 ON?NVW;I@NO(.]#KY*#GQ9T?3F7N*INXI+^9=<J===S<5
M[T-(XJ)@T"G,4OG+*2MN5=6O 2@4<DC.+)&ONM:IDJZU4D?NNS5&MWWO]4I[
M/] QLDC.K!&(.9BA<^21G%DDR^BJYXUK:NW#;^+C]]U_>AKI(V?W1]N:V)T4
MA++]!!W3>D_;RNC!&$'ZR)G] 2?"83\C@>3,!L&8U,4YLDK.K!4X8P];$WDE
M9Q8+'MRT-0LDEH)9+!B3KFT*I)F"63.GYB!Q]JWC#K]32!BZL,<N8#(29Q03
M::=@U@Y=*8JS&YV&3S-L1&2;@MLV<!8:_"&1> IF\6#,&<5$ZBE&5<^<8B+U
M%*.JYYQB(O448T8TCQ<4$ZFG8%8/QKRD.12DGI)9/0CSL8^V?F(B]93<ZH&8
M.<5$\BF9Y8,Q!XDSF#ECE@_&I,NB$EFH9$^>H47F !-9J.0/?P FE66)+%2R
M)] 0)I5EB2Q4,EL(8U)9ELA"Y:@!$)5EB2Q4,EOHEY35R;6F1 :2S 8:)*].
MXR'S2&;SX-B,#AN)S"/'S+8-AHU$YI&C9MOHL)'PK0VS>3 F76-*9![);!Z,
M2=>8$IE'<L<_I_(&;\1GY7TZ>4\QD7DD=_QS&G.9JJYW#4U82V0>R1W_(,Q!
MZDTB\TCN^.<TYJTR7CRHAK[Y1/:9,=L'IXO>4$QDH1G[9P, <_@>&5EHUEMH
M<OSLHM8K8W7].=TBI/)*-=6]%]W/X>V1G'79V]6N::Y3V1>;5%T?O^(X?H'R
M[A]02P,$%     @ CH%E4XHQ=E_/ 0  ,Q\  !H   !X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<\W9RVK"0!B&X5N17(#C?X@]H%UUTVWQ!H(=#WA(R$RI
MWGU%%_8+7713YEN%2<B?%P(/83)[C_LF;]MCVFR[-#H=]L<TKS8Y=\\AI.4F
M'IHT;KMXO%Q9M?VAR9=EOPY=L]PUZQAT,IF&_N>,ZF7V<^9H<>[B7R:VJ]5V
M&5_;Y><A'O,O@\-7V^_2)L9<C19-OXYY7H73_GXZA>M!QI?)U>CM8U[U;Q]2
MA=)!"D%:/L@@R,H'.01Y^: :@NKR05,(FI8/>H"@A_)!CQ#T6#[H"8*>R@?)
M!&6<$"0-L";06I!K(?!:$&PA$%N0;"$P6Q!M(5!;D&TA<%L0;B&06Y!N(;!;
M$&\AT%M1;R706U%O)=!;!Q_;!'HKZJT$>BOJK01Z*^JM!'HKZJT$>BOJK01Z
M*^JM!'HKZJT$>AOJ;01Z&^IM!'H;ZFT$>MM@LX1 ;T.]C4!O0[V-0&]#O8U
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M%%D5BJQ#%%F'*+(._U/6=V-6?_V7MKFGE2[J8SYK?X5//P%02P$"% ,4
M" ".@653!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( (Z!95,NRT/6[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( (Z!95.97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ CH%E4^E3<RU2!0  !18  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( (Z!95/-R$_C
M$0<  &4>   8              " @94-  !X;"]W;W)K<VAE971S+W-H965T
M,BYX;6Q02P$"% ,4    " ".@653XD7YOWD#  #V#0  &
M@('<%   >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ CH%E
M4SF,8:&F!0  F!8  !@              ("!BQ@  'AL+W=O<FMS:&5E=',O
M<VAE970T+GAM;%!+ 0(4 Q0    ( (Z!95-==[/6EPP  $!=   8
M      " @6<>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4
M" ".@653YH<3T]D'  !D(@  &               @($T*P  >&PO=V]R:W-H
M965T<R]S:&5E=#8N>&UL4$L! A0#%     @ CH%E4R\&&6*M @  +0<  !@
M             ("!0S,  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4
M Q0    ( (Z!95/2]50<P 0  #D*   8              " @28V  !X;"]W
M;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " ".@653)I @:_ F   A
MA@  &               @($<.P  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL
M4$L! A0#%     @ CH%E4XUDTKP"!0  K0L  !D              ("!0F(
M 'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " ".@653*M*:
M *T$   ^"P  &0              @(%[9P  >&PO=V]R:W-H965T<R]S:&5E
M=#$Q+GAM;%!+ 0(4 Q0    ( (Z!95/ -'!^E0<  &D4   9
M  " @5]L  !X;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @
MCH%E4Z6=.1DM"P  RBP  !D              ("!*W0  'AL+W=O<FMS:&5E
M=',O<VAE970Q,RYX;6Q02P$"% ,4    " ".@653ZP3'&2L+  "F+   &0
M            @(&/?P  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4
M Q0    ( (Z!95-%^4OQU@L  ,,C   9              " @?&*  !X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ CH%E4WUKPD&B!P
M<"$  !D              ("!_I8  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX
M;6Q02P$"% ,4    " ".@6539.^AJ? J   IE0  &0              @('7
MG@  >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( (Z!95,/
MC#&]G D  /,@   9              " @?[)  !X;"]W;W)K<VAE971S+W-H
M965T,3@N>&UL4$L! A0#%     @ CH%E4^W!B;4E!0  =PT  !D
M     ("!T=,  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4
M" ".@653F9J(5M@$  #&"@  &0              @($MV0  >&PO=V]R:W-H
M965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( (Z!95-[599Y/P,  - &   9
M              " @3S>  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L!
M A0#%     @ CH%E4QO<#"&B!   ! L  !D              ("!LN$  'AL
M+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " ".@653:^B\=L8#
M  #>#   &0              @(&+Y@  >&PO=V]R:W-H965T<R]S:&5E=#(S
M+GAM;%!+ 0(4 Q0    ( (Z!95/MG+/@WP(  (,'   9              "
M@8CJ  !X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ CH%E
M4S,(D(/(!P  5"8  !D              ("!GNT  'AL+W=O<FMS:&5E=',O
M<VAE970R-2YX;6Q02P$"% ,4    " ".@6531>V'AFX$  "N%@  &0
M        @(&=]0  >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0
M   ( (Z!95/>5Z[O=P,  ,$*   9              " @4+Z  !X;"]W;W)K
M<VAE971S+W-H965T,C<N>&UL4$L! A0#%     @ CH%E4]\)Y5?P @  P@@
M !D              ("!\/T  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q0
M2P$"% ,4    " ".@6537F@6&KH$  !7$@  &0              @($7 0$
M>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( (Z!95.''E4!
M<@0  %L4   9              " @0@& 0!X;"]W;W)K<VAE971S+W-H965T
M,S N>&UL4$L! A0#%     @ CH%E4TAW43-Z @  308  !D
M ("!L0H! 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " ".
M@653-M]X *@#  !_#0  &0              @(%B#0$ >&PO=V]R:W-H965T
M<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( (Z!95//,B$V,P,  (@-   9
M          " @4$1 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#
M%     @ CH%E4Z7<CJK> @  3@L  !D              ("!JQ0! 'AL+W=O
M<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " ".@653,&NA#)T"  "6
M!@  &0              @(' %P$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM
M;%!+ 0(4 Q0    ( (Z!95,%_15IWP(  !0(   9              " @90:
M 0!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ CH%E4V:0
M(XEH P  '0P  !D              ("!JAT! 'AL+W=O<FMS:&5E=',O<VAE
M970S-RYX;6Q02P$"% ,4    " ".@653,-"95@(#  !\"   &0
M    @(%)(0$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    (
M (Z!95-S-9C=A@,  !T+   9              " @8(D 0!X;"]W;W)K<VAE
M971S+W-H965T,SDN>&UL4$L! A0#%     @ CH%E4YY]R<?T @  F@D  !D
M             ("!/R@! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"
M% ,4    " ".@653!\Z24;\'  !$*P  &0              @(%J*P$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( (Z!95.;$[D=Y (
M -D(   9              " @6 S 0!X;"]W;W)K<VAE971S+W-H965T-#(N
M>&UL4$L! A0#%     @ CH%E4[^X]^A6!   U!,  !D              ("!
M>S8! 'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " ".@653
M6YHUE:0$   Q&   &0              @($(.P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0T+GAM;%!+ 0(4 Q0    ( (Z!95-":?=9Z 0  %<5   9
M      " @>,_ 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%
M  @ CH%E4Q(K-?G  P  51$  !D              ("! D4! 'AL+W=O<FMS
M:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " ".@653IR_@/$P&   #'P
M&0              @('Y2 $ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+
M 0(4 Q0    ( (Z!95.M7*/^8@,  $4,   9              " @7Q/ 0!X
M;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ CH%E4QBT=#1Y
M P  M P  !D              ("!%5,! 'AL+W=O<FMS:&5E=',O<VAE970T
M.2YX;6Q02P$"% ,4    " ".@6534T'%&DX#  #!"P  &0
M@('%5@$ >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( (Z!
M95,F#X,2$ 4  )L6   9              " @4I: 0!X;"]W;W)K<VAE971S
M+W-H965T-3$N>&UL4$L! A0#%     @ CH%E4TS1%^>0!   UQ4  !D
M         ("!D5\! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4
M    " ".@653IU:A4F@#  #-%P  #0              @ %89 $ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( (Z!95.7BKL<P    !,"   +
M  "  >MG 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( (Z!95/8X9.V[0,   4C
M   /              "  =1H 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" ".@653BC%V7\\!   S'P  &@              @ 'N; $ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " ".@653,N&!X<<!   2'P
M$P              @ 'U;@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
../  \ %L0  #M< $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>264</ContextCount>
  <ElementCount>411</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/Coverpage</Role>
      <ShortName>Cover page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets - Parentheticals</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>Condensed Consolidated Balance Sheets - Parentheticals</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1405401 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Parenthetical</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Parenthetical</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/Organization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2116103 - Disclosure - Composition of Certain Consolidated Financial Statement Items</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItems</Role>
      <ShortName>Composition of Certain Consolidated Financial Statement Items</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2123104 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2125105 - Disclosure - Loan Facility</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/LoanFacility</Role>
      <ShortName>Loan Facility</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2127106 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiability</Role>
      <ShortName>Redeemable Convertible Preferred Stock Warrant Liability</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2131107 - Disclosure - Redeemable Convertible Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStock</Role>
      <ShortName>Redeemable Convertible Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2136108 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2142109 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2317302 - Disclosure - Composition of Certain Consolidated Financial Statement Items (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables</Role>
      <ShortName>Composition of Certain Consolidated Financial Statement Items (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItems</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2328303 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock Warrant Liability (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiability</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2332304 - Disclosure - Redeemable Convertible Preferred Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockTables</Role>
      <ShortName>Redeemable Convertible Preferred Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiability</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2337305 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/StockholdersEquity</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2343306 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CommitmentsandContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/CommitmentsandContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Organization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/OrganizationDetails</Role>
      <ShortName>Organization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/Organization</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Summary of Significant Accounting Policies - Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2408405 - Disclosure - Summary of Significant Accounting Policies - Fair Value Rollforward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value Rollforward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2409406 - Disclosure - Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Summary of Significant Accounting Policies - Loan Facility Derivative Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Loan Facility Derivative Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2411408 - Disclosure - Summary of Significant Accounting Policies - Revenue by Type and Geographic Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Revenue by Type and Geographic Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2412409 - Disclosure - Summary of Significant Accounting Policies - Significant Geographical Locations Outside the United States (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Significant Geographical Locations Outside the United States (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2413410 - Disclosure - Summary of Significant Accounting Policies - Earning Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesEarningPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Earning Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2414411 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2415412 - Disclosure - Summary of Significant Accounting Policies - Customer Concentration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Customer Concentration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2418413 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails</Role>
      <ShortName>Composition of Certain Consolidated Financial Statement Items - Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2419414 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Composition of Certain Consolidated Financial Statement Items - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2420415 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails</Role>
      <ShortName>Composition of Certain Consolidated Financial Statement Items - Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2421416 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Composition of Certain Consolidated Financial Statement Items - Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2422417 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Interest and Other Income (Expense), net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails</Role>
      <ShortName>Composition of Certain Consolidated Financial Statement Items - Interest and Other Income (Expense), net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2424418 - Disclosure - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/IntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/IntangibleAssets</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2426419 - Disclosure - Loan Facility (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/LoanFacilityDetails</Role>
      <ShortName>Loan Facility (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/LoanFacility</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2429420 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability - Schedule of Warrants to Purchase Shares of Redeemable Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock Warrant Liability - Schedule of Warrants to Purchase Shares of Redeemable Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2430421 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock Warrant Liability - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2433422 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Temporary Equity by Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Schedule of Temporary Equity by Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2434423 - Disclosure - Redeemable Convertible Preferred Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2435424 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Liquidation Preference (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails</Role>
      <ShortName>Redeemable Convertible Preferred Stock - Schedule of Liquidation Preference (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2438425 - Disclosure - Stockholders' Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails</Role>
      <ShortName>Stockholders' Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2439426 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2440427 - Disclosure - Stockholders' Equity - Schedule of Share Base d Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Share Base d Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2441428 - Disclosure - Stockholders' Equity - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails</Role>
      <ShortName>Stockholders' Equity - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2444429 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="prct-20210930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2445430 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Long-Term Debt Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Lease Payments and Long-Term Debt Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="prct-20210930.htm">prct-20210930.htm</File>
    <File>prct-20210930.xsd</File>
    <File>prct-20210930_cal.xml</File>
    <File>prct-20210930_def.xml</File>
    <File>prct-20210930_lab.xml</File>
    <File>prct-20210930_pre.xml</File>
    <File>prct-ex311soxcertification.htm</File>
    <File>prct-ex312soxcertification.htm</File>
    <File>prct-ex321soxcertification.htm</File>
    <File>prct-ex322soxcertification.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>70
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "prct-20210930.htm": {
   "axisCustom": 0,
   "axisStandard": 27,
   "contextCount": 264,
   "dts": {
    "calculationLink": {
     "local": [
      "prct-20210930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "prct-20210930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "prct-20210930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "prct-20210930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "prct-20210930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "prct-20210930.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 529,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 1,
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 6
   },
   "keyCustom": 57,
   "keyStandard": 354,
   "memberCustom": 29,
   "memberStandard": 37,
   "nsprefix": "prct",
   "nsuri": "http://www.procept-biorobotics.com/20210930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover page",
     "role": "http://www.procept-biorobotics.com/role/Coverpage",
     "shortName": "Cover page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116103 - Disclosure - Composition of Certain Consolidated Financial Statement Items",
     "role": "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItems",
     "shortName": "Composition of Certain Consolidated Financial Statement Items",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123104 - Disclosure - Intangible Assets",
     "role": "http://www.procept-biorobotics.com/role/IntangibleAssets",
     "shortName": "Intangible Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2125105 - Disclosure - Loan Facility",
     "role": "http://www.procept-biorobotics.com/role/LoanFacility",
     "shortName": "Loan Facility",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2127106 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability",
     "role": "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiability",
     "shortName": "Redeemable Convertible Preferred Stock Warrant Liability",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131107 - Disclosure - Redeemable Convertible Preferred Stock",
     "role": "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStock",
     "shortName": "Redeemable Convertible Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2136108 - Disclosure - Stockholders' Equity",
     "role": "http://www.procept-biorobotics.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareholdersEquityAndShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142109 - Disclosure - Commitments and Contingencies",
     "role": "http://www.procept-biorobotics.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317302 - Disclosure - Composition of Certain Consolidated Financial Statement Items (Tables)",
     "role": "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables",
     "shortName": "Composition of Certain Consolidated Financial Statement Items (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2328303 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability (Tables)",
     "role": "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityTables",
     "shortName": "Redeemable Convertible Preferred Stock Warrant Liability (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": null
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332304 - Disclosure - Redeemable Convertible Preferred Stock (Tables)",
     "role": "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockTables",
     "shortName": "Redeemable Convertible Preferred Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2337305 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.procept-biorobotics.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2343306 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Organization (Details)",
     "role": "http://www.procept-biorobotics.com/role/OrganizationDetails",
     "shortName": "Organization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockPricePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "ib8664e9a7cee4889bdb472916c610c7d_D20210901-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PaymentsForUnderwritingExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Summary of Significant Accounting Policies - Fair Value (Details)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails",
     "shortName": "Summary of Significant Accounting Policies - Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "ia13ef5c367424e9b87f0aa0201302d21_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:Cash",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "ib383b7e5ad6141079ebfdfb1678720a6_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408405 - Disclosure - Summary of Significant Accounting Policies - Fair Value Rollforward (Details)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails",
     "shortName": "Summary of Significant Accounting Policies - Fair Value Rollforward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "ib383b7e5ad6141079ebfdfb1678720a6_I20210630",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prct:WarrantsAndRightsOutstandingWeightedAverageTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409406 - Disclosure - Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock Assumptions (Details)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails",
     "shortName": "Summary of Significant Accounting Policies - Redeemable Convertible Preferred Stock Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i3d48d6746f734dc08e257b8e1ce2054f_D20200101-20200930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "prct:WarrantsAndRightsOutstandingWeightedAverageTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i149316ff5b004dd4a6c20c85ec67c952_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "prct:LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410407 - Disclosure - Summary of Significant Accounting Policies - Loan Facility Derivative Liability (Details)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails",
     "shortName": "Summary of Significant Accounting Policies - Loan Facility Derivative Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i3604760cd7da443ebd82948c1de89a0c_I20210630",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets - Parentheticals",
     "role": "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
     "shortName": "Condensed Consolidated Balance Sheets - Parentheticals",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411408 - Disclosure - Summary of Significant Accounting Policies - Revenue by Type and Geographic Location (Details)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails",
     "shortName": "Summary of Significant Accounting Policies - Revenue by Type and Geographic Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "if05a3e115a3c4a69bedce4615d0524f0_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i7708603bb2ff47579ddc870b44b0fbb0_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412409 - Disclosure - Summary of Significant Accounting Policies - Significant Geographical Locations Outside the United States (Details)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails",
     "shortName": "Summary of Significant Accounting Policies - Significant Geographical Locations Outside the United States (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i7708603bb2ff47579ddc870b44b0fbb0_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413410 - Disclosure - Summary of Significant Accounting Policies - Earning Per Share (Details)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesEarningPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Earning Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414411 - Disclosure - Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "shortName": "Summary of Significant Accounting Policies - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i621e3ef4440f48c2b9f769e24af4620f_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415412 - Disclosure - Summary of Significant Accounting Policies - Customer Concentration (Details)",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails",
     "shortName": "Summary of Significant Accounting Policies - Customer Concentration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i621e3ef4440f48c2b9f769e24af4620f_D20200701-20200930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418413 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Inventory (Details)",
     "role": "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails",
     "shortName": "Composition of Certain Consolidated Financial Statement Items - Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "prct:PrepaidInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419414 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Composition of Certain Consolidated Financial Statement Items - Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "prct:PrepaidInventory",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420415 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Property and Equipment, net (Details)",
     "role": "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails",
     "shortName": "Composition of Certain Consolidated Financial Statement Items - Property and Equipment, net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "prct:AccruedPurchases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421416 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Other Current Liabilities (Details)",
     "role": "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails",
     "shortName": "Composition of Certain Consolidated Financial Statement Items - Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "prct:AccruedPurchases",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422417 - Disclosure - Composition of Certain Consolidated Financial Statement Items - Interest and Other Income (Expense), net (Details)",
     "role": "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails",
     "shortName": "Composition of Certain Consolidated Financial Statement Items - Interest and Other Income (Expense), net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfRevenue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i323691aee3ba4470beeb781efc9f7d5a_D20190301-20190331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424418 - Disclosure - Intangible Assets (Details)",
     "role": "http://www.procept-biorobotics.com/role/IntangibleAssetsDetails",
     "shortName": "Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i323691aee3ba4470beeb781efc9f7d5a_D20190301-20190331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsToAcquireIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i149316ff5b004dd4a6c20c85ec67c952_D20210101-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "prct:LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426419 - Disclosure - Loan Facility (Details)",
     "role": "http://www.procept-biorobotics.com/role/LoanFacilityDetails",
     "shortName": "Loan Facility (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "ic9df1ea4e38a48c3958b823d207dc494_I20190930",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429420 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability - Schedule of Warrants to Purchase Shares of Redeemable Convertible Preferred Stock (Details)",
     "role": "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock Warrant Liability - Schedule of Warrants to Purchase Shares of Redeemable Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "ib8ca34d460bd431e9f40af8ba7f4941d_I20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "prct:TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430421 - Disclosure - Redeemable Convertible Preferred Stock Warrant Liability - Narrative (Details)",
     "role": "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
     "shortName": "Redeemable Convertible Preferred Stock Warrant Liability - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i90bf229ad34d4baba483ea11a398bc08_I20170630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433422 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Temporary Equity by Stock (Details)",
     "role": "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Schedule of Temporary Equity by Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:TemporaryEquityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "ied497de295f14e1f827bd811b22ff9f1_I20201231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434423 - Disclosure - Redeemable Convertible Preferred Stock - Narrative (Details)",
     "role": "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DividendsPayableCurrentAndNoncurrent",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i894ed293fa3742e3a04a1df94f575575_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DividendsPayableCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "prct:TemporaryEquityDividends",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435424 - Disclosure - Redeemable Convertible Preferred Stock - Schedule of Liquidation Preference (Details)",
     "role": "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
     "shortName": "Redeemable Convertible Preferred Stock - Schedule of Liquidation Preference (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i7aa86dd5567043e78dbeaa1869e5a838_I20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquityLiquidationPreferencePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438425 - Disclosure - Stockholders' Equity - Narrative (Details)",
     "role": "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
     "shortName": "Stockholders' Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29a3508d251b4bde9f8eb210f942bfaa_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439426 - Disclosure - Stockholders' Equity - Schedule of Stock Option Activity (Details)",
     "role": "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i69d76d77405240c68aef85b1fc24420e_D20210101-20210930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440427 - Disclosure - Stockholders' Equity - Schedule of Share Base d Compensation Expense (Details)",
     "role": "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails",
     "shortName": "Stockholders' Equity - Schedule of Share Base d Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "ifa21a99062154fbdb875876427776118_I20191231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i33765b1a92a74ef19800e242dae1e333_D20200101-20200331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "prct:TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441428 - Disclosure - Stockholders' Equity - Fair Value Assumptions (Details)",
     "role": "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails",
     "shortName": "Stockholders' Equity - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "idce66466805b401388fdeeb4bc84b2c4_D20210701-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444429 - Disclosure - Commitments and Contingencies - Narrative (Details)",
     "role": "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
     "shortName": "Commitments and Contingencies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeaseExpense",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i8fafd986ad0d4dc28dbdee90a0d48862_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445430 - Disclosure - Commitments and Contingencies - Future Minimum Lease Payments and Long-Term Debt Maturities (Details)",
     "role": "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails",
     "shortName": "Commitments and Contingencies - Future Minimum Lease Payments and Long-Term Debt Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i06ef5a3561da4e20a7b17f4ed74847c6_I20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "ib8664e9a7cee4889bdb472916c610c7d_D20210901-20210930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1405401 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Parenthetical",
     "role": "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
     "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - Parenthetical",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization",
     "role": "http://www.procept-biorobotics.com/role/Organization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "prct-20210930.htm",
      "contextRef": "i29deca7b987d45ceaacbc1de9b145fe1_D20210101-20210930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 73,
   "tag": {
    "country_DE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "GERMANY",
        "terseLabel": "Germany"
       }
      }
     },
     "localname": "DE",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r574"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r575"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Coverpage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "prct_A2008StockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2008 Stock Plan",
        "label": "2008 Stock Plan [Member]",
        "terseLabel": "2008 Stock Plan"
       }
      }
     },
     "localname": "A2008StockPlanMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_A2021EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Employee Stock Purchase Plan",
        "label": "2021 Employee Stock Purchase Plan [Member]",
        "terseLabel": "2021 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "A2021EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_A2021EquityIncentiveAwardPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 Equity Incentive Award Plan",
        "label": "2021 Equity Incentive Award Plan [Member]",
        "terseLabel": "2021 Equity Incentive Award Plan"
       }
      }
     },
     "localname": "A2021EquityIncentiveAwardPlanMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_AccruedClinicalTrialExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expenses",
        "label": "Accrued Clinical Trial Expenses",
        "terseLabel": "Clinical trial expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenses",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_AccruedPurchases": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Purchases",
        "label": "Accrued Purchases",
        "terseLabel": "Accrued purchases"
       }
      }
     },
     "localname": "AccruedPurchases",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_CommonStockValuationPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Valuation Policy",
        "label": "Common Stock Valuation Policy [Policy Text Block]",
        "terseLabel": "Common Stock Valuation"
       }
      }
     },
     "localname": "CommonStockValuationPolicyPolicyTextBlock",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prct_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Warrants",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common stock warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_Customer1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 1",
        "label": "Customer 1 [Member]",
        "terseLabel": "Customer 1"
       }
      }
     },
     "localname": "Customer1Member",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_Customer2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 2",
        "label": "Customer 2 [Member]",
        "terseLabel": "Customer 2"
       }
      }
     },
     "localname": "Customer2Member",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_Customer3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer 3",
        "label": "Customer 3 [Member]",
        "terseLabel": "Customer 3"
       }
      }
     },
     "localname": "Customer3Member",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, Contingent Borrowing, Extended Interest Only Period",
        "label": "Debt instrument, Contingent Borrowing, Extended Interest Only Period",
        "terseLabel": "Extended interest only period (in months)"
       }
      }
     },
     "localname": "DebtInstrumentContingentBorrowingExtendedInterestOnlyPeriod",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prct_DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, Contingent Borrowing, Extended Principal and Interest Period",
        "label": "Debt instrument, Contingent Borrowing, Extended Principal and Interest Period",
        "terseLabel": "Extended principal and interest period (in months)"
       }
      }
     },
     "localname": "DebtInstrumentContingentBorrowingExtendedPrincipalAndInterestPeriod",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount",
        "label": "Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount",
        "terseLabel": "Covenant compliance, IPO capital raised in threshold amount"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmount",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount Achieved, Extended Interest Only Period",
        "label": "Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount Achieved, Extended Interest Only Period",
        "terseLabel": "Covenant compliance, IPO capital raised in threshold amount achieved, extended interest only period (in months)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedInterestOnlyPeriod",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prct_DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount Achieved, Extended Principal and Interest Period",
        "label": "Debt Instrument, Covenant Compliance, Capital Raised in IPO Threshold Amount Achieved, Extended Principal and Interest Period",
        "terseLabel": "Covenant compliance, IPO capital raised in threshold amount achieved, extended principal and interest only period (in months)"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceCapitalRaisedInIPOThresholdAmountAchievedExtendedPrincipalAndInterestPeriod",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prct_DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Revenue Forecast Amount, All Installments Drawn",
        "label": "Debt Instrument, Covenant Compliance, Revenue Forecast Amount, All Installments Drawn",
        "terseLabel": "Covenant compliance, revenue forecast amount, all installments"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceRevenueForecastAmountAllInstallmentsDrawn",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Revenue Forecast Amount, First Three Installments Only",
        "label": "Debt Instrument, Covenant Compliance, Revenue Forecast Amount, First Three Installments Only",
        "terseLabel": "Covenant compliance, revenue forecast amount, first three installments only"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceRevenueForecastAmountFirstThreeInstallmentsOnly",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Revenue Forecast Amount, First Two Installments Only",
        "label": "Debt Instrument, Covenant Compliance, Revenue Forecast Amount, First Two Installments Only",
        "terseLabel": "Covenant compliance, revenue forecast amount, first two installments only"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceRevenueForecastAmountFirstTwoInstallmentsOnly",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant Compliance, Revenue Forecast for Commensurate Period, Percent",
        "label": "Debt Instrument, Covenant Compliance, Revenue Forecast for Commensurate Period, Percent",
        "terseLabel": "Covenant compliance, revenue forecast for commensurate period, percent"
       }
      }
     },
     "localname": "DebtInstrumentCovenantComplianceRevenueForecastForCommensuratePeriodPercent",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prct_DebtInstrumentInterestOnlyPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, Interest Only Period",
        "label": "Debt instrument, Interest Only Period",
        "terseLabel": "Interest only period"
       }
      }
     },
     "localname": "DebtInstrumentInterestOnlyPeriod",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prct_DebtInstrumentPrincipalAndInterestPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, Principal and Interest Period",
        "label": "Debt instrument, Principal and Interest Period",
        "terseLabel": "Principal and interest period (in months)"
       }
      }
     },
     "localname": "DebtInstrumentPrincipalAndInterestPeriod",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prct_DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Offering Costs Incurred During Noncash or Partial Noncash Transaction",
        "label": "Deferred Offering Costs Incurred During Noncash or Partial Noncash Transaction",
        "terseLabel": "Deferred offering costs included in accounts payable and other current liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsIncurredDuringNoncashOrPartialNoncashTransaction",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_EvaluationUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evaluation Units",
        "label": "Evaluation Units [Member]",
        "terseLabel": "Evaluation units"
       }
      }
     },
     "localname": "EvaluationUnitsMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value Adjustment of Warrants and Gain (Loss) on Derivative Instruments, Net, Pretax",
        "label": "Fair Value Adjustment of Warrants and Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Change in fair value of redeemable convertible preferred stock warrants and derivative liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrantsAndGainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived Intangible Asset, Expected Annual Amortization Expense",
        "label": "Finite-Lived Intangible Asset, Expected Annual Amortization Expense",
        "terseLabel": "Expected annual amortization expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetExpectedAnnualAmortizationExpense",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_HandPiecesAndOtherConsumablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hand Pieces and Other Consumables",
        "label": "Hand Pieces and Other Consumables [Member]",
        "terseLabel": "Handpieces and other consumables"
       }
      }
     },
     "localname": "HandPiecesAndOtherConsumablesMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_IncentiveStockOptionsAndNonqualifiedStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incentive Stock Options and Nonqualified Stock Options",
        "label": "Incentive Stock Options and Nonqualified Stock Options [Member]",
        "terseLabel": "Incentive Stock Options and Nonqualified Stock Options"
       }
      }
     },
     "localname": "IncentiveStockOptionsAndNonqualifiedStockOptionsMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_InitialPublicOfferingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Initial Public Offering",
        "label": "Initial Public Offering [Abstract]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "InitialPublicOfferingAbstract",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/OrganizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prct_InterestAndOtherIncomeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest And Other Income (Expense)",
        "label": "Interest And Other Income (Expense)",
        "terseLabel": "Interest and other income, net",
        "totalLabel": "Total interest and other income (expense), net"
       }
      }
     },
     "localname": "InterestAndOtherIncomeExpense",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_JobsActAccountingElectionPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jobs Act Accounting Election",
        "label": "Jobs Act Accounting Election [Policy Text Block]",
        "terseLabel": "Jobs Act Accounting Election"
       }
      }
     },
     "localname": "JobsActAccountingElectionPolicyTextBlock",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prct_LaboratoryAndManufacturingEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory and Manufacturing Equipment",
        "label": "Laboratory and Manufacturing Equipment [Member]",
        "terseLabel": "Laboratory, manufacturing and computer equipment and furniture"
       }
      }
     },
     "localname": "LaboratoryAndManufacturingEquipmentMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Covenant Compliance, Contingent Trailing Six Twelve Month Revenue Target",
        "label": "Line of Credit Facility, Covenant Compliance, Contingent Trailing Six Twelve Month Revenue Target",
        "terseLabel": "Trailing six months revenue target"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantComplianceContingentTrailingSixTwelveMonthRevenueTarget",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Covenant Compliance, Contingent Trailing Twelve Month Revenue Target",
        "label": "Line of Credit Facility, Covenant Compliance, Contingent Trailing Twelve Month Revenue Target",
        "terseLabel": "Trailing twelve month revenue target"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantComplianceContingentTrailingTwelveMonthRevenueTarget",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Four Installments Drawn",
        "label": "Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Four Installments Drawn",
        "terseLabel": "Fee if all four installments are drawn"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantTermsLiquidityOccurrenceFourInstallmentsDrawn",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Covenant Terms, Liquidity Occurrence, One Installment Drawn",
        "label": "Line of Credit Facility, Covenant Terms, Liquidity Occurrence, One Installment Drawn",
        "terseLabel": "Fee on first installment drawn"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantTermsLiquidityOccurrenceOneInstallmentDrawn",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Three Installments Drawn",
        "label": "Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Three Installments Drawn",
        "terseLabel": "Fee if first three installments drawn"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantTermsLiquidityOccurrenceThreeInstallmentsDrawn",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Two Installments Drawn",
        "label": "Line of Credit Facility, Covenant Terms, Liquidity Occurrence, Two Installments Drawn",
        "terseLabel": "Fee if first two installments drawn"
       }
      }
     },
     "localname": "LineOfCreditFacilityCovenantTermsLiquidityOccurrenceTwoInstallmentsDrawn",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Early Repayment Fee First Twelve Month, Percent",
        "label": "Line of Credit Facility, Early Repayment Fee First Twelve Month, Percent",
        "terseLabel": "Early repayment fee first twelve month, percent"
       }
      }
     },
     "localname": "LineOfCreditFacilityEarlyRepaymentFeeFirstTwelveMonthPercent",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prct_LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Early Repayment Fee Second Twelve Month Period, Percent",
        "label": "Line of Credit Facility, Early Repayment Fee Second Twelve Month Period, Percent",
        "terseLabel": "Early repayment fee second twelve month period, percent"
       }
      }
     },
     "localname": "LineOfCreditFacilityEarlyRepaymentFeeSecondTwelveMonthPeriodPercent",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prct_LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Early Repayment Fee, Twenty Four Months Thru Maturity, Percent",
        "label": "Line of Credit Facility, Early Repayment Fee, Twenty Four Months Thru Maturity, Percent",
        "terseLabel": "Early repayment fee, twenty four months thereafter, percent"
       }
      }
     },
     "localname": "LineOfCreditFacilityEarlyRepaymentFeeTwentyFourMonthsThruMaturityPercent",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prct_LineOfCreditFacilityFinalPaymentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Final Payment Fee, Percentage",
        "label": "Line of Credit Facility, Final Payment Fee, Percentage",
        "terseLabel": "Final payment fee, percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityFinalPaymentFeePercentage",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "prct_LineOfCreditFacilityNumberOfInstallments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line of Credit Facility, Number of Installments",
        "label": "Line of Credit Facility, Number of Installments",
        "terseLabel": "Number of installments"
       }
      }
     },
     "localname": "LineOfCreditFacilityNumberOfInstallments",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "prct_LoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Facility",
        "label": "Loan Facility [Member]",
        "terseLabel": "Loan Facility"
       }
      }
     },
     "localname": "LoanFacilityMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_LoanFacilityTrancheFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Facility, Tranche Four",
        "label": "Loan Facility, Tranche Four [Member]",
        "terseLabel": "Loan Facility, Tranche Four"
       }
      }
     },
     "localname": "LoanFacilityTrancheFourMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_LoanFacilityTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Facility, Tranche One",
        "label": "Loan Facility, Tranche One [Member]",
        "terseLabel": "Loan Facility, Tranche One"
       }
      }
     },
     "localname": "LoanFacilityTrancheOneMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_LoanFacilityTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Facility, Tranche Three",
        "label": "Loan Facility, Tranche Three [Member]",
        "terseLabel": "Loan Facility, Tranche Three"
       }
      }
     },
     "localname": "LoanFacilityTrancheThreeMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_LoanFacilityTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan Facility, Tranche Two",
        "label": "Loan Facility, Tranche Two [Member]",
        "terseLabel": "Loan Facility, Tranche Two"
       }
      }
     },
     "localname": "LoanFacilityTrancheTwoMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_NonCashLeaseAccretionExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-cash Lease Accretion Expense",
        "label": "Non-cash Lease Accretion Expense",
        "negatedTerseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NonCashLeaseAccretionExpense",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_OperatingLeaseLiabilityAndLongTermDebt": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability and Long-Term Debt",
        "label": "Operating Lease Liability and Long-Term Debt",
        "totalLabel": "Present value of future payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndLongTermDebt",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_OperatingLeaseLiabilityAndLongTermDebtCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "prct_OperatingLeaseLiabilityAndLongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability and Long-Term Debt, Current",
        "label": "Operating Lease Liability and Long-Term Debt, Current",
        "negatedTerseLabel": "Less: current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndLongTermDebtCurrent",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "prct_OperatingLeaseLiabilityAndLongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability and Long-Term Debt, Excluding Current Maturities",
        "label": "Operating Lease Liability and Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndLongTermDebtExcludingCurrentMaturities",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability and Long-Term Debt Maturity",
        "label": "Operating Lease Liability and Long-Term Debt Maturity [Abstract]",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndLongTermDebtMaturityAbstract",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability and Long-Term Debt Maturity, Gross",
        "label": "Operating Lease Liability and Long-Term Debt Maturity, Gross",
        "terseLabel": "Total minimum payments",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndLongTermDebtMaturityGross",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails",
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability and Long-Term Debt Maturity, Remainder of Fiscal year",
        "label": "Operating Lease Liability and Long-Term Debt Maturity, Remainder of Fiscal year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndLongTermDebtMaturityRemainderOfFiscalYear",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability and Long-Term Debt Maturity, Unamortized Debt Discount",
        "label": "Operating Lease Liability and Long-Term Debt Maturity, Unamortized Debt Discount",
        "negatedTerseLabel": "Less: amount representing interest/unamortized debt discount"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndLongTermDebtMaturityUnamortizedDebtDiscount",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability and Long-Term Debt Maturity, Year One",
        "label": "Operating Lease Liability and Long-Term Debt Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndLongTermDebtMaturityYearOne",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability and Long-Term Debt Maturity, Year Three",
        "label": "Operating Lease Liability and Long-Term Debt Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndLongTermDebtMaturityYearThree",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "prct_OperatingLeaseLiabilityAndLongTermDebtMaturityGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Liability and Long-Term Debt Maturity, Year Two",
        "label": "Operating Lease Liability and Long-Term Debt Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityAndLongTermDebtMaturityYearTwo",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_OutsideTheUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outside the United States",
        "label": "Outside the United States [Member]",
        "terseLabel": "Outside of U.S."
       }
      }
     },
     "localname": "OutsideTheUnitedStatesMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_PrepaidInventory": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Inventory",
        "label": "Prepaid Inventory",
        "terseLabel": "Prepaid Inventory"
       }
      }
     },
     "localname": "PrepaidInventory",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_PrepaidSoftware": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid Software",
        "label": "Prepaid Software",
        "terseLabel": "Prepaid Software"
       }
      }
     },
     "localname": "PrepaidSoftware",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from Issuance of Redeemable Convertible Preferred Stock, Net of Issuance Costs",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock, Net of Issuance Costs",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStockNetOfIssuanceCosts",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_ProductWarrantyTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product Warranty Term",
        "label": "Product Warranty Term",
        "terseLabel": "Product warranty period (in years)"
       }
      }
     },
     "localname": "ProductWarrantyTerm",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prct_RedeemableConvertiblePreferredStockPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Convertible Preferred Stock Policy",
        "label": "Redeemable Convertible Preferred Stock Policy [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockPolicyPolicyTextBlock",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prct_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Convertible Preferred Stock Warrant Liability, Policy",
        "label": "Redeemable Convertible Preferred Stock Warrant Liability, Policy [Policy Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockWarrantLiabilityPolicyPolicyTextBlock",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "prct_RedeemableConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable Convertible Preferred Stock Warrants",
        "label": "Redeemable Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Redeemable convertible preferred stock warrants"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_RedwoodCityCAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redwood City, CA",
        "label": "Redwood City, CA [Member]",
        "terseLabel": "Redwood City, CA"
       }
      }
     },
     "localname": "RedwoodCityCAMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_SeriesARedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Redeemable Convertible Preferred Stock",
        "label": "Series A Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A"
       }
      }
     },
     "localname": "SeriesARedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Redeemable Convertible Preferred Stock",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_SeriesCRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series C Redeemable Convertible Preferred Stock",
        "label": "Series C Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series C"
       }
      }
     },
     "localname": "SeriesCRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_SeriesDRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Redeemable Convertible Preferred Stock",
        "label": "Series D Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series D, Redeemable Convertible Preferred Stock",
        "verboseLabel": "Series D"
       }
      }
     },
     "localname": "SeriesDRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_SeriesERedeemableConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E Redeemable Convertible Preferred Stock Warrants",
        "label": "Series E Redeemable Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Series E, Redeemable Convertible Preferred Stock Warrants",
        "verboseLabel": "Series E"
       }
      }
     },
     "localname": "SeriesERedeemableConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_SeriesFRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series F Redeemable Convertible Preferred Stock",
        "label": "Series F Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series F"
       }
      }
     },
     "localname": "SeriesFRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_SeriesGRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series G Redeemable Convertible Preferred Stock",
        "label": "Series G Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series G"
       }
      }
     },
     "localname": "SeriesGRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_ServiceAgreementAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Agreement, Amortization Period",
        "label": "Service Agreement, Amortization Period",
        "terseLabel": "Service agreement, amortization period"
       }
      }
     },
     "localname": "ServiceAgreementAmortizationPeriod",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prct_ServiceRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Revenue",
        "label": "Service Revenue [Member]",
        "terseLabel": "Service"
       }
      }
     },
     "localname": "ServiceRevenueMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Award Cliff Vesting Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Cliff Vesting Period",
        "terseLabel": "Award cliff vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardCliffVestingPeriod",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "prct_ShareholderOfTenPercentOwnershipOrGreaterMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shareholder of Ten Percent Ownership or Greater",
        "label": "Shareholder of Ten Percent Ownership or Greater [Member]",
        "terseLabel": "Shareholder of Ten Percent Ownership or Greater"
       }
      }
     },
     "localname": "ShareholderOfTenPercentOwnershipOrGreaterMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_SystemSalesAndRentalsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "System Sales and Rentals",
        "label": "System Sales and Rentals [Member]",
        "terseLabel": "System sales and rentals"
       }
      }
     },
     "localname": "SystemSalesAndRentalsMember",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "prct_TemporaryEquityAmountConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Amount, Conversion Of Convertible Securities",
        "label": "Temporary Equity, Amount, Conversion Of Convertible Securities",
        "negatedTerseLabel": "Issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "TemporaryEquityAmountConversionOfConvertibleSecurities",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_TemporaryEquityDividends": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Dividends",
        "label": "Temporary Equity, Dividends",
        "terseLabel": "8% Dividend Per Share"
       }
      }
     },
     "localname": "TemporaryEquityDividends",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "prct_TemporaryEquitySharesConversionOfConvertibleSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Shares, Conversion Of Convertible Securities",
        "label": "Temporary Equity, Shares, Conversion Of Convertible Securities",
        "negatedTerseLabel": "Issuance of redeemable convertible preferred stock, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesConversionOfConvertibleSecurities",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "prct_TemporaryEquityStockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "label": "Temporary Equity, Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "prct_TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Shares, Warrant Exercises",
        "label": "Temporary Equity, Stock Issued During Period, Shares, Warrant Exercises",
        "terseLabel": "Issuance upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodSharesWarrantExercises",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "prct_TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Stock Issued During Period, Value, Warrant Exercises",
        "label": "Temporary Equity, Stock Issued During Period, Value, Warrant Exercises",
        "terseLabel": "Issuance upon exercise of warrants"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueWarrantExercises",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity, Voting Rights, Number Of Votes Per Share Of Common Stock If Converted",
        "label": "Temporary Equity, Voting Rights, Number Of Votes Per Share Of Common Stock If Converted",
        "terseLabel": "Common stock voting rights, number of votes (per share)"
       }
      }
     },
     "localname": "TemporaryEquityVotingRightsNumberOfVotesPerShareOfCommonStockIfConverted",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "prct_TransferFromInventoryToPropertyAndEquipmentNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transfer From Inventory to Property and Equipment, Net",
        "label": "Transfer From Inventory to Property and Equipment, Net",
        "terseLabel": "Transfer of evaluation units from inventory to property and equipment, net"
       }
      }
     },
     "localname": "TransferFromInventoryToPropertyAndEquipmentNet",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "prct_WarrantsAndRightsOutstandingWeightedAverageTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants and Rights Outstanding, Weighted Average Term",
        "label": "Warrants and Rights Outstanding, Weighted Average Term",
        "terseLabel": "Warrant term (in years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingWeightedAverageTerm",
     "nsuri": "http://www.procept-biorobotics.com/20210930",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember": {
     "auth_ref": [
      "r2",
      "r135",
      "r142",
      "r217",
      "r387",
      "r388",
      "r389",
      "r404",
      "r405",
      "r425",
      "r430",
      "r431",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption, Adjusted Balance [Member]",
        "terseLabel": "Cumulative Effect, Period of Adoption, Adjusted Balance"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAdjustedBalanceMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionAxis": {
     "auth_ref": [
      "r2",
      "r135",
      "r142",
      "r148",
      "r217",
      "r387",
      "r388",
      "r389",
      "r404",
      "r405",
      "r425",
      "r428",
      "r430",
      "r431",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Axis]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Axis]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CumulativeEffectPeriodOfAdoptionDomain": {
     "auth_ref": [
      "r2",
      "r135",
      "r142",
      "r148",
      "r217",
      "r387",
      "r388",
      "r389",
      "r404",
      "r405",
      "r425",
      "r428",
      "r430",
      "r431",
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cumulative Effect, Period of Adoption [Domain]",
        "terseLabel": "Cumulative Effect, Period of Adoption [Domain]"
       }
      }
     },
     "localname": "CumulativeEffectPeriodOfAdoptionDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r206",
      "r329",
      "r333",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r262",
      "r298",
      "r351",
      "r353",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r533",
      "r537",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r262",
      "r298",
      "r351",
      "r353",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r533",
      "r537",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r206",
      "r329",
      "r333",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r202",
      "r329",
      "r331",
      "r503",
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r202",
      "r329",
      "r331",
      "r503",
      "r532",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r262",
      "r298",
      "r340",
      "r351",
      "r353",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r533",
      "r537",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r262",
      "r298",
      "r340",
      "r351",
      "r353",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r499",
      "r533",
      "r537",
      "r568",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r143",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r143",
      "r148",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r203",
      "r204",
      "r329",
      "r332",
      "r535",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r203",
      "r204",
      "r329",
      "r332",
      "r535",
      "r553",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r143",
      "r148",
      "r242",
      "r352",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r53",
      "r487"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r9",
      "r35",
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r57"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r57"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Salaries, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r51",
      "r233"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r38",
      "r80",
      "r81",
      "r82",
      "r524",
      "r545",
      "r549"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r79",
      "r82",
      "r89",
      "r90",
      "r91",
      "r132",
      "r133",
      "r134",
      "r411",
      "r540",
      "r541",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Composition of Certain Consolidated Financial Statement Items"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItems"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r36",
      "r390",
      "r487"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r387",
      "r388",
      "r389",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r136",
      "r137",
      "r138",
      "r139",
      "r148",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r247",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r402",
      "r403",
      "r404",
      "r405",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r484",
      "r504",
      "r505",
      "r506",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement, classified as other.",
        "label": "APIC, Share-based Payment Arrangement, Other, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationOtherLongtermIncentivePlansRequisiteServicePeriodRecognition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising Expenses"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r356",
      "r379",
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r111",
      "r228",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share, amount (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r128",
      "r185",
      "r194",
      "r200",
      "r213",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r408",
      "r412",
      "r448",
      "r485",
      "r487",
      "r508",
      "r521"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r13",
      "r15",
      "r71",
      "r128",
      "r213",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r408",
      "r412",
      "r448",
      "r485",
      "r487"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r357",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r6",
      "r131",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/Organization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r116",
      "r117",
      "r118"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Property and equipment included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r48",
      "r487",
      "r551",
      "r552"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r48",
      "r113"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Total cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.procept-biorobotics.com/role/OrganizationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r23",
      "r114",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r106",
      "r113",
      "r119"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash - End of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash- Beginning of period",
        "totalLabel": "Cash, cash equivalents and restricted cash in balance sheets"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to balance sheets:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r106",
      "r457"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r125",
      "r128",
      "r151",
      "r152",
      "r153",
      "r155",
      "r157",
      "r164",
      "r165",
      "r166",
      "r213",
      "r248",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r296",
      "r297",
      "r300",
      "r304",
      "r448",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.procept-biorobotics.com/role/OrganizationDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r316",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class of Warrant or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Warrants exercised for redeemable convertible preferred stock (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r316",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class of Warrant or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r61",
      "r241",
      "r513",
      "r528"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (see Note 9)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r238",
      "r239",
      "r240",
      "r243",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r132",
      "r133",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/OrganizationDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r34",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r34",
      "r487"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value: 300,000 and 40,000 shares authorized, 43472 and 4,713 shares issued and outstanding as of September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r84",
      "r86",
      "r87",
      "r94",
      "r515",
      "r530"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r206",
      "r446",
      "r447",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r206",
      "r446",
      "r447",
      "r550",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r174",
      "r175",
      "r206",
      "r446",
      "r447",
      "r550",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r169",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r174",
      "r175",
      "r206",
      "r446",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Revenue by significant geographical locations outside the United States",
        "verboseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r174",
      "r175",
      "r206",
      "r446",
      "r447",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r318",
      "r319",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "negatedTerseLabel": "Contract with Customer, Liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r318",
      "r319",
      "r330"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r32",
      "r33",
      "r307",
      "r312",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Convertible preferred stock, shares, number of shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r97",
      "r128",
      "r213",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r448"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of Revenue",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]",
        "terseLabel": "Cost of Sales"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r172",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r276",
      "r283",
      "r284",
      "r285",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt Disclosure"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacility"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r27",
      "r28",
      "r29",
      "r127",
      "r130",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r288",
      "r289",
      "r290",
      "r291",
      "r467",
      "r509",
      "r511",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Facility interest, spread on base rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r29",
      "r286",
      "r511",
      "r520"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r59",
      "r127",
      "r130",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r266",
      "r272",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r288",
      "r289",
      "r290",
      "r291",
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Facility term (in years)"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r272",
      "r465",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "Debt Instrument, Unamortized Discount",
        "negatedTerseLabel": "Less: amount representing interest/unamortized debt discount"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredChargesPolicyTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for deferral and amortization of significant deferred charges.",
        "label": "Deferred Charges, Policy [Policy Text Block]",
        "terseLabel": "Deferred Offering Costs"
       }
      }
     },
     "localname": "DeferredChargesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.",
        "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredOfferingCosts": {
     "auth_ref": [
      "r70",
      "r227"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.",
        "label": "Deferred Offering Costs",
        "terseLabel": "Deferred offering costs"
       }
      }
     },
     "localname": "DeferredOfferingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r111",
      "r184"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r72",
      "r75",
      "r76",
      "r419",
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, loan facility"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r73",
      "r74",
      "r75",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Loan facility derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Loan facility derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r129",
      "r414",
      "r415",
      "r416",
      "r417",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Loan Facility Derivative Liability"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r329",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r357",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]",
        "terseLabel": "Schedule of Fair Value Assumptions"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DividendsPayableCurrentAndNoncurrent": {
     "auth_ref": [
      "r28",
      "r30",
      "r510",
      "r522"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding.",
        "label": "Dividends Payable",
        "terseLabel": "Dividends declared and payable"
       }
      }
     },
     "localname": "DividendsPayableCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r95",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r149",
      "r151",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r431",
      "r432",
      "r516",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesEarningPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r95",
      "r140",
      "r141",
      "r142",
      "r143",
      "r144",
      "r151",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r431",
      "r432",
      "r516",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesEarningPerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Average vesting period for unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee stock options"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Common stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Rental equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r89",
      "r90",
      "r91",
      "r132",
      "r133",
      "r134",
      "r137",
      "r145",
      "r147",
      "r163",
      "r217",
      "r311",
      "r314",
      "r387",
      "r388",
      "r389",
      "r404",
      "r405",
      "r430",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r540",
      "r541",
      "r542",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r111",
      "r293"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails": {
       "order": 2.0,
       "parentTag": "prct_InterestAndOtherIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "negatedTerseLabel": "Decrease (increase) in fair value of preferred stock warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r274",
      "r288",
      "r289",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r434",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r433",
      "r434",
      "r436",
      "r437",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r274",
      "r341",
      "r342",
      "r347",
      "r348",
      "r434",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r274",
      "r288",
      "r289",
      "r341",
      "r342",
      "r347",
      "r348",
      "r434",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r274",
      "r288",
      "r289",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r434",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r438",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r439"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sales of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Sales",
        "negatedTerseLabel": "Exercised"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySales",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "terseLabel": "Cancelled"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r438"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "End of the period",
        "periodStartLabel": "Beginning of the period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r274",
      "r288",
      "r289",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r489",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r441",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]",
        "terseLabel": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings": {
     "auth_ref": [
      "r439",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from derivative asset (liability) after deduction of derivative liability (asset), measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Gain (Loss) Included in Earnings",
        "negatedTerseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues": {
     "auth_ref": [
      "r440",
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of issuances of financial instrument classified as a derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Issues",
        "terseLabel": "Issued"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements": {
     "auth_ref": [
      "r440",
      "r442"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a derivative asset (liability) after deduction of derivative liability, measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Inputs Reconciliation, Settlements",
        "terseLabel": "Payment of success fee"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs": {
     "auth_ref": [
      "r433",
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as derivative asset (liability) after deduction of derivative liability (asset), measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis with Unobservable Inputs",
        "periodEndLabel": "End of the period",
        "periodStartLabel": "Beginning of the period"
       }
      }
     },
     "localname": "FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r229"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r418"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails": {
       "order": 1.0,
       "parentTag": "prct_InterestAndOtherIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "terseLabel": "Decrease (increase) in fair value of loan facility derivative liability"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r173",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r96",
      "r128",
      "r185",
      "r193",
      "r196",
      "r199",
      "r201",
      "r213",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r448"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GuaranteeObligationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Guarantor Obligations [Line Items]",
        "terseLabel": "Guarantor Obligations"
       }
      }
     },
     "localname": "GuaranteeObligationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/OrganizationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r236",
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedSalaries": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in accrued salaries.",
        "label": "Increase (Decrease) in Accrued Salaries",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedSalaries",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r110",
      "r500"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInterestPayableNet": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in interest payable, which represents the amount owed to note holders, bond holders, and other parties for interest earned on loans or credit extended to the reporting entity.",
        "label": "Increase (Decrease) in Interest Payable, Net",
        "terseLabel": "Accrued interest expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInInterestPayableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInTemporaryEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Temporary Equity [Roll Forward]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "IncreaseDecreaseInTemporaryEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets Disclosure"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/IntangibleAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r92",
      "r183",
      "r464",
      "r466",
      "r517"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedTerseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r105",
      "r107",
      "r115"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPayableCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r57"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of [accrued] interest payable on all forms of debt, including trade payables, that has been incurred and is unpaid. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Interest Payable, Current",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r8",
      "r68",
      "r487"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r21",
      "r69",
      "r121",
      "r162",
      "r220",
      "r222",
      "r223",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r99",
      "r182"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails": {
       "order": 3.0,
       "parentTag": "prct_InterestAndOtherIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total minimum payments",
        "totalLabel": "Total minimum payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails",
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r477"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r477"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less: amount representing interest/unamortized debt discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term (in years)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorLeasesPolicyTextBlock": {
     "auth_ref": [
      "r480",
      "r481",
      "r482",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangements entered into by lessor.",
        "label": "Lessor, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LessorLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r56",
      "r128",
      "r195",
      "r213",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r409",
      "r412",
      "r413",
      "r448",
      "r485",
      "r486"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r41",
      "r128",
      "r213",
      "r448",
      "r487",
      "r512",
      "r526"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r58",
      "r128",
      "r213",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r409",
      "r412",
      "r413",
      "r448",
      "r485",
      "r486",
      "r487"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Current borrowing amount"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate at the end of the reporting period.",
        "label": "Line of Credit Facility, Interest Rate at Period End",
        "terseLabel": "Facility interest rate at period end (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateAtPeriodEnd",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityInterestRateDuringPeriod": {
     "auth_ref": [
      "r54"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The effective interest rate during the reporting period.",
        "label": "Line of Credit Facility, Interest Rate During Period",
        "terseLabel": "Facility base interest rate (percent)"
       }
      }
     },
     "localname": "LineOfCreditFacilityInterestRateDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Loan facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r54",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]",
        "terseLabel": "London Interbank Offered Rate (LIBOR)"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r29",
      "r273",
      "r287",
      "r288",
      "r289",
      "r511",
      "r523"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Present value of future payments"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "negatedTerseLabel": "Less: current portion",
        "terseLabel": "Less: current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r130",
      "r245",
      "r278"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r130",
      "r245",
      "r278"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r130",
      "r245",
      "r278"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "Long-Term Debt, Maturity, Remainder of Fiscal Year",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMeasurementInput": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure long-term debt.",
        "label": "Long-term Debt, Measurement Input",
        "terseLabel": "Cash flow discount"
       }
      }
     },
     "localname": "LongTermDebtMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r59"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r59",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaturitiesOfLongTermDebtAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maturities of Long-term Debt [Abstract]",
        "terseLabel": "Debt Repayments"
       }
      }
     },
     "localname": "MaturitiesOfLongTermDebtAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputOptionVolatilityMember": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of option increases (decreases) for given set of returns.",
        "label": "Measurement Input, Option Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputOptionVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Ownership interest, percent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r106"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r106",
      "r109",
      "r112"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r83",
      "r85",
      "r91",
      "r93",
      "r112",
      "r128",
      "r136",
      "r140",
      "r141",
      "r142",
      "r143",
      "r146",
      "r147",
      "r154",
      "r185",
      "r193",
      "r196",
      "r199",
      "r201",
      "r213",
      "r248",
      "r249",
      "r250",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r432",
      "r448",
      "r514",
      "r529"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesEarningPerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r185",
      "r193",
      "r196",
      "r199",
      "r201"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r472"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Minimum Lease Payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Present value of future payments",
        "totalLabel": "Present value of future payments",
        "verboseLabel": "Operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails",
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "negatedTerseLabel": "Less: current portion",
        "terseLabel": "Operating lease \u2013 current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r471"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Non-current portion",
        "verboseLabel": "Operating lease \u2013 non-current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesFutureMinimumLeasePaymentsandLongTermDebtMaturitiesDetails",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r470"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets, net"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r476",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r475",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining operating lease term (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r20",
      "r57"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r406",
      "r407",
      "r410"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Unrealized (loss) gain on cash equivalents"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r77",
      "r78",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on cash equivalents"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r18",
      "r57",
      "r487"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities",
        "totalLabel": "Total other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails": {
       "order": 4.0,
       "parentTag": "prct_InterestAndOtherIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Interest and other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsInterestandOtherIncomeExpensenetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "auth_ref": [
      "r10",
      "r14",
      "r226"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other Prepaid Expense, Current"
       }
      }
     },
     "localname": "OtherPrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OverAllotmentOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right given to the underwriter to sell additional shares over the initial allotment.",
        "label": "Over-Allotment Option [Member]",
        "terseLabel": "Over-Allotment Option"
       }
      }
     },
     "localname": "OverAllotmentOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForUnderwritingExpense": {
     "auth_ref": [
      "r108"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash paid for expenses incurred during underwriting activities (the process to review insurance applications, evaluate risks, accept or reject applications, and determine the premiums to be charged) for insurance companies.",
        "label": "Payments for Underwriting Expense",
        "terseLabel": "Payments for underwriting discount and commissions"
       }
      }
     },
     "localname": "PaymentsForUnderwritingExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payments of stock issuance costs",
        "verboseLabel": "Stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficitParenthetical",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "terseLabel": "Payments to acquire intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/IntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r101"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy": {
     "auth_ref": [
      "r349",
      "r350",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for plans, other than pension plans, that provide postretirement benefits (including both defined benefit and defined contribution plans). This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Nonpension Benefits, Policy [Policy Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansNonpensionBenefitsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r357",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r33",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred Stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r33",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred Stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred Stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r33",
      "r487"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000 and none shares authorized, no shares issued and outstanding as of September\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r13",
      "r46",
      "r47"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r11",
      "r14",
      "r224",
      "r226"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid Insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidRent": {
     "auth_ref": [
      "r12",
      "r14",
      "r225",
      "r226"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Rent",
        "terseLabel": "Prepaid Rent"
       }
      }
     },
     "localname": "PrepaidRent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": {
     "auth_ref": [
      "r103"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination.",
        "label": "Proceeds from Debt, Net of Issuance Costs",
        "terseLabel": "Proceeds from issuance of note payable, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of common stock from the initial public offering, net of underwriting discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [
      "r102"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.",
        "label": "Proceeds from Issuance of Redeemable Convertible Preferred Stock",
        "terseLabel": "Proceeds from issuance of redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLongTermLinesOfCredit": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Proceeds from Long-term Lines of Credit",
        "terseLabel": "Proceeds from long-term lines of credit"
       }
      }
     },
     "localname": "ProceedsFromLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r102",
      "r382"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock from the exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from the exercise of redeemable convertible preferred stock warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r51",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r50",
      "r232"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r24",
      "r25",
      "r234",
      "r487",
      "r518",
      "r527"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r234",
      "r557",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment and Intangible Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r24",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r24",
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": {
     "auth_ref": [
      "r42",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized.",
        "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]",
        "terseLabel": "Allowance for Doubtful Accounts"
       }
      }
     },
     "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationsOfTemporaryToPermanentEquity": {
     "auth_ref": [
      "r295",
      "r421"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.",
        "label": "Reclassifications of Temporary to Permanent Equity",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "ReclassificationsOfTemporaryToPermanentEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable convertible preferred stock outstanding"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueRollforwardDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r395",
      "r502",
      "r570"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r7",
      "r23",
      "r113",
      "r119"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r16",
      "r26",
      "r119",
      "r554"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r37",
      "r314",
      "r390",
      "r487",
      "r525",
      "r544",
      "r549"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/OrganizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r132",
      "r133",
      "r134",
      "r137",
      "r145",
      "r147",
      "r217",
      "r387",
      "r388",
      "r389",
      "r404",
      "r405",
      "r430",
      "r540",
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r180",
      "r181",
      "r192",
      "r197",
      "r198",
      "r202",
      "r203",
      "r206",
      "r328",
      "r329",
      "r503"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Total revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRevenuebyTypeandGeographicLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Deferred Revenue and Cost of Sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Sale of stock, consideration received on transaction"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/OrganizationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/OrganizationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesAndExciseTaxPayableCurrent": {
     "auth_ref": [
      "r19",
      "r53"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred through that date and payable for statutory sales and use taxes, including value added tax. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Sales and Excise Tax Payable, Current",
        "terseLabel": "Sales tax"
       }
      }
     },
     "localname": "SalesAndExciseTaxPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r174",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesSignificantGeographicalLocationsOutsidetheUnitedStatesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicByCommonClassTextBlock": {
     "auth_ref": [
      "r152",
      "r157",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on basic earnings per share.",
        "label": "Schedule of Earnings Per Share, Basic, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock": {
     "auth_ref": [
      "r152",
      "r157",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effect of income (loss) on an entity's diluted earnings per share.",
        "label": "Schedule of Earnings Per Share, Diluted, by Common Class, Including Two Class Method [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareDilutedByCommonClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r356",
      "r378",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r356",
      "r378",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Products and Services"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r433",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGuaranteeObligationsTable": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure about the type or nature of guarantees, for example performance, indemnification, payment and other guarantees, and related information such as term, origin and purpose, triggering event, maximum exposure, and carrying value. Represents the guarantor's disclosures which include the information about each guarantee, or each group of similar guarantees, even if the likelihood of the guarantor's need to make any payments under the guarantee is remote. This excludes disclosures for product warranties.",
        "label": "Schedule of Guarantor Obligations [Table]",
        "terseLabel": "Schedule of Guarantor Obligations [Table]"
       }
      }
     },
     "localname": "ScheduleOfGuaranteeObligationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r21",
      "r43",
      "r44",
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r245"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Maturities of Long-term Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Interest and Other Income (Expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]",
        "terseLabel": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesCustomerConcentrationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r51",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CompositionofCertainConsolidatedFinancialStatementItemsPropertyandEquipmentnetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r357",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r316",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrants",
        "verboseLabel": "Schedule of Stockholders' Equity Note, Warrants or Rights"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityTables",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment, Geographical and Customer Concentration"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r98"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofShareBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r110"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangements"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Options exercised in the period, intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r364",
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Balance at the end of the period (in dollars per share)",
        "periodStartLabel": "Balance at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r371"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Options outstanding and exercisable, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r371"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding and exercisable options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block]",
        "terseLabel": "Schedule of Stock Option Activity and Related Information"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAndExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of outstanding stock maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r355",
      "r360"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r357",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Award contractual life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r373",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r362"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Options vested in the period, fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average fair value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityFairValueAssumptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Purchase price of common stock, percent"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r317",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).",
        "label": "Shareholders' Equity and Share-based Payments [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "ShareholdersEquityAndShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance at the end of the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r120",
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r32",
      "r33",
      "r34",
      "r125",
      "r128",
      "r151",
      "r152",
      "r153",
      "r155",
      "r157",
      "r164",
      "r165",
      "r166",
      "r213",
      "r248",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258",
      "r296",
      "r297",
      "r300",
      "r304",
      "r311",
      "r448",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.procept-biorobotics.com/role/OrganizationDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r64",
      "r89",
      "r90",
      "r91",
      "r132",
      "r133",
      "r134",
      "r137",
      "r145",
      "r147",
      "r163",
      "r217",
      "r311",
      "r314",
      "r387",
      "r388",
      "r389",
      "r404",
      "r405",
      "r430",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r540",
      "r541",
      "r542",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r163",
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r63",
      "r277",
      "r311",
      "r312",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Warrants issued (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r33",
      "r34",
      "r311",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock upon Initial public offering, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r33",
      "r34",
      "r311",
      "r314",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "verboseLabel": "Issuance of common stock upon exercise of vested options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/StockholdersEquityScheduleofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r64",
      "r311",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Warrants issued, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r33",
      "r34",
      "r311",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock upon initial public offering, net of underwriting discounts, commissions and offering expenses of $16,076"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r311",
      "r314"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance upon exercise of options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r34",
      "r39",
      "r40",
      "r128",
      "r210",
      "r213",
      "r448",
      "r487"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "totalLabel": "Total stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r126",
      "r297",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r308",
      "r309",
      "r310",
      "r314",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability",
        "verboseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStock",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiability"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split, conversion ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]",
        "terseLabel": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/OrganizationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/OrganizationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]",
        "terseLabel": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/OrganizationDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityByClassOfStockTable": {
     "auth_ref": [
      "r22",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table of capital stock that is classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer. This table may include a description by series, value, shares authorized, shares issued and outstanding, redemption price per share and subscription receivable.",
        "label": "Temporary Equity, by Class of Stock [Table]",
        "terseLabel": "Temporary Equity, by Class of Stock [Table]"
       }
      }
     },
     "localname": "TemporaryEquityByClassOfStockTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r248",
      "r252",
      "r253",
      "r254",
      "r257",
      "r258"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at the beginning of the period",
        "terseLabel": "Redeemable convertible preferred stock issuable in series, $0.00001 par value;",
        "verboseLabel": "Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Temporary Equity [Line Items]",
        "terseLabel": "Temporary Equity [Line Items]"
       }
      }
     },
     "localname": "TemporaryEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreference": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference",
        "terseLabel": "Redeemable convertible preferred stock, liquidation preference"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreference",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityLiquidationPreferencePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Liquidation Preference Per Share",
        "terseLabel": "Liquidation Preference Per Share (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityLiquidationPreferencePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofLiquidationPreferenceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquityParOrStatedValuePerShare": {
     "auth_ref": [
      "r22",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.",
        "label": "Temporary Equity, Par or Stated Value Per Share",
        "terseLabel": "Redeemable convertible preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "TemporaryEquityParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TemporaryEquitySharesAuthorized": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Authorized",
        "terseLabel": "Redeemable convertible preferred stock, shares authorized (in shares)",
        "verboseLabel": "Shares Authorized (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesIssued": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Issued",
        "terseLabel": "Redeemable convertible preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r31"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balance at the end f the period (in shares)",
        "periodStartLabel": "Balance at the beginning of the period (in shares)",
        "terseLabel": "Redeemable convertible preferred stock, shares outstanding (in shares)",
        "verboseLabel": "Shares Issued and Outstanding (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheetsParentheticals",
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockScheduleofTemporaryEquitybyStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TemporaryEquityStockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of new stock classified as temporary equity issued during the period.",
        "label": "Temporary Equity, Stock Issued During Period, Value, New Issues",
        "terseLabel": "Conversion of redeemable convertible preferred stock to common stock upon initial public offering"
       }
      }
     },
     "localname": "TemporaryEquityStockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityTableTextBlock": {
     "auth_ref": [
      "r22",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity [Table Text Block]",
        "terseLabel": "Schedule of Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "TemporaryEquityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r136",
      "r137",
      "r138",
      "r139",
      "r148",
      "r211",
      "r212",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r247",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r402",
      "r403",
      "r404",
      "r405",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r484",
      "r504",
      "r505",
      "r506",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CommitmentsandContingenciesNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r167",
      "r168",
      "r170",
      "r171",
      "r176",
      "r177",
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Valuation Technique, Discounted Cash Flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesLoanFacilityDerivativeLiabilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/LoanFacilityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/StockholdersEquityNarrativeDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrants and Rights Outstanding",
        "terseLabel": "Convertible preferred stock warrant liability"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityScheduleofWarrantstoPurchaseSharesofRedeemableConvertiblePreferredStockDetails",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement input (percent)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesRedeemableConvertiblePreferredStockAssumptionsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Warrant term (in years)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/RedeemableConvertiblePreferredStockWarrantLiabilityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r150",
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "verboseLabel": "Weighted-average common stock outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesEarningPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r149",
      "r157"
     ],
     "calculation": {
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common stock outstanding, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.procept-biorobotics.com/role/SummaryofSignificantAccountingPoliciesEarningPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common shareholders"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.procept-biorobotics.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(3)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21728-107793"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5144-111524"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(27)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.A)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=122040515&loc=d3e105025-122735"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12069-110248"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=SL6540498-122764"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235172"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235144"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL77919352-209981"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL119206284-209981"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=124258985&loc=SL117410129-209981"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r571": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r572": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r573": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r574": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r575": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r576": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r577": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r578": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>71
<FILENAME>0001628280-21-022015-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-21-022015-xbrl.zip
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MIT<5(2:M2_-? %RF$=AICVF 'A>>>CN)E^:#F]RDMV(Z\^EHP-9*B _!);$
M["PJ[S@TU6#G(Z-/UP--9AF/ HTQ+D89I3)> A,,VE&)N&#:.,6461QH9I1S
MF1),G&@K-(D>$<<8 JY'I>2(H!@"I9HL#DRSS[E,"3+!N;= T;Q"F EKM.'1
M,:FQ-P@.A86![*ES+E/"AW"I/#8!(1J8CU1C#M$P<L&'R)&G,YCLVV3O-/M9
MR#)2(%D!>4DA3%+:.DL)\<)[3IRP?O$ G5D,_/3@.N.1YL+C:!PC+&K..<4V
MIIP'IU8L(+CS$ ,_/=#&<RXH"UY1S31 :YB46$GM)$UK0A</Z*>/@6=@FV5
MED1%1" ,"ZU"9,@[014SDCOY=&O*FNQC'V6Q&XF2>(DDHY:FI11:1.V) ,63
M5BE"%P::&46 4X+)($V<3M45D&+..QNM!M51&.RB8D$M#DRSCP"GI5E:$*>(
MD@ 5$X(HZI0R*:-+D)7(+ QD3QT!3@F?: @V6B-!,&?1>JM GV0:.)928%RK
M%-9SM\P7Z^FM6;! KZS0+J:Y@$C:E LTWG$';44!/UT/+(9;GB(TE",,[AC+
M(!WSQFM.C!,<?N,$8XP6!IH9N.4IPF2CESA*HS#SS'%FO1%,>T\0>&B']>+
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M1W%*#XU)Y'SL%'23IDUIU8;%)NKHD;<8,^:"U9I33R0RE)- _-/U0)/9V:-
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MNE]HU5;_9#BHZC-P0THF^;3AIT<^*-!K)Y6Q1C)*'/;66><:4"QN006(-$2
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M*)?J]GO#. D^"-]\&O232,],>(\A6BC"A>6*,/ABB'$*4>JD4-ZY)FQ:,[>
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MW;Q_]#KT0VFZ /.:[^7]O!J4)F7UQT@O9&PKK!<.(8"9.19QFB?)DOW&PH6
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MFYP57Y5(?(NS^I)GFG@><G*6?,]OU\Q%-\2[?5.</+K98_>*P]1-1RS*GAG
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M8A.WL#H:[DHA;C5*7MW(2EYK28HO<Y>HZ_5<0 HPQ@XO26!QPT1=B\EC2@5
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M19L F-L$K#&27R'M.B-Y7B1/)3%I93CE0$&2\JY5 )(+!9SSZ>],!^'3&9"
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M^:C>"0FXL1)']K8(R;2CDJID<S=I>AN9DJ5-'?B4HC#/.DWGN[V"L,7O%5\
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M6@/WI<,R,G 7%),Q JY#RF#NXLZH:*J;I$G<&:D%DB@)L2.2!;<ZP"W%J=,
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M[$YZ0 *,4!6( T^C_D]=,$ K:%+?>(R"Q\JC(K^C&M6J#-YU!.]R[?P,WCG
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M,-#,6:"D1L08))!3&YNB"METX[0,ZC4 ]7)= QG4+P'J21\!#-10P2G@3$)
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MN &:8@R,EMHBAN(&$C8V614C\29)):/^047C>9#/#;B7B/91 ^X"[=>G)RQ
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M 9A'O#-#HS@CZC&B5:HR]#/T%W!$D*'_2M _&H/^Z?4)E\%S0@(@PF- /?5
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M+# "N:+:F(U-@>?6]S,;9-+.8LIB6E$Q+==+EO?6E=Q;)[QIP6CN,-) QZ4
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MD-H):K57E@@8E4VEK:12/Q'O3RD&ET$_E^4P6?M!8P:Y0Q!XPS2@RE.@&<,
M&6AUW.(Q3GL\QE4)20;]&P#]+&<?#"O#%0X.8DLIM$81(1C$,'A/B,(/H_Z!
MN-V,\ 4@?"(7 @D'M18.1( [0)UD0,:-'EB(/'%60<;BODX6$(*;@;TNP.:,
M.4,Q<1(BRHU6F@5+A4).Q^7B_!. G??UY:)^(C0A2,F1]P($P06@6 :@%+/
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M5;!\+^D,CM#BS?T!B8YJ^;BL9LRD9AQ-.45]BM<C7 %L= JQ1A@HKCR  KO
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M)G@E6>!;VY2S-E%W2:XH&%<P;GV>^MYCE079?CVR?;B*;('%1 *UR(NZ*ZC
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MKQ7+6+I+G)X"BC^U>XLMNY0MNSO?M$<0JAC6 <D0-.*":62%TB@%&2,3EJ5
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M(:3%J%-7GERFUV9A&G>$E=FJD\P'*8.FB'IE$5<A(N,91YR3%$"F\)[;VF9
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M^^B,$2Q0A2T3--*P&+'J$J%+0%8A>G>%I$EYT DD!:\CQ3(AS8U#7 6*'(M
M^;#G@=&0J');V[PML[E4 *GPO,+S5LCS;H>:LSPO=;[%@+['JK^PU-EQOPN3
M.FA87@',)0'SX,55P$R2$2QQ0('I&B8],C9)A+'CS"JM06(7 ;<"F04R"V2N
M%#*]ME;*1%SDD>,@@*U(#2C*K"82_ER):5QP\^ZV[T51F#VX=N?;)V$Q9BHQ
M1'T^N.YH0%KZB+2*BAEGDE8 G$2US<KJ0!;<++A9<+/!31H=5T01PS'GQE"G
M@K3,66P5LU*1ZW&S0./*H7'W*C0::;1D6J&$<>Z\K@3221)$J;(I>:NB#%O;
M=^X;75"QH.)30,6ETNA M8SUEID@N6#2!DEPPM)Y*1*PE>MA\38Y-P4\5P">
M;V; 4SLGI0]@AO,,GC@A'2-'C#CL'&,$5CWP2BW;3)N['PHKZ%G0LZ#GG>/4
M!3T?"#T_7$5/24!2GD9D%.>(,[#*090,<1$E=]$PRG+:HM1MSN;-\HU"SSK?
M\5]U1@/\&SI?M_\7?DR&?.E>N:)AK.Y?_6A6O\/CV+(^]URPO9R.T>KUAW!W
M6\'+O58'1G94V6[KU%;#W'1V>!P',2MER&T9\O[0JZ?-#N&/U.G9GN_ Y8,A
MO% 7>WQV(;+9&1@/@PL8YVE_4-=K?%[%KLWE'7\[ZX3A\<3LO/2IL2CQ]"/6
MP0A&P^L_<F*KHTYOL@C,U3WB02=?7YV<RS_S^!N(D=K(X *EQ()%S;7PD7!#
MC$S.)\X_4;TU^=!Q-7F"4WL4D:NB_8)L@@=\;KMG]GRP]:^K,P/3,AZ0X##B
M)6=P7 &1Z'J[;Y[$5? 5"Y[J09>^6CC[K]\>O'CU^K#U>Z?_M@_/UO&#UHM^
ME9.4\L*Z=N&NR_A?'.R_?+7_[M7+%OSV[N"OW9<[A_#'NT/X9^_5_N&[UL$?
MK1<[[_ZO]<=?!W^_:ZW] _VCTP. Z8_@'F'PS_4?[JAG1Z$#R/?/Z^=V3G5@
ML/6>, 6T>A."07?MZ2 ^G_SR6^@,3KOV_'FG5W]U_:'?KMY.S)<>K2>G>7NJ
MSL]PH]+C[/OQ-X_??E:_-;.C-N\I_(PI?NW;^!FY]KT?W9;09YK36]WVQ^]Q
M?KM/_G2P[*:W76 O3>0(1":NQY4_.8GQT\0U,W?I N.K4<W[,37TC?1U'UYI
M[<%EQX/6*]BZPM4S&M<>SUB7:;]D@M^4N*ZW0,!8(S>8]2<Y,=>?%MI@9%F_
M 3_ )*SW03=S(\/E12XHGKK]LT$K5?V35O\T9M(,YF.VU+_6Q<B>WV %_\QP
M_X$BWR5K>X69WW<;X2-8O(M/B*[SXKVN;-B=SX6OVX/>W-V\Z D?R&U\LT=;
MQFM,38C>*F>T"ESX:*UWGH1H'.$BQ>; .\&D.?!.'O>!]X,78\_QR7YWG[XY
M__CW*[[_>8]^R)[C/_<$7/=]_^4>W_\3OOOSOSL?#S^>3#W''J[_0/8/X9KO
M;\3'SV]//GSW_./G+V=[W[O=O;_W/^^_?"\._OSX9<YS_/W?W8^?WQ/X+K;_
MLGNR_^?'S_O?CT\.#G>^'_S]_ML'NH?W#[_PCR=OT_XD!_8=AK&\.=M[\PEC
MJ;41$EE. N(A:>2TX0@'SJQT*BF'M[8Y:0LLUN.X^XH*5Q10>IR@)(T,3*>@
MF*'<<JY9TI$J)Z+1+GD_KL)!GD05C@T!I>^SH*2T<$9$1(/5.805D"6)(ZU5
MQ%C 5N/=UC93;<7O$LOZY:#T"%CH#TKHUM[<]>C@=#,8N=0JK37LMZH(P.$[
MW=CJC8EK?K5NZ33*(;A.;_7FU[H86<64>O!:S#=;LR_C*:S33ATX:]E>:-F3
M/@SN^]5(VH87X[K95-RO9;+$WG]91O![-^9?=GIAYY*H"B58AA)TYNP4IB*1
MCC@D:  [)2J*G%"PJ"V/(M*@ TE;V[0MY)T/G:R?K5+T>G7DONCU@^KU+-4/
MQA"75$2.!8XX<0%I; RBD@JNC0#8EEFO ;?77J\? 5/Z$=U?<Z949Y6BNLMQ
MRU]J<]R*W_+O\;'T9MUPLE27?OE]MA=U@=%E8/1\CAXIP,P0N4.YUFQVXQKD
M/-"C1# GU@JLK<@PRO"JRK^LT3F(HLD/0H^*)J]"DV<)D4^!<FD4\CPG\LM(
MD(W CRQCGC!8O5ZPK6T"AL[\(:AUT^1'0(A^0!K7J(/]#9-+CFWO*&:_9K*=
MJO75=D<QGSVH8HCQI,Z=!3BI!YQ_!^,GQ0K>A&$"M6J=V:JRV7>:W5 !1O"U
M/E'0ZG:LZW0[P_.GY8YZJ$AY \*GE1\^_P/$^)\LQ:EG^R#]/183&*I_VDXO
MQZ,.P'R=B&NW-QA6H]H)OA^'KZLX7*-FAIN V0?S073!F?(X%XGGV"-.@T9Y
M)Z[)6'0B<"JS<XH]K@AZ4>]?$7,NZOW@ZCU+R3185M)8!>JM->(Q"J2!BB&?
MO,0\:&=DKJVY+OT@'BT7VV#GU'Z_A^K(<C>"P?0T75+W3)@N 2G,?DZL_BO/
M_8[W5>W(?]7(H(#C,N#X;H[[$*IP#$8B&B78JX"'R!(9D8:M4&&+J:8^UT)?
M0<F.XG):0TU= ?<IFOI+-'66QBCNJ8A>(LY8A!^*($<-0S9A;FQ(FDF[M:WG
M&Q:LD:(^ A:SP<E(N[VO8%CTJ_/66=491A3Z9R4'Z9=3F(F__6+V_\Z3_Q+F
MOB#B$H@X+60[+0(NA'0\LI03#W+5'"4S;Z%(I$088*(FEFYM"W;GDHU/T7LS
M[)^NO9*NC+T4)5V=DLYT6Q*:D<@(0=K"#YZ$1D8$C1*65H"%8:S/WM4[-UJZ
MDXXVBWT-^$@Y4_[@5Y:)71>NO<$>PR98.Y@YA3(8Q'$ =A)U+2=2UN#*E1J!
M9KT7YH[WN;'D()^?BIVO.6V@G4]0/2U#\)Z=V4ND9>WV?)7=9R]C\^]N;R*Q
MMQ<"*YQT*4[Z9LYP--IBKUQ$QN?C*,)(Y *C8#UJ9Z6T8$7*W&Y/8[[.0<$U
MM!HW1:E_@>58]';U>CO;N3<135ENU<MB!+UE#)E@!3*,"(4EE2*JK6U%[Q*M
M*J'\NQ'S-><_%QZ>$KU?5\(S$5$GEE(<RR'F^SFF$RRAEEF/!+> F"9(9&72
M*/DH#-4J2F&VMEE;Z/F3)6L4."P1_G5F.D5A[Z"P,Q1'*09@JS'"D1'$0XA(
M$TZ1#,D$S(D4N8^.-G=)1BYQ_D?MXGE=Q5/;"9,TQ<;AV!\>QZKE1U4%JCKV
M1!:?SSU&_V=!<RREE^-3.N,LJ9U>.,B2VJD%5-!T*33],$]_HA=,&88P#@YQ
M3PTR43BD%/ ?KGUDG&QM2RS7V6 L;IYU)C]%CW^%'L^R(I]D$#2!"@N66[-J
MI#$H,_P@3 90;)7KC"PX'K]&>OP(6-$&.WXN E^G]CP[8Y^6_V>#W#\30;UN
MY%2P<RGL]',<B&$>B8\)>4T%XMQ19*-G2#D:<OLT[C"MBXO(.^=@%3_0HZ9"
M,Z=<BPK_,A6>I3^<)>I30B90"QR(*V2U$4@:&X5((<4(>SI=H,#%*52<0A/Z
M4XUF:JL]+?_/>KE_QO)X9[NV^,V7ALBC.98CB94>VP# Z"GB+!"D0R[BX23F
M"N09B5Y<Q*.<!7DL:GN_!=2*3J]<IV?3?3"7(5=$3 '4F2LKD2$Z(H!GR8Q5
MG/"4BZDQO/XGO!X!^]ELYT_-?G+C]BH.AD^SA,=Z,:#=L2S&1N)^'!; 7 HP
MO\P?B"48-CY*D:6)(]C_,-(.YW9@B1O"N4\12-"BK.;BZ'DLFGLO^3Y%<^^J
MN;.G9"/'VAJ%I"<2<1\2TD0;Y#'VG$LOB%6@N7(^4+UNFOL(B,X&NWDF8>A6
M%;_&WNAV!.<IV(KW0'!>P/?ED?S=&1Z_& U@5F+UUZ3:;D',91#S\WSQ#RHY
M25P U\$T@''H<VH/%\CSX+1CUD<:MK8E*0Z?QZO$]\!UBA*O5(EG:(]C/C &
M%HITBB(N'4=:8(\<#E(''[RVV<.SH*K9NBGQQM&>]1OPIESYE!QG=1+CY6H5
MQ6/V<(2R%L;!I)S(7U.AE'UHJ7UH=XY,@O$=" T",489XDXQ9"5U*"DM=!)2
M,FJVMM7=XPS%<58RI(HJKU259RBEY88SYBF*V'N@E$*!*H> <%1*$X4Y_ MV
MH2JY4L6)=EVY_SC\>2/YNWC67+\*L4+#_NGS/">#?K<36OFQ'CG"KK*1TA*9
M&B#/7);\==7_V@DQ_'[^'N0*&#R1ZLZ%4 OZ+H6^>W-$RBGNM',$I>@2XLPS
MY @U2.;^ HD)PFC*S5;:P*ON?E;G9GJT0=ZZIPH,JZ1>!1C6 AAF<[F,))8D
MBUP,-3!XY&AB2!JNO4H!R^BWMAEO:[.AP/ (.-MB7KO.5"VK;RMU^V>#5JKZ
M)T#6OL;!#%.[4X'5GZ^DARZ]NI(1;MSB7;\!;\J596+7!6XWV$1^/:K\L<W%
M9?JI=5IE WEX7A>:B?\==4YS!\NGE7KRH-5E7MOSNF?H87_'P_17\?58(J^[
MMC?<Z857$Z$4'KL4CYT_3>VDS1Y$B2*7#'$>/+)>2^0EQ\%28*\IY*.8:UV)
MHF2<K$]%F:*[OTYW9Y-L&2@H5@1I;R7B*M?68\F!*N-D#!9*IMSLDJYUT>]'
MP'M^$#YA? 'OJ?_N] +HP'.457J-L&,N5K#( KU+TL13=0FN,E9P(Z_?[D1P
MQ>MW2\2=/Y4M-%,J4(H42 SQ%!.RR3#D#?')*&.:]L)W8DM+Z<D&)5L\5<7_
M=6D81?%_G>+/4"W.L)<B:D2<TH@+(%W6Y'(,U*I$'?:8QKM2K0=4_$= PA83
MU77V.<WZ^E.G9WM^%;[^&T>-;N6GOZEM?5\C? 2+]P<6!*4;9D' =@1/$R8!
MK,%@!*LZ9K^J[Y^<]/-P^OY+\^[P.+;BMUCYSJ"^HGFK?YJ1LZ1FKT=%RXD\
M_P"!O<OR.6C$\VHLMU#(Q3+DXOO\T3\0'><D8:1$[I%@B4?:9YK!="#$)<83
MSTU-^((N"25?^[%H]?U6>RI:O7*MGLT0LM+QE!SB08,NZWP6T"B)E/><!&HC
M=2[7J<6"K+U6/P**]0-']B.B6+W^,$XJ@M=]</.+%Q?X_N"I=4EY.%J5.M]B
M0-]CU?\1]KZ,;K@?AP=I=RRD%UE&!7R7 M]7\T7"8S11XX"TR*7VN-7(D2@0
M38Q9KWD4VF\!S&I*Z&]K?QB[Q+<WCU05Q5Z-8L^PJASJCD$[$(%.B&/BD"8L
M>V,))XQ;Q1,#5L7;4J]_I91'0*L>K^=JUC=5Q1#C2296&6+J8>??3ZM)B:K&
M>75FJ\KV;DFSGH*=N_ILP4NH^W<S^Q,KMN#M<G@[7TE <4U(# J11'+@2P3D
M&/Q(7LMDC8Q.\JWM1:??ULV&+9ZIS2-119WOJLXS] F#*BNJ#;(!?G 1##+*
M>@2O:QF983JR[&IF9#Z%9=T4^A&PIZ?AE'H7<_N UA\WI%#%;[4</!NI3!*.
MD^08]TE:EVPDDAL XTB\N+/?ZK3RPRNP/#%I#]+;"XF^F KT]42>=6"A&,%W
M1/'YJ@3*<$$"-L#"#) RD]O$."I0S#$'1@(ABA3OUN/7_$0=\1@K[X3EQF";
M2 2>#ELY]3Q0OAIB5M3_H=5_AL01F2@C)B "$(\X=?G<AW:()[#)4M0A<+VU
MK62;ZSN;9<4']I1]8 M8W)\/P.*>@I'-K$]1*:=SKQ,>E8G&>L&Y4UP*3OAJ
MDKH*EC\HEK^9K]0)=)T%$*JH.\&;2)")$@.TX\"-E,21W"B#M]4&6.3%Q79%
M^\<$?-VD] AVW*?A-UF<+]V!/:1CNZW3D>MV/%P'  V3<+'?PC3%ZJSJU&<V
M8;:;UM7M^FYP]YSD5Q>VF'QPTCNN.%C6+]]ZLM?N-C)_78O\8"RXLO<NM?>^
MO]A[]U^^^9;W7MAB9<PUW)A6 O9>%I#&5B,>?9!82"5#[M:@:)MCL_:&5'&C
MK$E\ZV:)?T6U5ZK:YY=5^\LG KJK)6BU2U@A[C!#.OJ$?."*2*$2"79S/*2/
M@+']R$<BUON<YD5)C-/Q0>N6.U]X6+.4Q5AS:G7-@?D_)K(L!^;OS*TF?@WI
MN+&&1V0T<X@KQ9!)"2,L0(C6*:XBSI4R2)LO:%UP.Y.YE,QX'*!PO_E&!11^
M.2N;)F^+B'TBR%E,$2=:(Z>\0EX03@T37AA@& 3+MF"KZNE=RFFLO)8KWC /
M6R9PG7'+HES2+).Y=D/I<G77KZ#3O6'C%,MMP*N.'P+)R^^7IBAKSN@R<N?_
M7DWE^/9"A/F-G5ZX^L*E*U_#7/3#?#,KWQUE^;SZYH]M[RB^M</X"@QS7RI6
M+K<!?)B/=@4) E<2&6Y%/I9GD),&J*&1. J;N!0TEU'";2;NO $\8.^$TE1E
MTUEA 9;U!I;9QLM$^B2U1T3 C[J8BB'6HA2UHI+SF C9VE9@;9)5]5XNQ'*%
MCL#U\/^I:^NTW9$NKL)?L'[W> 2K\4=F#EN79;EXZ_P]'G5ZO>R![J<Z,>"T
MWG5*%/\:_J -CX$:EBQ3G$9F,;<D),.34 +^_VDWTP9"&7DHVE!8P%(L8+X\
MLTW!YN[6"!NN$;<I(FLC18D&1[W06OO:OX3;YNZMKTM ?VU5/5E*K#%84B)X
M<L%I);22G"JE)"$ZJSHQ1=4W2=5GJZMQP[VV$441+>+1!01KO>[.2JW2GD@E
MM[8Y;:N5$?Y"ZV\7WU]W(O6J3H;\ 87ZA6&Z=9N+__E%S_Y8=A8L8Q*6"4F"
MY9%BJQQ1"8BEXIHK+VL2^:!.[;*S++6S?)DCD8FH$)G"B%B6NRJ1B(P@&A$>
MO;#*I.CTUC:CI$WEJBIWKH>/^B<>@ *#!08GA]48HYS:&+PAW'OK@%E'^.D]
M(UJGV-C2!08W"09G";;CL+0]6- D'S+6)E?0) 9A'9)T3F'"@6 3PMMD0=>3
MS8'!1\"]%]LGZXRO;R/ B>]T.[9&FGS6Z<9.]M:PWW*V6Q^2&AS'.%Q9DQ2P
M4UJA/\J'F=>U2\H=AO@(%OH&&YEULY^\FF>7^%W.A3Y.+O4H&=.]&8Y BF:H
MT,[PA:VJ<YC2_]CN*!9FM 0SVG\Y7UL\Y0QVXW-"N_2(.^*1Q4DA3#3&R<58
MM\QF%+=!M(_OS'X!J$<)4/=FTA6 6CE S9ANT5H6J TH!!$!H%)$3JB(F!%1
MNVBDXB*;;JS-^)W#H*5<Q:/.,GF[NH3X1QUROCV_NXJ0<QZN@I4KQ,KY^N8)
M&VR),RC([.;"T2&GHT Q:"4I"\8(('-*E721QZN[MZ<^17?O57=G>(XE2MF0
M$EA>TB).E$'6)HZTPBH1K9+F&Z*[CX#C;'"!AYLG>.?3@U=]SR57I 1)']KE
M5X*D][,#S1=BY\I9*;5 P@B*N/0:69,,<IX&:9RWUIF2*U)@\"G#8,D5>7PP
M.$/$%>-)D,00RZ=ON;42&2$,(B!CXS4SEI9<D?6@Z>N<*[+X^.6[T>EI-YZ
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M3IHC(FC0TD?J?9U019[-'ZA:#"6U"7/!9Q:8,=DAWHVU 5-GT71R/*MU.G+
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M0>7W>B^8U.%K.L'E[:(]??'4GM<;R/C*V;))%SO^]$#EY:&%T:2^-KPT8=5
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M4@3D<0!$^1268SJ&9&PQN0K\K,&C+0$_7AD<A!+&.LZ9=Y8I 9#DE8K):]O
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M=VR\%A^1=:@D;426.HIX2 8Y3PVBRO+HI"$Q]FS\ -CXLT44]+R\,UY>CS7
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M.U[!-=OXM[ OH$GSO*,"'1L/<[8"=IY?3FK8J8 Q@,,]/&T!-_/QQ,%<WA2
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MC$5*2$NEQ3;Z[' AK.?O^\;?+' =I.(YRX$'CW6D0CD=B8\4"YX:^4UZ^7U
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M+%X^>XI/_OJ-'I]Z>GSVVBKC!7$8*2] _Q+,(%"])4J.46.H(;!/[Y$Q6^F
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MXPW0J)))T3/%-4L\Y&K[*29N13"):J)"#8V$,M)#XP%#XT8?)<D9BY8A0[A
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M0\;V^E5'K<%4S2\NR]/SNC1WA6S>#<?Y]#*&H\8ZF^5/2A&1;!^ULU@%T0L
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MA/WRVDG.(G8$"1")J%0ZU"E1Y*BT7FD2,4D;"9<N@FBF5,G N<SEKHW%@?)
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M_8DZNC&*:+U30LY8TU$E8A+G8$ H@15<C"5VVC%V73#$S5;'6I@)3SJY!!M
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M7^,@KI7X^5!R9C27&3&+JNS\'<7CBV6/7PD^E),?7!:2!JVZ/\B)+PUY+ 2
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M&O6FMJGG;WL9)#WI3)EG0G;;&6&6H FTG$F!UW4)>Z?S<L8=BYZ"B=^B46V
MZ;*W-:\U?CZ+H2H$#Z]T6HT*SDZ].7,/.1X#] $M3$ S%YN?9[(N1.-!M[J
MK3W/9)C1\J0:CD %K NJ>L<H'UAS=KX+1SUEG;HV/A_^<%C[<'JY[46M+A7K
M-"\VGV%_4/Y9JZ7-O2:ZW0B$_-0%E&\X4<H"$!I\W?>'C;J>]Z.A)R";$>P
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M( .@"MSJ,;+>!Z2=-CZ*)+$0H-RW(;R'QK(W$;7W%WYOF?<NF7?9,@^8)BI
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MUJ]@>?$^P?#F3?5G\S[!(B=*C0UY[\Q99[EFT1*2E\QYK&_9\V^\SQ^-N.>
MN,$G;C41R$NF$1<X(' S+1)4"2>3B2QW5"18;Q)^3;OOI_<^7^52]ED.3T"H
M6B5:??]:S3.$M*I1OP0I);<T";V>AU*B-;8XX6BY4,DI'G)1;D=ALL!8U<7<
MU6U-C1N*\>-X:/9YK#)>$(>1\L* P#.##+82)<>H,=006*=E$R.Y]0XP#PL
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MRIRNR@[80V.HU8%K&%M[]Y ?[/_6:W\^))U]>.;^$3SW/SVXGG[<W_G6WOV
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M+.'(J<0HQA$'Q3@/VCCO&*5!AB"HERY\VBWBI#!!U\D5$DN)51&A2GAVQP-
MSC^ \_5#:0=\)4E[:4K\WD</5XZZ61%J 9,_L8!U/L/?WGT*PG*LB$4ZY+9Y
M1"1DC&4HV,2\3+""*A_'IV9KL81."TAXKV;)]S1<8)ZRLY6_;GNM4]L-0/Q;
MWIYV1_![OM5XD&\ OL P9@?DI/AI-ALW9WOVQ$<0X!A'6Y?.8?$WUL&_>'O2
M^L\8S'4.:("O<-*RAX>#> COEB=P&5V+5A%M0.6-5IPY[A*8 *:\$8(ICDG1
M-3S1-?AA+GJRG*[]>0D)WN:1#??294!EOP^*!S,#4UO%5GY:W6KO[XB]_0_?
MVOL'%YW/_J)]]LD;0TV0%#F!.>(,IZQE!D5/,0.K*R)1&]OD-LVZ NM[*MB9
M'4[Q05"W69 ?PGW^;QR'19_.BV][U.^%.-AJ[1?/%VXU!&M<R*B?M%K_6KJL
MGY5O3YF'-.@?+Z'X"^9F#@E:5TBPA'9_/V4N=_PE#Z?K;V],7]3[/=P([O^F
M]>?5C$R9G]8E_6D5X]5:4P [B76P8RHNTNH62[RDYY%2D 9CX3S!7&)CC252
M\JAHX-016A-0^3@"^H)W6Y^&:.Y^*:==N$G6"@O3R"P"?T BC1-!B@ /L Q;
M*\'#X)L\5]YB^(:([15<5=I0_?7-?4$"EK5U..@/A_!)W\<8ALM:1HDCHQYK
M&KWAX!B9* /6W/EH/256UBQ43EBH?!0+_:,>Y6L PBQ2F9[LI2O]O]'Y^6FM
MY)SD<7!Q$BR&%X(#9BF-.'<6N1@](D8+;33!(>=K:[&U*'03,[G5FLP^2,,P
MQU5REN&2#LP/%AU[?@QP#ESJTI7)X_\]#[^1CLH_(;G,)TQ]K@.' C<4.%34
MR 5,$?B40*6H%]$ +N&MQ8(MEQPJ4XVS.(B9O.0]H)!ID,U>2QK&468FLYBS
MQN3C]3W)QYIR#W">\F+NC _'PU'M1SV:AN!('+<Z>'"JN$C,,2JPCKGXI%=>
MN&H'&NLFZ>L[NTRX<_@).^L5M0E%98&&@.8C395'.%%!K?!.Y2;6]?D\N5CO
MH37/0$ E?ACY<)QHX57@FEH>.-9>X9B<ULY3*4"2YMQR_2BWO"$?CY0WVC[\
M!$M E',22>-RTR%/D(Y@:)AQ.@;MC>5I8UNI[TT^?K#H-.3C;O(!:!2L"00K
MBK#/M6<T-<BFJ%"0R00N..4Z9?)Q2P!G:?(Q%Q> ^V9!Z9Z,2^RM6I($$*E5
M%)XRQ3GV&AN3A/+!&Q\%81OK8=-W6L/Q,8SN_*8TB_O&EN+@>%C-,DQNZO=Z
M_;/A+TL$6.#]2_;*9891E2H$\]"SI\/XR^2'7R?9+]V3\C;E2[_.WBYGR,UE
M"I7IKC[^]:P;1D<Y36X+5ZER]<FO^LGUQUOEH[F\I^HS!5Q7\1L_QEODQL]N
MNRVA6YK3!]WV]L\X?]@W[QPLN]=M[SA=MV3%H5'_]*EU1<^IR@*_QU?\_A[G
MYFYY(0_J'@<K\TK_[0(3#@75_M<-_KU=D90(=JCZ-0Y:A24O\=(WGHI9Q_G1
M_RCSL-O]V@6@#K=,RD-/D-X[(_(9U.)N$U(F:>>!.:)/E7S^?&_^T,3S1Z>6
M/]\KW\:G03.*8LQG)5BK<PJ"D IS%I4.+EI+M#116%T7A;P^R>56_WT*O*YP
MZVH,+R%[_+._./C\\;BS_]OGO;_A.Y__[!WL_WG4N?CK^./^N[.<!;[WIG/4
M?O,*SV>/=RXZW<[Q 6F_:8L#>(?.F[^..F]>L<[?'WN=W9WSSO$'?D!?G<']
MTF7YCJLB/>#<!(5M0"9Z<,J"3LAR&G-L6">NN#>1;FS3+4'4H_OZ+ N%]TP.
MKY3D&<[<-,#V<P ;QI)0YGFR(G#-+. 9ETP0PXQ0'+MZMX+<D&[%)_AV.O"C
M>7";4(YA V3+ =G%?+4Q;4@.)2-E@T(\88PT"QA%@"B'70J$^1P_H)@\\1F8
M[P%D/ZBJZ_.IX6\WNAK?K5C:6F&.SMG!T5BE).$R1*V2)#A&9S@V082&3#T[
M!G47R%0,V)(@%5+4 @8)+9'V(:"@J ,R3(178F.;;5&F'ET?_U'ET!Y F9Z]
MUN%:J:],3-A @#(8SVT*)A&-J>'1TR2")0UE> 9UG:<,*8!C*GQ -$7P?7R@
MN7HA1UYYKH,R.(18*(,P-R5A_7!U_4']P9Y/V7Y_$#%X5-N-M4(6%2*CQ!)/
MI>:86D<=D<E&*V0*#M.&&#P[TIPO$ .7D@J2<12ES!F?7B,=L,B]5JVFG%J?
M-Q+YEI#XT4CSJ+X:3Q]+:=1W+@.*ZVBI##XZKD 0E,F\,&?7X6!T;(C!,ZCK
M/#'PBIC<W0@ECAGP>,^1"U2CH"6A 4O)<Q\<O,4D?W19XZ=2UQ<?,=AM(@:W
MNQR1,RZ$Y802[BRSE!BJ8@C:<LV;B,'S(TWG]P5BP"QQ N. ',T=FF/RR&"L
MD+8>W$<':Y@ :<06UO31VR]-Q&"5U9=9\$658B'BP!,EVF,B:0Q*8@*T4#7$
MX!G4=9X8$!ZU=9XBH7/)2P8\WN9D5N:BBU(I##PN$P,.'&%5U/7%1PQN[B;>
MN!Q5OC,#,\(QN)F))^$=\XDP3S!5)@C2$(/G1YK%O(S(@1 ($I%4-I_4RRVT
MO9>(J$BYX(SH9#:V"=M2],D2,YJ0P4KJ+S>:^B!2<"S!PGL;BPH+KK@UAON&
M&3R#OB[L)8 T"JHDHEY3Q+%B2.M@D,58BV0E2R'D^A,8%G-5U/7%APQN;AO;
M^!P967S4@4F7P >5/$3C%"=)\6@PX])&TS"#9T>:Q22#8!4FAFF@ CEDH!TP
M T,3BDD['9-4DF9FP#,S>'23[B9FL,KZ:Z0R23A06L>X3]*Z9".1W(#:1N)%
MPPR>05_GF8$D#F!68$2P<Z"O!)B!QQ1%@9G 0B7O4V8&1#V>&30Q@WLJVYLF
M9G![E@&/6"0EA+&!\T@=9C[X:*B6G&D3&V;P[$BSF&4@HU9<D%Q(2F>D<119
MI@,R5GD:F)*P@( T9HL0\NCP9!,S6&7]9=:GJ)33EB;07V6BL5YP#@Q?"DYX
MPPR>05_GF0&SV%(>?6Z;)1!/6B"K+$88"VR45<1Y66I64OUH(O^D,8/%_A/3
M=1/6HR#"_E0MH\MZ$;E._'W+PH]:R78'=;W.NIM%+IY;%9RORWQLMD[B:/H/
M5=V2K=9.><[Q:5'H^!4FHW76'_<"W*EWWNI[/QZTQI,F&;TKJ]GJ#UIGW:IF
MZ/ATKIC#9LNV#@<1!C& /\.<"OR/EH<?#F,I^ F3,NCW-O,]AJ"X^=O#L<L%
M\4?=4MT^-]6H;VF'PS@:SCT QET*Z5\S> O7CD=#0(:ZKT=YUN( X0G+%UK-
MY2;@C\-\:CQ</@=N<#JIB-N*!9NV6J_' WC@8+98U9$-@&ZY=@7(0:@&.%-P
M]?)%[SFBX5%9K)/^J.5@KL+G\;"N 3LW.[5XY(GV1_6;;[:&W2P*W6K:QO#S
M8&1A@<Z.8AY[6>.C> *K.5M7XU9-JZ5;41#_T_ZP5'O]91![<.77>%4+XQ^S
M!4MJQ<177[%NV.^-1S=_Y0:5GC[8_TPZ3>7<?$W]>S2X*DMP&)$#-?F";(+!
M_F)[9_9\N/'OV;>$5YR>TB5G8Q'@MDM5@>L&>&W=&4J)E 1SXP7CFD:G&>:8
M*V;R&42:*H,/WXEA)U<B8HQHIE1TT2JN+5#U*&324?D =\F;1<]47>_6%;L)
M!#/^;;7> SCE$LKP]TK%2B6EK&6@/[" P_@$JGR#S@[KH1S9KQ%T'+3QV +F
M%+WL9JWW0)!R*2%7G@!P.ZIT?.I&,R^S4U=*J]L85?:;X<VZQ.])_X&X.-72
M9+,J]5QNL1O]]'/(9EW#KP:=C%SW'_P:5FF\9*EK6/QY_[)4^*4PUQ7V=C=;
MKS9;K\LZW[?4[V:V_:>7WO9$X*<>4-]\9[/U6[GS[_<F02=AIM3X9B62,'W=
M4:^RA\"M(A@@$+@3/SX>5^:H%2Y7!R2OJ%]=FO\!O@XUX+A8Y8Q6@0L?K?7.
MD[R=D6M,QKO.6M'E?!U$U]/9>:)*?H<7[9U/1%LP+,(B(7.@0>7C#-H[)!,X
M,5QCY83=V%Y,C?Y'YFL5S$WDN@\.1S=7I;\DR*>#;N;-%0&JX"SD2OB#JS+Z
MKF\'(=\A=$&\1OU!)M2I8KUP@ZKB7OX\<[\K40-I7!3ZAVE4Z>!RAU;-*L;-
M*K>YG,[-FZ5&V5ZPLI6:W=9@'#ER0AK$G=;(<.J0I]SZJ W64OYH95NBVN;#
M6E_-%]E,W6\QH(LXZ,\'F"^%Y@][7DJQC@>YJ^S.2>AD)1C,M)C]Z:K^?O8P
M%L_V]G?@?A]P9^>3UMSRW-E,L)#RH5>&G.$2,>T8)RXYDVYK;_9D786;!?Y.
M"YP,"8I1CJ+%8)PEX(7U%/YA6,5H30PI;FQW^O=H7W9E. JMNT2&C!2GU6J4
M4LX9)DZ Q;; WHV.AF"2<C#MJF/KQ,LI7SR/=E!?<;V/,E^6=2W<C:F-K35T
M.-Y6<<;*!:]YTU30<1,D85BB0N67JQ DNB8$":YY;USBD[9U' >'.19G/=RK
MBB_-1!^K(.-F9792B<UUZ[[ F?Z4+ECE0KAI?Y"Y0G6+:,%7K=C4%)FZ=^^3
M[ !?1YOL3*1UBMS9TKU\LW7:&P_G2.65N1R/ "9+<R4702MBN; FHS>0SXK^
M_;Y96&B>F'M74)_WO+9:;V^)VU;ZVST9CA/,:3>O,HSGV'ZY8LLP[VG<ZY6N
M<?"?):>T?K5"<T]FQE%:S.5P;;5V"_05)*OJ"0^W@DO@0>=YND%\2D!B,F>%
M;/=! LI-:K)=!GSKDI5Y/SOJPIVF"7@=V\C!UK/N,%[/IM>P[=V5$U2F9LH3
MFM]&N$\\X/[NT/7Z>&]AOLVE<;%J6/:,NIF%^-6**>9]Y_9%*N8:6MBGU<S[
MKOY-FGEO:5YES<PBO+MB:GG?B6W4\B6JY7U7_R:UO+<TKZQ:9OE]\.[!=]+)
M^\YJHY,O42?ON_HWZ>3RFV*KI9S?4\$>CP%/JFQ-LLQ2R3+JY23+W)G\,I<L
M0YW"5D2C+%9<2&N%(R[E4IW>1<W=:B;+/+LQ66=;,F=&;INI60!= LC@VF/;
M/2FQSVL1MA</JSS+K[;;NPR?7R+:?>%NT=A5*9?32+^&,?2_^J/N HRO@Y2]
MFF(..=6TB$+^/*_4C5MI?@Q+=0SX_Q0;IO,]4N%5?&Y->-8?A&$\N6W;O9KV
M/_-XAYUQWH_92_"W.)RD .REWXMH50T,4]WL\B=NIKJWW\:=_4,8SR$NXWSW
M*7!+E,,>R< (XM0ZY*P%T\F(=8((9J/=V.Z?Q,5=MJ\PUP4'"@&]W+"?5F=
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MS '9-?'4?RT;,5BA@.D+5_.70/\F.MXPP.^  PO10T8=B]3E$WP>Y9HQ2&M
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M3DIN/,,(7#(09,$5,C)A%'@D2M&@6$@@R&(37Y,'47EH()*Y-4/IEGP83^(
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M_EC6,8C'0*MR8+0B4:T<?3H>']?S<?F*$RX'(Z@^@1^6"FR2*$!R&(F,\4!
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M\VSD1_XH#5?K]TO9L'V^L5!+@T'/:CZAEM<R^_5P,ER?&#F<\\L_;1N3^</
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M$8]R+ $+'G#"R4#@+XW 7_H(^\<C[T53(L[BQ&9V:&61!^3M.I$5A7%D)4[
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MEJ<L#@-3AMGO@]_DQ<Q^?RPFM5SKX?MYFJ=^9N5^D($ZDB56Y(:>Y40!=^*
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M8"!7#;G3A0 6,HYT3N Z0J=!4$6A#3SB<FR!<0O(TSTE1"/0%ZK<)FGI('1
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M*P GQNV0L!S"=)O"=*,A3/<PD!3M2>OZ%MD%R<G6:+];N2)9(61MLR!LA2-
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M6!"AHG1P2%^SP$5,H4A*Z3D&'&'3VU?#97W9RVI28#."W(LK8L6YQ@7[Z3'
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M+&J K?V;XH2@I!+.2],H"Q  C2(RZ>#4POY"";GAI(?P!N-\13,>[O +WR$
MO[[DTMV(1"4*NW0Z(K>%=$A?\[KARE>IV5W-*[S6X;*^[&61SP*IA.(*;<H:
M":EZPH3E5=X>8?3M!])II8^NB^I,2S:AV)!TQI2W1L++ O!.L L1]"H:^O+:
M )W9R])3!:.4%7C-BI+B81L2DD30),$P6(YA/'0S8&2,<[$!%6+M!5IP=8S
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M9)81@RL=KQ+GU4+_/;+@R4H?,>3/[TG:>5XV]UPV%15\U?=MR#FZ]<@O[3N
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M9=N6M?'LQP.O G&07ZG\%W(/TD5E51U9V0X4RF 5)K@I&!IJ7*K_Q3)8M8B
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MB[NV7;P/M5.$M:YIB6KOW'RN$#OV#IW3G>('EQ@47RC[6.JV6R3\TLQ +X/
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MDK_H"9 SP*(C/9KAA)4!XH-H3X.;*K^N$(T$Z/V>C*.V)$^L</[<O4>@C,B
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MR<ZT8)/);(<>WB>?U_ED6P[VS $G)QLB'9NDAZ8*71*PW_N02N288W)[L-K
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M3U2I2Z?;L2@!N?U;3AZT(5Q@5\9+5LT:^]<E:D9M)-!+GAYP]&N2#)6G@.V
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MS@R8FJR1Z[+_H.LP+_-><F/S(TG*;.JN'\2@E8U?<.A0,!0#(AWA\[^!+DZ
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M8 ACAD6- CUX8DAE7=^DOG6*N9,DEA>))<(MS6!L%!3\8O$&:RI1FL WL^5
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M&F[SKB+\7]O 5RWA* 5*[F4F4G]&9^'O.0?.&F^0[$]$0Q$\D&4XBPH],4"
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M&A?<)EA?YAWE$0AAZ9;H(8R@R)/ $O:?PF1<]X D4N$PC5=7N[8F=VP(1F;
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M4BWFN6[KR6UNJH?/JWJH!XCE*:EDB#%2AG4_:C9"7@)I@M(,BS'CUV!U(BK
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MK.R4P#H)>UJ(*'5]8!F-^HIXM>/:%/GU-.1?9WK.K.5LYN;43*<#1;*NY(G
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M"R_0=<8ZX^"NK*ME>"AVH:WK+\S*F]=_G;QA\-'#9L P!]H)J/_-RGN0_4C
MKO3Z]Q7"(N6-(>L2[GJ5Y@2%HQ$+A9&X2<6EC;((=/)A(ZB1^R@H*3Y(DA7K
M,R 2*QW#X=*@\HM0_@$L#NU-R4Q!$X8$%PYR8)(5V 81E@CW4THG$48H83RP
MYU+[!V%2J:Q-@IAP0_P63V_4^AQ);;C$56D9/;!2(V1C(:MYT(1CZ?$>RRK7
ME(?% C1R,7<&9?I 20BK";+-T#P3A!K"K2WHJ0_(8<UP#.FF=-W4X:[K:E-Q
MB0YV>[ VM '#*/"9"'L5%@!B_[#<S;>,<F(>X25%Z29!8,3-RZ@"72N=0)C
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MR+6(F$#AWZH7VQ?A_8^:=G)?^_=K=-:^J59</UH^D@-##NC)@A9!2P<"TBU
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M!:/KZ\7 %U.A=]*C+E<[=G/".V+  X:CH-<*1[K/!9Z+'!BETE7;,NP%EB]
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M%'[.P_9I"(("Q @$7.<HXD&G/ZBI0*4LAS]SZW('[DGJ+A)(B3@W&VJGA.=
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M8O%=.&9;9,[TO+3P5.'YQJ-;N$#Q>T2F.DIA ]BU9O#M 3.]73#@'1NSLE]
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MW3D@H4\)(6L2WA<<,X]3+H_PT-VVN!JDFDLE"M$W*[YM=7)%3LN7C!SZI0\
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MHI%?(VVTZ\F#LUEM%X5S&NB,@#W-!]/Y=+D:UAO9&VPA6>L\DM67NB;?=8&
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M&=."M3,'KB]SW%GT[6M@WX;/O]*T&FA^U0/NW)*#G\!C-9C9"B K:\%J42\
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MQAF3WR-?=M3-EH<[3EZO7R(]]1]_^W]02P,$%     @ CH%E4_//VS*+<P
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MO;"F)R4LT\/W4/93D RDJY5?51]:H9) SL$8@152@AA]AAP]4YII7AK%25:
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M!AYH_9Y!*L$*Q7W0MDW4X'%L3XH_/:BG\?:S-&+5EAS(3F/ 74B@4BV#-:B
M)Y.<=,9SUJ:[T4.HGA1I=E))WPFV=X'=D/BLO,6,>%'#]7=ZP[Z97M\_+W;-
M%;1G*2H,1D$QK@K(9/!<!-!2"JX"MU+>2YA;DX_;(ZB39=9!M=?@)GC54EY5
M7871F\LX&J:S0OAKU\54&-?!2Y#(ZZ0!4<"C%R"BM<PXGVUJ<QW3&>+)DJZM
MLAK<%'>7RT P7;O+NJM^=LK5Z=&6#NU8-+K$5)('=^E.GE>-U-7@#KG"K/^K
MT;%/882+5%&2P##-,==?/!OG;W]PYR^OVALOWSZET65MYOK;G^D\C#_@6W*C
M?Z,7J69(1QF<30QLJ2Y)E :\S_16<>LTLRAMHQ8*^UWG=Q^K.&):-+@[VFFU
M VTE*]X&*-9K4"(A^%+[>=.!D616)/TV3NQ.L)\V13=26@,K<3?PKGB9,IT4
M)DB\:B@8%6=0G,?BK*HCLX^=<7N6V>VQ'H5!4SN!:^/J %B6(#K# 6W1Q9#J
M<SI"V9U,$'S_2FQD-!'.^^CF-R/)%^7* ^Y]D@PC&*PSXT7DX!TZR-E8QW2*
MQ;>IN^L$;_],.H#J5Y"O7[TU")LOR>01N$'I*A !VL4$RF0%+D<)AALMHV89
M59N)51L"?8J$:ZG+!@'WW:P2M"++P#0(*0*H0@9)X)*1)1\<+^BC]6T"#P>U
M2MY=?OQX-=8AC&Y:,+X:E\GT8M$4Y99&)I4@/>TE2N4(REJRV;03Q"5-O^)1
M)MMHS'LW@-^]9=%"$4V2JF_*"(:YUA D&6W*:"$(0Z<-2QI"4AXPF9)"(??$
MM)F >0_( ?3?0F%+F=';2[M%[_WK9?X^&2?Z\FL.T3BOB V^&,[J-)G+*=[*
M(D3/8^0.T!621;09'/,)9,*B#'E_);=IL[8K\M.DUU[UV7?+K/?3,)X5G"XN
M/VX:G+R?W.1-WDV97!0["1F##0PR\Z;6RM6ZW.)KM%HFE^J,S7O9TFMN13=[
M[F',QOTI=;(?C339S!85+(LJ[CR<DP1FK\;ILM[-_GHY_WTR__]PL>\.O LN
M,V<@9>M \<PA"C(1O56..1=*;)3ETQ7A$^%84\7UO3O=- FXN8%=7.[?P+R:
MKGDMO+/IFS"M5[;7WR_>(I)1;4G(B1GT+A@(M1$A&90"7%$"A#91<QUML+;3
MIM4+G"?"LP/IK\'%T+VA<85EIBWG((24H'SM)4@\ 2Y#U+((%EVKX>!',G!Q
M)P=M>V$>W<#%YZ,PFYV510[28DQ8DMP[9258%C0)I@8-<S' / \YLN"#;E.E
MOQ;2D0Q:W$C-ZQBSD[A;F#YW\%Q/>NF"J.F$Q65,!QZON)O2[MLL_4A\3UP(
M)M*#.81<VXK87.<ITR%FE3:BD,6N4IMYROOB0->)BLTIL(&@>U3]PL!YA[6%
MS,L.2:JW@[M0EMI8/2 )0''+Z*LD(''ABRAD9L5N#O2F3SZ V;FCJB;[DG./
M<V#N@/W/[F -BI"MM(#2UI[IKLZ&U!:,5"IFR4DL>0-2='_R*9"BD9S7[A2M
MIJ:=33^$\?40AA=UZMMH]BV6;E/15GU,OU//'@5Z;ZI9T<S)Q')"'E2,WLG
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M4M_*:##$>.UHR3]F6"Y'KX<%!R8:QY+/P%) 4$5E<$IDT#E[:W2F_V\3Z.D
M[J3XTK<REOGB=^7+REXH YF3B=)K<,9(4(K5\6R*UY$BA6GR %1LTS)B)9R3
MXL3N E\1W-NM,IAHFB_3_'IHUI?W.+T8%)UR$00HQ4Q+S,9#'<T'F1E)/E^B
M-=_SJ=8/FKK_X2>ASUXDMT*5.U?^?QHF?/9ABHN$@&<7$[)HKHI8K\R>05)H
MC4L<"JM37;A%" 4%9!43+TK[C*R39A]_UNDHNF>YKM#[SA'9V\'WK^M(D[?#
M#^?SLT('S;/9#!?-LC*SP4/RC%:.A,[S8B";'+FU+*K[6N]I1W\0UDD0I'\%
MK*#'SB'6;]&]'H8X' WG7P9D>Y0LR%X-OC9!"EK5P(V#:,BU-HHG5&T<U#6
M3I@2VPE]!1EVG_$R&2\*_OXQG)\_OYS-)Q<X_8I.I5*+=CVPVI5"<56'T,M
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MV=(AH@S)@TP;!T5XII-VW,8VY_LF*$^"2LW5TV(T>9\52BFIG'DJ8#4M2(6
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M.*UTL4PI$SI5IM!3[I"'OKM/G =A'"KTT9^2)WT+NT>_80'JBD1W(5U;O5U
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M I2#(%D$XY-GM '6F4W?J^8?J#_>B^(WD6WON4C74/C-@<-2':#L@$E/6,C
M 3IH-&0ZQPKZZ/G]T57K,I"^_>#]UAKW).M)3X+J.\WP!HNXQB)#2$6BAUP$
M8:&C!YQR KA/@LZ?3*2,&RE-G)C2MA%4JS=-WF0@RIR),?3PG,ALQ-K*@.L
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MU$UQ-SNV3H.]NU[]-5],_X=,(C&S4$\!0T0F@6OS:B<9Q(BURT:Q6K;9)I\
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MT_FF4"]I:31FH".IUEP%A)"8@J(\F=,GY4NGA&"GY;T7PNL]TD^WR( -)]>
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M#61J#-.C'OXIHX^B>*+-#<IB'1[43OQG:VL]_I</ HC&5+!2KY3@0HUWZ5(
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M"2I'9V#CZ@Q4SKICT2&[PBD'#V+HJ P^)-2'_#]H6_U&CW<TS]2#BT\B__)
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MYYZ:-V,D5%#( @81(AY, \8@I9'G4\DB0:S48VP-F%K4V%H,:&TRR%N;P>I
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M$IT07I$NT?W<'M*HVTH9;[:%,CZU=3(J/;_3VI)^*!FF$8-I&E&(J,\A3E
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M*7U=:')47C)S_Y!P#._JQR3;I;([N;N$MHD3_%#-8"1)(8V%!Y$7^A!3C\)
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MFQI?Z<.,V5KHX*M8W&<+N6!4!5WW8G6?TZ>'A2Z*6;U[>D@!*S5X++@ Y8,
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M:X3CZ^I"*VTQ8&OEA\YY[)$YVK.?#.=JPV'_JK+S;5^TQ9]U5U0.7$K>=:!
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MF@D*D3\OF.UVQP5\C:>LCE ;?MJJ#05[P&E3-Z(@3J>N!J"XGKYV-3GV%-;
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MND-OZ.71\\ -(!EBB(O;9=,+;8Z[BFH&P-&BJN%M_;A%!9>+XDX>G"-[.93
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MUBI5,6>_EYNGOR^6S.0\-9Y575!OAA1)82XPR%)6 $B$ (SR%" 1<R4X,\D
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M/^1[I21OENR/ZEXLJ_/K>_%?6U,%_%<Z-ZG5VF*PA;872@2D<;P@-_?HJ2
M2B(R63""I=4RN[<&DZ.1G1%1;<5=NZ=DZA VEMQ%K2U18XQ]J&._?NHFH%'0
M#TU,_8#W6'IV,(J#0S+[21\M=',0.(<AGL,:<C\_>+_8Z-7O5_F]--EN%QMS
MNCZ+LQBF"9,@JTH]PB(!.%<<Y#E+M,>$9<JLCKFO"9@:L]4Z1GLEJV 0^[.#
MBR#>/CH8"DU@VG%$Q>G<H,OT7L<&%QL<[=2@RYS#0X/.Y_JM=TX.'']]/72<
MJI75C"4YR6EF[E8(LZ,D*:!,*1/%G<24)UF:Y"X+G]LBIS; SP_8V6MTZN]7
MFCNNBRS0MUL@^<4T,#/X@--Y_62/D->%E(7845=4]C"<+JT<WNQ9Z+)N[W>Z
M,MSVN/I:?G_:/&XWZPU=B'+Q?::H2!7C N02:K^"00Q8G F@)",R33&FC#E5
MN[PA<&HTU"BJ1\E>1_?X-FNX[9C')XAC[= TRNJO,ZK4O8L.%/98^](2&K\%
M,&\)';<*IB4$9Z4P;=_K$2GQFUX3R?6'K[M@TX=]K.F7-M2T8K5FBR#%*L-%
MD0/MZ& 3,0$!20L&J$(X3I(DEYE]Z7I7Z5,CH5K_Z(/#D;XSX-W,$QS&P#34
M(ACME8\.M(]VZK>ND/N%,V?$'8(I0B(_4E"%8P]X"JKH"UQG<(5SH^,%6?2U
M]RC8HG<C 7)F_EU//6N^W"XV4KS_D^M'[Y_-OV:%*'",,P8$8XE>%ZL<L"PG
M0#$B,&9"YHK-%O*[J4GXS5/6S&O*6 TW4@^W,Y4"QC%I!?\CHI6*)J=/713%
M.+"EMD#_:_/O6_W^4O?L_]'C3I@R:*V!'O-M7NU".V<W7(],)\OFH1E1;4=4
M&S)2;LU;.(Z75O.J)M/)J'D++*=DFC<;ZQE3L67K4I1T]?JXJC</_B8W3TMA
M,AZO-U+^1JOD;H;$?WT]?[A]K-X/PYP5(D$)H"PA *8R!S3/8Y JFJ(,B1P)
MMS ,C\I-SE??J6N6NK7"46U>U"I^%QD+]QMO[#6Z^%K[?+^-3J^?@!U7OU7'
MAEX]O$6?ND>K! #?;X"+3P7'C8D) .U9&$T(&3TGC[TH[?IK0=7,M335,63Y
MP]3)^+:BBS7EU<HUCP6%@DM0Q.:LRI0M(BA!((/ZQZ)(:>)V5N4D?7+TWY!
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MWSPW9U+&37ISS<BS##A7'^PWFO]!5Z4)[/^J%_35?AQ24$-4)$"FF8E/T L
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MKB @.&9Z?8DS)A-.<XI<G 0+F5-S#+I&F9N78 .X'7UYAC$P:77S5)"K 0X
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MB*M+VY:?.I\9N8;Y+IKH?KW>/M<57,V5FP\K*=OCOJ^:1F<)Q$IR24"1J!C
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M!*>)2BQKMMF+G!JE&(UW%0Y[^B$60-NQB5_X G.*(W+N8=;68/B-M;XM=MR
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M4$F !<% P91FG"/(8ZN4FKVD3VV^JO6/WMU%=AOH#CSIW#$LP04A(@$%2@F
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MB7G6<5P7+@S 9[Y?(#$CYUW_H@?A$VWV+?5B;?G\;)+"FXQUS5Z&RC#,.9&
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M&>3;K^7QPGH'67X4R#NLI1[9K/2G*4^3YE3G:RBC)"X8 2A+8KV4S0M 8DJ
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MGH[FQCBUJ'5^MFJ&%+6T'H9('ZP.MEL@L$8FE0:G+SN<&D&'6&Y]@'D8;H&
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M/)UI#HG6&8Q230V%\T@SK[N*\UW-C:7K')B-J*"1]7()&U^ W>@C#&PCD\=
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M36XZ1R7@3A\4H=HK,OX8>'BFC3\6$_F?C30F?@YFUZ'9ZT8VL.GIG,6NT_W
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MY:GV\H"Y1IBYD<+=]KLJ=K>P';$]??NN&1\WJV0JU,?FFT8-Z^[7*@(:3:K
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M/6KL/YJD F*-,XE1*G3B=*33U\G<IGX;I5\+"JRD5?E8*ZM[&H^SD/;/_5!
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M[CXFV@"[C/;(>]S 8SC_;>SA%]!1N?%/^_G"%S#=#M5C:.:Q"741^,^QS_2
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MXBQB*8*$QQJB2#'(1(JAQKG(5<+-_WMFCSS=T=RHY,ARL:(.#, \"ZX;?X2
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MI/)+FKCXO'^TPA>S)+-BN?EU73XJL=1+)9OT, EF(L%Y"E&2F(T+326D:9;
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M;.U:6YNB@Q?*@A'!80I"\GM[O^Z/N4>3VDT2HAT2VZJO WS>(S?KL]4JLCK
MA3B)28 /4@*BU;30?+2Z3=W>@95Z@S<B?5+$#:20#J!UM=//]@Z\%2H)Y!R,
M$5A92!"CSY"C9THSS4NC3-@MQ(S=!F48/=^\N7F0T#O S:5>_UOZT3OD)47
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M)VTUUL6.O**]Y8S1B= 6G2HDK-HD34F3( INP$K#E:4X7#2JE;Q"QK@U'"V
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MBZ>2>1^ ^MONS!D4(5M)\82T)$;I:L]M;<%(I6*6G-V(\.X%U.Y/'O=^PO"
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M[_W)SZ'&N@M0?DJ]#Q)S!Q'J'POZ67E]OAUH<MWMPTS,F@O ^I9*&:? 16>
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MC6\TQ^(ITD[)D^V"ICL=U:/JJ(-\LD[@/\^O*3N^([H;;QENOEF8":%3ELZ
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M_\+5BL3T>HYA[\WG^WQF['7&![,ZTKKCWPAIY]^OU]HF9G/.09*[\_5%+:^
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M^)0=E&B5%M%Z(=KT69SF.)!=\+'_.)!=E/)<7KTW'0 RW<"/XPWXX)RYD+(
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M'9WN FQ&GY*RV<1&?1V/D37MF,8^>I#&TUL'(+S%P]8P=>*66<G 223#+*:
MLSD#A98I*N&D:%13NI><3C9!'*[NVP7)@V7? 8!>I#2OJL"S=SA/?RQ>XM?Y
M.9YM7;+71<M073+W=0T>SX V6$A.\^"DP1 '50-V[YQ\C*P>MAP=I/;;79&C
MZ: #0.T]+^/U]<RYDHLK3DA(6C!0@GZ%$@OX& HSPFO%V\P .YSV:<?6=G+
M'A<!'6#^QI;&K>U>[F]_3^I??<N) MU7%^<7JWRUWGC&9'0Q%O(/6-NF3/&
M45A 1%/+C;SD-CN_=B:U\S[+D;%T>^%34\5V@-P?KZ4?EV^X+=_?_OXZ7UU.
M?-T,8IG%''111@!GJDZO<P8\4@J7O!$A1$8Y7:.W[6.QT'F_75ND3P.$4[:
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MGY>E)/0Q!:L@6ZYJ1YJ$D%,$Q.2L\AQY:M-.LON&I!-8[+D3%![=D+2+7CH
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MA!><*Y!B<99+9X1I?4E_( LG?3&_"W[;3;S?!00]A!8_#;]6G%->0@!+E+&
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M4RHF(Z(CVZLWOH)S<&B(+ZE*PA)R-FUV#X[:7]BLLZ([1.ZDL/V!N#S'L_9
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MRHV2MG]ON\L'[25)/(\/'U!+ P04    " ".@653T*&_U"D(  !B)P  '@
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M!;HH$?/ [NY5-E8\X%1R8P!W"=%29&HD9<HD*0M=93.:)1"A&!3"OMX.FJ(
MXWX64\-[,,LJL4IV&.%2YWK&Q]68F8Z@)HQG@:4B\C8@-=X*J7=[)U[;5"S:
M6'Q2;[^ @7?-:G^KU?T9C3.+-@,+%H9(@'S&4E1FFXD,3/F,=>-NG\YJ=OU@
M(#"O7.X<BTQOG_LY*YO>]V:F, B_7LV1\;+DL%S G ^6>PTSP=L(>["=/YU?
M-^-CJOL\#=F61^'GYN5&ZHHB$PUB_+M6*SDICF7 AL+W,VG\OT8]#^0E0FD\
M,2]-($7Y$/&;VS22_8W.(<"#NOU1OUQ-%&#,;D/,#B7-[G4Y<)I$5-US,ZB0
M6K"QP.8%:SU5(D4V7V"S<<OB?$_RJ'_Q!0YY(;1VKJ9K?O\UG7UC$2Q70G'%
M"H:DUI&Y(@B#L&>'O+B9[Z$71;;70CH>,ZWV 80E-O>P)VEW+*BTW!9PZ&2'
M[P.Y8#EE6!3_3;6Q7&+LMXQ#9;NHLM2WNY2#_XNZL(/]G*G7.$)MBF)37ON<
M(3!Y8KJOS^:,WII,P]2205RE9]];+/=V?RK<>2GE=@I/T D-,%"Q>S9Y AIC
M'G-M.R/*0@*3-M$I9#F5)8@1O&3-R-GZR?WO&TMBVRNV#G)5*+%\BG ]L\L=
MP;.O>O(H%QWY\W0FXADS&2"ED_R-E<P9@B736"P86N>1<)Q 'V (,7]A,BQO
MC<2?X_@G#LTVHSH66HND=6A'F0TJNS^% **8-"<0,9TJUEI>M,&!TY@N6CRU
M_K>#V@_%&<5FADN1>O.3#JNG:\X/^4Y.RL?']IQ/0T\=+"?.CP#+MJFB@\VV
M1J/<.-G>7"U[6]O^D]A:^:AV^#^0>GQ2?W6IC29<L'WHNMB*=:]S,8*HIC3]
M4*@7OGK:E*.M59O>$>_A6:0!X., N]C^]>N^9M9]#TO8IBQR@665C+&RFD5[
MHGV_ '(W_3<>J!K["R^3\4PO@F6_D0O/%P]S_NO:Z@XZ=PHS[_8:1VUE?]?.
M A_8_]*E\QK ^=8R\CQ@TG^U7 .S$_O.B2P#M*M!WSC:MD'?./3].]ZO1/O?
MTP<.W8BSD/3OF)^9=TCDTFWVMK^UW'F+]J\D1QTY12&Y8=;!HR^G[I%>L;7;
MFKG/*1S7O]::"O>M6LN]LYZQC>^W5M6D+0RKJR%T#![)].:0KWSRE?^ZK\_L
M=W!G?P!02P,$%     @ CH%E4^4[I'4K"   Z2<  !X   !P<F-T+65X,S$R
M<V]X8V5R=&EF:6-A=&EO;BYH=&WM6FUSXK86_GY_A4KF[B8SO!G("Y#-# &V
MRW1+4D)FVT]WA"V#)K9%)1F6_OH^DDR $+K99KO+IC<?B&U)1^?ET7..+)__
MT+EJ#W^[[I*)CB-R?7OYOM<FN4*I]*':+I4ZPPYY-_SY/:D5RQX92IHHKKE(
M:%0J=?LYDIMH/6V42O/YO#BO%H4<EX:#DA%5*T5"*%8,=)"[.#=/\,MH</&?
M\Q\*!=(1?AJS1!-?,JI90%+%DS'Y$#!U1PJ%K%=;3!>2CR>:5,H5CWP0\H[/
MJ&O77$?L8BGGO.3NSTMVDO.1"!87YP&?$1Z\R?%JE5:\JN_1D-$:"\MU[S1D
M)[3"SDXJ9:]"_^=!R1*ZNS%*+R+V)A?SI#!A9O[&:66JFW,>Z$G#*Y?_F[/]
M+LY#D6A,)C'873H96Y(T^Z@+-.+CI&'MR;FAR^81]>_&4J1)4/!%)&3C(+1_
MS>RN;/^:9D@AI#&/%HW70QXS1?IL3@8BILGKO$)P"HI)'KJ.BO_!H"STMK?S
MS!#(B7C"EH9YWC&LZ7Z<\!'7I.H5*YNFK+N#RC$\HL6TX9U![)I1/D+ Y+Y9
MU>X.AKVWO79KV+OJ ]N#F]M6?TB&5SM-W'N3!K?ONS?$J]*"5SND1Z35[Q#O
M.,CN;ON=[H ,WW7)3;=].^@->^C<_;7]KM7_L4M:[2&Y>DN\>K66_WX]T+HA
MK<[5];#;68^H,=A&N5JN&".M#UJ#RU:_>U.X^O5]][>E^95R^6D0QXI_8/N7
M-['VJ(F]//F)S7A"/H :I<H3GTG-PP71$ZI?'1R?-9]J0'-*@P#$6HA8J!N5
M6O%XN6YY$B"\C8)[]HT,]8I+0[[^[)NN\4Z-$WID0F>,2#B?S9&4](0K\DM*
M)<(0+<B 38741"3DK9#QJP/OI-STRH5?B C)]>"JW;T>DDLN!F(D-/<5TI?$
M &H2)J)6?RE1J^Q9U"ZI0JP0E7A![A(QCU@P9GD7/.E"%@@HD B4&Y!/L;)H
MLB!IHF7*H#]6F:U%$$9*8K/F.(U(2'T\DD3$2(Q:N'Y;'1+F,Z6H7)@N,;UC
MF'=-IL*S ,I@RL@6,IC#=/"Y1.&";@F&0Y. 23*?<']"5&I^5N/G3+),B#$@
MYBI"A6.*I3G7$QBHILRW"AJY4Z@F I@YP[" C!;K;GA)(*Q^+R!D).0)PFP0
MLPIK'@A$=S3+M7:>A" 62QBX]J,T@$Q 9RV&><".&S*:(O(&M ;,4;1"908(
M]6!J #^PI7O>]$@C=  4!?!BIU-6'Y^J"0DC,5=+G$HVYDJC[M>$FH=.;VB9
M7X.;6BJSI>U+0EQMSQ WW C/:Y6A*:L5#$&(,.2X/51'-FH]0B6S^$"\^2AB
M)HZ$ 92CB*N)&6&ZQ>!'PY'F/N#*CX1*,<XPIQ21 \I4"I\%>*S((7 1, #-
M!;_[T9_09,Q("Z0T2"/TL-7J\2%S6MAJU=P=V>D?@@P]3 Y^1I53J^\5;%"7
MNTIA^[?#%.IL^,UR_J=]G3?IR*>I>OH0DQ=&# '*9G*91J02 K!X9UQ92D O
MEE@YIL1<D<DZ(4D6X0*@R%+-*FKYC*Q,(P>Q0!<E(A[8C;U*1XH'G$IN#. N
M(5J*3(RD5)DD9:&K;$:S!"(4@T+8TMM!4Q1@W$\C:G@/9EDE5LD.(USJ7,_X
MN!HQTQ'4A/$L> 85[1NB1CL1]>J@[C5-P:*-P?5J\P59[>^TNCNC46K!9E#!
MPA#YC\]8@L)L.X^!*)^P;-SMXTG-+A\,!.252YTCD>K=<S]E8=/[WLS4!>&G
MBSDR6E8<E@J8\\%RJV$F>!EA#W;3I_/K=GQ,<9]E(=OR(/S<O-9(7$UDHD&,
M?]=*)2?%D0S(4/A^*HW_UYAG0UXLE,83\[H$4I0/$;^[/2,YW.H< CPHVQ_T
MR]1$_<7L+L1L4)+T7I<CI\F$JGMJ!A-2"S86V+1@K:=*)$CF"^PU[EB4;4D>
M],\_PR'/A-;>E73'WW])9U]8!,N5D%^Q@B&I=62N",(@[,DASV^G>^A%D>RU
MD(['3*M] &&QS3WL4=H="2HMMP4<.MGAAT N6$X9%L5_4VPLEQC[/>50V2ZJ
M-/'M)N7H7U$6MK"=,^4:1ZA-36RJ:Y\S!"9+3/?EV9S1.Y-IF%HRB"OT[&N+
MY=;NL\*=55)NH_ (G=   Q6[9Y-'H#'B$=>V,Z(L)#!I$YU"EE-IC!C!2]:,
MC*T?W?Z^L"2VNV)K(5>%$LLG#]<SN]P1//NF)XMRWI$_3V8BFC&3 1(ZSEY8
MR8PA6#R-Q(*A=3X1CA/H!H80\V<FP^+.2'P>QS]R7+8=U9'06L2-$SO*[$_9
M_?D#$,6D.7N(Z%2QQO*B"0Z<1G31X(GUOQW4W!1G%)L9+D7JS<XXK)ZN.3O>
MJ]>+9V?VA$]#3QTL)\X._XJVJ:2#[;9:K5BK[VXN%[V=;7\EME(\K9S\ U+/
MZM4O+K5V#!?L'KHNMF3=ZUR,(*HI3=[DJKE/GC-E:&M4IA^)MWD*:0#X,, N
MME]_W5?,NN]@"=N41?I85O$(*^LX;\^R[Q= YJ:_XX&RL3_W/!E/]")8]ANY
M\'*QF?._K*WNB'.O,//JH';:5/9WXQ1PPP//73Q? CK?6D:6"4P!4"Y6P.W$
MOG0BRQ#M:]BWCK5MV/\?ZG^ \S_CNX:O]DW*A+.0O+VOKZ[<AH[\[0\ROI;B
MA]>20^4I=-[6WI3S>V_!RH"6[P-E=K^367#TX .N^Y57LH7DFE5/J6+7/QJ;
M"O?)7,.]/Y^QK<_(5J6MK5++JR%T!$I+]?:03WQYEOVZC^#LYW@7?P)02P,$
M%     @ CH%E4]Q-[?^R!0  -Q<  !X   !P<F-T+65X,S(Q<V]X8V5R=&EF
M:6-A=&EO;BYH=&WM6&UO&CD0_GZ_8DIT;2*QKRPD 1J) %4C]4(*6_5Z7TYF
M[06KRWK/-B'TU]_8NR0A-&W41M>TNBA:L3OV>.:9\7@>=Y\-1OWXP\40YGJ1
MP<6[TS=G?:@YGO>^T?>\03R U_$?;R!R_0!B27+%-1<YR3QO>%Z#VESKHNUY
MJ]7*735<(6=>//:,JLC+A%#,I9K63KKF"SX9H2>_=9\Y#@Q$LERP7$,B&=&,
MPE+Q? ;O*5,?P7&J47U1K"6?S36$?AC >R$_\DM2RC77&3O9Z.EZY7O7LXMT
MIX*N3[J47P*G+VN<L&;82)J,-?QI%#)*2#J-DB,:-%D8'1'_[P"-]'!X.4?I
M=<9>UA8\=^;,K-^.#MU65.C.BE,];P>^_WO-#CWIIB+7N)[$^>7/4LV.,LVN
MM$,R/LO;UJ5:.74CGI+DXTR*94Z=1&1"MO=2^]>IWGS[US%3G)0L>+9NOXCY
M@BDX9RL8BP7)7]05QL=13/*T'*CX)X;&HMWV=57Z<HAZ,IZSC6]!T$1OAE=S
M/N4:&J$;;+MR&Q$B9PB*%D4[.$*UMYQ*, I,/C6O^L-Q?/;JK-^+ST;GF-[C
MR;O>>0SQZ%X7G[Q+P1&\<R=NWX7)L&_="AI-OPZ]"?0&HXMX./@U_-QX=^RW
M8/0*XM=#F/3&I[WSX<09_?EF^ %Z_=A(0M\/'Y2QX29C>4[1Y788N<WB[D9\
M?/>BS[IWED,B\IPEII["BNLYZ#F#MTLB,1C9&L:L$%*#2.%B/.H/+V(XY6(L
MID+S1&%IE"@F=O*^F?A\[R@,_4Y?+ J2K^U;T#D %+\2<@&![[R%5$B[2($F
M"PHLIZ;H3EBAV6+*)#0PC6RE)0I2GF%9OK9KPI*EQ-J/ )"<PO JF9-\QM".
MQ8(K9<S ?S.28CV'.9,,+;]M6>G/QK ZG$'"I.;IN@[%4JHEP1AH 3?I_7PO
M:!UVJNQ&BP@5A3DJ;H^NQI@<P>6LH41.2<Z4,[K*V!IZB870Y$@=Y00-:!YU
M'IPN!:$&(R=C*0;R^$X".3\T@_:# ^.^W]E]Q@A$E3_I,L-D2C M,A.\ZX!*
M]L^22V8.3V404E4F!HU]@FDC(6CNTX-K5&_"?QWZ"MK@N!$AJ,<=DQB_!K#A
M%X'E.>ZC1;GU< MK@@HH?K5 ;5 GW.SA0C)E *X;,<DRP&EH$\D0?E4@XJIN
M9Z4\)WEBOJ-":ELLN\UPU#*S* O<LW9)M0E)M=/=>R'?@K@$] L@?Z:'V0T?
M%A\M%NV6G:7)-&/7QX60E$ES5&2D4*R]^=&A7!496;=Y;H&VDSK;ZHQAEZ86
M)"2KCB1K9RF^Z;E<O^R[-!JJZ6;E2NQ:D:?IKBR*W*C9O%?LN\&]LB^I;;A^
MJ_7H6D.WU;Q?^JU:HZ8;A<</4NM9>$N(,8H*D^QEK5'[:E]0I5L[+*X@V.X-
M30;>C7 9W/]^AX<F$0:X#>U! .?BLCS[FN71=[T#*IB^!0'?^%_[/AT/1!'K
MZ0^"\'2]?9(^KJ]E2_JD<N;Y7G384?:)5?X3@;\(S<66_]^[=1XC<7ZTCNH@
M, >][X98VD&)C%/8!.BI!GV'A-B@WP2Z#A=S=^#^'^]'*OL_$Q7MSSE+L?'%
M)ECS2P:C-.5(7N#G)=?[%Y)CPUE@Q[GCUL&=FZSK3/=L\_8SD6S3KF.SSF;"
M$-V2;V(RVOZ:*Y@R\SE=RIRK.?;P6*D8=NW(*TF2E.WU[:;^(305FW94G N]
M46YIM"'>.+L0BMG^?;(A6T</)%@E 4:R1AG=6@5-F1I*DE3W ;C8=(V\(44"
MGB=&8KQ!/] 08\\V>:C#:L[P72(QH0PU&; ,^2,I)NU=.E]'O3,B:<:4]<*H
MG;$<B4EVRP+C5X;V+\G,+ ]JF<RKU7>YRD.X1Q711LO01E%>0+<ERXA)VIT;
MV1M"8KF%?S.%3#&^2[T[Y2N7N-6SO%*VE]LG_P)02P,$%     @ CH%E4Q\.
MDH.Z!0  J!<  !X   !P<F-T+65X,S(R<V]X8V5R=&EF:6-A=&EO;BYH=&WM
M6&US&C<0_MY?L<73Q)Z!>^/ &(AG,,833U/CP&7<?.J(DPXT.4Y721C37]^5
M[L#&Q(F;N(F;J<=SP]U*J]UG7Z1'W9]/A_WH_>4 9GJ>PN6[DS?G?:C47/>J
MWG?=T^@47D>_O8'0\7R(),D4UUQD)'7=P44%*C.M\[;K+I=+9UEWA)RZT<@U
MJD(W%4(QAVI:.>Z:+_ADA![_U/VY5H-3$2_F+-,02T8TH[!0/)O"%67J ]1J
MY:B^R%>23V<: B_PX4K(#_R:%'+-=<J.UWJZ;O'>=>TBW8F@J^,NY=? Z:L*
M3^CD,&'UYE'8",.8M"8-TCJ*8^:S1A@'+?:'CT:Z.+R8H_0J9:\J<Y[59LRL
MWPX/G6:8Z\Z24SUK^Y[W2\4./>XF(M.XGL3YQ<]"S8XRS6YTC:1\FK6M2Y5B
MZEH\(?&'J12+C-9BD0K9WDOL7Z=\\^Q?QTRI)63.TU7[9<3G3,$%6\)(S$GV
MLJHP/C7%)$^*@8K_Q=!8M-N^+@M?#E%/RC.V]LWW&^C-X&;&)UQ#/7"";5?N
M(D+D%$'1(F_[+51[QZD8H\#D<_.J/QA%YV?G_5YT/KS ]!Z-W_4N(HB&#[KX
M[%WR6_#.&3M]!\:#OG7+KS>\*O3&T#L=7D:#TQ_#S[5W1UX3AF<0O1[ N#<Z
MZ5T,QK7A[V\&[Z'7CXPD\+S'96RPSEB>472Y'81.([]?B$_O7OA1]\XSB$66
ML=CT4UAR/0,]8_!V020&(UW!B.5":A )7(Z&_<%E!"=<C,1$:!XK;(T2Q<1.
MWC<37^RU@L#K],4\)]G*OOF= T#QF9!S\+W:6TB$M(OD:+*@P#)JFNZ8Y9K-
M)TQ"'=/(=EJB(.$IMN6-76,6+R3V?@2 9!0&-_&,9%.&=LSG7"EC!OZ;D13[
M.<R89&CY7<L*?]:&5>$<8B8U3U95R!=2+0C&0 NX3>\7>W[SL%-F-UI$J,C-
M5G%W=#G&Y @N9PTE<D(RIFK#FY2MH!=;"$V.5%%.T(!&J_/H=,D)-1C54I9@
M((_N)5#MNV;0OG]@W/<ZN\\(@2CS)UFDF$PQID5J@K<)J&1_+KAD9O-4!B%5
M9J)?WR>8-A+\QCX]V*!Z&_Y-Z$MH_:-ZB* >=4QB_!C !I\$EF=81_.B]+"$
M-4$%%+]:H-:H$VYJ.)=,&8"K1DS2%' :VD12A%_EB+BJVED)ST@6F^^HD-HC
MEBTS'+5(+<H":]8NJ=8A*2O=>1#R+8@+0#\!\D?.,+OAP^:CQ;S=M+,TF:1L
MLUT(29DT6T5*<L7:ZQ\=RE6>DE6;9Q9H.ZFSK<X8=FUZ04S2<DNR=A;BVS.7
MXQ7G+HV&:KI>N10[5N1JNBL+0R=L-!X4>X[_H.Q3:NN.UVP^N=; :38>EGZI
MUK#AA,'1H]2Z%MX"8HRBPB1[5:E7/GLN*-.M'>0WX&^?#4T&WH]P$=QO7^&!
M2813+$.[$<"%N"[VOD:Q]6TJH(3I2Q#PC/^5K]/Q2!2QGWXG"$]6VSOIT_I:
M'$F?5<Z\V L/.\H^X5=VC0W]RC1SM87 UQ;/4Z3.]]91;@5FJ_>< )L[*)%R
M"NL0/=>P[] 0&_;_0_TO]/Q_P$._V4W!C+,$SC8'L6&2<"0H\,4$^EL9OG\I
M.9J<H\V[UIM#Y+/WX-:!7AQCEFG#2DL/#NY=JVTJS[4GR?\2XS?< 9D#FPKC
M7T%^L3CL89\KF##S.5G(C*L9$@ILF@PI!))<$L?%6?\NPW@,9\;@H^),Z+5R
MR^G-+0#.SH5BEDR,U\RO]4BV5[!Q9(Z4T:U5T)2)X4=Q>3F!BTU62&(2)ED6
M&XGQ!OU 0XP]VTRF"LL9PW>)+(DRU&3 ,DR4))B;]^\6JJAW2B1-F;)>&+53
MEB%+2N]88/Q*T?X%F9KE02WB6;GZP\2IC%J]:7BJ*&Z\VY*EJ.Z:[5P!WS(@
M2V:\VRED@C%<Z-TIG[DU+I_%';:]33_^&U!+ 0(4 Q0    ( (Z!95.2( !A
MKX0# &HW(0 1              "  0    !P<F-T+3(P,C$P.3,P+FAT;5!+
M 0(4 Q0    ( (Z!95-6P^IO$Q(  .#-   1              "  =Z$ P!P
M<F-T+3(P,C$P.3,P+GAS9%!+ 0(4 Q0    ( (Z!95,<3<KO[AP  "H8 0 5
M              "  2"7 P!P<F-T+3(P,C$P.3,P7V-A;"YX;6Q02P$"% ,4
M    " ".@653\\_;,HMS  #\-@4 %0              @ %!M , <')C="TR
M,#(Q,#DS,%]D968N>&UL4$L! A0#%     @ CH%E4[_BS;?K^   )8(* !4
M             ( !_R<$ '!R8W0M,C R,3 Y,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( (Z!95.2LW61OIX   =T!P 5              "  1TA!0!P<F-T+3(P
M,C$P.3,P7W!R92YX;6Q02P$"% ,4    " ".@653T*&_U"D(  !B)P  '@
M            @ $.P 4 <')C="UE>#,Q,7-O>&-E<G1I9FEC871I;VXN:'1M
M4$L! A0#%     @ CH%E4^4[I'4K"   Z2<  !X              ( !<\@%
M '!R8W0M97@S,3)S;WAC97)T:69I8V%T:6]N+FAT;5!+ 0(4 Q0    ( (Z!
M95/<3>W_L@4  #<7   >              "  =K0!0!P<F-T+65X,S(Q<V]X
M8V5R=&EF:6-A=&EO;BYH=&U02P$"% ,4    " ".@653'PZ2@[H%  "H%P
M'@              @ '(U@4 <')C="UE>#,R,G-O>&-E<G1I9FEC871I;VXN
9:'1M4$L%!@     *  H N@(  +[<!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
